<SEC-DOCUMENT>0001628280-25-038858.txt : 20250807
<SEC-HEADER>0001628280-25-038858.hdr.sgml : 20250807
<ACCEPTANCE-DATETIME>20250807160444
ACCESSION NUMBER:		0001628280-25-038858
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		97
CONFORMED PERIOD OF REPORT:	20250630
FILED AS OF DATE:		20250807
DATE AS OF CHANGE:		20250807

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARROWHEAD PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0000879407
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				460408024
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38042
		FILM NUMBER:		251193847

	BUSINESS ADDRESS:	
		STREET 1:		177 E COLORADO BLVD
		STREET 2:		SUITE 700
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91105
		BUSINESS PHONE:		626-696-4702

	MAIL ADDRESS:	
		STREET 1:		177 E COLORADO BLVD
		STREET 2:		SUITE 700
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91105

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ARROWHEAD RESEARCH CORP
		DATE OF NAME CHANGE:	20040112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE GROUP INC
		DATE OF NAME CHANGE:	20020509

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE INC
		DATE OF NAME CHANGE:	19940224
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>arwr-20250630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:774aaf13-8f26-4ca1-8d87-74a19a24be14,g:58a47ad1-6a7b-4244-af8c-bd7fa2a79e94,d:b8da3572c2184cf591d7511966d9e9c1-->
<html xmlns:arwr="http://www.arrowheadresearch.com/20250630" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2025" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>arwr-20250630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-26">0000879407</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="f-27">09-30</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-28">2025</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-29">Q3</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-30">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="arwr-20250630.xsd"/></ix:references><ix:resources><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="bundle"><xbrli:measure>arwr:bundle</xbrli:measure></xbrli:unit><xbrli:unit id="agreement"><xbrli:measure>arwr:agreement</xbrli:measure></xbrli:unit><xbrli:unit id="program"><xbrli:measure>arwr:program</xbrli:measure></xbrli:unit><xbrli:unit id="obligation"><xbrli:measure>arwr:obligation</xbrli:measure></xbrli:unit><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="option"><xbrli:measure>arwr:option</xbrli:measure></xbrli:unit><xbrli:unit id="cny"><xbrli:measure>iso4217:CNY</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SareptaCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SareptaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-27</xbrli:startDate><xbrli:endDate>2025-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SareptaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SareptaCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-07</xbrli:startDate><xbrli:endDate>2025-02-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SareptaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SareptaCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SareptaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SareptaCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-24</xbrli:startDate><xbrli:endDate>2025-02-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:GSKHBVAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:GSKHSDLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-22</xbrli:startDate><xbrli:endDate>2021-11-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:GSKHSDLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:GSKHSDLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:GSKHSDLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:GSKHBVAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:GSKHBVAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:GSKHBVAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SareptaCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SareptaCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SareptaCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-14</xbrli:startDate><xbrli:endDate>2025-02-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SareptaCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-07</xbrli:startDate><xbrli:endDate>2025-02-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SareptaCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-25</xbrli:startDate><xbrli:endDate>2024-11-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SareptaCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SareptaCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ComputerAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ComputerAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ConstructionInProgressReclassifiedToBuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ConstructionInProgressReclassifiedToManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ConstructionInProgressReclassifiedToBuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ConstructionInProgressReclassifiedToManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-11-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-25</xbrli:startDate><xbrli:endDate>2024-11-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-25</xbrli:startDate><xbrli:endDate>2024-11-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-02</xbrli:startDate><xbrli:endDate>2022-12-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:DrugManufacturingFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:LaboratoryAndOfficeFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:FacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:LaboratoryAndOfficeFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:CorporateHeadquartersInPasadenaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:ColoradoOwnerLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:CorporateHeadquartersInPasadenaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-25</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInMadisonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInMadisonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:InducementPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:InducementAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:InducementAwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:VisirnaESOPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:VisirnaESOPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:VisirnaESOPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:VisirnaESOPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:VisirnaESOPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:VisirnaESOPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">arwr:CommercialNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">arwr:CommercialNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">arwr:CommercialNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">arwr:CommercialNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-07</xbrli:startDate><xbrli:endDate>2024-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementMOICPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-07</xbrli:startDate><xbrli:endDate>2024-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementInitialTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-26</xbrli:startDate><xbrli:endDate>2024-11-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementMOICPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-26</xbrli:startDate><xbrli:endDate>2024-11-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementMOICPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-07</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementMOICPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementInitialTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementInitialTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementInitialTermLoanInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementInitialTermLoanInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-01</xbrli:startDate><xbrli:endDate>2025-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SanofiLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:VisirnaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ib8da3572c2184cf591d7511966d9e9c1_1"></div><div style="min-height:22.5pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.220%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Washington, DC 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________________</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.796%"><tr><td style="width:1.0%"/><td style="width:3.009%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">x</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">June&#160;30, 2025</ix:nonNumeric></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.220%"><tr><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-38042</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">ARROWHEAD PHARMACEUTICALS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________________</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.220%"><tr><td style="width:1.0%"/><td style="width:48.596%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">46-0408024</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">(I.R.S. Employer Identification No.)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">177 E. Colorado Blvd</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-10">Suite 700</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">Pasadena</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-12">California</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">91105</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">626</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">304-3400</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Address and telephone number of principal executive offices) </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Former name, former address, and former fiscal year, if changed since last report: N/A</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________________</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Exchange Act:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.220%"><tr><td style="width:1.0%"/><td style="width:37.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 2.78pt;text-align:center;text-indent:-0.8pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 2.38pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:1.38pt;padding-right:1.38pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">ARWR</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 2.38pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-19">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-20">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.220%"><tr><td style="width:1.0%"/><td style="width:44.809%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.809%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" id="f-21">Large Accelerated Filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:114%">x</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Accelerated Filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%">o</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Non-Accelerated Filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%">o</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Smaller Reporting Company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-22">o</ix:nonNumeric></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Emerging Growth Company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-23">o</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-24">x</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares of the registrant&#8217;s common stock outstanding as of August&#160;1, 2025 was <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-25">138,257,550</ix:nonFraction>. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.220%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:22.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ib8da3572c2184cf591d7511966d9e9c1_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.636%"><tr><td style="width:1.0%"/><td style="width:91.680%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.120%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">Page(s)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline" href="#ib8da3572c2184cf591d7511966d9e9c1_10">PART I &#8212; FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ib8da3572c2184cf591d7511966d9e9c1_13">ITEM 1. FINANCIAL STATEMENTS </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ib8da3572c2184cf591d7511966d9e9c1_13">1</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt;text-indent:-13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ib8da3572c2184cf591d7511966d9e9c1_16">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ib8da3572c2184cf591d7511966d9e9c1_16">1</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt;text-indent:-13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ib8da3572c2184cf591d7511966d9e9c1_19">Consolidated Statements of Operations and Comprehensive</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ib8da3572c2184cf591d7511966d9e9c1_19"> (Loss)</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ib8da3572c2184cf591d7511966d9e9c1_19"> </a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ib8da3572c2184cf591d7511966d9e9c1_19">Income</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ib8da3572c2184cf591d7511966d9e9c1_19">2</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt;text-indent:-13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ib8da3572c2184cf591d7511966d9e9c1_22">Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ib8da3572c2184cf591d7511966d9e9c1_22">3</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt;text-indent:-13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ib8da3572c2184cf591d7511966d9e9c1_25">Consolidated Statements of Cash Flows</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ib8da3572c2184cf591d7511966d9e9c1_25">4</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt;text-indent:-13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ib8da3572c2184cf591d7511966d9e9c1_28">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ib8da3572c2184cf591d7511966d9e9c1_28">5</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib8da3572c2184cf591d7511966d9e9c1_73">ITEM 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ib8da3572c2184cf591d7511966d9e9c1_73">27</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib8da3572c2184cf591d7511966d9e9c1_91">ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ib8da3572c2184cf591d7511966d9e9c1_91">35</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib8da3572c2184cf591d7511966d9e9c1_94">ITEM 4. CONTROLS AND PROCEDURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ib8da3572c2184cf591d7511966d9e9c1_94">35</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline" href="#ib8da3572c2184cf591d7511966d9e9c1_97">PART II &#8212; OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ib8da3572c2184cf591d7511966d9e9c1_97">36</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib8da3572c2184cf591d7511966d9e9c1_100">ITEM 1. LEGAL PROCEEDINGS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ib8da3572c2184cf591d7511966d9e9c1_100">36</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib8da3572c2184cf591d7511966d9e9c1_103">ITEM 1A. RISK FACTORS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ib8da3572c2184cf591d7511966d9e9c1_103">36</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib8da3572c2184cf591d7511966d9e9c1_106">ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ib8da3572c2184cf591d7511966d9e9c1_106">36</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib8da3572c2184cf591d7511966d9e9c1_109">ITEM 3. DEFAULTS UPON SENIOR SECURITIES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ib8da3572c2184cf591d7511966d9e9c1_109">36</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib8da3572c2184cf591d7511966d9e9c1_112">ITEM 4. MINE SAFETY DISCLOSURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ib8da3572c2184cf591d7511966d9e9c1_112">36</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib8da3572c2184cf591d7511966d9e9c1_115">ITEM 5. OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ib8da3572c2184cf591d7511966d9e9c1_115">36</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib8da3572c2184cf591d7511966d9e9c1_121">ITEM 6. EXHIBITS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ib8da3572c2184cf591d7511966d9e9c1_121">37</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib8da3572c2184cf591d7511966d9e9c1_124">SIGNATURE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ib8da3572c2184cf591d7511966d9e9c1_124">38</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ib8da3572c2184cf591d7511966d9e9c1_10"></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION </span></div><div id="ib8da3572c2184cf591d7511966d9e9c1_13"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS </span></div><div id="ib8da3572c2184cf591d7511966d9e9c1_16"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Arrowhead Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share amounts)</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.166%"><tr><td style="width:1.0%"/><td style="width:67.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.386%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.389%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">June 30, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-31">129,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-32">102,685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-33">9,699</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="3" id="f-34">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Available-for-sale securities, at fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-35">770,579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-36">578,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-37">23,692</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-38">9,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-39">13,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-40">4,973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-41">946,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-42">695,471</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-43">381,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-44">386,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-45">7,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-46">8,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-47">44,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-48">45,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-49">1,353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-50">4,482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">Total Assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-51">1,380,612</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-52">1,139,802</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">LIABILITIES, NONCONTROLLING INTEREST AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-53">33,050</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-54">11,388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-55">64,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-56">63,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Accrued payroll and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-57">19,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-58">21,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-59">7,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-60">6,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-61">22,979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="f-62">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Credit facility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LinesOfCreditCurrent" format="ixt:num-dot-decimal" scale="3" id="f-63">40,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LinesOfCreditCurrent" format="ixt:fixed-zero" scale="3" id="f-64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-65">7,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="f-66">432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-67">194,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-68">103,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Long-term liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-69">105,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-70">111,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Liability related to the sale of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="arwr:RoyaltiesLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-71">360,254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="arwr:RoyaltiesLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-72">341,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Credit facility, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermLineOfCredit" format="ixt:num-dot-decimal" scale="3" id="f-73">200,332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermLineOfCredit" format="ixt:num-dot-decimal" scale="3" id="f-74">393,183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Total long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-75">666,276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-76">845,571</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Commitments and contingencies (Note 7)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-3" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-77"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-78"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Noncontrolling interest and stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-79"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-80">0.001</ix:nonFraction></ix:nonFraction> par value:</span></div><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Authorized <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-81"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-82">290,000</ix:nonFraction></ix:nonFraction> shares; issued and outstanding <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-83"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-84">138,144</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-85"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-86">124,376</ix:nonFraction></ix:nonFraction> shares</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-87">230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-88">217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-89">2,120,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-90">1,806,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-91">5,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-92">4,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-93">1,603,404</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-94">1,625,523</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-95">522,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-96">185,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="f-97">2,507</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="f-98">5,619</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Total noncontrolling interest and stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-99">519,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-100">191,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">Total Liabilities, Noncontrolling Interest and Stockholders&#8217; Equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-101">1,380,612</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-102">1,139,802</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited consolidated financial statements. </span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="ib8da3572c2184cf591d7511966d9e9c1_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Arrowhead Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations and Comprehensive (Loss) Income</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited) </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.311%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.942%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.367%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.367%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.084%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.367%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.087%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">Nine Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-103">27,767</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-104">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-105">572,976</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-106">3,551</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="f-107">162,368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="f-108">152,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="f-109">432,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="f-110">370,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-111">30,949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-112">23,710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-113">86,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-114">72,384</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-115">193,317</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-116">176,141</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-117">518,736</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-118">442,428</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Operating (loss) income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-119">165,550</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-120">176,141</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-121">54,240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-122">438,877</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">Other (expense) income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InvestmentIncomeInterestAndDividend" format="ixt:num-dot-decimal" scale="3" id="f-123">11,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InvestmentIncomeInterestAndDividend" format="ixt:num-dot-decimal" scale="3" id="f-124">6,498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InvestmentIncomeInterestAndDividend" format="ixt:num-dot-decimal" scale="3" id="f-125">28,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InvestmentIncomeInterestAndDividend" format="ixt:num-dot-decimal" scale="3" id="f-126">15,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-127">24,382</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-128">5,094</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-129">67,667</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-130">17,705</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-131">176</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-132">760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-133">603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-134">1,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Total other (expense) income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-135">13,539</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-136">2,164</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-137">38,828</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="f-138">785</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#160;(Loss) income before income tax expense and noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-139">179,089</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-140">173,977</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-141">15,412</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-142">439,662</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Income tax (benefit) expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-143">437</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-144">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-145">1,419</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-146">3,313</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Net (loss) income including noncontrolling interest</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-147">178,652</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-148">173,977</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-149">13,993</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-150">436,349</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Net loss attributable to noncontrolling interest, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-151">3,411</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-152">3,184</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-153">8,126</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-154">7,392</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Net (loss) income attributable to Arrowhead Pharmaceuticals, Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-155">175,241</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-156">170,793</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-157">22,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-158">428,957</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Net (loss) income per share attributable to Arrowhead Pharmaceuticals, Inc.:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-159">1.26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-160">1.38</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-161">0.17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-162">3.63</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-163">1.26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-164">1.38</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-165">0.17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-166">3.63</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Weighted-average shares used in calculating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-167">139,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-168">124,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-169">132,385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-170">118,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-171">139,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-172">124,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-173">133,352</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-174">118,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Other comprehensive income (loss), net of tax:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Unrealized gains on available-for-sale securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-175">876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-176">249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-177">1,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-178">2,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-179">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-180">141</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-181">415</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-182">139</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Comprehensive (loss) income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-183">177,685</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-184">173,869</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-185">14,600</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-186">434,114</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited consolidated financial statements. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ib8da3572c2184cf591d7511966d9e9c1_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Arrowhead Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Stockholders&#8217; Equity </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.305%"><tr><td style="width:1.0%"/><td style="width:35.123%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.872%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.872%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.270%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.969%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.711%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.872%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.157%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:115%">Common</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:115%">Stock</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">Amount ($)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:115%">Additional</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:115%">Paid-In</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:115%">Capital</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:115%">Accumulated </span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:115%">Other </span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:115%">Comprehensive </span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:115%">Income</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:115%">Accumulated</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:115%">Deficit</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:115%">Non-<br/>controlling Interest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">Balance at September 30, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-187">124,376</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-188">217</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-189">1,806,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-190">4,750</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-191">1,625,523</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-192">5,619</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-193">191,063</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-194">15,209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-195">15,209</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">Exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-196">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-197">634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-198">634</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">Common stock - restricted stock units vesting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="3" id="f-199">209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">Issuance of pre-funded warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="3" id="f-200">25,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="3" id="f-201">25,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-202">106</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-203">106</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">Unrealized losses on available-for-sale securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-204">507</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-205">507</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-206">173,085</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-207">2,133</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-208">175,218</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">Balance at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-209">124,655</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-210">217</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-211">1,846,843</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-212">4,137</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-213">1,798,608</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-214">3,486</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-215">56,075</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-216">16,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-217">16,027</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">Exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-218">353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-219">2,619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-220">2,619</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">Common stock - restricted stock units vesting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="3" id="f-221">1,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="f-222">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="f-223">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">Common stock issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-224">11,926</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-225">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-226">241,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-227">241,387</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-228">400</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-229">400</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">Unrealized gains on available-for-sales securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-230">653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-231">653</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:120%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-232">370,445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-233">2,582</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-234">367,863</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">Balance at March 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-31" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-235">138,062</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-236">230</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-237">2,106,864</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-238">4,390</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-239">1,428,163</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-240">904</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-241">684,225</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-242">13,043</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-243">13,043</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">Exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-38" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-244">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-245">223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-246">223</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">Common stock - restricted stock units vesting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-38" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="3" id="f-247">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-248">91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-249">91</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">Unrealized gains on available-for-sales securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-250">876</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-251">876</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.22pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:120%">Net loss</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-252">175,241</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-253">3,411</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-254">178,652</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">Balance at June 30, 2025</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-42" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-255">138,144</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-256">230</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-257">2,120,130</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-258">5,357</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-259">1,603,404</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-260">2,507</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-261">519,806</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"/><td style="width:35.200%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.827%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.827%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.913%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.218%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.827%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.112%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:115%">Common</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:115%">Stock</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">Amount ($)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:115%">Additional</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:115%">Paid-In</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:115%">Capital</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:115%">Accumulated </span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:115%">Other </span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:115%">Comprehensive </span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:115%">Loss</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:115%">Accumulated</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:115%">Deficit</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:115%">Non-<br/>controlling Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">Balance at September 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-47" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-262">107,312</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-263">200</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-264">1,300,395</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-265">3,222</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-266">1,026,030</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-267">15,819</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-268">287,162</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-269">19,694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-270">19,694</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">Exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-55" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-271">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-272">267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-273">267</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">Common stock - restricted stock units vesting</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-55" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="3" id="f-274">154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-275">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-276">58</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">Unrealized gains on available-for-sale securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-277">1,909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-278">1,909</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-279">132,864</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-280">2,512</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-281">135,376</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">Balance at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-59" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-282">107,500</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-283">200</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-284">1,320,356</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-285">1,255</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-286">1,158,894</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-287">13,307</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-288">173,714</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-289">17,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-290">17,750</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">Exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-67" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-291">120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-292">1,512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-293">1,512</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">Common stock - restricted stock units vesting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-67" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="3" id="f-294">723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="f-295">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="f-296">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:fixed-zero" scale="3" id="f-297">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">Common stock issued, net of offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-67" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-298">15,790</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-299">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-300">429,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-301">429,265</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-302">56</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-303">56</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">Unrealized gains on available-for-sale securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-304">216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-305">216</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-306">125,300</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-307">1,696</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-308">126,996</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">Balance at March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-71" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-309">124,133</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-310">217</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-311">1,768,866</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-312">1,095</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-313">1,284,194</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-314">11,611</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-315">495,405</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-316">17,050</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-317">17,050</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">Exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-78" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-318">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-319">388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-320">388</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">Common stock - restricted stock units vesting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-78" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="3" id="f-321">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-322">141</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-323">141</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">Unrealized gains on available-for-sale securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-324">249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-325">249</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-326">170,793</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-327">3,184</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-328">173,977</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">Balance at June 30, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-82" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-329">124,227</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-330">217</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-331">1,786,304</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-332">987</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-333">1,454,987</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-334">8,427</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-335">338,974</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="ib8da3572c2184cf591d7511966d9e9c1_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Arrowhead Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Nine Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">CASH FLOWS FROM OPERATING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-336">13,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-337">436,349</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Adjustments to reconcile net income (loss) to net cash flow from operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-338">44,279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-339">54,494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 26.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-340">17,542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-341">13,570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(Accretion) amortization of note premiums/discounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" format="ixt:num-dot-decimal" scale="3" id="f-342">4,545</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" format="ixt:num-dot-decimal" scale="3" id="f-343">7,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 26.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Realized loss on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RealizedInvestmentGainsLosses" format="ixt:fixed-zero" scale="3" id="f-344">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RealizedInvestmentGainsLosses" scale="3" id="f-345">80</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Non-cash interest expense on liability related to the sale of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="f-346">18,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="f-347">17,705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 26.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Non-cash interest expense on credit facility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaidInKindInterest" format="ixt:num-dot-decimal" scale="3" id="f-348">48,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PaidInKindInterest" format="ixt:fixed-zero" scale="3" id="f-349">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 26.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-350">9,841</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:fixed-zero" scale="3" id="f-351">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-352">22,342</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-353">1,746</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 26.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-354">21,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-355">2,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-356">7,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-357">13,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 26.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-358">22,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="f-359">866</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Operating lease, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-360">3,417</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-361">3,880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 26.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" format="ixt:num-dot-decimal" scale="3" id="f-362">3,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" format="ixt:fixed-zero" scale="3" id="f-363">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 38.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Net cash provided by (used in) operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-364">159,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-365">325,635</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">CASH FLOWS FROM INVESTING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-366">15,177</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-367">117,180</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Purchases of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="f-368">774,616</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="f-369">428,611</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Proceeds from sales and maturities of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="f-370">587,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="f-371">348,642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 38.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-372">201,913</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-373">197,149</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">CASH FLOWS FROM FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Proceeds from the exercises of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-374">3,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-375">2,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Proceeds from the issuance of common stock, net of offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-376">429,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Proceeds from the sales of future royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="arwr:ProceedsFromSaleOfFutureRoyalties" format="ixt:fixed-zero" scale="3" id="f-377">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="arwr:ProceedsFromSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="f-378">50,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Proceeds from the issuance of warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfWarrants" format="ixt:num-dot-decimal" scale="3" id="f-379">25,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfWarrants" format="ixt:fixed-zero" scale="3" id="f-380">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Payments of debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-381">5,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:fixed-zero" scale="3" id="f-382">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Proceeds from the issuance of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-383">241,388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Repayments of credit facility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RepaymentsOfLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="f-384">201,625</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RepaymentsOfLinesOfCredit" format="ixt:fixed-zero" scale="3" id="f-385">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Proceeds from Visirna credit agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="f-386">7,098</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 14.5pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromLinesOfCredit" format="ixt:fixed-zero" scale="3" id="f-387">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 38.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-388">70,337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-389">481,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Net increase (decrease) in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-390">27,485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-391">41,353</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 2.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Effect of exchange rate on cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-392">377</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-393">139</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">CASH, CASH EQUIVALENTS AND RESTRICTED CASH:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">BEGINNING OF PERIOD</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-394">102,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-395">110,891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">END OF PERIOD</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-396">129,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-397">69,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 2.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">Supplementary disclosure of cash flows:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Interest paid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="f-398">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:fixed-zero" scale="3" id="f-399">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Income taxes paid</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="f-400">81</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-401">3,062</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Supplemental disclosure of non-cash investing activities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Capital expenditures included in accrued expenses</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-402">346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="f-403">6,909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="ib8da3572c2184cf591d7511966d9e9c1_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Arrowhead Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div id="ib8da3572c2184cf591d7511966d9e9c1_31"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1. <ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="f-404" continuedAt="f-404-1" escape="true">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="f-404-1" continuedAt="f-404-2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Recent Developments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Arrowhead Pharmaceuticals, Inc. and its subsidiaries (referred to herein collectively as the &#8220;Company&#8221;) are primarily engaged in developing medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, the Company&#8217;s therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference (&#8220;RNAi&#8221;) is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. The Company&#8217;s RNAi-based therapeutics may leverage this natural pathway of gene silencing to target and shut down specific disease-causing genes. </span></div><ix:nonNumeric contextRef="c-1" name="arwr:ScheduleOfCurrentProductsTableTextBlock" id="f-405" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s current pipeline:</span><span style="color:#ee2724;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:28.035%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Therapeutic Area</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Name</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Stage</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Product Rights</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Cardiometabolic</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">plozasiran</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Phase 3</span></div></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">zodasiran</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Phase 3</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">olpasiran</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Phase 3</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Amgen</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">ARO-PNPLA3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">GSK-4532990</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Phase 2b</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">GSK</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">ARO-INHBE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">ARO-ALK7</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Pulmonary</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">ARO-RAGE</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></div></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">SRP-1002 (ARO-MMP7)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Sarepta</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Liver</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">fazirsiran</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Phase 3</span></div></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Takeda and Arrowhead</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">GSK5637608</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Phase 2</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">GSK</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Neuromuscular</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">SRP-1001 (ARO-DUX4)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Sarepta</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">SRP-1003 (ARO-DM1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Sarepta</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Central Nervous System (CNS)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">SRP-1004 (ARO-ATXN2)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Sarepta</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Other</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">ARO-C3</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">ARO-CFB</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates lab facilities in California and Wisconsin, where its research and development activities, including the development of RNAi therapeutics, take place. The Company also operates an active pharmaceutical ingredient manufacturing and supporting laboratory facility in Verona, Wisconsin. The Company&#8217;s principal executive offices are located in Pasadena, California.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the first three quarters of fiscal 2025, the Company has continued to develop and advance its pipeline and partnered candidates. The following is a summary of select significant developments affecting our business that have occurred since the filing of our Annual Report on Form 10-K for the fiscal year ended September 30, 2024:  </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Triggered a $<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="arwr:DevelopmentMilestonePayments" scale="6" id="f-406">100.0</ix:nonFraction> million milestone payment from Sarepta Therapeutics, Inc., which was triggered on July 27, 2025, when the Company reached the first of two prespecified enrollment targets and subsequent authorization to dose escalate in a Phase 1/2 clinical study of ARO-DM1, an investigational RNAi therapeutic for the treatment of type 1 myotonic dystrophy (DM1);</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Announced the signing of an asset purchase agreement between Sanofi and Visirna Therapeutics, a majority-owned subsidiary of the Company, created to develop and commercialize four of the Company&#8217;s investigational cardiometabolic candidates in Greater China. Under the terms of the agreement, Sanofi will acquire rights to develop and commercialize investigational plozasiran, the Company's first-in-class RNAi therapeutic candidate designed to reduce production of apolipoprotein C-III (APOC3) as a potential treatment for familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia (SHTG), in Greater China;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Initiated and dosed the first subject in the YOSEMITE Phase 3 clinical trial of zodasiran, the Company&#8217;s investigational RNAi therapeutic being developed as a potential treatment for homozygous familial </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-404-2" continuedAt="f-404-3"><div style="margin-top:6pt;padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">hypercholesterolemia (HoFH), a rare genetic condition that leads to severely elevated LDL-cholesterol and early onset cardiovascular disease; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10pt">Completed enrollment of SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 clinical trials of plozasiran. The Company&#8217;s global Phase 3 clinical studies are designed to support regulatory submissions for approval of investigational plozasiran in the treatment of severe hypertriglyceridemia. The Company previously submitted a New Drug Application to the U.S. Food and Drug Administration (&#8220;FDA&#8221;) on November 16, 2024 for plozasiran based on positive Phase 3 PALISADE study results in patients with familial chylomicronemia syndrome, which the FDA accepted on January 17, 2025, with a Prescription Drug User Fee Act (PDUFA) action date of November 18, 2025, and indicated it is not currently planning to hold an advisory committee meeting;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Initiated a Phase 1/2a clinical trial of ARO-ALK7 for the treatment of obesity. ARO-ALK7 is the first RNAi-based therapy designed to silence adipocyte expression of  the </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ACVR1C </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">gene to reduce the production of Activin receptor-like kinase 7 (ALK7), which acts as a receptor in a pathway that regulates energy homeostasis in adipose tissue;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Announced Topline results from Part 2 of a Phase 1/2 clinical study of ARO-C3, the Company&#8217;s investigational RNAi therapeutic designed to reduce liver production of complement component 3 (C3) as a potential therapy for various complement mediated diseases. ARO-C3 achieved reductions in alternative pathway complement activity and proteinuria;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Entered into a global licensing and collaboration agreement with Sarepta Therapeutics, Inc (&#8220;Sarepta&#8221;) on November 25, 2024, which closed on February 7, 2025. Closing of the transaction was subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary conditions. Upon closing, the Company received $<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-407">325.0</ix:nonFraction> million through the purchase of <ix:nonFraction unitRef="shares" contextRef="c-89" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-408">11,926,301</ix:nonFraction> shares of Company common stock by Sarepta, at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-90" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-409">27.25</ix:nonFraction>, and received $<ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-5" name="arwr:ProceedsFromCollaborationArrangements" scale="6" id="f-410">500.0</ix:nonFraction> million as an upfront payment on February 24, 2025. The Company will also receive $<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="arwr:AdditionalCashReceivableUnderCollaborationAgreement" scale="6" id="f-411">250.0</ix:nonFraction> million to be paid in equal installments over <ix:nonNumeric contextRef="c-89" name="arwr:CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod" format="ixt-sec:durwordsen" id="f-412">five years</ix:nonNumeric> and is eligible to receive an additional $<ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-5" name="arwr:EnrollmentRelatedMilestonePayments" scale="6" id="f-413">300.0</ix:nonFraction> million in near-term payments. Additionally, the Company is eligible to receive royalties on commercial sales and up to approximately $<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-8" name="arwr:FuturePotentialMilestonePayments" scale="9" id="f-414">10.0</ix:nonFraction> billion in future potential milestone payments;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">GSK dosed its fifth patient in a Phase 2 trial in December 2024, triggering a $<ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-5" name="arwr:DevelopmentMilestonePayments" scale="6" id="f-415">2.5</ix:nonFraction> million milestone payment to the Company which was paid in the second quarter of fiscal 2025;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.7pt">Announced that the Company dosed the first subjects in a Phase 1/2a clinical trial of ARO-INHBE; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Presented interim results from a Phase 1/2a clinical study of ARO-CFB at the 8th Complement-Based Drug Development Summit. The study resulted in multiple findings including: (1) ARO-CFB led to dose dependent reductions in circulating CFB protein by up to 90% with greater than 3 months duration, (2) single and multiple doses of ARO-CFB led to near complete inhibition of alternative pathway activity based on Wieslab AP, and (3) single and multiple doses of ARO-CFB led to near complete inhibition of alternative pathway hemolytic activity, measured by AH50.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation and Basis of Presentation </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The interim Consolidated Financial Statements include the accounts of Arrowhead Pharmaceuticals, Inc. and its subsidiaries (wholly-owned subsidiaries and a variable interest entity for which the Company is the primary beneficiary). Subsidiaries refer to Arrowhead Madison, Inc., Arrowhead Australia Pty Ltd., Arrowhead Pharmaceuticals Ireland Limited, Arrowhead Pharmaceuticals NZ Limited and Visirna Therapeutics, Inc. (&#8220;Visirna&#8221;). For subsidiaries in which the Company owns or is exposed to less than 100% of the economics, the Company records net loss attributable to noncontrolling interests in its consolidated statements of operations equal to the percentage of the economic or ownership interests retained in such entity by the respective noncontrolling party.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The interim Consolidated Financial Statements have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). The financial data of the Company included herein are unaudited. In the opinion of management, all material adjustments of a normal recurring nature have been made to present fairly the Company&#8217;s financial position as of June&#160;30, 2025 and the results of operations and cash flows for the periods presented. All intercompany transactions and balances have been eliminated. Certain prior period amounts have been reclassified to conform with the current period presentation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certain financial information that is normally included in annual financial statements prepared in accordance with GAAP, but that is not required for interim reporting purposes, has been omitted from the accompanying interim consolidated financial statements and related notes. Readers are urged to review the Company&#8217;s Annual Report on Form </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-404-3" continuedAt="f-404-4"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10-K for the fiscal year ended September&#160;30, 2024 for more complete descriptions and discussions. Operating results and cash flows for the nine months ended June&#160;30, 2025 are not necessarily indicative of the results that may be expected for the fiscal year ending September&#160;30, 2025.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s primary sources of financing have been through the sale of its equity securities, credit facility, revenue from its licensing and collaboration agreements and the sale of certain future royalties. Research and development activities have required significant investment since the Company&#8217;s inception and are expected to continue to require significant cash expenditure in the future, particularly as the Company&#8217;s pipeline of drug candidates and its headcount have both expanded. Additionally, significant investment will be required as the Company&#8217;s pipeline matures into later stage clinical trials and commercialization efforts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, the Company had $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-416">129.8</ix:nonFraction> million in cash, cash equivalents and restricted cash ($<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="6" id="f-417">2.2</ix:nonFraction> million in restricted cash) and $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-418">770.6</ix:nonFraction> million in available-for-sale securities to fund operations. During the nine months ended June&#160;30, 2025, the Company&#8217;s cash, cash equivalents and restricted cash and investments balance increased by</span><span style="color:#ee2724;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="arwr:IncreaseDecreaseInCashAndInvestments" scale="6" id="f-419">219.4</ix:nonFraction> million, which was primarily due to the $<ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-5" name="arwr:ProceedsFromCollaborationArrangements" scale="6" id="f-420">500.0</ix:nonFraction> million as an upfront payment under the Sarepta agreement and $<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-421">325.0</ix:nonFraction> million in the form of an equity investment under the Sarepta agreement, and $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="6" id="f-422">25.0</ix:nonFraction> million in the form of pre-funded warrants, partially offset by ongoing expenses related to the Company&#8217;s research and development programs, $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:RepaymentsOfLinesOfCredit" scale="6" id="f-423">201.6</ix:nonFraction> million payments on its credit facility, and $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="6" id="f-424">28.2</ix:nonFraction> million interest income earned on investments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In total, the Company is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-8" name="arwr:DevelopmentRegulatoryAndSalesMilestonesPayments" scale="9" id="f-425">13.3</ix:nonFraction> billion in additional developmental, regulatory and sales milestones, and may receive various royalties on net sales from its licensing and collaboration agreements, subject to the terms and conditions of those agreements. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Significant Accounting Policies </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes to the significant accounting policies disclosed in the Company&#8217;s most recent Annual Report on Form 10-K for the fiscal year ended September&#160;30, 2024.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-426" continuedAt="f-426-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In January 2025, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standard Update (&#8220;ASU&#8221;) 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">in November 2024, and ASU 2025-01,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Clarifying the Effective Date</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. These updates require entities to provide disaggregated disclosures of income statement expenses. The ASUs do not affect the expense captions presented on the face of the income statement but instead require the disaggregation of certain expense captions into specified categories within the footnotes to the financial statements. The ASUs will become effective for the Company beginning October 1, 2027, and the Company is currently evaluating the impact on its consolidated financial statements and related disclosures.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, to improve its income tax disclosure requirements. Under the guidance, entities must annually (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold. This ASU will become effective for the Company beginning October 1, 2025, and is not expected to have a material impact on its consolidated financial statements and related disclosures.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, which is intended to improve reportable segment disclosure requirements, primarily through additional disclosures about significant segment expenses. This ASU requires public companies with a single reportable segment to provide all disclosures required under ASC 280. In addition, this ASU requires public companies to include in interim reports all disclosures related to a reportable segment&#8217;s profit or loss and assets that are currently required in annual reports. While the ASU implements further segment disclosure requirements, it does not change how an entity identifies its operating or reportable segments and it will have no impact on the Company&#8217;s consolidated financial condition, results of operations or cash flows. The Company plans to adopt the ASU's in connection with our Annual Report on Form 10-K for the fiscal year ending September 30, 2025, as required and will be applied retrospectively to all periods presented. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On July 4, 2025, the One Big Beautiful Bill Act (&#8220;OBBBA&#8221;) was signed into law, which enacts significant changes to U.S. tax and related laws. Some of the provisions of the new tax law affecting corporations include but are not limited to expensing of domestic research expenses, reinstate the limit of the deduction of interest expense to thirty percent of EBITDA, and one hundred percent bonus depreciation on eligible property acquired after January 19, 2025. The Company is currently evaluating the impact the new tax law will have on its financial condition and results of operations.  </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-426-1"><ix:continuation id="f-404-4">Preliminarily, the Company does not anticipate a material change to its effective income tax rate and its net deferred federal income tax assets as the Company maintains a full valuation allowance.</ix:continuation></ix:continuation> </span></div><div id="ib8da3572c2184cf591d7511966d9e9c1_34"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2. <ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="f-427" continuedAt="f-427-1" escape="true">COLLABORATION AND LICENSE AGREEMENTS</ix:nonNumeric></span></div><ix:continuation id="f-427-1" continuedAt="f-427-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="f-428" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of revenue recognized:</span></div><div style="margin-top:6pt;text-align:center;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.878%"><tr><td style="width:1.0%"/><td style="width:27.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.166%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.166%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.775%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">GSK</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-429">143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-430">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-431">2,646</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-432">2,685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Takeda</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-433">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-434">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-435">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-436">866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Sarepta</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-437">27,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-438">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-439">570,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-440">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-441">27,767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-442">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-443">572,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-444">3,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="f-445" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balance of receivables and contract liabilities related to the Company&#8217;s collaboration and license agreements:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.787%"><tr><td style="width:1.0%"/><td style="width:61.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.153%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">June 30, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Receivables included in accounts receivable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsReceivableNet" format="ixt:num-dot-decimal" scale="3" id="f-446">9,699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsReceivableNet" format="ixt:fixed-zero" scale="3" id="f-447">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Contract liabilities included in deferred revenue</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-448">22,979</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:fixed-zero" scale="3" id="f-449">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GlaxoSmithKline Intellectual Property (No. 3) Limited (&#8220;GSK&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">GSK-HSD License Agreement</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On November 22, 2021, GSK and the Company entered into an Exclusive License Agreement (the &#8220;GSK-HSD License Agreement&#8221;). Under the GSK-HSD License Agreement, GSK has received an exclusive license for GSK-4532990 (formerly ARO-HSD). The exclusive license is worldwide with the exception of greater China. GSK is wholly responsible for all clinical development and commercialization of GSK-4532990 in its territory. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has completed its performance obligation related to this agreement, and the upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-5" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="f-450">120.0</ix:nonFraction>&#160;million was fully recognized in the year ended September 30, 2022. Further, GSK dosed the first patient in a Phase 2b trial in March 2023 and paid a $<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-5" name="arwr:MilestonePaymentReceivable" format="ixt:num-dot-decimal" scale="6" id="f-451">30.0</ix:nonFraction>&#160;million milestone payment to the Company in the third quarter of fiscal 2023. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is eligible for an additional payment of $<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-5" name="arwr:MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" format="ixt:num-dot-decimal" scale="6" id="f-452">100.0</ix:nonFraction>&#160;million upon achieving the first patient dosed in a Phase 3 trial. Furthermore, should the Phase 3 trial read out positively, and the potential new medicine receives regulatory approval in major markets, the deal provides for commercial milestone payments to the Company of up to $<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-5" name="arwr:CommercialMilestonePaymentsAtFirstCommercialSale" format="ixt:num-dot-decimal" scale="6" id="f-453">190.0</ix:nonFraction>&#160;million at first commercial sale, and up to $<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-5" name="arwr:SalesRelatedMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-454">590.0</ix:nonFraction>&#160;million in sales-related milestone payments. The Company is further eligible to receive tiered royalties on net product sales in a range of mid-teens to twenty percent. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">GSK-HBV Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On December 11, 2023, the Company entered into an Amended and Restated License Agreement with GSK (the &#8220;GSK-HBV Agreement&#8221;) pursuant to which GSK received a worldwide, exclusive license to develop and commercialize daplusiran/tomligisiran (GSK5637608, formerly JNJ-3989), the Company&#8217;s third-generation subcutaneously administered RNAi therapeutic candidate being developed as a potential therapy for patients with chronic hepatitis B virus infection. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the GSK-HBV Agreement, the Company received $<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-5" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="f-455">2.7</ix:nonFraction>&#160;million in December 2023, upon signing the amended GSK-HBV Agreement. Further, GSK dosed the fifth patient in a Phase 2 trial in December 2024, triggering a $<ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-5" name="arwr:DevelopmentMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-456">2.5</ix:nonFraction>&#160;million milestone payment to the Company which was paid in the second quarter of fiscal 2025. The Company is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-5" name="arwr:DevelopmentAndSalesMilestonesPayments" format="ixt:num-dot-decimal" scale="6" id="f-457">830.0</ix:nonFraction>&#160;million in development and sales milestone payments under the GSK-HBV Agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, the Company had <ix:nonFraction unitRef="usd" contextRef="c-111" decimals="INF" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:fixed-zero" scale="0" id="f-458"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="INF" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="0" id="f-459">no</ix:nonFraction></ix:nonFraction> contract assets and liabilities recorded.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, Takeda and the Company entered into an Exclusive License and Co-Funding Agreement (the &#8220;Takeda License Agreement&#8221;). Under the Takeda License Agreement, Takeda and the Company will co-develop the Company&#8217;s fazirsiran program (formerly TAK-999 and ARO-AAT), the Company&#8217;s second-generation subcutaneously administered RNAi therapeutic candidate being developed as a treatment for liver disease associated with alpha-1 antitrypsin deficiency. Within the United States, fazirsiran, if approved, will be co-commercialized under a </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">50/50 profit </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-427-2" continuedAt="f-427-3"><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">sharing</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> structure. Outside the United States, Takeda received an exclusive license to commercialize fazirsiran and will lead the global commercialization strategy, while the Company will be eligible to receive tiered royalties of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-112" decimals="2" name="arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" scale="-2" id="f-460">20</ix:nonFraction>%</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-113" decimals="2" name="arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" scale="-2" id="f-461">25</ix:nonFraction>%</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> on net sales. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the key deliverables included the license and certain research and development services including the Company&#8217;s responsibilities to complete the initial portion of the SEQUOIA study, to complete the ongoing Phase 2 AROAAT2002 study, and to ensure certain manufacturing of fazirsiran drug product is completed and delivered to Takeda (the &#8220;Takeda R&amp;D Services&#8221;). Due to the specialized and unique nature of these Takeda R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represent <ix:nonFraction unitRef="bundle" contextRef="c-114" decimals="INF" name="arwr:NumberOfDistinctBundle" format="ixt-sec:numwordsen" scale="0" id="f-462">one</ix:nonFraction> distinct bundle and, thus, <ix:nonFraction unitRef="bundle" contextRef="c-114" decimals="INF" name="arwr:NumberOfDistinctBundle" format="ixt-sec:numwordsen" scale="0" id="f-463">one</ix:nonFraction> performance obligation. Takeda is responsible for managing clinical development and commercialization outside the United States. Within the United States, the Company and Takeda are responsible in the co-development and co-commercialization efforts. The Company considers the collaborative activities, including the co-development and co-commercialization, to be a separate unit of account within Topic 808, and as such, these co-funding amounts are recorded as research and development expenses or general and administrative expenses, as appropriate. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Takeda License Agreement, the Company received $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-5" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="f-464">300.0</ix:nonFraction>&#160;million as an upfront payment in January 2021 and an additional $<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="arwr:MilestonePaymentEarned" format="ixt:num-dot-decimal" scale="6" id="f-465">40.0</ix:nonFraction>&#160;million upon Takeda&#8217;s initiation of a Phase 3 REDWOOD clinical study of fazirsiran in March 2023, and is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="arwr:DevelopmentRegulatoryAndSalesMilestonesPayments" format="ixt:num-dot-decimal" scale="6" id="f-466">527.5</ix:nonFraction>&#160;million in additional potential development, regulatory and commercial milestones. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocated the total $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-5" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="f-467">300.0</ix:nonFraction>&#160;million initial transaction price to its <ix:nonFraction unitRef="bundle" contextRef="c-114" decimals="INF" name="arwr:NumberOfDistinctBundle" format="ixt-sec:numwordsen" scale="0" id="f-468">one</ix:nonFraction> distinct performance obligation for the fazirsiran license and the associated Takeda R&amp;D Services. The Company has substantially completed its performance obligation under the Takeda License Agreement by December 31, 2023. As such, all revenue has been fully recognized as of December 31, 2023. There were <ix:nonFraction unitRef="usd" contextRef="c-118" decimals="INF" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt-sec:numwordsen" scale="0" id="f-469">no</ix:nonFraction> further deferred revenue and contract liabilities as of June&#160;30, 2025.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-470">24.6</ix:nonFraction>&#160;million as accrued expenses as of June&#160;30, 2025 that was primarily driven by co-development and co-commercialization activities.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Janssen Pharmaceuticals, Inc. (&#8220;Janssen&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On April 7, 2023, Janssen voluntarily terminated its collaboration agreement with the Company and the Company regained full rights to ARO-PNPLA3, formerly called JNJ-75220795. There are no currently active trials for ARO-PNPLA3.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Further, on December 11, 2023, the Company entered into the GSK-HBV Agreement, as discussed above, pursuant to which GSK received an exclusive license for JNJ-3989 (formerly ARO-HBV). JNJ-3989 had previously been licensed to Janssen in October 2018.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Amgen Inc. (&#8220;Amgen&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In September 2016, Amgen and the Company entered into <ix:nonFraction unitRef="agreement" contextRef="c-119" decimals="INF" name="arwr:NumberOfAgreements" format="ixt-sec:numwordsen" scale="0" id="f-471">two</ix:nonFraction> collaboration and license agreements and a common stock purchase agreement. Under the Second Collaboration and License Agreement (the &#8220;Olpasiran Agreement&#8221;), Amgen received a worldwide, exclusive license to the Company&#8217;s novel RNAi olpasiran (previously referred to as AMG- 890 or ARO-LPA) program. These RNAi molecules are designed to reduce elevated lipoprotein(a), which is a genetically validated, independent risk factor for atherosclerotic cardiovascular disease. Under the Olpasiran Agreement, Amgen is wholly responsible for clinical development and commercialization.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has substantially completed its performance obligations under the Olpasiran Agreement. There were <ix:nonFraction unitRef="usd" contextRef="c-120" decimals="INF" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:fixed-zero" scale="0" id="f-472"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="INF" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="0" id="f-473">no</ix:nonFraction></ix:nonFraction> contract assets and liabilities recorded as of June&#160;30, 2025. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, Royalty Pharma Investments 2019 ICAV (&#8220;Royalty Pharma&#8221;) and the Company entered into a Royalty Purchase Agreement with Royalty Pharma (the &#8220;Royalty Pharma Agreement&#8221;). In consideration for the payments under the Royalty Pharma Agreement, Royalty Pharma is entitled to receive all royalties otherwise payable by Amgen to the Company under the Olpasiran Agreement. The Company remains eligible to receive up to an additional $<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-5" name="arwr:AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" format="ixt:num-dot-decimal" scale="6" id="f-474">485.0</ix:nonFraction>&#160;million in remaining development, regulatory and sales milestone payments payable from Amgen and Royalty Pharma. See Note 11.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Sarepta Therapeutics, Inc. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On November 25, 2024, the Company entered into an Exclusive License and Collaboration Agreement (the &#8220;Sarepta Collaboration Agreement&#8221;) with Sarepta for the development and commercialization of multiple clinical and preclinical programs in rare, genetic diseases of the muscle, central nervous system, and lungs. The Company concurrently entered into a Stock Purchase Agreement (the &#8220;Stock Purchase Agreement&#8221;) with Sarepta (see Note 6). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the Sarepta Collaboration Agreement, Sarepta received an exclusive sublicensable worldwide license to </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-427-3" continuedAt="f-427-4"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">SRP-1001 (formerly ARO-DUX4), SRP-1003 (formerly ARO-DM1), SRP-1002 (formerly ARO-MMP7), and SRP-1004 (formerly ARO-ATXN2) clinical stage programs (the &#8220;C1&#8221; programs). Sarepta also received an exclusive sublicensable worldwide license to the Company&#8217;s ARO-HTT, ARO-ATXN1, and ARO-ATXN3 preclinical stage programs (the &#8220;C2&#8221; programs). The Company will perform certain research and development activities for the C1 and C2 programs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Further, Sarepta may select up to <ix:nonFraction unitRef="program" contextRef="c-122" decimals="INF" name="arwr:NumberOfNewTargetPrograms" format="ixt-sec:numwordsen" scale="0" id="f-475">six</ix:nonFraction> gene targets for which the Company will perform discovery, optimization and preclinical development activities to identify RNAi compounds against each selected target (the &#8220;C3&#8221; programs). Upon target acceptance, Sarepta will receive an exclusive license to the Company&#8217;s intellectual property rights to exploit compounds directed to those targets and is wholly responsible for clinical development and commercialization of each compound after the Company delivers a Clinical Trial Application ready data package (the "CTA package").</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company identified <ix:nonFraction unitRef="obligation" contextRef="c-123" decimals="INF" name="arwr:NumberOfPerformanceObligations" scale="0" id="f-476">17</ix:nonFraction> performance obligations under the Sarepta Collaboration Agreement. The four C1 licenses are distinct performance obligations from the four C1 research and development performance obligations since the customer can use and benefit from the licenses separately. The performance obligations for the licenses were satisfied in the second quarter of fiscal 2025 upon delivery, and the research and development performance obligations will be satisfied as the work is performed. The remaining nine performance obligations include three C2 preclinical stage program licenses and research and development activities, and six C3 unidentified discovery target licenses and research and development activity. Each of the three C2 programs and the six C3 programs were determined to represent one performance obligation, as the customer cannot benefit from the use of the product license at the point of transfer until the specified research and development activities are performed. As such, each of the C2 and C3 product licenses and respective research and development work will be combined to form one performance obligation. For these nine performance obligations, revenue is recognized over time as the work is performed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For performance obligations recognized over time, the estimated performance period over which revenue will be recognized is determined to be the period over which the Company estimates it will perform the research and development activities. The Company determined that the most appropriate method of measuring progress for these performance obligations is an input method based on research and development costs in the program budget. Accordingly, the Company has estimated the total cost required to complete its obligation and recognized an amount of revenue equal to the proportion of services performed, which is reassessed on an ongoing basis as the program progresses. In the period an agreement expires or is terminated, remaining deferred revenue, if any, is recognized as revenue.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Sarepta Collaboration Agreement, the Company received an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-5" name="arwr:ProceedsFromCollaborationArrangements" format="ixt:num-dot-decimal" scale="6" id="f-477">500.0</ix:nonFraction>&#160;million on February 14, 2025. In addition, on February 7, 2025, the Company received $<ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-478">325.0</ix:nonFraction>&#160;million in the form of an equity investment under the Stock Purchase Agreement. Based upon the Company's share price on February 7, 2025, (the &#8220;Closing Date&#8221;), the difference between the $<ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-479">325.0</ix:nonFraction>&#160;million and the fair value of the shares on the Closing date resulted in a premium of $<ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-5" name="arwr:SaleOfStockPremiumOnIssuanceOfShares" format="ixt:num-dot-decimal" scale="6" id="f-480">83.6</ix:nonFraction>&#160;million. The premium is included as part of the total consideration of the Sarepta Collaboration Agreement for revenue recognition purposes. The Company is entitled to receive $<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-5" name="arwr:AdditionalCashReceivableUnderCollaborationAgreement" format="ixt:num-dot-decimal" scale="6" id="f-481">250.0</ix:nonFraction>&#160;million to be paid in annual installments of $<ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-5" name="arwr:CashReceivableUnderCollaborationAgreementAnnualInstallments" format="ixt:num-dot-decimal" scale="6" id="f-482">50.0</ix:nonFraction>&#160;million over the first <ix:nonNumeric contextRef="c-126" name="arwr:CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod" format="ixt-sec:durwordsen" id="f-483">five years</ix:nonNumeric> of the agreement. The Company is also eligible receive reimbursement of certain costs related to carrying out the research and development activities for the C1 programs. The fixed consideration of $<ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-5" name="arwr:CollaborationArrangementFixedConsideration" format="ixt:num-dot-decimal" scale="6" id="f-484">833.6</ix:nonFraction>&#160;million and an estimated variable consideration of $<ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-5" name="arwr:CollaborationArrangementVariableConsideration" format="ixt:num-dot-decimal" scale="6" id="f-485">71.2</ix:nonFraction>&#160;million were allocated to all performance obligations based on their relative standalone selling price. Standalone selling prices for the product licenses were determined using an adjusted market-based approach through the net present value of the expected future cash flows for each program. The standalone selling prices for the research and development work were determined based on an expected cost plus margin approach. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="f-486" continuedAt="f-486-1" escape="true">The fixed and estimated variable consideration of $<ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-5" name="arwr:CollaborationArrangementConsideration" format="ixt:num-dot-decimal" scale="6" id="f-487">904.9</ix:nonFraction>&#160;million was allocated in accordance to the following table:</ix:nonNumeric></span></div><ix:continuation id="f-486-1"><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:48.939%"><tr><td style="width:1.0%"/><td style="width:57.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.696%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">June 30, 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Upfront payment</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-3" name="arwr:ProceedsFromCollaborationArrangements" format="ixt:num-dot-decimal" scale="3" id="f-488">500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Annual fees</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-3" name="arwr:AdditionalCashReceivableUnderCollaborationAgreement" format="ixt:num-dot-decimal" scale="3" id="f-489">250,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Equity premium</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-3" name="arwr:SaleOfStockPremiumOnIssuanceOfShares" format="ixt:num-dot-decimal" scale="3" id="f-490">83,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Fixed consideration</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-3" name="arwr:CollaborationArrangementFixedConsideration" format="ixt:num-dot-decimal" scale="3" id="f-491">833,612</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Estimated variable consideration</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-3" name="arwr:CollaborationArrangementVariableConsideration" format="ixt:num-dot-decimal" scale="3" id="f-492">71,243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Total transaction price</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-3" name="arwr:CollaborationArrangementConsideration" format="ixt:num-dot-decimal" scale="3" id="f-493">904,855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the stand-alone selling price for each distinct performance obligation, which involves assumptions that may require significant judgment. The Company&#8217;s estimates of the stand-alone selling price for license-related performance obligations includes forecasted revenues and expenses, phase dates, probability of success, development timelines, and the discount rate. The estimates of the stand-alone selling price for research and development </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-427-4"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">or other service-related performance obligations generally include forecasting the expected costs of satisfying a performance obligation at market rates. The Company identified a discount based on the difference between the aggregate stand-alone selling price and the transaction price for accounting revenue recognition purposes. The Company allocated the discount proportionally to each of the performance obligations based upon their standalone selling price. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company receives reimbursement of certain costs related to carrying out the research and development activities for the C1 programs and may receive development milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-5" name="arwr:EnrollmentRelatedMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-494">300.0</ix:nonFraction>&#160;million</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Further, for each of the <ix:nonFraction unitRef="program" contextRef="c-123" decimals="INF" name="arwr:NumberOfCollaborationPrograms" scale="0" id="f-495">13</ix:nonFraction> programs, the Company is eligible to receive regulatory milestone payments between $<ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-5" name="arwr:RegulatoryMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-496">110.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-5" name="arwr:RegulatoryMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-497">180.0</ix:nonFraction>&#160;million per program. Variable consideration associated with the milestones that may be achieved will be allocated to the performance obligation to which it is determined to be related, which will be the respective development work that is being reimbursed and the respective programs to which the milestones relate. ARO-DM1 development milestones were allocated between the license and development work based on the allocation of the standalone selling price. The Company will recognize the ARO-DM1 development milestones and other development milestones as revenue in the periods the underlying milestone events are achieved as achievement of the milestone events are highly susceptible to factors outside of the entity's influence and therefore there is a possibility that the milestone event will not be achieved.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also eligible to receive sales milestone payments between $<ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-5" name="arwr:SalesRelatedMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-498">500.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-5" name="arwr:SalesRelatedMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-499">700.0</ix:nonFraction>&#160;million per program as well as tiered royalties on net sales of licensed products of up to the low double digits, subject to the terms and conditions of the Sarepta Collaboration Agreement. The Company has applied the sales-based scope exception to the sales milestones and the royalty-based payments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Sarepta Collaboration Agreement commenced in February 2025 and may be terminated by either party in the event of a material breach as defined therein. In addition, Sarepta may voluntarily terminate the Sarepta Collaboration Agreement with <ix:nonNumeric contextRef="c-123" name="arwr:CollaborationArrangementTerminationNoticePeriodPriorToRegulatoryApproval" format="ixt-sec:durday" id="f-500">30</ix:nonNumeric> days' written notice to the Company if terminated prior to any regulatory approval of a licensed product. Unless earlier terminated, the Sarepta Collaboration Agreement expires on a product-by-product and country-by-country basis, upon the date of expiration of the relevant royalty term for such product in such country.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-501">570.3</ix:nonFraction>&#160;million in revenue from Sarepta, $<ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-502">9.7</ix:nonFraction>&#160;million in accounts receivable and $<ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-503">23.0</ix:nonFraction>&#160;million in deferred revenue. The recognition of the remaining revenue for the performance obligations is dependent upon the time it takes to complete the respective research and development activities and in consideration of the timing of the selection of the C3 programs.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="ib8da3572c2184cf591d7511966d9e9c1_37"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 3. <ix:nonNumeric contextRef="c-1" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="f-504" continuedAt="f-504-1" escape="true">BALANCE SHEET ACCOUNTS</ix:nonNumeric></span></div><ix:continuation id="f-504-1"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-505" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s major classes of property, plant and equipment:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">June 30, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Land</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-506">2,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-507">2,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Buildings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-508">249,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-509">75,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Research equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-510">59,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-511">65,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Manufacturing equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-512">16,548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:fixed-zero" scale="3" id="f-513">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Furniture</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-514">5,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-515">5,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Computers and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-516">1,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-517">981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-518">104,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-519">104,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-520">15,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-521">188,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-522">455,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-523">444,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-524">74,230</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-525">58,021</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Property, plant and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-526">381,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-527">386,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense for property, plant and equipment for the three months ended June&#160;30, 2025 and 2024 was $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-528">5.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-529">4.4</ix:nonFraction>&#160;million, respectively. Depreciation and amortization expense for property, plant and equipment for the nine months ended June&#160;30, 2025 and 2024 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-530">16.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-531">12.3</ix:nonFraction>&#160;million, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of fiscal 2025, the Company substantially completed the build out of its manufacturing facility in Verona, Wisconsin, leading to the reclassification of $<ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentTransfersAndChanges" format="ixt:num-dot-decimal" scale="6" id="f-532"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-5" sign="-" name="us-gaap:PropertyPlantAndEquipmentTransfersAndChanges" format="ixt:num-dot-decimal" scale="6" id="f-533">162.7</ix:nonFraction></ix:nonFraction>&#160;million from construction in progress to buildings and $<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentTransfersAndChanges" format="ixt:num-dot-decimal" scale="6" id="f-534"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-5" sign="-" name="us-gaap:PropertyPlantAndEquipmentTransfersAndChanges" format="ixt:num-dot-decimal" scale="6" id="f-535">2.6</ix:nonFraction></ix:nonFraction>&#160;million from construction in progress to manufacturing equipment. The Company subsequently incurred and capitalized $<ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-5" sign="-" name="us-gaap:PropertyPlantAndEquipmentTransfersAndChanges" format="ixt:num-dot-decimal" scale="6" id="f-536"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentTransfersAndChanges" format="ixt:num-dot-decimal" scale="6" id="f-537">10.6</ix:nonFraction></ix:nonFraction>&#160;million to buildings and $<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-5" sign="-" name="us-gaap:PropertyPlantAndEquipmentTransfersAndChanges" format="ixt:num-dot-decimal" scale="6" id="f-538"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentTransfersAndChanges" format="ixt:num-dot-decimal" scale="6" id="f-539">13.9</ix:nonFraction></ix:nonFraction>&#160;million to manufacturing equipment during the second and third quarters of fiscal 2025. Furthermore, the Company began depreciating the newly completed manufacturing facility over a <ix:nonNumeric contextRef="c-155" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-540">39</ix:nonNumeric>-year period and the manufacturing equipment over <ix:nonNumeric contextRef="c-156" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-541">7</ix:nonNumeric>- or <ix:nonNumeric contextRef="c-157" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-542">10</ix:nonNumeric>-year periods.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of fiscal 2024, the Company completed the build out of its laboratory and office facilities in Verona, Wisconsin, which resulted in the reclassification of $<ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-5" sign="-" name="us-gaap:PropertyPlantAndEquipmentTransfersAndChanges" format="ixt:num-dot-decimal" scale="6" id="f-543"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentTransfersAndChanges" format="ixt:num-dot-decimal" scale="6" id="f-544">71.8</ix:nonFraction></ix:nonFraction>&#160;million from construction in progress to buildings. The Company subsequently incurred and capitalized $<ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-5" sign="-" name="us-gaap:PropertyPlantAndEquipmentTransfersAndChanges" format="ixt:num-dot-decimal" scale="6" id="f-545"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentTransfersAndChanges" format="ixt:num-dot-decimal" scale="6" id="f-546">4.2</ix:nonFraction></ix:nonFraction>&#160;million from construction in progress to buildings in fiscal 2024.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-547" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#242424;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following as of:</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">June 30, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Accrued research and development expenses</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="arwr:AccruedResearchAndDevelopmentExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-548">31,708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="arwr:AccruedResearchAndDevelopmentExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-549">28,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Accrued research and development expenses; co-development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="arwr:AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-550">24,627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="arwr:AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-551">23,351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Accrued capital expenditures</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="arwr:AccruedCapitalExpenditureCurrent" scale="3" id="f-552">346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="arwr:AccruedCapitalExpenditureCurrent" format="ixt:num-dot-decimal" scale="3" id="f-553">4,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-554">8,137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-555">7,391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Total accrued expenses</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-556">64,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-557">63,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, the Company&#8217;s accrued research and development expenses was primarily attributable to ongoing clinical trial operations, preclinical animal studies, and associated toxicology assessments. In addition, accrued research and development expenses; co-development relates to the co-development and co-commercialization activities under the Takeda License Agreement (see Note 2).</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><div id="ib8da3572c2184cf591d7511966d9e9c1_40"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4. <ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="f-558" continuedAt="f-558-1" escape="true">INVESTMENTS</ix:nonNumeric></span></div><ix:continuation id="f-558-1" continuedAt="f-558-2"><ix:nonNumeric contextRef="c-1" name="arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" id="f-559" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investments consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.787%"><tr><td style="width:1.0%"/><td style="width:33.869%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.237%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.026%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.237%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.026%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.237%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.026%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">As of June 30, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Adjusted Basis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Available-for-sale securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="f-560">768,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-3" name="arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent" format="ixt:num-dot-decimal" scale="3" id="f-561">1,938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-3" name="arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent" scale="3" id="f-562">105</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-563">770,579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Total current investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="f-564">768,746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent" format="ixt:num-dot-decimal" scale="3" id="f-565">1,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent" scale="3" id="f-566">105</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-567">770,579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.787%"><tr><td style="width:1.0%"/><td style="width:33.869%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.237%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.026%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.084%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.026%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.237%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.241%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">As of September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Adjusted Basis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Available-for-sale securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="f-568">577,465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-3" name="arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent" scale="3" id="f-569">837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-3" name="arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent" scale="3" id="f-570">26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-571">578,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Total current investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="f-572">577,465</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent" scale="3" id="f-573">837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent" scale="3" id="f-574">26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-575">578,276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="f-576" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the contract maturity of the available-for-sale securities as of:</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">   </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.484%"><tr><td style="width:1.0%"/><td style="width:51.207%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.440%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">June 30, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Within one year</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" format="ixt:num-dot-decimal" scale="3" id="f-577">224,571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" format="ixt:num-dot-decimal" scale="3" id="f-578">578,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">After one to two years</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="arwr:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" format="ixt:num-dot-decimal" scale="3" id="f-579">450,889</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="arwr:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" format="ixt:fixed-zero" scale="3" id="f-580">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">After two to three years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="arwr:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree" format="ixt:num-dot-decimal" scale="3" id="f-581">95,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="arwr:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree" format="ixt:fixed-zero" scale="3" id="f-582">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-583">770,579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-584">578,276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-558-2">As of June&#160;30, 2025 and September&#160;30, 2024, the gross unrealized losses were immaterial. The Company has determined that the available-for-sale securities that were in an unrealized loss position did not have any credit loss impairment as of June&#160;30, 2025 and 2024.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="ib8da3572c2184cf591d7511966d9e9c1_43"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 5. <ix:nonNumeric contextRef="c-1" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="f-585" continuedAt="f-585-1" escape="true">INTANGIBLE ASSETS</ix:nonNumeric></span></div><ix:continuation id="f-585-1"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets subject to amortization include patents and a license agreement capitalized as part of the Novartis RNAi asset acquisition in March 2015. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="f-586" continuedAt="f-586-1" escape="true">The following table presents the components of intangible assets: </ix:nonNumeric></span></div><ix:continuation id="f-586-1"><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.361%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross Carrying Amount</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Impairment</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Useful Lives</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">As of June 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Patents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-587">21,728</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-588">16,037</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-3" name="arwr:FiniteLivedIntangibleAssetsImpairment" format="ixt:fixed-zero" scale="3" id="f-589">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-590">5,691</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-164" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-591">14</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">License</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-592">3,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-593">1,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" name="arwr:FiniteLivedIntangibleAssetsImpairment" format="ixt:fixed-zero" scale="3" id="f-594">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-595">1,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-165" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-596">21</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Total intangible assets, net</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-597">24,857</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-598">17,571</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="arwr:FiniteLivedIntangibleAssetsImpairment" format="ixt:fixed-zero" scale="3" id="f-599">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-600">7,286</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">As of September 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Patents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-601">21,728</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-602">14,873</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-3" name="arwr:FiniteLivedIntangibleAssetsImpairment" format="ixt:fixed-zero" scale="3" id="f-603">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-604">6,855</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-167" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-605">14</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">License</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-606">3,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-607">1,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-3" name="arwr:FiniteLivedIntangibleAssetsImpairment" format="ixt:fixed-zero" scale="3" id="f-608">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-609">1,707</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-168" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-610">21</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Total intangible assets, net</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-611">24,857</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-612">16,295</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-3" name="arwr:FiniteLivedIntangibleAssetsImpairment" format="ixt:fixed-zero" scale="3" id="f-613">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-614">8,562</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are reviewed annually for impairment and more frequently if potential impairment indicators exist. No impairment indicators were identified during the nine months ended June&#160;30, 2025 and 2024.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with definite useful lives are amortized on a straight-line basis over their useful lives. Intangible assets amortization expense was $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-615"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-616">0.4</ix:nonFraction></ix:nonFraction> million for the three months ended June&#160;30, 2025 and 2024, and $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-617"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-618">1.3</ix:nonFraction></ix:nonFraction> million for each of the nine months ended June&#160;30, 2025 and 2024. None of the intangible assets with definite useful lives are anticipated to have a residual value.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="f-619" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the estimated future amortization expense related to intangible assets as of June&#160;30, 2025:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.727%"><tr><td style="width:1.0%"/><td style="width:72.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.505%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.552%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amortization Expense</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Year Ending September 30, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2025 (remainder)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" scale="3" id="f-620">424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-621">1,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-622">1,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="f-623">1,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="3" id="f-624">795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2030 and thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="arwr:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" scale="3" id="f-625">967</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-626">7,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="ib8da3572c2184cf591d7511966d9e9c1_46"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 6. <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-627" continuedAt="f-627-1" escape="true">STOCKHOLDERS&#8217; EQUITY</ix:nonNumeric></span></div><ix:continuation id="f-627-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfStockByClassTextBlock" id="f-628" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s shares of common stock and preferred stock:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"><tr><td style="width:1.0%"/><td style="width:30.310%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.049%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Par Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Authorized</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Issued</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">As of June 30, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Common stock </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-629">0.001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-630">290,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-631">138,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-632">138,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Preferred stock</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-633">0.001</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-634">5,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="3" id="f-635">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="f-636">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">As of September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-637">0.001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-638">290,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-639">124,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-640">124,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Preferred stock</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-641">0.001</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-642">5,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="3" id="f-643">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="f-644">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;(1) Does not include shares of common stock into which the Avoro Pre-Funded Warrants may be exercised.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2025 and September&#160;30, 2024, respectively, <ix:nonFraction unitRef="shares" contextRef="c-170" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-645">10,081,964</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-171" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-646">11,492,293</ix:nonFraction> shares of common stock were reserved for issuance upon exercise of options and vesting of restricted stock units granted or available for grant under the Company&#8217;s 2013 and 2021 Incentive Plans, as well as for other inducement grants made to new employees under Rule 5635(c)(4) of the Nasdaq Listing Rules.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On November 25, 2024, the Company entered into a Securities Purchase Agreement (the &#8220;Securities Purchase Agreement&#8221;) with an institutional and accredited investor for a private placement of pre-funded warrants to purchase shares of common stock with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-172" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-647">0.001</ix:nonFraction> per share (&#8220;Avoro Pre-Funded Warrants&#8221;). Pursuant to the Securities Purchase Agreement, the Company sold pre-funded warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-172" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-648">917,441</ix:nonFraction> shares of common stock at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-173" decimals="2" name="arwr:ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights" scale="0" id="f-649">27.25</ix:nonFraction> per pre-funded warrant, for an aggregate value of approximately $<ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="6" id="f-650">25.0</ix:nonFraction> million. The outstanding Avoro Pre-Funded Warrants are exercisable at any time and do not have an expiration date. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the Avoro Pre-Funded Warrants are freestanding financial instruments because they (i) are immediately exercisable, (ii) do not embody an obligation for the Company to repurchase its shares, (iii) permit the holders to receive a fixed number of shares of common stock upon exercise, and (iv) are indexed to the Company&#8217;s common stock. As such, the Company evaluated the Avoro Pre-Funded Warrants to determine whether they represent instruments that require liability classification pursuant to the guidance in ASC 480. However, the Company concluded that the Avoro Pre-Funded Warrants are not a liability within the scope of ASC 480 due to their characteristics. Further, the Company determined that the Avoro Pre-Funded Warrants do not meet the definition of a derivative under ASC 815 because they do not meet the criteria regarding no or little initial net investment. Accordingly, the Company assessed the Avoro Pre-Funded Warrants relative to the guidance in ASC 815-40, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts in Entity's Own Equity</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, to determine the appropriate treatment. The Company concluded that the Avoro Pre-funded Warrants are both indexed to its own stock and meet all other conditions for equity classification. Accordingly, the Company has classified the Avoro Pre-funded Warrants as permanent equity. As of June&#160;30, 2025, <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="arwr:ClassOfWarrantOrRightNumberOfWarrantsExercised" format="ixt-sec:numwordsen" scale="0" id="f-651">no</ix:nonFraction> shares underlying the Avoro Pre-Funded Warrants had been exercised. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Sarepta Collaboration Agreement, on November 25, 2024, the Company entered into the Stock Purchase Agreement with an affiliate of Sarepta for a private placement of shares of common stock of the Company (the &#8220;Private Placement&#8221;). Pursuant to the Stock Purchase Agreement, the Company sold <ix:nonFraction unitRef="shares" contextRef="c-174" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-652">11,926,301</ix:nonFraction> shares of common stock, at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-175" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-653">27.25</ix:nonFraction>, for an aggregate value of approximately $<ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-654">325.0</ix:nonFraction>&#160;million. The Private Placement closed on February 7, 2025.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On December 2, 2022, the Company entered into an open market sale agreement (the &#8220;Open Market Sale Agreement&#8221;), pursuant to which the Company may, from time to time, sell up to $<ix:nonFraction unitRef="usd" contextRef="c-176" decimals="INF" name="arwr:CommonStockCapitalSharesValueReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-655">250,000,000</ix:nonFraction> in shares of the Company&#8217;s common stock through Jefferies LLC, acting as the sales agent and/or principal, in an at-the-market offering (&#8220;ATM Offering&#8221;). The Company is not required to sell shares under the Open Market Sale Agreement. The Company will pay Jefferies LLC a commission of up to <ix:nonFraction unitRef="number" contextRef="c-177" decimals="3" name="arwr:PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" scale="-2" id="f-656">3.0</ix:nonFraction>% of the aggregate gross proceeds received from all sales of the common stock under the Open Market Sale Agreement. Unless otherwise terminated, the ATM Offering shall terminate upon the earlier of (i) the sale of all shares of common stock subject to the Open Market Sale Agreement and (ii) the termination of the Open Market Sale Agreement as permitted therein. The Company and Jefferies may each terminate the Open Market Sale Agreement at any time upon prior notice. As of June&#160;30, 2025, <ix:nonFraction unitRef="shares" contextRef="c-178" decimals="INF" name="us-gaap:SharesIssued" format="ixt:fixed-zero" scale="0" id="f-657">no</ix:nonFraction> shares have been issued under the Open Market Sale Agreement.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="ib8da3572c2184cf591d7511966d9e9c1_49"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7. <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-658" continuedAt="f-658-1" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="f-658-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be subject to various claims and legal proceedings in the ordinary course of business. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount is reasonably estimable, the Company will accrue a liability for the estimated loss. There were <ix:nonFraction unitRef="usd" contextRef="c-3" decimals="INF" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:fixed-zero" scale="0" id="f-659">no</ix:nonFraction> contingent liabilities recorded as of June&#160;30, 2025. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company owns land in the Verona Technology Park in Verona, Wisconsin, where it has constructed an approximately <ix:nonFraction unitRef="sqft" contextRef="c-179" decimals="-3" name="us-gaap:AreaOfLand" format="ixt:num-dot-decimal" scale="0" id="f-660">160,000</ix:nonFraction> square foot drug manufacturing facility and an approximately <ix:nonFraction unitRef="sqft" contextRef="c-180" decimals="-3" name="us-gaap:AreaOfLand" format="ixt:num-dot-decimal" scale="0" id="f-661">140,000</ix:nonFraction> square foot laboratory and office facility to support manufacturing process development and analytical activities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, the build-out of these facilities was substantially completed, with total costs incurred of $<ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-5" name="arwr:CommitmentsCapitalExpendituresIncurredToDate" scale="6" id="f-662">293.2</ix:nonFraction> million. These costs included (i) $<ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-5" name="arwr:CommitmentsCapitalExpendituresIncurredToDate" scale="6" id="f-663">76.0</ix:nonFraction> million capitalized to building, related to the laboratory and office facility, and (ii) $<ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-5" name="arwr:CommitmentsCapitalExpendituresIncurredToDate" scale="6" id="f-664">11.5</ix:nonFraction> million capitalized to research equipment, $<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="arwr:CommitmentsCapitalExpendituresIncurredToDate" scale="6" id="f-665">173.3</ix:nonFraction> million capitalized to building, $<ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-5" name="arwr:CommitmentsCapitalExpendituresIncurredToDate" scale="6" id="f-666">16.5</ix:nonFraction> million capitalized to manufacturing equipment, and $<ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-5" name="arwr:CommitmentsCapitalExpendituresIncurredToDate" scale="6" id="f-667">15.9</ix:nonFraction> million in construction in progress, related to the drug manufacturing facility. The Company has an expected outstanding balance of approximately $<ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-5" name="arwr:AmountIntendsToInvestForBuildoutOfFacilities" scale="6" id="f-668">3.3</ix:nonFraction> million remaining to be settled.</span></div></ix:continuation><div id="ib8da3572c2184cf591d7511966d9e9c1_52"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8. <ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-669" continuedAt="f-669-1" escape="true">LEASES</ix:nonNumeric></span></div><ix:continuation id="f-669-1" continuedAt="f-669-2"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Pasadena, California</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: The Company leases <ix:nonFraction unitRef="sqft" contextRef="c-183" decimals="-3" name="us-gaap:LandSubjectToGroundLeases" format="ixt:num-dot-decimal" scale="0" id="f-670">49,000</ix:nonFraction> square feet of office space located at 177 East Colorado Blvd. for its corporate headquarters from 177 Colorado Owner, LLC, which lease expires on April&#160;30, 2027. The lease contains an option to renew for <ix:nonFraction unitRef="option" contextRef="c-184" decimals="INF" name="arwr:NumberOfOptionsToRenew" format="ixt-sec:numwordsen" scale="0" id="f-671">one</ix:nonFraction> additional <ix:nonNumeric contextRef="c-184" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-672">five-year</ix:nonNumeric> term. The Company is not reasonably certain that it will exercise this option to renew and therefore it is not included in right-of-use assets and liabilities as of June&#160;30, 2025.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">San Diego, California</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: The Company leases <ix:nonFraction unitRef="sqft" contextRef="c-185" decimals="-3" name="us-gaap:LandSubjectToGroundLeases" format="ixt:num-dot-decimal" scale="0" id="f-673">144,000</ix:nonFraction> square feet of office and research and development laboratory space located at 10102 Hoyt Park from 11404 &amp; 11408 Sorrento Valley Owner, LLC, which lease expires on April&#160;30, 2038. Pursuant to the lease, within twelve months of the expiration of the initial <ix:nonNumeric contextRef="c-185" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-674">15</ix:nonNumeric>-year term, the Company has the option to extend the lease for up to <ix:nonFraction unitRef="option" contextRef="c-186" decimals="INF" name="arwr:NumberOfOptionsToRenew" format="ixt-sec:numwordsen" scale="0" id="f-675">one</ix:nonFraction> additional <ix:nonNumeric contextRef="c-185" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-676">ten-year</ix:nonNumeric> term, with certain annual increases in base rent. The Company is not reasonably certain that it will exercise this option to renew and therefore it is not included in right-of-use assets and liabilities as of June&#160;30, 2025.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The lease agreement, as amended, granted the Company the right to receive an Additional Tenant Improvement Allowance (&#8220;ATIA&#8221;) funded by the lessor. The Company received $<ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-5" name="arwr:ProceedsFromTenantImprovementAllowance" format="ixt:num-dot-decimal" scale="6" id="f-677">30.8</ix:nonFraction>&#160;million in ATIA, including a final payment of $<ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-5" name="arwr:ProceedsFromTenantImprovementAllowance" scale="6" id="f-678">3.1</ix:nonFraction> million during the first quarter of fiscal 2024. As a result, the Company remeasured its lease liability and right-of-use assets to reflect these additional allowances and the related increased lease payments. The Company has further concluded that these ATIAs have no effects on the classification of the lease.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Madison, Wisconsin</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: The Company leases <ix:nonFraction unitRef="sqft" contextRef="c-189" decimals="0" name="us-gaap:LandSubjectToGroundLeases" format="ixt:num-dot-decimal" scale="0" id="f-679">110,956</ix:nonFraction> square feet space, which it increased from <ix:nonFraction unitRef="sqft" contextRef="c-190" decimals="0" name="us-gaap:LandSubjectToGroundLeases" format="ixt:num-dot-decimal" scale="0" id="f-680">107,000</ix:nonFraction> square feet on June&#160;30, 2025, located at 502 South Rosa Road for its office and laboratory facilities, which lease expires on September&#160;30, 2031. The lease contains options to renew for <ix:nonFraction unitRef="option" contextRef="c-189" decimals="INF" name="arwr:NumberOfOptionsToRenew" format="ixt-sec:numwordsen" scale="0" id="f-681">two</ix:nonFraction> terms of <ix:nonNumeric contextRef="c-189" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-682">five years</ix:nonNumeric>. The Company is not reasonably certain that it will exercise this option and therefore it is not included in right-of-use assets and liabilities as of June&#160;30, 2025.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LeaseCostTableTextBlock" id="f-683" continuedAt="f-683-1" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease assets and liabilities along with their classification on the Company&#8217;s consolidated balance sheets were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.144%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Lease Assets and Liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-684">44,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-685">45,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Current operating lease liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-686">7,010</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-687">6,342</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-688">105,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-689">111,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-669-2"><ix:continuation id="f-683-1"><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:16.493%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.569%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.401%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.982%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.401%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.982%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.401%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.982%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.401%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.988%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Lease Cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-690">2,233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-691">2,965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-692">7,754</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-693">8,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">General and administrative expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="f-694">449</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="f-695">537</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-696">1,442</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-697">1,504</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Variable lease cost </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="f-698">893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="f-699">863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-700">2,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-701">2,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">General and administrative expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:fixed-zero" scale="3" id="f-702">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:fixed-zero" scale="3" id="f-703">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:fixed-zero" scale="3" id="f-704">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:fixed-zero" scale="3" id="f-705">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-706">3,575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-707">4,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-708">12,026</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-709">12,513</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(1) Variable lease cost is primarily related to operating expenses associated with the Company&#8217;s operating leases.</span></div></ix:continuation><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There was <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:ShortTermLeaseCost" format="ixt-sec:numwordsen" scale="0" id="f-710"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="INF" name="us-gaap:ShortTermLeaseCost" format="ixt-sec:numwordsen" scale="0" id="f-711"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="INF" name="us-gaap:ShortTermLeaseCost" format="ixt-sec:numwordsen" scale="0" id="f-712"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="INF" name="us-gaap:ShortTermLeaseCost" format="ixt-sec:numwordsen" scale="0" id="f-713">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> short-term lease cost during the three and nine months ended June&#160;30, 2025 and 2024, respectively. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-714" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents maturities of operating lease liabilities on an undiscounted basis as of June&#160;30, 2025:</span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"><tr><td style="width:1.0%"/><td style="width:83.996%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.804%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amounts</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">2025 (remainder)</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="f-715">3,902</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-716">15,799</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-717">14,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="f-718">13,619</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">2029</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="f-719">13,905</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">2030 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="arwr:LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="f-720">114,790</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-721">176,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Less imputed interest</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="f-722">64,289</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Total operating lease liabilities (includes current portion)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-723">112,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow and other information related to leases was as follows:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.079%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.079%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Cash received for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="arwr:OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities" format="ixt:fixed-zero" scale="3" id="f-724">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="arwr:OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities" format="ixt:fixed-zero" scale="3" id="f-725">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="arwr:OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities" format="ixt:fixed-zero" scale="3" id="f-726">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="arwr:OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-727">3,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Right-of-use assets obtained in exchange for amended operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="arwr:RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="0" id="f-728">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="arwr:RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="0" id="f-729">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="arwr:RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-730">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="arwr:RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability" scale="3" id="f-731">64</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-732">3,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-733">3,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-734">11,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-735">7,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-3" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-736">11.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-87" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-737">12.8</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Weighted-average discount rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-3" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-738">8.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-87" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-739">8.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="ib8da3572c2184cf591d7511966d9e9c1_454"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 9. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-740" continuedAt="f-740-1" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="f-740-1" continuedAt="f-740-2"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has three plans that provide for equity-based compensation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2013 Incentive Plan (the &#8220;2013 Plan&#8221;), <ix:nonFraction unitRef="shares" contextRef="c-199" decimals="INF" name="arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-741"><ix:nonFraction unitRef="shares" contextRef="c-199" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-742">2,350,117</ix:nonFraction></ix:nonFraction> awards are granted and outstanding, relating to stock options and restricted stock awards to employees and directors as of June&#160;30, 2025. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2021 Incentive Plan (the &#8220;2021 Plan&#8221;), <ix:nonFraction unitRef="shares" contextRef="c-200" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-743">8,000,000</ix:nonFraction> shares (subject to certain adjustments) of the Company&#8217;s common stock are authorized for grants of stock options, stock appreciation rights, restricted and unrestricted stock, performance awards, cash awards and other awards convertible into or otherwise based on shares of the Company&#8217;s common stock. The maximum number of shares authorized under the 2021 Plan will be (i) reduced by any shares subject to awards made under the 2013 Plan after January 1, 2021, and (ii) increased by any shares subject to outstanding awards under the 2013 Plan as of January 1, 2021 that, after January 1, 2021, are canceled, expired, forfeited or otherwise not issued under such awards (other than as a result of being tendered or withheld to pay the exercise price or withholding taxes in connection with any such awards) or settled in cash. As of June&#160;30, 2025, <ix:nonFraction unitRef="shares" contextRef="c-201" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-744">6,215,559</ix:nonFraction> shares have been granted under the 2021 Plan. The total number of shares available for issuance was <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-745">2,308,495</ix:nonFraction> shares, which includes <ix:nonFraction unitRef="shares" contextRef="c-202" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-746">170,898</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-201" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-747">353,156</ix:nonFraction> shares that were forfeited under the 2013 and 2021 Plans, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">s Inducement Plan (the &#8220;Inducement Plan&#8221;), <ix:nonFraction unitRef="shares" contextRef="c-203" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-748">832,950</ix:nonFraction> shares of the Company&#8217;s common stock are authorized for issuance pursuant to grants of stock options, stock appreciation rights, restricted and unrestricted stock, stock units (including restricted stock units), performance awards, cash awards, and other awards convertible into or otherwise based on shares of the Company&#8217;s common stock. Awards under the Inducement Plan may only be granted to new employees of the Company in accordance with the provisions of Rule 5635(c)(4) of the Nasdaq Listing Rules. As of June&#160;30, 2025,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-204" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-749">607,340</ix:nonFraction> shares have been granted under the Inducement Plan. The total number of shares remaining available for issuance was <ix:nonFraction unitRef="shares" contextRef="c-203" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-750">307,924</ix:nonFraction> shares.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, prior to adoption of the Inducement Plan, the Company previously granted stand-alone inducement awards in the form of stock options and restricted stock units outside of the Company</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">s equity plans to new employees under Rule 5635(c)(4) of the Nasdaq Listing Rules. As of June&#160;30, 2025, there were <ix:nonFraction unitRef="shares" contextRef="c-203" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-751">602,355</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-205" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-752">138,775</ix:nonFraction> shares underlying outstanding stand-alone inducement options and restricted stock units, respectively.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="f-753" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of awards outstanding attributable to Arrowhead Pharmaceuticals, Inc.:</span></div><div style="margin-top:6pt;text-align:center;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.036%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.036%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.036%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.041%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2013 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2021 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Inducement Awards</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Granted and outstanding awards:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-199" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-754">850,117</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-206" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-755">32,151</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-207" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-756">602,355</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-757">1,484,623</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-208" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-758">1,500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-209" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-759">3,888,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-210" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-760">592,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-211" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-761">5,980,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-199" decimals="INF" name="arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-762"><ix:nonFraction unitRef="shares" contextRef="c-199" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-763">2,350,117</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-206" decimals="INF" name="arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-764">3,920,811</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-207" decimals="INF" name="arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-765">1,194,617</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-766">7,465,545</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-767" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock-based compensation expenses included in operating expenses attributable to Arrowhead Pharmaceuticals, Inc.:</span></div><div style="margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.939%"><tr><td style="width:1.0%"/><td style="width:43.769%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.226%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Nine Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-768">6,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-769">6,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-770">21,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-771">21,634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-772">5,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-773">8,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-774">20,242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-775">27,350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-776">11,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-777">14,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-778">41,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-779">48,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Awards</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">            <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-780" continuedAt="f-780-1" escape="true">The following table presents a summary of the stock option activity for the nine months ended June&#160;30, 2025:</ix:nonNumeric></span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-740-2" continuedAt="f-740-3"><ix:continuation id="f-780-1"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Exercise<br/>Price<br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at September&#160;30, 2024</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-781">1,978,516</ix:nonFraction></span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-782">23.39</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="f-783">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-784">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Cancelled or expired</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-785">35,341</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-786">45.92</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Exercised</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-787">458,552</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-788">7.55</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-789">1,484,623</ix:nonFraction></span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-790">27.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-791">3.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="f-792">5,750,674</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Exercisable at June&#160;30, 2025</span></div></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-793">1,484,623</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-794">27.75</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-795">3.5</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="0" id="f-796">5,750,674</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic values represent the amount by which the market price of the underlying stock exceeds the exercise price of the option. The total intrinsic value of the options exercised during the three months ended June&#160;30, 2025 and 2024 was $<ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-797">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-798">0.7</ix:nonFraction> million, respectively. The total intrinsic value of the options exercised during the nine months ended June&#160;30, 2025 and 2024 was $<ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-799">4.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-800">3.8</ix:nonFraction> million, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June&#160;30, 2025, there was <ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="0" id="f-801">no</ix:nonFraction> stock-based compensation expense related to stock options outstanding, while $<ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-802">0.4</ix:nonFraction> million was recorded for the same period in 2024. Stock-based compensation expense related to stock options outstanding for the nine months ended June&#160;30, 2025 and 2024, was $<ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-803">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-804">2.5</ix:nonFraction> million, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, the pre-tax compensation expense for all outstanding unvested stock options is considered nominal. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which do not have vesting restrictions and are fully transferable. The determination of the fair value of each stock option is affected by the Company&#8217;s stock price on the date of grant, as well as assumptions regarding a number of highly complex and subjective variables. No options were granted during the nine months ended June&#160;30, 2025 and 2024.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Visirna ESOP</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: On October 1, 2023, Visirna, a subsidiary of the Company, granted <ix:nonFraction unitRef="shares" contextRef="c-216" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-805">7,500,000</ix:nonFraction> stock options to its employees from the Employee Stock Option Plan (the &#8220;Visirna ESOP&#8221;), which authorizes <ix:nonFraction unitRef="shares" contextRef="c-217" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-806">20,000,000</ix:nonFraction> shares for issuance. The Visirna ESOP is independently managed by Visirna, including the valuation process. For the three months ended June&#160;30, 2025 and 2024, stock-based compensation expense related to the Visirna ESOP was $<ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-807">1.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-808">2.3</ix:nonFraction> million, respectively. For the nine months ended June&#160;30, 2025 and 2024, stock-based compensation expense related to the Visirna ESOP was $<ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-809">3.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-810">5.5</ix:nonFraction>&#160;million, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restricted Stock Units (&#8220;RSUs&#8221;), including market-based, time-based and performance-based awards, have been granted under the Company&#8217;s 2013 and 2021 Plans, the Inducement Plan, and as inducements awards granted outside of the Company&#8217;s equity-based compensation plans. At vesting, each outstanding RSU will be exchanged for one share of the Company&#8217;s common stock. RSU awards generally vest subject to the satisfaction of service requirements or the satisfaction of both service requirements and achievement of certain performance targets.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="f-811" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity of the Company&#8217;s RSUs:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Grant<br/>Date<br/>Fair Value<br/>Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at September&#160;30, 2024</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-222" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-812">4,913,312</ix:nonFraction></span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-222" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-813">49.61</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-223" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-814">2,711,009</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-223" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-815">19.49</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Vested</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="c-223" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-816">1,383,568</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-223" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-817">43.96</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="c-223" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-818">259,831</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-223" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-819">32.96</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-211" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-820">5,980,922</ix:nonFraction></span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-211" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-821">37.97</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-740-3"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of RSUs was determined based on the closing price of the Company&#8217;s common stock on the grant date, with consideration given to the probability of achieving service and/or performance conditions for awards.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June&#160;30, 2025 and 2024, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-822">11.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-823">14.3</ix:nonFraction> million of expense related to RSUs, respectively. For the nine months ended June&#160;30, 2025 and 2024, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-824">41.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-825">46.5</ix:nonFraction> million of expense related to RSUs, respectively. As of June&#160;30, 2025, there was $<ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="f-826">85.8</ix:nonFraction>&#160;million of total unrecognized compensation cost related to RSUs that is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="c-223" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-827">1.7</ix:nonNumeric> years.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="ib8da3572c2184cf591d7511966d9e9c1_58"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 10. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-828" continuedAt="f-828-1" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="f-828-1"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company employs a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The Company&#8217;s valuation techniques and inputs used to measure fair value and the definition of the three levels (Level 1, Level 2, and Level 3) of the fair value hierarchy are disclosed in Note 10 - Fair Value Measurements of Notes to Consolidated Financial Statements of Part IV, &#8220;Item 15. Exhibits and Financial Statement Schedules&#8221; of its Annual Report on Form 10-K for the fiscal year ended September&#160;30, 2024.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses prices and inputs that are current as of the measurement date, including during periods of market disruption. In periods of market disruption, the ability to observe prices and inputs may be reduced for many instruments. This condition could cause an instrument to be reclassified from Level 1 to Level 2, or from Level 2 to Level 3. The Company recognizes transfers between levels at either the actual date of the event or a change in circumstances that caused the transfer. As of June&#160;30, 2025 and September&#160;30, 2024, the Company did not have any financial assets or financial liabilities based on Level 3 measurements.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-829" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present information about the Company&#8217;s assets and liabilities measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques utilized by the Company:  </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.449%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Available-for-sale securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-830">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-831">221,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-832">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-833">221,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-834">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-835">7,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-836">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-837">7,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Commercial notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-838">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-839">26,449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-840">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-841">26,449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-842">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-843">515,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-844">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-845">515,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Total available-for-sale securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-846">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-847">770,579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-848">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-849">770,579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Money market instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-850">81,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-851">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-249" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-852">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-250" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-853">81,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Term deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-854">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-855">11,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-856">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-857">11,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-858">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-859">7,960</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-860">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-861">7,960</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Commercial notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-862">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-863">23,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-864">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-865">23,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Total cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-866">81,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-867">42,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-868">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-869">124,062</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Total financial assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-870">81,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-871">813,358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-872">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-873">894,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.449%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Available-for-sale securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-263" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-874">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-264" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-875">160,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-876">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-877">160,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Commercial notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-878">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-879">179,714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-880">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-881">179,714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-271" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-882">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-272" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-883">237,839</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-273" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-884">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-274" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-885">237,839</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Total available-for-sale securities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-275" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-886">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-276" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-887">578,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-888">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-889">578,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Money market instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-890">66,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-891">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-892">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-893">66,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Total cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-275" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-894">66,966</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-276" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-895">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-896">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-897">66,966</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Total financial assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-275" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-898">66,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-276" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-899">578,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-900">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-901">645,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="ib8da3572c2184cf591d7511966d9e9c1_61"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 11. <ix:nonNumeric contextRef="c-1" name="arwr:LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" id="f-902" continuedAt="f-902-1" escape="true">LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES</ix:nonNumeric></span></div><ix:continuation id="f-902-1"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, the Company and Royalty Pharma entered into the Royalty Pharma Agreement, pursuant to which Royalty Pharma agreed to pay up to $<ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-5" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="f-903">410.0</ix:nonFraction>&#160;million in cash to the Company in consideration for the Company&#8217;s future royalty interest in olpasiran, originally developed by the Company and licensed to Amgen in September 2016 under the Olpasiran Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Royalty Pharma Agreement, Royalty Pharma paid $<ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-5" name="arwr:UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties" scale="6" id="f-904">250.0</ix:nonFraction> million upfront and agreed to pay up to an additional $<ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-5" name="arwr:MilestonePaymentReceivable" format="ixt:num-dot-decimal" scale="6" id="f-905">160.0</ix:nonFraction>&#160;million in aggregate one-time milestone payments due if and when the following milestone events occur: (i) $<ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-5" name="arwr:MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" format="ixt:num-dot-decimal" scale="6" id="f-906">50.0</ix:nonFraction>&#160;million on completion of enrollment in the OCEAN Phase 3 clinical trial for olpasiran, (ii) $<ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-5" name="arwr:MilestonePaymentReceivableUponFDAApproval" format="ixt:num-dot-decimal" scale="6" id="f-907">50.0</ix:nonFraction>&#160;million upon receipt of FDA approval of olpasiran for an approved indication (reduction in the risk of myocardial infarction, urgent coronary revascularization, or coronary heart disease death in adults with established cardiovascular disease and elevated Lp(a)), and (iii) $<ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-5" name="arwr:MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" format="ixt:num-dot-decimal" scale="6" id="f-908">60.0</ix:nonFraction>&#160;million upon Royalty Pharma&#8217;s receipt of at least $<ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-5" name="arwr:RoyaltyPaymentThreshold" format="ixt:num-dot-decimal" scale="6" id="f-909">70.0</ix:nonFraction>&#160;million of royalty payments under the Royalty Pharma Agreement in any single calendar year. During the third quarter of fiscal 2024, Amgen completed enrollment of the Phase 3 OCEAN(a) outcomes trial of olpasiran, which triggered a $<ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-5" name="arwr:MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="6" id="f-910">50.0</ix:nonFraction>&#160;million milestone payment that the Company received in the same quarter. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for the payment of the foregoing amounts under the Royalty Pharma Agreement, Royalty Pharma is entitled to receive all royalties otherwise payable by Amgen to the Company under the Olpasiran Agreement. The Company remains eligible to receive any milestone payments potentially payable by Amgen under the Olpasiran Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated the terms of the Royalty Pharma Agreement and concluded, in accordance with the relevant accounting guidance, that the Company accounted for the transaction as debt and the funding of $<ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-5" name="arwr:UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="6" id="f-911">250.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-5" name="arwr:MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="6" id="f-912">50.0</ix:nonFraction>&#160;million from Royalty Pharma were recorded as liabilities related to the sale of future royalties on its consolidated balance sheets. The Company is not obligated to repay these funds received under the Royalty Pharma Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company records the obligations at their carrying value using the effective interest method. In order to amortize the sale of future royalties, the Company utilizes the prospective method to estimate the future royalties to be paid by the Company to the counterparty over the life of the arrangement. Under the prospective method, a new effective interest rate is determined based on the revised estimate of remaining cash flows. The new rate is the discount rate that equates the present value of the revised estimate of remaining cash flows with the carrying amount of the debt, and it will be used to recognize non-cash interest expense for the remaining periods. The Company periodically assesses the amount and the timing of expected royalty payments using a combination of internal projections and forecasts from external sources. The estimates of future net product sales (and resulting royalty payments) are based on key assumptions including population, penetration, probability of success and sales price, among others. To the extent such payments are greater or less than the Company&#8217;s initial estimates or the timing of such payments is different than its original estimates, the Company will prospectively adjust the amortization of the royalty financing obligations and the effective interest rate. As of June&#160;30, 2025, the estimated effective interest rate was <ix:nonFraction unitRef="number" contextRef="c-288" decimals="3" name="arwr:LiabilitySaleOfFutureRoyaltiesInterestRate" scale="-2" id="f-913">9.1</ix:nonFraction>%. </span></div><ix:nonNumeric contextRef="c-1" name="arwr:ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock" id="f-914" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the activity with respect to the liability related to the sale of future royalties.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.574%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.577%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Beginning carrying value</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="arwr:RoyaltiesLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-915">341,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="arwr:RoyaltiesLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-916">268,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Milestone payment received</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="arwr:MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties" format="ixt:fixed-zero" scale="3" id="f-917">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-3" name="arwr:MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="f-918">50,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Non-cash interest expense recognized</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="f-919">18,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-3" name="arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="f-920">23,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Ending carrying value</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="arwr:RoyaltiesLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-921">360,254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="arwr:RoyaltiesLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-922">341,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="ib8da3572c2184cf591d7511966d9e9c1_64"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 12. <ix:nonNumeric contextRef="c-1" name="us-gaap:LongTermDebtTextBlock" id="f-923" continuedAt="f-923-1" escape="true">FINANCING AGREEMENT </ix:nonNumeric></span></div><ix:continuation id="f-923-1" continuedAt="f-923-2"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On August 7, 2024 (the &#8220;Closing Date&#8221;), the Company entered into a Financing Agreement with the guarantors party thereto, the lenders party thereto (the &#8220;Lenders&#8221;), and Sixth Street Lending Partners (&#8220;Sixth Street&#8221;), as the administrative agent and collateral agent for the Lenders (the &#8220;Financing Agreement&#8221;). The Financing Agreement establishes a senior secured term loan facility of $<ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-924">500.0</ix:nonFraction>&#160;million (the &#8220;Credit Facility&#8221;), consisting of $<ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-5" name="us-gaap:LineOfCredit" format="ixt:num-dot-decimal" scale="6" id="f-925">400.0</ix:nonFraction>&#160;million funded on the Closing Date and an additional $<ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-5" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-926">100.0</ix:nonFraction>&#160;million available at the Company&#8217;s option, subject to mutual agreement with Sixth Street. The loans under the Credit Facility bear interest at an annual rate of <ix:nonFraction unitRef="number" contextRef="c-291" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-927">15.0</ix:nonFraction>%, which is paid in kind and added to the outstanding principal balance of the Credit Facility each period. The outstanding principal balance of this Credit Facility, including amounts representing accrued but unpaid interest previously paid in kind, is due and payable on August </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-923-2" continuedAt="f-923-3"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7, 2031.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is permitted to use the net proceeds for working capital, capital expenditures and general corporate purposes of the Company and its subsidiaries.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company will have the right to prepay loans under the Credit Facility at any time. The Company is required to partially repay loans under the Credit Facility with proceeds from certain asset sales, condemnation events and extraordinary receipts, subject, in some cases, to reinvestment rights. If the Company repays in full the aggregate principal outstanding under the Credit Facility and such payment in full occurs on or prior to August 7, 2028, the Company will be required to make an additional payment to the lenders under the Credit Facility on such date in an amount necessary for the lenders to achieve a <ix:nonFraction unitRef="number" contextRef="c-292" decimals="INF" name="arwr:DebtInstrumentCovenantMultipleOfInvestCapital" format="ixt-sec:numwordsen" scale="0" id="f-928">two</ix:nonFraction> times multiple of invested capital (&#8220;MOIC&#8221;) of the aggregate principal amount funded on the Closing Date (the &#8220;MOIC Payment&#8221;). If such payment in full occurs after August 7, 2028, the Company will be required to make a payment to the lenders under the Credit Facility on such date in an amount necessary for the lenders to achieve the greater of the MOIC Payment and the present value of all interest payments that would have been payable from such date through the maturity date of the Credit Facility discounted at the Treasury Rate (as defined in the Financing Agreement) plus <ix:nonFraction unitRef="number" contextRef="c-292" decimals="3" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-929">0.5</ix:nonFraction>%; provided that such payment amount in this instance will not exceed the amount necessary for the lenders to achieve a <ix:nonFraction unitRef="number" contextRef="c-293" decimals="INF" name="arwr:DebtInstrumentCovenantMultipleOfInvestCapital" scale="0" id="f-930">2.5</ix:nonFraction> times MOIC. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On November 26, 2024, the Company entered into an amendment to the Financing Agreement (the "Amendment") to modify, amongst other things, some of the prepayment terms of the loans under the Credit Facility, including, the prepayment terms related to the Sarepta Collaboration Agreement. The Amendment was effective on February 14, 2025, following the closing of the Sarepta Collaboration Agreement and receipt of the $<ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-5" name="arwr:ProceedsFromCollaborationArrangements" format="ixt:num-dot-decimal" scale="6" id="f-931">500.0</ix:nonFraction>&#160;million upfront payment from Sarepta. The Amendment added an additional prepayment clause that requires certain contractual prepayments of principle and MOIC payments throughout the life of the loans under the Credit Facility. Additionally, any prepayment will be split with <ix:nonFraction unitRef="number" contextRef="c-294" decimals="2" name="arwr:DebtInstrumentPrepaymentPercentage" scale="-2" id="f-932">50</ix:nonFraction>% of any such prepayment paying down the principle balance of the loans under the Credit Facility and the other <ix:nonFraction unitRef="number" contextRef="c-295" decimals="2" name="arwr:DebtInstrumentPrepaymentPercentage" scale="-2" id="f-933">50</ix:nonFraction>% being applied to prepay the MOIC Payment. In the event the prepayment amounts result in fees being prepaid in excess of the actual amounts required to be paid, the excess fees shall be reallocated and applied to reduce the amount of the principal balance upon repayment in full of the loans under the Credit Facility. As of June 30, 2025, the Company has paid $<ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-3" name="us-gaap:RepaymentsOfLinesOfCredit" format="ixt:num-dot-decimal" scale="6" id="f-934">100.0</ix:nonFraction>&#160;million in MOIC payments of which $<ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-3" name="arwr:DebtInstrumentMultipleOfInvestmentCapitalExpectedToBeAppliedToPrincipalUponRepayment" format="ixt:num-dot-decimal" scale="6" id="f-935">25.3</ix:nonFraction>&#160;million is expected to be applied to principal upon repayment in full. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has paid $<ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-5" name="us-gaap:RepaymentsOfLinesOfCredit" format="ixt:num-dot-decimal" scale="6" id="f-936">201.6</ix:nonFraction>&#160;million of the loans under the Credit Facility during fiscal 2025. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Amendment was accounted for as a debt modification under ASC 470-50, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Debt&#8212;Modification and extinguishments</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; since the Amendment did not result in substantially different terms. In connection with the Amendment, the Company did not incur significant third-party fees.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All obligations under the Financing Agreement are secured on a first-priority basis by security interests in substantially all assets of the Company and material subsidiaries of the Company, including its intellectual property, subject to certain exceptions, and is guaranteed by material subsidiaries of the Company, including foreign subsidiaries, subject to certain exceptions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Financing Agreement contains customary covenants, including, without limitation, a financial covenant to maintain liquidity (cash, cash equivalents and investments) of at least $<ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-5" name="arwr:DebtInstrumentCovenantMinimumLiquidityIfCapitalizationIsAboveThreshold" format="ixt:num-dot-decimal" scale="6" id="f-937">100.0</ix:nonFraction>&#160;million if the Company</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">s market capitalization is above $<ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-8" name="arwr:DebtInstrumentCovenantMarketCapitalizationThreshold" scale="9" id="f-938">1.5</ix:nonFraction> billion, and negative covenants that, subject to certain exceptions, restrict indebtedness, liens, investments (including acquisitions), fundamental changes, asset sales and licensing transactions, dividends, modifications to material agreements, payment of subordinated indebtedness, distributions from certain parties, and other matters customarily restricted in such agreements. The Company is subject to restrictions on sales and licensing transactions with respect to certain core intellectual property, subject to certain exceptions, including certain transactions related to areas outside the United States, United Kingdom, European Union, Japan and China.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Financing Agreement contains certain embedded features that were identified and evaluated as not material to the consolidated financial statements.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock" id="f-939" continuedAt="f-939-1" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The outstanding balance of the Credit Facility consisted of the following:</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-923-3"><ix:continuation id="f-939-1"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.719%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Initial Term Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-940">400,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-941">400,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated interest on the Initial Term Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-942">53,454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-943">9,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated accretion of the MOIC Payment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="f-944">2,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:fixed-zero" scale="3" id="f-945">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Less: Unamortized debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-3" name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="3" id="f-946">14,284</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="3" id="f-947">15,817</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Less: Current portion of credit facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-3" name="us-gaap:LinesOfCreditCurrent" format="ixt:num-dot-decimal" scale="3" id="f-948">40,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="us-gaap:LinesOfCreditCurrent" format="ixt:fixed-zero" scale="3" id="f-949">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Less: Payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-3" name="us-gaap:RepaymentsOfLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="f-950">201,625</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="us-gaap:RepaymentsOfLinesOfCredit" format="ixt:fixed-zero" scale="3" id="f-951">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Credit facility, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-952">200,332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-953">393,183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="arwr:SummaryOfInterestExpenseRecognizedRelatedToCreditFacilityTableTextBlock" id="f-954" escape="true"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth total interest expense recognized related to the Credit Facility:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.540%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of debt issuance costs</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="f-955">420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-307" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:fixed-zero" scale="3" id="f-956">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="f-957">1,533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-308" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:fixed-zero" scale="3" id="f-958">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Accretion of the MOIC Payment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="f-959">2,218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-307" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:fixed-zero" scale="3" id="f-960">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="f-961">2,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-308" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:fixed-zero" scale="3" id="f-962">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Contractual interest expense</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="f-963">13,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-307" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:fixed-zero" scale="3" id="f-964">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="f-965">44,454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-308" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:fixed-zero" scale="3" id="f-966">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;Total interest expense</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-967">16,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-307" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:fixed-zero" scale="3" id="f-968">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-969">48,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-308" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:fixed-zero" scale="3" id="f-970">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="f-971" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The amounts shown in the table below, related to the Credit Facility, represent the expected repayments of principle and accrued interest balance as of June 30, 2025 as well as any mandatory prepayments that the Company is obligated to make to the Lenders during the indicated periods. The principal balance will increase from accrued paid in kind interest and the table does not include MOIC payments beyond those contractually determined. Actual payments on current principal may vary from the amounts presented in the table. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"><tr><td style="width:1.0%"/><td style="width:78.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.933%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Year</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amounts</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2025 (remainder)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" format="ixt:fixed-zero" scale="3" id="f-972">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-973">40,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-974">40,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="3" id="f-975">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:num-dot-decimal" scale="3" id="f-976">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Thereafter</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-3" name="arwr:LongTermDebtMaturityAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="f-977">216,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-978">326,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In May 2025, Visirna entered into the Revolving Credit Agreement with Bank of Zhejiang. The maximum aggregate credit facility is <ix:nonFraction unitRef="cny" contextRef="c-309" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-979">73.0</ix:nonFraction>&#160;million Chinese Yuan ($<ix:nonFraction unitRef="usd" contextRef="c-309" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-980">10.0</ix:nonFraction>&#160;million) bearing an annual interest rate of <ix:nonFraction unitRef="number" contextRef="c-309" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-981">4.1</ix:nonFraction>%. The term of each loan is <ix:nonNumeric contextRef="c-310" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="f-982">twelve months</ix:nonNumeric>. The amount outstanding as of June 30, 2025 was <ix:nonFraction unitRef="cny" contextRef="c-311" decimals="-5" name="us-gaap:LinesOfCreditCurrent" format="ixt:num-dot-decimal" scale="6" id="f-983">50.8</ix:nonFraction>&#160;million Chinese Yuan ($<ix:nonFraction unitRef="usd" contextRef="c-311" decimals="-5" name="us-gaap:LinesOfCreditCurrent" format="ixt:num-dot-decimal" scale="6" id="f-984">7.1</ix:nonFraction>&#160;million) on the credit facility which was classified as other current liabilities.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><div id="ib8da3572c2184cf591d7511966d9e9c1_67"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 13. <ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-985" continuedAt="f-985-1" escape="true">NET (LOSS) INCOME PER SHARE</ix:nonNumeric></span></div><ix:continuation id="f-985-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-986" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the computation of basic and diluted net (loss) income per share for the three and nine months ended June&#160;30, 2025 and 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">                            </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.545%"><tr><td style="width:1.0%"/><td style="width:43.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.146%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Nine Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands, except per share amounts)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Net (loss) income attributable to Arrowhead Pharmaceuticals, Inc.</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-987">175,241</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-988">170,793</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-989">22,119</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-990">428,957</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Weighted-average basic shares outstanding</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-991">139,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-992">124,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-993">132,385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-994">118,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Effect of dilutive securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="3" id="f-995">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="3" id="f-996">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="3" id="f-997">967</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="3" id="f-998">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Weighted-average diluted shares outstanding </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-999">139,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-1000">124,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-1001">133,352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-1002">118,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Basic net (loss) income per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1003">1.26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1004">1.38</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1005">0.17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1006">3.63</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Diluted net (loss) income per share</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1007">1.26</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1008">1.38</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1009">0.17</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1010">3.63</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(1) Includes shares of common stock into which the Avoro Pre-Funded Warrants may be exercised. See Note 6.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-1011" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net (loss) income per share because to include them would be anti-dilutive.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.545%"><tr><td style="width:1.0%"/><td style="width:43.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.146%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Nine Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-312" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="f-1012">768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-313" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="f-1013">753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-314" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="f-1014">756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-315" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="f-1015">711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-316" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-1016">5,178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-317" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-1017">3,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-318" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-1018">4,770</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-319" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-1019">4,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-1020">5,946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-1021">4,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-1022">5,526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-1023">4,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="ib8da3572c2184cf591d7511966d9e9c1_70"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 14. <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-1024" continuedAt="f-1024-1" escape="true">INCOME TAXES</ix:nonNumeric></span></div><ix:continuation id="f-1024-1" continuedAt="f-1024-2"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company's estimated annual effective tax rate significantly fluctuates for fiscal 2025 with small changes to the Company&#8217;s estimated income. For the three months ended June&#160;30, 2025, the Company has recorded a discrete income tax benefit of $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-1025">0.4</ix:nonFraction>&#160;million. The income tax provision for the three months ended June&#160;30, 2024, resulted in <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-1026">no</ix:nonFraction> tax expense. For the nine months ended June&#160;30, 2025, the Company has recorded a discrete income tax expense of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-1027">1.4</ix:nonFraction>&#160;million, and for the nine months ended June&#160;30, 2024, the Company has recorded a discrete income tax benefit of $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-1028">3.3</ix:nonFraction>&#160;million. Income tax expense for the three and nine months ended June&#160;30, 2025 was based on actual year to date income recorded and statutory tax rates. </span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1024-2">The Company does not anticipate any changes in its unrecognized tax benefits over the next 12 months. Due to the presence of net operating loss carryforwards, all of the income tax years remain open for examination domestically. The Company has not been notified that it is under audit by the Internal Revenue Service or foreign taxing authorities; however, the Company has been notified of an income tax examination by the State of California. There are no other audits in any other jurisdictions.</ix:continuation> </span></div><div id="ib8da3572c2184cf591d7511966d9e9c1_492"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 15. <ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsTextBlock" id="f-1029" continuedAt="f-1029-1" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric><br/><br/></span><ix:continuation id="f-1029-1" continuedAt="f-1029-2"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Visirna</span></ix:continuation></div><ix:continuation id="f-1029-2" continuedAt="f-1029-3"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">On August 1, 2025, Visirna Therapeutics HK Limited (&#8220;Visirna HK&#8221;), a wholly owned subsidiary of Visirna Therapeutics, Inc, a majority owned subsidiary of the Company, entered into an Asset Purchase Agreement (the &#8220;Asset Purchase Agreement&#8221;) with Genzyme Corporation (&#8220;Sanofi&#8221;), a wholly owned subsidiary of Sanofi S.A., pursuant to which Visirna HK sold all of its assets and rights in investigational plozasiran to Sanofi, which included an assignment of Visirna HK&#8217;s rights (as successor by assignment from Visirna) to develop and commercialize investigational plozasiran in Greater China pursuant to that certain License Agreement by and between the Company and Visirna dated, April 25, 2022 (the &#8220;Visirna License Agreement&#8221;).  The Asset Purchase Agreement is scheduled to close during the second half of the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-1029-3"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">year.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Asset Purchase Agreement, the Company consented to the partial assignment of the Visirna License Agreement by Visirna HK to Sanofi (as so assigned, the &#8220;Sanofi License Agreement&#8221;), amongst other agreements between the Company and Visirna, effective as of the closing of the Asset Purchase Agreement. After giving effect to the Asset Purchase Agreement, Visirna HK retains rights to develop and commercialize in Greater China three other cardiometabolic drugs licensed to it pursuant to the Visirna License Agreement.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Upon closing of the Asset Purchase Agreement, Visirna will receive an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-320" decimals="-5" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="f-1030">130.0</ix:nonFraction>&#160;million from Sanofi and is eligible to receive further milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="c-320" decimals="-5" name="arwr:FuturePotentialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-1031">265.0</ix:nonFraction>&#160;million upon approval of plozasiran across various indications in mainland China. The Company is also eligible to receive royalties from Sanofi on net commercial product sales in Greater China under the Sanofi License Agreement. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Sarepta DM1 Milestone</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">On July 27, 2025, the Company triggered a $<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="arwr:DevelopmentMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-1032">100.0</ix:nonFraction>&#160;million milestone payment from Sarepta. The Company reached the first of two prespecified enrollment targets and subsequent authorization to dose escalate in a Phase 1/2 clinical study of ARO-DM1, an investigational RNAi therapeutic for treatment of type 1 myotonic dystrophy (DM1), as outlined in the Sarepta Collaboration Agreement, triggering the milestone. The Company is eligible to receive up to an additional $<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="arwr:FuturePotentialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-1033">200.0</ix:nonFraction>&#160;million in near-term milestone payments associated with the continued enrollment of certain cohorts of a Phase 1/2 study of ARO-DM1.</span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="ib8da3572c2184cf591d7511966d9e9c1_73"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and we intend that such forward-looking statements be subject to the safe harbors created thereby. For this purpose, any statements contained in this Quarterly Report on Form 10-Q except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;anticipate,&#8221;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;goal,&#8221; &#8220;endeavor,&#8221; &#8220;strive,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;target,&#8221; &#8220;might,&#8221; &#8220;forecast,&#8221; &#8220;potential,&#8221; or &#8220;continue&#8221; or the negative of these words or other variations thereof or comparable terminology are intended to identify forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs, our expectations regarding regulatory approval for and commercial launch of plozasiran; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding the amount and timing of future milestone, royalty or other payments that could be due to or from third parties under existing agreements; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The forward-looking statements included herein are based on current expectations of our management based on available information and involve a number of risks and uncertainties, all of which are difficult or impossible to predict accurately, and many of which are beyond our control. As such, our actual results or outcomes and timing of certain events may differ materially from those discussed, projected, anticipated or indicated in any forward-looking statements. Forward-looking statements are not guarantees of future performance and our actual results of operations, financial condition and cash flows may differ materially. Factors that may cause or contribute to such differences include, but are not limited to, those discussed in more detail in &#8220;Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations&#8221; of Part I and &#8220;Item 1A. Risk Factors&#8221; of Part II of this Quarterly Report on Form 10-Q as well as &#8220;Item 1. Business&#8221; and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors&#8221; of Part I and &#8220;Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; of Part II of our most recent Annual Report on Form 10-K. Readers should carefully review these risks, as well as the additional risks described in other documents we file from time to time with the Securities and Exchange Commission (the &#8220;SEC&#8221;). In light of the significant risks and uncertainties inherent in the forward-looking information included herein, the inclusion of such information should not be regarded as a representation by us or any other person that such results will be achieved, and readers are cautioned not to place undue reliance on such forward-looking information. Statements made herein are as of the date of the filing of this Quarterly Report on Form 10-Q with the SEC and should not be relied upon as of any subsequent date. Except as may be required by law, we disclaim any intent to revise the forward-looking statements contained herein to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.</span></div><div id="ib8da3572c2184cf591d7511966d9e9c1_76"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">OVERVIEW</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, the Company&#8217;s therapies trigger the RNAi interference mechanism to induce rapid, deep and durable knockdown of target genes. RNAi is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. RNAi-based therapeutics may leverage this natural pathway of gene silencing to target and shut down specific disease-causing genes. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that TRiM</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> enabled therapeutics offer several potential advantages over prior generations and competing technologies, including: simplified manufacturing and reduced costs; multiple routes of administration including subcutaneous injection and inhaled administration; the ability to target multiple tissue types including liver, lung, central nervous system (CNS), muscle, and adipose tissue; and the potential for improved safety and reduced risk of intracellular buildup, because there are fewer metabolites from smaller, simpler molecules. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s pipeline includes:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Hypertriglyceridemia - plozasiran (formerly ARO-APOC3);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Homozygous familial hypercholesterolemia (HoFH) - zodasiran (formerly ARO-ANG3);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Cardiovascular disease - olpasiran (formerly AMG 890 or ARO-LPA, out-licensed to Amgen);</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Inflammatory pulmonary conditions - ARO-RAGE;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Idiopathic pulmonary fibrosis - SRP-1002 (formerly ARO-MMP7, out-licensed to Sarepta);</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Metabolic-dysfunction associated steatohepatitis (MASH) - GSK-4532990 (formerly ARO-HSD, out<br/>licensed to GSK);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Alpha-1 antitrypsin deficiency (AATD) - fazirsiran (formerly ARO-AAT, a collaboration with Takeda);</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Chronic Hepatitis B virus - daplusiran/tomligisiran - GSK5637608 (formerly JNJ-3989 and ARO-HBV, out-licensed to GSK); </span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Complement mediated diseases - ARO-C3 and ARO-CFB;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Metabolic-dysfunction associated steatohepatitis (MASH) - ARO-PNPLA3 (formerly JNJ-75220795 or ARO-JNJ1);</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Obesity - ARO-INHBE and ARO- ALK7</span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Facioscapulohumeral muscular dystrophy - SRP-1001 (formerly ARO-DUX4, out-licensed to Sarepta);</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:23.5pt">Myotonic Dystrophy Type 1 - SRP1003 (formerly ARO-DM1 out-licensed to Sarepta; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:23.5pt">Spinocerebellar ataxia 2 - SRP-1004 (formerly ARO-ATXN2, out-licensed to Sarepta).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates lab facilities in California and Wisconsin, where its research and development activities, including the development of RNAi therapeutics, take place. The Company&#8217;s principal executive offices are located in Pasadena, California.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to develop other clinical candidates for future clinical trials. Clinical candidates are tested internally and through Good Laboratory Practice (GLP) toxicology studies at outside laboratories. Drug materials for such studies and clinical trials are either manufactured internally or contracted to third-party manufacturers. The Company engages third-party contract research organizations (CROs) to manage clinical trials and works cooperatively with such organizations on all aspects of clinical trial management, including plan design, patient recruiting, and follow up. These outside costs, including toxicology/efficacy testing and manufacturing costs, as well as the preparation for and administration of clinical trials, are referred to as &#8220;candidate costs.&#8221; As clinical candidates progress through clinical development, candidate costs will increase. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The First Three Quarters of Fiscal 2025 Business Highlights</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Key recent developments through the first three quarters of fiscal 2025 included the following: </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Triggered a $100.0 million milestone payment from Sarepta Therapeutics, Inc., which was triggered on July 27, 2025, when the Company reached the first of two prespecified enrollment targets and subsequent authorization to dose escalate in a Phase 1/2 clinical study of ARO-DM1, an investigational RNAi therapeutic for the treatment of type 1 myotonic dystrophy (DM1);</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Announced the signing of an asset purchase agreement between Sanofi and Visirna Therapeutics, a majority-owned subsidiary of the Company, created to develop and commercialize four of the Company&#8217;s investigational cardiometabolic candidates in Greater China. Under the terms of the agreement, Sanofi will acquire rights to develop and commercialize investigational plozasiran, the Company's first-in-class RNAi therapeutic candidate designed to reduce production of apolipoprotein C-III (APOC3) as a potential treatment for familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia (SHTG), in Greater China;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Initiated and dosed the first subject in the YOSEMITE Phase 3 clinical trial of zodasiran, the Company&#8217;s investigational RNAi therapeutic being developed as a potential treatment for homozygous familial hypercholesterolemia (HoFH), a rare genetic condition that leads to severely elevated LDL-cholesterol and early onset cardiovascular disease; <br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10pt">Completed enrollment of SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 clinical trials of plozasiran. The Company&#8217;s global Phase 3 clinical studies are designed to support regulatory submissions for approval of investigational plozasiran in the treatment of severe hypertriglyceridemia. The Company previously submitted a New Drug Application to the U.S. Food and Drug Administration (&#8220;FDA&#8221;) on November 16, 2024 for plozasiran based on positive Phase 3 PALISADE study results in patients with familial chylomicronemia syndrome, which the FDA accepted on January 17, 2025, with a Prescription Drug User Fee Act (PDUFA) action date of November 18, 2025, and indicated it is not currently planning to hold an advisory committee meeting;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Initiated a Phase 1/2a clinical trial of ARO-ALK7 for the treatment of obesity. ARO-ALK7 is the first RNAi-based therapy designed to silence adipocyte expression of  the </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ACVR1C </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">gene to reduce the production of Activin receptor-like kinase 7 (ALK7), which acts as a receptor in a pathway that regulates energy homeostasis in adipose tissue;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Announced Topline results from Part 2 of a Phase 1/2 clinical study of ARO-C3, the Company&#8217;s investigational RNAi therapeutic designed to reduce liver production of complement component 3 (C3) as a potential therapy for various complement mediated diseases. ARO-C3 achieved reductions in alternative pathway complement activity and proteinuria;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Entered into a global licensing and collaboration agreement with Sarepta on November 25, 2024, which closed on February 7, 2025. Closing of the transaction was subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary conditions. Upon closing, the Company received $325.0 million through the purchase of 11,926,301 shares of Company common stock by Sarepta, at a price per share of $27.25, and received $500.0 million as an upfront payment on February 24, 2025. The Company will also receive $250.0 million to be paid in equal installments over five years and is eligible to receive an additional $300.0 million in near-term payments. Additionally, the Company is eligible to receive royalties on commercial sales and up to approximately $10.0 billion in future potential milestone payments;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">GSK dosed its fifth patient in a Phase 2 trial in December 2024, triggering a $2.5 million milestone payment to the Company which was paid in the second quarter of fiscal 2025;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.7pt">Announced that the Company dosed the first subjects in a Phase 1/2a clinical trial of ARO-INHBE; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Presented interim results from a Phase 1/2a clinical study of ARO-CFB at the 8th Complement-Based Drug Development Summit. The study resulted in multiple findings including: (1) ARO-CFB led to dose dependent reductions in circulating CFB protein by up to 90% with greater than 3 months duration, (2) single and multiple doses of ARO-CFB led to near complete inhibition of alternative pathway activity based on Wieslab AP, and (3) single and multiple doses of ARO-CFB led to near complete inhibition of alternative pathway hemolytic activity, measured by AH50.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Critical Accounting Estimates </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes to the Company&#8217;s critical accounting estimates disclosed in the most recent Annual Report on Form 10-K for the fiscal year ended September&#160;30, 2024.</span></div><div id="ib8da3572c2184cf591d7511966d9e9c1_79"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following data summarizes the Company&#8217;s results of operations for the following periods indicated: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.288%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.288%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.288%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.807%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.291%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended June 30,</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Nine Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="18" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:115%">(in thousands, except per share amounts)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">27,767&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">572,976&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">3,551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Operating (loss) income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(165,550)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(176,141)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">54,240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(438,877)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Net (loss) income attributable to Arrowhead</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(175,241)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(170,793)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">22,119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(428,957)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Net (loss) income per diluted share attributable to Arrowhead</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(1.26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(1.38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">0.17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(3.63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div id="ib8da3572c2184cf591d7511966d9e9c1_82"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Revenue</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue for the three and nine months ended June&#160;30, 2025 increased by $27.8 million and $569.4 million, respectively, from the same periods of 2024. The change was primarily driven by the revenue recognition associated with GSK and Sarepta license agreements as discussed below.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated each agreement in accordance with FASB Topic 808&#8211;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and Topic 606-</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue for Contracts from Customers</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. See Note 2 &#8212; Collaboration and License Agreements of the Notes to Consolidated Financial Statements of Part I, &#8220;Item 1. Financial Statements&#8221; for more information on revenue recognized under the collaboration and license agreements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Takeda</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: In October 2020, Takeda and the Company entered into the Takeda License Agreement. The Company has allocated the total $300.0&#160;million initial transaction price to its one distinct performance obligation for the fazirsiran license and the associated Takeda R&amp;D Services. Revenue was recognized using the input method (based on actual patient visits completed versus total estimated visits completed for the ongoing SEQUOIA and AROAAT2002 clinical studies). The Phase 2 study visits for patients in the SEQUOIA and AROAAT2002 studies concluded by December 31, 2023, and the Company has substantially completed its performance obligation under the Takeda License Agreement. As such, all revenue has been fully recognized as of December 31, 2023. During the nine months ended June 30, 2024, the Company recorded $0.9&#160;million revenue.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">GSK</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: On December 11, 2023, the Company entered into the GSK-HBV Agreement pursuant to which GSK received a worldwide, exclusive license to develop and commercialize daplusiran/tomligisiran (GSK5637608, formerly JNJ-3989), the Company&#8217;s third-generation subcutaneously administered RNAi therapeutic candidate being developed as a potential therapy for patients with chronic hepatitis B virus infection. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the GSK-HBV Agreement, the Company received $2.7&#160;million in December 2023, upon signing the GSK-HBV Agreement. Further, GSK dosed the fifth patient in a Phase 2 trial in December 2024, triggering a $2.5&#160;million milestone payment to the Company which was paid in the second quarter of fiscal 2025. During the nine months ended June&#160;30, 2025, the Company recorded $2.6&#160;million revenue.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Sarepta</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: On November 25, 2024, the Company entered into the Sarepta Collaboration Agreement and Stock Purchase Agreement with Sarepta for the development and commercialization of multiple clinical and preclinical programs in rare, genetic diseases of the muscle, central nervous system, and lungs. During the nine months ended June&#160;30, 2025, the Company recorded $570.3&#160;million in revenue. As of June&#160;30, 2025, no revenue was recorded for the milestone payments or royalties, as none had been achieved. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="ib8da3572c2184cf591d7511966d9e9c1_85"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Operating Expenses </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The analysis below details the operating expenses and discusses the expenditures of the Company within the major expense categories. For purposes of comparison, the amounts for the three and nine months ended June&#160;30, 2025 and 2024 are shown in the tables below. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development (&#8220;R&amp;D&#8221;) Expenses </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses are related to the Company&#8217;s research and development discovery efforts and related candidate costs, which are comprised primarily of outsourced costs related to the manufacturing of clinical supplies, toxicity/efficacy studies and clinical trial expenses. Internal costs primarily relate to discovery operations at the Company&#8217;s research facilities in California and Wisconsin, including facility costs and laboratory-related expenses. The Company does not separately track research and development expenses by individual research and development projects, or by individual drug candidates. The Company operates in a cross-functional manner across projects and does not separately allocate facilities-related costs, candidate costs, discovery costs, compensation expenses, depreciation and amortization expenses, and other expenses related to research and development activities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide details of research and development expenses for the periods indicated:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.354%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.448%"/><td style="width:0.1%"/></tr><tr style="height:20pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended <br/>June 30, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">% of</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Expense</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Category </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended <br/>June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">% of</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Expense</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Category </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Increase (Decrease) </span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">% </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Candidate costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">95,007&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">58&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">91,623&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">3,384&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">R&amp;D discovery costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">21,043&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">17,634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">3,409&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Salaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">26,531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">24,532&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">1,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Facilities related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">6,457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">7,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(675)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Total research and development expense, excluding non-cash expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">149,038&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">91&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">140,921&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">92&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">8,117&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">7,612&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">7,241&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">371&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">5,718&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">4,269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">1,449&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Total research and development expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">162,368&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">152,431&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">9,937&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.475%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.448%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Nine Months Ended <br/>June 30, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">% of</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Expense</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Category </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Nine Months Ended <br/>June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">% of</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Expense</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Category </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Increase (Decrease)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Candidate costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">243,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">56&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">185,708&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">57,386&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">R&amp;D discovery costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">48,785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">56,736&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(7,951)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Salaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">80,583&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">72,048&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">8,535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Facilities related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">20,944&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">19,597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">1,347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Total research and development expense, excluding non-cash expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">393,406&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">91&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">334,089&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">91&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">59,317&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">23,049&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">23,735&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(686)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Depreciation and amortization</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">16,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">12,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">3,797&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Total research and development expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">432,472&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">370,044&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">62,428&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Candidate costs increased $3.4 million, or 4%, for the three months ended June&#160;30, 2025 compared to the same period of 2024, and $57.4 million, or 31%, for the nine months ended June&#160;30, 2025 compared to the same period of 2024. The increase for both periods was primarily due to the additional progression of the Company&#8217;s pipeline of candidates into and through clinical trials, which resulted in higher manufacturing, outsourced clinical trial, and toxicity study costs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D discovery costs increased $3.4 million, or 19%, for the three months ended June&#160;30, 2025 compared to the same period of 2024, primarily driven by animal studies and system support costs. R&amp;D discovery costs decreased $8.0 million, or 14%, for the nine months ended June&#160;30, 2025 compared to the same period of 2024, primarily driven by strategic shifts toward clinical development and commercial launch. R&amp;D discovery costs are influenced by the Company&#8217;s ongoing discovery efforts, continued advancements into novel therapeutic areas and tissue types, and increasing costs related to CNS studies and lab supplies.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Salaries consist of salary, bonuses, payroll taxes, and related benefits for the Company&#8217;s R&amp;D personnel. Salaries </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">expense increased $2.0 million, or 8%, for the three months ended June&#160;30, 2025 and $8.5 million, or 12%, for the nine months ended June&#160;30, 2025 compared to the same periods of 2024. The increase for both periods was primarily due to an increase in headcount that has occurred as the Company has expanded its pipeline of candidates, in addition to annual salary increases.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Facilities-related expense includes lease costs for the Company&#8217;s research and development facilities in San Diego, California and in Madison and Verona, Wisconsin. These expenses decreased $0.7 million, or 9%, for the three months ended June&#160;30, 2025 compared to the same period of 2024, due to refunds received related to the San Diego and Madison buildings. These expenses increased $1.3 million, or 7%, for the nine months ended June&#160;30, 2025 compared to the same period of 2024, primarily due to property taxes charged to the laboratory and office facilities in Verona, Wisconsin, which completed their build out during the first quarter of fiscal 2024. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stock compensation expense, a non-cash expense, is primarily based on the valuation of the restricted stock units granted to employees, which is based on the closing stock price on the grant date. Stock compensation expense increased $0.4 million, or 5%, for the three months ended June&#160;30, 2025 compared to the same period of 2024, primarily due to an increase in headcount. Stock compensation decreased $0.7 million, or 3%, for the nine months ended June&#160;30, 2025 compared to the same period of 2024, primarily due to the cancellation of awards upon the departure of employees.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense, a non-cash expense, relates to depreciation on buildings, lab equipment and leasehold improvements. These expenses increased $1.4 million, or 34% for the three months ended June&#160;30, 2025 and $3.8 million, or 31%, for the nine months ended June&#160;30, 2025 compared to the same periods of 2024. The increase was primarily attributable to completion of the build out of facilities in Verona, Wisconsin, and the commencement of depreciation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General &amp; Administrative Expenses </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide details of general and administrative expenses for the periods indicated: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.687%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.450%"/><td style="width:0.1%"/></tr><tr style="height:18pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended <br/>June 30, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">% of</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Expense</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Category </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended <br/>June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">% of</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Expense</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Category </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Increase (Decrease)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">% </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:114%">Salaries</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">7,964&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">6,740&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">1,224&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:114%">Professional, outside services, and other </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">14,869&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">5,410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">9,459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:114%">Facilities related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2,180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">1,238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">942&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:114%">Total general &amp; administrative expense, excluding non-cash expenses</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">25,013&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">80&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">13,388&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">57&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">11,625&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">87&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:114%">Stock compensation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">5,431&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">9,809&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(4,378)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(45)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:114%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">505&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:114%">Total general &amp; administrative expenses</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">30,949&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">23,710&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">7,239&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">31&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.541%"/><td style="width:0.1%"/></tr><tr style="height:18pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Nine Months Ended <br/>June 30, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">% of<br/>Expense<br/>Category </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Nine Months Ended <br/>June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">% of<br/>Expense<br/>Category </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Increase (Decrease)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">% </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:114%">Salaries</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">23,152&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">20,087&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">3,065&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:114%">Professional, outside services, and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">35,811&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">16,910&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">18,901&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:114%">Facilities related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">4,546&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">3,278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">1,268&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:114%">Total general &amp; administrative expense, excluding non-cash expense</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">63,509&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">73&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">40,275&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">56&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">23,234&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">58&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:114%">Stock compensation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">21,230&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">30,759&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">42&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(9,529)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(31)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:114%">Depreciation and amortization</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">1,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">1,350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:114%">Total general &amp; administrative expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">86,264&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">72,384&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">13,880&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Salaries expense increased $1.2 million, or 18%, for the three months ended June&#160;30, 2025 and $3.1 million, or 15%, for the nine months ended June&#160;30, 2025 compared to the same periods of 2024. The increase was driven by the combination of annual salary increases and an increase in headcount required to support the Company&#8217;s growth as the Company prepares for commercialization. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Professional, outside services, and other expenses include costs related to legal, audit, consulting, patent filings, business insurance, other external services, as well as travel, communication, and technology expenses. These expenses </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">increased $9.5 million, or 175%, for the three months ended June&#160;30, 2025 and $18.9 million, or 112%, for the nine months ended June&#160;30, 2025 compared to the same periods of 2024. The increase for both periods were mainly due to professional services associated with commercialization and business development efforts as the Company prepares for a product launch, including costs for data analytics, marketing and commercial launch support. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Facilities related expense primarily includes rental costs and other facilities-related costs for the Company&#8217;s corporate headquarters in Pasadena, California. These expenses increased $0.9 million, or 76%, for the three months ended June&#160;30, 2025 and $1.3 million, or 39%, for the nine months ended June&#160;30, 2025 compared to the same periods of 2024. The increase was primarily driven by higher common area maintenance charges, increased staff amenities expenses, and an increase in headcount.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stock compensation expense, a non-cash expense, is based on the valuation of the restricted stock units granted to employees, which is based on the closing stock price on the grant date. These expenses decreased $4.4 million, or 45%, for the three months ended June&#160;30, 2025 and $9.5 million, or 31%, for the nine months ended June&#160;30, 2025 compared to the same periods of 2024. The decrease was primarily due to lower compensation costs related to performance awards, as the timing of these expenses can vary based on the achievement of related performance targets. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense, a noncash expense, was primarily related to amortization of leasehold improvements for the Company&#8217;s corporate headquarters.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other (Expense) Income</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other (expense) income is primarily related to interest income and expense. Other expense increased $15.7 million and $38.0 million for the three and nine months ended June&#160;30, 2025 compared to the same periods of 2024. The increase was primarily due to non-cash interest expense associated with the liability related to the sale of future royalties and the Credit Facility, partially offset by higher income from increased investment yields.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net loss attributable to Arrowhead Pharmaceuticals, Inc. was $175.2 million and $170.8 million for the three months ended June&#160;30, 2025 and 2024, respectively. Net income attributable to Arrowhead Pharmaceuticals, Inc. was $22.1 million for the nine months ended June&#160;30, 2025 compared to a net loss attributable to Arrowhead Pharmaceuticals, Inc. of $429.0 million for the same period of 2024. Net loss per diluted share was $1.26 and $1.38 for the three months ended June&#160;30, 2025 and 2024, respectively. Net income per diluted share was $0.17 for the nine months ended June&#160;30, 2025 compared to net loss per diluted share of $3.63 for the same period of 2024. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The increase in net loss attributable to Arrowhead Pharmaceuticals, Inc. for the three months ended June&#160;30, 2025 compared to the same period of 2024 was primarily due to higher research and development expenses as the Company's pipeline of candidates has expanded and progressed through clinical trial phases, as well as higher interest expense related to the Financing Agreement. The increase in net income for the nine months ended June&#160;30, 2025 compared to the same period of 2024 was primarily due to an increase in revenue from the Sarepta Collaboration Agreement, partially offset by higher research and development expenses, which have continued to increase as the Company's pipeline of candidates has expanded and progressed through clinical trial phases.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="ib8da3572c2184cf591d7511966d9e9c1_88"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has historically financed its operations through the sale of its equity securities, credit facility, revenue from its licensing and collaboration agreements, and the sale of certain future royalties. Research and development activities have required significant capital investment since the Company&#8217;s inception and are expected to continue to require significant cash expenditure as the Company&#8217;s pipeline continues to expand and matures into later stage clinical trials, including commercialization efforts. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash, cash equivalents and restricted cash was $129.8 million as of June&#160;30, 2025 compared to $102.7 million as of September&#160;30, 2024. Cash invested in available-for-sale securities was $770.6 million as of June&#160;30, 2025 compared to $578.3 million as of September&#160;30, 2024.</span><span style="color:#ee2724;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On December 2, 2022, the Company entered into an open market sale agreement (the &#8220;Open Market Sale Agreement&#8221;), pursuant to which the Company may, from time to time, sell up to $250.0 million in shares of the Company&#8217;s common stock through Jefferies LLC, acting as the sales agent and/or principal, in an at-the-market offering. As of June&#160;30, 2025, no shares have been issued under the Open Market Sale Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In August 2024, the Company entered into the Credit Facility, which provides for a senior secured term loan facility of $500.0&#160;million, which includes $400.0&#160;million funded on the closing date with an additional $100.0&#160;million at the Company&#8217;s option during the seven-year term of the agreement. The Company received net proceeds of $388.9&#160;million, after issuance costs as of September&#160;30, 2024.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On November 25, 2024, the Company entered into a licensing and collaboration agreement with Sarepta. Upon closing, the Company received $325.0 million for the purchase of 11,926,301 shares of common stock, at a price per share of $27.25, and received $500.0 million as an upfront payment on February 24, 2025. The Company is eligible to receive additional milestones of up to $350.0 million over the 12 months from the date of this report. In the event of Sarepta's termination of the licensing and collaboration agreement for convenience, the Company would remain entitled to receive milestone payments totaling $300.0 million in the aggregate minus any milestone previously paid.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Based upon the Company's current cash and investment resources and operating plan, the Company expects to have sufficient liquidity to fund its operations through at least the next twelve months from the date of the issuance of these unaudited consolidated financial statements.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of cash flows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Nine Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Cash Flow from:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">159,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(325,635)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(201,913)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(197,149)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">70,337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">481,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Net increase (decrease) in cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">27,485&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(41,353)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Cash, cash equivalents and restricted cash at end of period</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">129,793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">69,399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended June&#160;30, 2025, cash flow provided by operating activities was $159.1 million, which was primarily due to $500.0 million of cash received as part of the Sarepta agreement, partially offset by ongoing expenses related to the Company's research and development programs and general and administrative expenses. Cash used in investing activities amounted to $201.9 million, which was primarily attributable to capital expenditures of $15.2 million and investment purchases of $774.6 million, partially offset by proceeds from maturities of investments of $587.9 million. Cash provided by financing activities of $70.3 million was primarily related to cash received from the issuance of common stock in the Sarepta agreement and pre-funded warrants and stock option exercises (See Note 6 &#8212; Stockholders&#8217;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Equity of Notes to Consolidated Financial Statements of Part I, &#8220;Item 1. Financial Statements&#8221;). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended June&#160;30, 2024, cash flow used in operating activities was $325.6 million, which was primarily due to the ongoing expenses related to the Company&#8217;s research and development programs and general and administrative expenses. Cash used in investing activities was $197.1 million, which was primarily attributable to capital expenditures of $117.2 million and investment purchases of $428.6 million, partially offset by proceeds from sales and maturities of investments of $348.6 million. Cash provided by financing activities of $481.4 million was primarily related to cash received from the issuance of common stock as well as stock option exercises.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Contractual Obligations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into an amendment to the Financing Agreement with Sixth Street Lending Partners on November 24, 2024 (see Note 12). There has been no other material change in the Company&#8217;s contractual obligations from that described in Item 7 of its Annual Report on Form 10-K for the fiscal year ended September&#160;30, 2024.</span></div><div id="ib8da3572c2184cf591d7511966d9e9c1_91"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There has been no material change in the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Company</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">s</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> exposure to market risk from that described in Item 7A of its Annual Report on Form 10-K for the fiscal year ended September&#160;30, 2024.</span></div><div id="ib8da3572c2184cf591d7511966d9e9c1_94"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:12pt;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains disclosure controls and procedures designed to ensure that information required to be disclosed in its reports filed under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC rules and forms, and that such information is accumulated and communicated to its management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management necessarily was required to apply its judgment in evaluating the cost benefit relationship of possible controls and procedures.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As required by Rule 13a-15(b) of the Exchange Act, the Company carried out an evaluation, under the supervision and with the participation of its management, including its Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of the Company&#8217;s disclosure controls and procedures as of the end of the quarter covered by this Quarterly Report on Form 10-Q. Based on the foregoing, the Company&#8217;s Chief Executive Officer and Chief Financial Officer concluded that the Company&#8217;s disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There has been no change in the Company&#8217;s internal control over financial reporting during the Company&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting. The Company regularly evaluates its controls and procedures and makes improvements in the design and effectiveness of established controls and procedures and the remediation of any deficiencies which may be identified during this process.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><div id="ib8da3572c2184cf591d7511966d9e9c1_97"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PART II&#8212;OTHER INFORMATION</span></div><div id="ib8da3572c2184cf591d7511966d9e9c1_100"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be involved in routine legal proceedings, as well as demands, claims and threatened litigation, which arise in the normal course of its business. Litigation can be expensive and disruptive to normal business operations. Moreover, the results of legal proceedings, particularly complex legal proceedings, cannot be predicted with any certainty. There have been no material developments in the legal proceedings that the Company disclosed in Part I, Item 3 of its Annual Report on Form 10-K for the fiscal year ended September&#160;30, 2024.</span></div><div id="ib8da3572c2184cf591d7511966d9e9c1_103"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A.&#160;&#160;&#160;&#160;RISK FACTORS</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">s business, results of operations and financial conditions are subject to various risks. These risks are described elsewhere in this Quarterly Report on Form 10-Q and in the Company</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">s other filings with the SEC, including the Company</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">s Annual Report on Form 10-K for the fiscal year ended September&#160;30, 2024. There have been no material changes from the risk factors identified in the Company</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">s Annual Report on Form 10-K for the fiscal year ended September&#160;30, 2024.</span></div><div id="ib8da3572c2184cf591d7511966d9e9c1_106"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ib8da3572c2184cf591d7511966d9e9c1_109"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">None. </span></div><div id="ib8da3572c2184cf591d7511966d9e9c1_112"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable. </span></div><div id="ib8da3572c2184cf591d7511966d9e9c1_115"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(c) Trading Plans</span></div><div style="margin-top:3pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the quarter ended June&#160;30, 2025, no director or officer (as defined in Exchange Act Rule 16a-1(f)) <ix:nonNumeric contextRef="c-5" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-1034"><ix:nonNumeric contextRef="c-5" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-1035">adopted</ix:nonNumeric></ix:nonNumeric> or <ix:nonNumeric contextRef="c-5" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-1036"><ix:nonNumeric contextRef="c-5" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-1037">terminated</ix:nonNumeric></ix:nonNumeric> any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><div id="ib8da3572c2184cf591d7511966d9e9c1_121"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6.&#160;&#160;&#160;&#160;EXHIBITS</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.173%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Document Description</span></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000119312516532364/d175317dex33.htm">Amended and Restated Certificate of Incorporation (incorporated by reference from Exhibit 3.3 of the Company&#8217;s Form 8-K filed on April 6, 2016)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828023014856/arrowheadpharmaceuticals.htm">Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Arrowhead Pharmaceuticals, Inc</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">. </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000119312516532364/d175317dex33.htm">(incorporated by reference from Exhibit 3.2 of the Company&#8217;s Form 10-Q filed on May 2, 2023)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">3.3</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828023001757/arrowheadpharmaceuticals.htm">Second Amended and Restated Bylaws of Arrowhead Pharmaceuticals, Inc., as amended January 24, 2023</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828023001757/arrowheadpharmaceuticals.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828023001757/arrowheadpharmaceuticals.htm">(incorporated by reference from Exhibit 3.3 of the Company&#8217;s Form 10-Q filed on May 2, 2023)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">10.1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828025024666/ceoseveranceandchangeofcon.htm">Severance and Change of Control Agreement by and between Company and Christopher Anzalone, dated May 9, 2025</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828025024666/ceoseveranceandchangeofcon.htm"> (incorporated by reference from Exhibit 10.1 of the </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828025024666/ceoseveranceandchangeofcon.htm">Company&#8217;s</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828025024666/ceoseveranceandchangeofcon.htm"> Form 10-Q filed on May 12, 2025)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">10.2</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828025024666/cfoseveranceandchangeofcon.htm">Severance and Change of Control Agreement by and between Company and Daniel Apel, dated May 8, 2025</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828025024666/cfoseveranceandchangeofcon.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828025024666/cfoseveranceandchangeofcon.htm">(incorporated by reference from Exhibit 10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828025024666/cfoseveranceandchangeofcon.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828025024666/cfoseveranceandchangeofcon.htm"> of the </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828025024666/cfoseveranceandchangeofcon.htm">Company&#8217;s</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828025024666/cfoseveranceandchangeofcon.htm"> Form 10-Q filed on May 12, 2025)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">10.3</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828025024666/severanceandchangeofcontro.htm">Severance and Change of Control Agreement by and between Company and Patrick O'Brien, dated May 9, 2025</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828025024666/severanceandchangeofcontro.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828025024666/severanceandchangeofcontro.htm">(incorporated by reference from Exhibit 10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828025024666/severanceandchangeofcontro.htm">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828025024666/severanceandchangeofcontro.htm"> of the </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828025024666/severanceandchangeofcontro.htm">Company&#8217;s</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828025024666/severanceandchangeofcontro.htm"> Form 10-Q filed on May 12, 2025)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">10.4</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828025024666/cmoseveranceandchangeofcon.htm">Severance and Change of Control Agreement by and between Company and James Hamilton, dated May 8, 2025</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828025024666/cmoseveranceandchangeofcon.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828025024666/cmoseveranceandchangeofcon.htm">(incorporated by reference from Exhibit 10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828025024666/cmoseveranceandchangeofcon.htm">4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828025024666/cmoseveranceandchangeofcon.htm"> of the </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828025024666/cmoseveranceandchangeofcon.htm">Company&#8217;s</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828025024666/cmoseveranceandchangeofcon.htm"> Form 10-Q filed on May 12, 2025)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">10.5</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828025024666/retirementletteragreement-.htm">CFO Retirement Letter by and between Company and Ken Myszkowski, dated May 9, 2025</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828025024666/retirementletteragreement-.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828025024666/retirementletteragreement-.htm">(incorporated by reference from Exhibit 10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828025024666/retirementletteragreement-.htm">5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828025024666/retirementletteragreement-.htm"> of the </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828025024666/retirementletteragreement-.htm">Company&#8217;s</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828025024666/retirementletteragreement-.htm"> Form 10-Q filed on May 12, 2025)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">10.6*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="a106amendmentno12tolease.htm">Amendment No. 1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="a106amendmentno12tolease.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="a106amendmentno12tolease.htm"> to Lease Agreement by and between Arrowhead Madison, Inc. and University Research Park, dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="a106amendmentno12tolease.htm">June</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="a106amendmentno12tolease.htm"> 1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="a106amendmentno12tolease.htm">1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="a106amendmentno12tolease.htm">, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="a106amendmentno12tolease.htm">5</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">31.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="arwr-06302025xexx311.htm">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">31.2*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="arwr-06302025xexx312.htm">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">32.1**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="arwr-06302025xexx321.htm">Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">32.2**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="arwr-06302025xexx322.htm">Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Inline XBRL Instance Document </span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">104*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">The cover page from this Quarterly Report on Form 10-Q, formatted in Inline XBRL (included as Exhibit 101)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_________________</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31pt">Filed herewith.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">**</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26pt">Furnished herewith.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8224;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">          </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Certain portions of this exhibit were redacted by means of marking such portions with asterisks because the identified portions are (i) not material and (ii) treated as private or confidential by the Company.</span></div><div style="text-indent:-18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><div id="ib8da3572c2184cf591d7511966d9e9c1_124"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">SIGNATURE</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Quarterly Report on Form 10-Q to be signed on its behalf by the undersigned, thereunto duly authorized. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Dated: August&#160;7, 2025</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.720%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ARROWHEAD PHARMACEUTICALS, INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Daniel Apel</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Daniel Apel<br/>Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Financial Officer and Duly Authorized Officer)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>2
<FILENAME>a106amendmentno12tolease.htm
<DESCRIPTION>EX-10.6
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>a106amendmentno12tolease</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- a106amendmentno12tolease001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="a106amendmentno12tolease001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- a106amendmentno12tolease002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="a106amendmentno12tolease002.jpg" title="slide2" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- a106amendmentno12tolease003.jpg -->
<DIV style="padding-top:2em;">
<IMG src="a106amendmentno12tolease003.jpg" title="slide3" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- a106amendmentno12tolease004.jpg -->
<DIV style="padding-top:2em;">
<IMG src="a106amendmentno12tolease004.jpg" title="slide4" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- a106amendmentno12tolease005.jpg -->
<DIV style="padding-top:2em;">
<IMG src="a106amendmentno12tolease005.jpg" title="slide5" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- a106amendmentno12tolease006.jpg -->
<DIV style="padding-top:2em;">
<IMG src="a106amendmentno12tolease006.jpg" title="slide6" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>arwr-06302025xexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="idbfaa372f0274f31a5ff532f13f1eb56_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">I, Christopher Anzalone, Chief Executive Officer of Arrowhead Pharmaceuticals, Inc., certify that&#58; </font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Arrowhead Pharmaceuticals, Inc.&#59; </font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58; </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and </font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August&#160;7, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; CHRISTOPHER ANZALONE</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Christopher Anzalone</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>arwr-06302025xexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ia70cdc79f6e14e00928b4894f5ea9ff1_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">I, Daniel Apel, Chief Financial Officer of Arrowhead Pharmaceuticals, Inc., certify that&#58; </font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Arrowhead Pharmaceuticals, Inc.&#59; </font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58; </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and </font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August&#160;7, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Daniel Apel</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Daniel Apel</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>arwr-06302025xexx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i4ed09446122d421c9eb1b077505943f6_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">I, Christopher Anzalone, Chief Executive Officer of Arrowhead Pharmaceuticals, Inc. (the &#8220;Company&#8221;), certify, pursuant to Rule 13(a)-14(b) or Rule 15(d)-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, that (i) the Quarterly Report on Form 10-Q of the Company for the quarterly period ended June&#160;30, 2025, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and (ii) the information contained in such Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of the Company. </font></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August&#160;7, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; C</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">HRISTOPHER</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"> A</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">NZALONE</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Christopher Anzalone</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of these written statements required by 18 U.S.C. Section 1350 has been provided to Arrowhead Pharmaceuticals, Inc. and will be retained by Arrowhead Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff upon request. </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>arwr-06302025xexx322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i45f046fbada84bf2865a1121f717e3b9_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="margin-top:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">I, Daniel Apel, Chief Financial Officer of Arrowhead Pharmaceuticals, Inc. (the &#8220;Company&#8221;), certify, pursuant to Rule 13(a)-14(b) or Rule 15(d)-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, that (i) the Quarterly Report on Form 10-Q of the Company for the quarterly period ended June&#160;30, 2025, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and (ii) the information contained in such Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of the Company. </font></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August&#160;7, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Daniel Apel</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Daniel Apel</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of these written statements required by 18 U.S.C. Section 1350 has been provided to Arrowhead Pharmaceuticals, Inc. and will be retained by Arrowhead Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff upon request. </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>arwr-20250630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:774aaf13-8f26-4ca1-8d87-74a19a24be14,g:58a47ad1-6a7b-4244-af8c-bd7fa2a79e94-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:arwr="http://www.arrowheadresearch.com/20250630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.arrowheadresearch.com/20250630">
  <xs:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2025" schemaLocation="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arwr-20250630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arwr-20250630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arwr-20250630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arwr-20250630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.arrowheadresearch.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets">
        <link:definition>9952151 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>9952152 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperationsandComprehensiveLossIncome" roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome">
        <link:definition>9952153 - Statement - Consolidated Statements of Operations and Comprehensive (Loss) Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>9952154 - Statement - Consolidated Statements of Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>9952155 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSignificantAccountingPolicies" roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies">
        <link:definition>9952156 - Disclosure - Organization and Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreements" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreements">
        <link:definition>9952157 - Disclosure - Collaboration and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccounts" roleURI="http://www.arrowheadresearch.com/role/BalanceSheetAccounts">
        <link:definition>9952158 - Disclosure - Balance Sheet Accounts</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investments" roleURI="http://www.arrowheadresearch.com/role/Investments">
        <link:definition>9952159 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssets" roleURI="http://www.arrowheadresearch.com/role/IntangibleAssets">
        <link:definition>9952160 - Disclosure - Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.arrowheadresearch.com/role/StockholdersEquity">
        <link:definition>9952161 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.arrowheadresearch.com/role/CommitmentsandContingencies">
        <link:definition>9952162 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.arrowheadresearch.com/role/Leases">
        <link:definition>9952163 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensation">
        <link:definition>9952164 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurements">
        <link:definition>9952165 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilityRelatedtotheSaleofFutureRoyalties" roleURI="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyalties">
        <link:definition>9952166 - Disclosure - Liability Related to the Sale of Future Royalties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancingAgreement" roleURI="http://www.arrowheadresearch.com/role/FinancingAgreement">
        <link:definition>9952167 - Disclosure - Financing Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossIncomePerShare" roleURI="http://www.arrowheadresearch.com/role/NetLossIncomePerShare">
        <link:definition>9952168 - Disclosure - Net (Loss) Income Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.arrowheadresearch.com/role/IncomeTaxes">
        <link:definition>9952169 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.arrowheadresearch.com/role/SubsequentEvents">
        <link:definition>9952170 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSignificantAccountingPoliciesPolicies" roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies">
        <link:definition>9955511 - Disclosure - Organization and Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSignificantAccountingPoliciesTables" roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesTables">
        <link:definition>9955512 - Disclosure - Organization and Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsTables" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTables">
        <link:definition>9955513 - Disclosure - Collaboration and License Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountsTables" roleURI="http://www.arrowheadresearch.com/role/BalanceSheetAccountsTables">
        <link:definition>9955514 - Disclosure - Balance Sheet Accounts (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsTables" roleURI="http://www.arrowheadresearch.com/role/InvestmentsTables">
        <link:definition>9955515 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsTables" roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsTables">
        <link:definition>9955516 - Disclosure - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.arrowheadresearch.com/role/StockholdersEquityTables">
        <link:definition>9955517 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.arrowheadresearch.com/role/LeasesTables">
        <link:definition>9955518 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationTables">
        <link:definition>9955519 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurementsTables">
        <link:definition>9955520 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilityRelatedtotheSaleofFutureRoyaltiesTables" roleURI="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesTables">
        <link:definition>9955521 - Disclosure - Liability Related to the Sale of Future Royalties (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancingAgreementTables" roleURI="http://www.arrowheadresearch.com/role/FinancingAgreementTables">
        <link:definition>9955522 - Disclosure - Financing Agreement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossIncomePerShareTables" roleURI="http://www.arrowheadresearch.com/role/NetLossIncomePerShareTables">
        <link:definition>9955523 - Disclosure - Net (Loss) Income Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>9955524 - Disclosure - Organization and Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsRevenueDetails" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails">
        <link:definition>9955525 - Disclosure - Collaboration and License Agreements - Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsReceivablesandContractLiabilitiesDetails" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsReceivablesandContractLiabilitiesDetails">
        <link:definition>9955526 - Disclosure - Collaboration and License Agreements - Receivables and Contract Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedGSKDetails" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedGSKDetails">
        <link:definition>9955527 - Disclosure - Collaboration and License Agreements - GlaxoSmithKline Intellectual Property (No. 3) Limited (&#8220;GSK&#8221;) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails">
        <link:definition>9955528 - Disclosure - Collaboration and License Agreements - Takeda Pharmaceutical Company Limited (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsAmgenIncDetails" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails">
        <link:definition>9955529 - Disclosure - Collaboration and License Agreements - Amgen, Inc (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails">
        <link:definition>9955530 - Disclosure - Collaboration and License Agreements - Sarepta Therapeutics, Inc. (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsSareptaTherapeuticsIncConsiderationComponentsDetails" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncConsiderationComponentsDetails">
        <link:definition>9955531 - Disclosure - Collaboration and License Agreements - Sarepta Therapeutics, Inc. Consideration Components (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountsPropertyPlantandEquipmentDetails" roleURI="http://www.arrowheadresearch.com/role/BalanceSheetAccountsPropertyPlantandEquipmentDetails">
        <link:definition>9955532 - Disclosure - Balance Sheet Accounts - Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountsNarrativeDetails" roleURI="http://www.arrowheadresearch.com/role/BalanceSheetAccountsNarrativeDetails">
        <link:definition>9955533 - Disclosure - Balance Sheet Accounts - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountsAccruedExpensesDetails" roleURI="http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails">
        <link:definition>9955534 - Disclosure - Balance Sheet Accounts - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsScheduleofShorttermLongtermInvestmentsandMarketableSecuritiesDetails" roleURI="http://www.arrowheadresearch.com/role/InvestmentsScheduleofShorttermLongtermInvestmentsandMarketableSecuritiesDetails">
        <link:definition>9955535 - Disclosure - Investments - Schedule of Short-term, Long-term Investments and Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsScheduleofContractMaturityofAvailableforSaleDetails" roleURI="http://www.arrowheadresearch.com/role/InvestmentsScheduleofContractMaturityofAvailableforSaleDetails">
        <link:definition>9955536 - Disclosure - Investments - Schedule of Contract Maturity of Available for Sale (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsScheduleofIntangibleAssetsDetails" roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails">
        <link:definition>9955537 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsScheduleofExpectedFutureAmortizationDetails" roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofExpectedFutureAmortizationDetails">
        <link:definition>9955538 - Disclosure - Intangible Assets - Schedule of Expected Future Amortization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleofSharesofCommonStockandPreferredStockDetails" roleURI="http://www.arrowheadresearch.com/role/StockholdersEquityScheduleofSharesofCommonStockandPreferredStockDetails">
        <link:definition>9955539 - Disclosure - Stockholders' Equity - Schedule of Shares of Common Stock and Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>9955540 - Disclosure - Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.arrowheadresearch.com/role/CommitmentsandContingenciesDetails">
        <link:definition>9955541 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.arrowheadresearch.com/role/LeasesNarrativeDetails">
        <link:definition>9955542 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofComponentsofLeaseAssetsandLiabilitiesDetails" roleURI="http://www.arrowheadresearch.com/role/LeasesScheduleofComponentsofLeaseAssetsandLiabilitiesDetails">
        <link:definition>9955543 - Disclosure - Leases - Schedule of Components of Lease Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails" roleURI="http://www.arrowheadresearch.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails">
        <link:definition>9955544 - Disclosure - Leases - Schedule of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1" roleURI="http://www.arrowheadresearch.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1">
        <link:definition>9955544 - Disclosure - Leases - Schedule of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofCashFlowandOtherInformationRelatedtoLeasesDetails" roleURI="http://www.arrowheadresearch.com/role/LeasesScheduleofCashFlowandOtherInformationRelatedtoLeasesDetails">
        <link:definition>9955545 - Disclosure - Leases - Schedule of Cash Flow and Other Information Related to Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>9955546 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofGrantedandOutstandingSharesDetails" roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofGrantedandOutstandingSharesDetails">
        <link:definition>9955547 - Disclosure - Stock-Based Compensation - Schedule of Granted and Outstanding Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofExpensesIncludedinOperatingExpensesDetails" roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofExpensesIncludedinOperatingExpensesDetails">
        <link:definition>9955548 - Disclosure - Stock-Based Compensation - Schedule of Expenses Included in Operating Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofInformationaboutStockOptionsDetails" roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofInformationaboutStockOptionsDetails">
        <link:definition>9955549 - Disclosure - Stock-Based Compensation - Schedule of Information about Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofRSUsActivityDetails" roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofRSUsActivityDetails">
        <link:definition>9955550 - Disclosure - Stock-Based Compensation - Schedule of RSUs Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
        <link:definition>9955551 - Disclosure - Fair Value Measurements - Schedule of Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails" roleURI="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails">
        <link:definition>9955552 - Disclosure - Liability Related to the Sale of Future Royalties - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilityRelatedtotheSaleofFutureRoyaltiesActivityDetails" roleURI="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesActivityDetails">
        <link:definition>9955553 - Disclosure - Liability Related to the Sale of Future Royalties - Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancingAgreementNarrativeDetails" roleURI="http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails">
        <link:definition>9955554 - Disclosure - Financing Agreement - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancingAgreementScheduleofOutstandingBalanceofCreditFacilityDetails" roleURI="http://www.arrowheadresearch.com/role/FinancingAgreementScheduleofOutstandingBalanceofCreditFacilityDetails">
        <link:definition>9955555 - Disclosure - Financing Agreement - Schedule of Outstanding Balance of Credit Facility (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancingAgreementScheduleofInterestExpenseRecognizedRelatedtoCreditFacilityDetails" roleURI="http://www.arrowheadresearch.com/role/FinancingAgreementScheduleofInterestExpenseRecognizedRelatedtoCreditFacilityDetails">
        <link:definition>9955556 - Disclosure - Financing Agreement - Schedule of Interest Expense Recognized Related to Credit Facility (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails" roleURI="http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails">
        <link:definition>9955557 - Disclosure - Financing Agreement - Principal Repayment Related to Credit Facility (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossIncomePerShareScheduleofBasicandDilutedNetLossPerShareDetails" roleURI="http://www.arrowheadresearch.com/role/NetLossIncomePerShareScheduleofBasicandDilutedNetLossPerShareDetails">
        <link:definition>9955558 - Disclosure - Net (Loss) Income Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossIncomePerShareScheduleofAntidilutiveSecuritiesDetails" roleURI="http://www.arrowheadresearch.com/role/NetLossIncomePerShareScheduleofAntidilutiveSecuritiesDetails">
        <link:definition>9955559 - Disclosure - Net (Loss) Income Per Share - Schedule of Antidilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.arrowheadresearch.com/role/IncomeTaxesDetails">
        <link:definition>9955560 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.arrowheadresearch.com/role/SubsequentEventsDetails">
        <link:definition>9955561 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="arwr_RoyaltiesLiabilityNoncurrent" abstract="false" name="RoyaltiesLiabilityNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" abstract="false" name="NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_ProceedsFromSaleOfFutureRoyalties" abstract="false" name="ProceedsFromSaleOfFutureRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_CashFlowNoncashInvestingActivitiesDisclosureAbstract" abstract="true" name="CashFlowNoncashInvestingActivitiesDisclosureAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arwr_CollaborationAndLicenseAgreementsAbstract" abstract="true" name="CollaborationAndLicenseAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract" abstract="true" name="LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" abstract="false" name="LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="arwr_ScheduleOfCurrentProductsTableTextBlock" abstract="false" name="ScheduleOfCurrentProductsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" abstract="false" name="HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="arwr_ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock" abstract="false" name="ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="arwr_SummaryOfInterestExpenseRecognizedRelatedToCreditFacilityTableTextBlock" abstract="false" name="SummaryOfInterestExpenseRecognizedRelatedToCreditFacilityTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="arwr_SareptaMember" abstract="true" name="SareptaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_GlaxosmithklineIntellectualPropertyLimitedMember" abstract="true" name="GlaxosmithklineIntellectualPropertyLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_SareptaCollaborationAgreementMember" abstract="true" name="SareptaCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_GSKHBVAgreementMember" abstract="true" name="GSKHBVAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_DevelopmentMilestonePayments" abstract="false" name="DevelopmentMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_ProceedsFromCollaborationArrangements" abstract="false" name="ProceedsFromCollaborationArrangements" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_AdditionalCashReceivableUnderCollaborationAgreement" abstract="false" name="AdditionalCashReceivableUnderCollaborationAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod" abstract="false" name="CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="arwr_EnrollmentRelatedMilestonePayments" abstract="false" name="EnrollmentRelatedMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_FuturePotentialMilestonePayments" abstract="false" name="FuturePotentialMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_IncreaseDecreaseInCashAndInvestments" abstract="false" name="IncreaseDecreaseInCashAndInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" abstract="false" name="DevelopmentRegulatoryAndSalesMilestonesPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" abstract="true" name="TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_SareptaTherapeuticsIncMember" abstract="true" name="SareptaTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_GSKHSDLicenseAgreementMember" abstract="true" name="GSKHSDLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_InitialTransactionPrice" abstract="false" name="InitialTransactionPrice" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_MilestonePaymentReceivable" abstract="false" name="MilestonePaymentReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" abstract="false" name="MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_CommercialMilestonePaymentsAtFirstCommercialSale" abstract="false" name="CommercialMilestonePaymentsAtFirstCommercialSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_SalesRelatedMilestonePayments" abstract="false" name="SalesRelatedMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_DevelopmentAndSalesMilestonesPayments" abstract="false" name="DevelopmentAndSalesMilestonesPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_LicenseAndCoFundingAgreementMember" abstract="true" name="LicenseAndCoFundingAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" abstract="false" name="PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="arwr_NumberOfDistinctBundle" abstract="false" name="NumberOfDistinctBundle" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="arwr_MilestonePaymentEarned" abstract="false" name="MilestonePaymentEarned" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_AmgenIncorporatedMember" abstract="true" name="AmgenIncorporatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_OlpasiranAgreementMember" abstract="true" name="OlpasiranAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_NumberOfAgreements" abstract="false" name="NumberOfAgreements" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" abstract="false" name="AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_NumberOfNewTargetPrograms" abstract="false" name="NumberOfNewTargetPrograms" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="arwr_NumberOfPerformanceObligations" abstract="false" name="NumberOfPerformanceObligations" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="arwr_SaleOfStockPremiumOnIssuanceOfShares" abstract="false" name="SaleOfStockPremiumOnIssuanceOfShares" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_CashReceivableUnderCollaborationAgreementAnnualInstallments" abstract="false" name="CashReceivableUnderCollaborationAgreementAnnualInstallments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_CollaborationArrangementFixedConsideration" abstract="false" name="CollaborationArrangementFixedConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_CollaborationArrangementConsideration" abstract="false" name="CollaborationArrangementConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_NumberOfCollaborationPrograms" abstract="false" name="NumberOfCollaborationPrograms" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="arwr_RegulatoryMilestonePayments" abstract="false" name="RegulatoryMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_CollaborationArrangementTerminationNoticePeriodPriorToRegulatoryApproval" abstract="false" name="CollaborationArrangementTerminationNoticePeriodPriorToRegulatoryApproval" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="arwr_CollaborationArrangementVariableConsideration" abstract="false" name="CollaborationArrangementVariableConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_ResearchEquipmentMember" abstract="true" name="ResearchEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_ManufacturingEquipmentMember" abstract="true" name="ManufacturingEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_ComputerAndSoftwareMember" abstract="true" name="ComputerAndSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_ConstructionInProgressReclassifiedToBuildingMember" abstract="true" name="ConstructionInProgressReclassifiedToBuildingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_ConstructionInProgressReclassifiedToManufacturingEquipmentMember" abstract="true" name="ConstructionInProgressReclassifiedToManufacturingEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_AccruedResearchAndDevelopmentExpenseCurrent" abstract="false" name="AccruedResearchAndDevelopmentExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent" abstract="false" name="AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_AccruedCapitalExpenditureCurrent" abstract="false" name="AccruedCapitalExpenditureCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" abstract="true" name="ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" abstract="true" name="ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent" abstract="false" name="DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent" abstract="false" name="DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" abstract="false" name="DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree" abstract="false" name="DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_NovartisMember" abstract="true" name="NovartisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_FiniteLivedIntangibleAssetsImpairment" abstract="false" name="FiniteLivedIntangibleAssetsImpairment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" abstract="false" name="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" abstract="true" name="TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_AtTheMarketAgreementMember" abstract="true" name="AtTheMarketAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights" abstract="false" name="ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="arwr_ClassOfWarrantOrRightNumberOfWarrantsExercised" abstract="false" name="ClassOfWarrantOrRightNumberOfWarrantsExercised" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" abstract="false" name="CommonStockCapitalSharesValueReservedForFutureIssuance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" abstract="false" name="PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="arwr_DrugManufacturingFacilityMember" abstract="true" name="DrugManufacturingFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_LaboratoryAndOfficeFacilityMember" abstract="true" name="LaboratoryAndOfficeFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_FacilitiesMember" abstract="true" name="FacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_CommitmentsCapitalExpendituresIncurredToDate" abstract="false" name="CommitmentsCapitalExpendituresIncurredToDate" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_AmountIntendsToInvestForBuildoutOfFacilities" abstract="false" name="AmountIntendsToInvestForBuildoutOfFacilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_CorporateHeadquartersInPasadenaMember" abstract="true" name="CorporateHeadquartersInPasadenaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_ResearchFacilityInSanDiegoMember" abstract="true" name="ResearchFacilityInSanDiegoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_ResearchFacilityInMadisonMember" abstract="true" name="ResearchFacilityInMadisonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_ColoradoOwnerLLCMember" abstract="true" name="ColoradoOwnerLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_NumberOfOptionsToRenew" abstract="false" name="NumberOfOptionsToRenew" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="arwr_ProceedsFromTenantImprovementAllowance" abstract="false" name="ProceedsFromTenantImprovementAllowance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" abstract="true" name="CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities" abstract="false" name="OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability" abstract="false" name="RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_TwoThousandsThirteenIncentivePlanMember" abstract="true" name="TwoThousandsThirteenIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_TwoThousandTwentyOneIncentivePlanMember" abstract="true" name="TwoThousandTwentyOneIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_InducementPlanMember" abstract="true" name="InducementPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_VisirnaESOPMember" abstract="true" name="VisirnaESOPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_InducementAwardsMember" abstract="true" name="InducementAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="arwr_CommercialNotesMember" abstract="true" name="CommercialNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_RoyaltyPharmaAgreementMember" abstract="true" name="RoyaltyPharmaAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties" abstract="false" name="UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" abstract="false" name="MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_MilestonePaymentReceivableUponFDAApproval" abstract="false" name="MilestonePaymentReceivableUponFDAApproval" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" abstract="false" name="MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_RoyaltyPaymentThreshold" abstract="false" name="RoyaltyPaymentThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties" abstract="false" name="MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_LiabilitySaleOfFutureRoyaltiesInterestRate" abstract="false" name="LiabilitySaleOfFutureRoyaltiesInterestRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="arwr_LiabilitySaleOfFutureRoyaltiesRollForward" abstract="true" name="LiabilitySaleOfFutureRoyaltiesRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arwr_FinancingAgreementMember" abstract="true" name="FinancingAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_FinancingAgreementInitialTermLoanMember" abstract="true" name="FinancingAgreementInitialTermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_FinancingAgreementMOICPaymentMember" abstract="true" name="FinancingAgreementMOICPaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_DebtInstrumentCovenantMultipleOfInvestCapital" abstract="false" name="DebtInstrumentCovenantMultipleOfInvestCapital" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="arwr_DebtInstrumentPrepaymentPercentage" abstract="false" name="DebtInstrumentPrepaymentPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="arwr_DebtInstrumentMultipleOfInvestmentCapitalExpectedToBeAppliedToPrincipalUponRepayment" abstract="false" name="DebtInstrumentMultipleOfInvestmentCapitalExpectedToBeAppliedToPrincipalUponRepayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_DebtInstrumentCovenantMinimumLiquidityIfCapitalizationIsAboveThreshold" abstract="false" name="DebtInstrumentCovenantMinimumLiquidityIfCapitalizationIsAboveThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_DebtInstrumentCovenantMarketCapitalizationThreshold" abstract="false" name="DebtInstrumentCovenantMarketCapitalizationThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_FinancingAgreementInitialTermLoanInterestMember" abstract="true" name="FinancingAgreementInitialTermLoanInterestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_LongTermDebtMaturityAfterYearFour" abstract="false" name="LongTermDebtMaturityAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_VisirnaTherapeuticsIncMember" abstract="true" name="VisirnaTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_SanofiLicenseAgreementMember" abstract="true" name="SanofiLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>arwr-20250630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:774aaf13-8f26-4ca1-8d87-74a19a24be14,g:58a47ad1-6a7b-4244-af8c-bd7fa2a79e94-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="arwr-20250630.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b695b52e-8e51-483b-8943-3c967ebde53b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_5b3643ce-b8e6-41bc-9a50-5b7fc621c1f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b695b52e-8e51-483b-8943-3c967ebde53b" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_5b3643ce-b8e6-41bc-9a50-5b7fc621c1f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f5bfaeea-b2af-4c99-8b9a-87de86005726" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b695b52e-8e51-483b-8943-3c967ebde53b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f5bfaeea-b2af-4c99-8b9a-87de86005726" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_7a0621bf-1938-4257-8468-20e608443ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b695b52e-8e51-483b-8943-3c967ebde53b" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_7a0621bf-1938-4257-8468-20e608443ebf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_fdd50ce1-47e3-42db-8645-ba38c80afa41" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b695b52e-8e51-483b-8943-3c967ebde53b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_fdd50ce1-47e3-42db-8645-ba38c80afa41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_1fcb344b-4ca2-4f78-8097-1790d0aee149" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b695b52e-8e51-483b-8943-3c967ebde53b" xlink:to="loc_us-gaap_OtherAssetsCurrent_1fcb344b-4ca2-4f78-8097-1790d0aee149" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_5e4c5d73-0a7e-472e-93c2-8af907e0a8da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0fdc1860-0012-40ad-8344-1d8cc5574c80" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5e4c5d73-0a7e-472e-93c2-8af907e0a8da" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0fdc1860-0012-40ad-8344-1d8cc5574c80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ca345793-e3bf-4b78-aab0-2a7be696956f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5e4c5d73-0a7e-472e-93c2-8af907e0a8da" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ca345793-e3bf-4b78-aab0-2a7be696956f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_8150375c-1e18-420c-9b42-5559a3786054" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5e4c5d73-0a7e-472e-93c2-8af907e0a8da" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_8150375c-1e18-420c-9b42-5559a3786054" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_dd056e18-9b30-4a63-a7f4-26bc80171b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5e4c5d73-0a7e-472e-93c2-8af907e0a8da" xlink:to="loc_us-gaap_AssetsCurrent_dd056e18-9b30-4a63-a7f4-26bc80171b2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_2f644aeb-ac93-4005-9bd1-a2d6c253fcb8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5e4c5d73-0a7e-472e-93c2-8af907e0a8da" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_2f644aeb-ac93-4005-9bd1-a2d6c253fcb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_686c3d93-b9e8-4866-98a9-3fdebd1a4343" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_58bb01a8-012e-426f-ab68-38669d897362" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_686c3d93-b9e8-4866-98a9-3fdebd1a4343" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_58bb01a8-012e-426f-ab68-38669d897362" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_2388b6b3-1d1b-4576-a8de-0cc90a044c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_686c3d93-b9e8-4866-98a9-3fdebd1a4343" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_2388b6b3-1d1b-4576-a8de-0cc90a044c8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_70d46a3b-fd30-4371-bf79-8664a93e7c05" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_686c3d93-b9e8-4866-98a9-3fdebd1a4343" xlink:to="loc_us-gaap_AccountsPayableCurrent_70d46a3b-fd30-4371-bf79-8664a93e7c05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_ae891766-8705-4658-bf4f-25e4cf17b8fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_686c3d93-b9e8-4866-98a9-3fdebd1a4343" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_ae891766-8705-4658-bf4f-25e4cf17b8fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_70761d90-b853-4c27-9547-8bacdb9df0b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_686c3d93-b9e8-4866-98a9-3fdebd1a4343" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_70761d90-b853-4c27-9547-8bacdb9df0b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_744e5031-c73e-4f65-91f3-ed3c436008d9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_686c3d93-b9e8-4866-98a9-3fdebd1a4343" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_744e5031-c73e-4f65-91f3-ed3c436008d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LinesOfCreditCurrent_7072cad4-2522-4d62-b30f-9a4a5099f04a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LinesOfCreditCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_686c3d93-b9e8-4866-98a9-3fdebd1a4343" xlink:to="loc_us-gaap_LinesOfCreditCurrent_7072cad4-2522-4d62-b30f-9a4a5099f04a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_158be84f-479d-486f-807e-37b8b081a3ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2e09ba5b-d947-48c3-a516-0da5d9b7279a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_158be84f-479d-486f-807e-37b8b081a3ad" xlink:to="loc_us-gaap_StockholdersEquity_2e09ba5b-d947-48c3-a516-0da5d9b7279a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_93cdac46-2d71-4723-9f2a-57a6aa56673a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_158be84f-479d-486f-807e-37b8b081a3ad" xlink:to="loc_us-gaap_MinorityInterest_93cdac46-2d71-4723-9f2a-57a6aa56673a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_16260f9a-e62a-4bda-a6ac-686cc91f6dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d2c050b9-33ae-4227-b3f6-9c80c88fd2cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_16260f9a-e62a-4bda-a6ac-686cc91f6dc1" xlink:to="loc_us-gaap_LiabilitiesCurrent_d2c050b9-33ae-4227-b3f6-9c80c88fd2cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_51645ecb-ead4-4484-9af4-9c15595f5f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_16260f9a-e62a-4bda-a6ac-686cc91f6dc1" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_51645ecb-ead4-4484-9af4-9c15595f5f5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_e7b03b20-7259-4d9f-99b1-168e32b7c1fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_16260f9a-e62a-4bda-a6ac-686cc91f6dc1" xlink:to="loc_us-gaap_CommitmentsAndContingencies_e7b03b20-7259-4d9f-99b1-168e32b7c1fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cc3dda59-bfef-4a0f-873f-7c905dc3277c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_16260f9a-e62a-4bda-a6ac-686cc91f6dc1" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cc3dda59-bfef-4a0f-873f-7c905dc3277c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1531492e-e3a7-4bf7-967e-5afd9e8ecc3d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b3711084-09dd-4b7a-b449-52826ee51193" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1531492e-e3a7-4bf7-967e-5afd9e8ecc3d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b3711084-09dd-4b7a-b449-52826ee51193" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_064d1639-f24a-45b1-aa27-cc3e9daf501f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1531492e-e3a7-4bf7-967e-5afd9e8ecc3d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_064d1639-f24a-45b1-aa27-cc3e9daf501f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_11e43fac-73c2-4b96-9510-976ab427d254" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1531492e-e3a7-4bf7-967e-5afd9e8ecc3d" xlink:to="loc_us-gaap_CommonStockValue_11e43fac-73c2-4b96-9510-976ab427d254" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e9f3f307-a0ab-4fcc-abc6-bfb7c73b2e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1531492e-e3a7-4bf7-967e-5afd9e8ecc3d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e9f3f307-a0ab-4fcc-abc6-bfb7c73b2e3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_73f49e12-db29-4beb-a6d4-aaf4a07f6700" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_adf237d1-88f8-475f-86b1-22f3bf8bf20e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_73f49e12-db29-4beb-a6d4-aaf4a07f6700" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_adf237d1-88f8-475f-86b1-22f3bf8bf20e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_ab72115f-9c16-43b5-afb5-0ad1deed64cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_73f49e12-db29-4beb-a6d4-aaf4a07f6700" xlink:to="loc_us-gaap_LongTermLineOfCredit_ab72115f-9c16-43b5-afb5-0ad1deed64cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltiesLiabilityNoncurrent_2aed043e-6881-4858-8e3c-99a9ca3f6b4e" xlink:href="arwr-20250630.xsd#arwr_RoyaltiesLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_73f49e12-db29-4beb-a6d4-aaf4a07f6700" xlink:to="loc_arwr_RoyaltiesLiabilityNoncurrent_2aed043e-6881-4858-8e3c-99a9ca3f6b4e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome" xlink:type="simple" xlink:href="arwr-20250630.xsd#ConsolidatedStatementsofOperationsandComprehensiveLossIncome"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_432007e0-e50b-4995-9afa-988c1affeab0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_ee724b1c-b042-40c8-8468-3488ebf02f27" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_432007e0-e50b-4995-9afa-988c1affeab0" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_ee724b1c-b042-40c8-8468-3488ebf02f27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3b0aa1f2-74f7-4bb5-8042-701bf78e2107" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_432007e0-e50b-4995-9afa-988c1affeab0" xlink:to="loc_us-gaap_OperatingIncomeLoss_3b0aa1f2-74f7-4bb5-8042-701bf78e2107" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_b7075b08-cca9-487e-9ce3-d70ebe4c40b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5cb95919-1bd6-4e13-ac69-0d33040e47ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_b7075b08-cca9-487e-9ce3-d70ebe4c40b2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5cb95919-1bd6-4e13-ac69-0d33040e47ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6cf26feb-4a43-4ff9-8e0e-b02bfda68c35" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_b7075b08-cca9-487e-9ce3-d70ebe4c40b2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_6cf26feb-4a43-4ff9-8e0e-b02bfda68c35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3bceff9a-2dd3-4642-b555-efb1e2e77fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e78c38a9-0599-4eae-a795-ed878ab62434" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_3bceff9a-2dd3-4642-b555-efb1e2e77fe0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e78c38a9-0599-4eae-a795-ed878ab62434" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_d75cc7ba-cb4a-497b-8d33-da1655e189a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_3bceff9a-2dd3-4642-b555-efb1e2e77fe0" xlink:to="loc_us-gaap_OperatingExpenses_d75cc7ba-cb4a-497b-8d33-da1655e189a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fd28df57-7f39-40c0-8ede-869d191331b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d90ed31a-219d-429e-8aa2-6f8a7134882f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_fd28df57-7f39-40c0-8ede-869d191331b2" xlink:to="loc_us-gaap_ProfitLoss_d90ed31a-219d-429e-8aa2-6f8a7134882f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e4dc4948-e465-45c6-8761-fd6bb843d704" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_fd28df57-7f39-40c0-8ede-869d191331b2" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e4dc4948-e465-45c6-8761-fd6bb843d704" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_fc7f6917-f326-42f3-9828-76c8ea10222f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_bb89124b-b560-4669-afd7-f840aeb8ee30" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_fc7f6917-f326-42f3-9828-76c8ea10222f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_bb89124b-b560-4669-afd7-f840aeb8ee30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_6cee722c-2ec4-453a-9e5d-9a615c54d012" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_fc7f6917-f326-42f3-9828-76c8ea10222f" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_6cee722c-2ec4-453a-9e5d-9a615c54d012" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_082a2337-93c6-437e-a3ae-1177d5084407" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_45b123d2-d11e-4cc2-8247-ccf2b37d9896" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_082a2337-93c6-437e-a3ae-1177d5084407" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_45b123d2-d11e-4cc2-8247-ccf2b37d9896" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_1e909952-d102-4bf8-90ec-705686360530" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_082a2337-93c6-437e-a3ae-1177d5084407" xlink:to="loc_us-gaap_InterestExpenseNonoperating_1e909952-d102-4bf8-90ec-705686360530" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_13b8ad7d-c35a-4132-b74e-eb91e73ea413" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_082a2337-93c6-437e-a3ae-1177d5084407" xlink:to="loc_us-gaap_InvestmentIncomeInterestAndDividend_13b8ad7d-c35a-4132-b74e-eb91e73ea413" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_8a24d3f5-0cb1-46a7-8d63-c0256f2ec1bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a1d8d909-a541-4318-bea3-7a0e365ad7f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_8a24d3f5-0cb1-46a7-8d63-c0256f2ec1bd" xlink:to="loc_us-gaap_ProfitLoss_a1d8d909-a541-4318-bea3-7a0e365ad7f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_5acd8876-3d98-4c4c-8ce9-a05a83ab3866" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_8a24d3f5-0cb1-46a7-8d63-c0256f2ec1bd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_5acd8876-3d98-4c4c-8ce9-a05a83ab3866" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_c99fcc4b-3f45-47e0-9d6f-d9a92c6e6f95" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_8a24d3f5-0cb1-46a7-8d63-c0256f2ec1bd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_c99fcc4b-3f45-47e0-9d6f-d9a92c6e6f95" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="arwr-20250630.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_60b4ea87-6909-499f-a024-4d75685ad6df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_87bf48fe-82ac-4d7b-a1db-c4796f16eaaf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_60b4ea87-6909-499f-a024-4d75685ad6df" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_87bf48fe-82ac-4d7b-a1db-c4796f16eaaf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_d568dab2-f463-4787-9534-740668adadd9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_60b4ea87-6909-499f-a024-4d75685ad6df" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_d568dab2-f463-4787-9534-740668adadd9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_ae447999-8eab-437f-8249-fd10c02d09c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_60b4ea87-6909-499f-a024-4d75685ad6df" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_ae447999-8eab-437f-8249-fd10c02d09c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2c2a90eb-7b2f-42ad-a170-ef0cadd6a3c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0df64997-8cfa-4ad9-b672-81f79d2f081e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2c2a90eb-7b2f-42ad-a170-ef0cadd6a3c1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0df64997-8cfa-4ad9-b672-81f79d2f081e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1fad884d-8d90-4054-9404-f523914491c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2c2a90eb-7b2f-42ad-a170-ef0cadd6a3c1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1fad884d-8d90-4054-9404-f523914491c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_85b386ff-4681-4b35-8736-c113205be9b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2c2a90eb-7b2f-42ad-a170-ef0cadd6a3c1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_85b386ff-4681-4b35-8736-c113205be9b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_da57f1c3-3520-452d-9c81-ac45ef97119a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_6e00316f-2740-471c-8ecc-962ec95da684" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_da57f1c3-3520-452d-9c81-ac45ef97119a" xlink:to="loc_us-gaap_ShareBasedCompensation_6e00316f-2740-471c-8ecc-962ec95da684" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_5f2688a7-e561-4c36-a0ad-29064493ec28" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_da57f1c3-3520-452d-9c81-ac45ef97119a" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_5f2688a7-e561-4c36-a0ad-29064493ec28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_0504c8bf-f401-4f4d-b34f-38b5addf9999" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_da57f1c3-3520-452d-9c81-ac45ef97119a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_0504c8bf-f401-4f4d-b34f-38b5addf9999" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_f58e87e0-a555-44c1-becd-3ee3ea46f37a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaidInKindInterest"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_da57f1c3-3520-452d-9c81-ac45ef97119a" xlink:to="loc_us-gaap_PaidInKindInterest_f58e87e0-a555-44c1-becd-3ee3ea46f37a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_6aa2691b-8c2e-4b75-a578-c0f2f7b0dba1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_da57f1c3-3520-452d-9c81-ac45ef97119a" xlink:to="loc_us-gaap_DepreciationAndAmortization_6aa2691b-8c2e-4b75-a578-c0f2f7b0dba1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d65bbb58-6666-43d3-8f2f-f3985db8fe47" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_da57f1c3-3520-452d-9c81-ac45ef97119a" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d65bbb58-6666-43d3-8f2f-f3985db8fe47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_ed9e3b05-8ab7-48f3-a259-5f66d3fc5fe9" xlink:href="arwr-20250630.xsd#arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_da57f1c3-3520-452d-9c81-ac45ef97119a" xlink:to="loc_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_ed9e3b05-8ab7-48f3-a259-5f66d3fc5fe9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_d45d026e-7516-45d4-b4aa-9192d86b0ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_da57f1c3-3520-452d-9c81-ac45ef97119a" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_d45d026e-7516-45d4-b4aa-9192d86b0ba1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_9a300bd8-1f7e-42eb-8b12-29df207cfb8a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_da57f1c3-3520-452d-9c81-ac45ef97119a" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_9a300bd8-1f7e-42eb-8b12-29df207cfb8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_61467192-7d06-46ac-ab91-d992f6dfc2b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_da57f1c3-3520-452d-9c81-ac45ef97119a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_61467192-7d06-46ac-ab91-d992f6dfc2b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a8416c0b-5645-4679-90c3-a071ad529239" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_da57f1c3-3520-452d-9c81-ac45ef97119a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a8416c0b-5645-4679-90c3-a071ad529239" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_654339e2-1b2c-41db-9587-25af44c4eeed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_da57f1c3-3520-452d-9c81-ac45ef97119a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_654339e2-1b2c-41db-9587-25af44c4eeed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_daed2019-4436-4f1f-ae8c-b845c351f696" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_da57f1c3-3520-452d-9c81-ac45ef97119a" xlink:to="loc_us-gaap_ProfitLoss_daed2019-4436-4f1f-ae8c-b845c351f696" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_4e788a5e-b304-40cf-8adb-4ac114dc32ef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_da57f1c3-3520-452d-9c81-ac45ef97119a" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_4e788a5e-b304-40cf-8adb-4ac114dc32ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9a58ef2b-455e-4219-a556-73b9d2db9746" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_4c7f8bb7-d7ff-4a96-8bfb-b82594e6a76f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9a58ef2b-455e-4219-a556-73b9d2db9746" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_4c7f8bb7-d7ff-4a96-8bfb-b82594e6a76f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_173fed19-891b-4fb7-a80b-582c76f97414" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9a58ef2b-455e-4219-a556-73b9d2db9746" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_173fed19-891b-4fb7-a80b-582c76f97414" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_1d155563-31e0-4bc1-a5a9-7d879dfad075" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9a58ef2b-455e-4219-a556-73b9d2db9746" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_1d155563-31e0-4bc1-a5a9-7d879dfad075" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_c3fad504-a09e-4414-940f-cd97cf0a032e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9a58ef2b-455e-4219-a556-73b9d2db9746" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_c3fad504-a09e-4414-940f-cd97cf0a032e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_0c9083ff-867e-4b5a-9943-4394294dc09d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9a58ef2b-455e-4219-a556-73b9d2db9746" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_0c9083ff-867e-4b5a-9943-4394294dc09d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ProceedsFromSaleOfFutureRoyalties_fe164e1f-aeb5-46f2-bf50-1e6f15e75543" xlink:href="arwr-20250630.xsd#arwr_ProceedsFromSaleOfFutureRoyalties"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9a58ef2b-455e-4219-a556-73b9d2db9746" xlink:to="loc_arwr_ProceedsFromSaleOfFutureRoyalties_fe164e1f-aeb5-46f2-bf50-1e6f15e75543" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_6dd93820-454c-4dfc-9f26-5cc8827f1af2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9a58ef2b-455e-4219-a556-73b9d2db9746" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_6dd93820-454c-4dfc-9f26-5cc8827f1af2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncConsiderationComponentsDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#CollaborationandLicenseAgreementsSareptaTherapeuticsIncConsiderationComponentsDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncConsiderationComponentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationArrangementFixedConsideration_37c9562e-b0e9-4273-a8b2-35943a944058" xlink:href="arwr-20250630.xsd#arwr_CollaborationArrangementFixedConsideration"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AdditionalCashReceivableUnderCollaborationAgreement_d1b0870a-a253-4c40-b730-36b0635e7b64" xlink:href="arwr-20250630.xsd#arwr_AdditionalCashReceivableUnderCollaborationAgreement"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_arwr_CollaborationArrangementFixedConsideration_37c9562e-b0e9-4273-a8b2-35943a944058" xlink:to="loc_arwr_AdditionalCashReceivableUnderCollaborationAgreement_d1b0870a-a253-4c40-b730-36b0635e7b64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ProceedsFromCollaborationArrangements_23782733-cb5d-4ad6-a950-1c0be5f61a8d" xlink:href="arwr-20250630.xsd#arwr_ProceedsFromCollaborationArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_arwr_CollaborationArrangementFixedConsideration_37c9562e-b0e9-4273-a8b2-35943a944058" xlink:to="loc_arwr_ProceedsFromCollaborationArrangements_23782733-cb5d-4ad6-a950-1c0be5f61a8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SaleOfStockPremiumOnIssuanceOfShares_8234e0ab-0f98-4afe-8e36-1839b1ba4534" xlink:href="arwr-20250630.xsd#arwr_SaleOfStockPremiumOnIssuanceOfShares"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_arwr_CollaborationArrangementFixedConsideration_37c9562e-b0e9-4273-a8b2-35943a944058" xlink:to="loc_arwr_SaleOfStockPremiumOnIssuanceOfShares_8234e0ab-0f98-4afe-8e36-1839b1ba4534" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationArrangementConsideration_c34d47cd-b662-4fc5-b60f-b275b7d9b208" xlink:href="arwr-20250630.xsd#arwr_CollaborationArrangementConsideration"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationArrangementFixedConsideration_928bd2bc-2722-4fbc-bdb5-21b82a10ebe5" xlink:href="arwr-20250630.xsd#arwr_CollaborationArrangementFixedConsideration"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_arwr_CollaborationArrangementConsideration_c34d47cd-b662-4fc5-b60f-b275b7d9b208" xlink:to="loc_arwr_CollaborationArrangementFixedConsideration_928bd2bc-2722-4fbc-bdb5-21b82a10ebe5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationArrangementVariableConsideration_c0b3f7da-356e-4970-a8cd-1bd15f66b6aa" xlink:href="arwr-20250630.xsd#arwr_CollaborationArrangementVariableConsideration"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_arwr_CollaborationArrangementConsideration_c34d47cd-b662-4fc5-b60f-b275b7d9b208" xlink:to="loc_arwr_CollaborationArrangementVariableConsideration_c0b3f7da-356e-4970-a8cd-1bd15f66b6aa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/BalanceSheetAccountsPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#BalanceSheetAccountsPropertyPlantandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/BalanceSheetAccountsPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_102e9bf0-1a35-40a2-adf0-9c6083a487a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_35b63a6f-5626-4fc9-861a-3b4dcf31452b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_102e9bf0-1a35-40a2-adf0-9c6083a487a3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_35b63a6f-5626-4fc9-861a-3b4dcf31452b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_58644628-77de-406e-b9a5-9f13c6b57956" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_102e9bf0-1a35-40a2-adf0-9c6083a487a3" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_58644628-77de-406e-b9a5-9f13c6b57956" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#BalanceSheetAccountsAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_cef8867b-1da6-4949-9008-2e514d06dbd4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AccruedCapitalExpenditureCurrent_1ff0df34-e878-4862-b65b-9d9e0ac48de9" xlink:href="arwr-20250630.xsd#arwr_AccruedCapitalExpenditureCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_cef8867b-1da6-4949-9008-2e514d06dbd4" xlink:to="loc_arwr_AccruedCapitalExpenditureCurrent_1ff0df34-e878-4862-b65b-9d9e0ac48de9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AccruedResearchAndDevelopmentExpenseCurrent_f85317d6-0981-4af1-9049-de6c169d5cb5" xlink:href="arwr-20250630.xsd#arwr_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_cef8867b-1da6-4949-9008-2e514d06dbd4" xlink:to="loc_arwr_AccruedResearchAndDevelopmentExpenseCurrent_f85317d6-0981-4af1-9049-de6c169d5cb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_918af289-bd5c-4439-a020-7d20448c0433" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_cef8867b-1da6-4949-9008-2e514d06dbd4" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_918af289-bd5c-4439-a020-7d20448c0433" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent_926358fc-c67e-4dcf-9c05-b7f95735f7aa" xlink:href="arwr-20250630.xsd#arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_cef8867b-1da6-4949-9008-2e514d06dbd4" xlink:to="loc_arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent_926358fc-c67e-4dcf-9c05-b7f95735f7aa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/InvestmentsScheduleofShorttermLongtermInvestmentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#InvestmentsScheduleofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/InvestmentsScheduleofShorttermLongtermInvestmentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_13ccbb20-6c73-4538-af35-cda36c4c70f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent_905e5101-f0a2-494b-ac0f-78cacb2cc748" xlink:href="arwr-20250630.xsd#arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_13ccbb20-6c73-4538-af35-cda36c4c70f8" xlink:to="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent_905e5101-f0a2-494b-ac0f-78cacb2cc748" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_6934f1fe-435f-4cdd-b809-2741c1be848b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_13ccbb20-6c73-4538-af35-cda36c4c70f8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_6934f1fe-435f-4cdd-b809-2741c1be848b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent_04ee20e9-fc1b-4590-a720-8e4f0b76054d" xlink:href="arwr-20250630.xsd#arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_13ccbb20-6c73-4538-af35-cda36c4c70f8" xlink:to="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent_04ee20e9-fc1b-4590-a720-8e4f0b76054d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/InvestmentsScheduleofContractMaturityofAvailableforSaleDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#InvestmentsScheduleofContractMaturityofAvailableforSaleDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/InvestmentsScheduleofContractMaturityofAvailableforSaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_835bde3d-3405-4773-8c05-37c9f6e2f044" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree_bb2c5e11-8da5-456f-bad8-a4826cb91f8d" xlink:href="arwr-20250630.xsd#arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_835bde3d-3405-4773-8c05-37c9f6e2f044" xlink:to="loc_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree_bb2c5e11-8da5-456f-bad8-a4826cb91f8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo_09b38cfc-1d1b-4b22-b1de-6fc85894e60f" xlink:href="arwr-20250630.xsd#arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_835bde3d-3405-4773-8c05-37c9f6e2f044" xlink:to="loc_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo_09b38cfc-1d1b-4b22-b1de-6fc85894e60f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_78ca584b-7e4e-4b56-92f6-9a4e24b9532a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_835bde3d-3405-4773-8c05-37c9f6e2f044" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_78ca584b-7e4e-4b56-92f6-9a4e24b9532a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#IntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5b067b67-7573-48ed-955d-14be93231245" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_2ba3ec64-a8dc-4723-865e-46cb474fc5e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5b067b67-7573-48ed-955d-14be93231245" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_2ba3ec64-a8dc-4723-865e-46cb474fc5e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_af930a23-8ac0-436f-88e6-a5ab06b21fca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5b067b67-7573-48ed-955d-14be93231245" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_af930a23-8ac0-436f-88e6-a5ab06b21fca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FiniteLivedIntangibleAssetsImpairment_86ca09c1-8f39-4c9c-a114-afc9f63613a6" xlink:href="arwr-20250630.xsd#arwr_FiniteLivedIntangibleAssetsImpairment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5b067b67-7573-48ed-955d-14be93231245" xlink:to="loc_arwr_FiniteLivedIntangibleAssetsImpairment_86ca09c1-8f39-4c9c-a114-afc9f63613a6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofExpectedFutureAmortizationDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#IntangibleAssetsScheduleofExpectedFutureAmortizationDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofExpectedFutureAmortizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_94a59899-afb1-4be0-870c-1147a6c41fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_16aefc8c-cd43-4a7d-afa2-10b2615c8bf1" xlink:href="arwr-20250630.xsd#arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_94a59899-afb1-4be0-870c-1147a6c41fb5" xlink:to="loc_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_16aefc8c-cd43-4a7d-afa2-10b2615c8bf1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_1aa8eab6-a74b-4c1a-a5cf-1552236b2ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_94a59899-afb1-4be0-870c-1147a6c41fb5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_1aa8eab6-a74b-4c1a-a5cf-1552236b2ae4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_1bc6fac7-726d-4c82-981b-cbc8ec8055e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_94a59899-afb1-4be0-870c-1147a6c41fb5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_1bc6fac7-726d-4c82-981b-cbc8ec8055e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_943ba31e-abe1-4d3e-b1a8-3d5756a9b8fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_94a59899-afb1-4be0-870c-1147a6c41fb5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_943ba31e-abe1-4d3e-b1a8-3d5756a9b8fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_09485713-5a4f-4678-95f3-fe8a753fb9a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_94a59899-afb1-4be0-870c-1147a6c41fb5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_09485713-5a4f-4678-95f3-fe8a753fb9a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_bebc8fdb-3a0e-4194-9c07-c45ec86fa39e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_94a59899-afb1-4be0-870c-1147a6c41fb5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_bebc8fdb-3a0e-4194-9c07-c45ec86fa39e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesScheduleofComponentsofLeaseAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#LeasesScheduleofComponentsofLeaseAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesScheduleofComponentsofLeaseAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_362ba46c-8642-485d-95fa-fd37bc3be799" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_24924399-2b9a-4a30-90bc-4df091a8d083" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_362ba46c-8642-485d-95fa-fd37bc3be799" xlink:to="loc_us-gaap_VariableLeaseCost_24924399-2b9a-4a30-90bc-4df091a8d083" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_70d7a807-859b-42ed-a8fe-210d10b915d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_362ba46c-8642-485d-95fa-fd37bc3be799" xlink:to="loc_us-gaap_OperatingLeaseCost_70d7a807-859b-42ed-a8fe-210d10b915d2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ad666f7b-569a-4f6c-bbd7-7a11c0b675fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e08c719e-8ee4-4d50-a8ed-1908ab38de78" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ad666f7b-569a-4f6c-bbd7-7a11c0b675fa" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e08c719e-8ee4-4d50-a8ed-1908ab38de78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8d3da33c-b9ef-4ae2-9832-9025eb51e9a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ad666f7b-569a-4f6c-bbd7-7a11c0b675fa" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8d3da33c-b9ef-4ae2-9832-9025eb51e9a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_edd32c37-427f-4752-bdc3-8da842ff1b31" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ad666f7b-569a-4f6c-bbd7-7a11c0b675fa" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_edd32c37-427f-4752-bdc3-8da842ff1b31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b8748abb-9b7d-4eb9-8280-4f9fe84e706c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ad666f7b-569a-4f6c-bbd7-7a11c0b675fa" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b8748abb-9b7d-4eb9-8280-4f9fe84e706c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_5ac74ce5-d552-4cf9-9d4c-ecf00b4a6ddc" xlink:href="arwr-20250630.xsd#arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ad666f7b-569a-4f6c-bbd7-7a11c0b675fa" xlink:to="loc_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_5ac74ce5-d552-4cf9-9d4c-ecf00b4a6ddc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3de0b17c-39b4-4090-b19a-cf1fa14ded63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ad666f7b-569a-4f6c-bbd7-7a11c0b675fa" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3de0b17c-39b4-4090-b19a-cf1fa14ded63" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1" xlink:type="simple" xlink:href="arwr-20250630.xsd#LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d067a655-635f-4901-87ac-4e8353809e98" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_a2fb2cc4-ef73-4108-9bc6-a7510c41243a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d067a655-635f-4901-87ac-4e8353809e98" xlink:to="loc_us-gaap_OperatingLeaseLiability_a2fb2cc4-ef73-4108-9bc6-a7510c41243a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_fd62a489-3abf-4c7e-a427-90d18ef413cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d067a655-635f-4901-87ac-4e8353809e98" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_fd62a489-3abf-4c7e-a427-90d18ef413cd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofGrantedandOutstandingSharesDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#StockBasedCompensationScheduleofGrantedandOutstandingSharesDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofGrantedandOutstandingSharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_952094c8-750c-4613-aace-451c852a4e69" xlink:href="arwr-20250630.xsd#arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_20623c28-4567-4b2a-9720-34610babea47" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_952094c8-750c-4613-aace-451c852a4e69" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_20623c28-4567-4b2a-9720-34610babea47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c91447dd-1fcc-4620-bf38-0e7dde002e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_952094c8-750c-4613-aace-451c852a4e69" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c91447dd-1fcc-4620-bf38-0e7dde002e6f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#FairValueMeasurementsScheduleofFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_f9a43626-b95d-4085-b62c-e3ee83004316" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3aea138f-206a-4fe1-a168-af36f007feb1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_f9a43626-b95d-4085-b62c-e3ee83004316" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3aea138f-206a-4fe1-a168-af36f007feb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e9aea6d6-3f49-46e7-86b5-1662235279fd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_f9a43626-b95d-4085-b62c-e3ee83004316" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e9aea6d6-3f49-46e7-86b5-1662235279fd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FinancingAgreementScheduleofInterestExpenseRecognizedRelatedtoCreditFacilityDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#FinancingAgreementScheduleofInterestExpenseRecognizedRelatedtoCreditFacilityDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/FinancingAgreementScheduleofInterestExpenseRecognizedRelatedtoCreditFacilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_f9543031-2f04-43e8-b724-3c135808c376" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_2bcec66c-5ee1-4e9c-b1f6-46aad754ea30" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_f9543031-2f04-43e8-b724-3c135808c376" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_2bcec66c-5ee1-4e9c-b1f6-46aad754ea30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_97cc34a9-c8f9-4c22-85e4-2b0efe300627" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_f9543031-2f04-43e8-b724-3c135808c376" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_97cc34a9-c8f9-4c22-85e4-2b0efe300627" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_f801cebf-ca5b-43a0-b1ff-552073d336f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_f9543031-2f04-43e8-b724-3c135808c376" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_f801cebf-ca5b-43a0-b1ff-552073d336f4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_8aa5001f-44c7-4c21-a88c-d70f973afe70" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_1da72b56-844c-4b13-a200-c6d6a42359c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_8aa5001f-44c7-4c21-a88c-d70f973afe70" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_1da72b56-844c-4b13-a200-c6d6a42359c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_6dc6f617-18d5-464c-8d67-b2a59204a3d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_8aa5001f-44c7-4c21-a88c-d70f973afe70" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_6dc6f617-18d5-464c-8d67-b2a59204a3d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_d2cdb61c-fa74-4088-9fb2-13af7ea26c82" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_8aa5001f-44c7-4c21-a88c-d70f973afe70" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_d2cdb61c-fa74-4088-9fb2-13af7ea26c82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_64e416ac-7539-43d2-9efc-0075bcfb28d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_8aa5001f-44c7-4c21-a88c-d70f973afe70" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_64e416ac-7539-43d2-9efc-0075bcfb28d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LongTermDebtMaturityAfterYearFour_f60ce440-3973-45ef-a6d4-3c36c64c7ad1" xlink:href="arwr-20250630.xsd#arwr_LongTermDebtMaturityAfterYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_8aa5001f-44c7-4c21-a88c-d70f973afe70" xlink:to="loc_arwr_LongTermDebtMaturityAfterYearFour_f60ce440-3973-45ef-a6d4-3c36c64c7ad1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_213c62d1-aa75-4cd5-a9fd-9a7c6a70fa76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_8aa5001f-44c7-4c21-a88c-d70f973afe70" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_213c62d1-aa75-4cd5-a9fd-9a7c6a70fa76" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/NetLossIncomePerShareScheduleofBasicandDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#NetLossIncomePerShareScheduleofBasicandDilutedNetLossPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/NetLossIncomePerShareScheduleofBasicandDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_51e66095-55be-40c0-9eac-23d9eeb4297d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_c4ee55bd-94b8-4212-be7d-d83b4cadb8a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_51e66095-55be-40c0-9eac-23d9eeb4297d" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_c4ee55bd-94b8-4212-be7d-d83b4cadb8a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_974cb4c1-63bf-455e-b090-19c9a614a8d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_51e66095-55be-40c0-9eac-23d9eeb4297d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_974cb4c1-63bf-455e-b090-19c9a614a8d1" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>arwr-20250630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:774aaf13-8f26-4ca1-8d87-74a19a24be14,g:58a47ad1-6a7b-4244-af8c-bd7fa2a79e94-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="arwr-20250630.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c1a25946-38ea-48c7-83f4-bfa5b6e32ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_32423226-1e5d-47de-ac9b-201e9eca7e12" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_c1a25946-38ea-48c7-83f4-bfa5b6e32ed1" xlink:to="loc_us-gaap_StatementTable_32423226-1e5d-47de-ac9b-201e9eca7e12" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_cc9c3636-edcb-4bab-8eca-d582f57e995c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_32423226-1e5d-47de-ac9b-201e9eca7e12" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_cc9c3636-edcb-4bab-8eca-d582f57e995c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_cc9c3636-edcb-4bab-8eca-d582f57e995c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_cc9c3636-edcb-4bab-8eca-d582f57e995c" xlink:to="loc_us-gaap_EquityComponentDomain_cc9c3636-edcb-4bab-8eca-d582f57e995c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9450d397-e5ee-4e7b-b8f4-cfb4adf81794" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_cc9c3636-edcb-4bab-8eca-d582f57e995c" xlink:to="loc_us-gaap_EquityComponentDomain_9450d397-e5ee-4e7b-b8f4-cfb4adf81794" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e845a83f-b33e-4e5c-bcef-24a02bf0a83d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9450d397-e5ee-4e7b-b8f4-cfb4adf81794" xlink:to="loc_us-gaap_CommonStockMember_e845a83f-b33e-4e5c-bcef-24a02bf0a83d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_9a383139-6f3c-4806-bd69-89b3e20a4624" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9450d397-e5ee-4e7b-b8f4-cfb4adf81794" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_9a383139-6f3c-4806-bd69-89b3e20a4624" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4ae5f614-5930-461d-b7dd-a45527e0fd7e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9450d397-e5ee-4e7b-b8f4-cfb4adf81794" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4ae5f614-5930-461d-b7dd-a45527e0fd7e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_19251b3a-c5f6-4e27-a9c9-f4da1d8c3c88" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9450d397-e5ee-4e7b-b8f4-cfb4adf81794" xlink:to="loc_us-gaap_RetainedEarningsMember_19251b3a-c5f6-4e27-a9c9-f4da1d8c3c88" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_a1a467d5-7ab9-46e6-a76b-628df9f5d6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9450d397-e5ee-4e7b-b8f4-cfb4adf81794" xlink:to="loc_us-gaap_NoncontrollingInterestMember_a1a467d5-7ab9-46e6-a76b-628df9f5d6cf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b20136-6874-4a1c-b75e-02cf9f14a003" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c1a25946-38ea-48c7-83f4-bfa5b6e32ed1" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b20136-6874-4a1c-b75e-02cf9f14a003" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_dbc6e062-adce-47e4-af55-1e9a9be9bf38" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b20136-6874-4a1c-b75e-02cf9f14a003" xlink:to="loc_us-gaap_SharesOutstanding_dbc6e062-adce-47e4-af55-1e9a9be9bf38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b922f40c-728b-47b9-9284-c694614d224a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b20136-6874-4a1c-b75e-02cf9f14a003" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b922f40c-728b-47b9-9284-c694614d224a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f141ec3c-db24-446c-b9f5-c0bda45f041e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b20136-6874-4a1c-b75e-02cf9f14a003" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f141ec3c-db24-446c-b9f5-c0bda45f041e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2ae60199-1017-4e87-b768-51ce111e15ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b20136-6874-4a1c-b75e-02cf9f14a003" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2ae60199-1017-4e87-b768-51ce111e15ec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_19389908-5838-4053-8d20-016d9bd4eab5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b20136-6874-4a1c-b75e-02cf9f14a003" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_19389908-5838-4053-8d20-016d9bd4eab5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_ecd4d009-e451-4916-aa13-c6c15f22d65b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b20136-6874-4a1c-b75e-02cf9f14a003" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_ecd4d009-e451-4916-aa13-c6c15f22d65b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_482472a7-8187-4548-a76f-a05ca62679c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b20136-6874-4a1c-b75e-02cf9f14a003" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_482472a7-8187-4548-a76f-a05ca62679c7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1fa7f699-c202-40af-b486-265fdc4593cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b20136-6874-4a1c-b75e-02cf9f14a003" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1fa7f699-c202-40af-b486-265fdc4593cd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_d4b0cc1d-d62f-4ced-9d20-cac3b41f027c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b20136-6874-4a1c-b75e-02cf9f14a003" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_d4b0cc1d-d62f-4ced-9d20-cac3b41f027c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_5db64e62-ef72-4a18-861e-a8aae52576ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b20136-6874-4a1c-b75e-02cf9f14a003" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_5db64e62-ef72-4a18-861e-a8aae52576ab" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_ff977e88-58e3-41de-af51-ffa7a8afbcee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b20136-6874-4a1c-b75e-02cf9f14a003" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_ff977e88-58e3-41de-af51-ffa7a8afbcee" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1226b53b-1dbf-4b17-a11b-7513e9401eba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b20136-6874-4a1c-b75e-02cf9f14a003" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1226b53b-1dbf-4b17-a11b-7513e9401eba" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_5cea7593-6079-4b36-a9f0-b9c2734738df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b20136-6874-4a1c-b75e-02cf9f14a003" xlink:to="loc_us-gaap_ProfitLoss_5cea7593-6079-4b36-a9f0-b9c2734738df" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_4d4dc9e5-69d4-4a0e-bf2f-4b92ce2d3aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0372c92d-3060-4978-9f12-4aab1b23c727" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#OrganizationandSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e8f62059-0d7e-4f6b-b08c-e2245c51bcdd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b472841b-bee0-466a-a772-c0cd3841d127" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e8f62059-0d7e-4f6b-b08c-e2245c51bcdd" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b472841b-bee0-466a-a772-c0cd3841d127" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_80fe4511-c5b2-4ba1-832b-ae38cb847924" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b472841b-bee0-466a-a772-c0cd3841d127" xlink:to="loc_srt_CounterpartyNameAxis_80fe4511-c5b2-4ba1-832b-ae38cb847924" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_80fe4511-c5b2-4ba1-832b-ae38cb847924_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_80fe4511-c5b2-4ba1-832b-ae38cb847924" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_80fe4511-c5b2-4ba1-832b-ae38cb847924_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_84efb94d-8cb1-46d6-b37a-f8bb386b67a5" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_80fe4511-c5b2-4ba1-832b-ae38cb847924" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_84efb94d-8cb1-46d6-b37a-f8bb386b67a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SareptaMember_11756959-b1f0-43bf-aca7-2ab5d55221e6" xlink:href="arwr-20250630.xsd#arwr_SareptaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_84efb94d-8cb1-46d6-b37a-f8bb386b67a5" xlink:to="loc_arwr_SareptaMember_11756959-b1f0-43bf-aca7-2ab5d55221e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_854f49b9-d23d-4c12-9135-367876c29aba" xlink:href="arwr-20250630.xsd#arwr_GlaxosmithklineIntellectualPropertyLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_84efb94d-8cb1-46d6-b37a-f8bb386b67a5" xlink:to="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_854f49b9-d23d-4c12-9135-367876c29aba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_accb6263-ceef-45c3-b1d8-47110b0b9378" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b472841b-bee0-466a-a772-c0cd3841d127" xlink:to="loc_us-gaap_TypeOfArrangementAxis_accb6263-ceef-45c3-b1d8-47110b0b9378" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_accb6263-ceef-45c3-b1d8-47110b0b9378_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_accb6263-ceef-45c3-b1d8-47110b0b9378" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_accb6263-ceef-45c3-b1d8-47110b0b9378_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_88b16f62-8ed6-4a86-a2ea-6f4b6d7586cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_accb6263-ceef-45c3-b1d8-47110b0b9378" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_88b16f62-8ed6-4a86-a2ea-6f4b6d7586cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SareptaCollaborationAgreementMember_44620e8e-accb-4ea4-828f-f7a781c65b46" xlink:href="arwr-20250630.xsd#arwr_SareptaCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_88b16f62-8ed6-4a86-a2ea-6f4b6d7586cf" xlink:to="loc_arwr_SareptaCollaborationAgreementMember_44620e8e-accb-4ea4-828f-f7a781c65b46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GSKHBVAgreementMember_056e4c3c-74a3-41d8-9db8-ace54f0c492a" xlink:href="arwr-20250630.xsd#arwr_GSKHBVAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_88b16f62-8ed6-4a86-a2ea-6f4b6d7586cf" xlink:to="loc_arwr_GSKHBVAgreementMember_056e4c3c-74a3-41d8-9db8-ace54f0c492a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_8f2317f1-b5d5-460e-8366-db168374ed62" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b472841b-bee0-466a-a772-c0cd3841d127" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_8f2317f1-b5d5-460e-8366-db168374ed62" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8f2317f1-b5d5-460e-8366-db168374ed62_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8f2317f1-b5d5-460e-8366-db168374ed62" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8f2317f1-b5d5-460e-8366-db168374ed62_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1cae32d3-3097-403b-925a-5f5ef4250420" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8f2317f1-b5d5-460e-8366-db168374ed62" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1cae32d3-3097-403b-925a-5f5ef4250420" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_8cfb52c7-3d65-476e-9d2b-5c862b36d51d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1cae32d3-3097-403b-925a-5f5ef4250420" xlink:to="loc_us-gaap_SubsequentEventMember_8cfb52c7-3d65-476e-9d2b-5c862b36d51d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentMilestonePayments_8afaf08e-4590-48e8-8a6b-9fbd8254e9a5" xlink:href="arwr-20250630.xsd#arwr_DevelopmentMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e8f62059-0d7e-4f6b-b08c-e2245c51bcdd" xlink:to="loc_arwr_DevelopmentMilestonePayments_8afaf08e-4590-48e8-8a6b-9fbd8254e9a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_3d251da8-314b-4dcf-b24a-0c65638245cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e8f62059-0d7e-4f6b-b08c-e2245c51bcdd" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_3d251da8-314b-4dcf-b24a-0c65638245cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_117373b4-452b-4a41-8f6a-131f6588c92a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e8f62059-0d7e-4f6b-b08c-e2245c51bcdd" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_117373b4-452b-4a41-8f6a-131f6588c92a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_48ed078c-9228-4a7c-8ac7-8a7a8b799ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e8f62059-0d7e-4f6b-b08c-e2245c51bcdd" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_48ed078c-9228-4a7c-8ac7-8a7a8b799ba5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ProceedsFromCollaborationArrangements_0458eeae-40a5-46c3-a244-d92a76791008" xlink:href="arwr-20250630.xsd#arwr_ProceedsFromCollaborationArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e8f62059-0d7e-4f6b-b08c-e2245c51bcdd" xlink:to="loc_arwr_ProceedsFromCollaborationArrangements_0458eeae-40a5-46c3-a244-d92a76791008" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AdditionalCashReceivableUnderCollaborationAgreement_76bb652b-3e80-4288-9775-f6a659cc51c2" xlink:href="arwr-20250630.xsd#arwr_AdditionalCashReceivableUnderCollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e8f62059-0d7e-4f6b-b08c-e2245c51bcdd" xlink:to="loc_arwr_AdditionalCashReceivableUnderCollaborationAgreement_76bb652b-3e80-4288-9775-f6a659cc51c2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod_02bd5a7d-e852-4887-8722-496a7be189d6" xlink:href="arwr-20250630.xsd#arwr_CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e8f62059-0d7e-4f6b-b08c-e2245c51bcdd" xlink:to="loc_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod_02bd5a7d-e852-4887-8722-496a7be189d6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EnrollmentRelatedMilestonePayments_79151e1a-578a-483e-92af-50a1f45b2365" xlink:href="arwr-20250630.xsd#arwr_EnrollmentRelatedMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e8f62059-0d7e-4f6b-b08c-e2245c51bcdd" xlink:to="loc_arwr_EnrollmentRelatedMilestonePayments_79151e1a-578a-483e-92af-50a1f45b2365" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FuturePotentialMilestonePayments_a778c49c-a500-49f3-992b-4e5ad0076904" xlink:href="arwr-20250630.xsd#arwr_FuturePotentialMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e8f62059-0d7e-4f6b-b08c-e2245c51bcdd" xlink:to="loc_arwr_FuturePotentialMilestonePayments_a778c49c-a500-49f3-992b-4e5ad0076904" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_01beb862-552f-4f23-bcd2-988acd6df239" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e8f62059-0d7e-4f6b-b08c-e2245c51bcdd" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_01beb862-552f-4f23-bcd2-988acd6df239" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_388a6bfd-eda6-4793-a6bc-7d8006aae817" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e8f62059-0d7e-4f6b-b08c-e2245c51bcdd" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_388a6bfd-eda6-4793-a6bc-7d8006aae817" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8a2f51cf-fdcf-4a33-bf15-043c27d3ea98" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e8f62059-0d7e-4f6b-b08c-e2245c51bcdd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8a2f51cf-fdcf-4a33-bf15-043c27d3ea98" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_IncreaseDecreaseInCashAndInvestments_bbc5a35e-28f6-48e3-8541-63245be7fb25" xlink:href="arwr-20250630.xsd#arwr_IncreaseDecreaseInCashAndInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e8f62059-0d7e-4f6b-b08c-e2245c51bcdd" xlink:to="loc_arwr_IncreaseDecreaseInCashAndInvestments_bbc5a35e-28f6-48e3-8541-63245be7fb25" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_60f56ccf-c944-43b6-9200-7f0f59d5a9e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e8f62059-0d7e-4f6b-b08c-e2245c51bcdd" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_60f56ccf-c944-43b6-9200-7f0f59d5a9e3" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_bf9c8dcc-3b1d-467e-af73-dd34379592f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e8f62059-0d7e-4f6b-b08c-e2245c51bcdd" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_bf9c8dcc-3b1d-467e-af73-dd34379592f3" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_b336d4a7-48a3-460e-87aa-61e9bd85449e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e8f62059-0d7e-4f6b-b08c-e2245c51bcdd" xlink:to="loc_us-gaap_InvestmentIncomeInterestAndDividend_b336d4a7-48a3-460e-87aa-61e9bd85449e" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_3c18270b-2cc9-4cf9-b847-b22b0ca2b09a" xlink:href="arwr-20250630.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e8f62059-0d7e-4f6b-b08c-e2245c51bcdd" xlink:to="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_3c18270b-2cc9-4cf9-b847-b22b0ca2b09a" xlink:type="arc" order="16"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#CollaborationandLicenseAgreementsRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_bec40a04-c375-45e6-af02-0c81e3a02883" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_97cfb7bb-2c83-4b78-b956-e780832af12a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_bec40a04-c375-45e6-af02-0c81e3a02883" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_97cfb7bb-2c83-4b78-b956-e780832af12a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_f7d7b510-9599-41c3-9007-ccec39c9b584" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_97cfb7bb-2c83-4b78-b956-e780832af12a" xlink:to="loc_srt_MajorCustomersAxis_f7d7b510-9599-41c3-9007-ccec39c9b584" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_f7d7b510-9599-41c3-9007-ccec39c9b584_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_f7d7b510-9599-41c3-9007-ccec39c9b584" xlink:to="loc_srt_NameOfMajorCustomerDomain_f7d7b510-9599-41c3-9007-ccec39c9b584_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_41adc18f-457a-4bcc-a918-7140ddb7da2d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_f7d7b510-9599-41c3-9007-ccec39c9b584" xlink:to="loc_srt_NameOfMajorCustomerDomain_41adc18f-457a-4bcc-a918-7140ddb7da2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_f6ba9579-f1c2-42e6-ac80-01c984cc9099" xlink:href="arwr-20250630.xsd#arwr_GlaxosmithklineIntellectualPropertyLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_41adc18f-457a-4bcc-a918-7140ddb7da2d" xlink:to="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_f6ba9579-f1c2-42e6-ac80-01c984cc9099" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_d5abb160-09ae-4206-89ca-66b10d252d26" xlink:href="arwr-20250630.xsd#arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_41adc18f-457a-4bcc-a918-7140ddb7da2d" xlink:to="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_d5abb160-09ae-4206-89ca-66b10d252d26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SareptaTherapeuticsIncMember_9bbcd2c0-3538-4c6c-a720-d05cbf03254a" xlink:href="arwr-20250630.xsd#arwr_SareptaTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_41adc18f-457a-4bcc-a918-7140ddb7da2d" xlink:to="loc_arwr_SareptaTherapeuticsIncMember_9bbcd2c0-3538-4c6c-a720-d05cbf03254a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_45725e79-2d47-49ad-a90a-0f8712dfa9c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_bec40a04-c375-45e6-af02-0c81e3a02883" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_45725e79-2d47-49ad-a90a-0f8712dfa9c4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedGSKDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedGSKDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedGSKDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5bc96a18-43f3-47e3-836a-fbcb9c8cf4c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d097b0c0-e5ed-41df-9b28-45c8c5dffdda" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5bc96a18-43f3-47e3-836a-fbcb9c8cf4c4" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d097b0c0-e5ed-41df-9b28-45c8c5dffdda" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_79b8bb09-9989-4888-ae7c-245230353c22" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d097b0c0-e5ed-41df-9b28-45c8c5dffdda" xlink:to="loc_srt_CounterpartyNameAxis_79b8bb09-9989-4888-ae7c-245230353c22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_79b8bb09-9989-4888-ae7c-245230353c22_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_79b8bb09-9989-4888-ae7c-245230353c22" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_79b8bb09-9989-4888-ae7c-245230353c22_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4fdb4692-be16-4569-ae79-87cda5487221" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_79b8bb09-9989-4888-ae7c-245230353c22" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4fdb4692-be16-4569-ae79-87cda5487221" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_562da0df-374d-4a80-928d-183a38bf7570" xlink:href="arwr-20250630.xsd#arwr_GlaxosmithklineIntellectualPropertyLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4fdb4692-be16-4569-ae79-87cda5487221" xlink:to="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_562da0df-374d-4a80-928d-183a38bf7570" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a8fad908-7106-47ca-83d5-988f7082e0c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d097b0c0-e5ed-41df-9b28-45c8c5dffdda" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a8fad908-7106-47ca-83d5-988f7082e0c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a8fad908-7106-47ca-83d5-988f7082e0c8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a8fad908-7106-47ca-83d5-988f7082e0c8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a8fad908-7106-47ca-83d5-988f7082e0c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_408814ba-1064-4452-b066-7294cba44c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a8fad908-7106-47ca-83d5-988f7082e0c8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_408814ba-1064-4452-b066-7294cba44c0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GSKHSDLicenseAgreementMember_8a784660-e396-469f-986b-539733364982" xlink:href="arwr-20250630.xsd#arwr_GSKHSDLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_408814ba-1064-4452-b066-7294cba44c0d" xlink:to="loc_arwr_GSKHSDLicenseAgreementMember_8a784660-e396-469f-986b-539733364982" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GSKHBVAgreementMember_a07413ee-4325-4c73-9875-970e92144958" xlink:href="arwr-20250630.xsd#arwr_GSKHBVAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_408814ba-1064-4452-b066-7294cba44c0d" xlink:to="loc_arwr_GSKHBVAgreementMember_a07413ee-4325-4c73-9875-970e92144958" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f7ef9846-afa4-4336-94e4-29afad8f7355" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d097b0c0-e5ed-41df-9b28-45c8c5dffdda" xlink:to="loc_srt_RangeAxis_f7ef9846-afa4-4336-94e4-29afad8f7355" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f7ef9846-afa4-4336-94e4-29afad8f7355_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f7ef9846-afa4-4336-94e4-29afad8f7355" xlink:to="loc_srt_RangeMember_f7ef9846-afa4-4336-94e4-29afad8f7355_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f81a7381-799f-4a58-9ebf-476053004576" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f7ef9846-afa4-4336-94e4-29afad8f7355" xlink:to="loc_srt_RangeMember_f81a7381-799f-4a58-9ebf-476053004576" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_dfad7f83-fe1c-40a0-865f-527af474b2aa" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f81a7381-799f-4a58-9ebf-476053004576" xlink:to="loc_srt_MaximumMember_dfad7f83-fe1c-40a0-865f-527af474b2aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_a400c530-e3e8-4a9d-b86a-bbc5e7b232e9" xlink:href="arwr-20250630.xsd#arwr_InitialTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5bc96a18-43f3-47e3-836a-fbcb9c8cf4c4" xlink:to="loc_arwr_InitialTransactionPrice_a400c530-e3e8-4a9d-b86a-bbc5e7b232e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivable_8b8738d9-196f-407c-9468-893f46b1666f" xlink:href="arwr-20250630.xsd#arwr_MilestonePaymentReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5bc96a18-43f3-47e3-836a-fbcb9c8cf4c4" xlink:to="loc_arwr_MilestonePaymentReceivable_8b8738d9-196f-407c-9468-893f46b1666f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_577b1ac7-c577-4af5-8f7b-7a0126b14526" xlink:href="arwr-20250630.xsd#arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5bc96a18-43f3-47e3-836a-fbcb9c8cf4c4" xlink:to="loc_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_577b1ac7-c577-4af5-8f7b-7a0126b14526" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialMilestonePaymentsAtFirstCommercialSale_6137cfce-efc5-4f4f-99b7-24681630aec6" xlink:href="arwr-20250630.xsd#arwr_CommercialMilestonePaymentsAtFirstCommercialSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5bc96a18-43f3-47e3-836a-fbcb9c8cf4c4" xlink:to="loc_arwr_CommercialMilestonePaymentsAtFirstCommercialSale_6137cfce-efc5-4f4f-99b7-24681630aec6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SalesRelatedMilestonePayments_06531963-f3ca-43b0-a000-c75c1996d7f2" xlink:href="arwr-20250630.xsd#arwr_SalesRelatedMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5bc96a18-43f3-47e3-836a-fbcb9c8cf4c4" xlink:to="loc_arwr_SalesRelatedMilestonePayments_06531963-f3ca-43b0-a000-c75c1996d7f2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentMilestonePayments_20cb166b-2c7e-48a4-91be-5707ec8cdee6" xlink:href="arwr-20250630.xsd#arwr_DevelopmentMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5bc96a18-43f3-47e3-836a-fbcb9c8cf4c4" xlink:to="loc_arwr_DevelopmentMilestonePayments_20cb166b-2c7e-48a4-91be-5707ec8cdee6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentAndSalesMilestonesPayments_d03cba47-6e1f-48de-aa56-7d5c202f6be0" xlink:href="arwr-20250630.xsd#arwr_DevelopmentAndSalesMilestonesPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5bc96a18-43f3-47e3-836a-fbcb9c8cf4c4" xlink:to="loc_arwr_DevelopmentAndSalesMilestonesPayments_d03cba47-6e1f-48de-aa56-7d5c202f6be0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_89e47486-d415-4670-8e7b-ea59de4ca947" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5bc96a18-43f3-47e3-836a-fbcb9c8cf4c4" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_89e47486-d415-4670-8e7b-ea59de4ca947" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_27299f29-1847-4663-a4a6-7e5cdb5ff3bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5bc96a18-43f3-47e3-836a-fbcb9c8cf4c4" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_27299f29-1847-4663-a4a6-7e5cdb5ff3bd" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1349cd0c-dfd9-4b72-ab2a-05f261156fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e940c581-059a-43fa-bc80-26c11dcbfb59" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1349cd0c-dfd9-4b72-ab2a-05f261156fb2" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e940c581-059a-43fa-bc80-26c11dcbfb59" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_9533d00f-bcc5-4923-99e8-16c544229550" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e940c581-059a-43fa-bc80-26c11dcbfb59" xlink:to="loc_srt_CounterpartyNameAxis_9533d00f-bcc5-4923-99e8-16c544229550" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9533d00f-bcc5-4923-99e8-16c544229550_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_9533d00f-bcc5-4923-99e8-16c544229550" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9533d00f-bcc5-4923-99e8-16c544229550_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c4fe307e-1870-4536-a796-b5274bfb09f4" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_9533d00f-bcc5-4923-99e8-16c544229550" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c4fe307e-1870-4536-a796-b5274bfb09f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_fc4334cf-5974-4293-acb7-d53b52358ce5" xlink:href="arwr-20250630.xsd#arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c4fe307e-1870-4536-a796-b5274bfb09f4" xlink:to="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_fc4334cf-5974-4293-acb7-d53b52358ce5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a0f6d69d-f58a-409a-a0d3-53ce93a84d20" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e940c581-059a-43fa-bc80-26c11dcbfb59" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a0f6d69d-f58a-409a-a0d3-53ce93a84d20" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a0f6d69d-f58a-409a-a0d3-53ce93a84d20_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a0f6d69d-f58a-409a-a0d3-53ce93a84d20" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a0f6d69d-f58a-409a-a0d3-53ce93a84d20_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5cbf8d42-dd0d-4ac8-b899-790b2bc18ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a0f6d69d-f58a-409a-a0d3-53ce93a84d20" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5cbf8d42-dd0d-4ac8-b899-790b2bc18ad0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LicenseAndCoFundingAgreementMember_522087a0-29f8-444d-b63f-3e3196c6c575" xlink:href="arwr-20250630.xsd#arwr_LicenseAndCoFundingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5cbf8d42-dd0d-4ac8-b899-790b2bc18ad0" xlink:to="loc_arwr_LicenseAndCoFundingAgreementMember_522087a0-29f8-444d-b63f-3e3196c6c575" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fd5cb27c-77da-4366-9896-ac3e18d0b2d4" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e940c581-059a-43fa-bc80-26c11dcbfb59" xlink:to="loc_srt_RangeAxis_fd5cb27c-77da-4366-9896-ac3e18d0b2d4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fd5cb27c-77da-4366-9896-ac3e18d0b2d4_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_fd5cb27c-77da-4366-9896-ac3e18d0b2d4" xlink:to="loc_srt_RangeMember_fd5cb27c-77da-4366-9896-ac3e18d0b2d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9234048d-e702-4fba-8ce3-18629fb4a904" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_fd5cb27c-77da-4366-9896-ac3e18d0b2d4" xlink:to="loc_srt_RangeMember_9234048d-e702-4fba-8ce3-18629fb4a904" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7145ce3e-0b1d-49d4-93c8-1b5dacab89a3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9234048d-e702-4fba-8ce3-18629fb4a904" xlink:to="loc_srt_MinimumMember_7145ce3e-0b1d-49d4-93c8-1b5dacab89a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7eba89a2-7ebe-4b3a-98a8-75ee536d49e6" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9234048d-e702-4fba-8ce3-18629fb4a904" xlink:to="loc_srt_MaximumMember_7eba89a2-7ebe-4b3a-98a8-75ee536d49e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_2636c824-ffb6-4e0a-9f53-33b5431b5c9d" xlink:href="arwr-20250630.xsd#arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1349cd0c-dfd9-4b72-ab2a-05f261156fb2" xlink:to="loc_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_2636c824-ffb6-4e0a-9f53-33b5431b5c9d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctBundle_2a314954-66a0-4fb9-bf95-c42bd50beafc" xlink:href="arwr-20250630.xsd#arwr_NumberOfDistinctBundle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1349cd0c-dfd9-4b72-ab2a-05f261156fb2" xlink:to="loc_arwr_NumberOfDistinctBundle_2a314954-66a0-4fb9-bf95-c42bd50beafc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_e905657e-d659-4f82-b469-8b96a67f6fee" xlink:href="arwr-20250630.xsd#arwr_InitialTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1349cd0c-dfd9-4b72-ab2a-05f261156fb2" xlink:to="loc_arwr_InitialTransactionPrice_e905657e-d659-4f82-b469-8b96a67f6fee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentEarned_fc20bb46-0de8-4180-8375-ad922955686d" xlink:href="arwr-20250630.xsd#arwr_MilestonePaymentEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1349cd0c-dfd9-4b72-ab2a-05f261156fb2" xlink:to="loc_arwr_MilestonePaymentEarned_fc20bb46-0de8-4180-8375-ad922955686d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_567a5e6a-9423-4863-910c-098f685ab37d" xlink:href="arwr-20250630.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1349cd0c-dfd9-4b72-ab2a-05f261156fb2" xlink:to="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_567a5e6a-9423-4863-910c-098f685ab37d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cbe7f39f-4ad0-46ea-ba29-0d20113e96c5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1349cd0c-dfd9-4b72-ab2a-05f261156fb2" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cbe7f39f-4ad0-46ea-ba29-0d20113e96c5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_0fca2797-7884-403c-898e-8943bda8dbb6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1349cd0c-dfd9-4b72-ab2a-05f261156fb2" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_0fca2797-7884-403c-898e-8943bda8dbb6" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#CollaborationandLicenseAgreementsAmgenIncDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5d82618e-ae7c-421d-916a-ea168a55a9b0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f5a145ff-3db7-4deb-871a-9ed53a662725" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5d82618e-ae7c-421d-916a-ea168a55a9b0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f5a145ff-3db7-4deb-871a-9ed53a662725" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_152c34f5-f084-4fd9-a9f8-20a20e641fae" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f5a145ff-3db7-4deb-871a-9ed53a662725" xlink:to="loc_srt_CounterpartyNameAxis_152c34f5-f084-4fd9-a9f8-20a20e641fae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_152c34f5-f084-4fd9-a9f8-20a20e641fae_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_152c34f5-f084-4fd9-a9f8-20a20e641fae" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_152c34f5-f084-4fd9-a9f8-20a20e641fae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6a9ad1de-2cab-41f5-945c-d5827dddb3a7" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_152c34f5-f084-4fd9-a9f8-20a20e641fae" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6a9ad1de-2cab-41f5-945c-d5827dddb3a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmgenIncorporatedMember_0dd4cabe-459a-4d88-a144-7797908ca5f4" xlink:href="arwr-20250630.xsd#arwr_AmgenIncorporatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6a9ad1de-2cab-41f5-945c-d5827dddb3a7" xlink:to="loc_arwr_AmgenIncorporatedMember_0dd4cabe-459a-4d88-a144-7797908ca5f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8562133f-9d54-41ac-aca8-6f2a62c46b04" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f5a145ff-3db7-4deb-871a-9ed53a662725" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8562133f-9d54-41ac-aca8-6f2a62c46b04" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8562133f-9d54-41ac-aca8-6f2a62c46b04_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8562133f-9d54-41ac-aca8-6f2a62c46b04" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8562133f-9d54-41ac-aca8-6f2a62c46b04_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dc5d9030-5c03-44eb-8e33-9e8a728f1423" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8562133f-9d54-41ac-aca8-6f2a62c46b04" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dc5d9030-5c03-44eb-8e33-9e8a728f1423" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OlpasiranAgreementMember_696da196-6428-4372-97a3-6c48d59e8dd8" xlink:href="arwr-20250630.xsd#arwr_OlpasiranAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dc5d9030-5c03-44eb-8e33-9e8a728f1423" xlink:to="loc_arwr_OlpasiranAgreementMember_696da196-6428-4372-97a3-6c48d59e8dd8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fdbbd7fc-c78c-44a4-afee-4a4651efe07c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f5a145ff-3db7-4deb-871a-9ed53a662725" xlink:to="loc_srt_RangeAxis_fdbbd7fc-c78c-44a4-afee-4a4651efe07c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fdbbd7fc-c78c-44a4-afee-4a4651efe07c_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_fdbbd7fc-c78c-44a4-afee-4a4651efe07c" xlink:to="loc_srt_RangeMember_fdbbd7fc-c78c-44a4-afee-4a4651efe07c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_784926b7-496f-4149-8d97-787e26a8cc8f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_fdbbd7fc-c78c-44a4-afee-4a4651efe07c" xlink:to="loc_srt_RangeMember_784926b7-496f-4149-8d97-787e26a8cc8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1e109520-80f6-4d2d-8d41-34e82346c4c2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_784926b7-496f-4149-8d97-787e26a8cc8f" xlink:to="loc_srt_MaximumMember_1e109520-80f6-4d2d-8d41-34e82346c4c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfAgreements_69eacdf6-de2e-499b-b4c4-d18568d03b76" xlink:href="arwr-20250630.xsd#arwr_NumberOfAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5d82618e-ae7c-421d-916a-ea168a55a9b0" xlink:to="loc_arwr_NumberOfAgreements_69eacdf6-de2e-499b-b4c4-d18568d03b76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_ae924ca0-3dd8-49fa-9f2d-bb775c941c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5d82618e-ae7c-421d-916a-ea168a55a9b0" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_ae924ca0-3dd8-49fa-9f2d-bb775c941c1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_106ffe11-4270-4354-86a0-a5d06547564b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5d82618e-ae7c-421d-916a-ea168a55a9b0" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_106ffe11-4270-4354-86a0-a5d06547564b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_360cfcff-62e2-44a2-b587-6c011acb3859" xlink:href="arwr-20250630.xsd#arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5d82618e-ae7c-421d-916a-ea168a55a9b0" xlink:to="loc_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_360cfcff-62e2-44a2-b587-6c011acb3859" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_31574779-b992-4f64-bc72-1dc168c9322b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_319eae47-feae-4c3a-ab91-64d9ae378a82" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_31574779-b992-4f64-bc72-1dc168c9322b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_319eae47-feae-4c3a-ab91-64d9ae378a82" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_20333e3f-1a40-4a03-9e7f-df283f1ee14d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_319eae47-feae-4c3a-ab91-64d9ae378a82" xlink:to="loc_srt_CounterpartyNameAxis_20333e3f-1a40-4a03-9e7f-df283f1ee14d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_20333e3f-1a40-4a03-9e7f-df283f1ee14d_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_20333e3f-1a40-4a03-9e7f-df283f1ee14d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_20333e3f-1a40-4a03-9e7f-df283f1ee14d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9a0d7822-8811-4514-a535-b6b82a82a533" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_20333e3f-1a40-4a03-9e7f-df283f1ee14d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9a0d7822-8811-4514-a535-b6b82a82a533" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SareptaTherapeuticsIncMember_c9886508-580a-43cb-afc9-afdceb398204" xlink:href="arwr-20250630.xsd#arwr_SareptaTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9a0d7822-8811-4514-a535-b6b82a82a533" xlink:to="loc_arwr_SareptaTherapeuticsIncMember_c9886508-580a-43cb-afc9-afdceb398204" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3f67328a-97e4-44b8-9c6e-993e076aa249" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_319eae47-feae-4c3a-ab91-64d9ae378a82" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3f67328a-97e4-44b8-9c6e-993e076aa249" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3f67328a-97e4-44b8-9c6e-993e076aa249_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3f67328a-97e4-44b8-9c6e-993e076aa249" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3f67328a-97e4-44b8-9c6e-993e076aa249_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7156b247-9639-497d-8c9c-3eaab25ff5a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3f67328a-97e4-44b8-9c6e-993e076aa249" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7156b247-9639-497d-8c9c-3eaab25ff5a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SareptaCollaborationAgreementMember_c25ab4e6-459a-4f50-b005-3592a9c46e5e" xlink:href="arwr-20250630.xsd#arwr_SareptaCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7156b247-9639-497d-8c9c-3eaab25ff5a0" xlink:to="loc_arwr_SareptaCollaborationAgreementMember_c25ab4e6-459a-4f50-b005-3592a9c46e5e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d8b1e2a4-c653-4df8-bcee-4794379cdbb0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_319eae47-feae-4c3a-ab91-64d9ae378a82" xlink:to="loc_srt_RangeAxis_d8b1e2a4-c653-4df8-bcee-4794379cdbb0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d8b1e2a4-c653-4df8-bcee-4794379cdbb0_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d8b1e2a4-c653-4df8-bcee-4794379cdbb0" xlink:to="loc_srt_RangeMember_d8b1e2a4-c653-4df8-bcee-4794379cdbb0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7d11e8b6-c738-4285-ad4d-768745a66f36" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d8b1e2a4-c653-4df8-bcee-4794379cdbb0" xlink:to="loc_srt_RangeMember_7d11e8b6-c738-4285-ad4d-768745a66f36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_60be10c0-7833-4726-8229-b76eb23e35d4" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7d11e8b6-c738-4285-ad4d-768745a66f36" xlink:to="loc_srt_MaximumMember_60be10c0-7833-4726-8229-b76eb23e35d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_66756082-3e13-4987-8f10-5acecc25a0e8" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7d11e8b6-c738-4285-ad4d-768745a66f36" xlink:to="loc_srt_MinimumMember_66756082-3e13-4987-8f10-5acecc25a0e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfNewTargetPrograms_a6a46455-058d-42b8-8fef-ff5fa4d6d433" xlink:href="arwr-20250630.xsd#arwr_NumberOfNewTargetPrograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_31574779-b992-4f64-bc72-1dc168c9322b" xlink:to="loc_arwr_NumberOfNewTargetPrograms_a6a46455-058d-42b8-8fef-ff5fa4d6d433" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfPerformanceObligations_07e31ace-ec54-451a-b1e7-e065d4ed398c" xlink:href="arwr-20250630.xsd#arwr_NumberOfPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_31574779-b992-4f64-bc72-1dc168c9322b" xlink:to="loc_arwr_NumberOfPerformanceObligations_07e31ace-ec54-451a-b1e7-e065d4ed398c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ProceedsFromCollaborationArrangements_d63efeb6-222e-4418-9ae9-569e590c4fdf" xlink:href="arwr-20250630.xsd#arwr_ProceedsFromCollaborationArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_31574779-b992-4f64-bc72-1dc168c9322b" xlink:to="loc_arwr_ProceedsFromCollaborationArrangements_d63efeb6-222e-4418-9ae9-569e590c4fdf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_8d87ac24-5357-4979-a498-8cb969c90695" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_31574779-b992-4f64-bc72-1dc168c9322b" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_8d87ac24-5357-4979-a498-8cb969c90695" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SaleOfStockPremiumOnIssuanceOfShares_67f5a19a-e74a-4812-af21-a95b2d15cbdd" xlink:href="arwr-20250630.xsd#arwr_SaleOfStockPremiumOnIssuanceOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_31574779-b992-4f64-bc72-1dc168c9322b" xlink:to="loc_arwr_SaleOfStockPremiumOnIssuanceOfShares_67f5a19a-e74a-4812-af21-a95b2d15cbdd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AdditionalCashReceivableUnderCollaborationAgreement_aaac3f3d-b763-4712-aeee-e16d47f5cb91" xlink:href="arwr-20250630.xsd#arwr_AdditionalCashReceivableUnderCollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_31574779-b992-4f64-bc72-1dc168c9322b" xlink:to="loc_arwr_AdditionalCashReceivableUnderCollaborationAgreement_aaac3f3d-b763-4712-aeee-e16d47f5cb91" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallments_5e332993-99bf-435f-94ed-205904840d59" xlink:href="arwr-20250630.xsd#arwr_CashReceivableUnderCollaborationAgreementAnnualInstallments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_31574779-b992-4f64-bc72-1dc168c9322b" xlink:to="loc_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallments_5e332993-99bf-435f-94ed-205904840d59" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod_78af8e67-6720-44c8-98a6-040efaeedbbb" xlink:href="arwr-20250630.xsd#arwr_CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_31574779-b992-4f64-bc72-1dc168c9322b" xlink:to="loc_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod_78af8e67-6720-44c8-98a6-040efaeedbbb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationArrangementFixedConsideration_d2502776-2343-41ba-b079-e287e7c7e256" xlink:href="arwr-20250630.xsd#arwr_CollaborationArrangementFixedConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_31574779-b992-4f64-bc72-1dc168c9322b" xlink:to="loc_arwr_CollaborationArrangementFixedConsideration_d2502776-2343-41ba-b079-e287e7c7e256" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationArrangementConsideration_e6c375a7-194e-4374-b06d-aa359b5de761" xlink:href="arwr-20250630.xsd#arwr_CollaborationArrangementConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_31574779-b992-4f64-bc72-1dc168c9322b" xlink:to="loc_arwr_CollaborationArrangementConsideration_e6c375a7-194e-4374-b06d-aa359b5de761" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EnrollmentRelatedMilestonePayments_4734b718-9822-454c-8a85-efb96989fe62" xlink:href="arwr-20250630.xsd#arwr_EnrollmentRelatedMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_31574779-b992-4f64-bc72-1dc168c9322b" xlink:to="loc_arwr_EnrollmentRelatedMilestonePayments_4734b718-9822-454c-8a85-efb96989fe62" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfCollaborationPrograms_7686d819-4c25-4b18-8fa4-1bcbce86313f" xlink:href="arwr-20250630.xsd#arwr_NumberOfCollaborationPrograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_31574779-b992-4f64-bc72-1dc168c9322b" xlink:to="loc_arwr_NumberOfCollaborationPrograms_7686d819-4c25-4b18-8fa4-1bcbce86313f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RegulatoryMilestonePayments_84499cd9-35c9-4355-9678-48b0e961b737" xlink:href="arwr-20250630.xsd#arwr_RegulatoryMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_31574779-b992-4f64-bc72-1dc168c9322b" xlink:to="loc_arwr_RegulatoryMilestonePayments_84499cd9-35c9-4355-9678-48b0e961b737" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SalesRelatedMilestonePayments_eae4f6ac-b5b8-44ab-9065-b68d141cfac7" xlink:href="arwr-20250630.xsd#arwr_SalesRelatedMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_31574779-b992-4f64-bc72-1dc168c9322b" xlink:to="loc_arwr_SalesRelatedMilestonePayments_eae4f6ac-b5b8-44ab-9065-b68d141cfac7" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationArrangementTerminationNoticePeriodPriorToRegulatoryApproval_518c4fe5-e954-454d-a5e9-dce1568d1574" xlink:href="arwr-20250630.xsd#arwr_CollaborationArrangementTerminationNoticePeriodPriorToRegulatoryApproval"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_31574779-b992-4f64-bc72-1dc168c9322b" xlink:to="loc_arwr_CollaborationArrangementTerminationNoticePeriodPriorToRegulatoryApproval_518c4fe5-e954-454d-a5e9-dce1568d1574" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_da8bbc93-6a7f-4d73-9ade-170df6944ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_31574779-b992-4f64-bc72-1dc168c9322b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_da8bbc93-6a7f-4d73-9ade-170df6944ecb" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_2b0b2225-61d2-4609-bc1b-aa261d11a2b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_31574779-b992-4f64-bc72-1dc168c9322b" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_2b0b2225-61d2-4609-bc1b-aa261d11a2b9" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_8a5cfcbb-49ac-48a0-b66f-f11ab9d84983" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_31574779-b992-4f64-bc72-1dc168c9322b" xlink:to="loc_us-gaap_ContractWithCustomerLiability_8a5cfcbb-49ac-48a0-b66f-f11ab9d84983" xlink:type="arc" order="17"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncConsiderationComponentsDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#CollaborationandLicenseAgreementsSareptaTherapeuticsIncConsiderationComponentsDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncConsiderationComponentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_327bed99-cc1a-4099-82ec-86c3aaa17a36" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0a8202e6-4fde-4849-96ba-0a8239367b00" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_327bed99-cc1a-4099-82ec-86c3aaa17a36" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0a8202e6-4fde-4849-96ba-0a8239367b00" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a589d6cb-7132-43dd-8a49-af4262c09ad0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0a8202e6-4fde-4849-96ba-0a8239367b00" xlink:to="loc_srt_CounterpartyNameAxis_a589d6cb-7132-43dd-8a49-af4262c09ad0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a589d6cb-7132-43dd-8a49-af4262c09ad0_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_a589d6cb-7132-43dd-8a49-af4262c09ad0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a589d6cb-7132-43dd-8a49-af4262c09ad0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b04e1ed3-2378-4d60-a554-b95e38466886" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_a589d6cb-7132-43dd-8a49-af4262c09ad0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b04e1ed3-2378-4d60-a554-b95e38466886" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SareptaTherapeuticsIncMember_fd5ab7d7-bdc8-4d40-b79b-c80b81aab775" xlink:href="arwr-20250630.xsd#arwr_SareptaTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b04e1ed3-2378-4d60-a554-b95e38466886" xlink:to="loc_arwr_SareptaTherapeuticsIncMember_fd5ab7d7-bdc8-4d40-b79b-c80b81aab775" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6699fc60-51bf-4c42-b673-05e16b4def44" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0a8202e6-4fde-4849-96ba-0a8239367b00" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6699fc60-51bf-4c42-b673-05e16b4def44" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6699fc60-51bf-4c42-b673-05e16b4def44_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6699fc60-51bf-4c42-b673-05e16b4def44" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6699fc60-51bf-4c42-b673-05e16b4def44_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_18fb6fa4-16a4-4674-8fae-6c08fbaca9f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6699fc60-51bf-4c42-b673-05e16b4def44" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_18fb6fa4-16a4-4674-8fae-6c08fbaca9f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SareptaCollaborationAgreementMember_8cec77c2-a1e2-47bb-aed6-0b6bfeaa8f26" xlink:href="arwr-20250630.xsd#arwr_SareptaCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_18fb6fa4-16a4-4674-8fae-6c08fbaca9f8" xlink:to="loc_arwr_SareptaCollaborationAgreementMember_8cec77c2-a1e2-47bb-aed6-0b6bfeaa8f26" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ProceedsFromCollaborationArrangements_1f5661de-1a85-4d47-b3e8-99d0bb69dc94" xlink:href="arwr-20250630.xsd#arwr_ProceedsFromCollaborationArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_327bed99-cc1a-4099-82ec-86c3aaa17a36" xlink:to="loc_arwr_ProceedsFromCollaborationArrangements_1f5661de-1a85-4d47-b3e8-99d0bb69dc94" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AdditionalCashReceivableUnderCollaborationAgreement_18194bab-2ba2-4313-94f4-05fcd4995593" xlink:href="arwr-20250630.xsd#arwr_AdditionalCashReceivableUnderCollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_327bed99-cc1a-4099-82ec-86c3aaa17a36" xlink:to="loc_arwr_AdditionalCashReceivableUnderCollaborationAgreement_18194bab-2ba2-4313-94f4-05fcd4995593" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SaleOfStockPremiumOnIssuanceOfShares_0b1fa7f1-4fde-4be2-b666-07a4d0ab62e0" xlink:href="arwr-20250630.xsd#arwr_SaleOfStockPremiumOnIssuanceOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_327bed99-cc1a-4099-82ec-86c3aaa17a36" xlink:to="loc_arwr_SaleOfStockPremiumOnIssuanceOfShares_0b1fa7f1-4fde-4be2-b666-07a4d0ab62e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationArrangementFixedConsideration_f8871e11-ea23-421a-9ccb-9b0b79f442f5" xlink:href="arwr-20250630.xsd#arwr_CollaborationArrangementFixedConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_327bed99-cc1a-4099-82ec-86c3aaa17a36" xlink:to="loc_arwr_CollaborationArrangementFixedConsideration_f8871e11-ea23-421a-9ccb-9b0b79f442f5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationArrangementVariableConsideration_b8351e08-a109-489e-a89a-ea36c685b702" xlink:href="arwr-20250630.xsd#arwr_CollaborationArrangementVariableConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_327bed99-cc1a-4099-82ec-86c3aaa17a36" xlink:to="loc_arwr_CollaborationArrangementVariableConsideration_b8351e08-a109-489e-a89a-ea36c685b702" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationArrangementConsideration_fb2564cb-19b9-43a2-9a5a-a8e89345a6ca" xlink:href="arwr-20250630.xsd#arwr_CollaborationArrangementConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_327bed99-cc1a-4099-82ec-86c3aaa17a36" xlink:to="loc_arwr_CollaborationArrangementConsideration_fb2564cb-19b9-43a2-9a5a-a8e89345a6ca" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/BalanceSheetAccountsPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#BalanceSheetAccountsPropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/BalanceSheetAccountsPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2f5c5840-5774-47b9-b3cf-5eaa2a6ea8a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4a860ab6-f845-458e-9b3b-d47abd165770" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2f5c5840-5774-47b9-b3cf-5eaa2a6ea8a7" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4a860ab6-f845-458e-9b3b-d47abd165770" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9c7db37b-eb77-4de8-9203-a613d9230911" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4a860ab6-f845-458e-9b3b-d47abd165770" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9c7db37b-eb77-4de8-9203-a613d9230911" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9c7db37b-eb77-4de8-9203-a613d9230911_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9c7db37b-eb77-4de8-9203-a613d9230911" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9c7db37b-eb77-4de8-9203-a613d9230911_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_415bda01-4ad1-4669-8c1a-aecadf3a417c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9c7db37b-eb77-4de8-9203-a613d9230911" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_415bda01-4ad1-4669-8c1a-aecadf3a417c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_f3602c66-6b2d-45da-9a96-91eb0881ed93" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_415bda01-4ad1-4669-8c1a-aecadf3a417c" xlink:to="loc_us-gaap_LandMember_f3602c66-6b2d-45da-9a96-91eb0881ed93" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_1e7b95fa-4adf-40cb-bc77-a0f0cf53e219" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_415bda01-4ad1-4669-8c1a-aecadf3a417c" xlink:to="loc_us-gaap_BuildingMember_1e7b95fa-4adf-40cb-bc77-a0f0cf53e219" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchEquipmentMember_14436bc5-3597-4e3b-8815-473d6105e2cf" xlink:href="arwr-20250630.xsd#arwr_ResearchEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_415bda01-4ad1-4669-8c1a-aecadf3a417c" xlink:to="loc_arwr_ResearchEquipmentMember_14436bc5-3597-4e3b-8815-473d6105e2cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ManufacturingEquipmentMember_b33d3ee4-d29b-4df2-b9a4-7cf07660e9c2" xlink:href="arwr-20250630.xsd#arwr_ManufacturingEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_415bda01-4ad1-4669-8c1a-aecadf3a417c" xlink:to="loc_arwr_ManufacturingEquipmentMember_b33d3ee4-d29b-4df2-b9a4-7cf07660e9c2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_ca60cada-8f4a-43f3-8455-5c8dc5dd3e21" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_415bda01-4ad1-4669-8c1a-aecadf3a417c" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_ca60cada-8f4a-43f3-8455-5c8dc5dd3e21" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ComputerAndSoftwareMember_6eb7eb81-b4f7-469a-b3bc-49a38e1467bd" xlink:href="arwr-20250630.xsd#arwr_ComputerAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_415bda01-4ad1-4669-8c1a-aecadf3a417c" xlink:to="loc_arwr_ComputerAndSoftwareMember_6eb7eb81-b4f7-469a-b3bc-49a38e1467bd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_99cf56a5-b0ef-4b8d-b72d-f28dd3e26394" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_415bda01-4ad1-4669-8c1a-aecadf3a417c" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_99cf56a5-b0ef-4b8d-b72d-f28dd3e26394" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_db31f856-724e-43b2-be46-9aa7c3e7b2af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_415bda01-4ad1-4669-8c1a-aecadf3a417c" xlink:to="loc_us-gaap_ConstructionInProgressMember_db31f856-724e-43b2-be46-9aa7c3e7b2af" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_15595246-84d0-4fc1-b95a-38bfc3675aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2f5c5840-5774-47b9-b3cf-5eaa2a6ea8a7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_15595246-84d0-4fc1-b95a-38bfc3675aa5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_45c54444-a42e-4127-8e22-d4239eb7ddb6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2f5c5840-5774-47b9-b3cf-5eaa2a6ea8a7" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_45c54444-a42e-4127-8e22-d4239eb7ddb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_848db3c1-31fb-446c-9502-5b2759083bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2f5c5840-5774-47b9-b3cf-5eaa2a6ea8a7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_848db3c1-31fb-446c-9502-5b2759083bb5" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/BalanceSheetAccountsNarrativeDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#BalanceSheetAccountsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/BalanceSheetAccountsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_675bd3c2-1c77-461b-91f5-559bf92e1f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f0c56ea0-9281-4f94-9903-f602e646d924" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_675bd3c2-1c77-461b-91f5-559bf92e1f3e" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f0c56ea0-9281-4f94-9903-f602e646d924" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_80bb409a-67e1-4d17-b8ea-8920d66c5fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f0c56ea0-9281-4f94-9903-f602e646d924" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_80bb409a-67e1-4d17-b8ea-8920d66c5fd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_80bb409a-67e1-4d17-b8ea-8920d66c5fd4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_80bb409a-67e1-4d17-b8ea-8920d66c5fd4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_80bb409a-67e1-4d17-b8ea-8920d66c5fd4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1e4cd9fc-aa6f-4082-95ef-2a50dd7a298c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_80bb409a-67e1-4d17-b8ea-8920d66c5fd4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1e4cd9fc-aa6f-4082-95ef-2a50dd7a298c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ConstructionInProgressReclassifiedToBuildingMember_e6eb21e0-979d-4755-bc48-3c98f5f6e48d" xlink:href="arwr-20250630.xsd#arwr_ConstructionInProgressReclassifiedToBuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1e4cd9fc-aa6f-4082-95ef-2a50dd7a298c" xlink:to="loc_arwr_ConstructionInProgressReclassifiedToBuildingMember_e6eb21e0-979d-4755-bc48-3c98f5f6e48d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_ae8f9d59-083c-491a-bfbb-b3bfb5adf51e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1e4cd9fc-aa6f-4082-95ef-2a50dd7a298c" xlink:to="loc_us-gaap_BuildingMember_ae8f9d59-083c-491a-bfbb-b3bfb5adf51e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ConstructionInProgressReclassifiedToManufacturingEquipmentMember_0442b0a7-dded-4f68-80d9-88638eb565ff" xlink:href="arwr-20250630.xsd#arwr_ConstructionInProgressReclassifiedToManufacturingEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1e4cd9fc-aa6f-4082-95ef-2a50dd7a298c" xlink:to="loc_arwr_ConstructionInProgressReclassifiedToManufacturingEquipmentMember_0442b0a7-dded-4f68-80d9-88638eb565ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ManufacturingEquipmentMember_381855fa-96ef-4b3d-8a74-4b491fa5dca1" xlink:href="arwr-20250630.xsd#arwr_ManufacturingEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1e4cd9fc-aa6f-4082-95ef-2a50dd7a298c" xlink:to="loc_arwr_ManufacturingEquipmentMember_381855fa-96ef-4b3d-8a74-4b491fa5dca1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManufacturingFacilityMember_18168dbf-7c00-41cf-9d76-2a3535487a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ManufacturingFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1e4cd9fc-aa6f-4082-95ef-2a50dd7a298c" xlink:to="loc_us-gaap_ManufacturingFacilityMember_18168dbf-7c00-41cf-9d76-2a3535487a4c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_cc1e66f2-fd1c-457e-ab3b-d3919800842c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1e4cd9fc-aa6f-4082-95ef-2a50dd7a298c" xlink:to="loc_us-gaap_ConstructionInProgressMember_cc1e66f2-fd1c-457e-ab3b-d3919800842c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ed2ab0b6-4a3c-449f-b3a1-5a3617f2e6d3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f0c56ea0-9281-4f94-9903-f602e646d924" xlink:to="loc_srt_RangeAxis_ed2ab0b6-4a3c-449f-b3a1-5a3617f2e6d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ed2ab0b6-4a3c-449f-b3a1-5a3617f2e6d3_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ed2ab0b6-4a3c-449f-b3a1-5a3617f2e6d3" xlink:to="loc_srt_RangeMember_ed2ab0b6-4a3c-449f-b3a1-5a3617f2e6d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_805391f8-fc34-406a-8ab6-c1f415fc4624" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ed2ab0b6-4a3c-449f-b3a1-5a3617f2e6d3" xlink:to="loc_srt_RangeMember_805391f8-fc34-406a-8ab6-c1f415fc4624" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0be13a6d-0cf2-4c53-8d7a-dd88dce2ee62" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_805391f8-fc34-406a-8ab6-c1f415fc4624" xlink:to="loc_srt_MinimumMember_0be13a6d-0cf2-4c53-8d7a-dd88dce2ee62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_40ce975a-9851-4a7b-8155-66ae78ac6da1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_805391f8-fc34-406a-8ab6-c1f415fc4624" xlink:to="loc_srt_MaximumMember_40ce975a-9851-4a7b-8155-66ae78ac6da1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_d6d87fce-3be4-4183-94dd-9e1f8dace32a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_675bd3c2-1c77-461b-91f5-559bf92e1f3e" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_d6d87fce-3be4-4183-94dd-9e1f8dace32a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges_0ffe5769-b9e9-4efb-8858-81cd18549cad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTransfersAndChanges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_675bd3c2-1c77-461b-91f5-559bf92e1f3e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges_0ffe5769-b9e9-4efb-8858-81cd18549cad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_f84b3307-aff7-4d66-8939-180b7638ea98" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_675bd3c2-1c77-461b-91f5-559bf92e1f3e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_f84b3307-aff7-4d66-8939-180b7638ea98" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/InvestmentsScheduleofShorttermLongtermInvestmentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#InvestmentsScheduleofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/InvestmentsScheduleofShorttermLongtermInvestmentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_4214f89d-7481-4784-9500-676c621c800f" xlink:href="arwr-20250630.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_9611cff4-f8e6-4256-aac9-90ac31f190dd" xlink:href="arwr-20250630.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_4214f89d-7481-4784-9500-676c621c800f" xlink:to="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_9611cff4-f8e6-4256-aac9-90ac31f190dd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_3194cca3-8936-40b9-b8eb-cd05460c8506" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_9611cff4-f8e6-4256-aac9-90ac31f190dd" xlink:to="loc_us-gaap_FinancialInstrumentAxis_3194cca3-8936-40b9-b8eb-cd05460c8506" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3194cca3-8936-40b9-b8eb-cd05460c8506_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_3194cca3-8936-40b9-b8eb-cd05460c8506" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3194cca3-8936-40b9-b8eb-cd05460c8506_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5f24a95c-dbd0-4406-8709-4a1ba7175ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_3194cca3-8936-40b9-b8eb-cd05460c8506" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5f24a95c-dbd0-4406-8709-4a1ba7175ac1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_07c0b922-e517-4a30-ba5d-d5275eed9400" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5f24a95c-dbd0-4406-8709-4a1ba7175ac1" xlink:to="loc_us-gaap_DebtSecuritiesMember_07c0b922-e517-4a30-ba5d-d5275eed9400" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_b84d88e7-8522-425e-ac87-25634d548a75" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_4214f89d-7481-4784-9500-676c621c800f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_b84d88e7-8522-425e-ac87-25634d548a75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent_6428bfc7-f883-47c7-af71-08f5a3b0a1e0" xlink:href="arwr-20250630.xsd#arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_4214f89d-7481-4784-9500-676c621c800f" xlink:to="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent_6428bfc7-f883-47c7-af71-08f5a3b0a1e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent_74af1229-d154-4120-b087-78b5042865a3" xlink:href="arwr-20250630.xsd#arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_4214f89d-7481-4784-9500-676c621c800f" xlink:to="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent_74af1229-d154-4120-b087-78b5042865a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_36653925-7fa2-415f-a57b-cf8e399eaa7c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_4214f89d-7481-4784-9500-676c621c800f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_36653925-7fa2-415f-a57b-cf8e399eaa7c" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#IntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5281d430-a373-4f45-bac6-4f4b20b7ad20" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_35f2e776-2ad3-4010-a459-f4e0be077f91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5281d430-a373-4f45-bac6-4f4b20b7ad20" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_35f2e776-2ad3-4010-a459-f4e0be077f91" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_da83372b-2c6d-449c-b7e6-f50a13050fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_35f2e776-2ad3-4010-a459-f4e0be077f91" xlink:to="loc_us-gaap_AssetAcquisitionAxis_da83372b-2c6d-449c-b7e6-f50a13050fbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_da83372b-2c6d-449c-b7e6-f50a13050fbf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_da83372b-2c6d-449c-b7e6-f50a13050fbf" xlink:to="loc_us-gaap_AssetAcquisitionDomain_da83372b-2c6d-449c-b7e6-f50a13050fbf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_46870a52-eb54-4fc4-822a-d11b93e8d3ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_da83372b-2c6d-449c-b7e6-f50a13050fbf" xlink:to="loc_us-gaap_AssetAcquisitionDomain_46870a52-eb54-4fc4-822a-d11b93e8d3ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NovartisMember_38ae12e2-0381-438e-b180-f2bf718a3d92" xlink:href="arwr-20250630.xsd#arwr_NovartisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_46870a52-eb54-4fc4-822a-d11b93e8d3ac" xlink:to="loc_arwr_NovartisMember_38ae12e2-0381-438e-b180-f2bf718a3d92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a4b2db1a-a417-4f25-84b6-f16456fec732" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_35f2e776-2ad3-4010-a459-f4e0be077f91" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a4b2db1a-a417-4f25-84b6-f16456fec732" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a4b2db1a-a417-4f25-84b6-f16456fec732_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a4b2db1a-a417-4f25-84b6-f16456fec732" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a4b2db1a-a417-4f25-84b6-f16456fec732_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ae26fc99-4093-4d57-a661-f33c3d67c3f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a4b2db1a-a417-4f25-84b6-f16456fec732" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ae26fc99-4093-4d57-a661-f33c3d67c3f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_7cd53f17-1422-4488-b348-282cb30146e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ae26fc99-4093-4d57-a661-f33c3d67c3f5" xlink:to="loc_us-gaap_PatentsMember_7cd53f17-1422-4488-b348-282cb30146e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_9e2d46ce-359e-40ae-b7b8-055c2ab6169e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ae26fc99-4093-4d57-a661-f33c3d67c3f5" xlink:to="loc_us-gaap_LicensingAgreementsMember_9e2d46ce-359e-40ae-b7b8-055c2ab6169e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_308141f6-c622-4ebb-99bb-57f420cc1ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5281d430-a373-4f45-bac6-4f4b20b7ad20" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_308141f6-c622-4ebb-99bb-57f420cc1ee8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_8cbd416f-cbbd-4f29-9cef-67810b14cd0c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5281d430-a373-4f45-bac6-4f4b20b7ad20" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_8cbd416f-cbbd-4f29-9cef-67810b14cd0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FiniteLivedIntangibleAssetsImpairment_7b3579e3-508d-4741-90e4-cc5910d2dc0f" xlink:href="arwr-20250630.xsd#arwr_FiniteLivedIntangibleAssetsImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5281d430-a373-4f45-bac6-4f4b20b7ad20" xlink:to="loc_arwr_FiniteLivedIntangibleAssetsImpairment_7b3579e3-508d-4741-90e4-cc5910d2dc0f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7f4a4f4c-c3d8-49ae-b39e-d277a7033602" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5281d430-a373-4f45-bac6-4f4b20b7ad20" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7f4a4f4c-c3d8-49ae-b39e-d277a7033602" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_62e41365-3f80-415d-887c-bcbee52b29fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5281d430-a373-4f45-bac6-4f4b20b7ad20" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_62e41365-3f80-415d-887c-bcbee52b29fa" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_9b50c1b4-5c8d-4b75-955f-0015e9eb27f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_6a9e6ecf-5632-48ab-a1c1-f8b84d5aa690" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_9b50c1b4-5c8d-4b75-955f-0015e9eb27f0" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_6a9e6ecf-5632-48ab-a1c1-f8b84d5aa690" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_83502b57-979c-49bd-be65-098d79bf8614" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6a9e6ecf-5632-48ab-a1c1-f8b84d5aa690" xlink:to="loc_us-gaap_PlanNameAxis_83502b57-979c-49bd-be65-098d79bf8614" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_83502b57-979c-49bd-be65-098d79bf8614_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_83502b57-979c-49bd-be65-098d79bf8614" xlink:to="loc_us-gaap_PlanNameDomain_83502b57-979c-49bd-be65-098d79bf8614_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ba04740e-484a-4154-9a77-161b97c5b46a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_83502b57-979c-49bd-be65-098d79bf8614" xlink:to="loc_us-gaap_PlanNameDomain_ba04740e-484a-4154-9a77-161b97c5b46a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_47b4e6a6-aeca-4173-8def-a389709ebe55" xlink:href="arwr-20250630.xsd#arwr_TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_ba04740e-484a-4154-9a77-161b97c5b46a" xlink:to="loc_arwr_TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_47b4e6a6-aeca-4173-8def-a389709ebe55" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8cd1a559-f751-4240-8c53-3a41b3bc856a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6a9e6ecf-5632-48ab-a1c1-f8b84d5aa690" xlink:to="loc_srt_RangeAxis_8cd1a559-f751-4240-8c53-3a41b3bc856a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8cd1a559-f751-4240-8c53-3a41b3bc856a_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8cd1a559-f751-4240-8c53-3a41b3bc856a" xlink:to="loc_srt_RangeMember_8cd1a559-f751-4240-8c53-3a41b3bc856a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9e243bf4-cd93-4f60-a206-320e59ac2338" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8cd1a559-f751-4240-8c53-3a41b3bc856a" xlink:to="loc_srt_RangeMember_9e243bf4-cd93-4f60-a206-320e59ac2338" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_322d66c7-480e-4a06-8a53-b8ce720f5f69" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9e243bf4-cd93-4f60-a206-320e59ac2338" xlink:to="loc_srt_MaximumMember_322d66c7-480e-4a06-8a53-b8ce720f5f69" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_08a0b7d9-b01e-4e5d-a441-bde824f22e80" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6a9e6ecf-5632-48ab-a1c1-f8b84d5aa690" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_08a0b7d9-b01e-4e5d-a441-bde824f22e80" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_08a0b7d9-b01e-4e5d-a441-bde824f22e80_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_08a0b7d9-b01e-4e5d-a441-bde824f22e80" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_08a0b7d9-b01e-4e5d-a441-bde824f22e80_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ff3d77f9-67f1-423a-bbd2-614a29b6b319" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_08a0b7d9-b01e-4e5d-a441-bde824f22e80" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ff3d77f9-67f1-423a-bbd2-614a29b6b319" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_c834d2f1-e8c6-418b-aead-164a5551af09" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ff3d77f9-67f1-423a-bbd2-614a29b6b319" xlink:to="loc_us-gaap_PrivatePlacementMember_c834d2f1-e8c6-418b-aead-164a5551af09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AtTheMarketAgreementMember_f91b9914-ba36-4ee9-a53b-506b47683cc6" xlink:href="arwr-20250630.xsd#arwr_AtTheMarketAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ff3d77f9-67f1-423a-bbd2-614a29b6b319" xlink:to="loc_arwr_AtTheMarketAgreementMember_f91b9914-ba36-4ee9-a53b-506b47683cc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6e4f7f84-1fbe-4c8c-a376-696688402a65" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9b50c1b4-5c8d-4b75-955f-0015e9eb27f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6e4f7f84-1fbe-4c8c-a376-696688402a65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_f9013677-b316-4b1d-b951-2f5b5524bba1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9b50c1b4-5c8d-4b75-955f-0015e9eb27f0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_f9013677-b316-4b1d-b951-2f5b5524bba1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_fe0af6cf-266f-40d1-ae74-b70c2fcde4be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9b50c1b4-5c8d-4b75-955f-0015e9eb27f0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_fe0af6cf-266f-40d1-ae74-b70c2fcde4be" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights_7655d8f7-90d3-4b5d-ba19-7ebf0a16043d" xlink:href="arwr-20250630.xsd#arwr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9b50c1b4-5c8d-4b75-955f-0015e9eb27f0" xlink:to="loc_arwr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights_7655d8f7-90d3-4b5d-ba19-7ebf0a16043d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_32a69d88-79ae-4384-bfe4-291e55f039ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9b50c1b4-5c8d-4b75-955f-0015e9eb27f0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_32a69d88-79ae-4384-bfe4-291e55f039ba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ClassOfWarrantOrRightNumberOfWarrantsExercised_4d65eed7-8f70-4f17-bfe7-4b5bcdb5a1d1" xlink:href="arwr-20250630.xsd#arwr_ClassOfWarrantOrRightNumberOfWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9b50c1b4-5c8d-4b75-955f-0015e9eb27f0" xlink:to="loc_arwr_ClassOfWarrantOrRightNumberOfWarrantsExercised_4d65eed7-8f70-4f17-bfe7-4b5bcdb5a1d1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a012e369-7ff4-44a5-be97-a2ba9babb963" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9b50c1b4-5c8d-4b75-955f-0015e9eb27f0" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a012e369-7ff4-44a5-be97-a2ba9babb963" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_ca6c6ac3-4b48-4315-9b41-7d463596254a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9b50c1b4-5c8d-4b75-955f-0015e9eb27f0" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_ca6c6ac3-4b48-4315-9b41-7d463596254a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_83993802-62b8-4b7e-8fa3-659e710a719a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9b50c1b4-5c8d-4b75-955f-0015e9eb27f0" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_83993802-62b8-4b7e-8fa3-659e710a719a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_77082986-cfb1-47c7-b5eb-6fdf2475cb06" xlink:href="arwr-20250630.xsd#arwr_CommonStockCapitalSharesValueReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9b50c1b4-5c8d-4b75-955f-0015e9eb27f0" xlink:to="loc_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_77082986-cfb1-47c7-b5eb-6fdf2475cb06" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_febc4aa5-8aa6-4aa7-8732-49d62bab9aea" xlink:href="arwr-20250630.xsd#arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9b50c1b4-5c8d-4b75-955f-0015e9eb27f0" xlink:to="loc_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_febc4aa5-8aa6-4aa7-8732-49d62bab9aea" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_52778111-e531-403d-a47b-5a77252f537e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9b50c1b4-5c8d-4b75-955f-0015e9eb27f0" xlink:to="loc_us-gaap_SharesIssued_52778111-e531-403d-a47b-5a77252f537e" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_9adc3e7e-0d84-440c-b53f-0ded04c4795b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_da4ee496-2dd4-4d58-9016-39ccedcace0b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9adc3e7e-0d84-440c-b53f-0ded04c4795b" xlink:to="loc_us-gaap_OtherCommitmentsTable_da4ee496-2dd4-4d58-9016-39ccedcace0b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6e25c620-7432-4c4d-af9c-9688b8e61386" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_da4ee496-2dd4-4d58-9016-39ccedcace0b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6e25c620-7432-4c4d-af9c-9688b8e61386" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6e25c620-7432-4c4d-af9c-9688b8e61386_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6e25c620-7432-4c4d-af9c-9688b8e61386" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6e25c620-7432-4c4d-af9c-9688b8e61386_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2ea445f3-8535-4ec4-8b98-fd1232a0cedb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6e25c620-7432-4c4d-af9c-9688b8e61386" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2ea445f3-8535-4ec4-8b98-fd1232a0cedb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DrugManufacturingFacilityMember_9d91ffd6-7387-4f27-a2d6-b8a95e7b5c8f" xlink:href="arwr-20250630.xsd#arwr_DrugManufacturingFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2ea445f3-8535-4ec4-8b98-fd1232a0cedb" xlink:to="loc_arwr_DrugManufacturingFacilityMember_9d91ffd6-7387-4f27-a2d6-b8a95e7b5c8f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LaboratoryAndOfficeFacilityMember_67db8487-f8e2-4de7-98bc-a858e9aced5b" xlink:href="arwr-20250630.xsd#arwr_LaboratoryAndOfficeFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2ea445f3-8535-4ec4-8b98-fd1232a0cedb" xlink:to="loc_arwr_LaboratoryAndOfficeFacilityMember_67db8487-f8e2-4de7-98bc-a858e9aced5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FacilitiesMember_debf743e-c039-4037-a66a-3597b1c3dcfc" xlink:href="arwr-20250630.xsd#arwr_FacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2ea445f3-8535-4ec4-8b98-fd1232a0cedb" xlink:to="loc_arwr_FacilitiesMember_debf743e-c039-4037-a66a-3597b1c3dcfc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchEquipmentMember_e0153c93-7013-4608-9435-05caede73670" xlink:href="arwr-20250630.xsd#arwr_ResearchEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2ea445f3-8535-4ec4-8b98-fd1232a0cedb" xlink:to="loc_arwr_ResearchEquipmentMember_e0153c93-7013-4608-9435-05caede73670" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_503a1206-c44f-4485-bf8d-e4ab55da015a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2ea445f3-8535-4ec4-8b98-fd1232a0cedb" xlink:to="loc_us-gaap_BuildingMember_503a1206-c44f-4485-bf8d-e4ab55da015a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ManufacturingEquipmentMember_88dbcbdd-b37d-49f9-8e50-9e57bebbebf2" xlink:href="arwr-20250630.xsd#arwr_ManufacturingEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2ea445f3-8535-4ec4-8b98-fd1232a0cedb" xlink:to="loc_arwr_ManufacturingEquipmentMember_88dbcbdd-b37d-49f9-8e50-9e57bebbebf2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_9090b12a-6a91-4a49-b9c1-f647dc093e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2ea445f3-8535-4ec4-8b98-fd1232a0cedb" xlink:to="loc_us-gaap_ConstructionInProgressMember_9090b12a-6a91-4a49-b9c1-f647dc093e5f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_785f6457-4794-4bd2-bc38-a2eba00d5d7a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_da4ee496-2dd4-4d58-9016-39ccedcace0b" xlink:to="loc_srt_StatementGeographicalAxis_785f6457-4794-4bd2-bc38-a2eba00d5d7a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_785f6457-4794-4bd2-bc38-a2eba00d5d7a_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_785f6457-4794-4bd2-bc38-a2eba00d5d7a" xlink:to="loc_srt_SegmentGeographicalDomain_785f6457-4794-4bd2-bc38-a2eba00d5d7a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8e5236e2-35ab-43fc-a8ac-01ed47438b7f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_785f6457-4794-4bd2-bc38-a2eba00d5d7a" xlink:to="loc_srt_SegmentGeographicalDomain_8e5236e2-35ab-43fc-a8ac-01ed47438b7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WI_9e212f1e-b6f7-47c1-87e7-90d7b2d9a6f7" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_WI"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8e5236e2-35ab-43fc-a8ac-01ed47438b7f" xlink:to="loc_stpr_WI_9e212f1e-b6f7-47c1-87e7-90d7b2d9a6f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_621607e1-8e64-4f3b-a811-31187a801ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9adc3e7e-0d84-440c-b53f-0ded04c4795b" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_621607e1-8e64-4f3b-a811-31187a801ba3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfLand_586c0ae0-5f07-4acd-832d-330ad5e0f0b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AreaOfLand"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9adc3e7e-0d84-440c-b53f-0ded04c4795b" xlink:to="loc_us-gaap_AreaOfLand_586c0ae0-5f07-4acd-832d-330ad5e0f0b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommitmentsCapitalExpendituresIncurredToDate_ca87eb2b-d55d-4d4c-b08e-a2fb6222fcb4" xlink:href="arwr-20250630.xsd#arwr_CommitmentsCapitalExpendituresIncurredToDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9adc3e7e-0d84-440c-b53f-0ded04c4795b" xlink:to="loc_arwr_CommitmentsCapitalExpendituresIncurredToDate_ca87eb2b-d55d-4d4c-b08e-a2fb6222fcb4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmountIntendsToInvestForBuildoutOfFacilities_296ebab7-e19f-40b0-b542-1ea3fd37698f" xlink:href="arwr-20250630.xsd#arwr_AmountIntendsToInvestForBuildoutOfFacilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9adc3e7e-0d84-440c-b53f-0ded04c4795b" xlink:to="loc_arwr_AmountIntendsToInvestForBuildoutOfFacilities_296ebab7-e19f-40b0-b542-1ea3fd37698f" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_46e416fa-c110-4f63-b26a-305516efea8a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_45d51690-83af-49fa-8afb-6f5749d36ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_46e416fa-c110-4f63-b26a-305516efea8a" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_45d51690-83af-49fa-8afb-6f5749d36ad0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_118eaa98-1689-4d66-993a-18484a6abf67" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_45d51690-83af-49fa-8afb-6f5749d36ad0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_118eaa98-1689-4d66-993a-18484a6abf67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_118eaa98-1689-4d66-993a-18484a6abf67_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_118eaa98-1689-4d66-993a-18484a6abf67" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_118eaa98-1689-4d66-993a-18484a6abf67_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_94c39ab5-bbd7-49aa-8782-849185bfd2f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_118eaa98-1689-4d66-993a-18484a6abf67" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_94c39ab5-bbd7-49aa-8782-849185bfd2f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CorporateHeadquartersInPasadenaMember_d4d8e64a-f6fd-4ea3-8ae6-bef252d046b5" xlink:href="arwr-20250630.xsd#arwr_CorporateHeadquartersInPasadenaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_94c39ab5-bbd7-49aa-8782-849185bfd2f0" xlink:to="loc_arwr_CorporateHeadquartersInPasadenaMember_d4d8e64a-f6fd-4ea3-8ae6-bef252d046b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchFacilityInSanDiegoMember_5870f169-c853-4166-8825-e18a5a78fd12" xlink:href="arwr-20250630.xsd#arwr_ResearchFacilityInSanDiegoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_94c39ab5-bbd7-49aa-8782-849185bfd2f0" xlink:to="loc_arwr_ResearchFacilityInSanDiegoMember_5870f169-c853-4166-8825-e18a5a78fd12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchFacilityInMadisonMember_40e29296-2314-48ee-aaee-b1c9fa1cff84" xlink:href="arwr-20250630.xsd#arwr_ResearchFacilityInMadisonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_94c39ab5-bbd7-49aa-8782-849185bfd2f0" xlink:to="loc_arwr_ResearchFacilityInMadisonMember_40e29296-2314-48ee-aaee-b1c9fa1cff84" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_4ba4ce78-e8ef-4d0a-892a-72806446a625" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_45d51690-83af-49fa-8afb-6f5749d36ad0" xlink:to="loc_srt_StatementGeographicalAxis_4ba4ce78-e8ef-4d0a-892a-72806446a625" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4ba4ce78-e8ef-4d0a-892a-72806446a625_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_4ba4ce78-e8ef-4d0a-892a-72806446a625" xlink:to="loc_srt_SegmentGeographicalDomain_4ba4ce78-e8ef-4d0a-892a-72806446a625_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_dc72155b-4bb1-4237-b2f0-ac77ca2ec84d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_4ba4ce78-e8ef-4d0a-892a-72806446a625" xlink:to="loc_srt_SegmentGeographicalDomain_dc72155b-4bb1-4237-b2f0-ac77ca2ec84d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_d2bef77c-830d-456f-bc1d-c26d44e7dca5" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_dc72155b-4bb1-4237-b2f0-ac77ca2ec84d" xlink:to="loc_stpr_CA_d2bef77c-830d-456f-bc1d-c26d44e7dca5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WI_2abb2569-0a06-41b3-aaa5-c3ab3e014718" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_WI"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_dc72155b-4bb1-4237-b2f0-ac77ca2ec84d" xlink:to="loc_stpr_WI_2abb2569-0a06-41b3-aaa5-c3ab3e014718" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c01b8595-714b-4d85-b4bb-b981b35def6e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_45d51690-83af-49fa-8afb-6f5749d36ad0" xlink:to="loc_srt_CounterpartyNameAxis_c01b8595-714b-4d85-b4bb-b981b35def6e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c01b8595-714b-4d85-b4bb-b981b35def6e_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_c01b8595-714b-4d85-b4bb-b981b35def6e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c01b8595-714b-4d85-b4bb-b981b35def6e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b552e736-a208-4650-bc52-7e2f305210f7" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_c01b8595-714b-4d85-b4bb-b981b35def6e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b552e736-a208-4650-bc52-7e2f305210f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ColoradoOwnerLLCMember_00c803c9-9058-419c-b231-9ff39349caa5" xlink:href="arwr-20250630.xsd#arwr_ColoradoOwnerLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b552e736-a208-4650-bc52-7e2f305210f7" xlink:to="loc_arwr_ColoradoOwnerLLCMember_00c803c9-9058-419c-b231-9ff39349caa5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9908d5fa-6ba4-489f-824f-022fb0d8d974" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_45d51690-83af-49fa-8afb-6f5749d36ad0" xlink:to="loc_srt_RangeAxis_9908d5fa-6ba4-489f-824f-022fb0d8d974" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9908d5fa-6ba4-489f-824f-022fb0d8d974_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9908d5fa-6ba4-489f-824f-022fb0d8d974" xlink:to="loc_srt_RangeMember_9908d5fa-6ba4-489f-824f-022fb0d8d974_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4a214eaa-b844-4d6f-9aee-e18b938c36ed" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9908d5fa-6ba4-489f-824f-022fb0d8d974" xlink:to="loc_srt_RangeMember_4a214eaa-b844-4d6f-9aee-e18b938c36ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a83723d5-6713-4081-8c3a-0b36761b3e90" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4a214eaa-b844-4d6f-9aee-e18b938c36ed" xlink:to="loc_srt_MaximumMember_a83723d5-6713-4081-8c3a-0b36761b3e90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases_52098a9b-3bc7-4cda-8c25-ba7d69e3e9a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_46e416fa-c110-4f63-b26a-305516efea8a" xlink:to="loc_us-gaap_LandSubjectToGroundLeases_52098a9b-3bc7-4cda-8c25-ba7d69e3e9a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfOptionsToRenew_303487d9-9b53-4f65-a101-1dd54002bec4" xlink:href="arwr-20250630.xsd#arwr_NumberOfOptionsToRenew"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_46e416fa-c110-4f63-b26a-305516efea8a" xlink:to="loc_arwr_NumberOfOptionsToRenew_303487d9-9b53-4f65-a101-1dd54002bec4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_7d0c2d92-3fdc-4c91-86f2-244b68a6ae97" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_46e416fa-c110-4f63-b26a-305516efea8a" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_7d0c2d92-3fdc-4c91-86f2-244b68a6ae97" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_f831a402-e42f-49a9-b74e-af31ac47e1cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_46e416fa-c110-4f63-b26a-305516efea8a" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_f831a402-e42f-49a9-b74e-af31ac47e1cf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ProceedsFromTenantImprovementAllowance_0f3b97ef-048b-4444-8a8e-4c5d66badf76" xlink:href="arwr-20250630.xsd#arwr_ProceedsFromTenantImprovementAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_46e416fa-c110-4f63-b26a-305516efea8a" xlink:to="loc_arwr_ProceedsFromTenantImprovementAllowance_0f3b97ef-048b-4444-8a8e-4c5d66badf76" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_89752f6b-7fef-4446-95c2-998442ac3de0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_46e416fa-c110-4f63-b26a-305516efea8a" xlink:to="loc_us-gaap_ShortTermLeaseCost_89752f6b-7fef-4446-95c2-998442ac3de0" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesScheduleofComponentsofLeaseAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#LeasesScheduleofComponentsofLeaseAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/LeasesScheduleofComponentsofLeaseAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_a10b2d46-dd31-459a-b5ed-cc8bd4fd0b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_f3e35633-fa90-479e-8204-00b342277ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_a10b2d46-dd31-459a-b5ed-cc8bd4fd0b6d" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_f3e35633-fa90-479e-8204-00b342277ed7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4a5e0e51-b062-403c-89f3-796093c4e7b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_f3e35633-fa90-479e-8204-00b342277ed7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4a5e0e51-b062-403c-89f3-796093c4e7b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4a5e0e51-b062-403c-89f3-796093c4e7b9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4a5e0e51-b062-403c-89f3-796093c4e7b9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4a5e0e51-b062-403c-89f3-796093c4e7b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8e2826c5-3639-4594-92c0-41a94cd553bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4a5e0e51-b062-403c-89f3-796093c4e7b9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8e2826c5-3639-4594-92c0-41a94cd553bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_358572f0-aed6-48b8-be46-d3bee66791a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8e2826c5-3639-4594-92c0-41a94cd553bd" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_358572f0-aed6-48b8-be46-d3bee66791a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4a82fcdc-e183-40e1-a58a-d96713686237" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8e2826c5-3639-4594-92c0-41a94cd553bd" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4a82fcdc-e183-40e1-a58a-d96713686237" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_5fb88148-23be-434e-8633-4c4a84623280" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_a10b2d46-dd31-459a-b5ed-cc8bd4fd0b6d" xlink:to="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_5fb88148-23be-434e-8633-4c4a84623280" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_9c8d8d63-27c4-4d6b-a495-5c00bbaaa689" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_5fb88148-23be-434e-8633-4c4a84623280" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_9c8d8d63-27c4-4d6b-a495-5c00bbaaa689" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_360ed63b-1b2f-42e2-9d47-c246201ebef1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_5fb88148-23be-434e-8633-4c4a84623280" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_360ed63b-1b2f-42e2-9d47-c246201ebef1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ff05413d-be12-49cb-862c-776f1099de4d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_5fb88148-23be-434e-8633-4c4a84623280" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ff05413d-be12-49cb-862c-776f1099de4d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_5209d901-0bc2-48fe-b0ed-3116133070bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_a10b2d46-dd31-459a-b5ed-cc8bd4fd0b6d" xlink:to="loc_us-gaap_LeaseCostAbstract_5209d901-0bc2-48fe-b0ed-3116133070bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_4ae33847-5057-4457-9416-d4256e82fdbf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseCostAbstract_5209d901-0bc2-48fe-b0ed-3116133070bb" xlink:to="loc_us-gaap_OperatingLeaseCost_4ae33847-5057-4457-9416-d4256e82fdbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_b54a7a36-dc7d-480c-9896-03bc2ac61c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseCostAbstract_5209d901-0bc2-48fe-b0ed-3116133070bb" xlink:to="loc_us-gaap_VariableLeaseCost_b54a7a36-dc7d-480c-9896-03bc2ac61c8c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_fc505bbd-d6e3-49a9-948f-45859037f3ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseCostAbstract_5209d901-0bc2-48fe-b0ed-3116133070bb" xlink:to="loc_us-gaap_LeaseCost_fc505bbd-d6e3-49a9-948f-45859037f3ac" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a1321e7-b5e9-4052-82fb-5587e5836226" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62f14a94-cfd1-4adf-a968-6d165c58ec33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a1321e7-b5e9-4052-82fb-5587e5836226" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62f14a94-cfd1-4adf-a968-6d165c58ec33" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_27ec3f67-ca4a-4740-99d4-77061f9fdaf8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62f14a94-cfd1-4adf-a968-6d165c58ec33" xlink:to="loc_us-gaap_PlanNameAxis_27ec3f67-ca4a-4740-99d4-77061f9fdaf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_27ec3f67-ca4a-4740-99d4-77061f9fdaf8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_27ec3f67-ca4a-4740-99d4-77061f9fdaf8" xlink:to="loc_us-gaap_PlanNameDomain_27ec3f67-ca4a-4740-99d4-77061f9fdaf8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_5fa6d8aa-776f-41bb-9838-2cddf6ea4133" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_27ec3f67-ca4a-4740-99d4-77061f9fdaf8" xlink:to="loc_us-gaap_PlanNameDomain_5fa6d8aa-776f-41bb-9838-2cddf6ea4133" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsThirteenIncentivePlanMember_49323e26-d4c8-4a60-939e-06ab3978876b" xlink:href="arwr-20250630.xsd#arwr_TwoThousandsThirteenIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_5fa6d8aa-776f-41bb-9838-2cddf6ea4133" xlink:to="loc_arwr_TwoThousandsThirteenIncentivePlanMember_49323e26-d4c8-4a60-939e-06ab3978876b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_769d7945-a43a-48e9-94ee-98da00d78500" xlink:href="arwr-20250630.xsd#arwr_TwoThousandTwentyOneIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_5fa6d8aa-776f-41bb-9838-2cddf6ea4133" xlink:to="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_769d7945-a43a-48e9-94ee-98da00d78500" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InducementPlanMember_32d6654e-217d-40ca-8eb3-6b83716ec3a5" xlink:href="arwr-20250630.xsd#arwr_InducementPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_5fa6d8aa-776f-41bb-9838-2cddf6ea4133" xlink:to="loc_arwr_InducementPlanMember_32d6654e-217d-40ca-8eb3-6b83716ec3a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VisirnaESOPMember_64f3128d-3af2-4192-aacf-9a479e94110d" xlink:href="arwr-20250630.xsd#arwr_VisirnaESOPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_5fa6d8aa-776f-41bb-9838-2cddf6ea4133" xlink:to="loc_arwr_VisirnaESOPMember_64f3128d-3af2-4192-aacf-9a479e94110d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a19f6890-9b3d-4709-8304-b87e2bfaf2e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62f14a94-cfd1-4adf-a968-6d165c58ec33" xlink:to="loc_us-gaap_AwardTypeAxis_a19f6890-9b3d-4709-8304-b87e2bfaf2e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a19f6890-9b3d-4709-8304-b87e2bfaf2e2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a19f6890-9b3d-4709-8304-b87e2bfaf2e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a19f6890-9b3d-4709-8304-b87e2bfaf2e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_523491b7-0b52-4318-a616-af55776434bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a19f6890-9b3d-4709-8304-b87e2bfaf2e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_523491b7-0b52-4318-a616-af55776434bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_cce84e6e-ff85-450c-a256-fbc418839aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_523491b7-0b52-4318-a616-af55776434bd" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_cce84e6e-ff85-450c-a256-fbc418839aa0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_65a27ae0-bdb7-4162-8ccb-ef4476dcc409" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_523491b7-0b52-4318-a616-af55776434bd" xlink:to="loc_us-gaap_EmployeeStockOptionMember_65a27ae0-bdb7-4162-8ccb-ef4476dcc409" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_c4e502f2-2866-4808-8aa0-8629b65f9b37" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a1321e7-b5e9-4052-82fb-5587e5836226" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_c4e502f2-2866-4808-8aa0-8629b65f9b37" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_d676f481-d0b3-4767-8932-d2c03bdfd623" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a1321e7-b5e9-4052-82fb-5587e5836226" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_d676f481-d0b3-4767-8932-d2c03bdfd623" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ceaa2d47-7508-4d09-a432-671568246b88" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a1321e7-b5e9-4052-82fb-5587e5836226" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ceaa2d47-7508-4d09-a432-671568246b88" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_978651d0-f3b3-463e-86d6-28f09dac3453" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a1321e7-b5e9-4052-82fb-5587e5836226" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_978651d0-f3b3-463e-86d6-28f09dac3453" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_374261f1-eab7-4d1d-88b8-7b7f9beca488" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a1321e7-b5e9-4052-82fb-5587e5836226" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_374261f1-eab7-4d1d-88b8-7b7f9beca488" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_73eb54ce-4eb7-4654-96bb-29d237c94b21" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a1321e7-b5e9-4052-82fb-5587e5836226" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_73eb54ce-4eb7-4654-96bb-29d237c94b21" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_69b86453-eb9e-49ca-88c6-cee009871ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a1321e7-b5e9-4052-82fb-5587e5836226" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_69b86453-eb9e-49ca-88c6-cee009871ecc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_15340836-cfe2-4f6a-81f4-edeb3f526905" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a1321e7-b5e9-4052-82fb-5587e5836226" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_15340836-cfe2-4f6a-81f4-edeb3f526905" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_4f90b98c-da77-425d-83f1-752081ffa395" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a1321e7-b5e9-4052-82fb-5587e5836226" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_4f90b98c-da77-425d-83f1-752081ffa395" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_c94eba51-9814-401f-bc1f-23d9ba01d698" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a1321e7-b5e9-4052-82fb-5587e5836226" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_c94eba51-9814-401f-bc1f-23d9ba01d698" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_512001f5-faef-489d-9d05-765e2994214d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a1321e7-b5e9-4052-82fb-5587e5836226" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_512001f5-faef-489d-9d05-765e2994214d" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofGrantedandOutstandingSharesDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#StockBasedCompensationScheduleofGrantedandOutstandingSharesDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofGrantedandOutstandingSharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e88d0a6-1781-4884-b1bf-d7f1a1b1869d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_04c46dcb-a713-4b37-bfff-964fb42a6985" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e88d0a6-1781-4884-b1bf-d7f1a1b1869d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_04c46dcb-a713-4b37-bfff-964fb42a6985" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_4644962f-b333-4edc-8cdc-f120fad63c34" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_04c46dcb-a713-4b37-bfff-964fb42a6985" xlink:to="loc_us-gaap_PlanNameAxis_4644962f-b333-4edc-8cdc-f120fad63c34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4644962f-b333-4edc-8cdc-f120fad63c34_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_4644962f-b333-4edc-8cdc-f120fad63c34" xlink:to="loc_us-gaap_PlanNameDomain_4644962f-b333-4edc-8cdc-f120fad63c34_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6d1037f9-bffe-4af3-a0d0-6cd575b613e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_4644962f-b333-4edc-8cdc-f120fad63c34" xlink:to="loc_us-gaap_PlanNameDomain_6d1037f9-bffe-4af3-a0d0-6cd575b613e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsThirteenIncentivePlanMember_a7c2d0cc-3ee6-4d5f-9e9e-787cabfd78ca" xlink:href="arwr-20250630.xsd#arwr_TwoThousandsThirteenIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_6d1037f9-bffe-4af3-a0d0-6cd575b613e7" xlink:to="loc_arwr_TwoThousandsThirteenIncentivePlanMember_a7c2d0cc-3ee6-4d5f-9e9e-787cabfd78ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_201898c9-1fe3-4ed7-8233-80fa1e2e0117" xlink:href="arwr-20250630.xsd#arwr_TwoThousandTwentyOneIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_6d1037f9-bffe-4af3-a0d0-6cd575b613e7" xlink:to="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_201898c9-1fe3-4ed7-8233-80fa1e2e0117" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InducementAwardsMember_24090581-e368-4d5f-b28c-c2705e487ede" xlink:href="arwr-20250630.xsd#arwr_InducementAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_6d1037f9-bffe-4af3-a0d0-6cd575b613e7" xlink:to="loc_arwr_InducementAwardsMember_24090581-e368-4d5f-b28c-c2705e487ede" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4327663d-c8f2-4903-90e4-8bbae653060b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_04c46dcb-a713-4b37-bfff-964fb42a6985" xlink:to="loc_us-gaap_AwardTypeAxis_4327663d-c8f2-4903-90e4-8bbae653060b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4327663d-c8f2-4903-90e4-8bbae653060b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_4327663d-c8f2-4903-90e4-8bbae653060b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4327663d-c8f2-4903-90e4-8bbae653060b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5cff460e-f10f-497c-8bbf-4698f993a7e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_4327663d-c8f2-4903-90e4-8bbae653060b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5cff460e-f10f-497c-8bbf-4698f993a7e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_65e57ea7-6019-4ae5-aeac-4581938a4c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5cff460e-f10f-497c-8bbf-4698f993a7e1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_65e57ea7-6019-4ae5-aeac-4581938a4c3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c03a7ff9-ae72-4764-81c0-447f72c478e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e88d0a6-1781-4884-b1bf-d7f1a1b1869d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c03a7ff9-ae72-4764-81c0-447f72c478e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ebdcbdee-88b2-4887-ad08-12586838a2a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e88d0a6-1781-4884-b1bf-d7f1a1b1869d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ebdcbdee-88b2-4887-ad08-12586838a2a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_6490e449-11f5-4cb1-945f-1904a4a9d66f" xlink:href="arwr-20250630.xsd#arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e88d0a6-1781-4884-b1bf-d7f1a1b1869d" xlink:to="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_6490e449-11f5-4cb1-945f-1904a4a9d66f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofExpensesIncludedinOperatingExpensesDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#StockBasedCompensationScheduleofExpensesIncludedinOperatingExpensesDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofExpensesIncludedinOperatingExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e25f3e70-17ce-42ef-87eb-bda78cb74846" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f0ff4206-a351-4d5c-ad92-58b3f21fd0ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e25f3e70-17ce-42ef-87eb-bda78cb74846" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f0ff4206-a351-4d5c-ad92-58b3f21fd0ed" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4d54d0a5-d447-4c1e-b6ce-4f19bbfbd50b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f0ff4206-a351-4d5c-ad92-58b3f21fd0ed" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4d54d0a5-d447-4c1e-b6ce-4f19bbfbd50b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4d54d0a5-d447-4c1e-b6ce-4f19bbfbd50b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4d54d0a5-d447-4c1e-b6ce-4f19bbfbd50b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4d54d0a5-d447-4c1e-b6ce-4f19bbfbd50b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_715eb615-c6c4-4c78-bc19-7fc7b380dbe1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4d54d0a5-d447-4c1e-b6ce-4f19bbfbd50b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_715eb615-c6c4-4c78-bc19-7fc7b380dbe1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_afd11191-8693-46ac-96fe-132a6456ef9c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_715eb615-c6c4-4c78-bc19-7fc7b380dbe1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_afd11191-8693-46ac-96fe-132a6456ef9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_14cc1f7f-f1b0-4ae6-a641-017115cafd2b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_715eb615-c6c4-4c78-bc19-7fc7b380dbe1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_14cc1f7f-f1b0-4ae6-a641-017115cafd2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_f462afae-bc76-4f96-8d90-d946b386d244" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e25f3e70-17ce-42ef-87eb-bda78cb74846" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_f462afae-bc76-4f96-8d90-d946b386d244" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofRSUsActivityDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#StockBasedCompensationScheduleofRSUsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofRSUsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0cf3d294-d2a0-47dc-a7ed-5b15f8d87111" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4372b918-b231-4f6b-b0f6-5bbafd5ec447" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0cf3d294-d2a0-47dc-a7ed-5b15f8d87111" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4372b918-b231-4f6b-b0f6-5bbafd5ec447" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0fba3892-6b0e-48b4-8c49-4e4b63487131" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4372b918-b231-4f6b-b0f6-5bbafd5ec447" xlink:to="loc_us-gaap_AwardTypeAxis_0fba3892-6b0e-48b4-8c49-4e4b63487131" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0fba3892-6b0e-48b4-8c49-4e4b63487131_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0fba3892-6b0e-48b4-8c49-4e4b63487131" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0fba3892-6b0e-48b4-8c49-4e4b63487131_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bb72a844-745d-4f50-816f-19bb48a91cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0fba3892-6b0e-48b4-8c49-4e4b63487131" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bb72a844-745d-4f50-816f-19bb48a91cb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c5b7dd87-34a2-4cd9-9d0f-e54c47159ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bb72a844-745d-4f50-816f-19bb48a91cb6" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c5b7dd87-34a2-4cd9-9d0f-e54c47159ebb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a51ebd58-169f-4b6a-90ac-b21d2380cd4e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0cf3d294-d2a0-47dc-a7ed-5b15f8d87111" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a51ebd58-169f-4b6a-90ac-b21d2380cd4e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6b89ade1-cc03-46fe-9ed6-5e391366b44a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a51ebd58-169f-4b6a-90ac-b21d2380cd4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6b89ade1-cc03-46fe-9ed6-5e391366b44a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b6991e91-2e88-48a1-a24c-5ad34a13069c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a51ebd58-169f-4b6a-90ac-b21d2380cd4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b6991e91-2e88-48a1-a24c-5ad34a13069c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b2cdf94d-ed24-4595-9b4d-44466783d106" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a51ebd58-169f-4b6a-90ac-b21d2380cd4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b2cdf94d-ed24-4595-9b4d-44466783d106" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_045bcc4f-6176-440b-af21-ff98741c4bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a51ebd58-169f-4b6a-90ac-b21d2380cd4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_045bcc4f-6176-440b-af21-ff98741c4bc7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e493e515-20d6-483f-8a56-95835f8c1865" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b2397706-36b9-4cdb-b978-b79cf7804362" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0cf3d294-d2a0-47dc-a7ed-5b15f8d87111" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b2397706-36b9-4cdb-b978-b79cf7804362" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2d2f0346-ec4a-4c28-8bb2-f99c65c87e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b2397706-36b9-4cdb-b978-b79cf7804362" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2d2f0346-ec4a-4c28-8bb2-f99c65c87e8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_45e940cb-8f59-413e-abea-5338b733bc8e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b2397706-36b9-4cdb-b978-b79cf7804362" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_45e940cb-8f59-413e-abea-5338b733bc8e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2d59a5c5-8a81-4133-8412-d70ba1a16588" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b2397706-36b9-4cdb-b978-b79cf7804362" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2d59a5c5-8a81-4133-8412-d70ba1a16588" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_fea479b2-2fc2-4cbd-97dd-21f73b282e84" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b2397706-36b9-4cdb-b978-b79cf7804362" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_fea479b2-2fc2-4cbd-97dd-21f73b282e84" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ec3b4d9b-05ee-4123-a4ed-e98fef63e428" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#FairValueMeasurementsScheduleofFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d4796807-c5a7-470d-8d0a-9edd500ceb15" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_09a98b3c-698c-4178-8769-5d718102945e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d4796807-c5a7-470d-8d0a-9edd500ceb15" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_09a98b3c-698c-4178-8769-5d718102945e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_665c6080-3efe-4504-8511-fe5dee4127f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_09a98b3c-698c-4178-8769-5d718102945e" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_665c6080-3efe-4504-8511-fe5dee4127f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_665c6080-3efe-4504-8511-fe5dee4127f0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_665c6080-3efe-4504-8511-fe5dee4127f0" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_665c6080-3efe-4504-8511-fe5dee4127f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_df413487-ce4c-4030-869e-6cb07a6f7925" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_665c6080-3efe-4504-8511-fe5dee4127f0" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_df413487-ce4c-4030-869e-6cb07a6f7925" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_b203b630-1f2a-4126-b431-5a2d88a84cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_df413487-ce4c-4030-869e-6cb07a6f7925" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_b203b630-1f2a-4126-b431-5a2d88a84cfe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b67c763a-2ace-4f5a-945a-bbe610890321" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_09a98b3c-698c-4178-8769-5d718102945e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b67c763a-2ace-4f5a-945a-bbe610890321" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b67c763a-2ace-4f5a-945a-bbe610890321_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b67c763a-2ace-4f5a-945a-bbe610890321" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b67c763a-2ace-4f5a-945a-bbe610890321_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f222bd5f-90d0-41fc-a00e-c5f10ee6301d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b67c763a-2ace-4f5a-945a-bbe610890321" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f222bd5f-90d0-41fc-a00e-c5f10ee6301d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_8951ef5b-0be8-4892-8bce-a086889921eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f222bd5f-90d0-41fc-a00e-c5f10ee6301d" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_8951ef5b-0be8-4892-8bce-a086889921eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_da7f7327-bf01-49cb-8057-5703917a4479" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f222bd5f-90d0-41fc-a00e-c5f10ee6301d" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_da7f7327-bf01-49cb-8057-5703917a4479" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_29f97ebb-8649-43cc-9e6e-2b2b169ac3bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f222bd5f-90d0-41fc-a00e-c5f10ee6301d" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_29f97ebb-8649-43cc-9e6e-2b2b169ac3bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1faa6ec9-b36e-47fc-b974-a076267c3ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_09a98b3c-698c-4178-8769-5d718102945e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1faa6ec9-b36e-47fc-b974-a076267c3ebe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1faa6ec9-b36e-47fc-b974-a076267c3ebe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1faa6ec9-b36e-47fc-b974-a076267c3ebe" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1faa6ec9-b36e-47fc-b974-a076267c3ebe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_803245da-25fa-4179-bd2b-5b31b610d9b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1faa6ec9-b36e-47fc-b974-a076267c3ebe" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_803245da-25fa-4179-bd2b-5b31b610d9b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_68d39ac5-e3a4-47a4-9ab2-133d3d73f4e6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_803245da-25fa-4179-bd2b-5b31b610d9b6" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_68d39ac5-e3a4-47a4-9ab2-133d3d73f4e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_c0bd4fc1-069e-4e0c-bfb0-96ecacc9c06b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_803245da-25fa-4179-bd2b-5b31b610d9b6" xlink:to="loc_us-gaap_MunicipalBondsMember_c0bd4fc1-069e-4e0c-bfb0-96ecacc9c06b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialNotesMember_841e1925-02d5-4a3c-8d55-a697cae80da3" xlink:href="arwr-20250630.xsd#arwr_CommercialNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_803245da-25fa-4179-bd2b-5b31b610d9b6" xlink:to="loc_arwr_CommercialNotesMember_841e1925-02d5-4a3c-8d55-a697cae80da3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_788f60c5-252d-420b-ae3e-bb54c466084d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_803245da-25fa-4179-bd2b-5b31b610d9b6" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_788f60c5-252d-420b-ae3e-bb54c466084d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_aac40e19-0f6d-48ec-b9f8-5aae58cafc7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_09a98b3c-698c-4178-8769-5d718102945e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_aac40e19-0f6d-48ec-b9f8-5aae58cafc7f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_aac40e19-0f6d-48ec-b9f8-5aae58cafc7f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_aac40e19-0f6d-48ec-b9f8-5aae58cafc7f" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_aac40e19-0f6d-48ec-b9f8-5aae58cafc7f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_00224a8b-2baf-43d1-a307-8f0cd140f3f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_aac40e19-0f6d-48ec-b9f8-5aae58cafc7f" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_00224a8b-2baf-43d1-a307-8f0cd140f3f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_c197103d-865d-4d68-8d36-8b812194c1e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_00224a8b-2baf-43d1-a307-8f0cd140f3f2" xlink:to="loc_us-gaap_MoneyMarketFundsMember_c197103d-865d-4d68-8d36-8b812194c1e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_98cbd331-9c6a-4380-8f20-68cad8c39c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_00224a8b-2baf-43d1-a307-8f0cd140f3f2" xlink:to="loc_us-gaap_BankTimeDepositsMember_98cbd331-9c6a-4380-8f20-68cad8c39c1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_4b791586-87d1-4f4e-9d04-fabfceacbc97" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_00224a8b-2baf-43d1-a307-8f0cd140f3f2" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_4b791586-87d1-4f4e-9d04-fabfceacbc97" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialNotesMember_eadc4d09-dd4b-43b0-84fc-08bb4159248d" xlink:href="arwr-20250630.xsd#arwr_CommercialNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_00224a8b-2baf-43d1-a307-8f0cd140f3f2" xlink:to="loc_arwr_CommercialNotesMember_eadc4d09-dd4b-43b0-84fc-08bb4159248d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_52851ca9-4545-4fd3-ab7b-11887ec73759" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d4796807-c5a7-470d-8d0a-9edd500ceb15" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_52851ca9-4545-4fd3-ab7b-11887ec73759" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_36379610-0bd7-4ea7-9d55-d7cd23502834" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d4796807-c5a7-470d-8d0a-9edd500ceb15" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_36379610-0bd7-4ea7-9d55-d7cd23502834" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_516388ea-9e6c-45d5-8b2d-a231bbb8b726" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d4796807-c5a7-470d-8d0a-9edd500ceb15" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_516388ea-9e6c-45d5-8b2d-a231bbb8b726" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fc640632-ee6e-42dc-8290-ca7dba2037ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3a596006-6adc-4b3c-9204-36abab4dab67" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fc640632-ee6e-42dc-8290-ca7dba2037ec" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3a596006-6adc-4b3c-9204-36abab4dab67" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_893c5d14-09e8-4ba1-825a-f29d79159f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3a596006-6adc-4b3c-9204-36abab4dab67" xlink:to="loc_us-gaap_TypeOfArrangementAxis_893c5d14-09e8-4ba1-825a-f29d79159f6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_893c5d14-09e8-4ba1-825a-f29d79159f6c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_893c5d14-09e8-4ba1-825a-f29d79159f6c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_893c5d14-09e8-4ba1-825a-f29d79159f6c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fe4cbf51-71a7-44ee-a012-c436689ec0b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_893c5d14-09e8-4ba1-825a-f29d79159f6c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fe4cbf51-71a7-44ee-a012-c436689ec0b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltyPharmaAgreementMember_66aef5e4-a373-491d-bd38-63a329f79570" xlink:href="arwr-20250630.xsd#arwr_RoyaltyPharmaAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fe4cbf51-71a7-44ee-a012-c436689ec0b7" xlink:to="loc_arwr_RoyaltyPharmaAgreementMember_66aef5e4-a373-491d-bd38-63a329f79570" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_84d9c71c-2ea4-42a2-bc43-344fc99e3ae2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3a596006-6adc-4b3c-9204-36abab4dab67" xlink:to="loc_srt_RangeAxis_84d9c71c-2ea4-42a2-bc43-344fc99e3ae2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_84d9c71c-2ea4-42a2-bc43-344fc99e3ae2_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_84d9c71c-2ea4-42a2-bc43-344fc99e3ae2" xlink:to="loc_srt_RangeMember_84d9c71c-2ea4-42a2-bc43-344fc99e3ae2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_86eac713-654a-4cdf-b698-99bc5c5415f0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_84d9c71c-2ea4-42a2-bc43-344fc99e3ae2" xlink:to="loc_srt_RangeMember_86eac713-654a-4cdf-b698-99bc5c5415f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6848e069-9889-423e-bc22-cbb30f4d387f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_86eac713-654a-4cdf-b698-99bc5c5415f0" xlink:to="loc_srt_MaximumMember_6848e069-9889-423e-bc22-cbb30f4d387f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0714426d-9752-4003-a57b-619b636dfacb" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3a596006-6adc-4b3c-9204-36abab4dab67" xlink:to="loc_srt_CounterpartyNameAxis_0714426d-9752-4003-a57b-619b636dfacb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0714426d-9752-4003-a57b-619b636dfacb_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_0714426d-9752-4003-a57b-619b636dfacb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0714426d-9752-4003-a57b-619b636dfacb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_604a2f85-677f-4e0a-ab48-79a11f8a8d46" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_0714426d-9752-4003-a57b-619b636dfacb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_604a2f85-677f-4e0a-ab48-79a11f8a8d46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmgenIncorporatedMember_95aae6b4-2605-4caf-a174-a6fd96f98075" xlink:href="arwr-20250630.xsd#arwr_AmgenIncorporatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_604a2f85-677f-4e0a-ab48-79a11f8a8d46" xlink:to="loc_arwr_AmgenIncorporatedMember_95aae6b4-2605-4caf-a174-a6fd96f98075" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_c49dc5a4-cb8e-45c3-aa36-35180e9c1232" xlink:href="arwr-20250630.xsd#arwr_InitialTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fc640632-ee6e-42dc-8290-ca7dba2037ec" xlink:to="loc_arwr_InitialTransactionPrice_c49dc5a4-cb8e-45c3-aa36-35180e9c1232" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties_a78b19db-6bd6-49a8-8636-680f9e3c552c" xlink:href="arwr-20250630.xsd#arwr_UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fc640632-ee6e-42dc-8290-ca7dba2037ec" xlink:to="loc_arwr_UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties_a78b19db-6bd6-49a8-8636-680f9e3c552c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivable_f543c94f-4ec5-459e-9319-71cb0695978f" xlink:href="arwr-20250630.xsd#arwr_MilestonePaymentReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fc640632-ee6e-42dc-8290-ca7dba2037ec" xlink:to="loc_arwr_MilestonePaymentReceivable_f543c94f-4ec5-459e-9319-71cb0695978f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial_2cc8f49b-34d0-46b9-ad17-c5010463487e" xlink:href="arwr-20250630.xsd#arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fc640632-ee6e-42dc-8290-ca7dba2037ec" xlink:to="loc_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial_2cc8f49b-34d0-46b9-ad17-c5010463487e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponFDAApproval_66d073a9-6889-4125-b6f6-2577d1ce4b99" xlink:href="arwr-20250630.xsd#arwr_MilestonePaymentReceivableUponFDAApproval"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fc640632-ee6e-42dc-8290-ca7dba2037ec" xlink:to="loc_arwr_MilestonePaymentReceivableUponFDAApproval_66d073a9-6889-4125-b6f6-2577d1ce4b99" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments_885262fb-2f36-4b9c-9e41-4d1523b52688" xlink:href="arwr-20250630.xsd#arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fc640632-ee6e-42dc-8290-ca7dba2037ec" xlink:to="loc_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments_885262fb-2f36-4b9c-9e41-4d1523b52688" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltyPaymentThreshold_b0f4efae-27a7-4ee7-b313-52ed11e15015" xlink:href="arwr-20250630.xsd#arwr_RoyaltyPaymentThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fc640632-ee6e-42dc-8290-ca7dba2037ec" xlink:to="loc_arwr_RoyaltyPaymentThreshold_b0f4efae-27a7-4ee7-b313-52ed11e15015" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties_13d6c5ee-8d35-47fe-a2a9-e445de3c416f" xlink:href="arwr-20250630.xsd#arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fc640632-ee6e-42dc-8290-ca7dba2037ec" xlink:to="loc_arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties_13d6c5ee-8d35-47fe-a2a9-e445de3c416f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilitySaleOfFutureRoyaltiesInterestRate_fa38eb7d-c909-49d1-b736-e811f7c4030c" xlink:href="arwr-20250630.xsd#arwr_LiabilitySaleOfFutureRoyaltiesInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fc640632-ee6e-42dc-8290-ca7dba2037ec" xlink:to="loc_arwr_LiabilitySaleOfFutureRoyaltiesInterestRate_fa38eb7d-c909-49d1-b736-e811f7c4030c" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#FinancingAgreementNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_19904961-689c-4b0d-8fd8-fa8a6d8bf972" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_a150ed85-a282-4f79-b6df-f7e69bed401c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_19904961-689c-4b0d-8fd8-fa8a6d8bf972" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_a150ed85-a282-4f79-b6df-f7e69bed401c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_9acdf76b-a5b7-454f-a75a-292e065caace" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_a150ed85-a282-4f79-b6df-f7e69bed401c" xlink:to="loc_us-gaap_CreditFacilityAxis_9acdf76b-a5b7-454f-a75a-292e065caace" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_9acdf76b-a5b7-454f-a75a-292e065caace_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_9acdf76b-a5b7-454f-a75a-292e065caace" xlink:to="loc_us-gaap_CreditFacilityDomain_9acdf76b-a5b7-454f-a75a-292e065caace_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_5509264b-9e79-4a64-be15-11e5dfa5ea0c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_9acdf76b-a5b7-454f-a75a-292e065caace" xlink:to="loc_us-gaap_CreditFacilityDomain_5509264b-9e79-4a64-be15-11e5dfa5ea0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_502b6bcb-3c6d-41c4-9c24-ef176e97a3c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_5509264b-9e79-4a64-be15-11e5dfa5ea0c" xlink:to="loc_us-gaap_SecuredDebtMember_502b6bcb-3c6d-41c4-9c24-ef176e97a3c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_3444fc8b-a08f-48a9-8411-69e34c1a101e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_5509264b-9e79-4a64-be15-11e5dfa5ea0c" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_3444fc8b-a08f-48a9-8411-69e34c1a101e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ec3c6d25-b5cc-4ae9-a737-ab8bba043557" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_a150ed85-a282-4f79-b6df-f7e69bed401c" xlink:to="loc_us-gaap_DebtInstrumentAxis_ec3c6d25-b5cc-4ae9-a737-ab8bba043557" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ec3c6d25-b5cc-4ae9-a737-ab8bba043557_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_ec3c6d25-b5cc-4ae9-a737-ab8bba043557" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ec3c6d25-b5cc-4ae9-a737-ab8bba043557_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8fe539a2-9b20-49d0-a49c-cc6d0e17b5c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_ec3c6d25-b5cc-4ae9-a737-ab8bba043557" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8fe539a2-9b20-49d0-a49c-cc6d0e17b5c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FinancingAgreementMember_9e9b0198-f57a-4e4f-a719-c5d766edf3e9" xlink:href="arwr-20250630.xsd#arwr_FinancingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8fe539a2-9b20-49d0-a49c-cc6d0e17b5c1" xlink:to="loc_arwr_FinancingAgreementMember_9e9b0198-f57a-4e4f-a719-c5d766edf3e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FinancingAgreementInitialTermLoanMember_f77a3c22-1a1d-44c8-bbab-73da5390e7ab" xlink:href="arwr-20250630.xsd#arwr_FinancingAgreementInitialTermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_FinancingAgreementMember_9e9b0198-f57a-4e4f-a719-c5d766edf3e9" xlink:to="loc_arwr_FinancingAgreementInitialTermLoanMember_f77a3c22-1a1d-44c8-bbab-73da5390e7ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FinancingAgreementMOICPaymentMember_bc74bfdc-5c5c-4d80-9b10-34899850ef30" xlink:href="arwr-20250630.xsd#arwr_FinancingAgreementMOICPaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_FinancingAgreementMember_9e9b0198-f57a-4e4f-a719-c5d766edf3e9" xlink:to="loc_arwr_FinancingAgreementMOICPaymentMember_bc74bfdc-5c5c-4d80-9b10-34899850ef30" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_60b32340-64ea-4cec-803e-674d3590617f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_a150ed85-a282-4f79-b6df-f7e69bed401c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_60b32340-64ea-4cec-803e-674d3590617f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_60b32340-64ea-4cec-803e-674d3590617f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_60b32340-64ea-4cec-803e-674d3590617f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_60b32340-64ea-4cec-803e-674d3590617f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_64c5f2c5-c46f-4e48-901a-251bd8fcfc4b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_60b32340-64ea-4cec-803e-674d3590617f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_64c5f2c5-c46f-4e48-901a-251bd8fcfc4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_02a9cbec-7771-42b1-854a-5f5b78922837" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_64c5f2c5-c46f-4e48-901a-251bd8fcfc4b" xlink:to="loc_us-gaap_LineOfCreditMember_02a9cbec-7771-42b1-854a-5f5b78922837" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_27c86105-6527-42b7-8f8b-5bc8f67adf56" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_a150ed85-a282-4f79-b6df-f7e69bed401c" xlink:to="loc_srt_CounterpartyNameAxis_27c86105-6527-42b7-8f8b-5bc8f67adf56" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_27c86105-6527-42b7-8f8b-5bc8f67adf56_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_27c86105-6527-42b7-8f8b-5bc8f67adf56" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_27c86105-6527-42b7-8f8b-5bc8f67adf56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_82aa379d-69da-4075-8626-08c7850b7d8b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_27c86105-6527-42b7-8f8b-5bc8f67adf56" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_82aa379d-69da-4075-8626-08c7850b7d8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SareptaMember_e329f85a-1230-4c9e-a543-e6c89cdcd2da" xlink:href="arwr-20250630.xsd#arwr_SareptaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_82aa379d-69da-4075-8626-08c7850b7d8b" xlink:to="loc_arwr_SareptaMember_e329f85a-1230-4c9e-a543-e6c89cdcd2da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_353da415-c4d9-40c0-a7e8-32448ad4cd47" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_a150ed85-a282-4f79-b6df-f7e69bed401c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_353da415-c4d9-40c0-a7e8-32448ad4cd47" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_353da415-c4d9-40c0-a7e8-32448ad4cd47_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_353da415-c4d9-40c0-a7e8-32448ad4cd47" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_353da415-c4d9-40c0-a7e8-32448ad4cd47_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_79101bc4-2706-4afc-8686-abc02a1a5be0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_353da415-c4d9-40c0-a7e8-32448ad4cd47" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_79101bc4-2706-4afc-8686-abc02a1a5be0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SareptaCollaborationAgreementMember_32720607-bb41-40ec-90c9-365116804989" xlink:href="arwr-20250630.xsd#arwr_SareptaCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_79101bc4-2706-4afc-8686-abc02a1a5be0" xlink:to="loc_arwr_SareptaCollaborationAgreementMember_32720607-bb41-40ec-90c9-365116804989" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_1c271ef6-f487-4264-81eb-eea064389c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_a150ed85-a282-4f79-b6df-f7e69bed401c" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_1c271ef6-f487-4264-81eb-eea064389c9a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_1c271ef6-f487-4264-81eb-eea064389c9a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_1c271ef6-f487-4264-81eb-eea064389c9a" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_1c271ef6-f487-4264-81eb-eea064389c9a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_d6927dad-2bdc-4f2e-9881-78072d2506a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_1c271ef6-f487-4264-81eb-eea064389c9a" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_d6927dad-2bdc-4f2e-9881-78072d2506a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_4af53ddf-221c-492b-849c-64c335d04f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_d6927dad-2bdc-4f2e-9881-78072d2506a2" xlink:to="loc_us-gaap_LineOfCreditMember_4af53ddf-221c-492b-849c-64c335d04f9f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7b17fabe-2a44-4d94-98d7-e327642de256" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_19904961-689c-4b0d-8fd8-fa8a6d8bf972" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7b17fabe-2a44-4d94-98d7-e327642de256" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_488674a7-fbd9-4bb5-a000-a9e4ebebb8a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_19904961-689c-4b0d-8fd8-fa8a6d8bf972" xlink:to="loc_us-gaap_LineOfCredit_488674a7-fbd9-4bb5-a000-a9e4ebebb8a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_68402baf-a77c-4743-be81-bd340baa96ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_19904961-689c-4b0d-8fd8-fa8a6d8bf972" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_68402baf-a77c-4743-be81-bd340baa96ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_32b84f21-7895-452a-8b23-0c69efb5af5e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_19904961-689c-4b0d-8fd8-fa8a6d8bf972" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_32b84f21-7895-452a-8b23-0c69efb5af5e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtInstrumentCovenantMultipleOfInvestCapital_0cbad0a9-26a5-4cd1-9a8c-dd598083d3fe" xlink:href="arwr-20250630.xsd#arwr_DebtInstrumentCovenantMultipleOfInvestCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_19904961-689c-4b0d-8fd8-fa8a6d8bf972" xlink:to="loc_arwr_DebtInstrumentCovenantMultipleOfInvestCapital_0cbad0a9-26a5-4cd1-9a8c-dd598083d3fe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_d54d1b62-564e-41db-bf1d-02a2dbb51c73" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_19904961-689c-4b0d-8fd8-fa8a6d8bf972" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_d54d1b62-564e-41db-bf1d-02a2dbb51c73" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ProceedsFromCollaborationArrangements_88885832-62bb-4b6c-8ae3-508bc434d693" xlink:href="arwr-20250630.xsd#arwr_ProceedsFromCollaborationArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_19904961-689c-4b0d-8fd8-fa8a6d8bf972" xlink:to="loc_arwr_ProceedsFromCollaborationArrangements_88885832-62bb-4b6c-8ae3-508bc434d693" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtInstrumentPrepaymentPercentage_b44a4b1c-59f1-4d55-9108-261eae4999e3" xlink:href="arwr-20250630.xsd#arwr_DebtInstrumentPrepaymentPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_19904961-689c-4b0d-8fd8-fa8a6d8bf972" xlink:to="loc_arwr_DebtInstrumentPrepaymentPercentage_b44a4b1c-59f1-4d55-9108-261eae4999e3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_f27f5aca-f3f7-47d4-80b6-4e011e5c4d50" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_19904961-689c-4b0d-8fd8-fa8a6d8bf972" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_f27f5aca-f3f7-47d4-80b6-4e011e5c4d50" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtInstrumentMultipleOfInvestmentCapitalExpectedToBeAppliedToPrincipalUponRepayment_ce91521e-55f4-40ff-87d6-eba291cbe7ac" xlink:href="arwr-20250630.xsd#arwr_DebtInstrumentMultipleOfInvestmentCapitalExpectedToBeAppliedToPrincipalUponRepayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_19904961-689c-4b0d-8fd8-fa8a6d8bf972" xlink:to="loc_arwr_DebtInstrumentMultipleOfInvestmentCapitalExpectedToBeAppliedToPrincipalUponRepayment_ce91521e-55f4-40ff-87d6-eba291cbe7ac" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtInstrumentCovenantMinimumLiquidityIfCapitalizationIsAboveThreshold_61534df5-58bd-4b65-87fc-60254b9ee79c" xlink:href="arwr-20250630.xsd#arwr_DebtInstrumentCovenantMinimumLiquidityIfCapitalizationIsAboveThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_19904961-689c-4b0d-8fd8-fa8a6d8bf972" xlink:to="loc_arwr_DebtInstrumentCovenantMinimumLiquidityIfCapitalizationIsAboveThreshold_61534df5-58bd-4b65-87fc-60254b9ee79c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtInstrumentCovenantMarketCapitalizationThreshold_ed6c9b02-b0c9-4a85-8398-c5459f23c396" xlink:href="arwr-20250630.xsd#arwr_DebtInstrumentCovenantMarketCapitalizationThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_19904961-689c-4b0d-8fd8-fa8a6d8bf972" xlink:to="loc_arwr_DebtInstrumentCovenantMarketCapitalizationThreshold_ed6c9b02-b0c9-4a85-8398-c5459f23c396" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_b19c7802-6a66-46e7-ba54-4590a69d4940" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_19904961-689c-4b0d-8fd8-fa8a6d8bf972" xlink:to="loc_us-gaap_DebtInstrumentTerm_b19c7802-6a66-46e7-ba54-4590a69d4940" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LinesOfCreditCurrent_16ee804a-056d-49b3-933b-0a6919827f81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LinesOfCreditCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_19904961-689c-4b0d-8fd8-fa8a6d8bf972" xlink:to="loc_us-gaap_LinesOfCreditCurrent_16ee804a-056d-49b3-933b-0a6919827f81" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FinancingAgreementScheduleofOutstandingBalanceofCreditFacilityDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#FinancingAgreementScheduleofOutstandingBalanceofCreditFacilityDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/FinancingAgreementScheduleofOutstandingBalanceofCreditFacilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_e715a4c4-b47c-4e78-abb1-2c1c713b9fff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_fa36a05b-b956-4ced-a4eb-b6e6843847d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e715a4c4-b47c-4e78-abb1-2c1c713b9fff" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_fa36a05b-b956-4ced-a4eb-b6e6843847d8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_5e935df4-39e6-402a-93cb-001d01fbe34f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_fa36a05b-b956-4ced-a4eb-b6e6843847d8" xlink:to="loc_us-gaap_CreditFacilityAxis_5e935df4-39e6-402a-93cb-001d01fbe34f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_5e935df4-39e6-402a-93cb-001d01fbe34f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_5e935df4-39e6-402a-93cb-001d01fbe34f" xlink:to="loc_us-gaap_CreditFacilityDomain_5e935df4-39e6-402a-93cb-001d01fbe34f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_a1a84e36-82f1-4be4-9372-86d85ce32d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_5e935df4-39e6-402a-93cb-001d01fbe34f" xlink:to="loc_us-gaap_CreditFacilityDomain_a1a84e36-82f1-4be4-9372-86d85ce32d8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_1d3fc94c-9e55-4b65-b33c-00338b250caa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_a1a84e36-82f1-4be4-9372-86d85ce32d8c" xlink:to="loc_us-gaap_SecuredDebtMember_1d3fc94c-9e55-4b65-b33c-00338b250caa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e63ced8a-9944-489e-bfb5-67339310b139" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_fa36a05b-b956-4ced-a4eb-b6e6843847d8" xlink:to="loc_us-gaap_DebtInstrumentAxis_e63ced8a-9944-489e-bfb5-67339310b139" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e63ced8a-9944-489e-bfb5-67339310b139_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_e63ced8a-9944-489e-bfb5-67339310b139" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e63ced8a-9944-489e-bfb5-67339310b139_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4acef216-46c9-4f96-b78f-5b7bcde5c605" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_e63ced8a-9944-489e-bfb5-67339310b139" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4acef216-46c9-4f96-b78f-5b7bcde5c605" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FinancingAgreementMember_4bb4711d-0931-4f0c-b2ca-38b715746902" xlink:href="arwr-20250630.xsd#arwr_FinancingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4acef216-46c9-4f96-b78f-5b7bcde5c605" xlink:to="loc_arwr_FinancingAgreementMember_4bb4711d-0931-4f0c-b2ca-38b715746902" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FinancingAgreementInitialTermLoanMember_3c934864-7213-401e-b3fd-e569cfced89a" xlink:href="arwr-20250630.xsd#arwr_FinancingAgreementInitialTermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_FinancingAgreementMember_4bb4711d-0931-4f0c-b2ca-38b715746902" xlink:to="loc_arwr_FinancingAgreementInitialTermLoanMember_3c934864-7213-401e-b3fd-e569cfced89a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FinancingAgreementInitialTermLoanInterestMember_238f569d-e114-41aa-8d31-c40f08da0269" xlink:href="arwr-20250630.xsd#arwr_FinancingAgreementInitialTermLoanInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_FinancingAgreementMember_4bb4711d-0931-4f0c-b2ca-38b715746902" xlink:to="loc_arwr_FinancingAgreementInitialTermLoanInterestMember_238f569d-e114-41aa-8d31-c40f08da0269" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_9bbae05d-575e-4010-8cd6-dea0093df56d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_fa36a05b-b956-4ced-a4eb-b6e6843847d8" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_9bbae05d-575e-4010-8cd6-dea0093df56d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9bbae05d-575e-4010-8cd6-dea0093df56d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9bbae05d-575e-4010-8cd6-dea0093df56d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9bbae05d-575e-4010-8cd6-dea0093df56d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_497a8403-8d1f-4962-95da-2141824ccadd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9bbae05d-575e-4010-8cd6-dea0093df56d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_497a8403-8d1f-4962-95da-2141824ccadd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_7ac95660-4474-4f80-9a93-888da4949551" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_497a8403-8d1f-4962-95da-2141824ccadd" xlink:to="loc_us-gaap_LineOfCreditMember_7ac95660-4474-4f80-9a93-888da4949551" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_ed14d474-a728-40ca-a6ea-a9f56ed91333" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e715a4c4-b47c-4e78-abb1-2c1c713b9fff" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_ed14d474-a728-40ca-a6ea-a9f56ed91333" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_5c55db40-ef0e-446d-888f-6e345bb2e29e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e715a4c4-b47c-4e78-abb1-2c1c713b9fff" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_5c55db40-ef0e-446d-888f-6e345bb2e29e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_d0072ab9-8a4d-4838-8f94-f62fcda57196" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e715a4c4-b47c-4e78-abb1-2c1c713b9fff" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_d0072ab9-8a4d-4838-8f94-f62fcda57196" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LinesOfCreditCurrent_209bdc1f-fe9d-4b66-8397-2586c64eea4d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LinesOfCreditCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e715a4c4-b47c-4e78-abb1-2c1c713b9fff" xlink:to="loc_us-gaap_LinesOfCreditCurrent_209bdc1f-fe9d-4b66-8397-2586c64eea4d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_a5625168-c951-4292-9c33-1b614d4fe990" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e715a4c4-b47c-4e78-abb1-2c1c713b9fff" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_a5625168-c951-4292-9c33-1b614d4fe990" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_157faed5-ae36-4e47-ab80-5737348c5bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e715a4c4-b47c-4e78-abb1-2c1c713b9fff" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_157faed5-ae36-4e47-ab80-5737348c5bbd" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FinancingAgreementScheduleofInterestExpenseRecognizedRelatedtoCreditFacilityDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#FinancingAgreementScheduleofInterestExpenseRecognizedRelatedtoCreditFacilityDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/FinancingAgreementScheduleofInterestExpenseRecognizedRelatedtoCreditFacilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_98680f92-fa07-4cdf-808d-f4e257e8d347" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_617c2147-10e4-4509-85f1-05ab003a8c74" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_98680f92-fa07-4cdf-808d-f4e257e8d347" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_617c2147-10e4-4509-85f1-05ab003a8c74" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_ce80bd01-b696-4c30-90d5-b9791d3b1e81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_617c2147-10e4-4509-85f1-05ab003a8c74" xlink:to="loc_us-gaap_CreditFacilityAxis_ce80bd01-b696-4c30-90d5-b9791d3b1e81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_ce80bd01-b696-4c30-90d5-b9791d3b1e81_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_ce80bd01-b696-4c30-90d5-b9791d3b1e81" xlink:to="loc_us-gaap_CreditFacilityDomain_ce80bd01-b696-4c30-90d5-b9791d3b1e81_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_3df6f29b-52a3-4efa-bebd-2e28c7c35a99" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_ce80bd01-b696-4c30-90d5-b9791d3b1e81" xlink:to="loc_us-gaap_CreditFacilityDomain_3df6f29b-52a3-4efa-bebd-2e28c7c35a99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_bc3834d1-e923-43cc-97d9-6eb89e841bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_3df6f29b-52a3-4efa-bebd-2e28c7c35a99" xlink:to="loc_us-gaap_SecuredDebtMember_bc3834d1-e923-43cc-97d9-6eb89e841bdd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c4e42e11-9817-435c-a16c-ad74e7f6cc0b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_617c2147-10e4-4509-85f1-05ab003a8c74" xlink:to="loc_us-gaap_DebtInstrumentAxis_c4e42e11-9817-435c-a16c-ad74e7f6cc0b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c4e42e11-9817-435c-a16c-ad74e7f6cc0b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_c4e42e11-9817-435c-a16c-ad74e7f6cc0b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c4e42e11-9817-435c-a16c-ad74e7f6cc0b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b3978da6-0f47-48f0-8d80-69f009d32c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_c4e42e11-9817-435c-a16c-ad74e7f6cc0b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b3978da6-0f47-48f0-8d80-69f009d32c4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FinancingAgreementMember_a782085c-b164-436b-b9c4-75b9f12f1061" xlink:href="arwr-20250630.xsd#arwr_FinancingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b3978da6-0f47-48f0-8d80-69f009d32c4f" xlink:to="loc_arwr_FinancingAgreementMember_a782085c-b164-436b-b9c4-75b9f12f1061" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_95a7597d-a26b-4c7e-8a40-1b2b41bacff6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_617c2147-10e4-4509-85f1-05ab003a8c74" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_95a7597d-a26b-4c7e-8a40-1b2b41bacff6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_95a7597d-a26b-4c7e-8a40-1b2b41bacff6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_95a7597d-a26b-4c7e-8a40-1b2b41bacff6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_95a7597d-a26b-4c7e-8a40-1b2b41bacff6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_98704b5e-c97e-4fad-a9d2-e1454afcb34a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_95a7597d-a26b-4c7e-8a40-1b2b41bacff6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_98704b5e-c97e-4fad-a9d2-e1454afcb34a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_cf4729c4-0873-4352-889e-1bb4e716ef67" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_98704b5e-c97e-4fad-a9d2-e1454afcb34a" xlink:to="loc_us-gaap_LineOfCreditMember_cf4729c4-0873-4352-889e-1bb4e716ef67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_0b5fdd43-86c9-4e5d-8bb5-f92cceb46d32" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_98680f92-fa07-4cdf-808d-f4e257e8d347" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_0b5fdd43-86c9-4e5d-8bb5-f92cceb46d32" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_ac7421f5-f7c7-48aa-b303-0cb98fd2ff0a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_98680f92-fa07-4cdf-808d-f4e257e8d347" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_ac7421f5-f7c7-48aa-b303-0cb98fd2ff0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_d8305556-e2b5-4797-ac1b-8810e307333a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_98680f92-fa07-4cdf-808d-f4e257e8d347" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_d8305556-e2b5-4797-ac1b-8810e307333a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_34165c74-0d1a-4228-afd0-cb5f1890578a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_98680f92-fa07-4cdf-808d-f4e257e8d347" xlink:to="loc_us-gaap_InterestExpenseDebt_34165c74-0d1a-4228-afd0-cb5f1890578a" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_377e5ce5-d901-4c17-b7e0-c8e5ce287604" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_1c79b81f-07c0-4788-80e6-784f459f066e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_377e5ce5-d901-4c17-b7e0-c8e5ce287604" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_1c79b81f-07c0-4788-80e6-784f459f066e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a642029c-d4c9-4270-992a-a03de17e426d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_1c79b81f-07c0-4788-80e6-784f459f066e" xlink:to="loc_us-gaap_DebtInstrumentAxis_a642029c-d4c9-4270-992a-a03de17e426d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a642029c-d4c9-4270-992a-a03de17e426d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_a642029c-d4c9-4270-992a-a03de17e426d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a642029c-d4c9-4270-992a-a03de17e426d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b1129c88-6e54-4818-8bd4-c44db6feaa65" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_a642029c-d4c9-4270-992a-a03de17e426d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b1129c88-6e54-4818-8bd4-c44db6feaa65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FinancingAgreementMember_80ed028c-c6bc-48d3-a71e-3e9d404578b0" xlink:href="arwr-20250630.xsd#arwr_FinancingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b1129c88-6e54-4818-8bd4-c44db6feaa65" xlink:to="loc_arwr_FinancingAgreementMember_80ed028c-c6bc-48d3-a71e-3e9d404578b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_32b9092a-b39c-4e74-9de5-b3eb34ed2e81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_1c79b81f-07c0-4788-80e6-784f459f066e" xlink:to="loc_us-gaap_CreditFacilityAxis_32b9092a-b39c-4e74-9de5-b3eb34ed2e81" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_32b9092a-b39c-4e74-9de5-b3eb34ed2e81_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_32b9092a-b39c-4e74-9de5-b3eb34ed2e81" xlink:to="loc_us-gaap_CreditFacilityDomain_32b9092a-b39c-4e74-9de5-b3eb34ed2e81_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_9ee2d698-58af-43a4-b78e-37b00606fb63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_32b9092a-b39c-4e74-9de5-b3eb34ed2e81" xlink:to="loc_us-gaap_CreditFacilityDomain_9ee2d698-58af-43a4-b78e-37b00606fb63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_12a2487b-25a9-4899-9c2c-74c066b6d796" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_9ee2d698-58af-43a4-b78e-37b00606fb63" xlink:to="loc_us-gaap_SecuredDebtMember_12a2487b-25a9-4899-9c2c-74c066b6d796" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_28b7ef07-27a8-4386-ba1e-0f3c7d9d97e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_1c79b81f-07c0-4788-80e6-784f459f066e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_28b7ef07-27a8-4386-ba1e-0f3c7d9d97e8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_28b7ef07-27a8-4386-ba1e-0f3c7d9d97e8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_28b7ef07-27a8-4386-ba1e-0f3c7d9d97e8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_28b7ef07-27a8-4386-ba1e-0f3c7d9d97e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5e8d49ae-e050-4648-b00a-923bdeccb9a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_28b7ef07-27a8-4386-ba1e-0f3c7d9d97e8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5e8d49ae-e050-4648-b00a-923bdeccb9a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_d4a676d5-3285-48d2-b2ca-7f14c8dec538" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5e8d49ae-e050-4648-b00a-923bdeccb9a0" xlink:to="loc_us-gaap_LineOfCreditMember_d4a676d5-3285-48d2-b2ca-7f14c8dec538" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_56d61f88-84bc-4296-81bb-6a36ced46f60" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_377e5ce5-d901-4c17-b7e0-c8e5ce287604" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_56d61f88-84bc-4296-81bb-6a36ced46f60" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_dcda8438-7dc3-454f-a5ce-4d0ce2b86098" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_377e5ce5-d901-4c17-b7e0-c8e5ce287604" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_dcda8438-7dc3-454f-a5ce-4d0ce2b86098" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_71f3f97a-3030-4504-ac83-cd9161b11586" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_377e5ce5-d901-4c17-b7e0-c8e5ce287604" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_71f3f97a-3030-4504-ac83-cd9161b11586" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_aed9fc1c-2ae0-419c-b5fe-7cdc5159e9e6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_377e5ce5-d901-4c17-b7e0-c8e5ce287604" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_aed9fc1c-2ae0-419c-b5fe-7cdc5159e9e6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_e995a0fd-e291-4a51-a045-aaddb9690ffd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_377e5ce5-d901-4c17-b7e0-c8e5ce287604" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_e995a0fd-e291-4a51-a045-aaddb9690ffd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LongTermDebtMaturityAfterYearFour_df9a5556-d3c1-441a-abcc-e577207d3aa4" xlink:href="arwr-20250630.xsd#arwr_LongTermDebtMaturityAfterYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_377e5ce5-d901-4c17-b7e0-c8e5ce287604" xlink:to="loc_arwr_LongTermDebtMaturityAfterYearFour_df9a5556-d3c1-441a-abcc-e577207d3aa4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_5a6aa26f-a37d-4eac-b6ff-2ada64be0a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_377e5ce5-d901-4c17-b7e0-c8e5ce287604" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_5a6aa26f-a37d-4eac-b6ff-2ada64be0a1e" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/NetLossIncomePerShareScheduleofAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#NetLossIncomePerShareScheduleofAntidilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/NetLossIncomePerShareScheduleofAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_162600b7-34ab-4517-9281-5c31b3130be3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_84a5cebc-d90d-4461-b855-549aef85a20b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_162600b7-34ab-4517-9281-5c31b3130be3" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_84a5cebc-d90d-4461-b855-549aef85a20b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e1af8855-fcc2-41fa-9469-dce6690167ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_84a5cebc-d90d-4461-b855-549aef85a20b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e1af8855-fcc2-41fa-9469-dce6690167ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e1af8855-fcc2-41fa-9469-dce6690167ad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e1af8855-fcc2-41fa-9469-dce6690167ad" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e1af8855-fcc2-41fa-9469-dce6690167ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_35a6519c-93c1-42f6-8483-9356e503e57b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e1af8855-fcc2-41fa-9469-dce6690167ad" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_35a6519c-93c1-42f6-8483-9356e503e57b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8a9b7b8e-6428-4c52-bf9d-fac308053220" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_35a6519c-93c1-42f6-8483-9356e503e57b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8a9b7b8e-6428-4c52-bf9d-fac308053220" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_12d539fa-52ca-4675-88b3-4153ef3cf7d9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_35a6519c-93c1-42f6-8483-9356e503e57b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_12d539fa-52ca-4675-88b3-4153ef3cf7d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_eaa4952c-f191-4d86-9aba-e1482361dac0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_162600b7-34ab-4517-9281-5c31b3130be3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_eaa4952c-f191-4d86-9aba-e1482361dac0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_b9b0b055-876c-4621-b62c-49f96564e088" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_d5f25b38-f561-4841-aa6c-a242e0e098af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_b9b0b055-876c-4621-b62c-49f96564e088" xlink:to="loc_us-gaap_SubsequentEventTable_d5f25b38-f561-4841-aa6c-a242e0e098af" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_f4e7704d-1177-4833-817b-ba1f9c2abb57" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_d5f25b38-f561-4841-aa6c-a242e0e098af" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_f4e7704d-1177-4833-817b-ba1f9c2abb57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f4e7704d-1177-4833-817b-ba1f9c2abb57_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f4e7704d-1177-4833-817b-ba1f9c2abb57" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f4e7704d-1177-4833-817b-ba1f9c2abb57_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c6b933e0-bc7e-44e7-93b2-a03d4104465e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f4e7704d-1177-4833-817b-ba1f9c2abb57" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c6b933e0-bc7e-44e7-93b2-a03d4104465e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_7e32aea8-dbbd-43e3-a754-70a3ddbb622e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_c6b933e0-bc7e-44e7-93b2-a03d4104465e" xlink:to="loc_us-gaap_SubsequentEventMember_7e32aea8-dbbd-43e3-a754-70a3ddbb622e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_147a1b9e-bdad-4588-8583-087c8d2d451a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_d5f25b38-f561-4841-aa6c-a242e0e098af" xlink:to="loc_srt_CounterpartyNameAxis_147a1b9e-bdad-4588-8583-087c8d2d451a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_147a1b9e-bdad-4588-8583-087c8d2d451a_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_147a1b9e-bdad-4588-8583-087c8d2d451a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_147a1b9e-bdad-4588-8583-087c8d2d451a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6acf0803-7230-402b-b64b-00a61feedb99" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_147a1b9e-bdad-4588-8583-087c8d2d451a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6acf0803-7230-402b-b64b-00a61feedb99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VisirnaTherapeuticsIncMember_32c880fe-594c-47bb-8901-39d6182607aa" xlink:href="arwr-20250630.xsd#arwr_VisirnaTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6acf0803-7230-402b-b64b-00a61feedb99" xlink:to="loc_arwr_VisirnaTherapeuticsIncMember_32c880fe-594c-47bb-8901-39d6182607aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SareptaMember_c7367635-af4d-430c-b9e9-4fa2309d7c5e" xlink:href="arwr-20250630.xsd#arwr_SareptaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6acf0803-7230-402b-b64b-00a61feedb99" xlink:to="loc_arwr_SareptaMember_c7367635-af4d-430c-b9e9-4fa2309d7c5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_04e6e088-9eb3-4a58-b6f2-14f170395250" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_d5f25b38-f561-4841-aa6c-a242e0e098af" xlink:to="loc_us-gaap_TypeOfArrangementAxis_04e6e088-9eb3-4a58-b6f2-14f170395250" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04e6e088-9eb3-4a58-b6f2-14f170395250_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_04e6e088-9eb3-4a58-b6f2-14f170395250" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04e6e088-9eb3-4a58-b6f2-14f170395250_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2c91d685-6eec-435c-89bf-9861fafa129a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_04e6e088-9eb3-4a58-b6f2-14f170395250" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2c91d685-6eec-435c-89bf-9861fafa129a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SanofiLicenseAgreementMember_44fb6076-5761-4558-9fa0-2527300da331" xlink:href="arwr-20250630.xsd#arwr_SanofiLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2c91d685-6eec-435c-89bf-9861fafa129a" xlink:to="loc_arwr_SanofiLicenseAgreementMember_44fb6076-5761-4558-9fa0-2527300da331" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SareptaCollaborationAgreementMember_80c2b93c-cbcc-4a4b-a7d2-4df26e571a3b" xlink:href="arwr-20250630.xsd#arwr_SareptaCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2c91d685-6eec-435c-89bf-9861fafa129a" xlink:to="loc_arwr_SareptaCollaborationAgreementMember_80c2b93c-cbcc-4a4b-a7d2-4df26e571a3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_076d95c9-05ac-461c-bdb0-ff0c89d036d3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_d5f25b38-f561-4841-aa6c-a242e0e098af" xlink:to="loc_srt_StatementScenarioAxis_076d95c9-05ac-461c-bdb0-ff0c89d036d3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_076d95c9-05ac-461c-bdb0-ff0c89d036d3_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_076d95c9-05ac-461c-bdb0-ff0c89d036d3" xlink:to="loc_srt_ScenarioUnspecifiedDomain_076d95c9-05ac-461c-bdb0-ff0c89d036d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_395302b9-1da6-4b43-b9d4-b5d211385d96" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_076d95c9-05ac-461c-bdb0-ff0c89d036d3" xlink:to="loc_srt_ScenarioUnspecifiedDomain_395302b9-1da6-4b43-b9d4-b5d211385d96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_c8c477d3-bf50-4122-a36c-da38e3f96ca4" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_395302b9-1da6-4b43-b9d4-b5d211385d96" xlink:to="loc_srt_ScenarioForecastMember_c8c477d3-bf50-4122-a36c-da38e3f96ca4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_807bd9bc-2c12-404f-8e85-5ccd77a9d5dc" xlink:href="arwr-20250630.xsd#arwr_InitialTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_b9b0b055-876c-4621-b62c-49f96564e088" xlink:to="loc_arwr_InitialTransactionPrice_807bd9bc-2c12-404f-8e85-5ccd77a9d5dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FuturePotentialMilestonePayments_91ea48f7-6551-49cf-8464-794a81caa231" xlink:href="arwr-20250630.xsd#arwr_FuturePotentialMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_b9b0b055-876c-4621-b62c-49f96564e088" xlink:to="loc_arwr_FuturePotentialMilestonePayments_91ea48f7-6551-49cf-8464-794a81caa231" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentMilestonePayments_10a82352-1732-41ff-bffc-7c3f30c82818" xlink:href="arwr-20250630.xsd#arwr_DevelopmentMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_b9b0b055-876c-4621-b62c-49f96564e088" xlink:to="loc_arwr_DevelopmentMilestonePayments_10a82352-1732-41ff-bffc-7c3f30c82818" xlink:type="arc" order="2"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>arwr-20250630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:774aaf13-8f26-4ca1-8d87-74a19a24be14,g:58a47ad1-6a7b-4244-af8c-bd7fa2a79e94-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_arwr_GSKHSDLicenseAgreementMember_4cfd328c-1715-4c33-ba0f-866f649e0979_terseLabel_en-US" xlink:label="lab_arwr_GSKHSDLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GSK-HSD License Agreement</link:label>
    <link:label id="lab_arwr_GSKHSDLicenseAgreementMember_label_en-US" xlink:label="lab_arwr_GSKHSDLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GSK-HSD License Agreement [Member]</link:label>
    <link:label id="lab_arwr_GSKHSDLicenseAgreementMember_documentation_en-US" xlink:label="lab_arwr_GSKHSDLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">GSK-HSD License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GSKHSDLicenseAgreementMember" xlink:href="arwr-20250630.xsd#arwr_GSKHSDLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_GSKHSDLicenseAgreementMember" xlink:to="lab_arwr_GSKHSDLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6f00a108-c2bc-4bb3-8e6b-6bf56db8e8d8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_RoyaltiesLiabilityNoncurrent_8a255b53-d2b7-4821-9fc3-e488c1797fcf_terseLabel_en-US" xlink:label="lab_arwr_RoyaltiesLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability related to the sale of future royalties</link:label>
    <link:label id="lab_arwr_RoyaltiesLiabilityNoncurrent_d1996ead-2953-4468-b92b-08fd8d7918d1_periodStartLabel_en-US" xlink:label="lab_arwr_RoyaltiesLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning carrying value</link:label>
    <link:label id="lab_arwr_RoyaltiesLiabilityNoncurrent_9ce19f53-8c5c-4315-8fb2-b33f1e00460e_periodEndLabel_en-US" xlink:label="lab_arwr_RoyaltiesLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending carrying value</link:label>
    <link:label id="lab_arwr_RoyaltiesLiabilityNoncurrent_label_en-US" xlink:label="lab_arwr_RoyaltiesLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalties, Liability, Noncurrent</link:label>
    <link:label id="lab_arwr_RoyaltiesLiabilityNoncurrent_documentation_en-US" xlink:label="lab_arwr_RoyaltiesLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalties, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltiesLiabilityNoncurrent" xlink:href="arwr-20250630.xsd#arwr_RoyaltiesLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_RoyaltiesLiabilityNoncurrent" xlink:to="lab_arwr_RoyaltiesLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_07ff79c9-9ea0-4827-a8b6-33b4f4f581b7_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_EnrollmentRelatedMilestonePayments_74cff1a1-7405-4dca-8045-71d0a087a5a6_terseLabel_en-US" xlink:label="lab_arwr_EnrollmentRelatedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Enrollment related milestone payments</link:label>
    <link:label id="lab_arwr_EnrollmentRelatedMilestonePayments_label_en-US" xlink:label="lab_arwr_EnrollmentRelatedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Enrollment Related Milestone Payments</link:label>
    <link:label id="lab_arwr_EnrollmentRelatedMilestonePayments_documentation_en-US" xlink:label="lab_arwr_EnrollmentRelatedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Enrollment Related Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EnrollmentRelatedMilestonePayments" xlink:href="arwr-20250630.xsd#arwr_EnrollmentRelatedMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_EnrollmentRelatedMilestonePayments" xlink:to="lab_arwr_EnrollmentRelatedMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_fd5beff8-08cd-4c97-b10f-665eabed31ae_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Realized loss on investments</link:label>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_label_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Realized Investment Gains (Losses)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:to="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_8319cfed-0cee-4400-b747-bba2a8ac6039_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025 (remainder)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_2294ae16-9bbc-449a-a81c-815d30668a1e_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_13a50a35-6230-4ea3-b0ab-568b8d629c2d_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_f07d221a-7911-4d05-a264-04902bf6408e_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod_ebf87d94-e163-4b7d-8f7d-898571040838_terseLabel_en-US" xlink:label="lab_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual installments period</link:label>
    <link:label id="lab_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod_label_en-US" xlink:label="lab_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Receivable Under Collaboration Agreement, Annual Installments Period</link:label>
    <link:label id="lab_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod_documentation_en-US" xlink:label="lab_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Receivable Under Collaboration Agreement, Annual Installments Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod" xlink:href="arwr-20250630.xsd#arwr_CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod" xlink:to="lab_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_77750499-3d17-4276-a23e-dc1304a81300_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ConstructionInProgressReclassifiedToManufacturingEquipmentMember_378f562b-9338-46d0-af88-cae70f205e99_terseLabel_en-US" xlink:label="lab_arwr_ConstructionInProgressReclassifiedToManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction In Progress Reclassified To Manufacturing Equipment</link:label>
    <link:label id="lab_arwr_ConstructionInProgressReclassifiedToManufacturingEquipmentMember_label_en-US" xlink:label="lab_arwr_ConstructionInProgressReclassifiedToManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction In Progress Reclassified To Manufacturing Equipment [Member]</link:label>
    <link:label id="lab_arwr_ConstructionInProgressReclassifiedToManufacturingEquipmentMember_documentation_en-US" xlink:label="lab_arwr_ConstructionInProgressReclassifiedToManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Construction In Progress Reclassified To Manufacturing Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ConstructionInProgressReclassifiedToManufacturingEquipmentMember" xlink:href="arwr-20250630.xsd#arwr_ConstructionInProgressReclassifiedToManufacturingEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ConstructionInProgressReclassifiedToManufacturingEquipmentMember" xlink:to="lab_arwr_ConstructionInProgressReclassifiedToManufacturingEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_ec5e25f0-086c-4b46-9490-3b5436f7a3e9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_ea5eadd1-914b-45f1-985e-8459331a4dc7_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_64e65596-afef-4b15-b645-6a23e181700a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesMember" xlink:to="lab_us-gaap_DebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AccruedResearchAndDevelopmentExpenseCurrent_e4d8f79c-0ed7-44dd-a163-fbd288e58e93_terseLabel_en-US" xlink:label="lab_arwr_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued research and development expenses</link:label>
    <link:label id="lab_arwr_AccruedResearchAndDevelopmentExpenseCurrent_label_en-US" xlink:label="lab_arwr_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Research And Development Expense, Current</link:label>
    <link:label id="lab_arwr_AccruedResearchAndDevelopmentExpenseCurrent_documentation_en-US" xlink:label="lab_arwr_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Research And Development Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AccruedResearchAndDevelopmentExpenseCurrent" xlink:href="arwr-20250630.xsd#arwr_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AccruedResearchAndDevelopmentExpenseCurrent" xlink:to="lab_arwr_AccruedResearchAndDevelopmentExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_e365da92-df39-43cf-8995-266fb1a8425c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_7a9c6dd3-6acf-41b0-b968-0e39d8318466_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic net (loss) income per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_175f6303-8008-43c9-a690-7470ca92e8ed_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Line of Credit Facilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Line of Credit Facilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:to="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_RegulatoryMilestonePayments_79603e2b-7eb0-4ed7-b922-2c65c62342e8_terseLabel_en-US" xlink:label="lab_arwr_RegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Regulatory milestone payments</link:label>
    <link:label id="lab_arwr_RegulatoryMilestonePayments_label_en-US" xlink:label="lab_arwr_RegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Regulatory Milestone Payments</link:label>
    <link:label id="lab_arwr_RegulatoryMilestonePayments_documentation_en-US" xlink:label="lab_arwr_RegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Regulatory Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RegulatoryMilestonePayments" xlink:href="arwr-20250630.xsd#arwr_RegulatoryMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_RegulatoryMilestonePayments" xlink:to="lab_arwr_RegulatoryMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2b9630eb-e63b-4cd1-97d5-9e8610c55757_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares reserve for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_241cfb73-e3e6-47ea-99a9-642a957b6e99_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fixed and Estimated Variable Consideration</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_7b8ad802-87c3-4001-9fbe-1b3448efca7c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Stock By Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_2bc0a265-4f77-44db-a3b9-cdbeabf5017a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_ed5c44dc-c073-4516-bcca-62c373bb07f7_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8f6dd958-a3b3-4106-b674-6c1e5df732f3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6f2e63f1-b369-4592-b7f1-e57bd8017a94_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_379bce0b-0750-4637-87e4-0fb8a1f32dc0_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_327bee56-53c1-400c-ba74-983e63f66c84_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_e1844796-cb03-407d-b472-925a885fc261_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_85fd66ed-ce25-4423-9f0a-18f37758b80c_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_9c831359-fd30-4e44-b1f8-e6cd273dc801_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_202934ef-fd5d-44c3-b05d-3a83ce2417a4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8df3fa11-1a15-40c0-829a-2eb615c3065b_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PatentsMember_b706a82e-9af8-4caf-8185-9deb68170d19_terseLabel_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Patents</link:label>
    <link:label id="lab_us-gaap_PatentsMember_label_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Patents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PatentsMember" xlink:to="lab_us-gaap_PatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3e8f2e4c-9ed8-42f2-b6d3-bb58db2ad24f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued, net of offering costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_b4074f1c-1e47-48f5-93d6-56c71a990875_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_372eb5c9-a5b5-4578-b5b7-867384442400_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_91c1f098-6e8d-4578-85d3-88b283e79f69_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Liabilities, Noncontrolling Interest and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_095e70cb-d7ce-419a-a688-e7f9ed256e15_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_3d6ca13e-ed2b-40bc-b917-5e9ea8b3ba4d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e241ce52-b341-4b29-95d5-12acd09d6956_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_bb3e0577-7142-4748-8da0-14e772dac18e_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_507088dc-4a2a-4138-9af2-275c1ab508c1_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES, NONCONTROLLING INTEREST AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_8ae89a63-0ee8-4296-9ce8-02f424fe1999_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_63e93401-db8c-4954-909f-14db8e1d7c37_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_d00be39a-b62f-4d14-8bb7-6c88ef0111a0_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_bc3cbe9d-61de-4817-b752-72ecd2fae9ca_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Exercise Price Per Share, Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_2b97ae56-a89f-44ad-a77e-09060f457a8a_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_571248e8-8131-40b5-ba73-a078a2718f25_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Useful Lives (in years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_cb393467-8cfc-4337-a387-a35e405d4103_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to noncontrolling interest, net of tax</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_a43e7c77-bf30-4b9d-aba3-cfa994a368f5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_6f5bd977-59d7-4495-8ac3-4ca6036de979_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_75d4bbff-a3a4-4149-be4c-ce5dd9a2907f_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AdditionalCashReceivableUnderCollaborationAgreement_de871bd6-e082-4b2d-b76a-cbe1e1c7336b_verboseLabel_en-US" xlink:label="lab_arwr_AdditionalCashReceivableUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Annual fees</link:label>
    <link:label id="lab_arwr_AdditionalCashReceivableUnderCollaborationAgreement_label_en-US" xlink:label="lab_arwr_AdditionalCashReceivableUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Cash Receivable Under Collaboration Agreement</link:label>
    <link:label id="lab_arwr_AdditionalCashReceivableUnderCollaborationAgreement_documentation_en-US" xlink:label="lab_arwr_AdditionalCashReceivableUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional Cash Receivable Under Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AdditionalCashReceivableUnderCollaborationAgreement" xlink:href="arwr-20250630.xsd#arwr_AdditionalCashReceivableUnderCollaborationAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AdditionalCashReceivableUnderCollaborationAgreement" xlink:to="lab_arwr_AdditionalCashReceivableUnderCollaborationAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_a85156fe-2af1-4af9-8057-e5481dc2ef75_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Operating Lease Liabilities on an Undiscounted Basis</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_361f0bd1-4cfe-498e-af96-ac9f0afb4612_terseLabel_en-US" xlink:label="lab_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock shares value reserved for future issuance</link:label>
    <link:label id="lab_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_label_en-US" xlink:label="lab_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Capital Shares Value Reserved For Future Issuance</link:label>
    <link:label id="lab_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_documentation_en-US" xlink:label="lab_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common stock, capital shares value reserved for future issuance.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:href="arwr-20250630.xsd#arwr_CommonStockCapitalSharesValueReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:to="lab_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c350ee4f-6136-4f31-b3fa-468e22547608_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DevelopmentMilestonePayments_1ad642a1-b00d-483c-b6f8-c8e84817a762_terseLabel_en-US" xlink:label="lab_arwr_DevelopmentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development milestone payments</link:label>
    <link:label id="lab_arwr_DevelopmentMilestonePayments_label_en-US" xlink:label="lab_arwr_DevelopmentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development Milestone Payments</link:label>
    <link:label id="lab_arwr_DevelopmentMilestonePayments_documentation_en-US" xlink:label="lab_arwr_DevelopmentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Development Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentMilestonePayments" xlink:href="arwr-20250630.xsd#arwr_DevelopmentMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DevelopmentMilestonePayments" xlink:to="lab_arwr_DevelopmentMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_8720ebcf-a5c5-418f-b39f-d858e5356524_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. government and agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_ea335bd3-72a5-4acd-9988-62ea5994254b_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total operating lease liabilities (includes current portion)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CashFlowNoncashInvestingActivitiesDisclosureAbstract_6a798bda-ec99-43a0-bb3b-2eeef036bbee_terseLabel_en-US" xlink:label="lab_arwr_CashFlowNoncashInvestingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of non-cash investing activities:</link:label>
    <link:label id="lab_arwr_CashFlowNoncashInvestingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_arwr_CashFlowNoncashInvestingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_arwr_CashFlowNoncashInvestingActivitiesDisclosureAbstract_documentation_en-US" xlink:label="lab_arwr_CashFlowNoncashInvestingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing Activities Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashFlowNoncashInvestingActivitiesDisclosureAbstract" xlink:href="arwr-20250630.xsd#arwr_CashFlowNoncashInvestingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CashFlowNoncashInvestingActivitiesDisclosureAbstract" xlink:to="lab_arwr_CashFlowNoncashInvestingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_FinancingAgreementMember_60b13d62-5aac-4baa-af28-965e1e2ea093_terseLabel_en-US" xlink:label="lab_arwr_FinancingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing Agreement</link:label>
    <link:label id="lab_arwr_FinancingAgreementMember_label_en-US" xlink:label="lab_arwr_FinancingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing Agreement [Member]</link:label>
    <link:label id="lab_arwr_FinancingAgreementMember_documentation_en-US" xlink:label="lab_arwr_FinancingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financing Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FinancingAgreementMember" xlink:href="arwr-20250630.xsd#arwr_FinancingAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_FinancingAgreementMember" xlink:to="lab_arwr_FinancingAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_e0b85fce-9736-420d-b725-ef9753c3ec5a_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b821f56a-98d4-4ef1-a5f8-3a21aa17245b_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">(Loss) income before income tax expense and noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_6dd9c130-d8bb-4297-925d-0f13e6b5261c_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_TwoThousandsThirteenIncentivePlanMember_d40a37b4-9f71-4cad-b369-9eefc42e985d_terseLabel_en-US" xlink:label="lab_arwr_TwoThousandsThirteenIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2013 Plan</link:label>
    <link:label id="lab_arwr_TwoThousandsThirteenIncentivePlanMember_label_en-US" xlink:label="lab_arwr_TwoThousandsThirteenIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousands Thirteen Incentive Plan [Member]</link:label>
    <link:label id="lab_arwr_TwoThousandsThirteenIncentivePlanMember_documentation_en-US" xlink:label="lab_arwr_TwoThousandsThirteenIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two thousands thirteen incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsThirteenIncentivePlanMember" xlink:href="arwr-20250630.xsd#arwr_TwoThousandsThirteenIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_TwoThousandsThirteenIncentivePlanMember" xlink:to="lab_arwr_TwoThousandsThirteenIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_0d61a4e6-5af3-430f-bb3a-ebbf1c535750_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_LongTermDebtMaturityAfterYearFour_83a2dfd5-cdf1-4cbc-a92e-3312bf765eb9_terseLabel_en-US" xlink:label="lab_arwr_LongTermDebtMaturityAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_arwr_LongTermDebtMaturityAfterYearFour_label_en-US" xlink:label="lab_arwr_LongTermDebtMaturityAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, After Year Four</link:label>
    <link:label id="lab_arwr_LongTermDebtMaturityAfterYearFour_documentation_en-US" xlink:label="lab_arwr_LongTermDebtMaturityAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LongTermDebtMaturityAfterYearFour" xlink:href="arwr-20250630.xsd#arwr_LongTermDebtMaturityAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_LongTermDebtMaturityAfterYearFour" xlink:to="lab_arwr_LongTermDebtMaturityAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_SalesRelatedMilestonePayments_3848e5b5-7214-4ba2-8c5e-53380cd46deb_terseLabel_en-US" xlink:label="lab_arwr_SalesRelatedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales-related milestone payments</link:label>
    <link:label id="lab_arwr_SalesRelatedMilestonePayments_label_en-US" xlink:label="lab_arwr_SalesRelatedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Related Milestone Payments</link:label>
    <link:label id="lab_arwr_SalesRelatedMilestonePayments_documentation_en-US" xlink:label="lab_arwr_SalesRelatedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales-related milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SalesRelatedMilestonePayments" xlink:href="arwr-20250630.xsd#arwr_SalesRelatedMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_SalesRelatedMilestonePayments" xlink:to="lab_arwr_SalesRelatedMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_11c2e7a8-6d11-42b9-81ff-0dd7757ace63_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d8db26b7-57f5-4e38-b6bb-7ba021b28618_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_2a9a8353-629f-4509-a66d-1b9a92b86f79_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_b2353816-e711-4ce4-8800-6cfc9be76e73_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: Unamortized debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_a1d5ddde-a225-48a5-9f7a-38468d64d61b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cancelled or expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent_e625369b-e0d8-4225-be9a-9d0c5199346d_negatedTerseLabel_en-US" xlink:label="lab_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Current investments, Gross Unrealized Losses</link:label>
    <link:label id="lab_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent_label_en-US" xlink:label="lab_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Current</link:label>
    <link:label id="lab_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent_documentation_en-US" xlink:label="lab_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent" xlink:href="arwr-20250630.xsd#arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent" xlink:to="lab_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_81729cce-b8d2-4839-ae04-7c7186959e6e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Arrangement, Expensed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_f801b265-3354-4a70-9bc3-82f8a009560f_negatedLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">(Accretion) amortization of note premiums/discounts</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Net, Amortization of Discount and Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_4c0f4b22-dac2-4112-8093-daa50fb5bb96_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_df3426b2-a884-4ce0-aa94-83d5a638d24e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_0a73ed6c-e158-4746-b55f-5435eca168c4_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class Of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_860a8a78-9bb2-4310-862f-64070ca20001_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_7c7fdc0d-8574-4086-9569-99737b6ebe80_terseLabel_en-US" xlink:label="lab_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of commission to sales agent</link:label>
    <link:label id="lab_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_label_en-US" xlink:label="lab_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Commission On Aggregate Gross Proceeds From Sale Of Common Stock</link:label>
    <link:label id="lab_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_documentation_en-US" xlink:label="lab_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of commission on aggregate gross proceeds from sale of common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" xlink:href="arwr-20250630.xsd#arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" xlink:to="lab_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_c98ad59f-53ef-4833-8efe-20e0f97e731f_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_f47d94e9-b7d4-4456-9c04-3e504155b85a_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CommercialNotesMember_9df18199-5e34-460d-b44f-40057b262ba8_terseLabel_en-US" xlink:label="lab_arwr_CommercialNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial notes</link:label>
    <link:label id="lab_arwr_CommercialNotesMember_label_en-US" xlink:label="lab_arwr_CommercialNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Notes [Member]</link:label>
    <link:label id="lab_arwr_CommercialNotesMember_documentation_en-US" xlink:label="lab_arwr_CommercialNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commercial Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialNotesMember" xlink:href="arwr-20250630.xsd#arwr_CommercialNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CommercialNotesMember" xlink:to="lab_arwr_CommercialNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_6151daa0-d8a5-4d39-890f-7bf77bf58774_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f1b084a4-dfde-4eb2-a540-9a7688a80df7_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_ae5a5e95-3180-4b48-9647-369b95992682_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ProceedsFromSaleOfFutureRoyalties_b2e20f36-b790-42ac-b464-a20ef9fbd04e_terseLabel_en-US" xlink:label="lab_arwr_ProceedsFromSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the sales of future royalties</link:label>
    <link:label id="lab_arwr_ProceedsFromSaleOfFutureRoyalties_label_en-US" xlink:label="lab_arwr_ProceedsFromSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Sale Of Future Royalties</link:label>
    <link:label id="lab_arwr_ProceedsFromSaleOfFutureRoyalties_documentation_en-US" xlink:label="lab_arwr_ProceedsFromSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Sale Of Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ProceedsFromSaleOfFutureRoyalties" xlink:href="arwr-20250630.xsd#arwr_ProceedsFromSaleOfFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ProceedsFromSaleOfFutureRoyalties" xlink:to="lab_arwr_ProceedsFromSaleOfFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_93878f70-d306-4fbf-a20f-adb7b2c0ad4b_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_03be1594-351a-4d7d-8776-46aa0245ffa9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_cb5a3302-10bc-43ba-b24d-71d387b3fb88_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_d49a589e-a71d-4f72-9401-813423b549bd_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_31fa6e61-aff1-4ea1-b52a-993f26728500_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_b8a8da26-2278-4409-b8d4-3d8c0c9bf9a0_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-Term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_adbb3eca-ce94-4e6d-bfeb-dc4ac49446aa_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_b503638a-ad49-407f-8f16-00ae385b517b_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization and Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ResearchFacilityInSanDiegoMember_184b9ccf-1a1b-4df6-a081-5ba3dca13fa0_terseLabel_en-US" xlink:label="lab_arwr_ResearchFacilityInSanDiegoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Facility in San Diego</link:label>
    <link:label id="lab_arwr_ResearchFacilityInSanDiegoMember_label_en-US" xlink:label="lab_arwr_ResearchFacilityInSanDiegoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Facility In San Diego [Member]</link:label>
    <link:label id="lab_arwr_ResearchFacilityInSanDiegoMember_documentation_en-US" xlink:label="lab_arwr_ResearchFacilityInSanDiegoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research Facility in San Diego.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchFacilityInSanDiegoMember" xlink:href="arwr-20250630.xsd#arwr_ResearchFacilityInSanDiegoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ResearchFacilityInSanDiegoMember" xlink:to="lab_arwr_ResearchFacilityInSanDiegoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_0ea5fac5-764e-4098-84bd-037b4c515124_terseLabel_en-US" xlink:label="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development regulatory and sales milestones payments</link:label>
    <link:label id="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_label_en-US" xlink:label="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development Regulatory And Sales Milestones Payments</link:label>
    <link:label id="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_documentation_en-US" xlink:label="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Development regulatory and sales milestones payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:href="arwr-20250630.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:to="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_0f20c038-d6dd-4fc8-b9c2-8b59631c19c9_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_03f019e8-04ff-4e57-ba5d-56560b3b9a87_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate on cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent_0364a966-397c-4e57-a207-98aaba00e57c_terseLabel_en-US" xlink:label="lab_arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued research and development expenses; co-development</link:label>
    <link:label id="lab_arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent_label_en-US" xlink:label="lab_arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Research And Development Co-Development Expense, Current</link:label>
    <link:label id="lab_arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent_documentation_en-US" xlink:label="lab_arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Research And Development Co-Development Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent" xlink:href="arwr-20250630.xsd#arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent" xlink:to="lab_arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_8e753b47-aa83-4a86-9c23-db9fb33900b9_terseLabel_en-US" xlink:label="lab_arwr_TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2013 and 2021 Incentive Plans and other inducement grants</link:label>
    <link:label id="lab_arwr_TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_label_en-US" xlink:label="lab_arwr_TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Thirteen Equity Incentive Plan, Two Thousand Twenty One Equity Incentive Plan And Inducement Grants [Member]</link:label>
    <link:label id="lab_arwr_TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_documentation_en-US" xlink:label="lab_arwr_TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Thousand Thirteen Equity Incentive Plan, Two Thousand Twenty One Equity Incentive Plan And Inducement Grants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" xlink:href="arwr-20250630.xsd#arwr_TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" xlink:to="lab_arwr_TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_9e652d7c-c4f9-45e4-b36d-574619a4ce43_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_49a5f4f7-ec9b-4642-ba36-0160b87810ef_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_544a516d-92dd-478e-9a03-4aa95dc435d0_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH, CASH EQUIVALENTS AND RESTRICTED CASH:</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_49f394f5-f6d0-4567-92ef-e6b484fd6667_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_4fc521b1-ce21-419f-924e-3529d3ee6816_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_e82635a2-2487-4717-987e-1b0664485f57_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_d9e06c77-43a5-4ab6-9df6-8b27468b2586_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_c5097512-07ef-4666-baf8-a6838631cf82_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability_7a466277-8fe8-4bb6-a0db-4fc14dfac71a_terseLabel_en-US" xlink:label="lab_arwr_RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets obtained in exchange for amended operating lease liabilities</link:label>
    <link:label id="lab_arwr_RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_arwr_RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-Of-Use Asset Adjustment In Exchange For Operating Lease Liability</link:label>
    <link:label id="lab_arwr_RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability_documentation_en-US" xlink:label="lab_arwr_RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Right-Of-Use Asset Adjustment In Exchange For Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability" xlink:href="arwr-20250630.xsd#arwr_RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability" xlink:to="lab_arwr_RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostAbstract_5efde7d0-847b-46b8-ada8-845321348e02_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostAbstract_label_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1dd6ff05-af26-4e29-941c-3067543f6336_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1f91fd2d-6cdd-4790-9a3c-7152ef053d22_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8b1bf6fb-4218-42aa-a4fa-7bb2d8750642_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b3d99af8-a225-4d92-abef-2f0762342c2d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_16cdb996-fd76-448e-9137-e66f5cc68b2e_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repayments of credit facility</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_b146edd4-17f0-4459-b752-468ef0f107b4_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayments of credit facility</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_5e428a97-c351-4fda-89e3-d2b4d465db55_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: Payments</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_8d45fd0c-9c99-45df-8722-0cee09368d6f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock_5ce7f1f1-439f-400e-b6b2-f7c11fe4d78f_terseLabel_en-US" xlink:label="lab_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Short-term and Long-term Investments and Marketable Securities</link:label>
    <link:label id="lab_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock_label_en-US" xlink:label="lab_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Held To Maturity Securities And Marketable Securities Table [Table Text Block]</link:label>
    <link:label id="lab_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock_documentation_en-US" xlink:label="lab_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Held to maturity securities and marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" xlink:href="arwr-20250630.xsd#arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" xlink:to="lab_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_6cfb4c7c-2200-440e-b06d-d15d1d994976_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_dc1e9a0e-f7c8-4700-a408-edafd4e939e1_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NumberOfNewTargetPrograms_b6444864-148e-47a6-a3e2-4c96b639770c_terseLabel_en-US" xlink:label="lab_arwr_NumberOfNewTargetPrograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of new target programs</link:label>
    <link:label id="lab_arwr_NumberOfNewTargetPrograms_label_en-US" xlink:label="lab_arwr_NumberOfNewTargetPrograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of New Target Programs</link:label>
    <link:label id="lab_arwr_NumberOfNewTargetPrograms_documentation_en-US" xlink:label="lab_arwr_NumberOfNewTargetPrograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of New Target Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfNewTargetPrograms" xlink:href="arwr-20250630.xsd#arwr_NumberOfNewTargetPrograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NumberOfNewTargetPrograms" xlink:to="lab_arwr_NumberOfNewTargetPrograms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_b0df8a96-64e3-407a-a8e8-7ab938e61f8d_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_59b67982-c9a4-4404-83d0-a4b6d450e033_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Contract Maturity of Available for Sale Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_649bd783-81be-469b-bb28-405847d56a01_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sales and maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7ee3ad5a-d54a-4867-aad8-b9f86c1913c0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_325e8236-2674-41f1-90dc-cfaa15bba7bb_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_b96aaaf8-6aed-4f9c-8550-1f5e4cdc5dd5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Intangible Assets Future Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_9a9ba09f-2d4d-4cd7-bd89-9f8016e4007c_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ad2f77d5-f0ab-4e2e-a2fc-3d75f4bfb1c2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of RSUs</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_92c5b3de-7a1e-4c33-bfd7-f6e6dfaf5ec2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_afbd1408-1278-45d1-bc8e-14ddb4b5e538_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e45db85e-94bd-49a3-a76b-ed1a10d4bb4b_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_62de8ec2-1f8c-4d12-8d0d-776d36875abf_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bcd88a7e-7fbd-463b-94ba-98b28ae9f7a6_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6ed6bfb8-ee18-4fb2-9304-7d1f8f5c63e7_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">BEGINNING OF PERIOD</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_29f564bd-38be-4fc0-b73a-0a8fef8918aa_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">END OF PERIOD</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_a4f9344f-4e96-490d-a7f1-7991b900af8b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax (benefit) expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_7c6b7bc9-059c-4e6e-adfc-4fd2ac12ad45_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_51e4c5f9-6355-487b-9c94-8bd14eac3add_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_8d6ae737-fe37-4a37-b2b4-6a4dd2bce74e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ScheduleOfCurrentProductsTableTextBlock_b3c3a674-cdfe-4dfe-a12d-7a380a5ca3f6_terseLabel_en-US" xlink:label="lab_arwr_ScheduleOfCurrentProductsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Company's Current Pipeline</link:label>
    <link:label id="lab_arwr_ScheduleOfCurrentProductsTableTextBlock_label_en-US" xlink:label="lab_arwr_ScheduleOfCurrentProductsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Current Products [Table Text Block]</link:label>
    <link:label id="lab_arwr_ScheduleOfCurrentProductsTableTextBlock_documentation_en-US" xlink:label="lab_arwr_ScheduleOfCurrentProductsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Current Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfCurrentProductsTableTextBlock" xlink:href="arwr-20250630.xsd#arwr_ScheduleOfCurrentProductsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ScheduleOfCurrentProductsTableTextBlock" xlink:to="lab_arwr_ScheduleOfCurrentProductsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_41044fa2-f689-45ac-b117-db3e4a95a627_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_dbf6964a-e743-4037-950d-c019eb3ed393_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Current investments, Adjusted Basis</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_6cc34e59-c875-4ed9-84a3-afabd163f795_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt, Excluding Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_05ea7d0b-015c-4dd4-806e-18a493c884c6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_FinancingAgreementInitialTermLoanInterestMember_eb289326-e7f8-47f6-ace1-77414fd75ebc_terseLabel_en-US" xlink:label="lab_arwr_FinancingAgreementInitialTermLoanInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing Agreement, Initial Term Loan Interest</link:label>
    <link:label id="lab_arwr_FinancingAgreementInitialTermLoanInterestMember_label_en-US" xlink:label="lab_arwr_FinancingAgreementInitialTermLoanInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing Agreement, Initial Term Loan Interest [Member]</link:label>
    <link:label id="lab_arwr_FinancingAgreementInitialTermLoanInterestMember_documentation_en-US" xlink:label="lab_arwr_FinancingAgreementInitialTermLoanInterestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financing Agreement, Initial Term Loan Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FinancingAgreementInitialTermLoanInterestMember" xlink:href="arwr-20250630.xsd#arwr_FinancingAgreementInitialTermLoanInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_FinancingAgreementInitialTermLoanInterestMember" xlink:to="lab_arwr_FinancingAgreementInitialTermLoanInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_521e151d-30cc-4568-b9c9-d9d14075fcbf_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income including noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_321789e9-4950-49ff-b610-a3dafefd8809_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_InducementAwardsMember_b0a80266-db27-4646-a0b3-559db1b30dc3_terseLabel_en-US" xlink:label="lab_arwr_InducementAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inducement Awards</link:label>
    <link:label id="lab_arwr_InducementAwardsMember_label_en-US" xlink:label="lab_arwr_InducementAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inducement Awards [Member]</link:label>
    <link:label id="lab_arwr_InducementAwardsMember_documentation_en-US" xlink:label="lab_arwr_InducementAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inducement Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InducementAwardsMember" xlink:href="arwr-20250630.xsd#arwr_InducementAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_InducementAwardsMember" xlink:to="lab_arwr_InducementAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_8c849c1e-2025-422e-897f-79638571f3f4_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
    <link:label id="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Operating Activities, Lessee [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:to="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ResearchEquipmentMember_c32643b7-5004-4d67-8ba1-dd4a12e3a877_terseLabel_en-US" xlink:label="lab_arwr_ResearchEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research equipment</link:label>
    <link:label id="lab_arwr_ResearchEquipmentMember_label_en-US" xlink:label="lab_arwr_ResearchEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Equipment [Member]</link:label>
    <link:label id="lab_arwr_ResearchEquipmentMember_documentation_en-US" xlink:label="lab_arwr_ResearchEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchEquipmentMember" xlink:href="arwr-20250630.xsd#arwr_ResearchEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ResearchEquipmentMember" xlink:to="lab_arwr_ResearchEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_InitialTransactionPrice_214e6ce1-424c-4bf0-9fea-90dfb310f4cf_terseLabel_en-US" xlink:label="lab_arwr_InitialTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial transaction price</link:label>
    <link:label id="lab_arwr_InitialTransactionPrice_label_en-US" xlink:label="lab_arwr_InitialTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial Transaction Price</link:label>
    <link:label id="lab_arwr_InitialTransactionPrice_documentation_en-US" xlink:label="lab_arwr_InitialTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Initial transaction price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice" xlink:href="arwr-20250630.xsd#arwr_InitialTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_InitialTransactionPrice" xlink:to="lab_arwr_InitialTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_4c1fe603-521b-49a2-92f3-26019ffc6ae3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the exercises of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CollaborationArrangementConsideration_dc6f1348-8820-4bad-b34b-863f435d1883_terseLabel_en-US" xlink:label="lab_arwr_CollaborationArrangementConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total transaction price</link:label>
    <link:label id="lab_arwr_CollaborationArrangementConsideration_bf804c38-b772-4e62-8796-99fe8de221f0_totalLabel_en-US" xlink:label="lab_arwr_CollaborationArrangementConsideration" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total transaction price</link:label>
    <link:label id="lab_arwr_CollaborationArrangementConsideration_label_en-US" xlink:label="lab_arwr_CollaborationArrangementConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Arrangement, Consideration</link:label>
    <link:label id="lab_arwr_CollaborationArrangementConsideration_documentation_en-US" xlink:label="lab_arwr_CollaborationArrangementConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Arrangement, Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationArrangementConsideration" xlink:href="arwr-20250630.xsd#arwr_CollaborationArrangementConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CollaborationArrangementConsideration" xlink:to="lab_arwr_CollaborationArrangementConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_aa383134-c7e9-4888-9fbb-6dbfb803c480_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_InducementPlanMember_097d5431-2162-4288-bbac-99deb94a1dcb_terseLabel_en-US" xlink:label="lab_arwr_InducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inducement Awards</link:label>
    <link:label id="lab_arwr_InducementPlanMember_label_en-US" xlink:label="lab_arwr_InducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inducement Plan [Member]</link:label>
    <link:label id="lab_arwr_InducementPlanMember_documentation_en-US" xlink:label="lab_arwr_InducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inducement Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InducementPlanMember" xlink:href="arwr-20250630.xsd#arwr_InducementPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_InducementPlanMember" xlink:to="lab_arwr_InducementPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock_f0255158-878c-4fcd-836b-cc001a135952_terseLabel_en-US" xlink:label="lab_arwr_ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Liability Related to the Sale of Future Royalties</link:label>
    <link:label id="lab_arwr_ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock_label_en-US" xlink:label="lab_arwr_ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Liability Related To The Sale Of Future Royalties [Table Text Block]</link:label>
    <link:label id="lab_arwr_ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock_documentation_en-US" xlink:label="lab_arwr_ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Liability Related To The Sale Of Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock" xlink:href="arwr-20250630.xsd#arwr_ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock" xlink:to="lab_arwr_ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_ce4dd2ed-89cd-4066-ab15-798778068528_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_5fc476ff-ee66-4416-a1c9-9d59456cf606_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b3170d35-2da3-4095-8997-be95ddb0a420_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payment award (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a8b6f4a7-2c9b-4c0e-a81e-a2aaaa6a9698_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d73136ce-4122-4d88-9462-00f2e393e4f4_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_420f0593-3c3d-47ba-86e7-e44f6f88df5b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">End of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_eadc262f-c3bb-4144-a5c3-308dcf4b50c7_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_160d23aa-02de-4c55-989b-bc5f967c3eeb_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Receivables and Contract Liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CommercialMilestonePaymentsAtFirstCommercialSale_2e6a59ce-741a-4f78-ba99-1c6c769b239f_terseLabel_en-US" xlink:label="lab_arwr_CommercialMilestonePaymentsAtFirstCommercialSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial milestone payments at first commercial sale</link:label>
    <link:label id="lab_arwr_CommercialMilestonePaymentsAtFirstCommercialSale_label_en-US" xlink:label="lab_arwr_CommercialMilestonePaymentsAtFirstCommercialSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Milestone Payments At First Commercial Sale</link:label>
    <link:label id="lab_arwr_CommercialMilestonePaymentsAtFirstCommercialSale_documentation_en-US" xlink:label="lab_arwr_CommercialMilestonePaymentsAtFirstCommercialSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commercial milestone payments at first commercial sale.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialMilestonePaymentsAtFirstCommercialSale" xlink:href="arwr-20250630.xsd#arwr_CommercialMilestonePaymentsAtFirstCommercialSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CommercialMilestonePaymentsAtFirstCommercialSale" xlink:to="lab_arwr_CommercialMilestonePaymentsAtFirstCommercialSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4eba0a60-ab24-4af5-8fec-1774437c5981_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_80818455-37bb-4310-abb2-d1896d5d954e_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_92e75507-1efc-4033-a84e-57285872b423_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_67a9e193-852f-446c-9862-92c9bcab23f1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_FuturePotentialMilestonePayments_14782b60-a5b8-4240-8e56-d65bbd6ed50f_terseLabel_en-US" xlink:label="lab_arwr_FuturePotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future potential milestone payments</link:label>
    <link:label id="lab_arwr_FuturePotentialMilestonePayments_label_en-US" xlink:label="lab_arwr_FuturePotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Potential Milestone Payments</link:label>
    <link:label id="lab_arwr_FuturePotentialMilestonePayments_documentation_en-US" xlink:label="lab_arwr_FuturePotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future Potential Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FuturePotentialMilestonePayments" xlink:href="arwr-20250630.xsd#arwr_FuturePotentialMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_FuturePotentialMilestonePayments" xlink:to="lab_arwr_FuturePotentialMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_6f196bf5-986a-4b33-bdc1-5216e1f79752_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_ea2bca35-fff4-4c01-ac0e-3905d0d609c3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_75b64e2f-67ce-4017-8297-87a4060f637a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_6c87555d-5416-4481-b5b9-cd95306655aa_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_f92151f4-2acf-481e-8c4a-b8c8caa316eb_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Lease Assets and Liabilities and Lease Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_efe89bec-36e7-4232-946b-26ff74ef9509_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_fdba25fa-eafb-440e-bb5a-ca78e2aa20c1_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market instruments</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_6990758e-b993-4ae4-aaac-fc77dc4214e9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025 (remainder)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_6eaa9bf2-87a3-4f79-a300-eaf3bc0212d0_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_1e415e25-0f39-4ef5-881e-e77e0e89eb45_terseLabel_en-US" xlink:label="lab_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional remaining development regulatory and sales milestones payments</link:label>
    <link:label id="lab_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_label_en-US" xlink:label="lab_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Remaining Development Regulatory And Sales Milestones Payments</link:label>
    <link:label id="lab_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_documentation_en-US" xlink:label="lab_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional remaining development regulatory and sales milestones payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" xlink:href="arwr-20250630.xsd#arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" xlink:to="lab_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_TwoThousandTwentyOneIncentivePlanMember_ba1d65ed-b4aa-498f-99ac-b1b84090c225_terseLabel_en-US" xlink:label="lab_arwr_TwoThousandTwentyOneIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021 Plan</link:label>
    <link:label id="lab_arwr_TwoThousandTwentyOneIncentivePlanMember_label_en-US" xlink:label="lab_arwr_TwoThousandTwentyOneIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Twenty One Incentive Plan [Member]</link:label>
    <link:label id="lab_arwr_TwoThousandTwentyOneIncentivePlanMember_documentation_en-US" xlink:label="lab_arwr_TwoThousandTwentyOneIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two thousand twenty one incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandTwentyOneIncentivePlanMember" xlink:href="arwr-20250630.xsd#arwr_TwoThousandTwentyOneIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_TwoThousandTwentyOneIncentivePlanMember" xlink:to="lab_arwr_TwoThousandTwentyOneIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_bde339e5-f55f-4f3d-a2f0-cf9aee51c49f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_0784f3bd-c2b8-4184-8fc3-b60edc68d13e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_FinancingAgreementInitialTermLoanMember_66294095-9fbe-4afb-ade5-1dddbb856621_terseLabel_en-US" xlink:label="lab_arwr_FinancingAgreementInitialTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing Agreement, Initial Term Loan</link:label>
    <link:label id="lab_arwr_FinancingAgreementInitialTermLoanMember_label_en-US" xlink:label="lab_arwr_FinancingAgreementInitialTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing Agreement, Initial Term Loan [Member]</link:label>
    <link:label id="lab_arwr_FinancingAgreementInitialTermLoanMember_documentation_en-US" xlink:label="lab_arwr_FinancingAgreementInitialTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financing Agreement, Initial Term Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FinancingAgreementInitialTermLoanMember" xlink:href="arwr-20250630.xsd#arwr_FinancingAgreementInitialTermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_FinancingAgreementInitialTermLoanMember" xlink:to="lab_arwr_FinancingAgreementInitialTermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_7f5d398a-36dd-4408-b5ae-1d98ec0535b5_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock - restricted stock units vesting</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_WI_183a3790-fc09-4c3d-b9f3-746e5e2c3265_terseLabel_en-US" xlink:label="lab_stpr_WI" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Wisconsin</link:label>
    <link:label id="lab_stpr_WI_label_en-US" xlink:label="lab_stpr_WI" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">WISCONSIN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WI" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_WI"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_WI" xlink:to="lab_stpr_WI" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_SanofiLicenseAgreementMember_b65db341-02dd-4393-925f-78db37db84f6_terseLabel_en-US" xlink:label="lab_arwr_SanofiLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sanofi License Agreement</link:label>
    <link:label id="lab_arwr_SanofiLicenseAgreementMember_label_en-US" xlink:label="lab_arwr_SanofiLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sanofi License Agreement [Member]</link:label>
    <link:label id="lab_arwr_SanofiLicenseAgreementMember_documentation_en-US" xlink:label="lab_arwr_SanofiLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sanofi License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SanofiLicenseAgreementMember" xlink:href="arwr-20250630.xsd#arwr_SanofiLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_SanofiLicenseAgreementMember" xlink:to="lab_arwr_SanofiLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c434d4db-d8ce-4066-bdcd-1dd408af3889_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cancelled or expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_3f22d083-cb25-43e5-8af9-65d8bd4d80ca_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_f397be92-2c36-47a0-8306-113752e7e0be_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplementary disclosure of cash flows:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_086c1a59-2914-4955-bf3c-70ce8ca88857_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- Average Exercise Price Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_1ec08e04-b025-497d-8df5-22d09a2c598b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_b8a263a2-ce80-4961-affe-9606c7a99d9e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f072167e-582c-44d7-a9d9-2c00cf53815f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_159477ec-d8f6-4d29-a9c4-721b86750943_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_cac718e4-bc31-4574-8942-80d961d5fc3a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_128c45b5-5bd4-4b27-9f46-1f19bb7986b3_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_VisirnaTherapeuticsIncMember_2da98bc4-6331-465a-b1a2-219110c5cfe8_terseLabel_en-US" xlink:label="lab_arwr_VisirnaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Visirna Therapeutics, Inc.</link:label>
    <link:label id="lab_arwr_VisirnaTherapeuticsIncMember_label_en-US" xlink:label="lab_arwr_VisirnaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Visirna Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_arwr_VisirnaTherapeuticsIncMember_documentation_en-US" xlink:label="lab_arwr_VisirnaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Visirna Therapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VisirnaTherapeuticsIncMember" xlink:href="arwr-20250630.xsd#arwr_VisirnaTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_VisirnaTherapeuticsIncMember" xlink:to="lab_arwr_VisirnaTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentEarned_3d580d5b-bcff-4f29-aa61-0c919983819e_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment</link:label>
    <link:label id="lab_arwr_MilestonePaymentEarned_label_en-US" xlink:label="lab_arwr_MilestonePaymentEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payment Earned</link:label>
    <link:label id="lab_arwr_MilestonePaymentEarned_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentEarned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone payment earned.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentEarned" xlink:href="arwr-20250630.xsd#arwr_MilestonePaymentEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentEarned" xlink:to="lab_arwr_MilestonePaymentEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_a38930d0-2095-43d4-9ac5-7c2c148fedda_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock - restricted stock units vesting (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_b4a17f1c-b5f8-423a-8f55-742946a0e943_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income per share attributable to Arrowhead Pharmaceuticals, Inc.:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_d7f32e91-4066-474a-9482-e4ede09f84e6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_604ab249-4ae6-4420-aac3-a03c393df9f4_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NumberOfPerformanceObligations_44cb72e0-dba1-4829-8cd2-8cf41331a06a_terseLabel_en-US" xlink:label="lab_arwr_NumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of performance obligations</link:label>
    <link:label id="lab_arwr_NumberOfPerformanceObligations_label_en-US" xlink:label="lab_arwr_NumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Performance Obligations</link:label>
    <link:label id="lab_arwr_NumberOfPerformanceObligations_documentation_en-US" xlink:label="lab_arwr_NumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Performance Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfPerformanceObligations" xlink:href="arwr-20250630.xsd#arwr_NumberOfPerformanceObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NumberOfPerformanceObligations" xlink:to="lab_arwr_NumberOfPerformanceObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_4a9d9708-e9da-422a-a39f-0fb436917c2a_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_362f7cb9-6d4e-47b5-9e9b-497dc8dc32f5_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DebtInstrumentMultipleOfInvestmentCapitalExpectedToBeAppliedToPrincipalUponRepayment_5cf5623b-88fe-4504-b9bd-8444cf95cdf3_terseLabel_en-US" xlink:label="lab_arwr_DebtInstrumentMultipleOfInvestmentCapitalExpectedToBeAppliedToPrincipalUponRepayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MOIC payments expected to be applied to principal upon repayment</link:label>
    <link:label id="lab_arwr_DebtInstrumentMultipleOfInvestmentCapitalExpectedToBeAppliedToPrincipalUponRepayment_label_en-US" xlink:label="lab_arwr_DebtInstrumentMultipleOfInvestmentCapitalExpectedToBeAppliedToPrincipalUponRepayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Multiple Of Investment Capital Expected To Be Applied To Principal Upon Repayment</link:label>
    <link:label id="lab_arwr_DebtInstrumentMultipleOfInvestmentCapitalExpectedToBeAppliedToPrincipalUponRepayment_documentation_en-US" xlink:label="lab_arwr_DebtInstrumentMultipleOfInvestmentCapitalExpectedToBeAppliedToPrincipalUponRepayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Multiple Of Investment Capital Expected To Be Applied To Principal Upon Repayment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtInstrumentMultipleOfInvestmentCapitalExpectedToBeAppliedToPrincipalUponRepayment" xlink:href="arwr-20250630.xsd#arwr_DebtInstrumentMultipleOfInvestmentCapitalExpectedToBeAppliedToPrincipalUponRepayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DebtInstrumentMultipleOfInvestmentCapitalExpectedToBeAppliedToPrincipalUponRepayment" xlink:to="lab_arwr_DebtInstrumentMultipleOfInvestmentCapitalExpectedToBeAppliedToPrincipalUponRepayment" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CommitmentsCapitalExpendituresIncurredToDate_ead71e5f-59a0-4c54-9174-d435d36e74a9_terseLabel_en-US" xlink:label="lab_arwr_CommitmentsCapitalExpendituresIncurredToDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital expenditures incurred</link:label>
    <link:label id="lab_arwr_CommitmentsCapitalExpendituresIncurredToDate_label_en-US" xlink:label="lab_arwr_CommitmentsCapitalExpendituresIncurredToDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments, Capital Expenditures Incurred To Date</link:label>
    <link:label id="lab_arwr_CommitmentsCapitalExpendituresIncurredToDate_documentation_en-US" xlink:label="lab_arwr_CommitmentsCapitalExpendituresIncurredToDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments, Capital Expenditures Incurred To Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommitmentsCapitalExpendituresIncurredToDate" xlink:href="arwr-20250630.xsd#arwr_CommitmentsCapitalExpendituresIncurredToDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CommitmentsCapitalExpendituresIncurredToDate" xlink:to="lab_arwr_CommitmentsCapitalExpendituresIncurredToDate" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ManufacturingEquipmentMember_cd774661-d87a-4e97-91b6-76c60f4796d8_terseLabel_en-US" xlink:label="lab_arwr_ManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Manufacturing equipment</link:label>
    <link:label id="lab_arwr_ManufacturingEquipmentMember_label_en-US" xlink:label="lab_arwr_ManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Manufacturing Equipment [Member]</link:label>
    <link:label id="lab_arwr_ManufacturingEquipmentMember_documentation_en-US" xlink:label="lab_arwr_ManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Manufacturing Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ManufacturingEquipmentMember" xlink:href="arwr-20250630.xsd#arwr_ManufacturingEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ManufacturingEquipmentMember" xlink:to="lab_arwr_ManufacturingEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_d80f2242-b81a-4078-991c-f4989c7d60ce_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_bbcb0c69-3301-435a-b314-48a4c65c0f71_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_9b8dfff8-1fb1-4650-998c-9abf2bd96208_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_9a719f5f-439b-4e5e-9c42-c5db5ea3ac48_verboseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_23426731-306c-459f-8837-8bccd9ebe38d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_91b62e23-fa5c-4b27-9cb1-e55af0df5654_terseLabel_en-US" xlink:label="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Held To Maturity Securities And Marketable Securities [Table]</link:label>
    <link:label id="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_label_en-US" xlink:label="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Held To Maturity Securities And Marketable Securities [Table]</link:label>
    <link:label id="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_documentation_en-US" xlink:label="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of held to maturity securities and marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:href="arwr-20250630.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:to="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_e6663fef-70a7-4192-941f-33e452935592_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_57811981-cf2b-4d1e-aa7c-c3c2ab7cd47c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average period to recognize pre-tax compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_OlpasiranAgreementMember_f59100b9-d53d-4e5a-8074-050a98835ffa_terseLabel_en-US" xlink:label="lab_arwr_OlpasiranAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Olpasiran Agreement</link:label>
    <link:label id="lab_arwr_OlpasiranAgreementMember_label_en-US" xlink:label="lab_arwr_OlpasiranAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Olpasiran Agreement [Member]</link:label>
    <link:label id="lab_arwr_OlpasiranAgreementMember_documentation_en-US" xlink:label="lab_arwr_OlpasiranAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Olpasiran agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OlpasiranAgreementMember" xlink:href="arwr-20250630.xsd#arwr_OlpasiranAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_OlpasiranAgreementMember" xlink:to="lab_arwr_OlpasiranAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3824cc24-72ee-4c77-847c-2abf9b1b75f7_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b0b61512-bee6-4667-a50a-8dda4f897806_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_87cabb38-a8a4-4cf7-b4a3-2f6d3073aeab_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ProceedsFromTenantImprovementAllowance_8120062c-c757-4395-a460-5dd8d8cab5dd_verboseLabel_en-US" xlink:label="lab_arwr_ProceedsFromTenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from additional tenant improvement allowance</link:label>
    <link:label id="lab_arwr_ProceedsFromTenantImprovementAllowance_label_en-US" xlink:label="lab_arwr_ProceedsFromTenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Tenant Improvement Allowance</link:label>
    <link:label id="lab_arwr_ProceedsFromTenantImprovementAllowance_documentation_en-US" xlink:label="lab_arwr_ProceedsFromTenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Tenant Improvement Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ProceedsFromTenantImprovementAllowance" xlink:href="arwr-20250630.xsd#arwr_ProceedsFromTenantImprovementAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ProceedsFromTenantImprovementAllowance" xlink:to="lab_arwr_ProceedsFromTenantImprovementAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_a9e4c7d3-a0e6-47ef-8518-874f5c6d8d36_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_a0828789-42ec-4424-be25-4a7468338a0e_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Buildings</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e04cc290-279e-4943-ac87-56f44748a3b5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_61088f37-3756-413f-8c34-988a2c57242c_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Treasuries</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_12727e0c-330f-49bf-bc0b-b0531bd6fdca_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AreaOfLand_221c5662-30a2-4748-856a-4cc4faf30dcb_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfLand" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Planned area of the site (in sq ft)</link:label>
    <link:label id="lab_us-gaap_AreaOfLand_label_en-US" xlink:label="lab_us-gaap_AreaOfLand" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Area of Land</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfLand" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AreaOfLand"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfLand" xlink:to="lab_us-gaap_AreaOfLand" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo_f90f2a11-984e-450c-838e-802d79be89cd_terseLabel_en-US" xlink:label="lab_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">After one to two years</link:label>
    <link:label id="lab_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo_label_en-US" xlink:label="lab_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, After Year One Through Two</link:label>
    <link:label id="lab_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo_documentation_en-US" xlink:label="lab_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, After Year One Through Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" xlink:href="arwr-20250630.xsd#arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" xlink:to="lab_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_296e1fbd-a4aa-4a9f-a356-411b333d6325_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_9b84ac68-d522-40c4-9356-72e3c93723de_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e41d5b19-e78d-4c3e-8be5-62a7f902e4bd_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_SaleOfStockPremiumOnIssuanceOfShares_9e50debd-0823-47ca-8b05-edf82291933e_verboseLabel_en-US" xlink:label="lab_arwr_SaleOfStockPremiumOnIssuanceOfShares" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity premium</link:label>
    <link:label id="lab_arwr_SaleOfStockPremiumOnIssuanceOfShares_label_en-US" xlink:label="lab_arwr_SaleOfStockPremiumOnIssuanceOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Premium On Issuance Of Shares</link:label>
    <link:label id="lab_arwr_SaleOfStockPremiumOnIssuanceOfShares_documentation_en-US" xlink:label="lab_arwr_SaleOfStockPremiumOnIssuanceOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Premium On Issuance Of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SaleOfStockPremiumOnIssuanceOfShares" xlink:href="arwr-20250630.xsd#arwr_SaleOfStockPremiumOnIssuanceOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_SaleOfStockPremiumOnIssuanceOfShares" xlink:to="lab_arwr_SaleOfStockPremiumOnIssuanceOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_38772892-2aa7-4863-ab44-078ca7a5bd72_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_87e460da-467a-4279-893c-7979fa26cbd4_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment receivable upon achievement of phase two and first patient dosed in phase three</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_label_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payment Receivable Upon Achievement Of Phase Two And First Patient Dosed In Phase Three</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone payment receivable upon achievement of phase two and first patient dosed in phase three.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" xlink:href="arwr-20250630.xsd#arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" xlink:to="lab_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DrugManufacturingFacilityMember_82ec7268-4e93-4000-b54d-85b4cbe081e7_terseLabel_en-US" xlink:label="lab_arwr_DrugManufacturingFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Drug Manufacturing Facility</link:label>
    <link:label id="lab_arwr_DrugManufacturingFacilityMember_label_en-US" xlink:label="lab_arwr_DrugManufacturingFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Drug Manufacturing Facility [Member]</link:label>
    <link:label id="lab_arwr_DrugManufacturingFacilityMember_documentation_en-US" xlink:label="lab_arwr_DrugManufacturingFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Drug manufacturing facility.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DrugManufacturingFacilityMember" xlink:href="arwr-20250630.xsd#arwr_DrugManufacturingFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DrugManufacturingFacilityMember" xlink:to="lab_arwr_DrugManufacturingFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ClassOfWarrantOrRightNumberOfWarrantsExercised_eebd7f6b-784c-4b98-93fa-f0f64b4a49f4_terseLabel_en-US" xlink:label="lab_arwr_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of warrants exercised (in shares)</link:label>
    <link:label id="lab_arwr_ClassOfWarrantOrRightNumberOfWarrantsExercised_label_en-US" xlink:label="lab_arwr_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Number Of Warrants Exercised</link:label>
    <link:label id="lab_arwr_ClassOfWarrantOrRightNumberOfWarrantsExercised_documentation_en-US" xlink:label="lab_arwr_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Number Of Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:href="arwr-20250630.xsd#arwr_ClassOfWarrantOrRightNumberOfWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:to="lab_arwr_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e723a850-aae9-482d-a067-7a394caa572c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_1e937ae7-7ca8-405b-bd74-e90a13fbec3c_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_d38be115-069e-4a56-9d3c-2063f207f95a_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalent, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CollaborationAndLicenseAgreementsAbstract_ad9b2d14-14d3-4c89-9037-2b998101984b_terseLabel_en-US" xlink:label="lab_arwr_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration And License Agreements [Abstract]</link:label>
    <link:label id="lab_arwr_CollaborationAndLicenseAgreementsAbstract_label_en-US" xlink:label="lab_arwr_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration And License Agreements [Abstract]</link:label>
    <link:label id="lab_arwr_CollaborationAndLicenseAgreementsAbstract_documentation_en-US" xlink:label="lab_arwr_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration and license agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementsAbstract" xlink:href="arwr-20250630.xsd#arwr_CollaborationAndLicenseAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CollaborationAndLicenseAgreementsAbstract" xlink:to="lab_arwr_CollaborationAndLicenseAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_fe77f40a-0e16-4e13-bb12-0f4168f70358_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization expense for property and equipment</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_26c69614-4999-4050-ae1c-8da474ac63c2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_b2e8b509-28b3-4f3a-82f6-7bee8585c6ea_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_08b0bea2-5308-4157-beb3-8310ee1f1610_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_c2171f2a-a51a-46ed-926c-0f6213196efe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_f1139e6b-e648-47d9-908b-12df05d26b6c_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_FinancingAgreementMOICPaymentMember_710d79e3-6a9b-4e80-b11e-2aad8bcc9c3f_terseLabel_en-US" xlink:label="lab_arwr_FinancingAgreementMOICPaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing Agreement, MOIC Payment</link:label>
    <link:label id="lab_arwr_FinancingAgreementMOICPaymentMember_label_en-US" xlink:label="lab_arwr_FinancingAgreementMOICPaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing Agreement, MOIC Payment [Member]</link:label>
    <link:label id="lab_arwr_FinancingAgreementMOICPaymentMember_documentation_en-US" xlink:label="lab_arwr_FinancingAgreementMOICPaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financing Agreement, MOIC Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FinancingAgreementMOICPaymentMember" xlink:href="arwr-20250630.xsd#arwr_FinancingAgreementMOICPaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_FinancingAgreementMOICPaymentMember" xlink:to="lab_arwr_FinancingAgreementMOICPaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_6be798e3-1aa0-45a9-a88b-90daeae5341e_terseLabel_en-US" xlink:label="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]</link:label>
    <link:label id="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_label_en-US" xlink:label="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]</link:label>
    <link:label id="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_documentation_en-US" xlink:label="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of held to maturity securities and marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:href="arwr-20250630.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:to="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_54d1b53d-92d2-418e-ad98-d4794b62ba6b_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_39165759-c1f9-485f-8ff6-5341278042e6_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), net of tax:</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DevelopmentAndSalesMilestonesPayments_1708ae5b-badd-4b13-b7e7-8449b435333b_terseLabel_en-US" xlink:label="lab_arwr_DevelopmentAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development and sales milestone payments</link:label>
    <link:label id="lab_arwr_DevelopmentAndSalesMilestonesPayments_label_en-US" xlink:label="lab_arwr_DevelopmentAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development And Sales Milestones Payments</link:label>
    <link:label id="lab_arwr_DevelopmentAndSalesMilestonesPayments_documentation_en-US" xlink:label="lab_arwr_DevelopmentAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Development And Sales Milestones Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentAndSalesMilestonesPayments" xlink:href="arwr-20250630.xsd#arwr_DevelopmentAndSalesMilestonesPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DevelopmentAndSalesMilestonesPayments" xlink:to="lab_arwr_DevelopmentAndSalesMilestonesPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_c2d8737c-321c-483d-84b2-5f0cc220e4e8_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ef8e79ff-8ad2-4f74-9603-99dd26c60526_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a4a7ab75-30b9-4e16-88c5-74700bc00c5f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_LiabilitySaleOfFutureRoyaltiesRollForward_bc1d4f24-5756-47b5-a1f9-753682eda9bf_terseLabel_en-US" xlink:label="lab_arwr_LiabilitySaleOfFutureRoyaltiesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability, Sale Of Future Royalties [Roll Forward]</link:label>
    <link:label id="lab_arwr_LiabilitySaleOfFutureRoyaltiesRollForward_label_en-US" xlink:label="lab_arwr_LiabilitySaleOfFutureRoyaltiesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability, Sale Of Future Royalties [Roll Forward]</link:label>
    <link:label id="lab_arwr_LiabilitySaleOfFutureRoyaltiesRollForward_documentation_en-US" xlink:label="lab_arwr_LiabilitySaleOfFutureRoyaltiesRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability, Sale Of Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilitySaleOfFutureRoyaltiesRollForward" xlink:href="arwr-20250630.xsd#arwr_LiabilitySaleOfFutureRoyaltiesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_LiabilitySaleOfFutureRoyaltiesRollForward" xlink:to="lab_arwr_LiabilitySaleOfFutureRoyaltiesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_1433723c-2798-45e3-85f8-8274f969e57a_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_b539f441-b37d-4986-9802-15ee6fc735ca_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_d607a9a6-440a-43af-8dcc-283328569d64_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized pre-tax compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1e505d49-9b14-41dd-8dce-1b03a642a731_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_e5a0f54e-721b-450f-aa5c-7a8f16db1b0d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_06443777-1dc7-4575-bfaf-9bd8472ffedd_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_d7f3f203-454c-47f5-abc8-66248a35c934_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_564a7299-760b-4835-b14b-cdf538f8f0f1_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit facility, net of current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_6cbfb2bc-f9d6-4df2-a45b-4f2eb1dfef0c_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ConstructionInProgressReclassifiedToBuildingMember_1d784ed6-8b26-461d-a4f9-078050f294aa_terseLabel_en-US" xlink:label="lab_arwr_ConstructionInProgressReclassifiedToBuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction In Progress Reclassified To Building</link:label>
    <link:label id="lab_arwr_ConstructionInProgressReclassifiedToBuildingMember_label_en-US" xlink:label="lab_arwr_ConstructionInProgressReclassifiedToBuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction In Progress Reclassified To Building [Member]</link:label>
    <link:label id="lab_arwr_ConstructionInProgressReclassifiedToBuildingMember_documentation_en-US" xlink:label="lab_arwr_ConstructionInProgressReclassifiedToBuildingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Construction In Progress Reclassified To Building</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ConstructionInProgressReclassifiedToBuildingMember" xlink:href="arwr-20250630.xsd#arwr_ConstructionInProgressReclassifiedToBuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ConstructionInProgressReclassifiedToBuildingMember" xlink:to="lab_arwr_ConstructionInProgressReclassifiedToBuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NumberOfOptionsToRenew_ea9bdf31-04a4-4cc3-9d26-77dcb0d3ed6a_terseLabel_en-US" xlink:label="lab_arwr_NumberOfOptionsToRenew" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of options to renew</link:label>
    <link:label id="lab_arwr_NumberOfOptionsToRenew_label_en-US" xlink:label="lab_arwr_NumberOfOptionsToRenew" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Options To Renew</link:label>
    <link:label id="lab_arwr_NumberOfOptionsToRenew_documentation_en-US" xlink:label="lab_arwr_NumberOfOptionsToRenew" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of options to renew.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfOptionsToRenew" xlink:href="arwr-20250630.xsd#arwr_NumberOfOptionsToRenew"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NumberOfOptionsToRenew" xlink:to="lab_arwr_NumberOfOptionsToRenew" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_9dda3987-d254-41c6-a963-151697346769_terseLabel_en-US" xlink:label="lab_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Takeda</link:label>
    <link:label id="lab_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_label_en-US" xlink:label="lab_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Takeda Pharmaceuticals United States Of America Incorporated [Member]</link:label>
    <link:label id="lab_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_documentation_en-US" xlink:label="lab_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Takeda Pharmaceuticals United States of America Incorporated.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:href="arwr-20250630.xsd#arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:to="lab_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_fc6de5cf-f7bc-444b-8e61-8020cffd629b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_9bc56e1e-956b-4f6f-9cb0-a2d577d17d05_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c0779f49-3ef7-43a0-adde-6dcb2bdebf41_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_20e42c33-9b9e-4659-8dc3-a554eaa09668_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_e6444bcd-63c8-4969-98c0-182d23a57fee_terseLabel_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term deposit</link:label>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_label_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bank Time Deposits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BankTimeDepositsMember" xlink:to="lab_us-gaap_BankTimeDepositsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_d2c63609-1980-4098-a1b4-d50602c6464a_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_cf8af63d-28f1-4cd1-a483-3c72dbc25de1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_52926ec3-5508-4a0b-9122-95765e2424ea_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_b4555726-5834-43d3-b231-fa78ee752c69_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_34246df6-5475-4f75-a0a5-3de6a132c9e2_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_459303be-84d1-4b6e-8480-bb81a4f952de_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_21001cc0-7ba8-42b0-a436-e8d061283d3b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock_56d11388-9e54-456e-9939-1ced058c1261_terseLabel_en-US" xlink:label="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability Related to the Sale of Future Royalties</link:label>
    <link:label id="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock_label_en-US" xlink:label="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Related To The Sale Of Future Royalties [Text Block]</link:label>
    <link:label id="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock_documentation_en-US" xlink:label="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability Related To The Sale Of Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" xlink:href="arwr-20250630.xsd#arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" xlink:to="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_ee1ac3c2-4df0-463e-880d-2196219b843a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Shares of Common Stock and Preferred Stock</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNet_ccaa6c44-48ef-4b5f-ad83-40af44d7ad05_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receivables included in accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNet_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNet" xlink:to="lab_us-gaap_AccountsReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_0ad5cc43-e913-4844-90fc-95723cefdad6_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MunicipalBondsMember_2752379f-e809-4f87-b9ee-cada56a40e91_terseLabel_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Municipal securities</link:label>
    <link:label id="lab_us-gaap_MunicipalBondsMember_label_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Municipal Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MunicipalBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MunicipalBondsMember" xlink:to="lab_us-gaap_MunicipalBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties_d4217259-4adc-4dca-9751-574d0cc39437_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment received</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties_label_en-US" xlink:label="lab_arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payment Received, Liability Related To Sale Of Future Royalties</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Payment Received, Liability Related To Sale Of Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties" xlink:href="arwr-20250630.xsd#arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties" xlink:to="lab_arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_958da33d-4d59-43b7-b89a-02df88cdecb2_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_e5ab8fa1-adfc-4766-8f7c-62a2a8b2e7ae_terseLabel_en-US" xlink:label="lab_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash received for amounts included in the measurement of lease liabilities:</link:label>
    <link:label id="lab_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_label_en-US" xlink:label="lab_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Operating Activities, Lessee, Cash Received For Amounts Included In Measurement Of Lease Liabilities [Abstract]</link:label>
    <link:label id="lab_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_documentation_en-US" xlink:label="lab_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Flow, Operating Activities, Lessee, Cash Received For Amounts Included In Measurement Of Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:href="arwr-20250630.xsd#arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:to="lab_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_a99aaf6f-f015-4ec1-b5c8-930ea5b87a7a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9d1984ec-e2d8-487b-ad5c-826d1045f023_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_f74d4ae4-3c2c-43a7-91a5-4b2cc1e9aff1_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_61edf3b3-fd3e-4bff-83f1-6ff693a92d5f_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total financial assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_81a8ae11-4157-41a7-8dcd-12f67dbc96af_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_02e30f7d-5365-43d1-aff1-942c727937ac_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0a5bf25e-67f6-4bb9-9c6d-ba0b24757031_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- Average Remaining Contractual Term (Years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5f64a376-a8ca-4f31-92f6-88520ea1b11d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_0541e8e5-e5cc-43f7-8bcc-96660f78ffde_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_7b134aec-0831-42b9-9e5b-01674a123dd6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract_label_en-US" xlink:label="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Related To The Sale Of Future Royalties [Abstract]</link:label>
    <link:label id="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract_documentation_en-US" xlink:label="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability Related To The Sale Of Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract" xlink:href="arwr-20250630.xsd#arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract" xlink:to="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_f6e71fdf-f864-4059-bd53-8e7befa48f41_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_ba78c54a-9e3c-474a-a48e-60e2cb077bb3_totalLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NovartisMember_9a593a3f-139f-4066-9a69-17f1fb928e70_terseLabel_en-US" xlink:label="lab_arwr_NovartisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Novartis</link:label>
    <link:label id="lab_arwr_NovartisMember_label_en-US" xlink:label="lab_arwr_NovartisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis [Member]</link:label>
    <link:label id="lab_arwr_NovartisMember_documentation_en-US" xlink:label="lab_arwr_NovartisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Novartis.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NovartisMember" xlink:href="arwr-20250630.xsd#arwr_NovartisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NovartisMember" xlink:to="lab_arwr_NovartisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_5ac43ce2-5007-45ee-b71c-d14885eab472_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandMember_bbf79e7e-a5ab-4062-999c-d26662978f27_terseLabel_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_LandMember_label_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandMember" xlink:to="lab_us-gaap_LandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallments_e05352f4-54da-4160-9eda-9cef6c7e30bc_terseLabel_en-US" xlink:label="lab_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual installment</link:label>
    <link:label id="lab_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallments_label_en-US" xlink:label="lab_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Receivable Under Collaboration Agreement, Annual Installments</link:label>
    <link:label id="lab_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallments_documentation_en-US" xlink:label="lab_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Receivable Under Collaboration Agreement, Annual Installments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallments" xlink:href="arwr-20250630.xsd#arwr_CashReceivableUnderCollaborationAgreementAnnualInstallments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallments" xlink:to="lab_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_babc5d8a-b4d1-454b-b8d7-7da96b1d44f5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_5daa6265-1fd7-416d-a014-f8fe2a3110db_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_59b67756-2e11-46e2-80b3-694a8857b07f_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_bcbf9972-3fa3-4459-8351-948a327c243f_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_f667c08d-4f06-4438-a064-edeaf3e9b026_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_IncreaseDecreaseInCashAndInvestments_9e1eddac-24b5-4a36-9964-ff71bfdca121_terseLabel_en-US" xlink:label="lab_arwr_IncreaseDecreaseInCashAndInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in cash and investments</link:label>
    <link:label id="lab_arwr_IncreaseDecreaseInCashAndInvestments_label_en-US" xlink:label="lab_arwr_IncreaseDecreaseInCashAndInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Cash And Investments</link:label>
    <link:label id="lab_arwr_IncreaseDecreaseInCashAndInvestments_documentation_en-US" xlink:label="lab_arwr_IncreaseDecreaseInCashAndInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase decrease in cash and investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_IncreaseDecreaseInCashAndInvestments" xlink:href="arwr-20250630.xsd#arwr_IncreaseDecreaseInCashAndInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_IncreaseDecreaseInCashAndInvestments" xlink:to="lab_arwr_IncreaseDecreaseInCashAndInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_LicenseAndCoFundingAgreementMember_126961c6-610b-4c6b-b76d-67eb0b533b7b_terseLabel_en-US" xlink:label="lab_arwr_LicenseAndCoFundingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License and Co-Funding Agreement</link:label>
    <link:label id="lab_arwr_LicenseAndCoFundingAgreementMember_label_en-US" xlink:label="lab_arwr_LicenseAndCoFundingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License And Co Funding Agreement [Member]</link:label>
    <link:label id="lab_arwr_LicenseAndCoFundingAgreementMember_documentation_en-US" xlink:label="lab_arwr_LicenseAndCoFundingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License and co-funding agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LicenseAndCoFundingAgreementMember" xlink:href="arwr-20250630.xsd#arwr_LicenseAndCoFundingAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_LicenseAndCoFundingAgreementMember" xlink:to="lab_arwr_LicenseAndCoFundingAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_c56a4c7a-ca25-4030-a273-e973f29f8f06_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Awards Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_c81e1fb1-d07d-41df-835e-5780a3d5ac83_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f7d75175-c099-4fae-88a7-ecfea83808d4_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b87b3120-1986-4e34-9f89-90459ecc9e6d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AtTheMarketAgreementMember_afc3beb0-39ef-4880-8df0-8298713b0c21_terseLabel_en-US" xlink:label="lab_arwr_AtTheMarketAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At The Market Agreement</link:label>
    <link:label id="lab_arwr_AtTheMarketAgreementMember_label_en-US" xlink:label="lab_arwr_AtTheMarketAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At The Market Agreement [Member]</link:label>
    <link:label id="lab_arwr_AtTheMarketAgreementMember_documentation_en-US" xlink:label="lab_arwr_AtTheMarketAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At-the-market agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AtTheMarketAgreementMember" xlink:href="arwr-20250630.xsd#arwr_AtTheMarketAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AtTheMarketAgreementMember" xlink:to="lab_arwr_AtTheMarketAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CorporateHeadquartersInPasadenaMember_a4c35972-0d8a-4e9b-959a-771bf0a02dc3_terseLabel_en-US" xlink:label="lab_arwr_CorporateHeadquartersInPasadenaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate Headquarters In Pasadena</link:label>
    <link:label id="lab_arwr_CorporateHeadquartersInPasadenaMember_label_en-US" xlink:label="lab_arwr_CorporateHeadquartersInPasadenaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Headquarters In Pasadena [Member]</link:label>
    <link:label id="lab_arwr_CorporateHeadquartersInPasadenaMember_documentation_en-US" xlink:label="lab_arwr_CorporateHeadquartersInPasadenaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Corporate Headquarters in Pasadena</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CorporateHeadquartersInPasadenaMember" xlink:href="arwr-20250630.xsd#arwr_CorporateHeadquartersInPasadenaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CorporateHeadquartersInPasadenaMember" xlink:to="lab_arwr_CorporateHeadquartersInPasadenaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_5b0d9579-c9ee-4cff-8d95-845fef0f7b8c_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares used in calculating</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_6ab37c30-c29b-4801-afe0-3451acfdcb1e_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c0c5b10d-9979-4f6c-9d7c-48b038179710_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NumberOfDistinctBundle_eef48615-9a33-4b2e-9b95-8808ceca4f59_terseLabel_en-US" xlink:label="lab_arwr_NumberOfDistinctBundle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of distinct bundle</link:label>
    <link:label id="lab_arwr_NumberOfDistinctBundle_label_en-US" xlink:label="lab_arwr_NumberOfDistinctBundle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Distinct Bundle</link:label>
    <link:label id="lab_arwr_NumberOfDistinctBundle_documentation_en-US" xlink:label="lab_arwr_NumberOfDistinctBundle" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of distinct bundle.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctBundle" xlink:href="arwr-20250630.xsd#arwr_NumberOfDistinctBundle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NumberOfDistinctBundle" xlink:to="lab_arwr_NumberOfDistinctBundle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_328efbe1-c2c1-40ff-b71b-284af40a8408_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_RoyaltyPaymentThreshold_063ae248-3eb8-4bc6-9ea5-e5225bf2e459_terseLabel_en-US" xlink:label="lab_arwr_RoyaltyPaymentThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty payment threshold</link:label>
    <link:label id="lab_arwr_RoyaltyPaymentThreshold_label_en-US" xlink:label="lab_arwr_RoyaltyPaymentThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Payment Threshold</link:label>
    <link:label id="lab_arwr_RoyaltyPaymentThreshold_documentation_en-US" xlink:label="lab_arwr_RoyaltyPaymentThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Payment Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltyPaymentThreshold" xlink:href="arwr-20250630.xsd#arwr_RoyaltyPaymentThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_RoyaltyPaymentThreshold" xlink:to="lab_arwr_RoyaltyPaymentThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_97a48e3e-c554-4a02-9080-5399e2d3941b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_764f66dd-2d1e-4660-8cbc-17dde037e422_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_869699d9-0408-4c9b-bb99-24f027d0bc0f_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_9b44c2fd-69e2-4887-a564-d6879b74b8aa_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_FacilitiesMember_0cf461ba-1485-4f91-a909-1d0be562a111_terseLabel_en-US" xlink:label="lab_arwr_FacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facilities</link:label>
    <link:label id="lab_arwr_FacilitiesMember_label_en-US" xlink:label="lab_arwr_FacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Facilities [Member]</link:label>
    <link:label id="lab_arwr_FacilitiesMember_documentation_en-US" xlink:label="lab_arwr_FacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Facilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FacilitiesMember" xlink:href="arwr-20250630.xsd#arwr_FacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_FacilitiesMember" xlink:to="lab_arwr_FacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_df0b5888-48aa-4a5b-9998-2dc27106f474_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_4c30f151-f789-4130-b1cb-ab4bf607cbeb_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of credit facility, remaining borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_62f2f2f3-6f12-4d59-a7a8-fcc5a7d68930_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cb84ea84-082b-41c7-b521-733b904ceeb9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LinesOfCreditCurrent_40d9c5a1-d941-4192-8500-275cfd19cf4c_terseLabel_en-US" xlink:label="lab_us-gaap_LinesOfCreditCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit facility</link:label>
    <link:label id="lab_us-gaap_LinesOfCreditCurrent_2ff9cc23-8f84-4c31-af55-b0a841b36f8b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LinesOfCreditCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: Current portion of credit facility</link:label>
    <link:label id="lab_us-gaap_LinesOfCreditCurrent_label_en-US" xlink:label="lab_us-gaap_LinesOfCreditCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LinesOfCreditCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LinesOfCreditCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LinesOfCreditCurrent" xlink:to="lab_us-gaap_LinesOfCreditCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_8f1c681b-75bb-4638-b281-87aabb2e5f86_terseLabel_en-US" xlink:label="lab_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest expense on liability related to the sale of future royalties</link:label>
    <link:label id="lab_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_7f8b3a5c-6faa-493c-9a34-a674e3b77372_verboseLabel_en-US" xlink:label="lab_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest expense recognized</link:label>
    <link:label id="lab_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_label_en-US" xlink:label="lab_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Cash Interest Expense, Liability Related To Sale Of Future Royalties</link:label>
    <link:label id="lab_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_documentation_en-US" xlink:label="lab_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Cash Interest Expense, Liability Related To Sale Of Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" xlink:href="arwr-20250630.xsd#arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" xlink:to="lab_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ee96406f-99f7-4dbe-be9f-aaa0115b14d9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_f442cd88-e171-411f-9c76-93d90e5acc37_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of securities called by warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_bda2d967-6db6-42e4-a656-b4347afd46ea_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a655b462-4e40-43f5-9bbf-6e8b440fe966_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges_8da85485-41b8-4efd-a020-5bd6d69dd7ec_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, reclassification</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Transfers and Changes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTransfersAndChanges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_RoyaltyPharmaAgreementMember_3b7db74d-28ba-4072-98bb-1ddd1090c263_terseLabel_en-US" xlink:label="lab_arwr_RoyaltyPharmaAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Pharma Agreement</link:label>
    <link:label id="lab_arwr_RoyaltyPharmaAgreementMember_label_en-US" xlink:label="lab_arwr_RoyaltyPharmaAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Pharma Agreement [Member]</link:label>
    <link:label id="lab_arwr_RoyaltyPharmaAgreementMember_documentation_en-US" xlink:label="lab_arwr_RoyaltyPharmaAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Pharma Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltyPharmaAgreementMember" xlink:href="arwr-20250630.xsd#arwr_RoyaltyPharmaAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_RoyaltyPharmaAgreementMember" xlink:to="lab_arwr_RoyaltyPharmaAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_SareptaTherapeuticsIncMember_3eb76484-45c3-4389-aecf-a0aea1bdfd8d_terseLabel_en-US" xlink:label="lab_arwr_SareptaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sarepta</link:label>
    <link:label id="lab_arwr_SareptaTherapeuticsIncMember_label_en-US" xlink:label="lab_arwr_SareptaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sarepta Therapeutics, Inc [Member]</link:label>
    <link:label id="lab_arwr_SareptaTherapeuticsIncMember_documentation_en-US" xlink:label="lab_arwr_SareptaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sarepta Therapeutics, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SareptaTherapeuticsIncMember" xlink:href="arwr-20250630.xsd#arwr_SareptaTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_SareptaTherapeuticsIncMember" xlink:to="lab_arwr_SareptaTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_1e44e1e3-7e99-498d-b34f-47e365c6c887_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_dbcc5eb5-1b3e-4311-a912-17aabf1e4f11_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ProceedsFromCollaborationArrangements_64726ab5-75a1-47b6-b25f-da734cee30a4_terseLabel_en-US" xlink:label="lab_arwr_ProceedsFromCollaborationArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_arwr_ProceedsFromCollaborationArrangements_label_en-US" xlink:label="lab_arwr_ProceedsFromCollaborationArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Collaboration Arrangements</link:label>
    <link:label id="lab_arwr_ProceedsFromCollaborationArrangements_documentation_en-US" xlink:label="lab_arwr_ProceedsFromCollaborationArrangements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Collaboration Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ProceedsFromCollaborationArrangements" xlink:href="arwr-20250630.xsd#arwr_ProceedsFromCollaborationArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ProceedsFromCollaborationArrangements" xlink:to="lab_arwr_ProceedsFromCollaborationArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_SummaryOfInterestExpenseRecognizedRelatedToCreditFacilityTableTextBlock_0f6f225a-25a5-4244-9252-8ae69a32f16a_terseLabel_en-US" xlink:label="lab_arwr_SummaryOfInterestExpenseRecognizedRelatedToCreditFacilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Interest Expense Recognized Related To Credit Facility</link:label>
    <link:label id="lab_arwr_SummaryOfInterestExpenseRecognizedRelatedToCreditFacilityTableTextBlock_label_en-US" xlink:label="lab_arwr_SummaryOfInterestExpenseRecognizedRelatedToCreditFacilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Interest Expense Recognized Related To Credit Facility [Table Text Block]</link:label>
    <link:label id="lab_arwr_SummaryOfInterestExpenseRecognizedRelatedToCreditFacilityTableTextBlock_documentation_en-US" xlink:label="lab_arwr_SummaryOfInterestExpenseRecognizedRelatedToCreditFacilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary Of Interest Expense Recognized Related To Credit Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SummaryOfInterestExpenseRecognizedRelatedToCreditFacilityTableTextBlock" xlink:href="arwr-20250630.xsd#arwr_SummaryOfInterestExpenseRecognizedRelatedToCreditFacilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_SummaryOfInterestExpenseRecognizedRelatedToCreditFacilityTableTextBlock" xlink:to="lab_arwr_SummaryOfInterestExpenseRecognizedRelatedToCreditFacilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties_ffb648f5-3113-4a24-817e-cff77cab8c6b_terseLabel_en-US" xlink:label="lab_arwr_UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront payment received</link:label>
    <link:label id="lab_arwr_UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties_label_en-US" xlink:label="lab_arwr_UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront Payment Received, Liability Related To Sale Of Future Royalties</link:label>
    <link:label id="lab_arwr_UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties_documentation_en-US" xlink:label="lab_arwr_UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upfront Payment Received, Liability Related To Sale Of Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties" xlink:href="arwr-20250630.xsd#arwr_UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties" xlink:to="lab_arwr_UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_983bb56b-5899-4530-be89-b38ca57a847d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value: Authorized 290,000 shares; issued and outstanding 138,144 and 124,376 shares</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities_38b93682-c6a3-4ee5-b06b-bae310b7e311_terseLabel_en-US" xlink:label="lab_arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities_label_en-US" xlink:label="lab_arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cash Received For Amounts Included In Measurement Of Lease Liabilities</link:label>
    <link:label id="lab_arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities_documentation_en-US" xlink:label="lab_arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Cash Received For Amounts Included In Measurement Of Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:href="arwr-20250630.xsd#arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:to="lab_arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_271e6912-090a-4e53-a4c3-f6db36ff1a6d_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3561723d-23e5-435c-b83a-1fb6a87ddf3f_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0442104d-36a6-409a-acf3-9bafa2b1e29f_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Weighted-average diluted shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_89690147-28d3-4a93-81ab-d82818a2fde8_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_1e9467bc-29e6-449e-aeee-532cce3127fd_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 7)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c4c85f13-4074-42f5-90e4-c6bd1a905627_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_a64dcf0f-b1b2-4fe4-bb9a-ed5f1a097f5b_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AmgenIncorporatedMember_2f9ca6a4-cc04-4d9d-9d82-b8df94d35d26_terseLabel_en-US" xlink:label="lab_arwr_AmgenIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amgen Incorporated</link:label>
    <link:label id="lab_arwr_AmgenIncorporatedMember_label_en-US" xlink:label="lab_arwr_AmgenIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amgen Incorporated [Member]</link:label>
    <link:label id="lab_arwr_AmgenIncorporatedMember_documentation_en-US" xlink:label="lab_arwr_AmgenIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amgen Incorporated.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmgenIncorporatedMember" xlink:href="arwr-20250630.xsd#arwr_AmgenIncorporatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AmgenIncorporatedMember" xlink:to="lab_arwr_AmgenIncorporatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_c6f1d0ae-cbd6-414b-a05b-84c19f3fc98d_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non- controlling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_61ed8f6c-0897-4907-9e70-985a0ff58122_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_f391bf6a-20c6-4fd2-a1df-7f9302f75d43_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing Agreement</link:label>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_label_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtTextBlock" xlink:to="lab_us-gaap_LongTermDebtTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_a2f2de77-072b-43de-baeb-daed317268ea_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DebtInstrumentCovenantMarketCapitalizationThreshold_c318307b-8f81-4f73-8eda-b4b84cc79564_terseLabel_en-US" xlink:label="lab_arwr_DebtInstrumentCovenantMarketCapitalizationThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Market capitalization threshold</link:label>
    <link:label id="lab_arwr_DebtInstrumentCovenantMarketCapitalizationThreshold_label_en-US" xlink:label="lab_arwr_DebtInstrumentCovenantMarketCapitalizationThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Market Capitalization, Threshold</link:label>
    <link:label id="lab_arwr_DebtInstrumentCovenantMarketCapitalizationThreshold_documentation_en-US" xlink:label="lab_arwr_DebtInstrumentCovenantMarketCapitalizationThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Market Capitalization, Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtInstrumentCovenantMarketCapitalizationThreshold" xlink:href="arwr-20250630.xsd#arwr_DebtInstrumentCovenantMarketCapitalizationThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DebtInstrumentCovenantMarketCapitalizationThreshold" xlink:to="lab_arwr_DebtInstrumentCovenantMarketCapitalizationThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_75a2af3e-8888-4359-858d-d5727c116dff_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_83036ab0-43c7-4cc7-b605-31b5f81bc64d_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e6fd8b3e-7a23-452e-a1bf-a100c97dbcb5_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermLineOfCredit_06d5a7a9-ef49-406e-b40c-0b878abd73b9_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermLineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit facility, net of current portion</link:label>
    <link:label id="lab_us-gaap_LongTermLineOfCredit_label_en-US" xlink:label="lab_us-gaap_LongTermLineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Line of Credit, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermLineOfCredit" xlink:to="lab_us-gaap_LongTermLineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_caa8fd16-bc25-4358-aad9-3ba48a272fd9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_71ed8300-cb3b-4fca-9e3f-24059452330a_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Accounts</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_e8acd7f6-92b7-480f-b004-52ae8bf1c168_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Visirna credit agreement</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_231e06b4-10f4-4e68-a989-5b19d0a0b643_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term lease cost</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_2d221f1c-91d6-4eeb-a958-65d52c87dc18_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_bcf7e934-27b1-40d1-81cc-24db98afa882_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Remaining Contractual Term, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_b4612352-8822-45e3-8be3-522a29c6df0b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4d1f66d3-fb3c-482f-ba89-50ad9ea07102_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total noncontrolling interest and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0a301da8-da72-46ee-a3c6-b3593405f9ec_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_09d1ebeb-935a-4d65-a0a4-f9dca3637dad_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_c9faf6a1-6077-4dd3-ad87-2998b395a021_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated accretion of the MOIC Payment</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_7e985075-f4cb-40f7-92f3-2bfbbdcc67df_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accretion of the MOIC Payment</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_4a8aff1e-20ac-4ff5-9375-cab8f7c56985_verboseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_14c41c0c-544c-4863-bbaa-7c1ecc4c334f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_d9e344d2-a381-41bc-9392-23443c7b1043_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net (Loss) Income Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CA_69f41da0-418d-499e-b6aa-0670396c68cc_terseLabel_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">California</link:label>
    <link:label id="lab_stpr_CA_label_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CALIFORNIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CA" xlink:to="lab_stpr_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_c5a08bb7-16a4-43ed-9b35-ff78dfa3bafa_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Acquisition</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NumberOfCollaborationPrograms_b38f04eb-8a1a-4b8c-b7db-3bfed1e54f7a_terseLabel_en-US" xlink:label="lab_arwr_NumberOfCollaborationPrograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of collaboration programs</link:label>
    <link:label id="lab_arwr_NumberOfCollaborationPrograms_label_en-US" xlink:label="lab_arwr_NumberOfCollaborationPrograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Collaboration Programs</link:label>
    <link:label id="lab_arwr_NumberOfCollaborationPrograms_documentation_en-US" xlink:label="lab_arwr_NumberOfCollaborationPrograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Collaboration Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfCollaborationPrograms" xlink:href="arwr-20250630.xsd#arwr_NumberOfCollaborationPrograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NumberOfCollaborationPrograms" xlink:to="lab_arwr_NumberOfCollaborationPrograms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_6e5ee08b-945b-4450-b319-6408f277cf14_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the issuance of common stock, net of offering costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_b8649f5a-0cff-4973-bac0-e970bb100426_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_62888b58-9ca4-4f4e-8de7-ca5099d4c25f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_41afa91c-1b2d-4c35-b7f4-a06234e348d6_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_112acb8b-83ec-4b96-b827-662ab778867e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e7a440a4-7a02-41de-b064-b122d43ec428_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_76c96a90-483f-40d4-8279-fd6987d81198_terseLabel_en-US" xlink:label="lab_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2030 and thereafter</link:label>
    <link:label id="lab_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_label_en-US" xlink:label="lab_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee Operating Lease Liability Payments Due Year Five And After Year Five</link:label>
    <link:label id="lab_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_documentation_en-US" xlink:label="lab_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee operating lease liability payments due year five and after year five.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" xlink:href="arwr-20250630.xsd#arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" xlink:to="lab_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_70fbd75c-891e-4122-9b87-fd74fdb15d87_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponFDAApproval_f84984cf-eeb9-4629-b396-d18c04800607_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponFDAApproval" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment receivable upon FDA approval</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponFDAApproval_label_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponFDAApproval" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payment Receivable, Upon FDA Approval</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponFDAApproval_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponFDAApproval" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Payment Receivable, Upon FDA Approval</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponFDAApproval" xlink:href="arwr-20250630.xsd#arwr_MilestonePaymentReceivableUponFDAApproval"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentReceivableUponFDAApproval" xlink:to="lab_arwr_MilestonePaymentReceivableUponFDAApproval" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract_f1cb2536-f94d-477b-b808-ad72f53bd3bd_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets and Liabilities, Lessee [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_d05b3dce-54f3-42aa-a484-95b442046f04_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree_8ea994d9-0de4-4308-acb2-5342e57125ac_terseLabel_en-US" xlink:label="lab_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">After two to three years</link:label>
    <link:label id="lab_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree_label_en-US" xlink:label="lab_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, After Year Two Through Three</link:label>
    <link:label id="lab_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree_documentation_en-US" xlink:label="lab_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, After Year Two Through Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree" xlink:href="arwr-20250630.xsd#arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree" xlink:to="lab_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_ccd652f0-6c9d-4a50-8d84-10cabf9a3845_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent liabilities</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial_c4eb2f15-f179-44b7-927b-bde380c652d1_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment receivable upon achievement of enrollment in phase 3 clinical trial</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial_label_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payment Receivable, Upon Achievement of Enrollment in Phase 3 Clinical Trial</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Payment Receivable, Upon Achievement of Enrollment in Phase 3 Clinical Trial</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" xlink:href="arwr-20250630.xsd#arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" xlink:to="lab_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_4d11e9be-373a-4b73-9442-a9d5eb5bb048_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivatePlacementMember_b54289ff-2897-437c-9ccd-33ca3b724c1c_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_FiniteLivedIntangibleAssetsImpairment_889d1e73-f4c6-4203-a56d-6541ce135ccc_terseLabel_en-US" xlink:label="lab_arwr_FiniteLivedIntangibleAssetsImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment</link:label>
    <link:label id="lab_arwr_FiniteLivedIntangibleAssetsImpairment_label_en-US" xlink:label="lab_arwr_FiniteLivedIntangibleAssetsImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Impairment</link:label>
    <link:label id="lab_arwr_FiniteLivedIntangibleAssetsImpairment_documentation_en-US" xlink:label="lab_arwr_FiniteLivedIntangibleAssetsImpairment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FiniteLivedIntangibleAssetsImpairment" xlink:href="arwr-20250630.xsd#arwr_FiniteLivedIntangibleAssetsImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_FiniteLivedIntangibleAssetsImpairment" xlink:to="lab_arwr_FiniteLivedIntangibleAssetsImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandSubjectToGroundLeases_16dfcccc-c769-418d-aaa7-b5bf17b1cbd3_terseLabel_en-US" xlink:label="lab_us-gaap_LandSubjectToGroundLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office space leases (in sq ft)</link:label>
    <link:label id="lab_us-gaap_LandSubjectToGroundLeases_label_en-US" xlink:label="lab_us-gaap_LandSubjectToGroundLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land Subject to Ground Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandSubjectToGroundLeases" xlink:to="lab_us-gaap_LandSubjectToGroundLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f0325886-173b-4024-8f6a-e5bd30ac13a3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Finite Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset, Finite-Lived [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_a50d6f26-7bdb-4aef-bc02-cc01c4967884_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_4240eb21-eaac-4f34-909e-4251fa40efb3_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_17b1c028-54cd-4fbe-95ce-39bf26715fbb_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CollaborationArrangementVariableConsideration_f24890ed-4f78-4159-b6a2-6613be80b334_terseLabel_en-US" xlink:label="lab_arwr_CollaborationArrangementVariableConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated variable consideration</link:label>
    <link:label id="lab_arwr_CollaborationArrangementVariableConsideration_label_en-US" xlink:label="lab_arwr_CollaborationArrangementVariableConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Arrangement, Variable Consideration</link:label>
    <link:label id="lab_arwr_CollaborationArrangementVariableConsideration_documentation_en-US" xlink:label="lab_arwr_CollaborationArrangementVariableConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Arrangement, Variable Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationArrangementVariableConsideration" xlink:href="arwr-20250630.xsd#arwr_CollaborationArrangementVariableConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CollaborationArrangementVariableConsideration" xlink:to="lab_arwr_CollaborationArrangementVariableConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_9f9b83e8-8c48-4dfc-8fd6-188a8962bd9b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee Lease Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_74955ae9-a0cc-462a-86eb-3c46d6b9c846_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_dfce1a29-b91c-485a-bed4-04509de88106_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_3253298c-e253-4a1a-99e4-46902940f9ee_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term line of credit</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_eafdc8cd-3c4a-4176-b131-0cd7f639b767_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_d945cb19-8e4e-4827-91d2-fef5e17332cc_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_ed0bff4c-9270-4749-bff4-99b85e7b105d_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ee3c41e7-43e8-4abd-990b-683d5988ca10_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_b947cc74-df9f-4645-8e89-fd770af616cb_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_9867b2db-1f23-4a34-9e2d-38725864fc79_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_74c2541b-09e0-4935-aa71-1e8dcfa8a44c_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Diluted net (loss) income per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_9b04cd55-f6f9-4330-9cde-793ea228e08f_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_8498385e-c295-47ae-a28b-b8de9eeb9eec_terseLabel_en-US" xlink:label="lab_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of eligible to receive tiered royalties on net sales</link:label>
    <link:label id="lab_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_label_en-US" xlink:label="lab_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Eligible To Receive Tiered Royalties On Net Sales</link:label>
    <link:label id="lab_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_documentation_en-US" xlink:label="lab_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of eligible to receive tiered royalties on net sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:href="arwr-20250630.xsd#arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:to="lab_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_de539205-6197-4036-ac24-8c739a84e743_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_64f64025-19c4-49e0-abe0-1f473297a7a7_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_1428db6d-7bf2-4be3-97ae-c13a1bbb4d40_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee Lease Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DebtInstrumentCovenantMultipleOfInvestCapital_491fe955-d503-476d-8928-db629d368634_terseLabel_en-US" xlink:label="lab_arwr_DebtInstrumentCovenantMultipleOfInvestCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Multiple of invested capital rate</link:label>
    <link:label id="lab_arwr_DebtInstrumentCovenantMultipleOfInvestCapital_label_en-US" xlink:label="lab_arwr_DebtInstrumentCovenantMultipleOfInvestCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Multiple Of Invest Capital</link:label>
    <link:label id="lab_arwr_DebtInstrumentCovenantMultipleOfInvestCapital_documentation_en-US" xlink:label="lab_arwr_DebtInstrumentCovenantMultipleOfInvestCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Multiple Of Invest Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtInstrumentCovenantMultipleOfInvestCapital" xlink:href="arwr-20250630.xsd#arwr_DebtInstrumentCovenantMultipleOfInvestCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DebtInstrumentCovenantMultipleOfInvestCapital" xlink:to="lab_arwr_DebtInstrumentCovenantMultipleOfInvestCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3f4d279d-a350-430f-b088-f744e87d0dae_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares of common stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaidInKindInterest_fa90d181-5523-4fb8-84c8-5bcd4e510ce6_terseLabel_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest expense on credit facility</link:label>
    <link:label id="lab_us-gaap_PaidInKindInterest_label_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Paid-in-Kind Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaidInKindInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaidInKindInterest" xlink:to="lab_us-gaap_PaidInKindInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_1160283f-c3ef-466e-989d-416bd4000922_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other (expense) income</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8d06025e-98b2-42b9-aeac-b87de6620674_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_ea99cabe-00fa-4eba-b99f-bdc4d39a4763_totalLabel_en-US" xlink:label="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total (in shares)</link:label>
    <link:label id="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_label_en-US" xlink:label="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Outstanding</link:label>
    <link:label id="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_documentation_en-US" xlink:label="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" xlink:href="arwr-20250630.xsd#arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" xlink:to="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_fa2e2746-07b1-482d-82d3-161b893eabe4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DebtInstrumentCovenantMinimumLiquidityIfCapitalizationIsAboveThreshold_7309fc9c-c995-4f0f-ad55-eebe25664c68_terseLabel_en-US" xlink:label="lab_arwr_DebtInstrumentCovenantMinimumLiquidityIfCapitalizationIsAboveThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, covenant, minimum liquidity cash, cash equivalents and investments</link:label>
    <link:label id="lab_arwr_DebtInstrumentCovenantMinimumLiquidityIfCapitalizationIsAboveThreshold_label_en-US" xlink:label="lab_arwr_DebtInstrumentCovenantMinimumLiquidityIfCapitalizationIsAboveThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Minimum Liquidity If Capitalization Is Above Threshold</link:label>
    <link:label id="lab_arwr_DebtInstrumentCovenantMinimumLiquidityIfCapitalizationIsAboveThreshold_documentation_en-US" xlink:label="lab_arwr_DebtInstrumentCovenantMinimumLiquidityIfCapitalizationIsAboveThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Minimum Liquidity If Capitalization Is Above Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtInstrumentCovenantMinimumLiquidityIfCapitalizationIsAboveThreshold" xlink:href="arwr-20250630.xsd#arwr_DebtInstrumentCovenantMinimumLiquidityIfCapitalizationIsAboveThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DebtInstrumentCovenantMinimumLiquidityIfCapitalizationIsAboveThreshold" xlink:to="lab_arwr_DebtInstrumentCovenantMinimumLiquidityIfCapitalizationIsAboveThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_5a2b24e5-7dd7-4a7e-864b-d1ceb254fd5f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale securities, at fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3112569f-a521-40bc-943d-ae34460e6a7a_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current investments, Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_18a4faed-a0da-4ab1-abcf-9c22f2d3f850_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DebtInstrumentPrepaymentPercentage_dc2815d3-7ddf-4fa9-8ad3-7968e9c32e07_terseLabel_en-US" xlink:label="lab_arwr_DebtInstrumentPrepaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, prepayment percentage</link:label>
    <link:label id="lab_arwr_DebtInstrumentPrepaymentPercentage_label_en-US" xlink:label="lab_arwr_DebtInstrumentPrepaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment, Percentage</link:label>
    <link:label id="lab_arwr_DebtInstrumentPrepaymentPercentage_documentation_en-US" xlink:label="lab_arwr_DebtInstrumentPrepaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtInstrumentPrepaymentPercentage" xlink:href="arwr-20250630.xsd#arwr_DebtInstrumentPrepaymentPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DebtInstrumentPrepaymentPercentage" xlink:to="lab_arwr_DebtInstrumentPrepaymentPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_35c4a98a-ab22-41a6-828c-4a5f7f7d7251_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-Term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CollaborationArrangementFixedConsideration_7a9943fc-fca2-46bf-bd68-7cbfb0d9facc_terseLabel_en-US" xlink:label="lab_arwr_CollaborationArrangementFixedConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed consideration</link:label>
    <link:label id="lab_arwr_CollaborationArrangementFixedConsideration_f0bc6cc8-e43f-4e23-8d24-21de7def2afe_totalLabel_en-US" xlink:label="lab_arwr_CollaborationArrangementFixedConsideration" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Fixed consideration</link:label>
    <link:label id="lab_arwr_CollaborationArrangementFixedConsideration_label_en-US" xlink:label="lab_arwr_CollaborationArrangementFixedConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Arrangement, Fixed Consideration</link:label>
    <link:label id="lab_arwr_CollaborationArrangementFixedConsideration_documentation_en-US" xlink:label="lab_arwr_CollaborationArrangementFixedConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Arrangement, Fixed Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationArrangementFixedConsideration" xlink:href="arwr-20250630.xsd#arwr_CollaborationArrangementFixedConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CollaborationArrangementFixedConsideration" xlink:to="lab_arwr_CollaborationArrangementFixedConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6f9c1cdc-6351-483d-bd26-388d5f48d22a_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_7a7b08c9-8bf8-49ca-9e4d-5121cead78cf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income taxes paid</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_7774fd52-e51c-4935-9dc1-2640bca6409f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_fdbdc04e-e741-4e81-8382-a3a2150a98b2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_01d89af9-71ea-4767-918a-cb02a715048e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_0e1d634c-b214-40a7-9e78-9144a4b006e3_terseLabel_en-US" xlink:label="lab_arwr_GlaxosmithklineIntellectualPropertyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GSK</link:label>
    <link:label id="lab_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_label_en-US" xlink:label="lab_arwr_GlaxosmithklineIntellectualPropertyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Glaxosmithkline Intellectual Property Limited [Member]</link:label>
    <link:label id="lab_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_documentation_en-US" xlink:label="lab_arwr_GlaxosmithklineIntellectualPropertyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Glaxosmithkline Intellectual Property Limited.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember" xlink:href="arwr-20250630.xsd#arwr_GlaxosmithklineIntellectualPropertyLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember" xlink:to="lab_arwr_GlaxosmithklineIntellectualPropertyLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ComputerAndSoftwareMember_4c81bd41-9faa-40f7-9cd8-e7586212e3ee_terseLabel_en-US" xlink:label="lab_arwr_ComputerAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computers and software</link:label>
    <link:label id="lab_arwr_ComputerAndSoftwareMember_label_en-US" xlink:label="lab_arwr_ComputerAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer And Software [Member]</link:label>
    <link:label id="lab_arwr_ComputerAndSoftwareMember_documentation_en-US" xlink:label="lab_arwr_ComputerAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Computer And Software</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ComputerAndSoftwareMember" xlink:href="arwr-20250630.xsd#arwr_ComputerAndSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ComputerAndSoftwareMember" xlink:to="lab_arwr_ComputerAndSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_950d13b1-da57-4df2-ab84-0df1da2ebea4_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Initial Term Loan</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_ec459bed-a0ba-4f78-ba69-9fa0e9337605_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ColoradoOwnerLLCMember_d89ba278-b583-42b9-a944-f2b6ad61f94b_terseLabel_en-US" xlink:label="lab_arwr_ColoradoOwnerLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Colorado Owner, LLC</link:label>
    <link:label id="lab_arwr_ColoradoOwnerLLCMember_label_en-US" xlink:label="lab_arwr_ColoradoOwnerLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Colorado Owner L L C [Member]</link:label>
    <link:label id="lab_arwr_ColoradoOwnerLLCMember_documentation_en-US" xlink:label="lab_arwr_ColoradoOwnerLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Colorado Owner, LLC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ColoradoOwnerLLCMember" xlink:href="arwr-20250630.xsd#arwr_ColoradoOwnerLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ColoradoOwnerLLCMember" xlink:to="lab_arwr_ColoradoOwnerLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_f4e572e1-e7e9-4325-a721-cdda6ac87383_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent_c4415b02-31cc-4925-9831-4754efb8dded_terseLabel_en-US" xlink:label="lab_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current investments, Gross Unrealized Gains</link:label>
    <link:label id="lab_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent_label_en-US" xlink:label="lab_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, Current</link:label>
    <link:label id="lab_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent_documentation_en-US" xlink:label="lab_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent" xlink:href="arwr-20250630.xsd#arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent" xlink:to="lab_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_f27f45d9-8962-454b-b794-b47bdb785e80_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_0fd0a984-16ca-4f60-bea4-e57409b714a5_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued payroll and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_af74542e-5e6f-481d-b001-583872bd710a_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_e30de58c-35f0-43d7-89b0-a2a8a41afc2a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NumberOfAgreements_c1df430c-ff9c-4e68-a3cf-6ba7e7049fc0_terseLabel_en-US" xlink:label="lab_arwr_NumberOfAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of agreements</link:label>
    <link:label id="lab_arwr_NumberOfAgreements_label_en-US" xlink:label="lab_arwr_NumberOfAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Agreements</link:label>
    <link:label id="lab_arwr_NumberOfAgreements_documentation_en-US" xlink:label="lab_arwr_NumberOfAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfAgreements" xlink:href="arwr-20250630.xsd#arwr_NumberOfAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NumberOfAgreements" xlink:to="lab_arwr_NumberOfAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_03b69fd2-27db-4662-8d7c-4dbe25e10d98_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_SareptaCollaborationAgreementMember_d3ffecd6-618d-498a-a1af-376c3295ac37_terseLabel_en-US" xlink:label="lab_arwr_SareptaCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sarepta Collaboration Agreement</link:label>
    <link:label id="lab_arwr_SareptaCollaborationAgreementMember_label_en-US" xlink:label="lab_arwr_SareptaCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sarepta Collaboration Agreement [Member]</link:label>
    <link:label id="lab_arwr_SareptaCollaborationAgreementMember_documentation_en-US" xlink:label="lab_arwr_SareptaCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sarepta Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SareptaCollaborationAgreementMember" xlink:href="arwr-20250630.xsd#arwr_SareptaCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_SareptaCollaborationAgreementMember" xlink:to="lab_arwr_SareptaCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_e217b904-4dfa-4550-b5d6-c2873239ae8f_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income attributable to Arrowhead Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_885c8bee-1530-41e5-bdd4-0d361d79962c_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income attributable to Arrowhead Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_1ce751a6-cfcb-4d05-aff3-5e326ff286c6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_a3eae3db-c4ea-4a9f-b4a5-8521e574b3f1_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_c5b027e1-3f2e-4d70-9048-3c09ae4a7707_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_df52cc05-f4c5-4e5a-83c0-3b8329a530d3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_f6f98f5c-8021-48dc-a6ea-251747b34a44_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interest and stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_7c6eb56d-7155-4263-8e88-3e73c6bc9765_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_f2b8cb76-4312-4893-b5bc-2d29daa840af_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_36620232-3b78-4b70-8d6f-c9db4b7a1ed9_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_e111bbdb-1d81-4421-b8ee-7a176bb3da51_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_a97e2990-9814-40b1-8b5a-fc654959ada1_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_76091883-aebc-4a35-a70c-efa4a7bba5ef_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_0325351f-6396-4606-81b0-01a92e36a737_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_c524a90f-3e4d-4c93-bb53-b675b8932cf0_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating (loss) income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_9c2ca331-0b47-485e-823a-884684dda6fa_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_fb831dbf-8656-4def-b860-27de44e27379_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AmountIntendsToInvestForBuildoutOfFacilities_c221688e-e543-45a7-9277-aced596c8421_terseLabel_en-US" xlink:label="lab_arwr_AmountIntendsToInvestForBuildoutOfFacilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount intends to invest for buildout of the facilities</link:label>
    <link:label id="lab_arwr_AmountIntendsToInvestForBuildoutOfFacilities_label_en-US" xlink:label="lab_arwr_AmountIntendsToInvestForBuildoutOfFacilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amount Intends To Invest For Buildout Of Facilities</link:label>
    <link:label id="lab_arwr_AmountIntendsToInvestForBuildoutOfFacilities_documentation_en-US" xlink:label="lab_arwr_AmountIntendsToInvestForBuildoutOfFacilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount intends to invest for buildout of facilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmountIntendsToInvestForBuildoutOfFacilities" xlink:href="arwr-20250630.xsd#arwr_AmountIntendsToInvestForBuildoutOfFacilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AmountIntendsToInvestForBuildoutOfFacilities" xlink:to="lab_arwr_AmountIntendsToInvestForBuildoutOfFacilities" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_VisirnaESOPMember_90da0231-4e3d-4ade-ac69-ac5cef04886c_terseLabel_en-US" xlink:label="lab_arwr_VisirnaESOPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Visirna ESOP</link:label>
    <link:label id="lab_arwr_VisirnaESOPMember_label_en-US" xlink:label="lab_arwr_VisirnaESOPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Visirna ESOP [Member]</link:label>
    <link:label id="lab_arwr_VisirnaESOPMember_documentation_en-US" xlink:label="lab_arwr_VisirnaESOPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Visirna ESOP</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VisirnaESOPMember" xlink:href="arwr-20250630.xsd#arwr_VisirnaESOPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_VisirnaESOPMember" xlink:to="lab_arwr_VisirnaESOPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_dc263aa8-665f-4b25-aa1e-8f1a38f6428b_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_a9d359bb-a1a1-4380-bee3-40dff0fb267a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments_85332bc7-7690-44fa-b06d-9e83dd9a6d5b_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment receivable upon receipt of royalty payments</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments_label_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payment Receivable, Upon Receipt Of Royalty Payments</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Payment Receivable, Upon Receipt Of Royalty Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" xlink:href="arwr-20250630.xsd#arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" xlink:to="lab_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_8f192277-0a7c-4d14-9f64-bfa07b856c5c_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_c149b067-32ba-4fa8-8ce2-4d4f1cb9e5a6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b094b6ca-e519-455e-8c41-c406c9c40e08_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_LiabilitySaleOfFutureRoyaltiesInterestRate_cad9ea16-4248-45b1-b428-96a5e268c23c_terseLabel_en-US" xlink:label="lab_arwr_LiabilitySaleOfFutureRoyaltiesInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability related to the sale of future royalties, interest rate</link:label>
    <link:label id="lab_arwr_LiabilitySaleOfFutureRoyaltiesInterestRate_label_en-US" xlink:label="lab_arwr_LiabilitySaleOfFutureRoyaltiesInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability, Sale Of Future Royalties, Interest Rate</link:label>
    <link:label id="lab_arwr_LiabilitySaleOfFutureRoyaltiesInterestRate_documentation_en-US" xlink:label="lab_arwr_LiabilitySaleOfFutureRoyaltiesInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability, Sale Of Future Royalties, Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilitySaleOfFutureRoyaltiesInterestRate" xlink:href="arwr-20250630.xsd#arwr_LiabilitySaleOfFutureRoyaltiesInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_LiabilitySaleOfFutureRoyaltiesInterestRate" xlink:to="lab_arwr_LiabilitySaleOfFutureRoyaltiesInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6f124eb0-1686-4fc6-9160-e2e5b90511c5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- Average Grant Date Fair Value Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_510936c0-1308-43dd-81d3-f0859e6b50d6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, share reserve for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_7e963a1a-72eb-4e10-835c-9b0cee004847_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_21a490a9-ada9-4a0c-9ee9-c429acf4ab2c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_67d7cf27-7c5b-4aec-8df6-ac9dec2fc7bd_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash flow from operating activities</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_90100691-124a-4e55-ad75-af1a439bd7da_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration and License Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4ab204af-df2e-4c17-99cf-50b068cde097_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_6677cb02-0472-4b32-9ff6-78bfc36d9ccf_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of pre-funded warrants</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_e2cc93d2-e9d1-4675-aa29-5c91fa5fe612_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued to institutional investors (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_c18e8365-7191-4438-895e-b6218827e050_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract liabilities included in deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_d9671263-3527-4b0c-ac44-4aa23faa9be3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e1856b2b-1d25-4372-8dd7-b6c48935c8f7_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potentially dilutive securities excluded from computation of diluted earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_7cbff28c-0ec6-4451-848d-a455ee8c687f_verboseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_9285a190-0bad-443e-aa6f-91a5c15a18c9_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock sold price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_754f5e65-29e3-47fa-8fcd-3e0c783bc343_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_b9ee7309-8107-4202-91e5-82700664c812_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_SareptaMember_efac7942-3a58-4b98-91bb-76286d88459e_terseLabel_en-US" xlink:label="lab_arwr_SareptaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sarepta</link:label>
    <link:label id="lab_arwr_SareptaMember_label_en-US" xlink:label="lab_arwr_SareptaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sarepta [Member]</link:label>
    <link:label id="lab_arwr_SareptaMember_documentation_en-US" xlink:label="lab_arwr_SareptaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sarepta</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SareptaMember" xlink:href="arwr-20250630.xsd#arwr_SareptaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_SareptaMember" xlink:to="lab_arwr_SareptaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_d478dfc4-5d47-4a28-848b-07e165de5b4c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_25b366da-5c5f-44b2-a015-3f2d6b15d98c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_cf33a880-75cb-4002-9692-d9b63caeef22_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CollaborationArrangementTerminationNoticePeriodPriorToRegulatoryApproval_237f01cf-a308-4c43-a9d1-686b2262a2ab_terseLabel_en-US" xlink:label="lab_arwr_CollaborationArrangementTerminationNoticePeriodPriorToRegulatoryApproval" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration agreement termination notice period prior to any regulatory approval of a licensed product</link:label>
    <link:label id="lab_arwr_CollaborationArrangementTerminationNoticePeriodPriorToRegulatoryApproval_label_en-US" xlink:label="lab_arwr_CollaborationArrangementTerminationNoticePeriodPriorToRegulatoryApproval" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Arrangement, Termination Notice Period Prior To Regulatory Approval</link:label>
    <link:label id="lab_arwr_CollaborationArrangementTerminationNoticePeriodPriorToRegulatoryApproval_documentation_en-US" xlink:label="lab_arwr_CollaborationArrangementTerminationNoticePeriodPriorToRegulatoryApproval" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Arrangement, Termination Notice Period Prior To Regulatory Approval</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationArrangementTerminationNoticePeriodPriorToRegulatoryApproval" xlink:href="arwr-20250630.xsd#arwr_CollaborationArrangementTerminationNoticePeriodPriorToRegulatoryApproval"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CollaborationArrangementTerminationNoticePeriodPriorToRegulatoryApproval" xlink:to="lab_arwr_CollaborationArrangementTerminationNoticePeriodPriorToRegulatoryApproval" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_da0783fb-327c-45c5-a297-4c4c0474b059_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_15421897-4130-444c-8e9c-c4efffb1b16f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Summarized Information about Stock Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_aecb4750-adc4-42f3-aea5-a8ef736a08bf_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_af2109cf-5ab3-4bdd-8695-02878e6a5a0d_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_613f8075-fc0b-4798-8bfa-d6a833789734_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average basic shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a32c81dd-a25f-4750-8ad9-ac32a4dbe272_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_4ab740cf-70d5-4dee-94b1-e2cbc3eb1b55_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights_be12b7b0-9a2f-408b-a0e1-733989d61d9c_terseLabel_en-US" xlink:label="lab_arwr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants purchase price (in dollars per share)</link:label>
    <link:label id="lab_arwr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights_label_en-US" xlink:label="lab_arwr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Purchase Price of Warrants or Rights</link:label>
    <link:label id="lab_arwr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights_documentation_en-US" xlink:label="lab_arwr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Purchase Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights" xlink:href="arwr-20250630.xsd#arwr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights" xlink:to="lab_arwr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AccruedCapitalExpenditureCurrent_6e84d1f5-3e06-4801-8284-5c593959737f_terseLabel_en-US" xlink:label="lab_arwr_AccruedCapitalExpenditureCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued capital expenditures</link:label>
    <link:label id="lab_arwr_AccruedCapitalExpenditureCurrent_label_en-US" xlink:label="lab_arwr_AccruedCapitalExpenditureCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Capital Expenditure, Current</link:label>
    <link:label id="lab_arwr_AccruedCapitalExpenditureCurrent_documentation_en-US" xlink:label="lab_arwr_AccruedCapitalExpenditureCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Capital Expenditure, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AccruedCapitalExpenditureCurrent" xlink:href="arwr-20250630.xsd#arwr_AccruedCapitalExpenditureCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AccruedCapitalExpenditureCurrent" xlink:to="lab_arwr_AccruedCapitalExpenditureCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentReceivable_99f4657a-32c7-43e4-87d1-00ce3c476227_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment receivable</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivable_label_en-US" xlink:label="lab_arwr_MilestonePaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payment Receivable</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivable_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Payment Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivable" xlink:href="arwr-20250630.xsd#arwr_MilestonePaymentReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentReceivable" xlink:to="lab_arwr_MilestonePaymentReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_22f48690-6c8a-4ba1-8c23-f22e932a3a19_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Options Outstanding, Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_308cba07-18ba-406a-b1d6-42344b5e6f46_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_8be6b643-6e8b-4065-81e3-675eb705cfae_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_214c0cf0-d39f-4c4f-8a42-e4f5d31f4620_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other (expense) income:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_1db254fe-775e-449d-bd2d-b4af1eee8a95_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_68eadde1-3e1e-49cc-bd7d-a4bed3c6a6b0_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_dd82a664-76fd-4f59-8f63-20e6bc2deeb6_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Acquisition</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_04f34a94-db0d-4437-ae51-68fe050a3f85_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_dca6c1bb-e39c-4e71-beac-bc84468f4abc_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_0db38887-f815-423c-a18c-ce77b407f4ef_terseLabel_en-US" xlink:label="lab_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2030 and thereafter</link:label>
    <link:label id="lab_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_label_en-US" xlink:label="lab_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Four</link:label>
    <link:label id="lab_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_documentation_en-US" xlink:label="lab_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:href="arwr-20250630.xsd#arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:to="lab_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_018c9ba8-c83e-43a1-9f94-b7dc7d774572_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_6e444844-1936-480f-8ed8-54288ac1fcac_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_46591045-b400-4bb4-ba6e-8c18156ebe0b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_09114a8f-33d7-49ce-a90d-b1ff98d36e62_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_13745073-680e-4ac4-8b63-95e66f6a55c9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining lease term (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5714c42a-4d6a-44ef-b745-4a9dcf977a4c_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9ae4a93a-0aaa-4127-8164-e196565592fb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_451ab4cf-2953-4f69-9351-b6b2fd068a0d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_label_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseNonoperating" xlink:to="lab_us-gaap_InterestExpenseNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_GSKHBVAgreementMember_6b5f4644-75ed-4e4f-a01d-9d2d29f2d0bf_terseLabel_en-US" xlink:label="lab_arwr_GSKHBVAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GSK-HBV Agreement</link:label>
    <link:label id="lab_arwr_GSKHBVAgreementMember_label_en-US" xlink:label="lab_arwr_GSKHBVAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GSK-HBV Agreement [Member]</link:label>
    <link:label id="lab_arwr_GSKHBVAgreementMember_documentation_en-US" xlink:label="lab_arwr_GSKHBVAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">GSK-HBV Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GSKHBVAgreementMember" xlink:href="arwr-20250630.xsd#arwr_GSKHBVAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_GSKHBVAgreementMember" xlink:to="lab_arwr_GSKHBVAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_734fe281-7ca1-48fd-840d-ddb1f59abc75_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_132e05b8-57fd-4a00-b633-50c2ac1d8b77_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_d3f430a5-60e9-4a8b-9b0b-76dd2753a797_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfWarrants_4b4c837e-c70a-4312-b3c2-7a6c5b0265ee_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the issuance of warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfWarrants_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_5addbf6a-3ab9-4608-85fb-a86cb55f0de1_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterestAndDividend_01440a44-2836-4f21-8976-076cb8e56413_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterestAndDividend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterestAndDividend_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterestAndDividend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest and Dividend</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterestAndDividend" xlink:to="lab_us-gaap_InvestmentIncomeInterestAndDividend" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_646dd609-84b3-4198-a1e8-3376e168de66_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025 (remainder)</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_79570ae5-0fb9-4a48-a481-5ba7b6f7a8b7_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total long-term liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_8698e689-032e-4850-8513-daf5961e4fcc_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_014c6084-2061-46cd-a0e4-28f0867f689c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_9c3563e3-5762-4c27-9388-368c5203928a_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital expenditures included in accrued expenses</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1e4c637f-b69c-4459-9371-7c375aef2633_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_LaboratoryAndOfficeFacilityMember_825b7932-457a-49e6-ba81-70753c0e5b93_terseLabel_en-US" xlink:label="lab_arwr_LaboratoryAndOfficeFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Laboratory and Office Facility</link:label>
    <link:label id="lab_arwr_LaboratoryAndOfficeFacilityMember_label_en-US" xlink:label="lab_arwr_LaboratoryAndOfficeFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory And Office Facility [Member]</link:label>
    <link:label id="lab_arwr_LaboratoryAndOfficeFacilityMember_documentation_en-US" xlink:label="lab_arwr_LaboratoryAndOfficeFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Laboratory and office facility.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LaboratoryAndOfficeFacilityMember" xlink:href="arwr-20250630.xsd#arwr_LaboratoryAndOfficeFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_LaboratoryAndOfficeFacilityMember" xlink:to="lab_arwr_LaboratoryAndOfficeFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_db69261b-1b8a-4acd-88ce-ce5da074e83e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_927c7d9f-506f-49a7-9b47-9f98a17910bc_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_689feaff-93af-4c3f-a8f1-24c2afb91dd1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ManufacturingFacilityMember_4a661054-f322-4dc1-9a82-927fe17ccb3b_terseLabel_en-US" xlink:label="lab_us-gaap_ManufacturingFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Manufacturing Facility</link:label>
    <link:label id="lab_us-gaap_ManufacturingFacilityMember_label_en-US" xlink:label="lab_us-gaap_ManufacturingFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Manufacturing Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManufacturingFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ManufacturingFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ManufacturingFacilityMember" xlink:to="lab_us-gaap_ManufacturingFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ResearchFacilityInMadisonMember_53dd2359-3821-44de-b110-d6b5905e147b_terseLabel_en-US" xlink:label="lab_arwr_ResearchFacilityInMadisonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Facility in Madison</link:label>
    <link:label id="lab_arwr_ResearchFacilityInMadisonMember_label_en-US" xlink:label="lab_arwr_ResearchFacilityInMadisonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Facility In Madison [Member]</link:label>
    <link:label id="lab_arwr_ResearchFacilityInMadisonMember_documentation_en-US" xlink:label="lab_arwr_ResearchFacilityInMadisonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research facility in Madison.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchFacilityInMadisonMember" xlink:href="arwr-20250630.xsd#arwr_ResearchFacilityInMadisonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ResearchFacilityInMadisonMember" xlink:to="lab_arwr_ResearchFacilityInMadisonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_0c34dad5-487d-48ef-830e-d3bb510295c1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued, net of offering costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_87207c44-c565-40cc-abca-e91e036ceac0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_44e39130-d319-4130-9607-9f26d828dfa6_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_028db96b-906c-4ada-abb7-fcbbeed35ad3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share Activity Related to RSUs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_fb160bbf-0d19-4e4a-b14d-4f6f600dbc02_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_94d54a76-fe07-4086-94d4-b3ef83c712e6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_5e011707-90fc-456f-b005-963a7d51363c_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_660a1dcf-2887-4013-b2bb-fc18e9f5eebe_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_be59d4c7-5336-49e0-aab0-59d9bfb4c44c_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_ba757dcb-c278-4d66-8bd1-607007dced8a_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_dd6e522c-8212-408a-bf5e-830fee287aec_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_0855c36a-627b-4c28-8379-c4b1221c0075_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>arwr-20250630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:774aaf13-8f26-4ca1-8d87-74a19a24be14,g:58a47ad1-6a7b-4244-af8c-bd7fa2a79e94-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/Cover" xlink:type="simple" xlink:href="arwr-20250630.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_1341cb6d-5d16-4047-a043-3ab0a3c9f582" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_6272dbc4-800e-402a-9348-cfc085540f62" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1341cb6d-5d16-4047-a043-3ab0a3c9f582" xlink:to="loc_dei_DocumentType_6272dbc4-800e-402a-9348-cfc085540f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_d8630241-5eea-42a3-bd65-97533160d1e3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1341cb6d-5d16-4047-a043-3ab0a3c9f582" xlink:to="loc_dei_DocumentQuarterlyReport_d8630241-5eea-42a3-bd65-97533160d1e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_4f41ddff-5b4d-4d06-b8d3-37d691254d5f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1341cb6d-5d16-4047-a043-3ab0a3c9f582" xlink:to="loc_dei_DocumentPeriodEndDate_4f41ddff-5b4d-4d06-b8d3-37d691254d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_175d4f01-51c8-4f90-ab94-422d62c0bdf8" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1341cb6d-5d16-4047-a043-3ab0a3c9f582" xlink:to="loc_dei_DocumentTransitionReport_175d4f01-51c8-4f90-ab94-422d62c0bdf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_9bcce577-1d2c-441d-b9c0-1bbb139eb86e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1341cb6d-5d16-4047-a043-3ab0a3c9f582" xlink:to="loc_dei_EntityFileNumber_9bcce577-1d2c-441d-b9c0-1bbb139eb86e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_c4190347-b33d-468c-86ab-6a301060c285" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1341cb6d-5d16-4047-a043-3ab0a3c9f582" xlink:to="loc_dei_EntityRegistrantName_c4190347-b33d-468c-86ab-6a301060c285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_b06cca41-46f9-4cd0-9447-a675f3408e3c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1341cb6d-5d16-4047-a043-3ab0a3c9f582" xlink:to="loc_dei_EntityIncorporationStateCountryCode_b06cca41-46f9-4cd0-9447-a675f3408e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_500f506b-36de-4131-8a7f-c9ec52d95cbf" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1341cb6d-5d16-4047-a043-3ab0a3c9f582" xlink:to="loc_dei_EntityTaxIdentificationNumber_500f506b-36de-4131-8a7f-c9ec52d95cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_0b086fdd-45c9-4345-9aab-2cb1369c17ec" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1341cb6d-5d16-4047-a043-3ab0a3c9f582" xlink:to="loc_dei_EntityAddressAddressLine1_0b086fdd-45c9-4345-9aab-2cb1369c17ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_a7cce3a5-7aa7-47c1-a856-52503d73c0c3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1341cb6d-5d16-4047-a043-3ab0a3c9f582" xlink:to="loc_dei_EntityAddressAddressLine2_a7cce3a5-7aa7-47c1-a856-52503d73c0c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_83fe1cc1-7790-4e6d-b79f-c3beb4f1cac3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1341cb6d-5d16-4047-a043-3ab0a3c9f582" xlink:to="loc_dei_EntityAddressCityOrTown_83fe1cc1-7790-4e6d-b79f-c3beb4f1cac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_0fa0f896-cbff-4f3e-90e2-8429b706bacf" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1341cb6d-5d16-4047-a043-3ab0a3c9f582" xlink:to="loc_dei_EntityAddressStateOrProvince_0fa0f896-cbff-4f3e-90e2-8429b706bacf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_804dcfd9-1979-48e7-8298-b3d255f06875" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1341cb6d-5d16-4047-a043-3ab0a3c9f582" xlink:to="loc_dei_EntityAddressPostalZipCode_804dcfd9-1979-48e7-8298-b3d255f06875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_4bc32140-f920-4870-8448-f9dd7bdac636" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1341cb6d-5d16-4047-a043-3ab0a3c9f582" xlink:to="loc_dei_CityAreaCode_4bc32140-f920-4870-8448-f9dd7bdac636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_8729f2a2-45cc-4524-9532-7961727efc7d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1341cb6d-5d16-4047-a043-3ab0a3c9f582" xlink:to="loc_dei_LocalPhoneNumber_8729f2a2-45cc-4524-9532-7961727efc7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_a994c56d-744b-42b0-a6a5-ce0a81be7ab3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1341cb6d-5d16-4047-a043-3ab0a3c9f582" xlink:to="loc_dei_Security12bTitle_a994c56d-744b-42b0-a6a5-ce0a81be7ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_38720ddb-b40e-4830-9082-d33fd66a2dce" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1341cb6d-5d16-4047-a043-3ab0a3c9f582" xlink:to="loc_dei_TradingSymbol_38720ddb-b40e-4830-9082-d33fd66a2dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_d180451f-a214-40b4-9c50-89f4d529b955" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1341cb6d-5d16-4047-a043-3ab0a3c9f582" xlink:to="loc_dei_SecurityExchangeName_d180451f-a214-40b4-9c50-89f4d529b955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_c36b849f-467c-4693-91d8-72639fdfefbf" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1341cb6d-5d16-4047-a043-3ab0a3c9f582" xlink:to="loc_dei_EntityCurrentReportingStatus_c36b849f-467c-4693-91d8-72639fdfefbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_6d0eb96c-73d0-46e4-b06a-035fdb8351a1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1341cb6d-5d16-4047-a043-3ab0a3c9f582" xlink:to="loc_dei_EntityInteractiveDataCurrent_6d0eb96c-73d0-46e4-b06a-035fdb8351a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_4dfff119-ac6f-4215-89e0-bf245078d873" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1341cb6d-5d16-4047-a043-3ab0a3c9f582" xlink:to="loc_dei_EntityFilerCategory_4dfff119-ac6f-4215-89e0-bf245078d873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_9a6434fd-ad69-40fc-98e7-aaa8b2659a81" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1341cb6d-5d16-4047-a043-3ab0a3c9f582" xlink:to="loc_dei_EntitySmallBusiness_9a6434fd-ad69-40fc-98e7-aaa8b2659a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_83d9fb35-ef0f-4109-8f95-66a74e06f5e2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1341cb6d-5d16-4047-a043-3ab0a3c9f582" xlink:to="loc_dei_EntityEmergingGrowthCompany_83d9fb35-ef0f-4109-8f95-66a74e06f5e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_ae67f397-ec6e-4e21-985c-bfc7910b125c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1341cb6d-5d16-4047-a043-3ab0a3c9f582" xlink:to="loc_dei_EntityShellCompany_ae67f397-ec6e-4e21-985c-bfc7910b125c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_f7960cff-8204-4011-b9f1-2a80da8a182f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1341cb6d-5d16-4047-a043-3ab0a3c9f582" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_f7960cff-8204-4011-b9f1-2a80da8a182f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_da6f6b0c-e59f-487d-bb42-7be0a39ed984" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1341cb6d-5d16-4047-a043-3ab0a3c9f582" xlink:to="loc_dei_EntityCentralIndexKey_da6f6b0c-e59f-487d-bb42-7be0a39ed984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_8b15ce6e-0728-403d-9ad8-3935424d65b3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1341cb6d-5d16-4047-a043-3ab0a3c9f582" xlink:to="loc_dei_CurrentFiscalYearEndDate_8b15ce6e-0728-403d-9ad8-3935424d65b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_bc7897cc-50d7-4ace-9acc-716095a0267a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1341cb6d-5d16-4047-a043-3ab0a3c9f582" xlink:to="loc_dei_DocumentFiscalYearFocus_bc7897cc-50d7-4ace-9acc-716095a0267a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_e8efa5c0-6f21-41a0-926f-40bbc7263857" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1341cb6d-5d16-4047-a043-3ab0a3c9f582" xlink:to="loc_dei_DocumentFiscalPeriodFocus_e8efa5c0-6f21-41a0-926f-40bbc7263857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_c637d05e-869f-4d24-adf1-f00b4eb21640" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1341cb6d-5d16-4047-a043-3ab0a3c9f582" xlink:to="loc_dei_AmendmentFlag_c637d05e-869f-4d24-adf1-f00b4eb21640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="arwr-20250630.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_11547472-9a49-460b-9537-649a50aa9f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_a165bbba-c7a1-47fe-84e5-37a48227b843" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_11547472-9a49-460b-9537-649a50aa9f5c" xlink:to="loc_us-gaap_AssetsAbstract_a165bbba-c7a1-47fe-84e5-37a48227b843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_df5505c3-f84b-40b4-83cd-f4d4e242cd30" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a165bbba-c7a1-47fe-84e5-37a48227b843" xlink:to="loc_us-gaap_AssetsCurrentAbstract_df5505c3-f84b-40b4-83cd-f4d4e242cd30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7aadc09d-14da-4f05-a11c-42484e1fb605" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_df5505c3-f84b-40b4-83cd-f4d4e242cd30" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7aadc09d-14da-4f05-a11c-42484e1fb605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_86d6875f-1488-43af-89f2-c049677f10b0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_df5505c3-f84b-40b4-83cd-f4d4e242cd30" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_86d6875f-1488-43af-89f2-c049677f10b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_85d6eb52-96f0-413c-9362-adeec99dabb1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_df5505c3-f84b-40b4-83cd-f4d4e242cd30" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_85d6eb52-96f0-413c-9362-adeec99dabb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_da9cde13-f99f-4ed6-aaca-f34b464e5ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_df5505c3-f84b-40b4-83cd-f4d4e242cd30" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_da9cde13-f99f-4ed6-aaca-f34b464e5ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_d79c5aaf-f3eb-433e-ae48-33263821d0d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_df5505c3-f84b-40b4-83cd-f4d4e242cd30" xlink:to="loc_us-gaap_OtherAssetsCurrent_d79c5aaf-f3eb-433e-ae48-33263821d0d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e3ad0e88-157e-4253-aa28-19766052c331" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_df5505c3-f84b-40b4-83cd-f4d4e242cd30" xlink:to="loc_us-gaap_AssetsCurrent_e3ad0e88-157e-4253-aa28-19766052c331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8b2c0107-c0ab-4f47-a4d1-75df4f9e693f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a165bbba-c7a1-47fe-84e5-37a48227b843" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8b2c0107-c0ab-4f47-a4d1-75df4f9e693f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d9b0870a-8736-493f-9d72-9bc5ef77c6d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a165bbba-c7a1-47fe-84e5-37a48227b843" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d9b0870a-8736-493f-9d72-9bc5ef77c6d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_0fcb8652-4e8d-49d3-b493-a47426b18138" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a165bbba-c7a1-47fe-84e5-37a48227b843" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_0fcb8652-4e8d-49d3-b493-a47426b18138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_d0db0e90-c75c-49a0-9543-77e922a24031" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a165bbba-c7a1-47fe-84e5-37a48227b843" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_d0db0e90-c75c-49a0-9543-77e922a24031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_d650be1b-5220-4e5d-a962-ab55b52b8aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a165bbba-c7a1-47fe-84e5-37a48227b843" xlink:to="loc_us-gaap_Assets_d650be1b-5220-4e5d-a962-ab55b52b8aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bf581540-3b35-4301-a12e-993a2d44d467" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_11547472-9a49-460b-9537-649a50aa9f5c" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bf581540-3b35-4301-a12e-993a2d44d467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_ac4e401b-e058-4024-ad6c-d4ad155ae475" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bf581540-3b35-4301-a12e-993a2d44d467" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_ac4e401b-e058-4024-ad6c-d4ad155ae475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_3a0aa311-443e-45de-aafa-2f1bb44bf458" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ac4e401b-e058-4024-ad6c-d4ad155ae475" xlink:to="loc_us-gaap_AccountsPayableCurrent_3a0aa311-443e-45de-aafa-2f1bb44bf458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_4700c21f-4520-4585-b077-73f600faf091" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ac4e401b-e058-4024-ad6c-d4ad155ae475" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_4700c21f-4520-4585-b077-73f600faf091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a0f3b0ed-a85d-4dee-9f31-2a31055028c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ac4e401b-e058-4024-ad6c-d4ad155ae475" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a0f3b0ed-a85d-4dee-9f31-2a31055028c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_a28dd04c-5893-4398-a8d1-c28594c4b8da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ac4e401b-e058-4024-ad6c-d4ad155ae475" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_a28dd04c-5893-4398-a8d1-c28594c4b8da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2114e4d5-7af8-41b8-aa67-b293ec4b68b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ac4e401b-e058-4024-ad6c-d4ad155ae475" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2114e4d5-7af8-41b8-aa67-b293ec4b68b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LinesOfCreditCurrent_59aeeb74-7eea-437f-ba98-05b92335ba9f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LinesOfCreditCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ac4e401b-e058-4024-ad6c-d4ad155ae475" xlink:to="loc_us-gaap_LinesOfCreditCurrent_59aeeb74-7eea-437f-ba98-05b92335ba9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_7c981121-4c89-4392-a0fc-00612b8abcb9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ac4e401b-e058-4024-ad6c-d4ad155ae475" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_7c981121-4c89-4392-a0fc-00612b8abcb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_37adb547-86ec-4a30-aaf4-e7570455f5c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ac4e401b-e058-4024-ad6c-d4ad155ae475" xlink:to="loc_us-gaap_LiabilitiesCurrent_37adb547-86ec-4a30-aaf4-e7570455f5c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_451da2c0-40ea-4371-959c-968df0371a92" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bf581540-3b35-4301-a12e-993a2d44d467" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_451da2c0-40ea-4371-959c-968df0371a92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0871e5d1-41a0-4efe-947a-dd04671e9e71" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_451da2c0-40ea-4371-959c-968df0371a92" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0871e5d1-41a0-4efe-947a-dd04671e9e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltiesLiabilityNoncurrent_6fa2fa27-f3d2-43e3-a261-eddf40e86f74" xlink:href="arwr-20250630.xsd#arwr_RoyaltiesLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_451da2c0-40ea-4371-959c-968df0371a92" xlink:to="loc_arwr_RoyaltiesLiabilityNoncurrent_6fa2fa27-f3d2-43e3-a261-eddf40e86f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_ab571138-2f6d-4650-9968-850eebee7b71" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_451da2c0-40ea-4371-959c-968df0371a92" xlink:to="loc_us-gaap_LongTermLineOfCredit_ab571138-2f6d-4650-9968-850eebee7b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_005b0d21-d26f-42ac-85db-c64ecc4a3fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_451da2c0-40ea-4371-959c-968df0371a92" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_005b0d21-d26f-42ac-85db-c64ecc4a3fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_9715ca91-1048-4928-8bbd-6cce15b7a17e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bf581540-3b35-4301-a12e-993a2d44d467" xlink:to="loc_us-gaap_CommitmentsAndContingencies_9715ca91-1048-4928-8bbd-6cce15b7a17e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_799f8f01-1467-426f-ab48-a05c906f9f16" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bf581540-3b35-4301-a12e-993a2d44d467" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_799f8f01-1467-426f-ab48-a05c906f9f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_a0dbffc9-a757-461d-b5eb-34b6ec510a63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_799f8f01-1467-426f-ab48-a05c906f9f16" xlink:to="loc_us-gaap_CommonStockValue_a0dbffc9-a757-461d-b5eb-34b6ec510a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_a3b4c3d6-caa9-40a4-a679-c4b9c3602ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_799f8f01-1467-426f-ab48-a05c906f9f16" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_a3b4c3d6-caa9-40a4-a679-c4b9c3602ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a3a1b3fc-e8be-48a3-88e9-9d3b3e19dfb8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_799f8f01-1467-426f-ab48-a05c906f9f16" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a3a1b3fc-e8be-48a3-88e9-9d3b3e19dfb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5bcca150-c8c3-4997-baf3-14fa8d09fea2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_799f8f01-1467-426f-ab48-a05c906f9f16" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5bcca150-c8c3-4997-baf3-14fa8d09fea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a010ca7a-8362-4d8d-84b1-d4661f83342b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_799f8f01-1467-426f-ab48-a05c906f9f16" xlink:to="loc_us-gaap_StockholdersEquity_a010ca7a-8362-4d8d-84b1-d4661f83342b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_dffbbf60-ceb3-4557-9012-56e6e6453937" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_799f8f01-1467-426f-ab48-a05c906f9f16" xlink:to="loc_us-gaap_MinorityInterest_dffbbf60-ceb3-4557-9012-56e6e6453937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_52802c9c-c8a4-4dd6-9519-f530c4c562b0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_799f8f01-1467-426f-ab48-a05c906f9f16" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_52802c9c-c8a4-4dd6-9519-f530c4c562b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_b9183166-94c2-46c7-9bfb-ebfa957f8352" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bf581540-3b35-4301-a12e-993a2d44d467" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_b9183166-94c2-46c7-9bfb-ebfa957f8352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="arwr-20250630.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_3fe40ba1-e870-4fb6-a5ca-9c696a45a2bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_12ece2b5-8333-4d68-af4b-cd8b4189e446" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3fe40ba1-e870-4fb6-a5ca-9c696a45a2bf" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_12ece2b5-8333-4d68-af4b-cd8b4189e446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_6a76ce0e-0742-4cc9-a5e9-7639fbf9585c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3fe40ba1-e870-4fb6-a5ca-9c696a45a2bf" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_6a76ce0e-0742-4cc9-a5e9-7639fbf9585c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_a7d2361b-94fc-40b8-959c-7a434519e61a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3fe40ba1-e870-4fb6-a5ca-9c696a45a2bf" xlink:to="loc_us-gaap_CommonStockSharesIssued_a7d2361b-94fc-40b8-959c-7a434519e61a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_715ffeb6-3651-4529-98e1-3fe8e722a9ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3fe40ba1-e870-4fb6-a5ca-9c696a45a2bf" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_715ffeb6-3651-4529-98e1-3fe8e722a9ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome" xlink:type="simple" xlink:href="arwr-20250630.xsd#ConsolidatedStatementsofOperationsandComprehensiveLossIncome"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_2fe40d40-9844-4e3d-b2fa-27a263bb83bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b1658cf7-dbb3-41dc-85d4-ccd2de3ec1d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2fe40d40-9844-4e3d-b2fa-27a263bb83bd" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b1658cf7-dbb3-41dc-85d4-ccd2de3ec1d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_c1199486-ccca-440f-a1a9-6882a62b6639" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2fe40d40-9844-4e3d-b2fa-27a263bb83bd" xlink:to="loc_us-gaap_OperatingExpensesAbstract_c1199486-ccca-440f-a1a9-6882a62b6639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_5a7bb509-9d74-406f-9eba-80da7b9d14fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c1199486-ccca-440f-a1a9-6882a62b6639" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_5a7bb509-9d74-406f-9eba-80da7b9d14fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_6d53aca1-b2a3-4641-8b71-1e65b8865576" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c1199486-ccca-440f-a1a9-6882a62b6639" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_6d53aca1-b2a3-4641-8b71-1e65b8865576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_cd8d68e8-4901-487a-9f8e-d2426d043da7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c1199486-ccca-440f-a1a9-6882a62b6639" xlink:to="loc_us-gaap_OperatingExpenses_cd8d68e8-4901-487a-9f8e-d2426d043da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2b6f42de-fbab-4e27-b34a-0dcb10446eab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2fe40d40-9844-4e3d-b2fa-27a263bb83bd" xlink:to="loc_us-gaap_OperatingIncomeLoss_2b6f42de-fbab-4e27-b34a-0dcb10446eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_00c7d03c-ebee-4a05-a854-8e470b24a781" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2fe40d40-9844-4e3d-b2fa-27a263bb83bd" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_00c7d03c-ebee-4a05-a854-8e470b24a781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_491a1b40-0c03-4dba-89ba-8231b37f9c26" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_00c7d03c-ebee-4a05-a854-8e470b24a781" xlink:to="loc_us-gaap_InvestmentIncomeInterestAndDividend_491a1b40-0c03-4dba-89ba-8231b37f9c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_f22f259e-052c-434e-b2bc-9b7275051b93" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_00c7d03c-ebee-4a05-a854-8e470b24a781" xlink:to="loc_us-gaap_InterestExpenseNonoperating_f22f259e-052c-434e-b2bc-9b7275051b93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_6cf427a8-2ed5-404d-b2ec-3caf9772071e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_00c7d03c-ebee-4a05-a854-8e470b24a781" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_6cf427a8-2ed5-404d-b2ec-3caf9772071e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_a176510f-75e4-496e-af06-9b88788dda5c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_00c7d03c-ebee-4a05-a854-8e470b24a781" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_a176510f-75e4-496e-af06-9b88788dda5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7efe3bed-bcdb-42cd-b981-b2bc32099072" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2fe40d40-9844-4e3d-b2fa-27a263bb83bd" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7efe3bed-bcdb-42cd-b981-b2bc32099072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_af5f6f7c-8007-4d26-bbc9-dd4fdc3e6053" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2fe40d40-9844-4e3d-b2fa-27a263bb83bd" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_af5f6f7c-8007-4d26-bbc9-dd4fdc3e6053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_81d75582-d8b1-4bb8-a4d9-6b6df921d262" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2fe40d40-9844-4e3d-b2fa-27a263bb83bd" xlink:to="loc_us-gaap_ProfitLoss_81d75582-d8b1-4bb8-a4d9-6b6df921d262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_fa391596-9bfa-4d6b-9a87-7aabceddda57" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2fe40d40-9844-4e3d-b2fa-27a263bb83bd" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_fa391596-9bfa-4d6b-9a87-7aabceddda57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_700d8416-54af-4e2d-9822-605ca84009e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2fe40d40-9844-4e3d-b2fa-27a263bb83bd" xlink:to="loc_us-gaap_NetIncomeLoss_700d8416-54af-4e2d-9822-605ca84009e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_c9b5e656-437a-4ffc-9230-ec8e2daeff77" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2fe40d40-9844-4e3d-b2fa-27a263bb83bd" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_c9b5e656-437a-4ffc-9230-ec8e2daeff77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_a75c34c2-239a-42a5-9598-25d5a5560c93" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_c9b5e656-437a-4ffc-9230-ec8e2daeff77" xlink:to="loc_us-gaap_EarningsPerShareBasic_a75c34c2-239a-42a5-9598-25d5a5560c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_0dbc799f-ae43-4443-8154-b80c9b4424ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_c9b5e656-437a-4ffc-9230-ec8e2daeff77" xlink:to="loc_us-gaap_EarningsPerShareDiluted_0dbc799f-ae43-4443-8154-b80c9b4424ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_8839be32-f6b6-45d5-bb71-0993aaa31064" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2fe40d40-9844-4e3d-b2fa-27a263bb83bd" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_8839be32-f6b6-45d5-bb71-0993aaa31064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_25d8ab55-de40-47cd-a1b5-7c25ec7c7dda" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_8839be32-f6b6-45d5-bb71-0993aaa31064" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_25d8ab55-de40-47cd-a1b5-7c25ec7c7dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f22816e2-c85f-4d51-98a4-ab7b1672e5c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_8839be32-f6b6-45d5-bb71-0993aaa31064" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f22816e2-c85f-4d51-98a4-ab7b1672e5c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_3ed78661-5328-43f6-a2f5-313cd64c2dee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2fe40d40-9844-4e3d-b2fa-27a263bb83bd" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_3ed78661-5328-43f6-a2f5-313cd64c2dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_24ee7fe5-1e79-4a1d-98c5-7bdbefc94684" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_3ed78661-5328-43f6-a2f5-313cd64c2dee" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_24ee7fe5-1e79-4a1d-98c5-7bdbefc94684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_845f04f3-ebf1-417e-858d-6f8bf4792b35" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_3ed78661-5328-43f6-a2f5-313cd64c2dee" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_845f04f3-ebf1-417e-858d-6f8bf4792b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c9b57a06-25e5-4eed-ad4c-94acd7080687" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_3ed78661-5328-43f6-a2f5-313cd64c2dee" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c9b57a06-25e5-4eed-ad4c-94acd7080687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="arwr-20250630.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_358d9b10-0a1e-4a14-afd1-e779b5e9d433" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_32423226-1e5d-47de-ac9b-201e9eca7e12" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_358d9b10-0a1e-4a14-afd1-e779b5e9d433" xlink:to="loc_us-gaap_StatementTable_32423226-1e5d-47de-ac9b-201e9eca7e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_cc9c3636-edcb-4bab-8eca-d582f57e995c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_32423226-1e5d-47de-ac9b-201e9eca7e12" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_cc9c3636-edcb-4bab-8eca-d582f57e995c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9450d397-e5ee-4e7b-b8f4-cfb4adf81794" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_cc9c3636-edcb-4bab-8eca-d582f57e995c" xlink:to="loc_us-gaap_EquityComponentDomain_9450d397-e5ee-4e7b-b8f4-cfb4adf81794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e845a83f-b33e-4e5c-bcef-24a02bf0a83d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9450d397-e5ee-4e7b-b8f4-cfb4adf81794" xlink:to="loc_us-gaap_CommonStockMember_e845a83f-b33e-4e5c-bcef-24a02bf0a83d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_9a383139-6f3c-4806-bd69-89b3e20a4624" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9450d397-e5ee-4e7b-b8f4-cfb4adf81794" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_9a383139-6f3c-4806-bd69-89b3e20a4624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4ae5f614-5930-461d-b7dd-a45527e0fd7e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9450d397-e5ee-4e7b-b8f4-cfb4adf81794" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4ae5f614-5930-461d-b7dd-a45527e0fd7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_19251b3a-c5f6-4e27-a9c9-f4da1d8c3c88" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9450d397-e5ee-4e7b-b8f4-cfb4adf81794" xlink:to="loc_us-gaap_RetainedEarningsMember_19251b3a-c5f6-4e27-a9c9-f4da1d8c3c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_a1a467d5-7ab9-46e6-a76b-628df9f5d6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9450d397-e5ee-4e7b-b8f4-cfb4adf81794" xlink:to="loc_us-gaap_NoncontrollingInterestMember_a1a467d5-7ab9-46e6-a76b-628df9f5d6cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c1a25946-38ea-48c7-83f4-bfa5b6e32ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_32423226-1e5d-47de-ac9b-201e9eca7e12" xlink:to="loc_us-gaap_StatementLineItems_c1a25946-38ea-48c7-83f4-bfa5b6e32ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b20136-6874-4a1c-b75e-02cf9f14a003" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c1a25946-38ea-48c7-83f4-bfa5b6e32ed1" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b20136-6874-4a1c-b75e-02cf9f14a003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_dbc6e062-adce-47e4-af55-1e9a9be9bf38" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b20136-6874-4a1c-b75e-02cf9f14a003" xlink:to="loc_us-gaap_SharesOutstanding_dbc6e062-adce-47e4-af55-1e9a9be9bf38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b922f40c-728b-47b9-9284-c694614d224a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b20136-6874-4a1c-b75e-02cf9f14a003" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b922f40c-728b-47b9-9284-c694614d224a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f141ec3c-db24-446c-b9f5-c0bda45f041e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b20136-6874-4a1c-b75e-02cf9f14a003" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f141ec3c-db24-446c-b9f5-c0bda45f041e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2ae60199-1017-4e87-b768-51ce111e15ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b20136-6874-4a1c-b75e-02cf9f14a003" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2ae60199-1017-4e87-b768-51ce111e15ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_19389908-5838-4053-8d20-016d9bd4eab5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b20136-6874-4a1c-b75e-02cf9f14a003" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_19389908-5838-4053-8d20-016d9bd4eab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_ecd4d009-e451-4916-aa13-c6c15f22d65b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b20136-6874-4a1c-b75e-02cf9f14a003" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_ecd4d009-e451-4916-aa13-c6c15f22d65b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_482472a7-8187-4548-a76f-a05ca62679c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b20136-6874-4a1c-b75e-02cf9f14a003" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_482472a7-8187-4548-a76f-a05ca62679c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1fa7f699-c202-40af-b486-265fdc4593cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b20136-6874-4a1c-b75e-02cf9f14a003" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1fa7f699-c202-40af-b486-265fdc4593cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_d4b0cc1d-d62f-4ced-9d20-cac3b41f027c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b20136-6874-4a1c-b75e-02cf9f14a003" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_d4b0cc1d-d62f-4ced-9d20-cac3b41f027c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_5db64e62-ef72-4a18-861e-a8aae52576ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b20136-6874-4a1c-b75e-02cf9f14a003" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_5db64e62-ef72-4a18-861e-a8aae52576ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_ff977e88-58e3-41de-af51-ffa7a8afbcee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b20136-6874-4a1c-b75e-02cf9f14a003" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_ff977e88-58e3-41de-af51-ffa7a8afbcee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1226b53b-1dbf-4b17-a11b-7513e9401eba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b20136-6874-4a1c-b75e-02cf9f14a003" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1226b53b-1dbf-4b17-a11b-7513e9401eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_5cea7593-6079-4b36-a9f0-b9c2734738df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b20136-6874-4a1c-b75e-02cf9f14a003" xlink:to="loc_us-gaap_ProfitLoss_5cea7593-6079-4b36-a9f0-b9c2734738df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_4d4dc9e5-69d4-4a0e-bf2f-4b92ce2d3aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b20136-6874-4a1c-b75e-02cf9f14a003" xlink:to="loc_us-gaap_SharesOutstanding_4d4dc9e5-69d4-4a0e-bf2f-4b92ce2d3aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0372c92d-3060-4978-9f12-4aab1b23c727" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_48b20136-6874-4a1c-b75e-02cf9f14a003" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0372c92d-3060-4978-9f12-4aab1b23c727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="arwr-20250630.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_8efdf477-8d7b-414f-8878-7c65e38b0dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2d5ed4d9-70e8-4b64-a81a-c467815f65cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8efdf477-8d7b-414f-8878-7c65e38b0dd2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2d5ed4d9-70e8-4b64-a81a-c467815f65cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1fabe579-4998-4b2d-85bd-8be76073938b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2d5ed4d9-70e8-4b64-a81a-c467815f65cd" xlink:to="loc_us-gaap_ProfitLoss_1fabe579-4998-4b2d-85bd-8be76073938b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_28a2b175-868f-41a6-99c1-59b8d5dcf65a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2d5ed4d9-70e8-4b64-a81a-c467815f65cd" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_28a2b175-868f-41a6-99c1-59b8d5dcf65a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_87d45d46-b195-4ced-9294-66910718c413" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_28a2b175-868f-41a6-99c1-59b8d5dcf65a" xlink:to="loc_us-gaap_ShareBasedCompensation_87d45d46-b195-4ced-9294-66910718c413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_cb808731-1b81-4816-84cf-dd27a50fe8ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_28a2b175-868f-41a6-99c1-59b8d5dcf65a" xlink:to="loc_us-gaap_DepreciationAndAmortization_cb808731-1b81-4816-84cf-dd27a50fe8ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_38d7cf92-6800-4c7d-934c-032cfb137afc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_28a2b175-868f-41a6-99c1-59b8d5dcf65a" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_38d7cf92-6800-4c7d-934c-032cfb137afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_12dc3f9c-0e61-4198-a213-8f54f778356e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_28a2b175-868f-41a6-99c1-59b8d5dcf65a" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_12dc3f9c-0e61-4198-a213-8f54f778356e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_f0b2a7ff-6b5c-49f8-af2a-8772476f863a" xlink:href="arwr-20250630.xsd#arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_28a2b175-868f-41a6-99c1-59b8d5dcf65a" xlink:to="loc_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_f0b2a7ff-6b5c-49f8-af2a-8772476f863a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_5ee2c8c3-262d-4c3f-9c77-b0eae2579fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaidInKindInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_28a2b175-868f-41a6-99c1-59b8d5dcf65a" xlink:to="loc_us-gaap_PaidInKindInterest_5ee2c8c3-262d-4c3f-9c77-b0eae2579fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_728c9c09-05dc-4cd1-b8f1-da2aea804a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2d5ed4d9-70e8-4b64-a81a-c467815f65cd" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_728c9c09-05dc-4cd1-b8f1-da2aea804a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_64290f19-baee-4374-8c21-ecaf567e2d90" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_728c9c09-05dc-4cd1-b8f1-da2aea804a5b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_64290f19-baee-4374-8c21-ecaf567e2d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c424c202-e747-43d4-9cb4-a2ad6be33208" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_728c9c09-05dc-4cd1-b8f1-da2aea804a5b" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c424c202-e747-43d4-9cb4-a2ad6be33208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_705b5ddd-6069-4def-9e2b-d503bd4b0bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_728c9c09-05dc-4cd1-b8f1-da2aea804a5b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_705b5ddd-6069-4def-9e2b-d503bd4b0bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1ab00e9d-640d-4546-b7bd-0ac24b4cc78d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_728c9c09-05dc-4cd1-b8f1-da2aea804a5b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1ab00e9d-640d-4546-b7bd-0ac24b4cc78d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_d4a10989-6204-4668-8874-9c1f3b6c23eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_728c9c09-05dc-4cd1-b8f1-da2aea804a5b" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_d4a10989-6204-4668-8874-9c1f3b6c23eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_6840c9af-3aaa-45a0-a1c4-4c36d022d83d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_728c9c09-05dc-4cd1-b8f1-da2aea804a5b" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_6840c9af-3aaa-45a0-a1c4-4c36d022d83d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_deca1c6a-06e1-452e-ba04-ee61496955ff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_728c9c09-05dc-4cd1-b8f1-da2aea804a5b" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_deca1c6a-06e1-452e-ba04-ee61496955ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eb8db196-3ab9-4cc5-bb82-02162948c3d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2d5ed4d9-70e8-4b64-a81a-c467815f65cd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eb8db196-3ab9-4cc5-bb82-02162948c3d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_759b5d6f-301b-43bf-9a04-a9b8bafebf63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8efdf477-8d7b-414f-8878-7c65e38b0dd2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_759b5d6f-301b-43bf-9a04-a9b8bafebf63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a4a56790-a100-4ff2-aa7e-3aef4a8ba388" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_759b5d6f-301b-43bf-9a04-a9b8bafebf63" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a4a56790-a100-4ff2-aa7e-3aef4a8ba388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_3afd1127-056f-4ded-97e8-8312444d7285" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_759b5d6f-301b-43bf-9a04-a9b8bafebf63" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_3afd1127-056f-4ded-97e8-8312444d7285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_bb899f56-06ee-41e2-87f8-e987a88899bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_759b5d6f-301b-43bf-9a04-a9b8bafebf63" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_bb899f56-06ee-41e2-87f8-e987a88899bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0e896f21-b0d2-421f-a80e-85edc836b898" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_759b5d6f-301b-43bf-9a04-a9b8bafebf63" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0e896f21-b0d2-421f-a80e-85edc836b898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_da891896-957f-4130-9097-ab735827ac15" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8efdf477-8d7b-414f-8878-7c65e38b0dd2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_da891896-957f-4130-9097-ab735827ac15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_825df27b-f4ab-4d52-a3c8-2e06c3889f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_da891896-957f-4130-9097-ab735827ac15" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_825df27b-f4ab-4d52-a3c8-2e06c3889f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_93807031-f59b-4606-ae75-b37a79216363" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_da891896-957f-4130-9097-ab735827ac15" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_93807031-f59b-4606-ae75-b37a79216363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ProceedsFromSaleOfFutureRoyalties_f2d0abde-ee57-4c8c-9e04-ec8a5c1cdbee" xlink:href="arwr-20250630.xsd#arwr_ProceedsFromSaleOfFutureRoyalties"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_da891896-957f-4130-9097-ab735827ac15" xlink:to="loc_arwr_ProceedsFromSaleOfFutureRoyalties_f2d0abde-ee57-4c8c-9e04-ec8a5c1cdbee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_5fe91ac0-b44e-4cf5-8627-7a9443000138" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_da891896-957f-4130-9097-ab735827ac15" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_5fe91ac0-b44e-4cf5-8627-7a9443000138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_87f003d5-2cad-409b-8b9e-7db18bdaefbd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_da891896-957f-4130-9097-ab735827ac15" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_87f003d5-2cad-409b-8b9e-7db18bdaefbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_d33ca2d0-a63b-4ad3-93fc-ea9a23e1e6f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_da891896-957f-4130-9097-ab735827ac15" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_d33ca2d0-a63b-4ad3-93fc-ea9a23e1e6f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_b0c5cc29-0eb6-44b3-940c-ba2d97126276" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_da891896-957f-4130-9097-ab735827ac15" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_b0c5cc29-0eb6-44b3-940c-ba2d97126276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7cd657f8-19ac-4227-90c3-9d2a2e4f6769" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_da891896-957f-4130-9097-ab735827ac15" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7cd657f8-19ac-4227-90c3-9d2a2e4f6769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_047b9ddd-6192-4dac-b1b6-22c1e4a0875d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8efdf477-8d7b-414f-8878-7c65e38b0dd2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_047b9ddd-6192-4dac-b1b6-22c1e4a0875d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d98d054f-e9a0-497e-a860-eec9aebf4f12" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8efdf477-8d7b-414f-8878-7c65e38b0dd2" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d98d054f-e9a0-497e-a860-eec9aebf4f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_dea777e3-514b-4120-885e-8a78d3302712" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8efdf477-8d7b-414f-8878-7c65e38b0dd2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_dea777e3-514b-4120-885e-8a78d3302712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_98b88736-dc1f-416d-8465-2860199955c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_dea777e3-514b-4120-885e-8a78d3302712" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_98b88736-dc1f-416d-8465-2860199955c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_887bc426-b6ab-4c8c-938d-4ccdf3e88e90" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_dea777e3-514b-4120-885e-8a78d3302712" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_887bc426-b6ab-4c8c-938d-4ccdf3e88e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_62f4edcd-388b-46b2-bc76-9ac210ed5461" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8efdf477-8d7b-414f-8878-7c65e38b0dd2" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_62f4edcd-388b-46b2-bc76-9ac210ed5461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_b739490e-5a6b-433c-a304-0bc4d0fb6941" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_62f4edcd-388b-46b2-bc76-9ac210ed5461" xlink:to="loc_us-gaap_InterestPaidNet_b739490e-5a6b-433c-a304-0bc4d0fb6941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_0bcd48c7-3863-499c-a486-58c32a9d97ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_62f4edcd-388b-46b2-bc76-9ac210ed5461" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_0bcd48c7-3863-499c-a486-58c32a9d97ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashFlowNoncashInvestingActivitiesDisclosureAbstract_7fcfd38f-93d7-4eb3-976b-499a85d57e57" xlink:href="arwr-20250630.xsd#arwr_CashFlowNoncashInvestingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8efdf477-8d7b-414f-8878-7c65e38b0dd2" xlink:to="loc_arwr_CashFlowNoncashInvestingActivitiesDisclosureAbstract_7fcfd38f-93d7-4eb3-976b-499a85d57e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_c7387a9f-c78b-4eb8-8971-a7fcef5086f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_CashFlowNoncashInvestingActivitiesDisclosureAbstract_7fcfd38f-93d7-4eb3-976b-499a85d57e57" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_c7387a9f-c78b-4eb8-8971-a7fcef5086f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies" xlink:type="simple" xlink:href="arwr-20250630.xsd#OrganizationandSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_808cd769-fa4f-43cb-a4d2-1189e44cbd84" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_77b5d4ed-f99b-481d-bed8-f081bfc4138b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_808cd769-fa4f-43cb-a4d2-1189e44cbd84" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_77b5d4ed-f99b-481d-bed8-f081bfc4138b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreements" xlink:type="simple" xlink:href="arwr-20250630.xsd#CollaborationandLicenseAgreements"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementsAbstract_c8b9a6af-72fb-4e3b-a8d7-c5992370a95d" xlink:href="arwr-20250630.xsd#arwr_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_4d0c2d4e-9c31-4b73-975f-eec6f95e56dc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_CollaborationAndLicenseAgreementsAbstract_c8b9a6af-72fb-4e3b-a8d7-c5992370a95d" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_4d0c2d4e-9c31-4b73-975f-eec6f95e56dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/BalanceSheetAccounts" xlink:type="simple" xlink:href="arwr-20250630.xsd#BalanceSheetAccounts"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/BalanceSheetAccounts" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ca2821a8-f8d1-4490-a84f-4f4794be22be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_4693ebb5-a54f-4c4d-92ba-249bfdb7f18c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ca2821a8-f8d1-4490-a84f-4f4794be22be" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_4693ebb5-a54f-4c4d-92ba-249bfdb7f18c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/Investments" xlink:type="simple" xlink:href="arwr-20250630.xsd#Investments"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/Investments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3dd1aee6-6f37-47ff-9bd0-b227f326fb69" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_b7977516-d183-46da-882e-105e2dfa5dca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3dd1aee6-6f37-47ff-9bd0-b227f326fb69" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_b7977516-d183-46da-882e-105e2dfa5dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IntangibleAssets" xlink:type="simple" xlink:href="arwr-20250630.xsd#IntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_277729c3-045e-4152-8a4c-f7822a42099f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_e8a1b140-2bd0-453e-9f8d-62cad5030e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_277729c3-045e-4152-8a4c-f7822a42099f" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_e8a1b140-2bd0-453e-9f8d-62cad5030e8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockholdersEquity" xlink:type="simple" xlink:href="arwr-20250630.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_84da02b1-9427-4567-8886-bff5b158c575" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_336fa332-9ee3-43e5-9602-22d6b1076e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_84da02b1-9427-4567-8886-bff5b158c575" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_336fa332-9ee3-43e5-9602-22d6b1076e4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="arwr-20250630.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1edb97e4-a11f-42d1-afd3-c963919ae93c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a873c954-ad27-4640-8eb9-ef549e92a233" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1edb97e4-a11f-42d1-afd3-c963919ae93c" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a873c954-ad27-4640-8eb9-ef549e92a233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/Leases" xlink:type="simple" xlink:href="arwr-20250630.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_0fe1c97e-84fc-4c26-961a-ef4039a9fe2f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_7681d322-eaf0-4840-8916-438a9a8f31b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0fe1c97e-84fc-4c26-961a-ef4039a9fe2f" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_7681d322-eaf0-4840-8916-438a9a8f31b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="arwr-20250630.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_01103519-8ea3-4450-ab87-a8323929d90c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9a3b0696-a4a1-466e-ac64-43a0208ea7cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_01103519-8ea3-4450-ab87-a8323929d90c" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9a3b0696-a4a1-466e-ac64-43a0208ea7cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="arwr-20250630.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_21a51a30-b072-4bfb-8525-7305db9c3500" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_10f5838e-8dd5-4048-8f95-8e6269069fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_21a51a30-b072-4bfb-8525-7305db9c3500" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_10f5838e-8dd5-4048-8f95-8e6269069fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyalties" xlink:type="simple" xlink:href="arwr-20250630.xsd#LiabilityRelatedtotheSaleofFutureRoyalties"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyalties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract_b9da61da-7e5e-4e66-b534-13a8ddd915cd" xlink:href="arwr-20250630.xsd#arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock_c0538a1b-c97f-4cd5-83f3-1714726a617d" xlink:href="arwr-20250630.xsd#arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract_b9da61da-7e5e-4e66-b534-13a8ddd915cd" xlink:to="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock_c0538a1b-c97f-4cd5-83f3-1714726a617d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FinancingAgreement" xlink:type="simple" xlink:href="arwr-20250630.xsd#FinancingAgreement"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/FinancingAgreement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ab2c11c9-b542-4aed-9b43-8f3055dff877" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock_4b2041df-22ef-4d0b-9fc0-40478861fcad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ab2c11c9-b542-4aed-9b43-8f3055dff877" xlink:to="loc_us-gaap_LongTermDebtTextBlock_4b2041df-22ef-4d0b-9fc0-40478861fcad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/NetLossIncomePerShare" xlink:type="simple" xlink:href="arwr-20250630.xsd#NetLossIncomePerShare"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/NetLossIncomePerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5097ec6a-7d6a-416a-9be2-36ec3bf7be9d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_3016a84e-bfa4-4c73-aa2d-1195807031e9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5097ec6a-7d6a-416a-9be2-36ec3bf7be9d" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_3016a84e-bfa4-4c73-aa2d-1195807031e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IncomeTaxes" xlink:type="simple" xlink:href="arwr-20250630.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7ba39e33-e59b-458d-a399-a27b9677b746" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_0fdbf40b-277b-4cb2-bb62-3a08788eb8cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7ba39e33-e59b-458d-a399-a27b9677b746" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_0fdbf40b-277b-4cb2-bb62-3a08788eb8cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/SubsequentEvents" xlink:type="simple" xlink:href="arwr-20250630.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_94b3e416-bd9c-4a51-9556-4604d60b5e94" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1e4ac1e8-e6f4-4c29-9286-09903ecec0f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_94b3e416-bd9c-4a51-9556-4604d60b5e94" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_1e4ac1e8-e6f4-4c29-9286-09903ecec0f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="arwr-20250630.xsd#OrganizationandSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d2c56cc2-9e97-4133-93c5-7a794dae4188" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_c01b71ef-531c-40bf-87dd-e0178372f835" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d2c56cc2-9e97-4133-93c5-7a794dae4188" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_c01b71ef-531c-40bf-87dd-e0178372f835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="arwr-20250630.xsd#OrganizationandSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_35734b95-cf6b-403f-8ea6-6b38804ec1af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfCurrentProductsTableTextBlock_8751491f-40b1-4b41-af61-c76236129151" xlink:href="arwr-20250630.xsd#arwr_ScheduleOfCurrentProductsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_35734b95-cf6b-403f-8ea6-6b38804ec1af" xlink:to="loc_arwr_ScheduleOfCurrentProductsTableTextBlock_8751491f-40b1-4b41-af61-c76236129151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTables" xlink:type="simple" xlink:href="arwr-20250630.xsd#CollaborationandLicenseAgreementsTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementsAbstract_2fd0fe8f-cd8a-40ec-85e1-3ec4809710f1" xlink:href="arwr-20250630.xsd#arwr_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_f821e584-b48c-43aa-91cc-b611387a5ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_CollaborationAndLicenseAgreementsAbstract_2fd0fe8f-cd8a-40ec-85e1-3ec4809710f1" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_f821e584-b48c-43aa-91cc-b611387a5ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_acc9b4e1-03a2-42a8-9fb6-e0fccbf6e022" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_CollaborationAndLicenseAgreementsAbstract_2fd0fe8f-cd8a-40ec-85e1-3ec4809710f1" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_acc9b4e1-03a2-42a8-9fb6-e0fccbf6e022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_ea6c0998-dcef-4fb1-a59a-ef9ebdc6ca74" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_CollaborationAndLicenseAgreementsAbstract_2fd0fe8f-cd8a-40ec-85e1-3ec4809710f1" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_ea6c0998-dcef-4fb1-a59a-ef9ebdc6ca74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/BalanceSheetAccountsTables" xlink:type="simple" xlink:href="arwr-20250630.xsd#BalanceSheetAccountsTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/BalanceSheetAccountsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a6607044-ed1e-4821-aff8-fec4d1289951" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_f62dcfb1-7e18-4fe0-b825-97cbaa7f0280" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a6607044-ed1e-4821-aff8-fec4d1289951" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_f62dcfb1-7e18-4fe0-b825-97cbaa7f0280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_2698c468-cca9-408e-be76-9f5f7bebda87" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a6607044-ed1e-4821-aff8-fec4d1289951" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_2698c468-cca9-408e-be76-9f5f7bebda87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/InvestmentsTables" xlink:type="simple" xlink:href="arwr-20250630.xsd#InvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/InvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_40e5666f-7013-4ad3-bbce-86d80f1efbb2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock_8f90c0a3-18d0-4c94-a7cc-f38f0d6bb1db" xlink:href="arwr-20250630.xsd#arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_40e5666f-7013-4ad3-bbce-86d80f1efbb2" xlink:to="loc_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock_8f90c0a3-18d0-4c94-a7cc-f38f0d6bb1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_16437bf8-c37f-4ff0-a2e5-cd18ad99b0e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_40e5666f-7013-4ad3-bbce-86d80f1efbb2" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_16437bf8-c37f-4ff0-a2e5-cd18ad99b0e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsTables" xlink:type="simple" xlink:href="arwr-20250630.xsd#IntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f6f76306-f95c-49d2-b777-a8b45f42ace2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_f4ae8d70-2441-40c3-9857-b6230608b904" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f6f76306-f95c-49d2-b777-a8b45f42ace2" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_f4ae8d70-2441-40c3-9857-b6230608b904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_d9329671-d449-4f93-8a95-c262abde2fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f6f76306-f95c-49d2-b777-a8b45f42ace2" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_d9329671-d449-4f93-8a95-c262abde2fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="arwr-20250630.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_2e82ebf8-32a1-40ab-b825-0456e111eddb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_ea078404-a4a5-43c8-839b-4c95752fac91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2e82ebf8-32a1-40ab-b825-0456e111eddb" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_ea078404-a4a5-43c8-839b-4c95752fac91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesTables" xlink:type="simple" xlink:href="arwr-20250630.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d3de5cb6-be1b-418e-9eb2-c0e3947b0e04" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_ab1c16ba-c6ec-4b09-85b4-10903ef03b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d3de5cb6-be1b-418e-9eb2-c0e3947b0e04" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_ab1c16ba-c6ec-4b09-85b4-10903ef03b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_e8829183-bb1c-49cc-ae1c-310f35853fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d3de5cb6-be1b-418e-9eb2-c0e3947b0e04" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_e8829183-bb1c-49cc-ae1c-310f35853fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="arwr-20250630.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a1505d9e-723f-4566-84b8-0513577a13df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_dcf8bc85-34e6-473c-a68b-7a65fc35be75" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a1505d9e-723f-4566-84b8-0513577a13df" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_dcf8bc85-34e6-473c-a68b-7a65fc35be75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_8e56cbcb-9d0d-4d8b-818b-96d7f899e5dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a1505d9e-723f-4566-84b8-0513577a13df" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_8e56cbcb-9d0d-4d8b-818b-96d7f899e5dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7ef5b7dc-60bd-4d20-828a-61375d79aae9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a1505d9e-723f-4566-84b8-0513577a13df" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7ef5b7dc-60bd-4d20-828a-61375d79aae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_795d94ff-d004-4d7d-b61d-64748104a450" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a1505d9e-723f-4566-84b8-0513577a13df" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_795d94ff-d004-4d7d-b61d-64748104a450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="arwr-20250630.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4ebd8c99-56fc-409b-b84d-2cb471a6d54e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_8756a7ab-88a3-431d-8c51-aca2a833a629" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4ebd8c99-56fc-409b-b84d-2cb471a6d54e" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_8756a7ab-88a3-431d-8c51-aca2a833a629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesTables" xlink:type="simple" xlink:href="arwr-20250630.xsd#LiabilityRelatedtotheSaleofFutureRoyaltiesTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract_37050238-179a-457f-b24c-561da364ec86" xlink:href="arwr-20250630.xsd#arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock_0302898b-4679-4039-bbec-3bad6756761b" xlink:href="arwr-20250630.xsd#arwr_ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract_37050238-179a-457f-b24c-561da364ec86" xlink:to="loc_arwr_ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock_0302898b-4679-4039-bbec-3bad6756761b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FinancingAgreementTables" xlink:type="simple" xlink:href="arwr-20250630.xsd#FinancingAgreementTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/FinancingAgreementTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_71f0cc45-9cb5-40b6-b263-17075e46dcff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_8ab57cad-f241-426f-ab7b-39f57d8436cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_71f0cc45-9cb5-40b6-b263-17075e46dcff" xlink:to="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_8ab57cad-f241-426f-ab7b-39f57d8436cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SummaryOfInterestExpenseRecognizedRelatedToCreditFacilityTableTextBlock_63c8e146-485b-4cc7-80c6-c85465555850" xlink:href="arwr-20250630.xsd#arwr_SummaryOfInterestExpenseRecognizedRelatedToCreditFacilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_71f0cc45-9cb5-40b6-b263-17075e46dcff" xlink:to="loc_arwr_SummaryOfInterestExpenseRecognizedRelatedToCreditFacilityTableTextBlock_63c8e146-485b-4cc7-80c6-c85465555850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_fbb86f0f-e468-47f9-8d18-9191bef3e041" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_71f0cc45-9cb5-40b6-b263-17075e46dcff" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_fbb86f0f-e468-47f9-8d18-9191bef3e041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/NetLossIncomePerShareTables" xlink:type="simple" xlink:href="arwr-20250630.xsd#NetLossIncomePerShareTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/NetLossIncomePerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d7911624-a45b-4d89-a287-79e433174a89" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_ebe4baa4-b8eb-4df4-a456-20164a30afa3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d7911624-a45b-4d89-a287-79e433174a89" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_ebe4baa4-b8eb-4df4-a456-20164a30afa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_da1d11fa-bb36-40c2-b707-da5c0c68975c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d7911624-a45b-4d89-a287-79e433174a89" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_da1d11fa-bb36-40c2-b707-da5c0c68975c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#OrganizationandSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ac34241e-ebf9-4229-9353-66a2758d1a63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b472841b-bee0-466a-a772-c0cd3841d127" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ac34241e-ebf9-4229-9353-66a2758d1a63" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b472841b-bee0-466a-a772-c0cd3841d127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_80fe4511-c5b2-4ba1-832b-ae38cb847924" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b472841b-bee0-466a-a772-c0cd3841d127" xlink:to="loc_srt_CounterpartyNameAxis_80fe4511-c5b2-4ba1-832b-ae38cb847924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_84efb94d-8cb1-46d6-b37a-f8bb386b67a5" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_80fe4511-c5b2-4ba1-832b-ae38cb847924" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_84efb94d-8cb1-46d6-b37a-f8bb386b67a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SareptaMember_11756959-b1f0-43bf-aca7-2ab5d55221e6" xlink:href="arwr-20250630.xsd#arwr_SareptaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_84efb94d-8cb1-46d6-b37a-f8bb386b67a5" xlink:to="loc_arwr_SareptaMember_11756959-b1f0-43bf-aca7-2ab5d55221e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_854f49b9-d23d-4c12-9135-367876c29aba" xlink:href="arwr-20250630.xsd#arwr_GlaxosmithklineIntellectualPropertyLimitedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_84efb94d-8cb1-46d6-b37a-f8bb386b67a5" xlink:to="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_854f49b9-d23d-4c12-9135-367876c29aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_accb6263-ceef-45c3-b1d8-47110b0b9378" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b472841b-bee0-466a-a772-c0cd3841d127" xlink:to="loc_us-gaap_TypeOfArrangementAxis_accb6263-ceef-45c3-b1d8-47110b0b9378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_88b16f62-8ed6-4a86-a2ea-6f4b6d7586cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_accb6263-ceef-45c3-b1d8-47110b0b9378" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_88b16f62-8ed6-4a86-a2ea-6f4b6d7586cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SareptaCollaborationAgreementMember_44620e8e-accb-4ea4-828f-f7a781c65b46" xlink:href="arwr-20250630.xsd#arwr_SareptaCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_88b16f62-8ed6-4a86-a2ea-6f4b6d7586cf" xlink:to="loc_arwr_SareptaCollaborationAgreementMember_44620e8e-accb-4ea4-828f-f7a781c65b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GSKHBVAgreementMember_056e4c3c-74a3-41d8-9db8-ace54f0c492a" xlink:href="arwr-20250630.xsd#arwr_GSKHBVAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_88b16f62-8ed6-4a86-a2ea-6f4b6d7586cf" xlink:to="loc_arwr_GSKHBVAgreementMember_056e4c3c-74a3-41d8-9db8-ace54f0c492a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_8f2317f1-b5d5-460e-8366-db168374ed62" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b472841b-bee0-466a-a772-c0cd3841d127" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_8f2317f1-b5d5-460e-8366-db168374ed62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1cae32d3-3097-403b-925a-5f5ef4250420" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8f2317f1-b5d5-460e-8366-db168374ed62" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1cae32d3-3097-403b-925a-5f5ef4250420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_8cfb52c7-3d65-476e-9d2b-5c862b36d51d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1cae32d3-3097-403b-925a-5f5ef4250420" xlink:to="loc_us-gaap_SubsequentEventMember_8cfb52c7-3d65-476e-9d2b-5c862b36d51d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e8f62059-0d7e-4f6b-b08c-e2245c51bcdd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b472841b-bee0-466a-a772-c0cd3841d127" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e8f62059-0d7e-4f6b-b08c-e2245c51bcdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentMilestonePayments_8afaf08e-4590-48e8-8a6b-9fbd8254e9a5" xlink:href="arwr-20250630.xsd#arwr_DevelopmentMilestonePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e8f62059-0d7e-4f6b-b08c-e2245c51bcdd" xlink:to="loc_arwr_DevelopmentMilestonePayments_8afaf08e-4590-48e8-8a6b-9fbd8254e9a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_3d251da8-314b-4dcf-b24a-0c65638245cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e8f62059-0d7e-4f6b-b08c-e2245c51bcdd" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_3d251da8-314b-4dcf-b24a-0c65638245cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_117373b4-452b-4a41-8f6a-131f6588c92a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e8f62059-0d7e-4f6b-b08c-e2245c51bcdd" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_117373b4-452b-4a41-8f6a-131f6588c92a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_48ed078c-9228-4a7c-8ac7-8a7a8b799ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e8f62059-0d7e-4f6b-b08c-e2245c51bcdd" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_48ed078c-9228-4a7c-8ac7-8a7a8b799ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ProceedsFromCollaborationArrangements_0458eeae-40a5-46c3-a244-d92a76791008" xlink:href="arwr-20250630.xsd#arwr_ProceedsFromCollaborationArrangements"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e8f62059-0d7e-4f6b-b08c-e2245c51bcdd" xlink:to="loc_arwr_ProceedsFromCollaborationArrangements_0458eeae-40a5-46c3-a244-d92a76791008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AdditionalCashReceivableUnderCollaborationAgreement_76bb652b-3e80-4288-9775-f6a659cc51c2" xlink:href="arwr-20250630.xsd#arwr_AdditionalCashReceivableUnderCollaborationAgreement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e8f62059-0d7e-4f6b-b08c-e2245c51bcdd" xlink:to="loc_arwr_AdditionalCashReceivableUnderCollaborationAgreement_76bb652b-3e80-4288-9775-f6a659cc51c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod_02bd5a7d-e852-4887-8722-496a7be189d6" xlink:href="arwr-20250630.xsd#arwr_CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e8f62059-0d7e-4f6b-b08c-e2245c51bcdd" xlink:to="loc_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod_02bd5a7d-e852-4887-8722-496a7be189d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EnrollmentRelatedMilestonePayments_79151e1a-578a-483e-92af-50a1f45b2365" xlink:href="arwr-20250630.xsd#arwr_EnrollmentRelatedMilestonePayments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e8f62059-0d7e-4f6b-b08c-e2245c51bcdd" xlink:to="loc_arwr_EnrollmentRelatedMilestonePayments_79151e1a-578a-483e-92af-50a1f45b2365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FuturePotentialMilestonePayments_a778c49c-a500-49f3-992b-4e5ad0076904" xlink:href="arwr-20250630.xsd#arwr_FuturePotentialMilestonePayments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e8f62059-0d7e-4f6b-b08c-e2245c51bcdd" xlink:to="loc_arwr_FuturePotentialMilestonePayments_a778c49c-a500-49f3-992b-4e5ad0076904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_01beb862-552f-4f23-bcd2-988acd6df239" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e8f62059-0d7e-4f6b-b08c-e2245c51bcdd" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_01beb862-552f-4f23-bcd2-988acd6df239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_388a6bfd-eda6-4793-a6bc-7d8006aae817" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e8f62059-0d7e-4f6b-b08c-e2245c51bcdd" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_388a6bfd-eda6-4793-a6bc-7d8006aae817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8a2f51cf-fdcf-4a33-bf15-043c27d3ea98" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e8f62059-0d7e-4f6b-b08c-e2245c51bcdd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8a2f51cf-fdcf-4a33-bf15-043c27d3ea98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_IncreaseDecreaseInCashAndInvestments_bbc5a35e-28f6-48e3-8541-63245be7fb25" xlink:href="arwr-20250630.xsd#arwr_IncreaseDecreaseInCashAndInvestments"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e8f62059-0d7e-4f6b-b08c-e2245c51bcdd" xlink:to="loc_arwr_IncreaseDecreaseInCashAndInvestments_bbc5a35e-28f6-48e3-8541-63245be7fb25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_60f56ccf-c944-43b6-9200-7f0f59d5a9e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e8f62059-0d7e-4f6b-b08c-e2245c51bcdd" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_60f56ccf-c944-43b6-9200-7f0f59d5a9e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_bf9c8dcc-3b1d-467e-af73-dd34379592f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e8f62059-0d7e-4f6b-b08c-e2245c51bcdd" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_bf9c8dcc-3b1d-467e-af73-dd34379592f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_b336d4a7-48a3-460e-87aa-61e9bd85449e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e8f62059-0d7e-4f6b-b08c-e2245c51bcdd" xlink:to="loc_us-gaap_InvestmentIncomeInterestAndDividend_b336d4a7-48a3-460e-87aa-61e9bd85449e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_3c18270b-2cc9-4cf9-b847-b22b0ca2b09a" xlink:href="arwr-20250630.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e8f62059-0d7e-4f6b-b08c-e2245c51bcdd" xlink:to="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_3c18270b-2cc9-4cf9-b847-b22b0ca2b09a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#CollaborationandLicenseAgreementsRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementsAbstract_2f6d3984-b9fd-4804-afbc-5f915a745b1d" xlink:href="arwr-20250630.xsd#arwr_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_97cfb7bb-2c83-4b78-b956-e780832af12a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_CollaborationAndLicenseAgreementsAbstract_2f6d3984-b9fd-4804-afbc-5f915a745b1d" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_97cfb7bb-2c83-4b78-b956-e780832af12a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_f7d7b510-9599-41c3-9007-ccec39c9b584" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_97cfb7bb-2c83-4b78-b956-e780832af12a" xlink:to="loc_srt_MajorCustomersAxis_f7d7b510-9599-41c3-9007-ccec39c9b584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_41adc18f-457a-4bcc-a918-7140ddb7da2d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_f7d7b510-9599-41c3-9007-ccec39c9b584" xlink:to="loc_srt_NameOfMajorCustomerDomain_41adc18f-457a-4bcc-a918-7140ddb7da2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_f6ba9579-f1c2-42e6-ac80-01c984cc9099" xlink:href="arwr-20250630.xsd#arwr_GlaxosmithklineIntellectualPropertyLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_41adc18f-457a-4bcc-a918-7140ddb7da2d" xlink:to="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_f6ba9579-f1c2-42e6-ac80-01c984cc9099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_d5abb160-09ae-4206-89ca-66b10d252d26" xlink:href="arwr-20250630.xsd#arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_41adc18f-457a-4bcc-a918-7140ddb7da2d" xlink:to="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_d5abb160-09ae-4206-89ca-66b10d252d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SareptaTherapeuticsIncMember_9bbcd2c0-3538-4c6c-a720-d05cbf03254a" xlink:href="arwr-20250630.xsd#arwr_SareptaTherapeuticsIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_41adc18f-457a-4bcc-a918-7140ddb7da2d" xlink:to="loc_arwr_SareptaTherapeuticsIncMember_9bbcd2c0-3538-4c6c-a720-d05cbf03254a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_bec40a04-c375-45e6-af02-0c81e3a02883" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_97cfb7bb-2c83-4b78-b956-e780832af12a" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_bec40a04-c375-45e6-af02-0c81e3a02883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_45725e79-2d47-49ad-a90a-0f8712dfa9c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_bec40a04-c375-45e6-af02-0c81e3a02883" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_45725e79-2d47-49ad-a90a-0f8712dfa9c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsReceivablesandContractLiabilitiesDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#CollaborationandLicenseAgreementsReceivablesandContractLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsReceivablesandContractLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementsAbstract_5ff2bab3-4174-4fb0-ab4f-c6e692ee0230" xlink:href="arwr-20250630.xsd#arwr_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_fed04b58-fdba-44a4-85a6-81e591316808" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_CollaborationAndLicenseAgreementsAbstract_5ff2bab3-4174-4fb0-ab4f-c6e692ee0230" xlink:to="loc_us-gaap_AccountsReceivableNet_fed04b58-fdba-44a4-85a6-81e591316808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_739fcaed-26c7-4d21-b667-a6410a4afda8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_CollaborationAndLicenseAgreementsAbstract_5ff2bab3-4174-4fb0-ab4f-c6e692ee0230" xlink:to="loc_us-gaap_ContractWithCustomerLiability_739fcaed-26c7-4d21-b667-a6410a4afda8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedGSKDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedGSKDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedGSKDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementsAbstract_d9971274-3b8f-4751-badd-a7ddd74d9615" xlink:href="arwr-20250630.xsd#arwr_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d097b0c0-e5ed-41df-9b28-45c8c5dffdda" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_CollaborationAndLicenseAgreementsAbstract_d9971274-3b8f-4751-badd-a7ddd74d9615" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d097b0c0-e5ed-41df-9b28-45c8c5dffdda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_79b8bb09-9989-4888-ae7c-245230353c22" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d097b0c0-e5ed-41df-9b28-45c8c5dffdda" xlink:to="loc_srt_CounterpartyNameAxis_79b8bb09-9989-4888-ae7c-245230353c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4fdb4692-be16-4569-ae79-87cda5487221" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_79b8bb09-9989-4888-ae7c-245230353c22" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4fdb4692-be16-4569-ae79-87cda5487221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_562da0df-374d-4a80-928d-183a38bf7570" xlink:href="arwr-20250630.xsd#arwr_GlaxosmithklineIntellectualPropertyLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4fdb4692-be16-4569-ae79-87cda5487221" xlink:to="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_562da0df-374d-4a80-928d-183a38bf7570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a8fad908-7106-47ca-83d5-988f7082e0c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d097b0c0-e5ed-41df-9b28-45c8c5dffdda" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a8fad908-7106-47ca-83d5-988f7082e0c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_408814ba-1064-4452-b066-7294cba44c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a8fad908-7106-47ca-83d5-988f7082e0c8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_408814ba-1064-4452-b066-7294cba44c0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GSKHSDLicenseAgreementMember_8a784660-e396-469f-986b-539733364982" xlink:href="arwr-20250630.xsd#arwr_GSKHSDLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_408814ba-1064-4452-b066-7294cba44c0d" xlink:to="loc_arwr_GSKHSDLicenseAgreementMember_8a784660-e396-469f-986b-539733364982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GSKHBVAgreementMember_a07413ee-4325-4c73-9875-970e92144958" xlink:href="arwr-20250630.xsd#arwr_GSKHBVAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_408814ba-1064-4452-b066-7294cba44c0d" xlink:to="loc_arwr_GSKHBVAgreementMember_a07413ee-4325-4c73-9875-970e92144958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f7ef9846-afa4-4336-94e4-29afad8f7355" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d097b0c0-e5ed-41df-9b28-45c8c5dffdda" xlink:to="loc_srt_RangeAxis_f7ef9846-afa4-4336-94e4-29afad8f7355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f81a7381-799f-4a58-9ebf-476053004576" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f7ef9846-afa4-4336-94e4-29afad8f7355" xlink:to="loc_srt_RangeMember_f81a7381-799f-4a58-9ebf-476053004576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_dfad7f83-fe1c-40a0-865f-527af474b2aa" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f81a7381-799f-4a58-9ebf-476053004576" xlink:to="loc_srt_MaximumMember_dfad7f83-fe1c-40a0-865f-527af474b2aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5bc96a18-43f3-47e3-836a-fbcb9c8cf4c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d097b0c0-e5ed-41df-9b28-45c8c5dffdda" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5bc96a18-43f3-47e3-836a-fbcb9c8cf4c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_a400c530-e3e8-4a9d-b86a-bbc5e7b232e9" xlink:href="arwr-20250630.xsd#arwr_InitialTransactionPrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5bc96a18-43f3-47e3-836a-fbcb9c8cf4c4" xlink:to="loc_arwr_InitialTransactionPrice_a400c530-e3e8-4a9d-b86a-bbc5e7b232e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivable_8b8738d9-196f-407c-9468-893f46b1666f" xlink:href="arwr-20250630.xsd#arwr_MilestonePaymentReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5bc96a18-43f3-47e3-836a-fbcb9c8cf4c4" xlink:to="loc_arwr_MilestonePaymentReceivable_8b8738d9-196f-407c-9468-893f46b1666f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_577b1ac7-c577-4af5-8f7b-7a0126b14526" xlink:href="arwr-20250630.xsd#arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5bc96a18-43f3-47e3-836a-fbcb9c8cf4c4" xlink:to="loc_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_577b1ac7-c577-4af5-8f7b-7a0126b14526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialMilestonePaymentsAtFirstCommercialSale_6137cfce-efc5-4f4f-99b7-24681630aec6" xlink:href="arwr-20250630.xsd#arwr_CommercialMilestonePaymentsAtFirstCommercialSale"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5bc96a18-43f3-47e3-836a-fbcb9c8cf4c4" xlink:to="loc_arwr_CommercialMilestonePaymentsAtFirstCommercialSale_6137cfce-efc5-4f4f-99b7-24681630aec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SalesRelatedMilestonePayments_06531963-f3ca-43b0-a000-c75c1996d7f2" xlink:href="arwr-20250630.xsd#arwr_SalesRelatedMilestonePayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5bc96a18-43f3-47e3-836a-fbcb9c8cf4c4" xlink:to="loc_arwr_SalesRelatedMilestonePayments_06531963-f3ca-43b0-a000-c75c1996d7f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentMilestonePayments_20cb166b-2c7e-48a4-91be-5707ec8cdee6" xlink:href="arwr-20250630.xsd#arwr_DevelopmentMilestonePayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5bc96a18-43f3-47e3-836a-fbcb9c8cf4c4" xlink:to="loc_arwr_DevelopmentMilestonePayments_20cb166b-2c7e-48a4-91be-5707ec8cdee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentAndSalesMilestonesPayments_d03cba47-6e1f-48de-aa56-7d5c202f6be0" xlink:href="arwr-20250630.xsd#arwr_DevelopmentAndSalesMilestonesPayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5bc96a18-43f3-47e3-836a-fbcb9c8cf4c4" xlink:to="loc_arwr_DevelopmentAndSalesMilestonesPayments_d03cba47-6e1f-48de-aa56-7d5c202f6be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_89e47486-d415-4670-8e7b-ea59de4ca947" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5bc96a18-43f3-47e3-836a-fbcb9c8cf4c4" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_89e47486-d415-4670-8e7b-ea59de4ca947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_27299f29-1847-4663-a4a6-7e5cdb5ff3bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5bc96a18-43f3-47e3-836a-fbcb9c8cf4c4" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_27299f29-1847-4663-a4a6-7e5cdb5ff3bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementsAbstract_9410c9f6-edcf-4ab0-8d5a-df3034742596" xlink:href="arwr-20250630.xsd#arwr_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e940c581-059a-43fa-bc80-26c11dcbfb59" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_CollaborationAndLicenseAgreementsAbstract_9410c9f6-edcf-4ab0-8d5a-df3034742596" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e940c581-059a-43fa-bc80-26c11dcbfb59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_9533d00f-bcc5-4923-99e8-16c544229550" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e940c581-059a-43fa-bc80-26c11dcbfb59" xlink:to="loc_srt_CounterpartyNameAxis_9533d00f-bcc5-4923-99e8-16c544229550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c4fe307e-1870-4536-a796-b5274bfb09f4" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_9533d00f-bcc5-4923-99e8-16c544229550" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c4fe307e-1870-4536-a796-b5274bfb09f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_fc4334cf-5974-4293-acb7-d53b52358ce5" xlink:href="arwr-20250630.xsd#arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c4fe307e-1870-4536-a796-b5274bfb09f4" xlink:to="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_fc4334cf-5974-4293-acb7-d53b52358ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a0f6d69d-f58a-409a-a0d3-53ce93a84d20" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e940c581-059a-43fa-bc80-26c11dcbfb59" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a0f6d69d-f58a-409a-a0d3-53ce93a84d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5cbf8d42-dd0d-4ac8-b899-790b2bc18ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a0f6d69d-f58a-409a-a0d3-53ce93a84d20" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5cbf8d42-dd0d-4ac8-b899-790b2bc18ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LicenseAndCoFundingAgreementMember_522087a0-29f8-444d-b63f-3e3196c6c575" xlink:href="arwr-20250630.xsd#arwr_LicenseAndCoFundingAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5cbf8d42-dd0d-4ac8-b899-790b2bc18ad0" xlink:to="loc_arwr_LicenseAndCoFundingAgreementMember_522087a0-29f8-444d-b63f-3e3196c6c575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fd5cb27c-77da-4366-9896-ac3e18d0b2d4" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e940c581-059a-43fa-bc80-26c11dcbfb59" xlink:to="loc_srt_RangeAxis_fd5cb27c-77da-4366-9896-ac3e18d0b2d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9234048d-e702-4fba-8ce3-18629fb4a904" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_fd5cb27c-77da-4366-9896-ac3e18d0b2d4" xlink:to="loc_srt_RangeMember_9234048d-e702-4fba-8ce3-18629fb4a904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7145ce3e-0b1d-49d4-93c8-1b5dacab89a3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9234048d-e702-4fba-8ce3-18629fb4a904" xlink:to="loc_srt_MinimumMember_7145ce3e-0b1d-49d4-93c8-1b5dacab89a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7eba89a2-7ebe-4b3a-98a8-75ee536d49e6" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9234048d-e702-4fba-8ce3-18629fb4a904" xlink:to="loc_srt_MaximumMember_7eba89a2-7ebe-4b3a-98a8-75ee536d49e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1349cd0c-dfd9-4b72-ab2a-05f261156fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e940c581-059a-43fa-bc80-26c11dcbfb59" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1349cd0c-dfd9-4b72-ab2a-05f261156fb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_2636c824-ffb6-4e0a-9f53-33b5431b5c9d" xlink:href="arwr-20250630.xsd#arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1349cd0c-dfd9-4b72-ab2a-05f261156fb2" xlink:to="loc_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_2636c824-ffb6-4e0a-9f53-33b5431b5c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctBundle_2a314954-66a0-4fb9-bf95-c42bd50beafc" xlink:href="arwr-20250630.xsd#arwr_NumberOfDistinctBundle"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1349cd0c-dfd9-4b72-ab2a-05f261156fb2" xlink:to="loc_arwr_NumberOfDistinctBundle_2a314954-66a0-4fb9-bf95-c42bd50beafc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_e905657e-d659-4f82-b469-8b96a67f6fee" xlink:href="arwr-20250630.xsd#arwr_InitialTransactionPrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1349cd0c-dfd9-4b72-ab2a-05f261156fb2" xlink:to="loc_arwr_InitialTransactionPrice_e905657e-d659-4f82-b469-8b96a67f6fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentEarned_fc20bb46-0de8-4180-8375-ad922955686d" xlink:href="arwr-20250630.xsd#arwr_MilestonePaymentEarned"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1349cd0c-dfd9-4b72-ab2a-05f261156fb2" xlink:to="loc_arwr_MilestonePaymentEarned_fc20bb46-0de8-4180-8375-ad922955686d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_567a5e6a-9423-4863-910c-098f685ab37d" xlink:href="arwr-20250630.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1349cd0c-dfd9-4b72-ab2a-05f261156fb2" xlink:to="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_567a5e6a-9423-4863-910c-098f685ab37d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cbe7f39f-4ad0-46ea-ba29-0d20113e96c5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1349cd0c-dfd9-4b72-ab2a-05f261156fb2" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cbe7f39f-4ad0-46ea-ba29-0d20113e96c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_0fca2797-7884-403c-898e-8943bda8dbb6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1349cd0c-dfd9-4b72-ab2a-05f261156fb2" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_0fca2797-7884-403c-898e-8943bda8dbb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#CollaborationandLicenseAgreementsAmgenIncDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementsAbstract_f26061ab-079d-472e-9965-47084550ad15" xlink:href="arwr-20250630.xsd#arwr_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f5a145ff-3db7-4deb-871a-9ed53a662725" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_CollaborationAndLicenseAgreementsAbstract_f26061ab-079d-472e-9965-47084550ad15" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f5a145ff-3db7-4deb-871a-9ed53a662725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_152c34f5-f084-4fd9-a9f8-20a20e641fae" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f5a145ff-3db7-4deb-871a-9ed53a662725" xlink:to="loc_srt_CounterpartyNameAxis_152c34f5-f084-4fd9-a9f8-20a20e641fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6a9ad1de-2cab-41f5-945c-d5827dddb3a7" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_152c34f5-f084-4fd9-a9f8-20a20e641fae" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6a9ad1de-2cab-41f5-945c-d5827dddb3a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmgenIncorporatedMember_0dd4cabe-459a-4d88-a144-7797908ca5f4" xlink:href="arwr-20250630.xsd#arwr_AmgenIncorporatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6a9ad1de-2cab-41f5-945c-d5827dddb3a7" xlink:to="loc_arwr_AmgenIncorporatedMember_0dd4cabe-459a-4d88-a144-7797908ca5f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8562133f-9d54-41ac-aca8-6f2a62c46b04" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f5a145ff-3db7-4deb-871a-9ed53a662725" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8562133f-9d54-41ac-aca8-6f2a62c46b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dc5d9030-5c03-44eb-8e33-9e8a728f1423" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8562133f-9d54-41ac-aca8-6f2a62c46b04" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dc5d9030-5c03-44eb-8e33-9e8a728f1423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OlpasiranAgreementMember_696da196-6428-4372-97a3-6c48d59e8dd8" xlink:href="arwr-20250630.xsd#arwr_OlpasiranAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dc5d9030-5c03-44eb-8e33-9e8a728f1423" xlink:to="loc_arwr_OlpasiranAgreementMember_696da196-6428-4372-97a3-6c48d59e8dd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fdbbd7fc-c78c-44a4-afee-4a4651efe07c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f5a145ff-3db7-4deb-871a-9ed53a662725" xlink:to="loc_srt_RangeAxis_fdbbd7fc-c78c-44a4-afee-4a4651efe07c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_784926b7-496f-4149-8d97-787e26a8cc8f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_fdbbd7fc-c78c-44a4-afee-4a4651efe07c" xlink:to="loc_srt_RangeMember_784926b7-496f-4149-8d97-787e26a8cc8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1e109520-80f6-4d2d-8d41-34e82346c4c2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_784926b7-496f-4149-8d97-787e26a8cc8f" xlink:to="loc_srt_MaximumMember_1e109520-80f6-4d2d-8d41-34e82346c4c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5d82618e-ae7c-421d-916a-ea168a55a9b0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f5a145ff-3db7-4deb-871a-9ed53a662725" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5d82618e-ae7c-421d-916a-ea168a55a9b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfAgreements_69eacdf6-de2e-499b-b4c4-d18568d03b76" xlink:href="arwr-20250630.xsd#arwr_NumberOfAgreements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5d82618e-ae7c-421d-916a-ea168a55a9b0" xlink:to="loc_arwr_NumberOfAgreements_69eacdf6-de2e-499b-b4c4-d18568d03b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_ae924ca0-3dd8-49fa-9f2d-bb775c941c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5d82618e-ae7c-421d-916a-ea168a55a9b0" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_ae924ca0-3dd8-49fa-9f2d-bb775c941c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_106ffe11-4270-4354-86a0-a5d06547564b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5d82618e-ae7c-421d-916a-ea168a55a9b0" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_106ffe11-4270-4354-86a0-a5d06547564b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_360cfcff-62e2-44a2-b587-6c011acb3859" xlink:href="arwr-20250630.xsd#arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5d82618e-ae7c-421d-916a-ea168a55a9b0" xlink:to="loc_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_360cfcff-62e2-44a2-b587-6c011acb3859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementsAbstract_9932c61c-5804-4776-94ba-72cf3bd50aef" xlink:href="arwr-20250630.xsd#arwr_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_319eae47-feae-4c3a-ab91-64d9ae378a82" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_CollaborationAndLicenseAgreementsAbstract_9932c61c-5804-4776-94ba-72cf3bd50aef" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_319eae47-feae-4c3a-ab91-64d9ae378a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_20333e3f-1a40-4a03-9e7f-df283f1ee14d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_319eae47-feae-4c3a-ab91-64d9ae378a82" xlink:to="loc_srt_CounterpartyNameAxis_20333e3f-1a40-4a03-9e7f-df283f1ee14d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9a0d7822-8811-4514-a535-b6b82a82a533" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_20333e3f-1a40-4a03-9e7f-df283f1ee14d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9a0d7822-8811-4514-a535-b6b82a82a533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SareptaTherapeuticsIncMember_c9886508-580a-43cb-afc9-afdceb398204" xlink:href="arwr-20250630.xsd#arwr_SareptaTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9a0d7822-8811-4514-a535-b6b82a82a533" xlink:to="loc_arwr_SareptaTherapeuticsIncMember_c9886508-580a-43cb-afc9-afdceb398204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3f67328a-97e4-44b8-9c6e-993e076aa249" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_319eae47-feae-4c3a-ab91-64d9ae378a82" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3f67328a-97e4-44b8-9c6e-993e076aa249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7156b247-9639-497d-8c9c-3eaab25ff5a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3f67328a-97e4-44b8-9c6e-993e076aa249" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7156b247-9639-497d-8c9c-3eaab25ff5a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SareptaCollaborationAgreementMember_c25ab4e6-459a-4f50-b005-3592a9c46e5e" xlink:href="arwr-20250630.xsd#arwr_SareptaCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7156b247-9639-497d-8c9c-3eaab25ff5a0" xlink:to="loc_arwr_SareptaCollaborationAgreementMember_c25ab4e6-459a-4f50-b005-3592a9c46e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d8b1e2a4-c653-4df8-bcee-4794379cdbb0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_319eae47-feae-4c3a-ab91-64d9ae378a82" xlink:to="loc_srt_RangeAxis_d8b1e2a4-c653-4df8-bcee-4794379cdbb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7d11e8b6-c738-4285-ad4d-768745a66f36" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d8b1e2a4-c653-4df8-bcee-4794379cdbb0" xlink:to="loc_srt_RangeMember_7d11e8b6-c738-4285-ad4d-768745a66f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_60be10c0-7833-4726-8229-b76eb23e35d4" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7d11e8b6-c738-4285-ad4d-768745a66f36" xlink:to="loc_srt_MaximumMember_60be10c0-7833-4726-8229-b76eb23e35d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_66756082-3e13-4987-8f10-5acecc25a0e8" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7d11e8b6-c738-4285-ad4d-768745a66f36" xlink:to="loc_srt_MinimumMember_66756082-3e13-4987-8f10-5acecc25a0e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_31574779-b992-4f64-bc72-1dc168c9322b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_319eae47-feae-4c3a-ab91-64d9ae378a82" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_31574779-b992-4f64-bc72-1dc168c9322b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfNewTargetPrograms_a6a46455-058d-42b8-8fef-ff5fa4d6d433" xlink:href="arwr-20250630.xsd#arwr_NumberOfNewTargetPrograms"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_31574779-b992-4f64-bc72-1dc168c9322b" xlink:to="loc_arwr_NumberOfNewTargetPrograms_a6a46455-058d-42b8-8fef-ff5fa4d6d433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfPerformanceObligations_07e31ace-ec54-451a-b1e7-e065d4ed398c" xlink:href="arwr-20250630.xsd#arwr_NumberOfPerformanceObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_31574779-b992-4f64-bc72-1dc168c9322b" xlink:to="loc_arwr_NumberOfPerformanceObligations_07e31ace-ec54-451a-b1e7-e065d4ed398c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ProceedsFromCollaborationArrangements_d63efeb6-222e-4418-9ae9-569e590c4fdf" xlink:href="arwr-20250630.xsd#arwr_ProceedsFromCollaborationArrangements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_31574779-b992-4f64-bc72-1dc168c9322b" xlink:to="loc_arwr_ProceedsFromCollaborationArrangements_d63efeb6-222e-4418-9ae9-569e590c4fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_8d87ac24-5357-4979-a498-8cb969c90695" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_31574779-b992-4f64-bc72-1dc168c9322b" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_8d87ac24-5357-4979-a498-8cb969c90695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SaleOfStockPremiumOnIssuanceOfShares_67f5a19a-e74a-4812-af21-a95b2d15cbdd" xlink:href="arwr-20250630.xsd#arwr_SaleOfStockPremiumOnIssuanceOfShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_31574779-b992-4f64-bc72-1dc168c9322b" xlink:to="loc_arwr_SaleOfStockPremiumOnIssuanceOfShares_67f5a19a-e74a-4812-af21-a95b2d15cbdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AdditionalCashReceivableUnderCollaborationAgreement_aaac3f3d-b763-4712-aeee-e16d47f5cb91" xlink:href="arwr-20250630.xsd#arwr_AdditionalCashReceivableUnderCollaborationAgreement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_31574779-b992-4f64-bc72-1dc168c9322b" xlink:to="loc_arwr_AdditionalCashReceivableUnderCollaborationAgreement_aaac3f3d-b763-4712-aeee-e16d47f5cb91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallments_5e332993-99bf-435f-94ed-205904840d59" xlink:href="arwr-20250630.xsd#arwr_CashReceivableUnderCollaborationAgreementAnnualInstallments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_31574779-b992-4f64-bc72-1dc168c9322b" xlink:to="loc_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallments_5e332993-99bf-435f-94ed-205904840d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod_78af8e67-6720-44c8-98a6-040efaeedbbb" xlink:href="arwr-20250630.xsd#arwr_CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_31574779-b992-4f64-bc72-1dc168c9322b" xlink:to="loc_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod_78af8e67-6720-44c8-98a6-040efaeedbbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationArrangementFixedConsideration_d2502776-2343-41ba-b079-e287e7c7e256" xlink:href="arwr-20250630.xsd#arwr_CollaborationArrangementFixedConsideration"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_31574779-b992-4f64-bc72-1dc168c9322b" xlink:to="loc_arwr_CollaborationArrangementFixedConsideration_d2502776-2343-41ba-b079-e287e7c7e256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationArrangementConsideration_e6c375a7-194e-4374-b06d-aa359b5de761" xlink:href="arwr-20250630.xsd#arwr_CollaborationArrangementConsideration"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_31574779-b992-4f64-bc72-1dc168c9322b" xlink:to="loc_arwr_CollaborationArrangementConsideration_e6c375a7-194e-4374-b06d-aa359b5de761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EnrollmentRelatedMilestonePayments_4734b718-9822-454c-8a85-efb96989fe62" xlink:href="arwr-20250630.xsd#arwr_EnrollmentRelatedMilestonePayments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_31574779-b992-4f64-bc72-1dc168c9322b" xlink:to="loc_arwr_EnrollmentRelatedMilestonePayments_4734b718-9822-454c-8a85-efb96989fe62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfCollaborationPrograms_7686d819-4c25-4b18-8fa4-1bcbce86313f" xlink:href="arwr-20250630.xsd#arwr_NumberOfCollaborationPrograms"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_31574779-b992-4f64-bc72-1dc168c9322b" xlink:to="loc_arwr_NumberOfCollaborationPrograms_7686d819-4c25-4b18-8fa4-1bcbce86313f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RegulatoryMilestonePayments_84499cd9-35c9-4355-9678-48b0e961b737" xlink:href="arwr-20250630.xsd#arwr_RegulatoryMilestonePayments"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_31574779-b992-4f64-bc72-1dc168c9322b" xlink:to="loc_arwr_RegulatoryMilestonePayments_84499cd9-35c9-4355-9678-48b0e961b737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SalesRelatedMilestonePayments_eae4f6ac-b5b8-44ab-9065-b68d141cfac7" xlink:href="arwr-20250630.xsd#arwr_SalesRelatedMilestonePayments"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_31574779-b992-4f64-bc72-1dc168c9322b" xlink:to="loc_arwr_SalesRelatedMilestonePayments_eae4f6ac-b5b8-44ab-9065-b68d141cfac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationArrangementTerminationNoticePeriodPriorToRegulatoryApproval_518c4fe5-e954-454d-a5e9-dce1568d1574" xlink:href="arwr-20250630.xsd#arwr_CollaborationArrangementTerminationNoticePeriodPriorToRegulatoryApproval"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_31574779-b992-4f64-bc72-1dc168c9322b" xlink:to="loc_arwr_CollaborationArrangementTerminationNoticePeriodPriorToRegulatoryApproval_518c4fe5-e954-454d-a5e9-dce1568d1574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_da8bbc93-6a7f-4d73-9ade-170df6944ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_31574779-b992-4f64-bc72-1dc168c9322b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_da8bbc93-6a7f-4d73-9ade-170df6944ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_2b0b2225-61d2-4609-bc1b-aa261d11a2b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_31574779-b992-4f64-bc72-1dc168c9322b" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_2b0b2225-61d2-4609-bc1b-aa261d11a2b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_8a5cfcbb-49ac-48a0-b66f-f11ab9d84983" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_31574779-b992-4f64-bc72-1dc168c9322b" xlink:to="loc_us-gaap_ContractWithCustomerLiability_8a5cfcbb-49ac-48a0-b66f-f11ab9d84983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncConsiderationComponentsDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#CollaborationandLicenseAgreementsSareptaTherapeuticsIncConsiderationComponentsDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncConsiderationComponentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d003805e-59f5-46d4-81f2-978a2a22034c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0a8202e6-4fde-4849-96ba-0a8239367b00" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d003805e-59f5-46d4-81f2-978a2a22034c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0a8202e6-4fde-4849-96ba-0a8239367b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a589d6cb-7132-43dd-8a49-af4262c09ad0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0a8202e6-4fde-4849-96ba-0a8239367b00" xlink:to="loc_srt_CounterpartyNameAxis_a589d6cb-7132-43dd-8a49-af4262c09ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b04e1ed3-2378-4d60-a554-b95e38466886" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_a589d6cb-7132-43dd-8a49-af4262c09ad0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b04e1ed3-2378-4d60-a554-b95e38466886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SareptaTherapeuticsIncMember_fd5ab7d7-bdc8-4d40-b79b-c80b81aab775" xlink:href="arwr-20250630.xsd#arwr_SareptaTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b04e1ed3-2378-4d60-a554-b95e38466886" xlink:to="loc_arwr_SareptaTherapeuticsIncMember_fd5ab7d7-bdc8-4d40-b79b-c80b81aab775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6699fc60-51bf-4c42-b673-05e16b4def44" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0a8202e6-4fde-4849-96ba-0a8239367b00" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6699fc60-51bf-4c42-b673-05e16b4def44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_18fb6fa4-16a4-4674-8fae-6c08fbaca9f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6699fc60-51bf-4c42-b673-05e16b4def44" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_18fb6fa4-16a4-4674-8fae-6c08fbaca9f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SareptaCollaborationAgreementMember_8cec77c2-a1e2-47bb-aed6-0b6bfeaa8f26" xlink:href="arwr-20250630.xsd#arwr_SareptaCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_18fb6fa4-16a4-4674-8fae-6c08fbaca9f8" xlink:to="loc_arwr_SareptaCollaborationAgreementMember_8cec77c2-a1e2-47bb-aed6-0b6bfeaa8f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_327bed99-cc1a-4099-82ec-86c3aaa17a36" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0a8202e6-4fde-4849-96ba-0a8239367b00" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_327bed99-cc1a-4099-82ec-86c3aaa17a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ProceedsFromCollaborationArrangements_1f5661de-1a85-4d47-b3e8-99d0bb69dc94" xlink:href="arwr-20250630.xsd#arwr_ProceedsFromCollaborationArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_327bed99-cc1a-4099-82ec-86c3aaa17a36" xlink:to="loc_arwr_ProceedsFromCollaborationArrangements_1f5661de-1a85-4d47-b3e8-99d0bb69dc94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AdditionalCashReceivableUnderCollaborationAgreement_18194bab-2ba2-4313-94f4-05fcd4995593" xlink:href="arwr-20250630.xsd#arwr_AdditionalCashReceivableUnderCollaborationAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_327bed99-cc1a-4099-82ec-86c3aaa17a36" xlink:to="loc_arwr_AdditionalCashReceivableUnderCollaborationAgreement_18194bab-2ba2-4313-94f4-05fcd4995593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SaleOfStockPremiumOnIssuanceOfShares_0b1fa7f1-4fde-4be2-b666-07a4d0ab62e0" xlink:href="arwr-20250630.xsd#arwr_SaleOfStockPremiumOnIssuanceOfShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_327bed99-cc1a-4099-82ec-86c3aaa17a36" xlink:to="loc_arwr_SaleOfStockPremiumOnIssuanceOfShares_0b1fa7f1-4fde-4be2-b666-07a4d0ab62e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationArrangementFixedConsideration_f8871e11-ea23-421a-9ccb-9b0b79f442f5" xlink:href="arwr-20250630.xsd#arwr_CollaborationArrangementFixedConsideration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_327bed99-cc1a-4099-82ec-86c3aaa17a36" xlink:to="loc_arwr_CollaborationArrangementFixedConsideration_f8871e11-ea23-421a-9ccb-9b0b79f442f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationArrangementVariableConsideration_b8351e08-a109-489e-a89a-ea36c685b702" xlink:href="arwr-20250630.xsd#arwr_CollaborationArrangementVariableConsideration"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_327bed99-cc1a-4099-82ec-86c3aaa17a36" xlink:to="loc_arwr_CollaborationArrangementVariableConsideration_b8351e08-a109-489e-a89a-ea36c685b702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationArrangementConsideration_fb2564cb-19b9-43a2-9a5a-a8e89345a6ca" xlink:href="arwr-20250630.xsd#arwr_CollaborationArrangementConsideration"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_327bed99-cc1a-4099-82ec-86c3aaa17a36" xlink:to="loc_arwr_CollaborationArrangementConsideration_fb2564cb-19b9-43a2-9a5a-a8e89345a6ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/BalanceSheetAccountsPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#BalanceSheetAccountsPropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/BalanceSheetAccountsPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bd39e211-da25-482f-972c-d262f41ba502" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4a860ab6-f845-458e-9b3b-d47abd165770" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bd39e211-da25-482f-972c-d262f41ba502" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4a860ab6-f845-458e-9b3b-d47abd165770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9c7db37b-eb77-4de8-9203-a613d9230911" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4a860ab6-f845-458e-9b3b-d47abd165770" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9c7db37b-eb77-4de8-9203-a613d9230911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_415bda01-4ad1-4669-8c1a-aecadf3a417c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9c7db37b-eb77-4de8-9203-a613d9230911" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_415bda01-4ad1-4669-8c1a-aecadf3a417c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_f3602c66-6b2d-45da-9a96-91eb0881ed93" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LandMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_415bda01-4ad1-4669-8c1a-aecadf3a417c" xlink:to="loc_us-gaap_LandMember_f3602c66-6b2d-45da-9a96-91eb0881ed93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_1e7b95fa-4adf-40cb-bc77-a0f0cf53e219" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_415bda01-4ad1-4669-8c1a-aecadf3a417c" xlink:to="loc_us-gaap_BuildingMember_1e7b95fa-4adf-40cb-bc77-a0f0cf53e219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchEquipmentMember_14436bc5-3597-4e3b-8815-473d6105e2cf" xlink:href="arwr-20250630.xsd#arwr_ResearchEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_415bda01-4ad1-4669-8c1a-aecadf3a417c" xlink:to="loc_arwr_ResearchEquipmentMember_14436bc5-3597-4e3b-8815-473d6105e2cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ManufacturingEquipmentMember_b33d3ee4-d29b-4df2-b9a4-7cf07660e9c2" xlink:href="arwr-20250630.xsd#arwr_ManufacturingEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_415bda01-4ad1-4669-8c1a-aecadf3a417c" xlink:to="loc_arwr_ManufacturingEquipmentMember_b33d3ee4-d29b-4df2-b9a4-7cf07660e9c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_ca60cada-8f4a-43f3-8455-5c8dc5dd3e21" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_415bda01-4ad1-4669-8c1a-aecadf3a417c" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_ca60cada-8f4a-43f3-8455-5c8dc5dd3e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ComputerAndSoftwareMember_6eb7eb81-b4f7-469a-b3bc-49a38e1467bd" xlink:href="arwr-20250630.xsd#arwr_ComputerAndSoftwareMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_415bda01-4ad1-4669-8c1a-aecadf3a417c" xlink:to="loc_arwr_ComputerAndSoftwareMember_6eb7eb81-b4f7-469a-b3bc-49a38e1467bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_99cf56a5-b0ef-4b8d-b72d-f28dd3e26394" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_415bda01-4ad1-4669-8c1a-aecadf3a417c" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_99cf56a5-b0ef-4b8d-b72d-f28dd3e26394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_db31f856-724e-43b2-be46-9aa7c3e7b2af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_415bda01-4ad1-4669-8c1a-aecadf3a417c" xlink:to="loc_us-gaap_ConstructionInProgressMember_db31f856-724e-43b2-be46-9aa7c3e7b2af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2f5c5840-5774-47b9-b3cf-5eaa2a6ea8a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4a860ab6-f845-458e-9b3b-d47abd165770" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2f5c5840-5774-47b9-b3cf-5eaa2a6ea8a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_15595246-84d0-4fc1-b95a-38bfc3675aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2f5c5840-5774-47b9-b3cf-5eaa2a6ea8a7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_15595246-84d0-4fc1-b95a-38bfc3675aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_45c54444-a42e-4127-8e22-d4239eb7ddb6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2f5c5840-5774-47b9-b3cf-5eaa2a6ea8a7" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_45c54444-a42e-4127-8e22-d4239eb7ddb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_848db3c1-31fb-446c-9502-5b2759083bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2f5c5840-5774-47b9-b3cf-5eaa2a6ea8a7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_848db3c1-31fb-446c-9502-5b2759083bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/BalanceSheetAccountsNarrativeDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#BalanceSheetAccountsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/BalanceSheetAccountsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_9e8d0af3-3ba7-4bfc-8607-4b062fa9d26f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f0c56ea0-9281-4f94-9903-f602e646d924" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_9e8d0af3-3ba7-4bfc-8607-4b062fa9d26f" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f0c56ea0-9281-4f94-9903-f602e646d924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_80bb409a-67e1-4d17-b8ea-8920d66c5fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f0c56ea0-9281-4f94-9903-f602e646d924" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_80bb409a-67e1-4d17-b8ea-8920d66c5fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1e4cd9fc-aa6f-4082-95ef-2a50dd7a298c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_80bb409a-67e1-4d17-b8ea-8920d66c5fd4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1e4cd9fc-aa6f-4082-95ef-2a50dd7a298c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ConstructionInProgressReclassifiedToBuildingMember_e6eb21e0-979d-4755-bc48-3c98f5f6e48d" xlink:href="arwr-20250630.xsd#arwr_ConstructionInProgressReclassifiedToBuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1e4cd9fc-aa6f-4082-95ef-2a50dd7a298c" xlink:to="loc_arwr_ConstructionInProgressReclassifiedToBuildingMember_e6eb21e0-979d-4755-bc48-3c98f5f6e48d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_ae8f9d59-083c-491a-bfbb-b3bfb5adf51e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1e4cd9fc-aa6f-4082-95ef-2a50dd7a298c" xlink:to="loc_us-gaap_BuildingMember_ae8f9d59-083c-491a-bfbb-b3bfb5adf51e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ConstructionInProgressReclassifiedToManufacturingEquipmentMember_0442b0a7-dded-4f68-80d9-88638eb565ff" xlink:href="arwr-20250630.xsd#arwr_ConstructionInProgressReclassifiedToManufacturingEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1e4cd9fc-aa6f-4082-95ef-2a50dd7a298c" xlink:to="loc_arwr_ConstructionInProgressReclassifiedToManufacturingEquipmentMember_0442b0a7-dded-4f68-80d9-88638eb565ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ManufacturingEquipmentMember_381855fa-96ef-4b3d-8a74-4b491fa5dca1" xlink:href="arwr-20250630.xsd#arwr_ManufacturingEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1e4cd9fc-aa6f-4082-95ef-2a50dd7a298c" xlink:to="loc_arwr_ManufacturingEquipmentMember_381855fa-96ef-4b3d-8a74-4b491fa5dca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManufacturingFacilityMember_18168dbf-7c00-41cf-9d76-2a3535487a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ManufacturingFacilityMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1e4cd9fc-aa6f-4082-95ef-2a50dd7a298c" xlink:to="loc_us-gaap_ManufacturingFacilityMember_18168dbf-7c00-41cf-9d76-2a3535487a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_cc1e66f2-fd1c-457e-ab3b-d3919800842c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1e4cd9fc-aa6f-4082-95ef-2a50dd7a298c" xlink:to="loc_us-gaap_ConstructionInProgressMember_cc1e66f2-fd1c-457e-ab3b-d3919800842c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ed2ab0b6-4a3c-449f-b3a1-5a3617f2e6d3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f0c56ea0-9281-4f94-9903-f602e646d924" xlink:to="loc_srt_RangeAxis_ed2ab0b6-4a3c-449f-b3a1-5a3617f2e6d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_805391f8-fc34-406a-8ab6-c1f415fc4624" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ed2ab0b6-4a3c-449f-b3a1-5a3617f2e6d3" xlink:to="loc_srt_RangeMember_805391f8-fc34-406a-8ab6-c1f415fc4624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0be13a6d-0cf2-4c53-8d7a-dd88dce2ee62" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_805391f8-fc34-406a-8ab6-c1f415fc4624" xlink:to="loc_srt_MinimumMember_0be13a6d-0cf2-4c53-8d7a-dd88dce2ee62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_40ce975a-9851-4a7b-8155-66ae78ac6da1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_805391f8-fc34-406a-8ab6-c1f415fc4624" xlink:to="loc_srt_MaximumMember_40ce975a-9851-4a7b-8155-66ae78ac6da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_675bd3c2-1c77-461b-91f5-559bf92e1f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f0c56ea0-9281-4f94-9903-f602e646d924" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_675bd3c2-1c77-461b-91f5-559bf92e1f3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_d6d87fce-3be4-4183-94dd-9e1f8dace32a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_675bd3c2-1c77-461b-91f5-559bf92e1f3e" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_d6d87fce-3be4-4183-94dd-9e1f8dace32a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges_0ffe5769-b9e9-4efb-8858-81cd18549cad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTransfersAndChanges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_675bd3c2-1c77-461b-91f5-559bf92e1f3e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges_0ffe5769-b9e9-4efb-8858-81cd18549cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_f84b3307-aff7-4d66-8939-180b7638ea98" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_675bd3c2-1c77-461b-91f5-559bf92e1f3e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_f84b3307-aff7-4d66-8939-180b7638ea98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#BalanceSheetAccountsAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_92d57c80-86bf-4124-9109-63bb59416f1c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AccruedResearchAndDevelopmentExpenseCurrent_1c160f03-4668-402a-94df-16b1b505b081" xlink:href="arwr-20250630.xsd#arwr_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_92d57c80-86bf-4124-9109-63bb59416f1c" xlink:to="loc_arwr_AccruedResearchAndDevelopmentExpenseCurrent_1c160f03-4668-402a-94df-16b1b505b081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent_b707e390-f3d7-4037-8abc-d195786a6ba0" xlink:href="arwr-20250630.xsd#arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_92d57c80-86bf-4124-9109-63bb59416f1c" xlink:to="loc_arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent_b707e390-f3d7-4037-8abc-d195786a6ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AccruedCapitalExpenditureCurrent_cad38674-a7a4-473d-9c53-e3d32641c272" xlink:href="arwr-20250630.xsd#arwr_AccruedCapitalExpenditureCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_92d57c80-86bf-4124-9109-63bb59416f1c" xlink:to="loc_arwr_AccruedCapitalExpenditureCurrent_cad38674-a7a4-473d-9c53-e3d32641c272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_6131cd24-b8a7-4124-b53e-cfe440e56d66" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_92d57c80-86bf-4124-9109-63bb59416f1c" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_6131cd24-b8a7-4124-b53e-cfe440e56d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_66c581d8-4ad3-423d-9dfa-0c525246a145" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_92d57c80-86bf-4124-9109-63bb59416f1c" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_66c581d8-4ad3-423d-9dfa-0c525246a145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/InvestmentsScheduleofShorttermLongtermInvestmentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#InvestmentsScheduleofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/InvestmentsScheduleofShorttermLongtermInvestmentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_fb7055d2-ebb0-48ad-8693-1cdeee096812" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_9611cff4-f8e6-4256-aac9-90ac31f190dd" xlink:href="arwr-20250630.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_fb7055d2-ebb0-48ad-8693-1cdeee096812" xlink:to="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_9611cff4-f8e6-4256-aac9-90ac31f190dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_3194cca3-8936-40b9-b8eb-cd05460c8506" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_9611cff4-f8e6-4256-aac9-90ac31f190dd" xlink:to="loc_us-gaap_FinancialInstrumentAxis_3194cca3-8936-40b9-b8eb-cd05460c8506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5f24a95c-dbd0-4406-8709-4a1ba7175ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_3194cca3-8936-40b9-b8eb-cd05460c8506" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5f24a95c-dbd0-4406-8709-4a1ba7175ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_07c0b922-e517-4a30-ba5d-d5275eed9400" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5f24a95c-dbd0-4406-8709-4a1ba7175ac1" xlink:to="loc_us-gaap_DebtSecuritiesMember_07c0b922-e517-4a30-ba5d-d5275eed9400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_4214f89d-7481-4784-9500-676c621c800f" xlink:href="arwr-20250630.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_9611cff4-f8e6-4256-aac9-90ac31f190dd" xlink:to="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_4214f89d-7481-4784-9500-676c621c800f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_b84d88e7-8522-425e-ac87-25634d548a75" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_4214f89d-7481-4784-9500-676c621c800f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_b84d88e7-8522-425e-ac87-25634d548a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent_6428bfc7-f883-47c7-af71-08f5a3b0a1e0" xlink:href="arwr-20250630.xsd#arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_4214f89d-7481-4784-9500-676c621c800f" xlink:to="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent_6428bfc7-f883-47c7-af71-08f5a3b0a1e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent_74af1229-d154-4120-b087-78b5042865a3" xlink:href="arwr-20250630.xsd#arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_4214f89d-7481-4784-9500-676c621c800f" xlink:to="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent_74af1229-d154-4120-b087-78b5042865a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_36653925-7fa2-415f-a57b-cf8e399eaa7c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_4214f89d-7481-4784-9500-676c621c800f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_36653925-7fa2-415f-a57b-cf8e399eaa7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/InvestmentsScheduleofContractMaturityofAvailableforSaleDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#InvestmentsScheduleofContractMaturityofAvailableforSaleDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/InvestmentsScheduleofContractMaturityofAvailableforSaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_228763c0-6a82-49ce-955c-8cf30312a776" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_0c2a35a6-f3fa-4f4c-a9ff-3ada4436a019" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_228763c0-6a82-49ce-955c-8cf30312a776" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_0c2a35a6-f3fa-4f4c-a9ff-3ada4436a019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo_28d69a8a-ae3a-463a-ac97-7f79b0f167d7" xlink:href="arwr-20250630.xsd#arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_228763c0-6a82-49ce-955c-8cf30312a776" xlink:to="loc_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo_28d69a8a-ae3a-463a-ac97-7f79b0f167d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree_834d542a-872f-47ee-b29f-47e71a65ffc6" xlink:href="arwr-20250630.xsd#arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_228763c0-6a82-49ce-955c-8cf30312a776" xlink:to="loc_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree_834d542a-872f-47ee-b29f-47e71a65ffc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ef383a5b-3657-4f9d-820f-8a57adc62514" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_228763c0-6a82-49ce-955c-8cf30312a776" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ef383a5b-3657-4f9d-820f-8a57adc62514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#IntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8179414a-69f9-42d8-bd0a-44e3814b1ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_35f2e776-2ad3-4010-a459-f4e0be077f91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8179414a-69f9-42d8-bd0a-44e3814b1ee2" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_35f2e776-2ad3-4010-a459-f4e0be077f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_da83372b-2c6d-449c-b7e6-f50a13050fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_35f2e776-2ad3-4010-a459-f4e0be077f91" xlink:to="loc_us-gaap_AssetAcquisitionAxis_da83372b-2c6d-449c-b7e6-f50a13050fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_46870a52-eb54-4fc4-822a-d11b93e8d3ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_da83372b-2c6d-449c-b7e6-f50a13050fbf" xlink:to="loc_us-gaap_AssetAcquisitionDomain_46870a52-eb54-4fc4-822a-d11b93e8d3ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NovartisMember_38ae12e2-0381-438e-b180-f2bf718a3d92" xlink:href="arwr-20250630.xsd#arwr_NovartisMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_46870a52-eb54-4fc4-822a-d11b93e8d3ac" xlink:to="loc_arwr_NovartisMember_38ae12e2-0381-438e-b180-f2bf718a3d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a4b2db1a-a417-4f25-84b6-f16456fec732" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_35f2e776-2ad3-4010-a459-f4e0be077f91" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a4b2db1a-a417-4f25-84b6-f16456fec732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ae26fc99-4093-4d57-a661-f33c3d67c3f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a4b2db1a-a417-4f25-84b6-f16456fec732" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ae26fc99-4093-4d57-a661-f33c3d67c3f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_7cd53f17-1422-4488-b348-282cb30146e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PatentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ae26fc99-4093-4d57-a661-f33c3d67c3f5" xlink:to="loc_us-gaap_PatentsMember_7cd53f17-1422-4488-b348-282cb30146e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_9e2d46ce-359e-40ae-b7b8-055c2ab6169e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ae26fc99-4093-4d57-a661-f33c3d67c3f5" xlink:to="loc_us-gaap_LicensingAgreementsMember_9e2d46ce-359e-40ae-b7b8-055c2ab6169e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5281d430-a373-4f45-bac6-4f4b20b7ad20" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_35f2e776-2ad3-4010-a459-f4e0be077f91" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5281d430-a373-4f45-bac6-4f4b20b7ad20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_308141f6-c622-4ebb-99bb-57f420cc1ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5281d430-a373-4f45-bac6-4f4b20b7ad20" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_308141f6-c622-4ebb-99bb-57f420cc1ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_8cbd416f-cbbd-4f29-9cef-67810b14cd0c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5281d430-a373-4f45-bac6-4f4b20b7ad20" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_8cbd416f-cbbd-4f29-9cef-67810b14cd0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FiniteLivedIntangibleAssetsImpairment_7b3579e3-508d-4741-90e4-cc5910d2dc0f" xlink:href="arwr-20250630.xsd#arwr_FiniteLivedIntangibleAssetsImpairment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5281d430-a373-4f45-bac6-4f4b20b7ad20" xlink:to="loc_arwr_FiniteLivedIntangibleAssetsImpairment_7b3579e3-508d-4741-90e4-cc5910d2dc0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7f4a4f4c-c3d8-49ae-b39e-d277a7033602" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5281d430-a373-4f45-bac6-4f4b20b7ad20" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7f4a4f4c-c3d8-49ae-b39e-d277a7033602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_62e41365-3f80-415d-887c-bcbee52b29fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5281d430-a373-4f45-bac6-4f4b20b7ad20" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_62e41365-3f80-415d-887c-bcbee52b29fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_26f36e24-4da9-4577-ad78-d7488a23b4bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8179414a-69f9-42d8-bd0a-44e3814b1ee2" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_26f36e24-4da9-4577-ad78-d7488a23b4bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofExpectedFutureAmortizationDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#IntangibleAssetsScheduleofExpectedFutureAmortizationDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofExpectedFutureAmortizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_52f46164-1b07-40d4-8260-815075225b63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_67141a26-cca6-4c39-bf08-13078f51f34f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_52f46164-1b07-40d4-8260-815075225b63" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_67141a26-cca6-4c39-bf08-13078f51f34f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_e62908d4-f75e-48eb-8614-203c26b45109" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_52f46164-1b07-40d4-8260-815075225b63" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_e62908d4-f75e-48eb-8614-203c26b45109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_14e60618-2346-4384-8deb-bafb8db27673" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_52f46164-1b07-40d4-8260-815075225b63" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_14e60618-2346-4384-8deb-bafb8db27673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_9de28fc2-041f-41d1-90e8-fa6dda470c73" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_52f46164-1b07-40d4-8260-815075225b63" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_9de28fc2-041f-41d1-90e8-fa6dda470c73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_ea69f409-4e6f-4253-bb17-09bb8ed56520" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_52f46164-1b07-40d4-8260-815075225b63" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_ea69f409-4e6f-4253-bb17-09bb8ed56520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_8fde05e5-c418-4278-b24b-c04a38b255f1" xlink:href="arwr-20250630.xsd#arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_52f46164-1b07-40d4-8260-815075225b63" xlink:to="loc_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_8fde05e5-c418-4278-b24b-c04a38b255f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b3c1a8d2-1feb-4987-b1c9-cac6bac6f3fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_52f46164-1b07-40d4-8260-815075225b63" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b3c1a8d2-1feb-4987-b1c9-cac6bac6f3fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockholdersEquityScheduleofSharesofCommonStockandPreferredStockDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#StockholdersEquityScheduleofSharesofCommonStockandPreferredStockDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockholdersEquityScheduleofSharesofCommonStockandPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_39b57196-d6d5-402d-96fb-8aaad049f9cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_869a0aec-c4f6-4ed1-bd3c-6eeeabe0d665" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_39b57196-d6d5-402d-96fb-8aaad049f9cb" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_869a0aec-c4f6-4ed1-bd3c-6eeeabe0d665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_583d70ce-78d2-4c59-9f29-4b5e11ecf3d9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_39b57196-d6d5-402d-96fb-8aaad049f9cb" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_583d70ce-78d2-4c59-9f29-4b5e11ecf3d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_e9b45d7f-1543-4153-8df3-d6e1236aaad7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_39b57196-d6d5-402d-96fb-8aaad049f9cb" xlink:to="loc_us-gaap_CommonStockSharesIssued_e9b45d7f-1543-4153-8df3-d6e1236aaad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_69d2b9ed-4647-42a8-bab9-836c8ec09a29" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_39b57196-d6d5-402d-96fb-8aaad049f9cb" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_69d2b9ed-4647-42a8-bab9-836c8ec09a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_e29aa38c-1ab3-46de-8fc1-1a468b4964de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_39b57196-d6d5-402d-96fb-8aaad049f9cb" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_e29aa38c-1ab3-46de-8fc1-1a468b4964de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_e420525c-8c30-4ee7-906f-9ae4da9960aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_39b57196-d6d5-402d-96fb-8aaad049f9cb" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_e420525c-8c30-4ee7-906f-9ae4da9960aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_41921c10-2f27-47df-a742-e5af3c1ac520" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_39b57196-d6d5-402d-96fb-8aaad049f9cb" xlink:to="loc_us-gaap_PreferredStockSharesIssued_41921c10-2f27-47df-a742-e5af3c1ac520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_5b05f22c-fd9e-40f0-a548-e3829bf9435e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_39b57196-d6d5-402d-96fb-8aaad049f9cb" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_5b05f22c-fd9e-40f0-a548-e3829bf9435e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ee571e7c-b1af-48a7-b9b1-10473f3e5013" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_6a9e6ecf-5632-48ab-a1c1-f8b84d5aa690" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ee571e7c-b1af-48a7-b9b1-10473f3e5013" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_6a9e6ecf-5632-48ab-a1c1-f8b84d5aa690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_83502b57-979c-49bd-be65-098d79bf8614" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6a9e6ecf-5632-48ab-a1c1-f8b84d5aa690" xlink:to="loc_us-gaap_PlanNameAxis_83502b57-979c-49bd-be65-098d79bf8614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ba04740e-484a-4154-9a77-161b97c5b46a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_83502b57-979c-49bd-be65-098d79bf8614" xlink:to="loc_us-gaap_PlanNameDomain_ba04740e-484a-4154-9a77-161b97c5b46a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_47b4e6a6-aeca-4173-8def-a389709ebe55" xlink:href="arwr-20250630.xsd#arwr_TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_ba04740e-484a-4154-9a77-161b97c5b46a" xlink:to="loc_arwr_TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_47b4e6a6-aeca-4173-8def-a389709ebe55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8cd1a559-f751-4240-8c53-3a41b3bc856a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6a9e6ecf-5632-48ab-a1c1-f8b84d5aa690" xlink:to="loc_srt_RangeAxis_8cd1a559-f751-4240-8c53-3a41b3bc856a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9e243bf4-cd93-4f60-a206-320e59ac2338" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8cd1a559-f751-4240-8c53-3a41b3bc856a" xlink:to="loc_srt_RangeMember_9e243bf4-cd93-4f60-a206-320e59ac2338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_322d66c7-480e-4a06-8a53-b8ce720f5f69" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9e243bf4-cd93-4f60-a206-320e59ac2338" xlink:to="loc_srt_MaximumMember_322d66c7-480e-4a06-8a53-b8ce720f5f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_08a0b7d9-b01e-4e5d-a441-bde824f22e80" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6a9e6ecf-5632-48ab-a1c1-f8b84d5aa690" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_08a0b7d9-b01e-4e5d-a441-bde824f22e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ff3d77f9-67f1-423a-bbd2-614a29b6b319" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_08a0b7d9-b01e-4e5d-a441-bde824f22e80" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ff3d77f9-67f1-423a-bbd2-614a29b6b319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_c834d2f1-e8c6-418b-aead-164a5551af09" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ff3d77f9-67f1-423a-bbd2-614a29b6b319" xlink:to="loc_us-gaap_PrivatePlacementMember_c834d2f1-e8c6-418b-aead-164a5551af09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AtTheMarketAgreementMember_f91b9914-ba36-4ee9-a53b-506b47683cc6" xlink:href="arwr-20250630.xsd#arwr_AtTheMarketAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ff3d77f9-67f1-423a-bbd2-614a29b6b319" xlink:to="loc_arwr_AtTheMarketAgreementMember_f91b9914-ba36-4ee9-a53b-506b47683cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_9b50c1b4-5c8d-4b75-955f-0015e9eb27f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6a9e6ecf-5632-48ab-a1c1-f8b84d5aa690" xlink:to="loc_us-gaap_ClassOfStockLineItems_9b50c1b4-5c8d-4b75-955f-0015e9eb27f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6e4f7f84-1fbe-4c8c-a376-696688402a65" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9b50c1b4-5c8d-4b75-955f-0015e9eb27f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6e4f7f84-1fbe-4c8c-a376-696688402a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_f9013677-b316-4b1d-b951-2f5b5524bba1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9b50c1b4-5c8d-4b75-955f-0015e9eb27f0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_f9013677-b316-4b1d-b951-2f5b5524bba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_fe0af6cf-266f-40d1-ae74-b70c2fcde4be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9b50c1b4-5c8d-4b75-955f-0015e9eb27f0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_fe0af6cf-266f-40d1-ae74-b70c2fcde4be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights_7655d8f7-90d3-4b5d-ba19-7ebf0a16043d" xlink:href="arwr-20250630.xsd#arwr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9b50c1b4-5c8d-4b75-955f-0015e9eb27f0" xlink:to="loc_arwr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights_7655d8f7-90d3-4b5d-ba19-7ebf0a16043d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_32a69d88-79ae-4384-bfe4-291e55f039ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9b50c1b4-5c8d-4b75-955f-0015e9eb27f0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_32a69d88-79ae-4384-bfe4-291e55f039ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ClassOfWarrantOrRightNumberOfWarrantsExercised_4d65eed7-8f70-4f17-bfe7-4b5bcdb5a1d1" xlink:href="arwr-20250630.xsd#arwr_ClassOfWarrantOrRightNumberOfWarrantsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9b50c1b4-5c8d-4b75-955f-0015e9eb27f0" xlink:to="loc_arwr_ClassOfWarrantOrRightNumberOfWarrantsExercised_4d65eed7-8f70-4f17-bfe7-4b5bcdb5a1d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a012e369-7ff4-44a5-be97-a2ba9babb963" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9b50c1b4-5c8d-4b75-955f-0015e9eb27f0" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a012e369-7ff4-44a5-be97-a2ba9babb963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_ca6c6ac3-4b48-4315-9b41-7d463596254a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9b50c1b4-5c8d-4b75-955f-0015e9eb27f0" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_ca6c6ac3-4b48-4315-9b41-7d463596254a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_83993802-62b8-4b7e-8fa3-659e710a719a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9b50c1b4-5c8d-4b75-955f-0015e9eb27f0" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_83993802-62b8-4b7e-8fa3-659e710a719a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_77082986-cfb1-47c7-b5eb-6fdf2475cb06" xlink:href="arwr-20250630.xsd#arwr_CommonStockCapitalSharesValueReservedForFutureIssuance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9b50c1b4-5c8d-4b75-955f-0015e9eb27f0" xlink:to="loc_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_77082986-cfb1-47c7-b5eb-6fdf2475cb06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_febc4aa5-8aa6-4aa7-8732-49d62bab9aea" xlink:href="arwr-20250630.xsd#arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9b50c1b4-5c8d-4b75-955f-0015e9eb27f0" xlink:to="loc_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_febc4aa5-8aa6-4aa7-8732-49d62bab9aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_52778111-e531-403d-a47b-5a77252f537e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9b50c1b4-5c8d-4b75-955f-0015e9eb27f0" xlink:to="loc_us-gaap_SharesIssued_52778111-e531-403d-a47b-5a77252f537e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e7c05214-c4a7-4ec1-ba6f-00804fe6eb86" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_da4ee496-2dd4-4d58-9016-39ccedcace0b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e7c05214-c4a7-4ec1-ba6f-00804fe6eb86" xlink:to="loc_us-gaap_OtherCommitmentsTable_da4ee496-2dd4-4d58-9016-39ccedcace0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6e25c620-7432-4c4d-af9c-9688b8e61386" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_da4ee496-2dd4-4d58-9016-39ccedcace0b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6e25c620-7432-4c4d-af9c-9688b8e61386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2ea445f3-8535-4ec4-8b98-fd1232a0cedb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6e25c620-7432-4c4d-af9c-9688b8e61386" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2ea445f3-8535-4ec4-8b98-fd1232a0cedb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DrugManufacturingFacilityMember_9d91ffd6-7387-4f27-a2d6-b8a95e7b5c8f" xlink:href="arwr-20250630.xsd#arwr_DrugManufacturingFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2ea445f3-8535-4ec4-8b98-fd1232a0cedb" xlink:to="loc_arwr_DrugManufacturingFacilityMember_9d91ffd6-7387-4f27-a2d6-b8a95e7b5c8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LaboratoryAndOfficeFacilityMember_67db8487-f8e2-4de7-98bc-a858e9aced5b" xlink:href="arwr-20250630.xsd#arwr_LaboratoryAndOfficeFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2ea445f3-8535-4ec4-8b98-fd1232a0cedb" xlink:to="loc_arwr_LaboratoryAndOfficeFacilityMember_67db8487-f8e2-4de7-98bc-a858e9aced5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FacilitiesMember_debf743e-c039-4037-a66a-3597b1c3dcfc" xlink:href="arwr-20250630.xsd#arwr_FacilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2ea445f3-8535-4ec4-8b98-fd1232a0cedb" xlink:to="loc_arwr_FacilitiesMember_debf743e-c039-4037-a66a-3597b1c3dcfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchEquipmentMember_e0153c93-7013-4608-9435-05caede73670" xlink:href="arwr-20250630.xsd#arwr_ResearchEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2ea445f3-8535-4ec4-8b98-fd1232a0cedb" xlink:to="loc_arwr_ResearchEquipmentMember_e0153c93-7013-4608-9435-05caede73670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_503a1206-c44f-4485-bf8d-e4ab55da015a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2ea445f3-8535-4ec4-8b98-fd1232a0cedb" xlink:to="loc_us-gaap_BuildingMember_503a1206-c44f-4485-bf8d-e4ab55da015a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ManufacturingEquipmentMember_88dbcbdd-b37d-49f9-8e50-9e57bebbebf2" xlink:href="arwr-20250630.xsd#arwr_ManufacturingEquipmentMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2ea445f3-8535-4ec4-8b98-fd1232a0cedb" xlink:to="loc_arwr_ManufacturingEquipmentMember_88dbcbdd-b37d-49f9-8e50-9e57bebbebf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_9090b12a-6a91-4a49-b9c1-f647dc093e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2ea445f3-8535-4ec4-8b98-fd1232a0cedb" xlink:to="loc_us-gaap_ConstructionInProgressMember_9090b12a-6a91-4a49-b9c1-f647dc093e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_785f6457-4794-4bd2-bc38-a2eba00d5d7a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_da4ee496-2dd4-4d58-9016-39ccedcace0b" xlink:to="loc_srt_StatementGeographicalAxis_785f6457-4794-4bd2-bc38-a2eba00d5d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8e5236e2-35ab-43fc-a8ac-01ed47438b7f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_785f6457-4794-4bd2-bc38-a2eba00d5d7a" xlink:to="loc_srt_SegmentGeographicalDomain_8e5236e2-35ab-43fc-a8ac-01ed47438b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WI_9e212f1e-b6f7-47c1-87e7-90d7b2d9a6f7" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_WI"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8e5236e2-35ab-43fc-a8ac-01ed47438b7f" xlink:to="loc_stpr_WI_9e212f1e-b6f7-47c1-87e7-90d7b2d9a6f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_9adc3e7e-0d84-440c-b53f-0ded04c4795b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_da4ee496-2dd4-4d58-9016-39ccedcace0b" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_9adc3e7e-0d84-440c-b53f-0ded04c4795b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_621607e1-8e64-4f3b-a811-31187a801ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9adc3e7e-0d84-440c-b53f-0ded04c4795b" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_621607e1-8e64-4f3b-a811-31187a801ba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfLand_586c0ae0-5f07-4acd-832d-330ad5e0f0b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AreaOfLand"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9adc3e7e-0d84-440c-b53f-0ded04c4795b" xlink:to="loc_us-gaap_AreaOfLand_586c0ae0-5f07-4acd-832d-330ad5e0f0b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommitmentsCapitalExpendituresIncurredToDate_ca87eb2b-d55d-4d4c-b08e-a2fb6222fcb4" xlink:href="arwr-20250630.xsd#arwr_CommitmentsCapitalExpendituresIncurredToDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9adc3e7e-0d84-440c-b53f-0ded04c4795b" xlink:to="loc_arwr_CommitmentsCapitalExpendituresIncurredToDate_ca87eb2b-d55d-4d4c-b08e-a2fb6222fcb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmountIntendsToInvestForBuildoutOfFacilities_296ebab7-e19f-40b0-b542-1ea3fd37698f" xlink:href="arwr-20250630.xsd#arwr_AmountIntendsToInvestForBuildoutOfFacilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9adc3e7e-0d84-440c-b53f-0ded04c4795b" xlink:to="loc_arwr_AmountIntendsToInvestForBuildoutOfFacilities_296ebab7-e19f-40b0-b542-1ea3fd37698f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_e8c4c64c-d2e1-4dbe-adc2-9ee57faccaf2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_45d51690-83af-49fa-8afb-6f5749d36ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e8c4c64c-d2e1-4dbe-adc2-9ee57faccaf2" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_45d51690-83af-49fa-8afb-6f5749d36ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_118eaa98-1689-4d66-993a-18484a6abf67" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_45d51690-83af-49fa-8afb-6f5749d36ad0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_118eaa98-1689-4d66-993a-18484a6abf67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_94c39ab5-bbd7-49aa-8782-849185bfd2f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_118eaa98-1689-4d66-993a-18484a6abf67" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_94c39ab5-bbd7-49aa-8782-849185bfd2f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CorporateHeadquartersInPasadenaMember_d4d8e64a-f6fd-4ea3-8ae6-bef252d046b5" xlink:href="arwr-20250630.xsd#arwr_CorporateHeadquartersInPasadenaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_94c39ab5-bbd7-49aa-8782-849185bfd2f0" xlink:to="loc_arwr_CorporateHeadquartersInPasadenaMember_d4d8e64a-f6fd-4ea3-8ae6-bef252d046b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchFacilityInSanDiegoMember_5870f169-c853-4166-8825-e18a5a78fd12" xlink:href="arwr-20250630.xsd#arwr_ResearchFacilityInSanDiegoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_94c39ab5-bbd7-49aa-8782-849185bfd2f0" xlink:to="loc_arwr_ResearchFacilityInSanDiegoMember_5870f169-c853-4166-8825-e18a5a78fd12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchFacilityInMadisonMember_40e29296-2314-48ee-aaee-b1c9fa1cff84" xlink:href="arwr-20250630.xsd#arwr_ResearchFacilityInMadisonMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_94c39ab5-bbd7-49aa-8782-849185bfd2f0" xlink:to="loc_arwr_ResearchFacilityInMadisonMember_40e29296-2314-48ee-aaee-b1c9fa1cff84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_4ba4ce78-e8ef-4d0a-892a-72806446a625" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_45d51690-83af-49fa-8afb-6f5749d36ad0" xlink:to="loc_srt_StatementGeographicalAxis_4ba4ce78-e8ef-4d0a-892a-72806446a625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_dc72155b-4bb1-4237-b2f0-ac77ca2ec84d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_4ba4ce78-e8ef-4d0a-892a-72806446a625" xlink:to="loc_srt_SegmentGeographicalDomain_dc72155b-4bb1-4237-b2f0-ac77ca2ec84d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_d2bef77c-830d-456f-bc1d-c26d44e7dca5" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_CA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_dc72155b-4bb1-4237-b2f0-ac77ca2ec84d" xlink:to="loc_stpr_CA_d2bef77c-830d-456f-bc1d-c26d44e7dca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WI_2abb2569-0a06-41b3-aaa5-c3ab3e014718" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_WI"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_dc72155b-4bb1-4237-b2f0-ac77ca2ec84d" xlink:to="loc_stpr_WI_2abb2569-0a06-41b3-aaa5-c3ab3e014718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c01b8595-714b-4d85-b4bb-b981b35def6e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_45d51690-83af-49fa-8afb-6f5749d36ad0" xlink:to="loc_srt_CounterpartyNameAxis_c01b8595-714b-4d85-b4bb-b981b35def6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b552e736-a208-4650-bc52-7e2f305210f7" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_c01b8595-714b-4d85-b4bb-b981b35def6e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b552e736-a208-4650-bc52-7e2f305210f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ColoradoOwnerLLCMember_00c803c9-9058-419c-b231-9ff39349caa5" xlink:href="arwr-20250630.xsd#arwr_ColoradoOwnerLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b552e736-a208-4650-bc52-7e2f305210f7" xlink:to="loc_arwr_ColoradoOwnerLLCMember_00c803c9-9058-419c-b231-9ff39349caa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9908d5fa-6ba4-489f-824f-022fb0d8d974" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_45d51690-83af-49fa-8afb-6f5749d36ad0" xlink:to="loc_srt_RangeAxis_9908d5fa-6ba4-489f-824f-022fb0d8d974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4a214eaa-b844-4d6f-9aee-e18b938c36ed" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9908d5fa-6ba4-489f-824f-022fb0d8d974" xlink:to="loc_srt_RangeMember_4a214eaa-b844-4d6f-9aee-e18b938c36ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a83723d5-6713-4081-8c3a-0b36761b3e90" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4a214eaa-b844-4d6f-9aee-e18b938c36ed" xlink:to="loc_srt_MaximumMember_a83723d5-6713-4081-8c3a-0b36761b3e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_46e416fa-c110-4f63-b26a-305516efea8a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_45d51690-83af-49fa-8afb-6f5749d36ad0" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_46e416fa-c110-4f63-b26a-305516efea8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases_52098a9b-3bc7-4cda-8c25-ba7d69e3e9a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_46e416fa-c110-4f63-b26a-305516efea8a" xlink:to="loc_us-gaap_LandSubjectToGroundLeases_52098a9b-3bc7-4cda-8c25-ba7d69e3e9a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfOptionsToRenew_303487d9-9b53-4f65-a101-1dd54002bec4" xlink:href="arwr-20250630.xsd#arwr_NumberOfOptionsToRenew"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_46e416fa-c110-4f63-b26a-305516efea8a" xlink:to="loc_arwr_NumberOfOptionsToRenew_303487d9-9b53-4f65-a101-1dd54002bec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_7d0c2d92-3fdc-4c91-86f2-244b68a6ae97" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_46e416fa-c110-4f63-b26a-305516efea8a" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_7d0c2d92-3fdc-4c91-86f2-244b68a6ae97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_f831a402-e42f-49a9-b74e-af31ac47e1cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_46e416fa-c110-4f63-b26a-305516efea8a" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_f831a402-e42f-49a9-b74e-af31ac47e1cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ProceedsFromTenantImprovementAllowance_0f3b97ef-048b-4444-8a8e-4c5d66badf76" xlink:href="arwr-20250630.xsd#arwr_ProceedsFromTenantImprovementAllowance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_46e416fa-c110-4f63-b26a-305516efea8a" xlink:to="loc_arwr_ProceedsFromTenantImprovementAllowance_0f3b97ef-048b-4444-8a8e-4c5d66badf76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_89752f6b-7fef-4446-95c2-998442ac3de0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_46e416fa-c110-4f63-b26a-305516efea8a" xlink:to="loc_us-gaap_ShortTermLeaseCost_89752f6b-7fef-4446-95c2-998442ac3de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesScheduleofComponentsofLeaseAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#LeasesScheduleofComponentsofLeaseAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesScheduleofComponentsofLeaseAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d0e65ea1-d813-413a-a932-8d3887575325" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_f3e35633-fa90-479e-8204-00b342277ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d0e65ea1-d813-413a-a932-8d3887575325" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_f3e35633-fa90-479e-8204-00b342277ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4a5e0e51-b062-403c-89f3-796093c4e7b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_f3e35633-fa90-479e-8204-00b342277ed7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4a5e0e51-b062-403c-89f3-796093c4e7b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8e2826c5-3639-4594-92c0-41a94cd553bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4a5e0e51-b062-403c-89f3-796093c4e7b9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8e2826c5-3639-4594-92c0-41a94cd553bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_358572f0-aed6-48b8-be46-d3bee66791a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8e2826c5-3639-4594-92c0-41a94cd553bd" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_358572f0-aed6-48b8-be46-d3bee66791a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4a82fcdc-e183-40e1-a58a-d96713686237" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8e2826c5-3639-4594-92c0-41a94cd553bd" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4a82fcdc-e183-40e1-a58a-d96713686237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_a10b2d46-dd31-459a-b5ed-cc8bd4fd0b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_f3e35633-fa90-479e-8204-00b342277ed7" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_a10b2d46-dd31-459a-b5ed-cc8bd4fd0b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_5fb88148-23be-434e-8633-4c4a84623280" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_a10b2d46-dd31-459a-b5ed-cc8bd4fd0b6d" xlink:to="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_5fb88148-23be-434e-8633-4c4a84623280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_9c8d8d63-27c4-4d6b-a495-5c00bbaaa689" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_5fb88148-23be-434e-8633-4c4a84623280" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_9c8d8d63-27c4-4d6b-a495-5c00bbaaa689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_360ed63b-1b2f-42e2-9d47-c246201ebef1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_5fb88148-23be-434e-8633-4c4a84623280" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_360ed63b-1b2f-42e2-9d47-c246201ebef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ff05413d-be12-49cb-862c-776f1099de4d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_5fb88148-23be-434e-8633-4c4a84623280" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ff05413d-be12-49cb-862c-776f1099de4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_5209d901-0bc2-48fe-b0ed-3116133070bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_a10b2d46-dd31-459a-b5ed-cc8bd4fd0b6d" xlink:to="loc_us-gaap_LeaseCostAbstract_5209d901-0bc2-48fe-b0ed-3116133070bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_4ae33847-5057-4457-9416-d4256e82fdbf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_5209d901-0bc2-48fe-b0ed-3116133070bb" xlink:to="loc_us-gaap_OperatingLeaseCost_4ae33847-5057-4457-9416-d4256e82fdbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_b54a7a36-dc7d-480c-9896-03bc2ac61c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_5209d901-0bc2-48fe-b0ed-3116133070bb" xlink:to="loc_us-gaap_VariableLeaseCost_b54a7a36-dc7d-480c-9896-03bc2ac61c8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_fc505bbd-d6e3-49a9-948f-45859037f3ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_5209d901-0bc2-48fe-b0ed-3116133070bb" xlink:to="loc_us-gaap_LeaseCost_fc505bbd-d6e3-49a9-948f-45859037f3ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a9a5a165-295d-4529-8666-af004a547c19" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_ab9f5a58-4889-4671-9812-c789c941f053" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a9a5a165-295d-4529-8666-af004a547c19" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_ab9f5a58-4889-4671-9812-c789c941f053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c111225d-b77f-437d-882a-3ee916f173d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a9a5a165-295d-4529-8666-af004a547c19" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c111225d-b77f-437d-882a-3ee916f173d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3c091ffa-0b5a-4ed4-9ea7-603cc20c7d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a9a5a165-295d-4529-8666-af004a547c19" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3c091ffa-0b5a-4ed4-9ea7-603cc20c7d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_75852a2e-9214-4ac4-b8a4-80863841ed22" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a9a5a165-295d-4529-8666-af004a547c19" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_75852a2e-9214-4ac4-b8a4-80863841ed22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_7dc637c3-67cd-48c3-b3ea-9ff8903dd492" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a9a5a165-295d-4529-8666-af004a547c19" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_7dc637c3-67cd-48c3-b3ea-9ff8903dd492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_a5d55d03-bf03-4007-87ad-04f72619033e" xlink:href="arwr-20250630.xsd#arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a9a5a165-295d-4529-8666-af004a547c19" xlink:to="loc_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_a5d55d03-bf03-4007-87ad-04f72619033e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_35ac4a78-30e8-4e81-8887-528638184f73" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a9a5a165-295d-4529-8666-af004a547c19" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_35ac4a78-30e8-4e81-8887-528638184f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a4b2d2d7-b699-4237-ba59-a948420bb30f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a9a5a165-295d-4529-8666-af004a547c19" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a4b2d2d7-b699-4237-ba59-a948420bb30f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_922bb3c3-52db-47ce-b7f3-46a8bddbe79f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a9a5a165-295d-4529-8666-af004a547c19" xlink:to="loc_us-gaap_OperatingLeaseLiability_922bb3c3-52db-47ce-b7f3-46a8bddbe79f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesScheduleofCashFlowandOtherInformationRelatedtoLeasesDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#LeasesScheduleofCashFlowandOtherInformationRelatedtoLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesScheduleofCashFlowandOtherInformationRelatedtoLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f8de98d3-e3ad-4ca9-b7b7-dd4ddcb30ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_360d23dc-2744-4b62-a1b8-47f31f1abbf5" xlink:href="arwr-20250630.xsd#arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f8de98d3-e3ad-4ca9-b7b7-dd4ddcb30ba9" xlink:to="loc_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_360d23dc-2744-4b62-a1b8-47f31f1abbf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities_0505699c-bc75-48ea-9fba-779abac0c2c6" xlink:href="arwr-20250630.xsd#arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_360d23dc-2744-4b62-a1b8-47f31f1abbf5" xlink:to="loc_arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities_0505699c-bc75-48ea-9fba-779abac0c2c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability_61d5324a-1786-41ab-a315-ad170de1dc7d" xlink:href="arwr-20250630.xsd#arwr_RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_360d23dc-2744-4b62-a1b8-47f31f1abbf5" xlink:to="loc_arwr_RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability_61d5324a-1786-41ab-a315-ad170de1dc7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_8e32bd67-8612-4cbc-a29c-cac6424943e9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f8de98d3-e3ad-4ca9-b7b7-dd4ddcb30ba9" xlink:to="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_8e32bd67-8612-4cbc-a29c-cac6424943e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_e655fd3a-7411-4623-944f-d8313a0bc0ff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_8e32bd67-8612-4cbc-a29c-cac6424943e9" xlink:to="loc_us-gaap_OperatingLeasePayments_e655fd3a-7411-4623-944f-d8313a0bc0ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_d7f512d0-f7c1-48ee-912f-96896f09cf20" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f8de98d3-e3ad-4ca9-b7b7-dd4ddcb30ba9" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_d7f512d0-f7c1-48ee-912f-96896f09cf20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_c1936c88-9e1b-4cef-bd97-e3eb1a79f0c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f8de98d3-e3ad-4ca9-b7b7-dd4ddcb30ba9" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_c1936c88-9e1b-4cef-bd97-e3eb1a79f0c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b828de58-41e2-4d4a-ac1c-f4a722bd67b0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62f14a94-cfd1-4adf-a968-6d165c58ec33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b828de58-41e2-4d4a-ac1c-f4a722bd67b0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62f14a94-cfd1-4adf-a968-6d165c58ec33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_27ec3f67-ca4a-4740-99d4-77061f9fdaf8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62f14a94-cfd1-4adf-a968-6d165c58ec33" xlink:to="loc_us-gaap_PlanNameAxis_27ec3f67-ca4a-4740-99d4-77061f9fdaf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_5fa6d8aa-776f-41bb-9838-2cddf6ea4133" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_27ec3f67-ca4a-4740-99d4-77061f9fdaf8" xlink:to="loc_us-gaap_PlanNameDomain_5fa6d8aa-776f-41bb-9838-2cddf6ea4133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsThirteenIncentivePlanMember_49323e26-d4c8-4a60-939e-06ab3978876b" xlink:href="arwr-20250630.xsd#arwr_TwoThousandsThirteenIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_5fa6d8aa-776f-41bb-9838-2cddf6ea4133" xlink:to="loc_arwr_TwoThousandsThirteenIncentivePlanMember_49323e26-d4c8-4a60-939e-06ab3978876b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_769d7945-a43a-48e9-94ee-98da00d78500" xlink:href="arwr-20250630.xsd#arwr_TwoThousandTwentyOneIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_5fa6d8aa-776f-41bb-9838-2cddf6ea4133" xlink:to="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_769d7945-a43a-48e9-94ee-98da00d78500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InducementPlanMember_32d6654e-217d-40ca-8eb3-6b83716ec3a5" xlink:href="arwr-20250630.xsd#arwr_InducementPlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_5fa6d8aa-776f-41bb-9838-2cddf6ea4133" xlink:to="loc_arwr_InducementPlanMember_32d6654e-217d-40ca-8eb3-6b83716ec3a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VisirnaESOPMember_64f3128d-3af2-4192-aacf-9a479e94110d" xlink:href="arwr-20250630.xsd#arwr_VisirnaESOPMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_5fa6d8aa-776f-41bb-9838-2cddf6ea4133" xlink:to="loc_arwr_VisirnaESOPMember_64f3128d-3af2-4192-aacf-9a479e94110d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a19f6890-9b3d-4709-8304-b87e2bfaf2e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62f14a94-cfd1-4adf-a968-6d165c58ec33" xlink:to="loc_us-gaap_AwardTypeAxis_a19f6890-9b3d-4709-8304-b87e2bfaf2e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_523491b7-0b52-4318-a616-af55776434bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a19f6890-9b3d-4709-8304-b87e2bfaf2e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_523491b7-0b52-4318-a616-af55776434bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_cce84e6e-ff85-450c-a256-fbc418839aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_523491b7-0b52-4318-a616-af55776434bd" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_cce84e6e-ff85-450c-a256-fbc418839aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_65a27ae0-bdb7-4162-8ccb-ef4476dcc409" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_523491b7-0b52-4318-a616-af55776434bd" xlink:to="loc_us-gaap_EmployeeStockOptionMember_65a27ae0-bdb7-4162-8ccb-ef4476dcc409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a1321e7-b5e9-4052-82fb-5587e5836226" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62f14a94-cfd1-4adf-a968-6d165c58ec33" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a1321e7-b5e9-4052-82fb-5587e5836226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_c4e502f2-2866-4808-8aa0-8629b65f9b37" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a1321e7-b5e9-4052-82fb-5587e5836226" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_c4e502f2-2866-4808-8aa0-8629b65f9b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_d676f481-d0b3-4767-8932-d2c03bdfd623" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a1321e7-b5e9-4052-82fb-5587e5836226" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_d676f481-d0b3-4767-8932-d2c03bdfd623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ceaa2d47-7508-4d09-a432-671568246b88" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a1321e7-b5e9-4052-82fb-5587e5836226" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ceaa2d47-7508-4d09-a432-671568246b88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_978651d0-f3b3-463e-86d6-28f09dac3453" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a1321e7-b5e9-4052-82fb-5587e5836226" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_978651d0-f3b3-463e-86d6-28f09dac3453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_374261f1-eab7-4d1d-88b8-7b7f9beca488" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a1321e7-b5e9-4052-82fb-5587e5836226" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_374261f1-eab7-4d1d-88b8-7b7f9beca488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_73eb54ce-4eb7-4654-96bb-29d237c94b21" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a1321e7-b5e9-4052-82fb-5587e5836226" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_73eb54ce-4eb7-4654-96bb-29d237c94b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_69b86453-eb9e-49ca-88c6-cee009871ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a1321e7-b5e9-4052-82fb-5587e5836226" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_69b86453-eb9e-49ca-88c6-cee009871ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_15340836-cfe2-4f6a-81f4-edeb3f526905" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a1321e7-b5e9-4052-82fb-5587e5836226" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_15340836-cfe2-4f6a-81f4-edeb3f526905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_4f90b98c-da77-425d-83f1-752081ffa395" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a1321e7-b5e9-4052-82fb-5587e5836226" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_4f90b98c-da77-425d-83f1-752081ffa395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_c94eba51-9814-401f-bc1f-23d9ba01d698" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a1321e7-b5e9-4052-82fb-5587e5836226" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_c94eba51-9814-401f-bc1f-23d9ba01d698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_512001f5-faef-489d-9d05-765e2994214d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a1321e7-b5e9-4052-82fb-5587e5836226" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_512001f5-faef-489d-9d05-765e2994214d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofGrantedandOutstandingSharesDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#StockBasedCompensationScheduleofGrantedandOutstandingSharesDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofGrantedandOutstandingSharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_820da4ed-29d8-4a1f-afb0-f1dda598f348" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_04c46dcb-a713-4b37-bfff-964fb42a6985" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_820da4ed-29d8-4a1f-afb0-f1dda598f348" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_04c46dcb-a713-4b37-bfff-964fb42a6985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_4644962f-b333-4edc-8cdc-f120fad63c34" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_04c46dcb-a713-4b37-bfff-964fb42a6985" xlink:to="loc_us-gaap_PlanNameAxis_4644962f-b333-4edc-8cdc-f120fad63c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6d1037f9-bffe-4af3-a0d0-6cd575b613e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_4644962f-b333-4edc-8cdc-f120fad63c34" xlink:to="loc_us-gaap_PlanNameDomain_6d1037f9-bffe-4af3-a0d0-6cd575b613e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsThirteenIncentivePlanMember_a7c2d0cc-3ee6-4d5f-9e9e-787cabfd78ca" xlink:href="arwr-20250630.xsd#arwr_TwoThousandsThirteenIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_6d1037f9-bffe-4af3-a0d0-6cd575b613e7" xlink:to="loc_arwr_TwoThousandsThirteenIncentivePlanMember_a7c2d0cc-3ee6-4d5f-9e9e-787cabfd78ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_201898c9-1fe3-4ed7-8233-80fa1e2e0117" xlink:href="arwr-20250630.xsd#arwr_TwoThousandTwentyOneIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_6d1037f9-bffe-4af3-a0d0-6cd575b613e7" xlink:to="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_201898c9-1fe3-4ed7-8233-80fa1e2e0117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InducementAwardsMember_24090581-e368-4d5f-b28c-c2705e487ede" xlink:href="arwr-20250630.xsd#arwr_InducementAwardsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_6d1037f9-bffe-4af3-a0d0-6cd575b613e7" xlink:to="loc_arwr_InducementAwardsMember_24090581-e368-4d5f-b28c-c2705e487ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4327663d-c8f2-4903-90e4-8bbae653060b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_04c46dcb-a713-4b37-bfff-964fb42a6985" xlink:to="loc_us-gaap_AwardTypeAxis_4327663d-c8f2-4903-90e4-8bbae653060b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5cff460e-f10f-497c-8bbf-4698f993a7e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4327663d-c8f2-4903-90e4-8bbae653060b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5cff460e-f10f-497c-8bbf-4698f993a7e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_65e57ea7-6019-4ae5-aeac-4581938a4c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5cff460e-f10f-497c-8bbf-4698f993a7e1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_65e57ea7-6019-4ae5-aeac-4581938a4c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e88d0a6-1781-4884-b1bf-d7f1a1b1869d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_04c46dcb-a713-4b37-bfff-964fb42a6985" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e88d0a6-1781-4884-b1bf-d7f1a1b1869d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c03a7ff9-ae72-4764-81c0-447f72c478e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e88d0a6-1781-4884-b1bf-d7f1a1b1869d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c03a7ff9-ae72-4764-81c0-447f72c478e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ebdcbdee-88b2-4887-ad08-12586838a2a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e88d0a6-1781-4884-b1bf-d7f1a1b1869d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ebdcbdee-88b2-4887-ad08-12586838a2a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_6490e449-11f5-4cb1-945f-1904a4a9d66f" xlink:href="arwr-20250630.xsd#arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e88d0a6-1781-4884-b1bf-d7f1a1b1869d" xlink:to="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_6490e449-11f5-4cb1-945f-1904a4a9d66f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofExpensesIncludedinOperatingExpensesDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#StockBasedCompensationScheduleofExpensesIncludedinOperatingExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofExpensesIncludedinOperatingExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_62b44b15-dc79-4420-9c2d-430af75c9eea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f0ff4206-a351-4d5c-ad92-58b3f21fd0ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_62b44b15-dc79-4420-9c2d-430af75c9eea" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f0ff4206-a351-4d5c-ad92-58b3f21fd0ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4d54d0a5-d447-4c1e-b6ce-4f19bbfbd50b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f0ff4206-a351-4d5c-ad92-58b3f21fd0ed" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4d54d0a5-d447-4c1e-b6ce-4f19bbfbd50b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_715eb615-c6c4-4c78-bc19-7fc7b380dbe1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4d54d0a5-d447-4c1e-b6ce-4f19bbfbd50b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_715eb615-c6c4-4c78-bc19-7fc7b380dbe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_afd11191-8693-46ac-96fe-132a6456ef9c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_715eb615-c6c4-4c78-bc19-7fc7b380dbe1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_afd11191-8693-46ac-96fe-132a6456ef9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_14cc1f7f-f1b0-4ae6-a641-017115cafd2b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_715eb615-c6c4-4c78-bc19-7fc7b380dbe1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_14cc1f7f-f1b0-4ae6-a641-017115cafd2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e25f3e70-17ce-42ef-87eb-bda78cb74846" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f0ff4206-a351-4d5c-ad92-58b3f21fd0ed" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e25f3e70-17ce-42ef-87eb-bda78cb74846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_f462afae-bc76-4f96-8d90-d946b386d244" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e25f3e70-17ce-42ef-87eb-bda78cb74846" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_f462afae-bc76-4f96-8d90-d946b386d244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofInformationaboutStockOptionsDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#StockBasedCompensationScheduleofInformationaboutStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofInformationaboutStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_51ad417a-7feb-4147-a144-aa7a5cb25022" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_54c16702-cd55-4512-a622-3fd13512e7fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_51ad417a-7feb-4147-a144-aa7a5cb25022" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_54c16702-cd55-4512-a622-3fd13512e7fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4c6c047b-1bb3-4d5a-8170-0dc40246186a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_54c16702-cd55-4512-a622-3fd13512e7fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4c6c047b-1bb3-4d5a-8170-0dc40246186a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ed788200-0983-46ea-9775-d7209b32c423" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_54c16702-cd55-4512-a622-3fd13512e7fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ed788200-0983-46ea-9775-d7209b32c423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_f470203e-25c4-4c6e-a468-baba579e73f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_54c16702-cd55-4512-a622-3fd13512e7fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_f470203e-25c4-4c6e-a468-baba579e73f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9ccc40cc-96fa-4c4d-8846-7cef59f84fea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_54c16702-cd55-4512-a622-3fd13512e7fe" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9ccc40cc-96fa-4c4d-8846-7cef59f84fea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_89c4b0c7-bfc0-45f4-a9cd-e65c6f0a0eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_54c16702-cd55-4512-a622-3fd13512e7fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_89c4b0c7-bfc0-45f4-a9cd-e65c6f0a0eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_34dfd46a-3e6e-4e56-a5c2-4bf6ff5506be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_51ad417a-7feb-4147-a144-aa7a5cb25022" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_34dfd46a-3e6e-4e56-a5c2-4bf6ff5506be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2c692452-fa51-4bee-bb9c-710239560c65" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_51ad417a-7feb-4147-a144-aa7a5cb25022" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2c692452-fa51-4bee-bb9c-710239560c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5eca5810-f7d0-46a5-ae85-78e42ed02300" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2c692452-fa51-4bee-bb9c-710239560c65" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5eca5810-f7d0-46a5-ae85-78e42ed02300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6520e591-a1c6-4241-9e01-2aed19ab32b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2c692452-fa51-4bee-bb9c-710239560c65" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6520e591-a1c6-4241-9e01-2aed19ab32b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_80296333-98f8-48c5-9693-b859d7f104c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2c692452-fa51-4bee-bb9c-710239560c65" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_80296333-98f8-48c5-9693-b859d7f104c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_fefb860f-dccf-410e-b7c1-f223c8c5f119" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2c692452-fa51-4bee-bb9c-710239560c65" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_fefb860f-dccf-410e-b7c1-f223c8c5f119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ce999868-e1e9-479b-b8f7-93e5bc9ccdee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2c692452-fa51-4bee-bb9c-710239560c65" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ce999868-e1e9-479b-b8f7-93e5bc9ccdee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_e55a719b-f4f4-4640-b9d1-683971b2a7de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_51ad417a-7feb-4147-a144-aa7a5cb25022" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_e55a719b-f4f4-4640-b9d1-683971b2a7de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5b9b3934-08a8-4a91-9625-e315fdb24fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_51ad417a-7feb-4147-a144-aa7a5cb25022" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5b9b3934-08a8-4a91-9625-e315fdb24fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_728f6b6b-cd51-4430-a5be-0455028b9ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_51ad417a-7feb-4147-a144-aa7a5cb25022" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_728f6b6b-cd51-4430-a5be-0455028b9ae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_aa94e3f1-8165-4cee-a06a-0b93e7a506a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_51ad417a-7feb-4147-a144-aa7a5cb25022" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_aa94e3f1-8165-4cee-a06a-0b93e7a506a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_33919c44-0a54-40d0-a5ae-afe6c9f92225" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_51ad417a-7feb-4147-a144-aa7a5cb25022" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_33919c44-0a54-40d0-a5ae-afe6c9f92225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofRSUsActivityDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#StockBasedCompensationScheduleofRSUsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofRSUsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b2c3bf32-68fa-493f-b1f4-c4b741a955bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4372b918-b231-4f6b-b0f6-5bbafd5ec447" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b2c3bf32-68fa-493f-b1f4-c4b741a955bd" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4372b918-b231-4f6b-b0f6-5bbafd5ec447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0fba3892-6b0e-48b4-8c49-4e4b63487131" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4372b918-b231-4f6b-b0f6-5bbafd5ec447" xlink:to="loc_us-gaap_AwardTypeAxis_0fba3892-6b0e-48b4-8c49-4e4b63487131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bb72a844-745d-4f50-816f-19bb48a91cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0fba3892-6b0e-48b4-8c49-4e4b63487131" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bb72a844-745d-4f50-816f-19bb48a91cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c5b7dd87-34a2-4cd9-9d0f-e54c47159ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bb72a844-745d-4f50-816f-19bb48a91cb6" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c5b7dd87-34a2-4cd9-9d0f-e54c47159ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0cf3d294-d2a0-47dc-a7ed-5b15f8d87111" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4372b918-b231-4f6b-b0f6-5bbafd5ec447" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0cf3d294-d2a0-47dc-a7ed-5b15f8d87111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a51ebd58-169f-4b6a-90ac-b21d2380cd4e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0cf3d294-d2a0-47dc-a7ed-5b15f8d87111" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a51ebd58-169f-4b6a-90ac-b21d2380cd4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6b89ade1-cc03-46fe-9ed6-5e391366b44a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a51ebd58-169f-4b6a-90ac-b21d2380cd4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6b89ade1-cc03-46fe-9ed6-5e391366b44a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b6991e91-2e88-48a1-a24c-5ad34a13069c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a51ebd58-169f-4b6a-90ac-b21d2380cd4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b6991e91-2e88-48a1-a24c-5ad34a13069c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b2cdf94d-ed24-4595-9b4d-44466783d106" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a51ebd58-169f-4b6a-90ac-b21d2380cd4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b2cdf94d-ed24-4595-9b4d-44466783d106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_045bcc4f-6176-440b-af21-ff98741c4bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a51ebd58-169f-4b6a-90ac-b21d2380cd4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_045bcc4f-6176-440b-af21-ff98741c4bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e493e515-20d6-483f-8a56-95835f8c1865" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a51ebd58-169f-4b6a-90ac-b21d2380cd4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e493e515-20d6-483f-8a56-95835f8c1865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b2397706-36b9-4cdb-b978-b79cf7804362" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0cf3d294-d2a0-47dc-a7ed-5b15f8d87111" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b2397706-36b9-4cdb-b978-b79cf7804362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2d2f0346-ec4a-4c28-8bb2-f99c65c87e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b2397706-36b9-4cdb-b978-b79cf7804362" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2d2f0346-ec4a-4c28-8bb2-f99c65c87e8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_45e940cb-8f59-413e-abea-5338b733bc8e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b2397706-36b9-4cdb-b978-b79cf7804362" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_45e940cb-8f59-413e-abea-5338b733bc8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2d59a5c5-8a81-4133-8412-d70ba1a16588" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b2397706-36b9-4cdb-b978-b79cf7804362" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2d59a5c5-8a81-4133-8412-d70ba1a16588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_fea479b2-2fc2-4cbd-97dd-21f73b282e84" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b2397706-36b9-4cdb-b978-b79cf7804362" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_fea479b2-2fc2-4cbd-97dd-21f73b282e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ec3b4d9b-05ee-4123-a4ed-e98fef63e428" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b2397706-36b9-4cdb-b978-b79cf7804362" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ec3b4d9b-05ee-4123-a4ed-e98fef63e428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#FairValueMeasurementsScheduleofFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6d3b623f-cb26-4bd0-a5b7-db85c680253a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_09a98b3c-698c-4178-8769-5d718102945e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6d3b623f-cb26-4bd0-a5b7-db85c680253a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_09a98b3c-698c-4178-8769-5d718102945e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_665c6080-3efe-4504-8511-fe5dee4127f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_09a98b3c-698c-4178-8769-5d718102945e" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_665c6080-3efe-4504-8511-fe5dee4127f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_df413487-ce4c-4030-869e-6cb07a6f7925" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_665c6080-3efe-4504-8511-fe5dee4127f0" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_df413487-ce4c-4030-869e-6cb07a6f7925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_b203b630-1f2a-4126-b431-5a2d88a84cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_df413487-ce4c-4030-869e-6cb07a6f7925" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_b203b630-1f2a-4126-b431-5a2d88a84cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b67c763a-2ace-4f5a-945a-bbe610890321" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_09a98b3c-698c-4178-8769-5d718102945e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b67c763a-2ace-4f5a-945a-bbe610890321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f222bd5f-90d0-41fc-a00e-c5f10ee6301d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b67c763a-2ace-4f5a-945a-bbe610890321" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f222bd5f-90d0-41fc-a00e-c5f10ee6301d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_8951ef5b-0be8-4892-8bce-a086889921eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f222bd5f-90d0-41fc-a00e-c5f10ee6301d" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_8951ef5b-0be8-4892-8bce-a086889921eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_da7f7327-bf01-49cb-8057-5703917a4479" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f222bd5f-90d0-41fc-a00e-c5f10ee6301d" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_da7f7327-bf01-49cb-8057-5703917a4479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_29f97ebb-8649-43cc-9e6e-2b2b169ac3bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f222bd5f-90d0-41fc-a00e-c5f10ee6301d" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_29f97ebb-8649-43cc-9e6e-2b2b169ac3bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1faa6ec9-b36e-47fc-b974-a076267c3ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_09a98b3c-698c-4178-8769-5d718102945e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1faa6ec9-b36e-47fc-b974-a076267c3ebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_803245da-25fa-4179-bd2b-5b31b610d9b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1faa6ec9-b36e-47fc-b974-a076267c3ebe" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_803245da-25fa-4179-bd2b-5b31b610d9b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_68d39ac5-e3a4-47a4-9ab2-133d3d73f4e6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_803245da-25fa-4179-bd2b-5b31b610d9b6" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_68d39ac5-e3a4-47a4-9ab2-133d3d73f4e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_c0bd4fc1-069e-4e0c-bfb0-96ecacc9c06b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_803245da-25fa-4179-bd2b-5b31b610d9b6" xlink:to="loc_us-gaap_MunicipalBondsMember_c0bd4fc1-069e-4e0c-bfb0-96ecacc9c06b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialNotesMember_841e1925-02d5-4a3c-8d55-a697cae80da3" xlink:href="arwr-20250630.xsd#arwr_CommercialNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_803245da-25fa-4179-bd2b-5b31b610d9b6" xlink:to="loc_arwr_CommercialNotesMember_841e1925-02d5-4a3c-8d55-a697cae80da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_788f60c5-252d-420b-ae3e-bb54c466084d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_803245da-25fa-4179-bd2b-5b31b610d9b6" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_788f60c5-252d-420b-ae3e-bb54c466084d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_aac40e19-0f6d-48ec-b9f8-5aae58cafc7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_09a98b3c-698c-4178-8769-5d718102945e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_aac40e19-0f6d-48ec-b9f8-5aae58cafc7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_00224a8b-2baf-43d1-a307-8f0cd140f3f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_aac40e19-0f6d-48ec-b9f8-5aae58cafc7f" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_00224a8b-2baf-43d1-a307-8f0cd140f3f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_c197103d-865d-4d68-8d36-8b812194c1e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_00224a8b-2baf-43d1-a307-8f0cd140f3f2" xlink:to="loc_us-gaap_MoneyMarketFundsMember_c197103d-865d-4d68-8d36-8b812194c1e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_98cbd331-9c6a-4380-8f20-68cad8c39c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_00224a8b-2baf-43d1-a307-8f0cd140f3f2" xlink:to="loc_us-gaap_BankTimeDepositsMember_98cbd331-9c6a-4380-8f20-68cad8c39c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_4b791586-87d1-4f4e-9d04-fabfceacbc97" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_00224a8b-2baf-43d1-a307-8f0cd140f3f2" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_4b791586-87d1-4f4e-9d04-fabfceacbc97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialNotesMember_eadc4d09-dd4b-43b0-84fc-08bb4159248d" xlink:href="arwr-20250630.xsd#arwr_CommercialNotesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_00224a8b-2baf-43d1-a307-8f0cd140f3f2" xlink:to="loc_arwr_CommercialNotesMember_eadc4d09-dd4b-43b0-84fc-08bb4159248d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d4796807-c5a7-470d-8d0a-9edd500ceb15" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_09a98b3c-698c-4178-8769-5d718102945e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d4796807-c5a7-470d-8d0a-9edd500ceb15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_52851ca9-4545-4fd3-ab7b-11887ec73759" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d4796807-c5a7-470d-8d0a-9edd500ceb15" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_52851ca9-4545-4fd3-ab7b-11887ec73759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_36379610-0bd7-4ea7-9d55-d7cd23502834" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d4796807-c5a7-470d-8d0a-9edd500ceb15" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_36379610-0bd7-4ea7-9d55-d7cd23502834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_516388ea-9e6c-45d5-8b2d-a231bbb8b726" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d4796807-c5a7-470d-8d0a-9edd500ceb15" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_516388ea-9e6c-45d5-8b2d-a231bbb8b726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract_46733a25-91df-45e6-8e7b-0f2b86623088" xlink:href="arwr-20250630.xsd#arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3a596006-6adc-4b3c-9204-36abab4dab67" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract_46733a25-91df-45e6-8e7b-0f2b86623088" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3a596006-6adc-4b3c-9204-36abab4dab67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_893c5d14-09e8-4ba1-825a-f29d79159f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3a596006-6adc-4b3c-9204-36abab4dab67" xlink:to="loc_us-gaap_TypeOfArrangementAxis_893c5d14-09e8-4ba1-825a-f29d79159f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fe4cbf51-71a7-44ee-a012-c436689ec0b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_893c5d14-09e8-4ba1-825a-f29d79159f6c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fe4cbf51-71a7-44ee-a012-c436689ec0b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltyPharmaAgreementMember_66aef5e4-a373-491d-bd38-63a329f79570" xlink:href="arwr-20250630.xsd#arwr_RoyaltyPharmaAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fe4cbf51-71a7-44ee-a012-c436689ec0b7" xlink:to="loc_arwr_RoyaltyPharmaAgreementMember_66aef5e4-a373-491d-bd38-63a329f79570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_84d9c71c-2ea4-42a2-bc43-344fc99e3ae2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3a596006-6adc-4b3c-9204-36abab4dab67" xlink:to="loc_srt_RangeAxis_84d9c71c-2ea4-42a2-bc43-344fc99e3ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_86eac713-654a-4cdf-b698-99bc5c5415f0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_84d9c71c-2ea4-42a2-bc43-344fc99e3ae2" xlink:to="loc_srt_RangeMember_86eac713-654a-4cdf-b698-99bc5c5415f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6848e069-9889-423e-bc22-cbb30f4d387f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_86eac713-654a-4cdf-b698-99bc5c5415f0" xlink:to="loc_srt_MaximumMember_6848e069-9889-423e-bc22-cbb30f4d387f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0714426d-9752-4003-a57b-619b636dfacb" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3a596006-6adc-4b3c-9204-36abab4dab67" xlink:to="loc_srt_CounterpartyNameAxis_0714426d-9752-4003-a57b-619b636dfacb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_604a2f85-677f-4e0a-ab48-79a11f8a8d46" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_0714426d-9752-4003-a57b-619b636dfacb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_604a2f85-677f-4e0a-ab48-79a11f8a8d46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmgenIncorporatedMember_95aae6b4-2605-4caf-a174-a6fd96f98075" xlink:href="arwr-20250630.xsd#arwr_AmgenIncorporatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_604a2f85-677f-4e0a-ab48-79a11f8a8d46" xlink:to="loc_arwr_AmgenIncorporatedMember_95aae6b4-2605-4caf-a174-a6fd96f98075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fc640632-ee6e-42dc-8290-ca7dba2037ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3a596006-6adc-4b3c-9204-36abab4dab67" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fc640632-ee6e-42dc-8290-ca7dba2037ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_c49dc5a4-cb8e-45c3-aa36-35180e9c1232" xlink:href="arwr-20250630.xsd#arwr_InitialTransactionPrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fc640632-ee6e-42dc-8290-ca7dba2037ec" xlink:to="loc_arwr_InitialTransactionPrice_c49dc5a4-cb8e-45c3-aa36-35180e9c1232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties_a78b19db-6bd6-49a8-8636-680f9e3c552c" xlink:href="arwr-20250630.xsd#arwr_UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fc640632-ee6e-42dc-8290-ca7dba2037ec" xlink:to="loc_arwr_UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties_a78b19db-6bd6-49a8-8636-680f9e3c552c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivable_f543c94f-4ec5-459e-9319-71cb0695978f" xlink:href="arwr-20250630.xsd#arwr_MilestonePaymentReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fc640632-ee6e-42dc-8290-ca7dba2037ec" xlink:to="loc_arwr_MilestonePaymentReceivable_f543c94f-4ec5-459e-9319-71cb0695978f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial_2cc8f49b-34d0-46b9-ad17-c5010463487e" xlink:href="arwr-20250630.xsd#arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fc640632-ee6e-42dc-8290-ca7dba2037ec" xlink:to="loc_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial_2cc8f49b-34d0-46b9-ad17-c5010463487e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponFDAApproval_66d073a9-6889-4125-b6f6-2577d1ce4b99" xlink:href="arwr-20250630.xsd#arwr_MilestonePaymentReceivableUponFDAApproval"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fc640632-ee6e-42dc-8290-ca7dba2037ec" xlink:to="loc_arwr_MilestonePaymentReceivableUponFDAApproval_66d073a9-6889-4125-b6f6-2577d1ce4b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments_885262fb-2f36-4b9c-9e41-4d1523b52688" xlink:href="arwr-20250630.xsd#arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fc640632-ee6e-42dc-8290-ca7dba2037ec" xlink:to="loc_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments_885262fb-2f36-4b9c-9e41-4d1523b52688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltyPaymentThreshold_b0f4efae-27a7-4ee7-b313-52ed11e15015" xlink:href="arwr-20250630.xsd#arwr_RoyaltyPaymentThreshold"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fc640632-ee6e-42dc-8290-ca7dba2037ec" xlink:to="loc_arwr_RoyaltyPaymentThreshold_b0f4efae-27a7-4ee7-b313-52ed11e15015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties_13d6c5ee-8d35-47fe-a2a9-e445de3c416f" xlink:href="arwr-20250630.xsd#arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fc640632-ee6e-42dc-8290-ca7dba2037ec" xlink:to="loc_arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties_13d6c5ee-8d35-47fe-a2a9-e445de3c416f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilitySaleOfFutureRoyaltiesInterestRate_fa38eb7d-c909-49d1-b736-e811f7c4030c" xlink:href="arwr-20250630.xsd#arwr_LiabilitySaleOfFutureRoyaltiesInterestRate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fc640632-ee6e-42dc-8290-ca7dba2037ec" xlink:to="loc_arwr_LiabilitySaleOfFutureRoyaltiesInterestRate_fa38eb7d-c909-49d1-b736-e811f7c4030c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesActivityDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#LiabilityRelatedtotheSaleofFutureRoyaltiesActivityDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract_c16a84b5-f63a-4b05-87d8-6a4a4c14d995" xlink:href="arwr-20250630.xsd#arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilitySaleOfFutureRoyaltiesRollForward_850591c5-f3c3-4894-b439-5aa48e799975" xlink:href="arwr-20250630.xsd#arwr_LiabilitySaleOfFutureRoyaltiesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract_c16a84b5-f63a-4b05-87d8-6a4a4c14d995" xlink:to="loc_arwr_LiabilitySaleOfFutureRoyaltiesRollForward_850591c5-f3c3-4894-b439-5aa48e799975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltiesLiabilityNoncurrent_db8d4573-bc9b-47f0-aa64-23b7f7468c72" xlink:href="arwr-20250630.xsd#arwr_RoyaltiesLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_LiabilitySaleOfFutureRoyaltiesRollForward_850591c5-f3c3-4894-b439-5aa48e799975" xlink:to="loc_arwr_RoyaltiesLiabilityNoncurrent_db8d4573-bc9b-47f0-aa64-23b7f7468c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties_822a790b-69c6-445d-b982-e08da9e079bb" xlink:href="arwr-20250630.xsd#arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_LiabilitySaleOfFutureRoyaltiesRollForward_850591c5-f3c3-4894-b439-5aa48e799975" xlink:to="loc_arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties_822a790b-69c6-445d-b982-e08da9e079bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_54ebf9a2-4d23-46b9-a8af-3e7c06fc7dae" xlink:href="arwr-20250630.xsd#arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_LiabilitySaleOfFutureRoyaltiesRollForward_850591c5-f3c3-4894-b439-5aa48e799975" xlink:to="loc_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_54ebf9a2-4d23-46b9-a8af-3e7c06fc7dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltiesLiabilityNoncurrent_bcb1bb2f-2b88-4ed6-96b3-03a4a6797990" xlink:href="arwr-20250630.xsd#arwr_RoyaltiesLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_LiabilitySaleOfFutureRoyaltiesRollForward_850591c5-f3c3-4894-b439-5aa48e799975" xlink:to="loc_arwr_RoyaltiesLiabilityNoncurrent_bcb1bb2f-2b88-4ed6-96b3-03a4a6797990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#FinancingAgreementNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_89892a61-8b3b-4c40-aef9-6dee8759f998" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_a150ed85-a282-4f79-b6df-f7e69bed401c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_89892a61-8b3b-4c40-aef9-6dee8759f998" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_a150ed85-a282-4f79-b6df-f7e69bed401c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_9acdf76b-a5b7-454f-a75a-292e065caace" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_a150ed85-a282-4f79-b6df-f7e69bed401c" xlink:to="loc_us-gaap_CreditFacilityAxis_9acdf76b-a5b7-454f-a75a-292e065caace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_5509264b-9e79-4a64-be15-11e5dfa5ea0c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_9acdf76b-a5b7-454f-a75a-292e065caace" xlink:to="loc_us-gaap_CreditFacilityDomain_5509264b-9e79-4a64-be15-11e5dfa5ea0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_502b6bcb-3c6d-41c4-9c24-ef176e97a3c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_5509264b-9e79-4a64-be15-11e5dfa5ea0c" xlink:to="loc_us-gaap_SecuredDebtMember_502b6bcb-3c6d-41c4-9c24-ef176e97a3c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_3444fc8b-a08f-48a9-8411-69e34c1a101e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_5509264b-9e79-4a64-be15-11e5dfa5ea0c" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_3444fc8b-a08f-48a9-8411-69e34c1a101e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ec3c6d25-b5cc-4ae9-a737-ab8bba043557" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_a150ed85-a282-4f79-b6df-f7e69bed401c" xlink:to="loc_us-gaap_DebtInstrumentAxis_ec3c6d25-b5cc-4ae9-a737-ab8bba043557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8fe539a2-9b20-49d0-a49c-cc6d0e17b5c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_ec3c6d25-b5cc-4ae9-a737-ab8bba043557" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8fe539a2-9b20-49d0-a49c-cc6d0e17b5c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FinancingAgreementMember_9e9b0198-f57a-4e4f-a719-c5d766edf3e9" xlink:href="arwr-20250630.xsd#arwr_FinancingAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8fe539a2-9b20-49d0-a49c-cc6d0e17b5c1" xlink:to="loc_arwr_FinancingAgreementMember_9e9b0198-f57a-4e4f-a719-c5d766edf3e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FinancingAgreementInitialTermLoanMember_f77a3c22-1a1d-44c8-bbab-73da5390e7ab" xlink:href="arwr-20250630.xsd#arwr_FinancingAgreementInitialTermLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_FinancingAgreementMember_9e9b0198-f57a-4e4f-a719-c5d766edf3e9" xlink:to="loc_arwr_FinancingAgreementInitialTermLoanMember_f77a3c22-1a1d-44c8-bbab-73da5390e7ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FinancingAgreementMOICPaymentMember_bc74bfdc-5c5c-4d80-9b10-34899850ef30" xlink:href="arwr-20250630.xsd#arwr_FinancingAgreementMOICPaymentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_FinancingAgreementMember_9e9b0198-f57a-4e4f-a719-c5d766edf3e9" xlink:to="loc_arwr_FinancingAgreementMOICPaymentMember_bc74bfdc-5c5c-4d80-9b10-34899850ef30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_60b32340-64ea-4cec-803e-674d3590617f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_a150ed85-a282-4f79-b6df-f7e69bed401c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_60b32340-64ea-4cec-803e-674d3590617f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_64c5f2c5-c46f-4e48-901a-251bd8fcfc4b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_60b32340-64ea-4cec-803e-674d3590617f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_64c5f2c5-c46f-4e48-901a-251bd8fcfc4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_02a9cbec-7771-42b1-854a-5f5b78922837" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_64c5f2c5-c46f-4e48-901a-251bd8fcfc4b" xlink:to="loc_us-gaap_LineOfCreditMember_02a9cbec-7771-42b1-854a-5f5b78922837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_27c86105-6527-42b7-8f8b-5bc8f67adf56" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_a150ed85-a282-4f79-b6df-f7e69bed401c" xlink:to="loc_srt_CounterpartyNameAxis_27c86105-6527-42b7-8f8b-5bc8f67adf56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_82aa379d-69da-4075-8626-08c7850b7d8b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_27c86105-6527-42b7-8f8b-5bc8f67adf56" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_82aa379d-69da-4075-8626-08c7850b7d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SareptaMember_e329f85a-1230-4c9e-a543-e6c89cdcd2da" xlink:href="arwr-20250630.xsd#arwr_SareptaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_82aa379d-69da-4075-8626-08c7850b7d8b" xlink:to="loc_arwr_SareptaMember_e329f85a-1230-4c9e-a543-e6c89cdcd2da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_353da415-c4d9-40c0-a7e8-32448ad4cd47" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_a150ed85-a282-4f79-b6df-f7e69bed401c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_353da415-c4d9-40c0-a7e8-32448ad4cd47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_79101bc4-2706-4afc-8686-abc02a1a5be0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_353da415-c4d9-40c0-a7e8-32448ad4cd47" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_79101bc4-2706-4afc-8686-abc02a1a5be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SareptaCollaborationAgreementMember_32720607-bb41-40ec-90c9-365116804989" xlink:href="arwr-20250630.xsd#arwr_SareptaCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_79101bc4-2706-4afc-8686-abc02a1a5be0" xlink:to="loc_arwr_SareptaCollaborationAgreementMember_32720607-bb41-40ec-90c9-365116804989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_1c271ef6-f487-4264-81eb-eea064389c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_a150ed85-a282-4f79-b6df-f7e69bed401c" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_1c271ef6-f487-4264-81eb-eea064389c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_d6927dad-2bdc-4f2e-9881-78072d2506a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_1c271ef6-f487-4264-81eb-eea064389c9a" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_d6927dad-2bdc-4f2e-9881-78072d2506a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_4af53ddf-221c-492b-849c-64c335d04f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_d6927dad-2bdc-4f2e-9881-78072d2506a2" xlink:to="loc_us-gaap_LineOfCreditMember_4af53ddf-221c-492b-849c-64c335d04f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_19904961-689c-4b0d-8fd8-fa8a6d8bf972" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_a150ed85-a282-4f79-b6df-f7e69bed401c" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_19904961-689c-4b0d-8fd8-fa8a6d8bf972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7b17fabe-2a44-4d94-98d7-e327642de256" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_19904961-689c-4b0d-8fd8-fa8a6d8bf972" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7b17fabe-2a44-4d94-98d7-e327642de256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_488674a7-fbd9-4bb5-a000-a9e4ebebb8a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_19904961-689c-4b0d-8fd8-fa8a6d8bf972" xlink:to="loc_us-gaap_LineOfCredit_488674a7-fbd9-4bb5-a000-a9e4ebebb8a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_68402baf-a77c-4743-be81-bd340baa96ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_19904961-689c-4b0d-8fd8-fa8a6d8bf972" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_68402baf-a77c-4743-be81-bd340baa96ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_32b84f21-7895-452a-8b23-0c69efb5af5e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_19904961-689c-4b0d-8fd8-fa8a6d8bf972" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_32b84f21-7895-452a-8b23-0c69efb5af5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtInstrumentCovenantMultipleOfInvestCapital_0cbad0a9-26a5-4cd1-9a8c-dd598083d3fe" xlink:href="arwr-20250630.xsd#arwr_DebtInstrumentCovenantMultipleOfInvestCapital"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_19904961-689c-4b0d-8fd8-fa8a6d8bf972" xlink:to="loc_arwr_DebtInstrumentCovenantMultipleOfInvestCapital_0cbad0a9-26a5-4cd1-9a8c-dd598083d3fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_d54d1b62-564e-41db-bf1d-02a2dbb51c73" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_19904961-689c-4b0d-8fd8-fa8a6d8bf972" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_d54d1b62-564e-41db-bf1d-02a2dbb51c73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ProceedsFromCollaborationArrangements_88885832-62bb-4b6c-8ae3-508bc434d693" xlink:href="arwr-20250630.xsd#arwr_ProceedsFromCollaborationArrangements"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_19904961-689c-4b0d-8fd8-fa8a6d8bf972" xlink:to="loc_arwr_ProceedsFromCollaborationArrangements_88885832-62bb-4b6c-8ae3-508bc434d693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtInstrumentPrepaymentPercentage_b44a4b1c-59f1-4d55-9108-261eae4999e3" xlink:href="arwr-20250630.xsd#arwr_DebtInstrumentPrepaymentPercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_19904961-689c-4b0d-8fd8-fa8a6d8bf972" xlink:to="loc_arwr_DebtInstrumentPrepaymentPercentage_b44a4b1c-59f1-4d55-9108-261eae4999e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_f27f5aca-f3f7-47d4-80b6-4e011e5c4d50" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_19904961-689c-4b0d-8fd8-fa8a6d8bf972" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_f27f5aca-f3f7-47d4-80b6-4e011e5c4d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtInstrumentMultipleOfInvestmentCapitalExpectedToBeAppliedToPrincipalUponRepayment_ce91521e-55f4-40ff-87d6-eba291cbe7ac" xlink:href="arwr-20250630.xsd#arwr_DebtInstrumentMultipleOfInvestmentCapitalExpectedToBeAppliedToPrincipalUponRepayment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_19904961-689c-4b0d-8fd8-fa8a6d8bf972" xlink:to="loc_arwr_DebtInstrumentMultipleOfInvestmentCapitalExpectedToBeAppliedToPrincipalUponRepayment_ce91521e-55f4-40ff-87d6-eba291cbe7ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtInstrumentCovenantMinimumLiquidityIfCapitalizationIsAboveThreshold_61534df5-58bd-4b65-87fc-60254b9ee79c" xlink:href="arwr-20250630.xsd#arwr_DebtInstrumentCovenantMinimumLiquidityIfCapitalizationIsAboveThreshold"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_19904961-689c-4b0d-8fd8-fa8a6d8bf972" xlink:to="loc_arwr_DebtInstrumentCovenantMinimumLiquidityIfCapitalizationIsAboveThreshold_61534df5-58bd-4b65-87fc-60254b9ee79c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtInstrumentCovenantMarketCapitalizationThreshold_ed6c9b02-b0c9-4a85-8398-c5459f23c396" xlink:href="arwr-20250630.xsd#arwr_DebtInstrumentCovenantMarketCapitalizationThreshold"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_19904961-689c-4b0d-8fd8-fa8a6d8bf972" xlink:to="loc_arwr_DebtInstrumentCovenantMarketCapitalizationThreshold_ed6c9b02-b0c9-4a85-8398-c5459f23c396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_b19c7802-6a66-46e7-ba54-4590a69d4940" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_19904961-689c-4b0d-8fd8-fa8a6d8bf972" xlink:to="loc_us-gaap_DebtInstrumentTerm_b19c7802-6a66-46e7-ba54-4590a69d4940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LinesOfCreditCurrent_16ee804a-056d-49b3-933b-0a6919827f81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LinesOfCreditCurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_19904961-689c-4b0d-8fd8-fa8a6d8bf972" xlink:to="loc_us-gaap_LinesOfCreditCurrent_16ee804a-056d-49b3-933b-0a6919827f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FinancingAgreementScheduleofOutstandingBalanceofCreditFacilityDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#FinancingAgreementScheduleofOutstandingBalanceofCreditFacilityDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/FinancingAgreementScheduleofOutstandingBalanceofCreditFacilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1e669e41-983f-4d7a-8813-b7564b3465e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_fa36a05b-b956-4ced-a4eb-b6e6843847d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1e669e41-983f-4d7a-8813-b7564b3465e0" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_fa36a05b-b956-4ced-a4eb-b6e6843847d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_5e935df4-39e6-402a-93cb-001d01fbe34f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_fa36a05b-b956-4ced-a4eb-b6e6843847d8" xlink:to="loc_us-gaap_CreditFacilityAxis_5e935df4-39e6-402a-93cb-001d01fbe34f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_a1a84e36-82f1-4be4-9372-86d85ce32d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_5e935df4-39e6-402a-93cb-001d01fbe34f" xlink:to="loc_us-gaap_CreditFacilityDomain_a1a84e36-82f1-4be4-9372-86d85ce32d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_1d3fc94c-9e55-4b65-b33c-00338b250caa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_a1a84e36-82f1-4be4-9372-86d85ce32d8c" xlink:to="loc_us-gaap_SecuredDebtMember_1d3fc94c-9e55-4b65-b33c-00338b250caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e63ced8a-9944-489e-bfb5-67339310b139" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_fa36a05b-b956-4ced-a4eb-b6e6843847d8" xlink:to="loc_us-gaap_DebtInstrumentAxis_e63ced8a-9944-489e-bfb5-67339310b139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4acef216-46c9-4f96-b78f-5b7bcde5c605" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_e63ced8a-9944-489e-bfb5-67339310b139" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4acef216-46c9-4f96-b78f-5b7bcde5c605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FinancingAgreementMember_4bb4711d-0931-4f0c-b2ca-38b715746902" xlink:href="arwr-20250630.xsd#arwr_FinancingAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4acef216-46c9-4f96-b78f-5b7bcde5c605" xlink:to="loc_arwr_FinancingAgreementMember_4bb4711d-0931-4f0c-b2ca-38b715746902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FinancingAgreementInitialTermLoanMember_3c934864-7213-401e-b3fd-e569cfced89a" xlink:href="arwr-20250630.xsd#arwr_FinancingAgreementInitialTermLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_FinancingAgreementMember_4bb4711d-0931-4f0c-b2ca-38b715746902" xlink:to="loc_arwr_FinancingAgreementInitialTermLoanMember_3c934864-7213-401e-b3fd-e569cfced89a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FinancingAgreementInitialTermLoanInterestMember_238f569d-e114-41aa-8d31-c40f08da0269" xlink:href="arwr-20250630.xsd#arwr_FinancingAgreementInitialTermLoanInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_FinancingAgreementMember_4bb4711d-0931-4f0c-b2ca-38b715746902" xlink:to="loc_arwr_FinancingAgreementInitialTermLoanInterestMember_238f569d-e114-41aa-8d31-c40f08da0269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_9bbae05d-575e-4010-8cd6-dea0093df56d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_fa36a05b-b956-4ced-a4eb-b6e6843847d8" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_9bbae05d-575e-4010-8cd6-dea0093df56d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_497a8403-8d1f-4962-95da-2141824ccadd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9bbae05d-575e-4010-8cd6-dea0093df56d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_497a8403-8d1f-4962-95da-2141824ccadd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_7ac95660-4474-4f80-9a93-888da4949551" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_497a8403-8d1f-4962-95da-2141824ccadd" xlink:to="loc_us-gaap_LineOfCreditMember_7ac95660-4474-4f80-9a93-888da4949551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_e715a4c4-b47c-4e78-abb1-2c1c713b9fff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_fa36a05b-b956-4ced-a4eb-b6e6843847d8" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_e715a4c4-b47c-4e78-abb1-2c1c713b9fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_ed14d474-a728-40ca-a6ea-a9f56ed91333" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e715a4c4-b47c-4e78-abb1-2c1c713b9fff" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_ed14d474-a728-40ca-a6ea-a9f56ed91333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_5c55db40-ef0e-446d-888f-6e345bb2e29e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e715a4c4-b47c-4e78-abb1-2c1c713b9fff" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_5c55db40-ef0e-446d-888f-6e345bb2e29e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_d0072ab9-8a4d-4838-8f94-f62fcda57196" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e715a4c4-b47c-4e78-abb1-2c1c713b9fff" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_d0072ab9-8a4d-4838-8f94-f62fcda57196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LinesOfCreditCurrent_209bdc1f-fe9d-4b66-8397-2586c64eea4d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LinesOfCreditCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e715a4c4-b47c-4e78-abb1-2c1c713b9fff" xlink:to="loc_us-gaap_LinesOfCreditCurrent_209bdc1f-fe9d-4b66-8397-2586c64eea4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_a5625168-c951-4292-9c33-1b614d4fe990" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e715a4c4-b47c-4e78-abb1-2c1c713b9fff" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_a5625168-c951-4292-9c33-1b614d4fe990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_157faed5-ae36-4e47-ab80-5737348c5bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e715a4c4-b47c-4e78-abb1-2c1c713b9fff" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_157faed5-ae36-4e47-ab80-5737348c5bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FinancingAgreementScheduleofInterestExpenseRecognizedRelatedtoCreditFacilityDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#FinancingAgreementScheduleofInterestExpenseRecognizedRelatedtoCreditFacilityDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/FinancingAgreementScheduleofInterestExpenseRecognizedRelatedtoCreditFacilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_719587e7-fee0-46f2-9e18-22b843dd0681" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_617c2147-10e4-4509-85f1-05ab003a8c74" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_719587e7-fee0-46f2-9e18-22b843dd0681" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_617c2147-10e4-4509-85f1-05ab003a8c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_ce80bd01-b696-4c30-90d5-b9791d3b1e81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_617c2147-10e4-4509-85f1-05ab003a8c74" xlink:to="loc_us-gaap_CreditFacilityAxis_ce80bd01-b696-4c30-90d5-b9791d3b1e81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_3df6f29b-52a3-4efa-bebd-2e28c7c35a99" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_ce80bd01-b696-4c30-90d5-b9791d3b1e81" xlink:to="loc_us-gaap_CreditFacilityDomain_3df6f29b-52a3-4efa-bebd-2e28c7c35a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_bc3834d1-e923-43cc-97d9-6eb89e841bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_3df6f29b-52a3-4efa-bebd-2e28c7c35a99" xlink:to="loc_us-gaap_SecuredDebtMember_bc3834d1-e923-43cc-97d9-6eb89e841bdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c4e42e11-9817-435c-a16c-ad74e7f6cc0b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_617c2147-10e4-4509-85f1-05ab003a8c74" xlink:to="loc_us-gaap_DebtInstrumentAxis_c4e42e11-9817-435c-a16c-ad74e7f6cc0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b3978da6-0f47-48f0-8d80-69f009d32c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_c4e42e11-9817-435c-a16c-ad74e7f6cc0b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b3978da6-0f47-48f0-8d80-69f009d32c4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FinancingAgreementMember_a782085c-b164-436b-b9c4-75b9f12f1061" xlink:href="arwr-20250630.xsd#arwr_FinancingAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b3978da6-0f47-48f0-8d80-69f009d32c4f" xlink:to="loc_arwr_FinancingAgreementMember_a782085c-b164-436b-b9c4-75b9f12f1061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_95a7597d-a26b-4c7e-8a40-1b2b41bacff6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_617c2147-10e4-4509-85f1-05ab003a8c74" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_95a7597d-a26b-4c7e-8a40-1b2b41bacff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_98704b5e-c97e-4fad-a9d2-e1454afcb34a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_95a7597d-a26b-4c7e-8a40-1b2b41bacff6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_98704b5e-c97e-4fad-a9d2-e1454afcb34a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_cf4729c4-0873-4352-889e-1bb4e716ef67" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_98704b5e-c97e-4fad-a9d2-e1454afcb34a" xlink:to="loc_us-gaap_LineOfCreditMember_cf4729c4-0873-4352-889e-1bb4e716ef67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_98680f92-fa07-4cdf-808d-f4e257e8d347" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_617c2147-10e4-4509-85f1-05ab003a8c74" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_98680f92-fa07-4cdf-808d-f4e257e8d347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_0b5fdd43-86c9-4e5d-8bb5-f92cceb46d32" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_98680f92-fa07-4cdf-808d-f4e257e8d347" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_0b5fdd43-86c9-4e5d-8bb5-f92cceb46d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_ac7421f5-f7c7-48aa-b303-0cb98fd2ff0a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_98680f92-fa07-4cdf-808d-f4e257e8d347" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_ac7421f5-f7c7-48aa-b303-0cb98fd2ff0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_d8305556-e2b5-4797-ac1b-8810e307333a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_98680f92-fa07-4cdf-808d-f4e257e8d347" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_d8305556-e2b5-4797-ac1b-8810e307333a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_34165c74-0d1a-4228-afd0-cb5f1890578a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_98680f92-fa07-4cdf-808d-f4e257e8d347" xlink:to="loc_us-gaap_InterestExpenseDebt_34165c74-0d1a-4228-afd0-cb5f1890578a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1ca174f1-718a-4d3b-80e5-e5bec332b982" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_1c79b81f-07c0-4788-80e6-784f459f066e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1ca174f1-718a-4d3b-80e5-e5bec332b982" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_1c79b81f-07c0-4788-80e6-784f459f066e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a642029c-d4c9-4270-992a-a03de17e426d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_1c79b81f-07c0-4788-80e6-784f459f066e" xlink:to="loc_us-gaap_DebtInstrumentAxis_a642029c-d4c9-4270-992a-a03de17e426d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b1129c88-6e54-4818-8bd4-c44db6feaa65" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_a642029c-d4c9-4270-992a-a03de17e426d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b1129c88-6e54-4818-8bd4-c44db6feaa65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FinancingAgreementMember_80ed028c-c6bc-48d3-a71e-3e9d404578b0" xlink:href="arwr-20250630.xsd#arwr_FinancingAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b1129c88-6e54-4818-8bd4-c44db6feaa65" xlink:to="loc_arwr_FinancingAgreementMember_80ed028c-c6bc-48d3-a71e-3e9d404578b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_32b9092a-b39c-4e74-9de5-b3eb34ed2e81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_1c79b81f-07c0-4788-80e6-784f459f066e" xlink:to="loc_us-gaap_CreditFacilityAxis_32b9092a-b39c-4e74-9de5-b3eb34ed2e81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_9ee2d698-58af-43a4-b78e-37b00606fb63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_32b9092a-b39c-4e74-9de5-b3eb34ed2e81" xlink:to="loc_us-gaap_CreditFacilityDomain_9ee2d698-58af-43a4-b78e-37b00606fb63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_12a2487b-25a9-4899-9c2c-74c066b6d796" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_9ee2d698-58af-43a4-b78e-37b00606fb63" xlink:to="loc_us-gaap_SecuredDebtMember_12a2487b-25a9-4899-9c2c-74c066b6d796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_28b7ef07-27a8-4386-ba1e-0f3c7d9d97e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_1c79b81f-07c0-4788-80e6-784f459f066e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_28b7ef07-27a8-4386-ba1e-0f3c7d9d97e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5e8d49ae-e050-4648-b00a-923bdeccb9a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_28b7ef07-27a8-4386-ba1e-0f3c7d9d97e8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5e8d49ae-e050-4648-b00a-923bdeccb9a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_d4a676d5-3285-48d2-b2ca-7f14c8dec538" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5e8d49ae-e050-4648-b00a-923bdeccb9a0" xlink:to="loc_us-gaap_LineOfCreditMember_d4a676d5-3285-48d2-b2ca-7f14c8dec538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_377e5ce5-d901-4c17-b7e0-c8e5ce287604" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_1c79b81f-07c0-4788-80e6-784f459f066e" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_377e5ce5-d901-4c17-b7e0-c8e5ce287604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_56d61f88-84bc-4296-81bb-6a36ced46f60" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_377e5ce5-d901-4c17-b7e0-c8e5ce287604" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_56d61f88-84bc-4296-81bb-6a36ced46f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_dcda8438-7dc3-454f-a5ce-4d0ce2b86098" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_377e5ce5-d901-4c17-b7e0-c8e5ce287604" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_dcda8438-7dc3-454f-a5ce-4d0ce2b86098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_71f3f97a-3030-4504-ac83-cd9161b11586" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_377e5ce5-d901-4c17-b7e0-c8e5ce287604" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_71f3f97a-3030-4504-ac83-cd9161b11586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_aed9fc1c-2ae0-419c-b5fe-7cdc5159e9e6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_377e5ce5-d901-4c17-b7e0-c8e5ce287604" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_aed9fc1c-2ae0-419c-b5fe-7cdc5159e9e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_e995a0fd-e291-4a51-a045-aaddb9690ffd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_377e5ce5-d901-4c17-b7e0-c8e5ce287604" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_e995a0fd-e291-4a51-a045-aaddb9690ffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LongTermDebtMaturityAfterYearFour_df9a5556-d3c1-441a-abcc-e577207d3aa4" xlink:href="arwr-20250630.xsd#arwr_LongTermDebtMaturityAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_377e5ce5-d901-4c17-b7e0-c8e5ce287604" xlink:to="loc_arwr_LongTermDebtMaturityAfterYearFour_df9a5556-d3c1-441a-abcc-e577207d3aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_5a6aa26f-a37d-4eac-b6ff-2ada64be0a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_377e5ce5-d901-4c17-b7e0-c8e5ce287604" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_5a6aa26f-a37d-4eac-b6ff-2ada64be0a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/NetLossIncomePerShareScheduleofBasicandDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#NetLossIncomePerShareScheduleofBasicandDilutedNetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/NetLossIncomePerShareScheduleofBasicandDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_e5fa91b2-56a4-4def-97e6-08b8b2f14b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_7f049f61-2542-493b-923f-1851c230b5d9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e5fa91b2-56a4-4def-97e6-08b8b2f14b1c" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_7f049f61-2542-493b-923f-1851c230b5d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c7d143ce-c0a5-48b5-8d72-c15c6e962f52" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_7f049f61-2542-493b-923f-1851c230b5d9" xlink:to="loc_us-gaap_NetIncomeLoss_c7d143ce-c0a5-48b5-8d72-c15c6e962f52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_4fec20be-e7c4-4b8c-8793-edb83be8f4ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e5fa91b2-56a4-4def-97e6-08b8b2f14b1c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_4fec20be-e7c4-4b8c-8793-edb83be8f4ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cbed0897-a8e2-4654-b33f-54f4dad772cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_4fec20be-e7c4-4b8c-8793-edb83be8f4ab" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cbed0897-a8e2-4654-b33f-54f4dad772cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_ef5021ff-3c54-49f3-bc72-efd6b9381b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_4fec20be-e7c4-4b8c-8793-edb83be8f4ab" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_ef5021ff-3c54-49f3-bc72-efd6b9381b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ea0c9c4b-866c-444d-9da7-d6b16bebe9a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_4fec20be-e7c4-4b8c-8793-edb83be8f4ab" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ea0c9c4b-866c-444d-9da7-d6b16bebe9a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_a5a93d10-726d-41ec-ba59-8acb17fd4829" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e5fa91b2-56a4-4def-97e6-08b8b2f14b1c" xlink:to="loc_us-gaap_EarningsPerShareBasic_a5a93d10-726d-41ec-ba59-8acb17fd4829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_875d6bac-67d4-469c-9e68-20cd922da881" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e5fa91b2-56a4-4def-97e6-08b8b2f14b1c" xlink:to="loc_us-gaap_EarningsPerShareDiluted_875d6bac-67d4-469c-9e68-20cd922da881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/NetLossIncomePerShareScheduleofAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#NetLossIncomePerShareScheduleofAntidilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/NetLossIncomePerShareScheduleofAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d0baeaaf-fa9d-402a-ab7a-3b7d8bd4cc7a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_84a5cebc-d90d-4461-b855-549aef85a20b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d0baeaaf-fa9d-402a-ab7a-3b7d8bd4cc7a" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_84a5cebc-d90d-4461-b855-549aef85a20b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e1af8855-fcc2-41fa-9469-dce6690167ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_84a5cebc-d90d-4461-b855-549aef85a20b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e1af8855-fcc2-41fa-9469-dce6690167ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_35a6519c-93c1-42f6-8483-9356e503e57b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e1af8855-fcc2-41fa-9469-dce6690167ad" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_35a6519c-93c1-42f6-8483-9356e503e57b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8a9b7b8e-6428-4c52-bf9d-fac308053220" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_35a6519c-93c1-42f6-8483-9356e503e57b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8a9b7b8e-6428-4c52-bf9d-fac308053220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_12d539fa-52ca-4675-88b3-4153ef3cf7d9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_35a6519c-93c1-42f6-8483-9356e503e57b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_12d539fa-52ca-4675-88b3-4153ef3cf7d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_162600b7-34ab-4517-9281-5c31b3130be3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_84a5cebc-d90d-4461-b855-549aef85a20b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_162600b7-34ab-4517-9281-5c31b3130be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_eaa4952c-f191-4d86-9aba-e1482361dac0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_162600b7-34ab-4517-9281-5c31b3130be3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_eaa4952c-f191-4d86-9aba-e1482361dac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7c2cfee5-f086-4bf5-be45-f515954fa78b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ea2d1160-6d1d-468a-8476-d78f87eea98a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7c2cfee5-f086-4bf5-be45-f515954fa78b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ea2d1160-6d1d-468a-8476-d78f87eea98a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="arwr-20250630.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_d8158466-509b-4327-8e31-517d970c28bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_d5f25b38-f561-4841-aa6c-a242e0e098af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_d8158466-509b-4327-8e31-517d970c28bb" xlink:to="loc_us-gaap_SubsequentEventTable_d5f25b38-f561-4841-aa6c-a242e0e098af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_f4e7704d-1177-4833-817b-ba1f9c2abb57" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_d5f25b38-f561-4841-aa6c-a242e0e098af" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_f4e7704d-1177-4833-817b-ba1f9c2abb57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c6b933e0-bc7e-44e7-93b2-a03d4104465e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f4e7704d-1177-4833-817b-ba1f9c2abb57" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c6b933e0-bc7e-44e7-93b2-a03d4104465e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_7e32aea8-dbbd-43e3-a754-70a3ddbb622e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_c6b933e0-bc7e-44e7-93b2-a03d4104465e" xlink:to="loc_us-gaap_SubsequentEventMember_7e32aea8-dbbd-43e3-a754-70a3ddbb622e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_147a1b9e-bdad-4588-8583-087c8d2d451a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_d5f25b38-f561-4841-aa6c-a242e0e098af" xlink:to="loc_srt_CounterpartyNameAxis_147a1b9e-bdad-4588-8583-087c8d2d451a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6acf0803-7230-402b-b64b-00a61feedb99" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_147a1b9e-bdad-4588-8583-087c8d2d451a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6acf0803-7230-402b-b64b-00a61feedb99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VisirnaTherapeuticsIncMember_32c880fe-594c-47bb-8901-39d6182607aa" xlink:href="arwr-20250630.xsd#arwr_VisirnaTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6acf0803-7230-402b-b64b-00a61feedb99" xlink:to="loc_arwr_VisirnaTherapeuticsIncMember_32c880fe-594c-47bb-8901-39d6182607aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SareptaMember_c7367635-af4d-430c-b9e9-4fa2309d7c5e" xlink:href="arwr-20250630.xsd#arwr_SareptaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6acf0803-7230-402b-b64b-00a61feedb99" xlink:to="loc_arwr_SareptaMember_c7367635-af4d-430c-b9e9-4fa2309d7c5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_04e6e088-9eb3-4a58-b6f2-14f170395250" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_d5f25b38-f561-4841-aa6c-a242e0e098af" xlink:to="loc_us-gaap_TypeOfArrangementAxis_04e6e088-9eb3-4a58-b6f2-14f170395250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2c91d685-6eec-435c-89bf-9861fafa129a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_04e6e088-9eb3-4a58-b6f2-14f170395250" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2c91d685-6eec-435c-89bf-9861fafa129a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SanofiLicenseAgreementMember_44fb6076-5761-4558-9fa0-2527300da331" xlink:href="arwr-20250630.xsd#arwr_SanofiLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2c91d685-6eec-435c-89bf-9861fafa129a" xlink:to="loc_arwr_SanofiLicenseAgreementMember_44fb6076-5761-4558-9fa0-2527300da331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SareptaCollaborationAgreementMember_80c2b93c-cbcc-4a4b-a7d2-4df26e571a3b" xlink:href="arwr-20250630.xsd#arwr_SareptaCollaborationAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2c91d685-6eec-435c-89bf-9861fafa129a" xlink:to="loc_arwr_SareptaCollaborationAgreementMember_80c2b93c-cbcc-4a4b-a7d2-4df26e571a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_076d95c9-05ac-461c-bdb0-ff0c89d036d3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_d5f25b38-f561-4841-aa6c-a242e0e098af" xlink:to="loc_srt_StatementScenarioAxis_076d95c9-05ac-461c-bdb0-ff0c89d036d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_395302b9-1da6-4b43-b9d4-b5d211385d96" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_076d95c9-05ac-461c-bdb0-ff0c89d036d3" xlink:to="loc_srt_ScenarioUnspecifiedDomain_395302b9-1da6-4b43-b9d4-b5d211385d96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_c8c477d3-bf50-4122-a36c-da38e3f96ca4" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_395302b9-1da6-4b43-b9d4-b5d211385d96" xlink:to="loc_srt_ScenarioForecastMember_c8c477d3-bf50-4122-a36c-da38e3f96ca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_b9b0b055-876c-4621-b62c-49f96564e088" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_d5f25b38-f561-4841-aa6c-a242e0e098af" xlink:to="loc_us-gaap_SubsequentEventLineItems_b9b0b055-876c-4621-b62c-49f96564e088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_807bd9bc-2c12-404f-8e85-5ccd77a9d5dc" xlink:href="arwr-20250630.xsd#arwr_InitialTransactionPrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_b9b0b055-876c-4621-b62c-49f96564e088" xlink:to="loc_arwr_InitialTransactionPrice_807bd9bc-2c12-404f-8e85-5ccd77a9d5dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FuturePotentialMilestonePayments_91ea48f7-6551-49cf-8464-794a81caa231" xlink:href="arwr-20250630.xsd#arwr_FuturePotentialMilestonePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_b9b0b055-876c-4621-b62c-49f96564e088" xlink:to="loc_arwr_FuturePotentialMilestonePayments_91ea48f7-6551-49cf-8464-794a81caa231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentMilestonePayments_10a82352-1732-41ff-bffc-7c3f30c82818" xlink:href="arwr-20250630.xsd#arwr_DevelopmentMilestonePayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_b9b0b055-876c-4621-b62c-49f96564e088" xlink:to="loc_arwr_DevelopmentMilestonePayments_10a82352-1732-41ff-bffc-7c3f30c82818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>a106amendmentno12tolease001.jpg
<TEXT>
begin 644 a106amendmentno12tolease001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,'.>E>=3ZQ=VR:B/#=]J>I0W-BD"27JNWEWDD@1-I(!& 69E VKM' SBI_\
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MH'@S2M,NP@N8(0)50Y56)+%0?09P/I6_0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2*J
MJ"%4#)SP*6B@!IC1G5V12ZYVL1R,]<4%%+ARH++D XY%.HH :(T#,P10S8+'
M')QTS0(T4L5106.6P.OUIU% '/ZMX0L=9ENOM-U?"VNPJW5I'/MBF   R,9'
M &=I&>^:W]HYX'/-+10 4$ C!&0:** # SG'-%%% !4%[:1W]A<6<V[RKB)H
MGVG!PPP<?G4]% $%E:16%A;V< (AMXEB3<<G:H &?P%3T44 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ^O+98-&NVM8A#;[7D^9U#L22.-@. .I_"NA^';H_P -_#A5U8#3H 2#G!"
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M(Q8?[**Y^HQWKG_!/B37O$?PJO/$5[JCK?H)WC,,,:JOEY(&"ISG'/U[5A^
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MJ ,C)##GI0!KVEMJ\MUJ<;:S/-I<EG ]C>1"/S VZ0OSM*L<!.=O0^O-<+X
M\2:UXK\)?VOJ_B2_M;N?4/[/MUM8(1&&*KM)5D)/))/-3_#K3(_"&N^);:TU
MKS_!T*(T5Q/*OEI.WWE#]"0."1W*YYKEOA-8Z-_PCWGZA=V>GWNGZ[]JA-U(
M(W>((H(P3R,;L<=10![GX>&I+X=T]=9_Y"2P(MT<J=T@&&;Y>.2,\>M4/'&N
MOX=\'ZC?VX9KP0LEJB+N9I2#MP.^/O'V4U;\-ZT/$.B1ZHD92">23R05*DQA
MV56(/0D#/XUSTUVWB;QT\.EZC8*-"C(*S1&;=/("KD*'7[B_+G)&78=10!J^
M!/$2>*?!6EZLLF^66%5G]1*O#C\P?SKF-#\5ZCX^\:ZO9:?<R:?H.C-Y4DD(
M7SKJ7+#J0=J?*QX&>!R,X'._#.]'@KQ[K?@JXN8Y=/N)_-L9XO\ 5++@;H\Y
M.T_=&TDG*X[\V/ &G2_#7QGXBTW6_+MM-U%UN+*_;Y86 9L(7/"MAONGTX[9
M /0(['7+/Q-9*NI3W>C/#,95E5-\<GR[,L -RXW8&,@CDGC'&:)J.MWWQB\2
M>%YO$&H?V;8VJ2P "+>K,(CRVSG[YZU8\/Z]KVH_%K4='CU2XN_#=I;K+%<)
M#&RO(50[&E5,'EGX!!^7KP:YFULK#7OC;XPCGNWBM-2L$M[6]AD*JTFR$?(X
MX)!!XSS@B@#K/ OB35M=UWQ9X;U"\:>/2;D1V^H1!5E*EF #8&TL-O7'KQ7-
M_#_Q1K&MVOB&77/$FI!;+4(;2W:W2%6S(Y11RF#DE:O_  KU>3PJ^I>"O$4,
M5G/ITK-#>E=D=RA.[)?H6P01GD@^U<O\.-)L+A/$Z:C)%9RIJ\%Y9S728R(Y
M2^5SC((&./6@#T/7F\1Z)\*+^\N]7N5UG3A<.MTHCS,HE81EE"E<&/8<8!'U
MK/T.;6];\&Z//'XDU1M<O;%KX1@0B.0(R!D^X,9W  YSUYJUXQ\0Q:]\,/$\
MD((AD\RVL0R%7N JKDA3R?FWXXZ &LCP7<:-X:\%Z1K^Z*.^M]'EMI[18SYT
M\F\.HV]<@ANW._T% %OXK7WB31Y6OO#FN3VSP6C7MQ:,BNDB1O&AVY'RXWDG
MUK?U7Q.VL>!;&[T2[6VNM9B_T>8\F !"\CX]4"L/][ IAEAU'Q9I5KK @^TW
M.@SPWD*Y5=\C0DIR<C.'P"<X%<KX#\/77A;0O$3:U,1!I<MU9:8)!@*C[69A
MQD[SY>.O0@=30 [P%K&K^(/@]K6MZGK-^^H+]H=)TDVF/RTW*%48&,]1WIG@
M2\U'Q5X#L[G4/$>KKK.HSW$$$D,P159%=@=O0J O/'4@>]5_AG_H'P/UJROE
M:VNC]I7R9D(?+IA?EZG)X'K3/A7;Z;I/A#2+W5HVLM4TNYNG,;VK">2-T(*A
M0-S9W*>_3% &_P".(/%2^&O#4&DZM<V?B.=1#(OG?),ZV[R.IX(+$H<'@>]9
MT'Q"F\3_  UU%FGN--\2Z2\<5Y%&YC8-YBH6 ]#R,'H>/0G>OM9?4;GP-J-Y
M UO))?27+P^6=T,3P3+&7'./O("3W/;I6-\1_  /B.P\6Z6'BC^T0Q:S!!D&
M> R+N;"\GC[P[@#TH W_ !;IFIV6A^(]737+^#[+:%K".*Y8*H2($L_!W,7W
M=>P'J:R?AY#KGB#P1X=\0OKNH2WKW3/=I+<'RY8EE="NW&!P ?PKL/'DRIX&
MUJ'<PEN;.:"%%0LTDC1MA5 Y)-8GP:22U^&.EV%S%+!>6QE6:":,H\9:5V&0
M0#R"#^- '>T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% %&XT72KN=Y[G3+.:9QAY)(%9F&,8)(YXJXB)&BI&JHBC
M"JHP *=10!&L,23/,L:B60!7<#E@,XR?;)_.E2*-'=TC56D.YR!@L< 9/KP
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M0 ">IQUI:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ@-T)'0XZ'@\T 6:*S8M>TV?7YM#CN=VHPP^?)$$;Y4R!G=C'4],T[6=;L-
ML1>:C,8H&E2$,%+$L[!5&![F@#0HHIKND4;22.J(HRS,< #U)H =15&+6+"8
M61CGW?;5W6XV-EUQG=C&0,=S@<CU%3WEY;V%J]S=S+#"F SL>!D@#]2!0!/1
M110 4444 %%%% !160/$^C'Q -!^VJ-4(+"V9&#$ 9R,C!& >>E:] !1110
M4444 %%96K^)=&T&V@N-3OX[>&>X%K&Y!8&7)&WY0<<J<YX&.:@?QAH:7^I6
M)O?])TS8;Q!&W[E6 (8\<KR,D9QWQ0!N44B.KHKHP96&0P.016?9:U9W^K:C
MID'F_:-/,8GW1E5^=2R[2>&X';I0!HT45FR:[91:_!HC&;[;-$TR#R6"%5QD
M[R-IZC@$GD4 :5%%% !134=)$#HRLK#(93D&G4 %%%% !1110 45CZWXET_P
M_+9QWXN ;R98(#% T@>5NB<="<'K4^KZU;:'IAU"]2<0+C>8XBY3/J!^5 &C
M13(I/-A238Z;AG:XP1]15'7-8BT'2WU":VN[E$=%,=I%YDAW,%R%].>: -&B
MBB@ HHHH **S];U:/0]&NM3EMKJY2W3>8;6/?(W./E7OUJVL\92$L?+,WW$?
MY6)QG&/7 /'L: ):*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@"EJ.DV6JFU^VP+,EM-YZ1NH92VUE!(/7 8GZX/:N,T'2=*O/&_CJRGTVS>(
MRVNY3"IR&@Y'3Z_F?7GT"N*\-6.K6_CKQ'JMYI$]K::LML86>:)FC,2%2'"N
M<$D\;=P]2* ,RQBDT/XEZK::58/>SKHEFJB294W[6E&Z20\ECA1G:<]\5?OO
M$]GJOAC0M6N= -S%<ZA#&(II%'V6<3>6&YZ[6W8P.<=LU:@LM5MOB)JFM'2Y
MGL9[".VC*2Q;F>-G;.TL.&W8'/7J .1B2^']=;P/8:2FDG[7;:JMZR^?$$*+
M<&? .>N#MZ 9![8) .CU/Q7<6VJZCI]AIT5Y/86JW,D+7)CFE!#$")-AWCC&
M<CDXZBMK5=+M-9L#97T0EMVDCD9#T8HZN 1W&5&1W%<AXJT"]\1B_2?0@]P@
M4Z/J$4Z136CF,9+,&W !\GY=V?3@$]Q LB6\2S/OE5 '8?Q'')H X9+.U'QQ
ME46T(7_A&T.-@QG[2PS6D-07POK^D>&[?3(X].U%YS;W G($;C=*R;-F!U.T
M9Q@8XQ48TO5A\47U[["O]G-IBZ>&\Y=^X2E]^W^[@^N>.E7?&FA76O:&B:<\
M46J6ES%=V4LOW8Y4;J?8J6'XT 9MOX\FFL?$KMIMN+S1+D6WV9;TMY['&WYO
M+^7<3@<'G.<4:CX^2RDU&-(+%Y--VK<QO?['>38'9(AL._ ;&3MRPQQ22>#9
MH?%VCW=K*3IL=MMU!7P?.EB?? QSWWR2/D=Q[T0Z5XG\/>(]5ET>"RO]+U2;
M[5Y=S<M$UK,5"L>%;<AP#@<C^8 Z>XM]1\;>$=3MT8+<V%W(I<;6VE8B P]?
MY5DV46IZKXQ\:6=SH^EW*RQ6L$T4UZ^P(8F(4'R<D'))Z8/3-;D^EZR/%/A^
M\:-+R*QMIHKJY:01L[R[,E4]!MZ>GKWDT/3]3M?&.O:E<V*16FI>1Y;+.&93
M&A7YAVSVP30!Q=W?WMY\%$U+5+>)W2\MY8VBF,K'_35R &4; /NJ,GC SQ7>
M6?B.[?Q7_8.H:6+626T:\MY4N!*&17"LKC:-K#<IP-PYZ\5RDWA7Q,_PUD\+
M):V27$=Q'Y%P+HE65;CSBY&WCH !SR3FNDET[5IO'FG:U]EA6SAT^2UE5I_G
M5I&1R0 ,$#R\=023Z4 ;FK:E#I&DW>HW'^JMHFD('5L#A1[D\#W-<-X5.I>&
M_&\VFZU<J[^(;8:BAR-JW: +-&G X"^7CV6NC\2:=?:O>:9:"S@GTA+A9[Y9
M)<&0+G8H7!W /M<@D9V@<UF>+O!\EW%ID_AG3],M-4L;Q;F*X<"%5 X9250D
MAAP1[#TH O7WB/4HO&(\/6>F0RO)I[W<4\EQM7AT7YAC(&6/3<3QTYQC_P#"
MPM1'AN]UEM 14TNY>VU%&N\$,CA6\GY/G&#GYMOI[UK)INLR^.K/79K6VCM4
MTZ2RDC%R6=69T?<!MP1\F.H/-84_A+Q!=>"/$VBO%8K=:O>37$+FY8QQK*V[
M#?)D%<8P 02>M &]JWBF6#59].TY+4S6L"3S-=2,JMOW;44*"<G:>3TXX.>*
M</C>^O!X=-KH3J=767,=Q-Y;PR1HQ*,"O RH^;DXS\M-DT;Q/IWB%=;T>/39
M!>VD4%_87,[1JLB9VR)(J-T!P1MZ"IY]%UZ77?#][*UK='3Y)Y+B5IC'GS59
M=D:!#D*".6() [DF@!L/C::WTK6'U33U34=,NTLV@MY2R3R2!#%M9@" WF+U
M''/6LZ=M4_X6GX8_M6.S24V%\4:U9B&/[K*G(R,=<]\]!W?>>$-:OKGQ1*)+
M.UDU"[MKVPF69G,<EN(P@D78, F,'@GKCMS9;1?$^H>,/#VMWT&DPKIT5Q%-
M'#<R/O\ ,5!N7,8[J>#T&.3V *3>/]93PYJ&O'1;0VFF7LT%VGVH[RD<FPF/
MY<,1U^;;GH!WK=@\0:K%XMM]*U/3(+>VOK:2:UEBN/,=6C*[UD&  <,#QD=L
MFN=/@OQ W@'Q'H>W31=ZM?3W$;&Y?9&DK[N3Y>=PZ8 Y]16_J.C:OJ/BW0-4
M>WL%M;"*X2X0W+EB9553M'E@'&WN1G/:@#+C^(-S/'8:E;:<+C2[VX6$1Q"0
MW,:,Q F8;=NWC)7/ (.>U377BW7S-XEBLM'LF;1'!8RW9Q,GE"3 PN0Y! Y
M ]33/#_AWQ9H.GCP_%>Z:='AD(MKS+_:D@W9V%-H4MC(W;N.#@XJ>'P]K:3^
M,)&BT\#6<&V NG.TB(1?/^[XZ9XSZ>] &?J.N:QJVN>"KC2GLH[+48I+M(YB
MY8MY!.&*XR '/XX-:?Q.O]3TWX?:I=:;+%%*L6V1W#$JC$*2FW'S?-P:H6OA
M3Q!8:;X.-NNER7^A0/;RI)<.(W5HA'N5A'G/ .W ^O>NA\9Z%<^)?!VHZ/:S
MQPW-S$!'(X.T,&##..<9'O\ C0! ^MZBNK67A]$M3JTMLUW/+M?R8HE<*"!U
M9B3@#(Z$YZ S>&_$$NKSZII][ D&I:7<"&Y6,Y1@PW(ZYYPRD'!Z'-4'T+6S
MX@T[Q*@T]=32V>RN[43OY+PLVY=LFS.Y6 .=HSDCBM#P_H4NG:AK&K7AB^WZ
MK.DDJ0L6CC5$"(H) ).!DG R3TH QKX#_A=6CG S_8MQS_VU2NE\0:U;^'=
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M:VK6K6XM#\X<JSG=OX)*+C@X''/6@#-^(119O"4CG[OB&VQSW*N/ZUH>/_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH 1W6-&=V"JHR6)P /6F+<0N 5FC(/3##FGLH92K
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M& -YEIYO$9+EL2 $@-A5QG(SBH7\3>)Y]1\46=I::4G]C%&CDD9W\U3&7VD
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M[: +&Q7*M"(_FQGC!)X/6L(>)-:MWT6\?4WNY+K65LKH6Z*;(([LH5&*ABP
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M'MGL7)MX;_S#N2U+9 9,<R!<@8.WH?:NVU'5=/TBV^TZC>P6D.0H>:0*"3T
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MEVY8D1[Q^_XZ#>P4G'7%=;10!SG@CPW)X4\*V^ES3_:+A&<R3%RV_G"\GGA
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MC'$%B$42$X#.$!/SG&"23@9  R<@&S15#3;&YLY;Y[C4);M;BY::)74 0(0
M(QZ@8)S[U?H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!K11NR,Z*S(=R$
MC)4XQD>G!(_&G444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5&71=
M+GU2/4Y=/MGOXAM2Y:,&11Z!NH%7J* "BBB@ HHHH **** "BBB@ J.*"*W0
MI#$D:DEB$4 $GDGCN:DHH **** "BBB@ HHHH **** "FM%&TB2,BETSM8CE
M<]<'M3J* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **YKQ[KM_P"&/"%]K=@M
MM))9J':*=&(<%@,9##'7WKE]5^(6M:'X TKQC<VMA=6MT(C/:1JT3IOSRKEV
M!QP,8_PH ]-HKSKXC?$"_P#"?A33O$>CQ6=U:WKQJ([A&!PZ,X8$,.P'&*VQ
MJFOQW^FIYVF7D4SQ_;(X;:2.2!)%8JX_>,",J1R* .JHKB]9\:S_ /":6_@_
M0+>&?5&B,]U/.3Y5I'C(+*,%B<C@$=16G=7>OZ?J.EP2M975K=SF&:>.!T:'
M]V[ [=S @LH&<C&>_8 Z&BO-]&\:^(+_ .(6N>&;A+(QZ/!YQDAMG\RXX4@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZP9VM+&V@:08=HX@I<>Y'7\: /+_  EG_AHGQKDC_CTB_P#08JC^/3;8/"C
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M;" 06=M#;PCD1PH$4?@.* )Z*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=Q8'@IG Q][FM:/7M>A\6PZ-J-M80QZA:S363P,\AA>/;D2YV[OO _+CT]Z
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\YP,],UZ-:R32VL4EQ!Y$S*"\6\/L/ID<'\*FHH YCQE8ZK>KI0L+9KRSCO
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MD":$'$D9/(W*>1^(J_0!S$>BZJGCJY\0,+(Q2:<MDD(D?<-KLX8G;CDM@C'
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MR3\C;,@'W)V]>:S;?3[KPO)X#@NHII9A>7DLL$1\QHC)%(VU0.JINQQZ<9H
MZ9OB#I46DZK>SVU_!+I0!O+22#$T0*[E) .-I'?.*L_\)E9J)_-LK^(B:*"V
M$D!4WCR)N41YZ]&!)P!M)/'-<KXFTC4-3LO&&I6NFW!;5=/BT^S@\DB24J')
MD93]T9?'S8("]LBMCQ+IM_J5EX:U;3[:6632KZ.YEM'79(\>TH^ V/F )(SC
M...U &O:^)X[B\N=.DT^[@U:W@%P;%RF^2,G&Y&#;6&>#SP>#VJK9^.++4+?
M39;.RO)GOYY8%@^198C&?G+J6&T#'/ID#J1F+RYKOQB/$<=E=K:6>F26RJT)
M26X=W5]H1L-@;.^!EO8U@:=IFK:%XFMO$T&F7$LFO9_MFQCB&+3@;&0\<KT;
MD[\E@.F #H;&]T@>/-;6#3[Q-62SB>YE8G$L8+! B;N>AYP,YJM;?$K3+G2]
M+U0V&HQZ?J$H@2Y:(;4D+%54C.3DCJH([9SQ1:17L/Q/UC5'L;L:?)IL,$<O
MEY#R([$@#KT;KCUKF;#1=8M?A1X;TE])O#?V>IPRW$"J,JB7'FELYP1MQT)Y
M^AP =S8>+;:ZU"^L;NQO--GM;<76V[51YD/=UVD\ \$'D>E5]/\ '%M?7NE0
M/I]Y;Q:PCR:=/(4*W"JF_. Q*Y7D;@/SJG?QZHWCNZO[#3YR/[#>WMYY5 B:
M<OO53W Z9)&.U<]9Z=K']H^#M2E\-:F][92R_P!H3SRPM(6>!T^7Y\"/<1_=
M  & : -[P_XUN9X?$E]KED]E9:??R0JY='$818U$>%.2Q8L> 1\V >E:UEXH
M@O\ 6AH5[I\]G=SVS3QQS/&ZR1@A6&48@$9Y!KD9O#.N7VB^-="-@\4E[JCZ
MA97$KKY$JYB94.&W9)1@1C [UO:#)=S3P7,G@N/17@C8W3LD+.[;3\D/EDD@
MDYW'' Q@YX ,+POX@C\(_#)-0;3;FYM4U"Z24P%<Q W#J&;<1QT!/.*[O^UW
M_MRVTO[#*7DMC<2RAU*PC.,-SG)/ P.<'TKF_ VB2MX'O=&UO39;<7%Q=>9#
M,!\T<KLPY!(Z-^!J;X<Z?=V^@_:K^[^V3M_HL4^W&^W@9DB;J?O#+]?XZ .P
M=!)&R,6 88.UBI_ CD5QOPW3R=*UR,R2.L6N7T:O+(TC;5D*C+-R<  <D]*[
M)VV(S;2V 3A>I^E<GX#L[ZSM=;34+":U^TZO=7D(EVG?%*Y9>A.#CJ#TH Y.
M*2>\^$LWC>1V3709-32XS\RJDAVQ9_YY[!MV]#G)YK:U?Q"VL>*UT58[\:=9
M6B7M\MFCEYFD!,<19<;5P"QY^;@>M5AX=U:T\!2^!8+*617D:V2^)7RQ:/(2
M7.3G<$8KMQR1QQS6RNFW?A[QO?ZO;V,UY8:G:00NMN5+P20[@O!(RK*W7G!'
M/!H V_#ESHU[H<%UH*0+I\N600Q>6,YPV5P,-D$'/.17)ZKK1UGQCJ&F/'=S
MZ-HL4;W<%FA9KF9QD*Y'5%7DIG))Y! IUJVI> ?#+77]C27GVS4YKN\ABN%'
MV**5RW&>&VC P#RV<'FM"WLK[PUXIUF[M]-N+^PU8I<;H&3?%.%V%"&(^4@*
M0W8YSZT 9.J:CHU[>>"8K0VH\*:A),=J+Y<,DFPF*-EP!RQ;Y3U8=,BLS4]<
MD\)W?CRUTB54M+33(KRUA3!2UG<,IV+T4$A6*^N3WKI] T$Z!X%LM'O]+74Y
M2TDDELB(T:N[M(5RY"X!;;GOZ57M/ "R>&/$%K?BVCU/7D87#6Z_NH0%*Q(@
MQ]U.O3DDGO0!6U.Q3P;?^#YK$*)[F_33K]U&#=B2-B7D/5F#H&!.3R>>37>W
M,QM[66989)BBEA''C<V.PR0,_C7'2:=K/B.[\,C5K$VPTJX^V7LF]<2SI&50
M1X.2I+ELD#C ZYQU]XS+9S%(GE?80(TQECZ#) _,T <C;_$6WDT8:U<Z3>6N
ME-8K=)=2X"M(SA!#ST;)')P.<YQS4UEX[CN-8N-'EL-NHI9F\AA@NHI1,@."
MH;( ;/8]N0365;>%M8N_@[:>'FM_L.KVD4)C2X='1I8G61<E&(*DKC^E;&F7
M7B*Z4R7OA>+3!% WF)'<12R3R'@+'@@!>IRQ!S@8ZF@"KIWQ$2^MM!OGT:Z@
MT[69%@BNGD3"3-G:A7.[!*D9QC.,9'-)IOBG5_\ A(_$PU.P2+3=+5"Q2;>T
M:"(R9"[<L6SV/&!^.&GAWQ!'X \$Z8=&G:\TK4K:XNXQ/#\J1,22"7P<@\ '
MZXK9DT[Q+;:[XO?3K0)_:<*265\\R;8Y%@V!2F2<[P.V,9.>,$ TK'Q6U]J.
MDV%[I36Z:Q9/=0$R!^%"DI(N!M.U@>X[5QGA+Q'-X4\(ZE-'H%S<Z;9ZK>&Y
MFMV15@C$QR57.6"CDX& !5VRT'74U_PIJR>&DMFLDFCU!I;N-IY'DC"F1F!.
MX97KDL<_=%7K'1=;LO#_ (@\/KI6XZA>71AO&FC,(BG8G<PSORH8Y7;R1C.#
MD %ADM6^,6G7EM'#FZT&=FF11F0"6+:2>_!XIJ_$_3'ELYD6WDTZ[NEMHYX[
MQ&E&YBJR-%U5"<<YR 02!4\>BWUMX\TJ=+&:33;/2'T]KDO'AF9HR#MW;L80
M@\=2.HYJAX6TWQ9X?TZ#PRVE6<EK:MY<.L&=<&#<2,Q8W;PN!CIG!S0!Z [B
M.-G/102<5R^B^+YM833+M-,"Z7J$#3+>1W(D$.%SMD 'RMU'4@$8SFNFG\W[
M/+Y&WSMA\O<,C=CC/MFN L/#-U<:U:WL>BSZ#]H@E36(HYXOL]PSQD95$<Y8
M.0=Q"G .<DT :4_CBXCTW3]6BT5GTN_O(K:"5I]DI61PB2&,KPI)SUSC''-:
M5KXAN+O7=;T=-/076FQ12QDW'R3B3?MYVY4_)SP>O?K7!ZFGB2P\$Z/HVM:7
M;I%8:E80&]CN01/&L\81D0#()'!W8QCC.:ZR6QUO3O'NH:I9:>EY9ZC900[C
M<+'Y,D3/]X'G:1(3\H/0\<B@!;'QM)JFD:)=V6DR-<:M)-&D<DI6.'R]^XR2
M!3@'8<<<DBJMQ\1XK?PEJ^N_V8\O]DW[6-S%'.I 964;@V.5^9>@SSTK&TSP
MYXHT_0/#EA<:7%=6=I-<_;K!+M0)U<EHV;.%(#$Y3D=#STJK<^#O$LO@SQCH
MBZ3:12:KJ1N[4PW*[ K&(XQ@8 \LC. 2>V.: .MN_&<^G.(-1TR&PN)[IX;,
M7E\B)-$J!C*6 .T<@;<$Y(_"[X3\5P^*(;X+"L-Q8W!@F6.42QMQD,D@ #*?
MH#P<@52\3V&O7%UHNO:%;0M?6#2)+8W<@02Q2A0XWKD!@44@YQUZ]*V=$?6;
MB.:YUB"&T:0@16<4@E\D#J6? W,2>W P.O- '/?$F>^CT_2(+>&![:XU>RBF
M\R8J7!F7Y"NP@J<<G/X&B\\1V'A_79X/L>DVNK7-NES?237_ ),;?>6,!RF7
M/RMSM& .>V;GCC3]2U2WTJ'3K$W!M]2M[V1O-1 %BD5B/F(R2,X[<<XJKJ5A
MXETWQ>^OZ%96][;ZA;107ME<W'E.C1[RC(W(_C((_P#UT -A^).GW/A_2=2C
MCA@EU%Y(UBO;D0I$8P=^Z3!R!C@@'.1[XR=<^(-[=^#;J]TB&U6X@U&*QG=+
MMG0;W0!HG51N!#CGC'/!QBM+5M$\4R3Z1XBM?L$^N63S"2S>5DA,$H&8E?&2
M050AB!DYZ#BE\0:+XC\3>$[I;J*WM[YIK>:WL$F#HHBD#D&3 ^9N><8&%]R0
M#M+=IVMT:YCCCF(^=(I"Z@^S$*3^0KD->\=S:%::KJ$^D[=/TVY2!GGG,4EP
M#MW/$I7#!=W'/S8/3'/5Z?)>2V,4E_;Q6]TP)>&*3S%3DX&[ R<8SQUS7FGB
M'P?XGU>Q\6V+65C<R:A(SV6H3W/SI#\I6%4V_(!M]0,DG% '4WGBK4T\6R:#
M9:%]H<6(O(II+H1HX+[<$[25QSV)/' ZU%9^.A?>']+O(=-/]I:C=O91V!F^
M[*C.),OM^ZH1F)QT XR<46=AK0\=QZS<:8D=L=(%H^RX5BLH??QTRO.W/'(Z
M8YK L_"GB:ST73[FVMK6/6-+U6YO8H)9\Q7$4Y?<FX?=;;)@$C&1[T :'AX3
MCXO>)/M-M%!(=.M"?*?<K_-)\W0$>F#Z=36E\3T1_AEXAWJK8LW(R,X..M,T
M;3O$#>.;O7=1L;.UMKK3X;?RX[HR/&R/(V/N@'[W)X'(QGFM#QOI5[KG@W4]
M)T](VN;R$PH9'VJN>Y.#P/84 5TUV6*?2-!TZ&*;4)K 73F9RJ0PKM7<< DD
MLP  ]SGCFM_PGJPZ=J9N=.9-5L+V.P:Q27/FRR%1$5? ^5@P.2. #QQ3#H6K
M6NMZ-XDM;='NH-._LZ]L3(,F/(8-&_3(8#KC(/8CFKJ7@C4-9T[6[EKB*QUB
M^O8;RU9/F6'R HA5SW)VDDCINXSCD VSKVKVEUJ<%YH4CK:6/VR&:T9G2X89
MS",J/GX'KG/:JNG^*[V?Q!'H=U;V"W\UB]T(X;DN;9UV?NY1C/\ RT'(ZX/%
M136?C36M#U".[>RTF[:RE@MUL[AY-TS 8D+;04 QP!DC<3G@54TW1/$,&N>'
MM072-*LK>UM9K6XMHKEB8PYC)<$)AF_=GC ]VYH @\.>+-3MO!MQJ^JQPW$\
MVI2V\$<<K#=(;AHU7)!V(,#GG@'C/73@\<&VN]2BU:T\NVLK(WOVZ!7\EU!P
M4^91AP<8&3D&LJW\(>(1X;OM%1[2U>UU%[_3+WS"_FOYYF7>F/E7G:>2?RYU
M;C1O$7BK0[[3_$7V&PBGM'MQ%8R--OD.")2S*-H!7A1G[QR>!0!G:S=:I=>(
M/ \^IZ=;VL<NHLZ^7.6DA8VTN(VRN#G/)']W'H:] D+K$YC4.X4E5)P">PSV
MK@;K2_&VJ'P])>6NCQW&E7JSRNMW(1.!'(A(^3*_>''/)/8<]](S+&S(F]@"
M0N<9/I0!P4'C&;3_ (>PZY;>'K>$F_>VEL8;@ 1L;IHBRG: Q+<_PY)/-;-G
MXDOO^$O70=4T^"V:YM&N[5XIS(<*P5D?Y0 WS \9'49-<^?#'B5_ #Z*;:Q6
M^.IF[W"[/EE#=?:",^7D'G;T]_:MFZT?6+CXB:3KHMK865O8R6TP-P=X9RI)
M VX(&W'49S[<@'3W:SM9SK:LJW!C81,_0-C@GVS7!^$X#X=UVUT/5_#VFV]]
M) QM-7LEW"[*C,@8L-ZOSDY)W<^E=MJIU%=+N#I"6SZ@%_<+=%A&6_VBO./I
M63;:?JVI:S8ZEK,%I:"P5S#!;3M-OD==K,S%5P N0!CODG@4 <G8VZ:M\//&
MM_<+BZN[F_9I, .ODEEB /\ L;%(]#4_AN\G\0>+_#UW?$OY/A>"]0'&!-.P
M#M]<)C/;)]:TKGPSJT-CKFB:?]G73=6FDD%P92KVHF'[X!-I#<[BO(^]STR;
M<WAN?2M6TO4M"B@?['8?V;):S.8Q)",&/# '!4CICD,?04 5? ,C0WOBO3%)
M^SV>LR>0O9%D59"H'8!F;\Z[2N$N+?6/!?A#4]2M9=-DU:[OFOKD73.(<N0/
M+3'S$A555]3VYQ7<QLSQ(S(48J"5)S@^E 'G.OP7/A_6;S7]=T/2-7T>:X3?
M<E-US8Q?*BG#*0R#[Q"XP78^]:Y8W?Q@\F==T=CHBS6X8 A7EF968>^(U'Y^
MM37VG^(]>LKS1]4@TR&PN)&CDN;>=R[VY)X$97"N1@$[B!DD>E6=4TB_C\3V
MOB#2EMY9A;-9W5O-(8Q+%NW*58 X96SP1@ACTH PO"5C;:K<>(=.O(_-LM,U
M^5K>W8YC&Y VTKT*AG9@.@.#V%6]&TVV'Q,U;4=+A6*R2QCM+HQ +')<ARW0
M=65" 3[@=C0GA_Q!I/AV]71Y+$ZWJEZ]W>3S2,L<1?J(_E).T!57(]_:K>@6
MOB6QDM[:ZM='L]+@B?(MIY)9'?C!)95 !)9B>23^)H ZFL'7-9NM.OX($6WM
MK-H))IM2N_\ 4PE2H5#R/F;<>X^[W[,\&:KJFL:#]HU=;(W23O%YMB6,$H!^
M\F[G'5?<J2.,5!K6C:O/XNTW5K);*YMH;=X6AO)&40.6!\Y %.6QE>W'?DT
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M>5Y@=6 YX[8'(Q[U+'XL.FZ-HJZF+=;^_C!3?=JJ,BHI>5G8# ^8< $Y8>Y
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M#SLPV.D6[D#^')'3GC'?(SK[Q7KUK>-I$D^CV6LI81S0Q7*.8K^<AMZQ.73
M! &.3SZ#D [^BN"@N-:E^,,]JU];"VCT=)EA-JWRHTQ!7/F??^7[W3VKO: *
M]Q?6MI-;0SS)')=2&*!6/+N%+8'X*Q_"K%>5^.[M=2N-1U."]MH[GPS)'+I\
M1G :6=<2397/(*?NP,==U=1XA\5RV_PWG\4Z(()/]#%U$)\D;2,\A3U&>F:
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M$=?*;.7*J,D8Z=*BT3PWJ%[X9\9:/?VD]@=9O;NX@DD*$>7./ESM)P1CD=J
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M];W!N4C,+R8W)(#S@$9!4-5BTTS68OB4NKW%C));)H2V+W"-$!),)-Y*KNR
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M)5AQC&0!CD\CIR!)K&LWNN:%XG&EI:&SL4N+-_-R6GD6/YP,<( 21R&R1V%
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M=SR2,%51ZDGI7)_%' ^'6J$@'!A/3_ILE=A0!1TC5['7=-CU'39Q<6DA8)*
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M0><L<'/..@'<T4 <J=#U:?QQ-K$PLDL9M,%@RI,S2 [B^[!0 \MC&>G/M3_
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M&KKH176;N6\E$[^3<S0"&26+C:S(/NGK@'G&,@&NAHH **** "BBB@ HHHH
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M"QP('7=O\Q@#@#8W;GC\([2#6!\1+K5+C1IDM'TF*W$J3Q,IE5W=E&6#8^;
M)4=.<5S&D:#XHLO#&DV5QH4TMM%J-T^H::;J%3<12,SQG(<JR@L-R$C/3!%
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MDSK@&##C[^2,8)R#T%-USPOJWB?3]3BOKN*SE<PMIXMY&E2W>)MXD.57+%L
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M >"*!YO+7=(!\LNUD)!;J<;:T= M[S_A8GB9YM5N)HHA;!86CC"A2C$+D+G
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M'5M6\$:??ZL8GEN(_.6596=G#$GY@5&W&< #(P!S0!UE%</J.K^($^*NF:5
MEF-/:RFFV&YD4R#?&"S (1N7G:ON?F&<5/-XSO'TW4=9T_2DN=)TZ:2*5S<;
M995B)$KQKM((7!QEANP>G&0#L:IQZMILLZP1ZA:/,QVB-9E+$^F,U-:W,5[9
MP7<#;H9XUDC;'56&0?R-<9X:BC7XL>.6$:AO*T_D#GF.0G\\"@#N:*R?$.N1
MZ!IJW+*CRS31V\"/)L5I';"[FYVCN3@\ X!.!6);^-9UFU:VN-.%U/96?VV%
MM-9IDNEY!13M&'! &WGJ#0!V-%<EIGBV\F\6KX>U&SM$N)+$W@-K<F3RR"H:
M-P5&#\P.>_H*A\.^,[W78K*_6RM?[,N&E$S1SEI;(HK$+,NW )VG)R #@<Y!
MH [.BN$L_B!/=3Z3<+81RZ=JDRQ1"!V:> /]R25=NT*>_/RY[\X[N@".2>&*
M2*.25$>9BL:LP!<@%B .YP"?H#4E>8>-+Z[N;JY\1Z;-(\?A2Y3;;KP)VQ_I
M.0>N(G4 ]B'ZUV>N>)(-(\*MKD*?:HV6+R%5P!*9&54YZ $L.?2@#<HKF8M;
MUN/Q:-"N+&QD5K3[6MTD[("H.UEV;6.X,5YS@AO48K)T[QYJ4V@'Q#?Z/%!I
M$$-VUV\5QOD22&1E"HN!N!VGGCGJ .H!WE%</IGCB[FUJPLKNR5X+U)"9;6*
M;_174;@LF]!D$9&X8Y'3FJUK\2)+I].NHK$SV5_<+&L4,$QFBB?&R5B5V'U8
M \ \$XH ]!HK@YO&/B(P^)&MM&L&?0YB) UTY$J")9,+A,ER#W  XY-3IXSU
M(:AX>GN--MH=&UQUBMW,Y:=&:(R(74#;@X(P"<<$GM0!VM%<%?\ Q G3^U)=
M-LGNETZY:V-HMI.\MP4?;(4=5VKCD <Y(Y(JT_BG6[GQ;<:#8:?9*W]FQW]O
M-<2OC:SE<2 *"#P?E&?J.E '9T5YAJ7B?5?$7AOPEJ5E]FM([[5H89X7WG][
M'(V1N4CY-T7<<\?2O2XRZP*9V3S HWE1A<XYQGM0!3UC7=+\/V?VO5KZ&TA)
MVJTAY8^BCJQ]ADUH5Y+\0=9U+Q!\']6UBU2U72+E5,4<B.LQA\P 2;LXR2 0
MNWH?O9XKMM:UK4K/59+>+['96<=L)OMEZ"RS2$L/*0!EP0%R3SU'% '245YQ
M>>(=4UNW\!ZA:3PV4&JSJTL+Q,Y$GD2, 2&&Y,CIP> <]JOZKXQU2.;5AI=D
MTYTQ_*$0T^XF-W(%5F57C&V/[VT9W<@Y % ';.ZQHSNP5%!+,3@ 55TO5K#6
MK%;W3;E+FV9F19$S@E25/7W!%8</B*]UK4TL-)CCM)8K**[N_M\#%H3+G9$4
M#*0WRN2<\8'!S47PY,Q\+SFYCBBG.IWWF1Q'**WVF3(4^F>E '6T5SFO:OJ=
MCJ4<%N;&SLC;M(U_>@NC2[@%A50ZG)&3G)Z8Q6&OQ!DE\-^&=4E^RZ;%JS,L
M]W<J7@MV56^4D,OWF& 20.N>>" =_4%Y96FH6[6][:PW,#<F.:,.I_ \54T*
MYU&ZTXRZFENL_FR!&MSF.2,,=CCD_>7!Z]ZS3K.I:IX@U72M(:T@_LM8UEFN
MH6E$DLB[PJA77 "E<GGKC'% &I;:?H_A^TGDM;2RTZW WS-%&L2X'=B,=.>M
M1Z;XATO5KN:TL[K=<PQI*\,D;QN$<95MK $@^HK@/%WB&\\1?![4-0A6"TDC
M?[+?6[QF3$BS*C!'# 8!R<X.1Z5Z39V\T:"2\:VEN\;&F@@,0*YR!@LQQSZT
M 5K7Q#I-[J\^DV]]$^H6ZEY;;D.J@@9P>V2.?>K=]?6NF6,U[?3QV]K"I>26
M0X51ZFO,/&0N=+\>77BRU1C+HUO9&<)D[[)WG$P(Z9! ;U&RKWQ,GB\0^'-6
MTZWF+V5GI,NHW+1L0';83;KD=02&?'^PN>#0!Z!8:A;:G9I=V<ADMY!E'V%0
MP]1D#(]^E6:XZ'5+W3]!\+Q0M:VUG/9I]IOKHC9!B)=J@;ER6/'7L:R#XYU^
M;P+<:_:V]D9-/U"6WOE:WD(:%)-K2HF\$$+\Q4GL>10!Z139)(X8VDE=4C49
M9F. !ZDUCVNJ7=[XFEM;=[=]-@M(Y))!&=QE<DA0V[&-H#$8_B'/-;+*KJ5=
M0RD8((R#0!6T[4K+5K07>GW*7%N79!+&<JQ5BK8/?!!&1Z476HVEG<6EO<3J
MDUY(8H$Y)D8*6(&/15)S[5S7@FYMM/\ ".H3SND%M::CJ+2.1M2-%N923[ "
MN8N-8TR_UWPMXANM2T\7DVI-M0SQ[K2U-O/A&.3@G*EO]H@?PB@#U:J][?6N
MFV4MY>SQP6T*[I))#@**L @@$'(/>JUW86M\]L]S$)#;3">(-T5P" <=\;CC
MT.#U% %/1?$FC>(XI9-(U&"[$1 D$9^9,]-RGD9]Q2CQ'I!U0Z:+U/M0D\G;
MM.WS,;MF[&W=CG;G/M6!&J3>.-9UVQA54LM-^QR3[?EN)@V_&>C; ,$^K$=J
MY2[D9/V;X]05B+M;>._64$AA.9A)O!ZYW$F@#T'6?&7A[P]<K;ZKJL%M,P#%
M&R2JG@%L [03W.!6C>:K8V&G_;[FZC2U.W;)G(;=@*%Q]XDD8 ZYXK.U)=-T
M31-2O);;S?M9+S1[=[7$C (J =\X50.@^E<I9Z3<:-<?#?P[?2F<VJ3RREOF
M4RQP84<]E\P[?]T>G !WUAJ5KJ<#2VDA=4<QNK(R,C#!*LK %3@@X('45:KB
M]&D:/XL^)[=>(I+&SF9?5_G7/UP /P%=I0!0U:RTJ[M6?5;&VNX807Q-;B;:
M.Y P?3MZ4S0=5TW6]$MM0TAPVGR K"1&4&%)7 4@8 *D=*Y_0AJ+?$?Q,9[]
M988HK1%C,&-J$2LJ@YXP6.3@DY^E<CX/UC6=#^&?AS4+3[$=--\+66VD5C*Z
MR7+(7$F0 0S9"[3P.IH ]@HR!CGK7">)O%&L:/=:XWF6=M%96@N-/A,?GRWN
M$+.656W(@8;,D <YS4,TVHZWXO\ !E^EZEM#<:=/?+;>1Y@1MD((+9&>)6&3
MT],F@#T&BLWQ#K$7A[P[J&L31F2.S@>8HIP6P.!GWZ5G6<WBB._TU[Q;*>PN
M(&>],2[&M9 H*A?F.]2<KZ\ T ='17GNG>+_ !%JMAI^K6&E33V]W<J6MS:[
M0MJS8#K(7&6"X;D8.<8&,U9L]7\5ZKXFUS3+6YTF.#3+^!#(T#EF@>/>P W'
M#C*XSP>>E '<YS39'6.-I&.%4$GZ"O/?#USK6G^!M5OX+FUN;C^TKK$DZB-$
M NW625R6 ("@MC(X7&:OZ+XFO=3\0:UI%M>1W"VUG#<6MU/9M&"S%PV1E?,7
M*@AEP.3R<4 =1I&J6VMZ1:ZG9ES;748DC\Q"K8/J#TJ[7G4WBOQ&/!OA+5K9
M[!KG5;JV@N8Y(F /FG^%@?E QCD$\]<]=O1=7U8>,]4T#5)[:Y$-I#>0300&
M+ =F5E(+-W3(Y[T =!J&HVFE63WE[,(H$P"V"223@  <DDD  <DFJ</B339M
M2M]-+SPWMPK/%!/;R1LRJ,DC<!P/ZU0\;Z%<:_H]O#8WT=GJ5K=QW=D\HRC3
M1Y8*P[C&?RSVK"T7Q'<7_B[3M)\7:,^F>(K=)7LI86WVUVI3Y]C=>@SMSQCG
MTH ['2M:M-8DOTM1+FQNFM)O,C*C>H!.,]1R.:T:X[1-2U_6(_$UM]MM8[RP
MU!K:UE%L1'@1HP#*6)QEN><_RJ+PGXBU3Q1*BES:-IJFVU:)HT)-XN 53DX3
MJ<]P5Q@AJ .GUC6+/0]*NM2O6D^S6JEI3%&TC* ,]%!/3\JM6UPEW:PW,6?+
ME19%R,'!&17F:PWB>!/B#+<7[W),VH*=Z("VV,*I)4#HJ@8K1L-7UO2-2\'V
MMY<VLMCJT!@,$<)!A9(MZ,')RV0"#D#V% 'H%59]1M;:_M+*64+<7>_R4[OM
M&6_(5:KQ[Q;JEO?_ &OQ5:2.VHZ+?(=.18W_ 'D$1VS#.W'SEI?J$2@#V&BN
M3\5^(+V#P0NO>'[BV.[R9$,R%U>-W48X/!^;KS522]\2P^-H]!?5;5H[VP>Z
M69;3:;<HZJ0B[CNSO'WB<8[]* .WHKSR/Q?K,?A]H)%$^J?VZ^C)/%&JEP&)
M\S8Q"AM@/!.,^HXJW<ZAXML]/\0S-$\-O;V1NK&ZO5@9Q(JL6B=8FP1P"&]S
MG/% '<52U?5(-$TFYU*Z29H+>,R2"&,NVT#).![5QQU[7=.;P?=W=]%=1:S+
M';7%NMN$"%X2X=6Y.0R\]CGH*BUN]U+7_!?B^_AOC;6L$=Y:P6WDK\RQ*R.7
MR-V68-C!&!CCK0!W.FWT.J:7::A;AA#=0I/&'&#M90PS[X-6J\TL-6UFU'PZ
MTFPO(8;;4]*/FB2#>5,=NC YR/[W3CD=QQ5FSU'Q/?/XIT\:S%'+HTQ6&Y%J
MFZ;=$LBAP1M &<' R<]L<@'H5%<+%XHU/6)]!LK:*:&2^T=-4N);01%U+; $
M7S3C&6))P3P/K5'4];\9:3HVDF^:"WNY]>AL=QC1O/MY'&UF"DA6QD$#\,<&
M@#TBFQR)*@>-U=#T93D5Q4EUKEMK6OZ1<:P\B?V6M]:7"11I) V75E VX(RH
MQD$CUJU\,A,?AWH<T]U+.TMHC_O ORY'8@ G\<T =;1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !7&:)I^J0_$7Q'JEUI<\5AJ$-M%#*\D1'[H,&R Y(!W<<'WQ79T4 <SXMLK
MR:TTF#3--EN%M]0M[AU@>)%2.)PQ&'9>PX ].U4Y['5&^*=IK*Z5<'3X]+>R
M:;S(N':17SC?G: "#QG/0'K794UY$BC:21U1%&69C@ ?6@#B)=-UN&#Q?8#2
M3<0ZG)++;SQ7$:[O,A2,+M8@@@J22>PXSTJ#4M)UFZL_!9CT>XWZ3<QS749E
MA! 2-HR!\^"23D<]/0\5W4=W;32&.*XB>0#=M5P3CUQ4U $%[-/!932VULUU
M.JYCA#A=[=AD\ >_\^E<SHWA.Q/AY3J^CI)J-PCO?))M8RRL27Z,5P23CGH0
M#CI76T4 >7)X>\3O\*-2\)7&F2//Y;6]A(;J/'DELQASG@JN%( (.!S73W=M
MJ=WXG\.:@NE3)!:13"XWRQ;HS(H4  ,<XV\X[$8SR!U5% 'FK^$]>NHO%GE1
M)9W5[J4.I:=+*ZLF^+RRH<*21DQ^_!KH8)_%5[:.]]I4%D(X'4VL%PLS7,A&
M!AB $4<GKDY'3!!ZFFF6,2K$742,"RH3R0,9('XC\Z //H?#^N6W@3POI(TX
M27>ESVSSCSD"D1==ISSGMG'OBK"Z-X@TU/$NF6EC#=V.JR3W-M.]P(S"\RY=
M'&#D;LX(SUY]1W=% 'G5AX<UVUMO ,<NGPLVA*1=M'<*>/(,0VY R><D=..I
MJ_'HVKC4_&MP;$;-6CC6T_?+DE8?*^;GCGGZ>]=M10!YU#X=\3:7%X6U33;>
MVDU#3-/_ +-OK*>?:L\1V<HX!P0R \CFKVN:;XEU73+/SK2WDG&K6]Z;>.90
MMO#$RMLW,/G<X)SC&2>P&>WHH Y!=(U,_$RYUHV@%A-I*6*OYJ[@XD9R2N>G
MS8_"K'@'3-6T/PI9Z/JMM;1/8QB!)()S()0,_-C:-O;CG\*Z>B@#D]6T;53\
M0-)UZQ@MY[>*SEM)EDF,93>ZL&'RG/W3Q5'3/#^NZ'HNL:!:P6T]M=3SO973
M3;?)28DD2+MR2I8],YXZ5W5% %/2--BT?1K'3("3#:0) A/4A5 !/Y5S.EZ7
MK>G^,O$6N/I\#P:FMLD40N?G7R5926^7'.[(P>W-=E5/4-5T_285EU&^M[2-
MVVJT\@3<WH,]3["@#E]<T'Q)KMC>RBZM;.^@O(;G28RQDB3RN<R$*"=Y+9ZX
M&WTIUW9^-=9T&_2:6PTF\>R>&WCM9VD5I6(_>,Y0%, $ +G&\DDD#'944 <!
M8>&]=@\4Z/JL6FZ5I]K!ITMG+;13LQA+,C;QA '.5Z<>NXTL7A/4-0US3M4O
M;"TTZ]2%HM5N+67*WZ,A4IM '<[LMRN,#/6N^IDTT5O"\TTB1Q(I9W=@%4#J
M23T% '%>&='\8Z-96V@3SZ:VF63*D6HH[>>\"GA#&5VAL *6W8 [$UV%\]VE
ME,UC%%+=!?W22N40MVW$ D#Z TEAJ%GJEE'>6%U#=6LF=DT+AD;!(.".#R"*
MLT <WHGAJWLO#<%M?Z78SWXB/VEMJOY\IY9BQ4'YFR>1WKC+C3-;\._"N?PU
MJYTR1IIX[#3F:XD<%))0$1CL4J54G##.-H...?5ZK7^GV>J64EEJ%K#=6LHP
M\,R!U;Z@T <=8/J6B:];O?Z+9FZU)1:)<1ZM)<R@(K,JD/$I"=<E<\G)!I^C
M>#[YOA]J/A?6#;P_:C<@36LIDP)I'?.&5>5W#ZX[5T>E^'-%T21Y-,TRUM))
M!M9XHP"1Z9]/:M">>*V@DGGE2*&-2[R2,%55')))Z"@#E]&LO&+16MEKT^E?
M9H%*S3VK.\EX-I50590$]206R>!BJ6@Z%XSTFS@T&34--;2+4K'!?)O^U?9U
M(Q&4(V[MHV[L\=<$UU.GZYINJ7$UO9W2R3P!6DB*E756Y5MK '!['H:?:ZQI
ME]=RVEIJ%K/<PC,L$<RL\8Z?,H.1SZT <M;>']>AC\7GRK 2:S(7MO\ 26(3
M,2Q?/^[_ -G=QGT]ZBN/"VMS:7X,M@E@'T*:*6<_:'P_EQF,!?D[@[N<8Z<]
M:ZVYUG3;.\AL[B]ACNIV"Q0EOG<GT'4_T[U>H X>WT'QAH^K:C#I&H:6^CW]
MU)=*UVCF>T>1MS[5'RN-Q8@$CK5FV\/ZM;>/)M=_T:6V&E)IT8DN&\V0HQ<.
M_P F!DG!QGUYZ5U]% 'G-GX*UVR\&:3I:G3I+W2]7%_'F9UCF4R/(5)"90_O
M".A'RCUP/0(XY'LUBNS&\C1[93&I56..< DD#\:FHH \QO/ GB=_ 5]X*M[O
M2VT[A+.[F:0S>5Y@8(Z@8! XW GH!MYR-Z;0?$ \7RZO%+IDJ7.GQVK/.'W6
MCJ26,2C[RMNR06!RJ\\5U%]?VNF6,M[>SI!;0KNDD?HH]32V5Y!J-C!>VLGF
M6]Q&LL3X(W*1D'!YZ4 <+8^$/$5CX<\,6WFZ9+?:'=;U&^18Y8_+>/EMI(;Y
M\],<8]ZN+X=\3Z1KFH7&A:CIGV'4Y1<3Q7<+EH)BH5WCVGD':#M)_&NUHH X
MX^&-9TK7QJVB7UK-)=6L5MJ']HAB93'PDH*_Q89LC@'VK0\(:+J.@Z;<VFH7
M%K.7O)[B-[>-DXDE9^02?[W3MTR>M="3@9/2L>T\6>'[_4_[-M=8LIKPE@(4
ME!9L==O]['M0!G:CH6M/XVCUS3[FQ\C[!]D*72,Q@;>6+H!C.00",C[HYJGH
M'ASQ#HFA:=IDTVF7L%OYT<\+AE6:-SE23M/S Y[8PQ'H:WM3\4Z#HUVEKJ6K
M6EK.X!"2R $ G )] 3W-:X.1D=* ,'PAX?/AK0_L'[M%,\LR01,S1P*[$B-"
MW) '<XYSP.E5T\/WNE>*M2UK26MY(]4C3[5:W#F,"5!M61656ZC@@CWSVKIJ
MQ;7Q=X>O=273K;6;.2[?/EQK*,R8Z[3T;&#TSTH Y_4/!5^W@&?P[836IN;Z
M1IKNZG9P/,>02,54 Y&<@ D8&,YYSVMN9VMT-RD:38^=8G+*#[$@']*JW^M:
M?IDB1W=P$D9&D"!68A!U<A0<*,C+'@>M%]K>EZ9I\=_>7T$5K)M$<I?(DW<C
M;C[V1SQ0!F0:/?R>(]7N;^"R?3]0MH[8HLSL^U/,Z@J!\PD.0#QCO6/!X#GT
MSX=WOA?3[E)9KV.6"6[NW8E8V!5>QSM3:H7@<5U>E:UIFN6K7.EWT%W"CE':
M)P=K#L?0^QJ.T\1:3?7:VUM>I)(^[RB%(2;;][RW(VOCOM)QWQ0!S4OA?Q"L
MWABZM;O35GTBV>VECG1WB;<JKYB 8(;"]#V8C/>C3+2#P;9:M;^)M8TYK'5+
MZ>6 ,AC9_,!9U;)P21G  [=3GCN*@NK6TN?):[MX)?)D$D1E0-L?H&7/0\]1
MSS0!A>!-'?1?"5G!.9C<2*))//;=(H( 1&/JJ!$_X#70RF00N851I0IV*[%5
M)[9(!P/P-48M=T^;7IM$25_[0AA$[QF)@ A. 0Q&#SZ&M&@#G_#6B76EZ7>:
M?J(M)XI[FXGS'DAQ-([LK*PZ#?CJ<CTJ/5O"&GZA?://%8V,<=E>&XE0P*/,
M7RI$"\#^\ZGG^[71DA022 !R2:4$$9'(H YRWNM9'CVYM//AFT7[(&$:PX:V
MD&T %^A+9<X[!1TSS>\16FK7VCRVNCW=O:7,ORM/-&SA4(.<!2#GMG/'6M6B
M@#E]#T?Q)8S6<-YJ.DQZ7:H0MKIUD\6_C #%W?Y1G/&"2!SUJI)X+N)=)'AQ
MKF >'Q=B?8%;S6B\SS/(/. N[C=UV\8SR>SI"0" 2 2<#WH Y'5="\4W7B4:
MG9ZGI MX%VVEO=V<DGDD_>?Y9%RQ'&3T' QDYGN/#FIWFGZ;<7FHP3:[I]VU
MU%<I$8XOF+!HMN20AC;9DDGOSTKJ*STUJT?Q#+H8,GVR.V6Z.8SL*%BO#=,Y
M'3W^N ##DT:]TVS\0:Q_:-O;:SJ*KBY,1DBME0;8T"GEL9)SW+$X[5M>'YK^
MX\/V,NJ*!>M$#+A-FX]F*_PDC!*]B<=JTJ* .;&A:G:^+=1U>RO;5;>^AB62
M&6$E]\:N%PP/"G<">">#C&<UA6_@/5;;P!I_AF/4+(R6=XES]I:)R&"S><!M
M!X.>,Y/'Z=5-XFTF&2X4W#NMLQ2XEBA>2.%AU5G4%01W!/'?%:-G=P7]E!>6
ML@DM[B-98G'1D89!_$&@#CKWP;K%S<^)%CU:VCL==B*RH]NSRQ$PB,JK[@-O
M?E>,GZTZ#PCK4$?AB5-6LA>:/;R6DC_9&*/$X0?*N_(8"->22,DG':NUHH I
M:OI=MK>CWFEW@8VUW"T,FTX.UA@X/K6!H'AO7M/6TM=6U^._L+$;8(X[7RY)
M !M7S6W'=@=@!D\G-=910!P^D^"M8T;S-)M?$(7PT9&:.U^S_P"D1HQR8EES
MPN21G&0. 0>1IZ#X>U#2O$NN:G/=VLL&JRK*8HX65HRJA%&[.#\HYXZUTA95
M95+ %N@)ZUG:/KEEKBWC61FQ:7!MI?-A:,APJL1M8 ]''4"@#FIO!>J/H=_I
M::O;"$Z@;^RS:D[&-Q]H*R_-\XW$C QQZU9MO#.N0>)9]<;6+22>YL%MIHS:
M$)O0N5VX?(3Y^026..HKKJBN;B*TMI;F=Q'#$A=W/15 R30!Q/\ PA6L#PQH
M6CKJECNTBZCN$F-J^)?*.44KOX[Y.?H*U[7P]?P^.KKQ#)?6[0SV:6AMU@(8
M!&9@V[<><L>W3\ZWK6YAO;."[MW#P3QK)&P_B5AD'\C4U &/X@T:XUA-/-K>
MBSGLKM;I)#'OR0CKM(R.#NP>>F>AY%2/0=0O=;T_4]:N[.9M.,C6L=K;M&-[
MKL+,69C]TG 'KGGC'1T4 <?9^%-;L8/$/V?7;6*YU>8W"S)8MFW<JJG \WGY
M5&/0\\]*?'X.N+#Q'8:KI.H6]FD%FEG<V_V5W%S&N,9)DX*\[3@GDY+"NMHH
M XZY\':E+9>(=/AUBWCL=7:5E1K/<T1E #DG>-V,''3J<YXPMSX0U2ZG\-3-
MJ]HLFAY*XL6(F)0IR/-^4;2.YYYZ<5M:3XBLM:U#4[*U6<2:=*L4_FQ%/F9=
MPP#STQV'6M:@"GJMM>7>F7%OI]ZEE<R(52X:+S/+SW"[ASZ<_G5?3=,N-.\-
MP:6L]LTT%N($E^SD1\+@$IOR?<;N?45J44 >?VGP^U:S\##PLGB*U:V257CE
M;3261!)YFS'F\C=C\./>MM_#NIR^+K'7WU6TS;636C0K9,-^\JS,#YO'S(,#
M!P,CGK72TT2QF5H@ZF15#,F>0#G!(]#@_D: .*7X?/<:1J>GZAK#.;R__M**
MXM(/)DMKC=G<I+-QP, \XSR<C%EO"&IW.D7D.H^(3>ZC<VK67VN2S54BA?[X
M2-6 W,,98D\JO&!BNKEEC@A>::1(XHU+.[G"J!R22>@I] ''77@V_N[7P_"^
MLP#^Q)5FA861S(R*47=^\Z;3@XQD\C'2FW?@6X;^V[?3]>FL]-U@3/<6IMTD
MVS2KAG1CR 3R5^N"N:[.LC7_ !'9^&K1;O4(KK[,6"&6&$R!6)"J#CD9) '&
M,]Q0!CQ>"9X;[PO<+JP9?#]N8(E>VR90RA'W$,,?*JA<#@@D[LXI]MX2OK2\
M\07,>KP[]:(:3-F?W1"A!M_>?W 1SW(/0;3TUI<&ZM4G,$T&_/[N90''/< F
MIJ .(D\ 7/\ 9VCFUUY[/6-(@^RVVH06PPT& -DD;,0_"CN.><#I5G4_!,NH
MVME&VL2F>"_349;B6!7>:>/'EY *JJ#&"H'(QR#DGKJ* ,$^'9)?$EQJT]\)
M$GM/L;VXA 'EY)X;.0<L>?T[T[PMX?D\,Z/%IAU&2[@@7R[</&J>7&"=HXZG
M! )/7 X%;E% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MV!7C5 X;;R1L!(P,YQGO0!/?_$"XCBO;[3=--_9V=T;8P1)(T\^U]DCIA2N
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M8G![J,\=":=K?A)M0\)0:18WSV5W:/'/;78&2)D.=S#ODYS]30!0;Q1K]O\
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MY99(C-:L3%OD+[>'^8 -@9Y]\<5ES?#R.UTK0XM"U*33[_10XMKIHQ() _\
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M?/\ WNN,9& ,=3KVOAN:U\5WFMIJ<@2]CB%Q:K$NUWC4J""<D##=!SD#GJ"
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MZT(W$D:R+G# $9&.M>97^K:UJWP[\>#59;1TL([RQC,%LT9DV)_K"Q<@YSC
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MWBT2VJ6L@UV3?%&^Y0WDQ9*G R">1P.#TKK=5U.VT;2;O4KQRMO:Q-+(0,G
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MFG2&>V:=LINF$0VMMYY.>0*GU/Q;J2:SJ^GZ59V=S<:9&KM:2S,L]P&0/NC
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M+<^:@D)78 (UR.GHO<L>YJCX.\*?8_"/AVVUJ,3W>G0-LCD 98F8\<?WD7Y
M?=O6EUK3/%%]XABN;>'1IM-M<-;6]S-(#YO_ #U8*F"0.%'..N<XP_4;'QA>
MZ&EM]HTQ;J>=C=;))$18,X$<;!=V2.2QP0<X[$ $?A2P5?%_BK5;1!'I]W-#
M$@5<++-$I660?B=N>Y4_6NPKD["'Q/INFW NG\/V5O:V+):1V_F"%9?X3(6
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MABTVY5[:%_NRM,1Y;@#&< #G@G&3:T_Q!XMU?6-3LK:TTB*/3M1%M/(YD?\
M=&-6RO(W,"V3G'&![TW0/"_BK1;2#0SK=E)H=LX$,HA<7?D@Y$6<[1_=W<G'
MOC&KX:T74M*UC7KJ\^R>3J5V+I!#(S,A"*FTY4 \+G/O0!@^%]7U]?AZ=5B6
MVU"ZGO)MB^7Y(0&ZD5Y')?!4+R ,8"XR>M:.G^*;V^NO$-C#+IU[+I]O%/;3
MQ(\<4H=6)#<MT*]0><^QK,'@?7X_";:&EWI;16FHK=V*NCE9D$S2E)_8[@,
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MR/'."?X>?YUTNEZ/_:46CZE<ZO\ VA'9Q[[0HBA2Y39YCD$[F +#@@<GC/-
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M/4D#@>YXKGKO7-:T.ZT-M62SDMM2N$M)A!&RM;3.I*8.X[U+#:3QU!]AI>,
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M[C$G!Z <=:YK1M0U'3/"FIR1S6JW*^(+B*]NWQ&D2&;#R*K'DX(PN3R0.>A
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M/3@CO6C7$_#^[E>[\2V=_8K9ZO%J1FO(TE$B-YB@QLI '!15'(SD$GK@=M0
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MF<$' SR,5+#X@9M3CL+C2=0M998GEA:41E9-F,J"KD!L,#@XZ'TKG?'WG_\
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M!1\<A2&(R*Z:B@#B]1T3Q+XG\/7<6I36>F7Q,,MC';.9EAFC<2*[LRC.6 !
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M0X8G: #&&'!Y]*[6B@#DX?#VL7PTFWUNZLY+;2YDG1X%;S+J1 0C,#PF"=Q
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M[5UJ.LB*Z,&1AE64Y!'J*=0!QFK^#M5U?3+6*;6XGO(]1AOY9GMCL)BQMC1
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M9%DG\JS6.6=L@L3(&SEB.3U.3S4]UX0D>375L]1$%KK>#=1/;B0HQ01NR'<
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MV=Y>:K=3_9-[1P[(UC\QAM#D!<DJ"<<XYS3_ !+XAM_"^C2ZM>6]Q+9P<S-
M%)C&< X+#/) XS3O#NNQ>)-&AU6WM;F"VN!NA^T!0TB=FP"< ^^#0!E6W@/3
MHM'UG2;JXN;VRU:XDNIUGV!EE=MS,I51CD*1Z$58T+PFNC2QRSZSJNJO"A2
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M\<@J">O.UH7A74=-DMO[4\27.JPV1_T.-X$BV_*RYD9>9"%; )P.^,XQU-%
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M*>2''FQJWSIGIN7J,X.,]<5Y"M]$+/Q/<6\AGM;/Q<EY=1VC!W%N!'EU49)
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M5H[#[1'XGC<SPQE([N-&&ZY"D\#GDCC(X."* /3=*U_2];:X73KQ)VMV"RJ
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MR+E@[,P4=.G)YSTYSC%<Y9WL>D_$;6=0OIP--U>QMGLKLDF(>5O#INZ _/N
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M5<^WV?V>.?[7!Y,K!8Y/,&UR3@ 'ODD"H9-9TN*UN;E]1M!!:C-Q)YR[8O\
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M^T[M+LC]J8/<9MT_>L"""W'S'(!R?2K]% %$Z-I1DDD.F6>^5661O(7+AOO
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW%O$"9)(9 X7'7.,^AXKR.?5(=&_:,UJ_N(IY(8=%WR>3&7*J%C).!VP*O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+C\C7>T4 >?6W@W6XOBM=^,)#IS6UQ:BT-L)GW*GR_-G9@GY>G'7K4?A_P
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG>%TM[UK20V=[AUC5BW^J.,'CW_"@#H(]2U;^TI;&;2[>-S;F:WE2Z9XW(8
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MT;RK*.XBU#4H+!W:8J8O,;&X+M.[C/<=JZ&@"MI^GVFE6,5E8P+!;Q#"HO\
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M91G"DA^@R>/<TWQEK%_H/ANXU+3H;:66':66<M@*2 2 O4C(XR/K6\6"@;F
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MM=0:W;^S[X6\+01E04,2."<D\_-ZT 7KOPOH6H/:R7FEVUQ):J$A>5-S(HY
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M0 4444 %>?ZW)!X<\<BYU&[OCH^KV,T/E-=R&.*X7YB$7=A6=,X P<KQR:]
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MHD>&)5+   #@=  ./:@#F?$(@NO'>GVL(C?4XM/EE47N#;11,ZJTFSJ\G&,
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M7;M#M$6X(#=.<UUGA^WT0^+;[4M,U6;4KN\M4^TRQR1-" IPF[RP!O.6QU.
M?:NI6V@2V^S+!&(-NWR@@VX],=,4VTLK6PMQ!9VT-O"O2.% BC\!0!Q_B&]M
M8OB'I<*RP6FH)IT\@O;QSY20ET#*BY :0X')/ &2#7)>%(XK_P $:7:VFN16
M6IVVMW364CJLD9D#RG8Z9 PR%L8P><BO79[&TNI89;BUAFD@;=$\D88QGU4G
MH?I4)TC3&BDB;3K0QR2-*Z&%<,[=6(QR3W/6@#%\$WLMY9:DMU96UK>P:A)%
M=?99"\,DNU273/(!R,@]#FJ=[,@^,.D1^8N[^Q[H%=W.?-B(XKKK>W@M(5AM
MH8X8E^ZD:A5'T J)M-L'N/M#65LT^=WF&)2V?7.,T >=:=/IEUX%\96&N2I#
M>+>7HU .?G!9F,3*#DD;/+"<?P@"DC:\3Q1\+4U5\:@-/N_M ?AMY@CSD>N<
M_CFO2);&TFN([B6U@DGC(*2-&"RX]#U'4TDNGV4\XGFL[>248Q(\0+#'N10!
MYIJ;7=Q_PM:+3'W7FR(1B+&\_P"B(& QWZCUS6AK=QI^JQ>!9]!9'E74(7MU
MML?N[;8WFY4=$"C!'8X'M7>0V%G;SM-#:01RMG<Z1@,<]<D4Z&SM;>5Y8;:&
M.23EW1 "WU(ZT >>ZQ:2:9XWU#2K9&\CQ?:[00N1%-& DK^@_<MNYZLOO3O!
MPN9+I]+OC-Y'A-);+<^/](+8\J0$=U@ !Z',AYZUZ(41G5RJEESM)'(SZ4BQ
M1JTC+&H,ARY ^\<8Y]> !^% 'F_AB66PU;PY9PWUIK6ASQ2?V9<YVW5HHB)V
MOM.UUVKMR0"#C/-=QHESHUU!=-HAM3&MU(EQ]G0*//!^?=@#YNF3WJW#8VEM
M*TL%K!%(PPSI&%)'U%3)''%N\M%3<Q8[1C)/4_6@!U%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB%HFL^$KSQ*#/:6-D[I<"Z0*\;+C(P"<GD8P>2<4_3/'6FZAJ(L9[>ZTZ=[
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M%7*';\W+=#MX[UTLGB77K?Q9'H<^DV6;VU>XLY$NB0FP@.)<J#_$N-H/7'N
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M:_>ZY?6/A34+]+&.TN]8M)1;I&_F0!MQ4,Q.&., X48- '>0ZUI\^MW.C17
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MP7$;3 E"T<JR ''(!VXS[U631=7_ .$NLM<FDL)/*L7LY@H="V]U?<O7H5
M[Y)SVK6T76]/\0Z5%J>ES^?:2E@DFPKDJQ4\$ ]0:T* //CX U&?3;I6U&&T
MU$:P^L65S I<0RN3E&4XW+@D9XSGH,8/3Z+9:XD[76NZA:S2^6(XX;.)HXEY
MR6.XDLQX],8XZFMJL[2-=T[75NVTZ<RBSN&M9\QLA250"5PP'3<* -&BBB@
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MM"UG'90W%_/>6WVN&&W"@F'CYR7*J!\PZG)[=#7&VBW:R?$1VT[4L7[9M/\
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M9D68(Q#AD+';N!7!&>>U=)HQO'MY9;RRCL?,DS%;*5+1IM ^<K\I8G<>"1C
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MI\6BM;NQ=G=-A:7>4V@$<XQGM7,>'K+5_#6BZ3J%Y8:)=6MJBB!X=3F9@TN
MWE(5,>XD\!>.2 0#0!T\?BN^O?$%_IUFVGB:ROHH'L90XG> LF^=22 1@N0
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MA8_O;03GD>E4)/ VM-\/K'PTL^GB6TNUG$^Y]KJDOFJ-NW@D\=3@#/? N_\
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MY%W!0TKE]K#T!8\CKZ"@#(TSQE>W?P^\/ZL(+6&]U>XBME 4^3"7D*[L9R<
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% ",JNA1U#*PP01D$5D67A3P[IMZ;VQT/3;:ZR3YT5JBL">N"!Q^%;%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M$SQ"=5BD!5AN/S#&-V<\9!] #TZN?U/6[ZQ\8:)I206QL]0$V^5F8R QINP
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MY.+P5<0-=M%XLUU'NY6EE<?9RQ)&,9,.< < 9XP,5UE% &5!H:6VH6-Q#>WJ
M06=J;5;3S<Q.#MP[ \LXVXR3W/K6K110 4444 %%%% %'5]-&KZ5<:>UU<6R
M7"&-Y+=@K[3U )!QD<9Z^F*J77AV*\\+MH$]Y<-;/"8'D"QAVC(QMX3:...
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQAR0LKQXP$.,GYL@$$CM4MWXSU8#7DLO#XDDT5QYYEN@J.GEB0[" <N0>%X
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[B22.&!8"9'*'#$ <!0>-Q('(YY%7-'UNRUVUDGLG?\ <RM!-'(A5XI%^\C
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M#DCTX +^G>&K33[Y+PW-Y=W$4;Q0R7<WF-$CL&8 ]3DA>N3\H%;-?/GPMO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3!X)QS71>%H[;R;JYLM"&DVMQ(&17MQ#+,<8+NG49Z#=SQSUK?HH X?Q!<W
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M#.UE; ;& 5YQD5V%% ' 6(UKPQX18KI5W-K&JWTUU,ELBS&U\V0DEB2%8JA
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M?+M]1G'6JFHK?Q^((_'EGI=^WEW?V.32TLI1+<0#<HG*E<^8 Q() &WY<Y-
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M-O*\-TP?6J%EX5OK/P5HG@JXL_.LKA7_ +4N%VE8E9FD*+R#DL=H8#@<\'&
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MUY;.V;9L2TLW,B@YR69B!D\   <<\G/ !M4444 %%%% !1110 4444 %%%%
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MZ@:[^PS;D%IC$GG$';@X&-W)/2N^U#7%M=3ATNUMGO-0DB,YA1@H2('&]F/
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M_6#<V[GJ0"<]*XSP=HMMH/CGQQK^B1-;Z!;0- L*'*23J [E!TPI!'U8@=Z
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M>Y\H,%+K'(&8 G S@<9(KJJ* .72&[UOQ98ZF]A/96FGVLJJUR%$DLDNT$
MG"J$Y/<L,=*XZPT7Q)9> ]'\/+H4KSZ/JEL\DIG15N(X[C?NCY] /O[?QKUF
MB@#C;6+44^)FJ:F^D7@LI--BMXYLQX=XWD8@#?GG< "0.?2N<TK0/$</@JV\
MK2VAU/3=<DU)+2Y=!]IC+R':K L%)60X)Z$?C7JM% '!V46M7GQ+A\0SZ!=6
MEC_8SVA$LT1=7\X/R%8]E[$]16))H^O2?#G5='70;P7UUJKW,:,T6!&UR)@2
M=^/NC!'K[<UZO5<ZA9+:_:C=VXM\[?.,@V9SMQG.,YX^M '+7AU"7X@Z+J0T
MB\6QAL)X9IF,0$32F)AD;\\>60<9YQC-<9HC74/AW3Y+[PMK<^CVDS:E;PP3
M6SP1@,SQE=S+(RJ#N //3CM7L,L4<\3Q2HLD;J5=&&0P/!!'<5S]MX'T2UB6
MW1;UK-?NV4E],]N!V7RRQ7:/[N,>U $GBW1F\6>#+[3;:8127<*O!(V<*X(=
M"?;(&:SK.3Q/XDL&L-9T>/2(6BE@O&\]9?M&Y"O[K;RJY(;)P>,8[UU[,J(6
M8A549))P *CM[F"\MTN+::.>"0922)@RL/4$<&@#SP:%K>I^ (/ VI:=(CQI
M%:S:BLB"!H8W7#)SO+%% P5'/?'-;=K'?VWCO6M3.D79M9[*&&-U:+]X\32D
M\%LC(=<9QWSBNMHH \IMO#6O1?"*Q\-OI$AOXKU7D7S8]NQ;GSLYW<Y7@>_H
M.:Z:"UU./XBWVM-I=Q]AFTN.V1O,CW&2-W?!7=W#X!]>N.M=5:7EK?VZW%G<
MPW$#$@20N'4X.#R..M34 >867AW7K+X2V_AUM*=]1BNPY198RA47/GYW;AQM
M^7US[<UN6ECJF@^*]7U6+3Y[VPUE89FAB:/S;:9$VD-N8 J0%Y!.".F.:[.B
M@#S@>%=6T[3-(CBLVNKA-=;6;Q8I554#F0F-=Q&XC>H[ XSQP*U/[/U1/%OB
M:_&ES-;7MC!;0,LL8+O'YF3R_ /F#!XZ'CUZQ;ZT:^:R6YA-VJ>8T <%U7CD
MKU Y%3T <&^E"/X.KHVMQ_8Y[+2U1CYBL5DA0;9$*GG#*I'?H*Z/PM8W5CX?
MMO[0;?J-P/M%Z^,9F?EN.P'W1[ 5)J7AK1]8U.PU'4+%+BZT]BUL[D_NR2#G
M&<'E1USC%:M '#>+O"LOB?Q3IXN+"1],CLIX)+E)45HY':-D=1G.5,><^XZ\
MU4U*R\7:Q\/I=&U'3!)JHDB7[0DT829$E5MYRV58JO(]37>W-]:600W5U! '
M.%\V0+N/MGK4*:SI<CJB:E9LS' 43J23Z=: .9UK2-0U;QCIEX=.F6P73KFT
MN'\V/<AFV=!NYQM.<>HQFJ">&-;E^'\7@F\MX7C54M&U!7'EM;JP(;9G=O*
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MRSM#:1ZJ]M+93I)O:*2 *%++@=2N>">*]"ILDD<,3RRNJ1HI9G8X"@=23V%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH YGXA;T^'^NSQ32PS06<LL4L,K1LCJI((*
MD&O-OA_+#XC\!:7876L:B^O:E]J'VA=4F$L*H6P^ _0'8.G.:]-\=I-/X(U>
MSMH+F:YN[62WACMXRS%V4@9P/E'N<#WKA_AUI<OAWP?HR:KH^IQZSIKW++#%
M9ES(DA;Y?,QM .5/WARM '8:WXRLO!MOIL6N178^T". 7,:!XC*1RI8D$'@G
M) X_'$]WXRLK+1-0UB>SOEL+&1HY)=BG=M8JS(-V64$8S[\9P<<[XIL;[Q=X
M'T[0-2L)QJ&HQQS74WV9F2R8#>>5 &[(V 9[Y/OSC3:VG[/^KZ3K^E7%C>V%
MEY2M(H"31@C:01QG'!!Y.,\YH [JR^(^B7MSHT7EWT$>L@_89Y[<HDK#'R]<
M@\C!Q@YX-+JWQ%T72/[49DNKF'271-0FMU4K;,YPH(+!CR?X0<5Y_8Z3?>)/
M#GPPL[.TN5&GR0WUU<&(^5'&@!&'^ZS-CA021W IOC+1?%'B >.+0>&YH8\P
MFQ:SVQI=[7!:20@AIGV!< Y"\]#U /1M9^(&BZ%>Z1;W@NRNK!39S10ET<L0
M,<?,#\RGIWXSSA-*\?Z/JMIKD_EWEHVB9^W0W46UXP QSP2#D*W0YXKB?$NC
M:SJ%W\-9XM&OO^)7)#+>CRU/D*#'G."<GY"<#/Y\4_1=)U>S\6_$/4)O#T\U
MIJ2#[+!(GR787<&7KP6![XZT =DGC&SU73+KR['5(P=--ZIC\O>\)R,QLKE=
MW4XSQ6/X3\5Z!HGPSTV^@N]4O+.2=K6U^U@-=7$AD*A0,XZYQDC '.*Q_#/A
M&]\,W7B2'2TU.7P[-IS"VL[I#O2X;.40$\CKD\ Y')QFL?3/ NOCX:^%X9=/
MGCU#0-7^V361*[IH_,+'8<X)VD8Y]1UH ]1@\8V<W]KP?9+M=0TE ]U8D)YN
MTKN#*=VU@1TY^N*P[+XN^'KVWTBY6VU.*UU2Z-I#<30*J+(#C#'=TZ<C('?!
M!QGQ>'M1E\<>+?%QL[F.VN=-^PVML5Q+.VQ,ML[#*X&<=ZY >$/$<?PQ\):.
M-!O3J&EZN;R[C!0@1AW.5.[DD.N /0^E 'O%Q!%=6[PSQK)$XPRL,@U\S^%;
M]+CX/ZT\6HW$OB8:D$T[RIF-XW$6 B@EL'Y^!Q]ZOI>XG\BU>;RI9-HSLC7<
MQ^@KS;X*:#K?A7P_?:1KVF3VMU+=M=JY9'1E*(N-RL1NRIX]* -$^/!X0T'P
MO!XOMKQ+_484BEGC171)0%#>9R&!Y!. >^,XJS_PLO3(M-N[N[T_4K1X;[[!
M#;SP[9+F4_=" GO[XQWK+^*.@ZGKFK^%9+'2I[ZVT^^%U=^6R#$8*Y #,-QX
M/ J7XN>$]5\3:+IEQHT"75WIMXMS]BD8!9U[@Y(&1QWZ$T :MU\0]-L=*UJ\
MNK.[$NBR)'?VT?EL\88 JP^8!E.?7/7CBJD?Q3TI]0TFV?3=3C35[;S["5HE
M/GG .P*&)!Y R<#/?'-8^O\ A_4-5\#:]#IO@R#2[S4H(HEMX_)6>20,69I'
M5MNP #&3G.<@<"LM_"?B>35OAM<OHTQ71+=8[\^=#^[(VCCY_F^[GCM[\4 =
MUH/CFR\2V6M^38W<-WI$KP7=G(R"0$9^Z0V.=I .1R#SWKE_!_C/PYH?P_T^
M72EU"2VNM1>SMEU*=%=I"2Q+,3M5<?KCN<T_P1X>UW1M;\?W-]I,L46K73W%
MEB2)C*-TIQPW!^=>&P.OO6+X7\"ZG#\-+;PQXD\,RSPR7\KW"Q3PF6!2F4FC
M._&0W!'7!/!'4 [^[\>V.G: VIW]E=6TIO3816;A?-DFS@*,'&#@G.<8YJO=
M?$?3=/L-9>_A-O>Z3/%;SVIE7!:7'ED/P-I!R2>FTY'%</J/P\\4W/PQTZPC
M+7E_I>JM=VEM>R+N>W!(1&.XKG&#C. #CM7476EWVI:+*EQX%L+>WOI(HKNP
M5HC/(GS%WWJ0H*D@ISG.>F1@ OZ@W_"=:#JVCSZ04N+=HMJ2W96-F8!TD62(
MY*C(/OC%6!X-AF\2Q:A=()U7319W4DLC,;WIC=']U=NTG.,DOVQS0^&GA;4?
M"D>L64LUX=(-PITV"\D5I(DV_/\ =) &XXXZ[<X&:[R@#F/"E]<+?ZWH%U.\
M\FDW"+#*_P!YK>1 \>XYY*_,N3R=H)Y-/U7Q4]EJ%_966FR7DNGVBWET3((E
M"-NPJD@[F(5CC@<=:J^%4^U>+/%NL1Y^S3W,-I&?[S0)M<CVW,5^JFJ&OZ7K
MNH^)-6AN-(_M'3)K 1::YG188)2K!S(C')8DC#!6P!@=Z -<>,8;R+1SI5H;
MF;5;0WD$4THAQ$ I.2<Y;YP,#/?D#FMG2;]]3TJWO)+9[5Y5RT,A!9#G!!(^
ME<!9>'KNX\(^'M%U[PK/<1VE@$+P7$0GM;A %!5O,&,C)R">@S[=IX6M=1LO
M#-C;ZM+)+>QH0[RN'?&X[0Q'!8+M!(XR#UH QKOQ_%:V%[JJZ9<3Z397C64T
MR2*)/,#!"P1L IO(7)8'J<8YJWJ7B]+2_;3K:U22_BMEN9H+BZ2#RPV=J;CD
M%R5/ X&,D\C/%Z;;WMW%JR2>'=3O=#NM5ENDBL+FV\B7;+D,-[J^UF0,1G!.
M<<'!UY!K"^)%\3Z+H\6MZ-K-G [1,R0SP.%.UAYF/E*D9&<Y_4 T(OB+9W<?
MAZ:PTR^NH=;,HA9=@*-&KED(+?>RF.R\YW<59M_'$ T_59]2L)[&YTRZ2UFM
MBRN6>3;Y>QLA2&WK@DC'? YK/OM/UV?Q!X4O)=*#"PNIYKG[+)&(XDE21%4;
MF4L5W*6( SR1GI5#4?#.NZE>>+C:V@LY;J[M+W39[@QM&\EN(\!@K$@,T?<=
M#SSQ0!M6GCN-]9ET>ZL +\6INX4L[J.=9D!P0&)4!QZ' X.":KP?$-I=#BUM
MM O1ILUE'<0S*P8O*\BH(MO4'+ [CP1DC-6["Z\2WULTE[X>CTP1PL)($GCE
MDN)", (00JH,DY8@GCIS6+%I/BBT^$-GHUC9S0:M9I##+$MPB-/&K+O$<BL0
MNY<@$X(YZ<&@#HK'7?[4UN^\,ZOIL,5TEFEP\:2^?#+$Y92,E5/48(([UPUA
M:6\GP/T)GMXV:WO;?RB4!,?^FA<@]N.,]>:W=*T74]-^($VLV_AR.UTV?2Q;
M^5%/&'5UD9OF X+-D="1ZMVJO!X?UN'X66.A?V3)_:,%Q%(R">(K\EP)20Q;
MN <>_M0!TK>)[B+QO!X<N-,$2W$,D\-V;@;953&0J[<[@2,@XP.<FKV@:M/K
M-G-=2VB6\0N)(H2LWF"5%8KO^Z, D''7C![UB>.+*:_TW2[RP<V>MV]Y$+1R
MH=XS*=DBG&1C8S$\X^7T%=18V<.G6%O96Z[8;>-8D'L!@4 <WKNLS7\&LZ?8
M:-#J=O9QF.\,TP12Y3=Y:+M;>P!4G.!R!G.<8WAGQ)!H'PZ\(VH%L;N[T]'C
M6YN5MX@JJNYF<@XY91@ DENG4B]#IWB#1M5\16MIIL5YI^J2M=VT_P!I5/)E
M=%5TD!YQE<@C/4#CME:;X=\5:+HOA*[L[*U?4-(MFL;RR><?OH'\LDJ^,!@8
MP?3KR: -)?B9:/H4FII823"UU%-/OD@F600LSJNY"/\ 6*2PQ@<^U:5EXMN9
M/$3Z)J6B36%U);M<V0,Z2"Y12 PR.%<9'&2.>M8_BZ77)/"+W6H6MO#.VJV!
MM;..7?L47,6 [X&6+9SC@# YY)UI],O=4\8:9KL]E+;0Z3:W"Q0M(ADFDEV
M]"5"@(>IY)]!0!0T#Q-86G@BRNM/T(69NKR2SM--@8'=-YCK\S 87[C,Q(.
M">>\NK^*M;M='\1A=$6"_P!*M/M"R/.QMY4*,VY)-@+,I4@K@<CKSFL:'PEX
MA/@FRAMXELM;TK59-0MDFE4QS!I';8Q0G *2$?7VYKH+NV\2^(O#^LVU]9VN
MFBZTZ6U@M?/\UC*Z$;W<# 7)P ,\9)]  4K?QF^B>%_#RZT]BFI7]NIC>?4
MD+JJ(6D>5E&"=P^4!B2>,C)%G3?B!;:CI4T\=IOO4O\ ^SDMX9A)'--V*2X
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M>YCB(1E*8A)X#D,>0"1P <^F.:FF\4"VCM()--O'U.XC:1;!6A\P(IP7)+A
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M[!(,F;UOWJ^7YGRXCR6QC@@#W- '5?V!HW_0(L/_  &3_"C^P-&_Z!%A_P"
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MC>+6(&M]-O\ [$UJDP)^Q$^5*^T')/F8;Z(M 'KM48-9TZZU:XTN"[BDO;9
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MP3Q_,,73[R_\81^)9["YMX["PDMH+5C&99W=@S'ABH "@#)Y)[8YZRB@#DO
MEGJ6F66H6FHZ9+:-)J%S=1L9$92DDI91\K$YP?3\:75=/U*W^(.FZY8Z<+R%
MM/EL)B)5C\K,L;JS$G)7"MP 3GZUUE% 'F,_A_7KCP-XRTL:/(MWJU]<3VJ-
M-%@I*1@L=V 1CGZC&>VA]E\3:)XB&LZ9HPU"WU&R@@O+1[I(I;>6(,%8$Y4J
M0Q! /O7?5!%>VLUW/:Q7,3W%N%,T2N"T>X97<.HR 2,T 0:2+\:<CZD(UNY"
MTCQ1G*Q;B2$!P-V <;L#.,URN@P:WIWBGQ+J,^@7 M]3N8I(-MQ"2%2()\PW
M\$XSCWKLI[NVMGB2>XBB>9MD2R.%+MZ+GJ?85-0!PFM:7XHUBUM]7AMXK?4]
M-U3[796,TJD/ (_+:-G7(#-EVSSC=CWJ35#XRUGPS?2)IRZ9<D1+%8QWBM+*
MH=6E_>@ (2NY5QTZYY&.WHH \^LM*URT\42ZI8^&K.QAFTDVZ)]H0F.4.[CS
M N-Q8E<X)Z_>J&W\&SW=U/':Z9+X>T^_T^>#4;5)T>%YG4*K)&K%01R2WRYZ
M=Z]'HH XOP\WC?[/8Z7JNG6-HMKL$^H0W D$\:X^5(\95F'!)X'..2,7O&FC
M:GJ5KIU[HKQ_VEI5XMY#%*=J3C:R-&6_ARKD9_\ UUOM>VJ7B6;7,(NG!982
MXWD#J0O7'3\ZGH Y0:AXQETJ[OCH5O;WJP[+73?MBR!Y"1\[R84!1Z#DC/<C
M&9I6BZUX8\4QRZ9837.DZC )=4$EP@87A/,J@MU(^\!A>!CIBN^HH \_T/2/
M%GAN.Z\-V%K9OI332R6>J-/M:V21BY4Q88NRLQP<@'C.*L)8>*O#GB+5&TFQ
MM-4TO5)OM0$MSY#VLQ55?=\IW*=H. .*[BB@#@;AM3T_XCZ0?LYU2[_L.9+E
MHRL.?WT664,=O4_=R" >I[PZGX0U6[\/:_=)#"=7U34(+X6OF !4A:/9$7Y&
M[;&<GIEO3FNQ?0-/DUM-899_MZ)Y:R"XD "<$KMW;=I(!QCJ*TZ *UK+=/8)
M+=6RQ7)4LT"2;MI[+NX!/09Z9K@[/PKJNIZ%XMT;5++[$FLW<UY!<+,L@C+!
M-@(!SD%,GM[UZ+10!Q4NF:YXE;0H=9T]+$:9=Q7T\RS+(L\L8(41@'(!)R2V
M, 8P<\6_".GZK8:EX@FU&Q2WCU&_-Y"4F#X4HB!6 Z-\F>,CGK7544 <QXTT
MK4=1BT6?2X([B?3M4BO&ADE\L.@5U(#8.#\^>G:H+73]:MO'.KZR^G0O!/I\
M,$12Y&YI(][$8(X#%\9/3;G'-==10!YEI/A3Q5I&A>')[)+)-5T5)[:6UEF)
MANX965CAP,J<JI''4=QU[C15UETGNM9,,4LQ'EV<#;TMU'&/,P"Y/4G '0 <
M9,\NLZ;#JT.E27]NNHS*7CM3(/,90"2=O7'!Y]C5Z@#A_/U"#XJ:P]E9+=(=
M*M!(OG>65/F3[3R,$=<\Y';-4Y/!^M6-AI[VL=K?L^IW&H:GI\TQCAF:;<0H
M;:V1&2N 1R1GBNR@T'3K;5I=4BAD%[+Q)*9W)8<X4@M@@9.!T&>,5I4 <;H%
ME>:%J>OS:Z-,M[/4KQ98I1<\.6C1!'M8#IM(Z\YZ"F?#S2$TO0;JYM9Y+R"6
M61+#>0 +5'?R44_W>6(/<,*V))O"WC")]/:XTK6$A82O LR3;". 2H)QWZU=
MN-6TC29[:PN+VTM)90%@@9U0D=!@>F< >_% '"3^&O$]Q\-M5T%["U%_=7<L
MRM]K^3$D[3$DA>HR!C'.<ULWVEZU=^.=$UC^SK<6EM92P7'^D_.&E*YQQR%V
M^V<UTNIZQIFBVXN-4U"ULH2=H>XE5 3Z#)Y-68+B&ZMX[BWFCFAD4,DD;!E8
M'H01P10!Q/A[1/%^B6<7ATW5@^DVQVV^I;F-PL ;(C,9&-VWY0V< 8.#C!;:
MZ!KL,_C*X>RM2=;(-O']J/RXC$7S';Z9;CTQ74V7B/1-2O&L['5["ZNDW;H(
M;A'==IP<J#D8-7YYXK6"2>>18XHU+.[' 4#N: .$A\.^(K>'P;/#;6'VO1K:
M2RG26X8IM:-$$JD+S]P';@=<9'6N@\8^'Y?$OAY[&VNA:W:2QW%O,RY59(V#
M+D>AQC\:E_X3#PT4$BZ]IKQG/SI<HR\=>0<5JV]Q#>6T5S;2I-!*@>.2-@RN
MI&001U!% '.+IFJZKKNFZOJEG;VC:6DQ@@BN#(9))%VDEMH 7&1W.3[<KX8T
MS5].UC6Y[^VMD@U*Y^UH8K@N8SL1-A!4?W<Y!]JZ>B@#E?%>BZKK&JZ'<645
MIY6EWJWA,T[*9?E=2@ 0X^\#FH=8\.:KXGUK1+C4!9V5CI=V+P)#*TLLSJ#M
M&XJNP9ZXSFNPHH \VUCP7XCO],\5Z?%+I['5+DS07DSN93'\I6 KCY5!! .X
MCK\O.:T_$/A_6?$%C=V6H:=H]\DT8%M*[LC64A3#,IV$D!@"""&^G;MJHW^L
M:?IEU8VUY<K%-?2^3;(029'QG Q[>M '+/X;\2:1XBFU;0KZQN5O;:&*]@U#
M>H:2-=JRJRY(..H/7^76Z?;W%O81Q7EQ]IN.6DD"[02220!SA1G &3P!UJU1
M0!P4/@[5[?P??>#HY[5M+G\R*"\9B)(;=V)*&,+AF ) .X#ITQ@ZL&@ZA:^-
MX-3A%J-+ATP:>J&9O-&&W;L;,=@,;O?/:NHJGJ>JV.C6;7FHW4=M;*<-+(<*
M/J>U $.O1:G<:+=6^D&!+R:-HTDGD*"/((W#"MDCL,5G3^%K%O";Z5%H^G*Y
MM#;K$QR@^7;CS-FX_7&:O:=XET35KC[/8:G;7$^W>(T<;BOJ!W'3\ZU: . A
M\(>(3X9T&WGO+$:SH$B/:7*N[1S@*4*R+M!7*'&02>_M5O\ X175M2UG5;G6
M9M/^R:II26$T-L)"R8,G(+<'_6=2/P&,GM** .!G\+^+;S1])TZYU/2V_LN\
MMITN/*DW7*PG(WC.%8X!."<GTK:M=%U&+QW>:Y)]D^RW-G':%%D?>-C,P?&,
M<ER-N>  <G)%=)6?9ZWI]_JNH:9;3[[S3C&+J/8P\O>"R\D8.0.V: ./D\&Z
MZ?A]J/A5;C3/+F\R*WE ==L;NS[F&#\WS ;1QQG/8:D_AS4TU[3/$5F]J-1M
M[$V-S:R2/Y4T98,,2!<J0PS]PYSCCK7644 </JO@R_O] UFW6>T.HZS=1SW,
MC[Q'&J;-J*.2<",#/&2Q.!PM7=3T#5M1\4V6K++:VZ06,UH0DK%P9=NYU.T#
MY=HP._M75T4 >=6O@;Q!#I_ABUDO])QH=T)1MMY/WPVLOF,=P^<[LD="<G/:
MNDT31M0T_P 1:YJ%R]LT.IRI*JQLVZ/8@C .1SD*#VP:Z&B@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH YWQY;QW'@/7-Z!FCL9I8SG!5U0D,".A%>=R"";PCX3'A*X!\5/':2N+.;)
M*;5\UKC!QLZYW=^!S7I'C,3R^#]5M;6TGNKBZM9;>*.%026=& SG@#/>N2_L
M#5XO#'A_6](T^2'Q-HEG%:26L^U/M<2JHDB)S@C()5L]1[T =KJ6O06&HV^F
MQQ/<7T\;3+"C*NV-2 69F( &2!W))Z8R1BGXC:6=+L[]+2]=;C4!IKQJBL\$
M^[!5PK'/<_+NS^-9FM0:M_PE-CXH@\-2W]LUH;"\TZ41>?%\X=9$RQ5N20<-
MC'/O3M>M-8O+'1V70'C,6M07WV6W$9:""+&[>P;:7/) 4G@@<XS0!M+XP+OK
M%M_8U]#J&G6ZW(M;@HIGC;=AE9688RK ]QCI5GP7JMWK7A#2M0O8F6>XM8I6
M<E<.64$D '@9/>L:XL]1NOB!J%RNGW$5I<Z,-/CN7"[1,&D?G!)"X<#.,$\<
MU7TG5]6\)?#?2/M/AVY9[!(K2Z1IXT*(BD-*O)W#*@!>K;A@4 =_7GOA_2M.
MC^+7B<)9VR^1;V<D*A!B)F5]S*.BD]R ,_C7H5<)IT.L6?Q"\0:RWAZ^DLKV
M"WA@=)+<,3&&W9!D!P<\9_*@#JM;U>/1;!;EX9)WDFCMXHH\ O)(P51DG &2
M,GL,FLE_&<<$.O?:-*O%N=$B6>YA0HV^-E9@T;%@&&%;.<'((YK.U[_A+M2T
M^X>UT^>& WD"_8%N(H[B6V /G8D#%5+$@#Y@<*>036=-HNKJ_BH6OA?[-!JN
MCI;VZ07$(_>A95(<;@ W[P<@D87[Q/% &_8>-EO+C1!+H][;6NLQAK6YE,94
MN8_,V%0Q8?*#@D=OQK&\>:Q#K7@/Q0EOI37MG:0SPM<%DPLR(<L@/4(W4\'(
M.,]Y1IVLPZ1X'MQHEU))I+1M=A9H/DV6[Q$#,@W9+ C';WXJF^C>)=/\(^)?
M"EOHXO8KE+PV%XEQ'&A6?<VQP3N#AG;MM/'(ZT :E];0)\1/"%PD,:R-8W:-
M(J@,5"QX&>I R<?4U=NO&:PV&I:G;Z9<7.F:;))'<SHZAB8R1(40_>5<'))!
MR#@'K5>6SU5O$7A>[72)Q!8VTL=P1-$1&9%11_&"<;><#H>,]*IV6CZYH^A:
MUX;ATPW5O<27)L+L31B-4G+-B4$AAM9SG:K9% &C?^.$AU'3['3M)N]1DU&R
MDN[.2)T5)E50<9)ROWARP YXR>*DEUYM66ZT^'0C>F&WC;4+:>10(S(H;R<$
M$.^""1PO(YYK+LO#FH:1XC\*)!92W%AI&F/82W0>-=S,(@&"ELX&PD\9YXS5
MNVM-=\/^*M9DM-,_M'3=6F2Z21;A(S;S"-48.&Y*G8IRN2/0T -^$W_)+= _
MZ]SVQ_&U:FL^(WT?7='TZ2QWQ:I-Y$=SYNU8W +$,,=2 =N,Y/''6JGPXTC4
M- \!Z9I6IVZV]U;(RNBRB3JQ;J.._O\ 6K7C319]<\,7$-D%_M*!ENK!C@;;
MB,[DY/3)&TGT8T 5[?QC')J/B2QGMH[:70HUEE+SY61&4N&X7(&T#/!(/&/6
MM%J\%QXVT-+KP]Y.I7FF2RB[>128(P4)CQU)RPSTQVSS6;?^!;Z;4-"FCFW>
M;YD6O-NP)XW/G'C/3S%V@#.%<CH*U]1T[4I?B/I&JPV+/86MI/;2R^8@YD*$
M$ MD@;<'OZ T <S)8VJ_#OXE6_V.%(8[K4'2+8-JD0*P8 ]#GYAZ'I7H.@?\
MBYI?_7I%_P"@"N571]6E\.>,K&329%DU:6X>V4SQ ,)8A& 2#\I!&3UZ]S75
MZ%'/#H5C#=6[03PP)$\;,K8*C&<J2,'&: ,G6_%=QI?B2QT2WT:>\GO8)987
M65$4E ,@YZ#D9)_ $\5E3?$=[7P]KM[=:%-'J.B2*E[8BX4A0PRKJ_=2#Z9]
MJ/$LLL'Q4\*2PVK7+?8[T&-&"MC$?(W$ _0D54U_PSK.IZ-XKN(K!?[0UP00
M0V_GJ/*BB'!=LXW99_NYZCKUH W#XLOT_<S:#)!=W5UY&F0R7*XNEV%S(S*#
MY8"AB?O$8XR3BI+7Q1>SWFI:.^EPIKUE MPMJ+HF&>-C@,DOE@]00<H,'VYJ
M+7=*U*_?P]K-C;A;_2IS(UI/*HWQNACD4,,C=@Y!Z>N*FT[1[B?QG<^);NW^
MRDV*6,$#,K/M#EV9BI(&20  3]TGO@ %2Q\:7.I>$+#6K;2X/M5[="UCLI;P
MJ5;>4(+>6?F7:Q(QT4\\4_3M;TZW\1^*S/I<6FOI\<$UY>[E)N$*.0QP/X54
MXSSST%-T?PK=:?XWU6^=U.D2/]KLX3@[+F0;9F]1PO'_ %T:J<_AJ^U;6O&$
M-W9O;Z?K=I':QW F1B#&CKN*CD [Q@<]#G&: *'B.^O=4N_!=]=:/!;0S:U"
M]O,+C?*JM'(0KKL&W(P<!F&1ST&=+5OB/;6+:H]K%87,6F2&.=)-16*X<I_K
M/+BVG=MZ#)7<00.Q-&;2?&%]IOAFUN=*T]9M&OX9I91?$+.L<;IN4!#C.[.#
MR.F.XNVFG^+/#NKZK!IEE8WVEZA=27<,LUT8WM99,%PR[?F3?DC'.* .U@FC
MN;>*>(YCE0.IQC((R*Y#6/'J6,^K)906LXTDXN8YKL132D('984VDN0K#&<9
M;@>M==;1R0VL4<TS3RH@5Y6 !<@<D@  9]JXR+2_$_AWQ-K$NC6=CJ&EZM.+
ML+/<F!K6?8JN3A6WJ=JGCGC\2 7I?%MQ<BWETJPA>UDT]+]KF_N#;QJKGY$W
M!&&XX.?3CKFJ_P#PGDDEGX8NK?1I)8]>(1/](4&)S&SXZ?,/EZ\<<^U-N-(U
M[_A*K>ZGL[/5[==/CB2:XF\M;>X#,9'$>UOOC;R.1MQT)K+L/#_B2VTCP=!-
MIELTNBW)><)<@AT\MXP5R!\QW[L=L=<] "ZKW5UXQ\+:A?:7'8:K+I]Z)K<R
M*VT@Q8!=>H[YQWJ:S\<7TMCXD>[TFWMK[19!%]D6[:0S,1E,-Y8P'R O!//(
M%:6IV.HS>--'U&"T#VEG%/%*YD4,?-V8('<#8<]/;-9=UI=KJGQ(L;W3[Q6A
M^RF34XXL.DQB=?LX8CH0Y<CUV8H [&T>XDM(7NHDBN&0&2-'WJK=P#@9_*N>
MUWQ)J.FWMY':Z= UO96BW,MQ=SF%)"Q?$<9VD%ODY/;(XYKIZXO5-"UFZ\5:
MA<_8[.\M+BS6&SFN9S_H388/B,J0=Q(.1@G !.* +D7BU]3BT>+2+1)+S5+
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M$NI&1K:8J%=AM1MZG"G!*XP>><U2A\%WNE2>$+?3&M'LM!#>8UP["28NA1B
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M\<:(Y7 (VD@D[LGG V]ZT-!\,>)](@@T676[670;5E$#K$ZWAB4Y6,N&V@#
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MOV;@RGMM].F<U6M/'6JMH%OK=YHT<5C>6UM]C83$N]Q*X38R@$A<D'(SQ[G
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M!)B98G,1D!((Q@@$8'3CF@#M:*X6^\<7L>C>(];L[2WDL]"NY+9[>4E9)_+
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M9UDB@<_++YA^5L AB ,8/!]0#NJIZAJEIIBQFZD8-*VR...-I'<XR0JJ"QP
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:O>>([ZRM]#O]+GU60NEW>S0+F/"8DB0%#RN<MRW!(Z8]*T'4GUC0K+47MQ
MUQ$',8?>%SZ-@9'<' XQ4<WAG0;B\-Y-HFG27+-N:9[5"['U)QDFM0    8
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M!CSL#88@#< ,@\**].K U"3PTWB?3[2_M[276IU9K7?;[Y J#<2&P=H'U&:
M,+6?!6J:S8:I<M<V<.K7TML_EX9[?RX2"(6. S*QW;C@9STXITW@O4]5UK4;
MG5KFP^R:GI*Z?<QV\;[H\%S\A)Q_'G<1V^[7=44 <CHN@^)H[>VL-=UFVN;&
MTRBM;QNDUXFTJOG,3QUR0O4@9/455T3PIXFTFU&A-KMN^@0D"WD2)UO%BSD1
M;PVT   ;L$XSTXKN** "N6UC1M9O/&&DZS;"P\C3%E1(Y)7#2B55#$D*0I7;
MP.<^HKJ:S=5U_3=$EL(K^=HGO[A;6W C9M\C' 7(! Z]\4 8MOX?UC1K_5AH
M]Q9M8ZI.]T5N=P:UF<?.R@ B120&VDK@YYYJI%X(N-,N_"HTN2V^R>'X9(U%
MQGS)C(NQ\D#"\?-WR?3%=O10 5SOB+0[[5M6T2\M9;:-=,N3<[9=Q,I*,FWC
M[HPV<\_2NBHH Y+_ (1?5(/$_B+4K'4H((-9MXP28R989DB,:E3D#'(;N<C'
MO4EGX:O'\5V>OZA+9I=6UH]L[6<94W9<KS)GH%V\+D\DG/:NIHH *Y"+PKJE
MM;ZWI]OJ5NMGJUU-<F;R3YT EQO0#.UN^&.,>AKKZ* .2N_!\]OJ^C:CH-W;
MVCZ;9'3_ "KF RHT!VXP%92&&T=\5'9^%=<TU+HVNO1M++JS:@#);D;E92K1
M/M8!@>,8 P0#SBNQHH X6\\ 376D>)K:.[M+677ROFB&W(BA 7:2%S\S'J3Q
MGTXR;\WAC49O$GA[5FO+4#2()(6C$3?O?,"JQ!W<8"C'7J:ZNB@#AKKP#<ZC
M8ZS;7>J)%)>Z@NIVUS:PE'M;A5101EB&&(QZ$Y:M&'0_$LNGSF_\1Q-J+0&*
MWEMK4Q11$L#O*[SO;Y1W QD <FM;6-<L]#2S>\\W%W=):1>7&7.]\XSCH.#D
MUI4 <A+X3U"?4;_5AJ%K9ZK<6:VB7-I;%>CAM[@L2QX  SP,C//%VQ\.3+XH
M/B"^EM?M8M3:XM(3&)%+!MSDDDD8X';)Y.>.BK*L/$%CJ6LZAI5N+@7-@$,_
MF0-&OS;L;2P&X?*>1Q[T :M%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% &?K>KV^A:3/J-RLKQQ;0(XEW/
M([,%5%'<EB /K5"+Q*8M?M-&U.Q:RN;V%I;5O,$B2% "Z9&,, 0<=,9YIGC;
M0KSQ!X;>UTZ:.*_AFBNK9I/N&2-PX#>QQBJDMGJ'B37-"O+O2YM-ATQGN9!/
M)&S/*T;1A%V,W W$DG'\.!R< #X?&?VBWLK^WTFZGTN]O5LX;B(Y?EB@E9,<
M1Y'WLYQ@XIU[XP,,&J7=EI<]_9Z7-Y%RT#9D9QC>(TQ\VW(SDCG(&<5C>%K/
MQ=H.F1^%!I<0MK0M';ZT;E64PEB0?*^]O .,'C(SG%265MXM\.ZUJ]A8:7#J
M.G:A=R7MM>O=+&+5I3ED=#RP#98;>H/K0!T4>OL_BNZ\/FSVSQ62WD<OFY21
M&<H >,J<J?6LE_'HCT/2]3.C7C+?7K61CC=&,4@E:/'7+9*'&!CU(IDVGZWI
MOCFTU6*S?54GTE-/GG5XX?+D20MYC@G[K;CPH)&.E<_<0:UHWA+0H+_38_ML
M7B42+%%.K"8/-*^03@#A^,GTSCI0!TT7CGRI]7M-3T:[LK_3K(W_ -F#+*9X
M!D90J<$Y&"/4]ZM6?B>ZEUQ=(O-*$-W)8M?1+#<B3*JRJ4;(7:^77V]S6'K.
MC^(]:NM2UW3(&TG4%TIK&PCN'0REV<.S$HS*O"A5Y/)).*;IVD:I9^*M)U6U
M\)P65JNGW$-Q&EU'YPD=HFRY'#D[#CYCDDEBM $UE\2)+W0]-UL:!<1:;=7P
MLY9I)US%F4Q*X49W+NQGIC/&<5L7_BB=+K5+?2M-&H-I40>['G%#N*EA'& K
M%WVC.#M'S+SR<<=:^&O$4'PKL/#YT>0ZA;ZBL[J+B+:4%UY^0V[T.WZ^W-;:
MV/B?0O%&IZGI6EPZA9:UY4TEO/=B![.94"')PP92 ,[<GCC/< TQXME_M_1-
M/?2I(8-7MS/#<32;"A"!C&R;>' /3/8\\8K3T?5)M4>_9[5(H+>Z>WAE24OY
MP0X9L;1C#97'/(/-<WXXL[N7P,H-V&U^TE@N;62(#(N3)A H_NDEDY[9SWK>
MFMKW0?"R6^A6<=[=VZHL<4L@C$A+#>Q;UP6;W/UH OZGIMMJ^GR6-Y'YEO+M
MWH>C ,#@^W'-<C)I]E_PN*VC^R0;/[ E;;Y8QG[1'SC%=S7'R6FKGXG1:P-)
MD.G1Z>UAYOGQ[BS2J^_;NSM 7Z\]* '7.M:7X0NK;P[9BS@>5)KL?:[I;>&)
M6D+8S@DDNQ 4#H#Z<U&^(R_V3I=\FC3NUYJ8TR6(2J#%*3@%2>'4XR#P"",X
M[6O$6G>(K3Q-;^(O#\5M?8M?LEUIT\ODF1=^Y61\'!!)X/&*H^)=+\3ZM;:*
M[V,,T]MJ\.I20PSJ$ACCX\I68*78Y)R0!G/08H TXO%\\=SKEIJ&D217>EVJ
MW@BMI//\^-@V OR@[\HPQC'3DT^S\4W,GB.'1+NRMDN9[)[M5@N_,:,J4!21
M2JE3\XP>^#67J^A^(+KQ)X@O+"(6YO=(6QL[L3@-%(ID;<0.0"7 !&2",XJ+
M3]'URRUCP_?V_ARPL[:UM;B">TBNP7C+F-MV[: Y)CQCU.21V '+\1+W_A&G
MU^3P_LL+:[:WNV-V"RA9O*+(-OS =3G;WQGK5J/5M7D^+<FE,L L8M)%PBK,
MW(>;;O(VXW?(..PSSS60?"_B!_AKJ7AS[! +N[NI9$<W(V!))C+EB!D$?=(
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M<$8]Z )[+QA<:O!HZ:?I;)>ZA;/<R0WC&,6R(0K;L*226( &!GD]JP-!UU]
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MUU=V[S6;6]R9HYF0 O&6**58 YZ8([]J .CJM<:A96MS;VUQ=P13W#;88Y)
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M1EP""4Q[9-+H7BW4-=N;>2VMK-K5KN6VNX5D;[19;=^TR*1CDH >F-PP6ZT
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M)!5<9'))Q@<@';T5PEWXD\3Z?H.L75QIH9K6XA^SW M6&^W=EWN8MY8L@+9
M(S@5M^%M6FUF&ZNUU"SU#3F=?L=S;(4)7'S*ZDG# _3KT% %V\O--T:X5WB
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M./0D _3BFW%AXOU;4O#%U?:781/I=V\ETR7QQ+F)DWI\G .XG:>>W'6N]HH
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M?E'9QMV\8.\C)SC&<'I0!Q?A[7M7\-?#J34[>SLY--L]3N1,996,LL9NF#%
M.%(W'J3G'Y]5J/B^Z&N:KIFG6[,^G(@)-C/<":5U#A,Q#$8"D<G/WLXP.<E_
M!OB.7X<:AX98:4+BYN9)5E%S)L"O,TIS^ZSD$A<=^O'2M&7P[XFLO%$VNZ)>
M:9$=3CB74K.[#R1K(BA1)&R[23CC! SC\@#IM#O[C5-#LKZ[LI;&YFB5I;64
M$-$_=3G'0US>M;1\6?"V=N38WP&>O_+/I^OZUU6G6TMI8QPW%R]S,-S22M_$
MS$L<#)PN3@#L !VKG=9T;7KKQEI^M64>F-!IT$L44<\TBM*90NXDA"$P5XQN
MSGM0!T]S(\-K++'$TSHA98E(!<@< 9[GI7#Z=XWOF\0>']*OA8O<:JDJW%O;
M@[K&9(_,*,VXAC@$$<$'GH:V;S2=;U=[D7=[#8PO8S6T26CLY660 >:20N=H
M' QW-8-GX.\1K-X2N+BXT:-]">16AMHI CQO&8RP/][G., 9SR: &W/C3Q+;
M>'-<UEK#30FC7<L4L>YS]H2-@#L/\)P3R0>1C'>NB_MN[U/77TS23;Q+;VL-
MU<3W"&3B4ML0(&7G",22>..#GC%E\(ZU>>$/$&B3R:?%)JUQ+*)8W=Q&)3E@
M05&XKP >,^V.;D/AO6[#5K?5M.NK"*YFM8K34H)5=XY!'G9(A&"& 9N#P<XX
MZT <6@E;X(ZP9U43#5IF=4R!N%[D@=3C->A7.MWMWXKF\/Z6;>)[6T2YN+F9
M#(%+L0B! R\D*Q)SQQQS6%_P@NKCP3?^'SJ5B\EU?O=+/]G90@:;S>5#<G/&
M,@ 'OCG6G\.ZA#XJ3Q-ITMLEW/:K:WUI*S>5* <JRN!D,O(Y!!![4 95QXWU
M1?#]_/#:6G]IZ9J<>GW<3;O+D+2(H:,YXRK@\YQWSBK[:SXABUBVT.X&F+J%
M[+//%+$KND-I'MP64E2SEG"\$#J>.E0WO@N\ET:[MK:[M5O;_44U"[N)(F*[
MT=&554'.,(HR3GKZ\7M=\.:AJ&J:3KFGWL-KJNG+(FR1"\,\;XW(V,$?=!!'
M0]C0!6\(?;!XF\7)?M"]RMY!EH4*JR_9TVG!)P<=1DU<^(*[OASXD&W/_$LN
M#C_MF:?H6AZGIVN:OJ-]?6DXU%HG,<-NR%62-4ZESQP>,>^>U6?%&EW6N>&M
M0TFTFAA>]@>W:652P174J2 ",GGUH QKW6]6L)?"5IIR6D\.J9AD,X8,N(&D
M##!QCY<D8[8XSD5=/USQ9J.J^(=#CDT=+W29(L7C6\GER+)&'5?*WY!Z@MN]
M.#5^;PWJLMSX7F^U60.BL6?]VQ\[,318'/R_*Q/?G'IS)IWAW4M.\2^)-76Y
MM'_M?RBD91AY1CCV+DY^;(Y/2@#.D\8:O<:3X/U'3[:RVZZR1RP3%LQLT+R9
M#CL"A_A)--/BG7M/U#7='U%=/>_LM._M.UN(87$<T.6!5D+DA@5(^]WS6=J&
MDWGAW2/ &C?;+4W-GJB0QS;"$<"WF'*YR,].O4_A70WGA6[O9]9U&2ZMQJ=_
M8_V="PC/EV\.6/KEFRY.>.@&.* ,T>+-?L] L=8U"'3MFJ0VD5E;PA]PNIB!
MAV)P4YW= 1R,G&3HW.MZMI'B;2M'OY;2XCU:.9+>XAMVC\F:-0V&4N=RD9Z$
M8VX[YHN/!SZGX&LM U"\5;JR6+[/>6R$>7)%CRY-I)Z8&1GGGI5M=!O+[7=,
MU75[BVD?34D\B.WB*J9' 5G.XD\*" /]H\F@#"M/%>N'2/$4%T;#^WM/OQ96
ML20L$D+[?)9@7)P^[/48 /I5J[\1ZR=4O],LU4S6$4:/,-.EF26=T#_PN-B@
M$<$D_-UXYU)_"\<WC:#Q"+@JJVWE2VP7Y99%)\N0\\E0[@9'<>E4[[PQK$/B
MBYUS0-9@M#>QQQWEM=6QFC<H,*ZX92&QQ[T 4G\3>(YM5\+VBV=M82:O:SR7
M$%U&S/;R1J,\AOF7+ X^4G'49JNWB+Q<-%\23[M'6;09IE:7R)"MT$C64 )O
MS&=K $[FY[<5J?\ ")WL>OZ%?IJ*RQZ8+C?]H4M),TY!D.[.!@C@8P.G:F+X
M6U7^R?$]F][9;M;DDD#+"^(2\:Q$8W?-\J9[<GTH )?%5U?:C8V.GH86GTQ-
M0E;[.9V19.$4 %0.0QR<YQC'<49?$WBNWM/#QN[&RM;N^U(V,\,J-AQMD82(
M0QV@A =I!/O5B3P9JT$FC7^E:S#::GI]F+&7=;EX+J%?NADW @CJ.>"34U_X
M1U*Z?2I1JT4D]EJ']HR23P$B63:R;5 ;Y$VMP.2,#KS0!1O]7\01V/C#3I;^
M%+O3;,7=M>P6VWY&C=MNTL<$%" <G@^M1+KE]X>\$>%I9IQ'8RP0B[OH[5G^
MRQ^2"N5R>"W!8\ 'IW&U+X5NKK6M=NKB\M_LNK60LVC2$B2-0' .XM@\.<\#
MH*-.T'Q!IVEZ9;C6;21[*%K=D-JPBFCPBKD;\AALSNR?O$8P: -7P]>W&H:0
MES<W%G<EW<QW%G_JI8]QV,/F;&5QGGKFM2N$FT;4_#5EI]KHFI)%-/J;W4UK
M'9[HY5=LM&O)\J, YS^/L>[H \I\6ZQ?^)?A?XEU>&XAATU5N+>&V,.[S41]
MA=FR"&)5B .!QD&NAN-9U*YU1=#TMYK<VMA!<RSQ6ZRL3)N"KAB !\A)[GMC
MFH+KX?7C:/K6@V6MI!HNI&2189+0226[R'<RHVX#9N.<;<C)P>]6[OP;J:ZQ
M9ZUI6O"TU**T%G<^9:^9#<Q@DJ60,"&&3@YH H7_ (F\0V>A:-=:Y VB>;)*
MNI7%O!]H%OMSY9Q\VU6QDDYQTXSFIX?$>IWCZ%H\>H6C7FIK<W!U&V4.GV>-
M_D**<KN963.3Q\W6MA-#U:VGM9H=:\TK',+M+F$LEP\A4A@ P";=I '. 2/>
ML<_#I8-.TW^S=4:PU33[F>Y@NHH 8T\YB9(Q%G&SG &>,#WH K^(]:\6^&_
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MX=<?>.1SGBLV\^'T<ECI/]GZK<6>JZ9-)<1:AY:R&227F4NIP"'/) ([8Z4
M0+K_ (GM-.-M?68BO;K4X['3[F:-3NC==WF2(CXW*%?(! ) Z4EA;7EM\876
M[OFO!_8.4=HU1@/M'0[< ^V />K^H>#9]5TEX[W6IWU7[1'=07\<2J+>2/[F
MR/.-@RV022=S9//$VG>&;^W\3IKU_K7VNX^Q?8WC2T6)"-Y;(Y)'..,GI^
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M2V7W9+?*,'''H: ,$Z[K^I^#[_Q?I]^(5MVGDM]/:)#%+#"[ AV(W[V"'D,
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M#1HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!N(&26=B>!V'.*YR'X;J/#VOZ7/<(ZW4DW]F8Z641?S44<=I?F/T4=J] HH
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M'B;PGJOB:RU/3[S^S9(Y9@VG7K;A-8KA<X 7E@RDC##.<'I7:1(8XD0NSE5
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M(EM;F&,DXR[#<=S<>P&3QS6_10!@^,-"N?$OAV72;>XBM_.DC9Y)$+8".'X
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5Q\-G!;_ !=EF02&6;1269Y&<#$XX&2=H]A@>U=A7+_9[\_$
M<:A_9D_V$:>;/[3NCQO\P/G&[=MP,9QU[=Z .HHHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>a106amendmentno12tolease002.jpg
<TEXT>
begin 644 a106amendmentno12tolease002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M $] !G@8Z5A^-O%4;^(8X9KB]M+#1]0M"0EM*5NI3*A8LRH1L1"<#(+,?89
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MT[!B=Y50BG!.!A0!QZ"KE% %>ZL+:]>V>XB$C6TPGAR2-K@$ \=>&/6K%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MNR,K8<D$D';C QP2#FNDNM2U'6/&.I:/:RRP0:?:0R;89UCD>27<=YRIX4*
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M-XF=PJ)NP3C*C>H/*D%C6SH/_)4/&/\ U[:=_P"@S4 =C17)^-;G5;6?P_\
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M;$V-U"EF8P+F10(YRR[CL/?;T/O7%:#K6J:UH>EZ4^HW$>N1W\MOJ<R*A9!
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MOB'2+^_>^;3[M!#-*B*_ER1*X#;  2"3S@5T] !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !65KV@P:_:V\,T
M\]O);7"7,$\!4/'(N<$;@1T)'([UJT4 8,'A6"W\0R:W'J%_]KDM%LVW,C+L
M7)4\IDD$DY)Y/7(XK//PZTEM!M-)DN]09+*Y-U:7 E5)K>0EF)5E4=V)Y!_2
MNNHH S=)T2#2!,ZSW-U<SD&:YNI-\DF.%!P   #P  .O<DU4U/PK:ZCKEOK4
M=Y>V.H0PFW,UI(J^;$3G8X92" >1QGFMVLU=0O3XD?3CI<@L5M1,-0\P;#(6
M(,6WKG'.>G]0#$'P^T]-.:TBU'5$_P")C_:44WVC<\,VYF)4D'(.Y@=V<YYY
MYJ>'P/I\5_JEU)=W\_\ :EJMM=QS3[EE 5EW'C.=K$8' ["NFHH Y2/P+;0V
M^C)%J^J)-I(=+>X$J;S$RA3&PV[=N%3MGY<YR2:T-!\,VWA^YU&:VN[R47UP
MUR\<\N]4=L;MO?G ZY]L5MT4 <]J_@^QU;6X-:2ZO;#4X83!]ILI0C/&3G8P
M8$$9Y'%)/X/LG328[:ZN[2+2YC/!'$4;=(0P+N75BQ(=\\\EB>O-=%45S<PV
M=K-=7,BQ00HTDDC' 50,DGV % &,_A6W74=1O;*]O+%]2 ^UI;LNV1@-H<!E
M.UL<9&,TH\+V]JUB=*N[C35LK4VD4< 1D,9*D!@ZMDC:,'.>3ZFMQ6#*&4Y!
M&0:6@#E;SP!I-S9Z9'%/>VESIKR26UY;2A95:0[I">"I#$Y(QCT %3W?@VQN
M]%;3WN[T2M=1WAO?,!G,Z%=KDD;>-JC&,8'2IO%7B,^&=-CO?[/FNT>:.%BC
MJJQEW5 6R<]6[ ].U;M $,$'D6B0":5RJ[?-D;<Y/J2>]8$'@Z*WTR>RCU;4
M1YMY]N\[,8=)=^\D83&"W4$$=JZ6N4M_&IN++Q'<?V1<J^B3-%)#YJ%I $#E
MNNT<'U/3\* -C3=%33[^]OWN9[F[O%C2627:,*F[:H"@  ;F/KS5/7/"5CK>
MIV>J&YO;'4;162*ZLI0C[#U0Y!!7/."*T-#U-=;T#3M52(Q+>VT=P(R<E0ZA
ML9[XS5^@#G;WP9IUYI5M9":[AEMKL7T5VLFZ83@DER6!!)R001C!Q@<5 ? ]
MHT^KSMJ>HF75K9;:[<NAWJ PSC;@'#$<  =@*ZFB@#G+CP?;7'A:S\/-J%\M
MG:^4$=?+\PK$04!)3'!5>W..:EUWPG9>(8+#[9<74=Y82>;;7UNXCGC;&"00
M,8(ZC&#Z5LFY@6[2T,JBX>-I%CSR5! )^@+#\ZEH YF[\%6M[I;V4NIZB6EF
MBGGN2Z-+*\94IDE2  54X4 =?4U:_P"$9B/BF+Q";^[-[':?8]N(]C1;@Q!&
MW.2PSD'Z8%+I/B%M3U[6-*>PEM7TWR<M(ZMY@D#$$!2<#"^N>>U;= '*1> [
M.'P[<Z#'JFI+I\S';'O0F%"Y?8A*$XRW4Y/ YXJIXH*ZV/\ A!Y;#4;LW4<3
MSWSP 0+$),L2XP-^$. !U(]Z[:B@!%4(H50 H& !VK&U#PY#?:_:ZPM[=VMS
M!"UNWD,H$L18-M;() RHY!!Z\UM44 <O_P (3;'1-5TE]4U!K?5)9);ECY6X
MF3[^"$X!_3M1>^"+:\O;'4!JNIVVIVD'V;[;;R(LDT62=CC:5."<].O-=110
M!5T[3X-+L4M+<-L7)+.VYG8G+,Q/4DDDGWKA= MY-0\;>,C;ZK>6<<]U"4\E
M$Q*BP(K,C,AZ'(R#VKT2B@#E[WP%I%Q!I*6DEWIDNDQF*SGLI=CHA RIR"&!
MP"<@\T7G@>SO+:PA;4+]3:7JZ@9MR-)-<+C:[EE.<8Q@ #&!C %=110!D7.B
M33:@E]#JUW;3BW%NWEK&5<!L[BK*1GKTQU-4E\%:=;QZ6;*:XM;K3(WCM[I"
MI<J_WPP(*L"><8Z],5/H_B0:MX@UK2#8S6TNE&$.TCJ?,\Q68$;2<# '?O6[
M0!S-YX*L[[1-3TR:]O/^)K)YE]<@IYLWRA<<KM4;54# & *LS>&C<:II>H2:
MK>F73HV2-0(PLF[ARXV\Y  XQC&16[10!QL7PZLX=.M+"/5]46VL+I;BQC61
M +;#;MHPOS#DCY]Q /&*U]/\.)I_B'4-96_NI9K]8TFCD";-L8(3&%!XW-WY
MSS6W10!Q/Q"FA,WAN!KBXA=-7BG9[=<O$@20;S\K +N(!R,8S6K)X4BF6_DF
MU"Z>]OH!;37>$#B$9^11MVJ/F8YQG)Z\#'0T4 8,GA.QN/"T/A^ZFN)[:!46
M&9BJRQ[,;"&4 ;EP,'';G-/@T2*TODU;4M0FO;FUA:.*:X"*(4;!<@(H&3M&
M2?3C'.=NL)O$JKXTB\-M8SH\EF]VMRS+L9595( !)ZMW H XOX?Z -9\#RZ?
M?7U\EI)>7!N+ HL>Y3,S 9*APK#!.#SD\UUFI>"[2]UY=:M=0U#3+[R5@E>R
MD51+&I)"LK*0<9ZXS6CINKRW>GW=W?:?/IRV\TJ%9SDLB$_O..Q R*Q!XPU5
MVT^2'PEJ$]IJ"QR0SPRHWEHQ&3*.-A"D-@9STSUP 73X2A34-,NK;4;RW73E
M<11*48.7^^7+*68MU)SUYJ2_\/Q'Q$/$B75['/%:B"6"WVD7"(QD53D9^\3T
M(SG!XK>HH XWP\+?Q/XD_P"$N_LNZLUCLA9VWVR'RY6RQ9SCT'R@'W;M78D
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M#<N !E\XP%& !V[Z7B3P]!XDTV.TFGFMVAN(KF&>';OCDC8,I&X$'IW%:]%
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M"22#ACWJX_@;1Y] GTF\-Y>+.ZR275Q<LUPSJ04;S.H*X&,<#\36+86:Z/\
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M(%R%)WJV& ) *XJOJ?@?1]1TK3[!/M-B-.;=9SV4QCFA)!!(?DG.><YR>30
MOA&+6;2*^L]:NK>:1)S)!&ER9Y(86Y5'8JI."#@D9(^E6/&$EQ!X-UFYM+J6
MUN+>SEFCEBQN#*A8=0>,BK.C:+;Z);/%#+<7$LK;YKFZE,DLK8 RS'V   P
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M'4_#VE6\GE1ZE=NDTGGM#N"QLPC#J"5+-CI@G;CO7.^)XM;T#P9XM=M:>/;
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M8'DN',D+(,(4?.5VC@ <8X[FM33]&M--N;FZC\R6[N=OG7$SEG<+G:/0 9.
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MBY1D8,GS;<D!AG!)Z\Y&  #D/%]]>BW\8WMIJ5_//IR P2VLSP0V!6,-L.&
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:HH SM%T.QT"TFMM/1TBEN)+A@SEOG=MS8ST&>U:-%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Q?Q99H_ACK4\4
MDD<T,:O')&Y5D;>O((Y[FNTKD_B9I]WJOP[UBPL+>2XNKB-(XHHQDL2Z_IW)
M["@#-\,>.-,L])\*Z7?)?02ZC91);75Q"1'/*$7<NXG=G)ZD 'L3D5WU>2W/
MA[4_$<G@/3#IUS:+X?>.74)KF+:H:)4 6-^0^XJ?NY&,$XKM_#^LZYJ/B#7K
M/4]&-E8V4RI8W)S_ *2AW9;GZ \?WL=J .CKSOXV,]M\-+^^MY)(+NWDA,4\
M3E'3,B@X(YP03Q7HE<#\7K&^UOP+<Z'I=A<W=]>/&8UBC.T!9%8[G/RKP.YY
MH XG6+V1;;P7#X+O[F3Q-,D$MU!!<NR20[ 7,P)V_>QU[;J]1U;QMI>DW]]8
MLEQ=75A9&^NHK=5)BB'<[B,GO@9/YC/GGC/PQX@\6>%O"6CZ3I<]K?Z?Y33W
MMPPA%L5C"D YRW/.5S]WWK1\6Z=X@U7Q7JFGIH,\M@VBO'!>6I6(W,Q7 $TI
M8$J#G"9/."01T .P;QSHQTO1K^W>6Y369!'91Q@*TC8)(^<J!C!SD]>.32W'
MC;3+/PZNLW<=U!')=-:10,@\Z282-'L50<9+*>_09.!7G-EX8EU/X8^&?#^O
M>']4B6%)V>YAC_?V4JL/+<*"25;>1MQGC.!C-5M<\&^+]0^&^@RO'+J&IZ-J
M#S1PS?++/;[OE+ G(; !P><'U% 'KVD^(+36+O4;*))8;S3I5CN;>8 ,FY=R
MGY200PY!!KS?XD*MI\3O!:)=SVMKJ,TB7R1W#1QS*I0C> 0#]XCWKL_"EO'+
M=7&JQ^&?[%%S$@;[1&JW4KC.=VUC\H&T#//7@<9Y7Q]:ZAJ'Q(\*7UIHVH7-
MEHLKO>3);DKA]F-G=R,'.T&@"*VOKRV^-]KI7AN^N;G1?L9;4K;SFE@MVPQ!
M7<2%8G;P/4^]=EJ7CW1--N-2B=IYDTH1G4)84#):[SA=W()/4D*"0!7$:=H.
ML?#_ .(DM[H.F7%WX4UE?.N;>*([[-AW"'!R"WW0,X)&"5%5K'0M0T7QUXG&
MI>$[W7=)\0S"XMG159%.2VV4.P" ;@/FZ;1@&@#N[WXA:18>)H- DM[Z2^N;
M<7-J((1(L\9#$%2IX^ZWWL=/3FJA^)FFW7P^O?%NE6=Y=0VQ=# R!'5U'\7/
M"\C)&>#TSQ6"VF:E!\9=&U8Z3.NGV6BK8SR6T#&%)?G.U,C)0;@ 0,?K65X7
M\.ZVGP@\6Z'/I5W!J%R\]Q;PRQ;?,6105 /3=\I&WJ#C- 'HO@+5[W6_!NFW
MU_%<"YEMT=Y9E11*64,64*3\O.!G!XKI:\WT76/$^C^!?"EK9^%;IYE>WL;I
M+C"M%&J*'D(!RHR& SV&3U%>D4 <?XNT6"+1?$6LRRW$MR+-W@Q*R"#9&<;,
M'@YRV?4^U2:'HMG#I.B:TUQ+!-!:+-<2-.S+*##AM^XG@$AL^J_6M#QBY_X1
M'5(4@N9Y;BVDACCMX6D9F92!PH.![GBJ.GVLNM_#0:6(;BRN)-,^QE;B%H6C
M?RMIX/. 3U&>G&: +$?C&R-UIT,]G?6RZF#]BEEC7;.0N[ "L64E>0& Z52;
MXC:2MA<7QL]3^S6MR;:[D^S8%NP8*2Y)Z GMD^U8OAJ*1EL;>?P!!IFK63(;
MN\>RB\D!?O-"Z'<S-C@ <$\].:.H"[N_ACXLT^+2M6^V7EW=-;PO8RAI!+*S
M(1D=,=?3C.* .\O?$UM:ZC+806EU?7,-J+N9;8(=D9W;22S+DDJ< 9-5Y/&^
MD)%HLJB[ECUE=UHT=NS _(7 /H< \=?PYKGY)+V]UF*"[T75);"6PA%H((S$
MC2 /Y@N22I&. %;*D$G!)JCHJWUKI?@"&YT74XGT[<MR#:LWECR&CW?+G W,
M.#SC)QCF@#H-2\=)%X7U_4++3;S[=I"-YUI<*B/$WE[U9LM@H00>"3CMFNDT
MFYN+K389+JVF@FV@,LVS+' ^;Y&8 'TS7G]S97NI3_$NUAT^_5]4M@MDSV[Q
MK,RVHC(#$ <N,<GD>U=YH=^^I:5%</8W=EQM$5V@23@=2N3CG/7TH SH?%UI
M=RVB)8WYM;VZ>T@NPJ>6SKOR>'W*/D8 D#]:Y/PUXFT_POIGB*2YAOY;6VUZ
MZ6>:.-I%MTWA5+LQY &.F2!VI;"VNX-;L-0T:QU;3II[QCJ]A);O]C9<-OF3
M<,!B<$;#D[N1UJE=QZC/\-O&UE%I.I&ZO+^Z:VA:RD#2)*^5(&/3.?3C/:@#
MOM0\46UCJ$EC%:7=[<16GVV5;8)\D1) )+LH.2IX&3Q7.^([VRUE_ NM64CO
M#=:M%Y;98!HVAE;!7IU53T[5#=M?:EK?DSZ1JLMA+ID8M%BC,*-*-V]9R2I&
M,#"L=I!/!)%9&G)?P>#OA]:S:-JL<^G7T4MR@LW8HBQ2H6.,X&YP,'G'.,4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445P7Q
M=AMU\&'4'5$N;6ZM_*N<[7B5ID#X;J 1P: .]HKSF"[MO^%CZ4OA*Z2XTS['
M/_:5O8R!K90 /*(P=BR%CCC!QUXK7L?B%87L!O/[/U"'3XUN&FO)(AY<)A8J
M58@GDX.,9[=Z .OHKE;/QQ;3ZQ;:7=6$]I<WD32VBM+$_G;0"5RCD*^T@X)Q
MCO5%?B;8MH]KK)TC5%TN6X-O-=-&NVW;S#&"PW;F!('W V,XZ\4 =Q2*RMG:
MP.#@X/0US]EXK6Y\12:+-I5_9SFV-U;-.$ N(U8*2N&)4Y*\-@\\@5E:)X@T
M'2_#FJ:E9:?=6< U66*2&9AOEN6D"DC+$*"Y Y( Z\"@#MJ*YP>+HX(M0.I:
M;>6,MEY0,;['\YI20BQE6(8D@+SCD_C5>'QY81WE]9ZI;3:=<6EFU\5D=)!)
M N=S*8V;)!&".#TZT =716!I'B9]2U&&SGTFYLVGM3=PR221NKQ@J.J,>?G'
M^-7]9UFTT*P^UW98AI$ABB09>:5SM1%'=B3_ %/ - &A16!9^*$FU672;S3K
MJQU%8#<Q02%&\^,'!*,K$$@X!!(/([<UG6WQ"L[JTTZ^72=433[RX%N;N2$(
MD#M(8T#@G=RP R 0-PR<\4 =A117*S^.[*"SEU,6-[)HL,K0RZDBJ8U*ML9M
MN[>4# @L!VSTYH ZJBN6U;QQ;:7JMSIB:7J=[=PV7VU4MH-XECW!?D.>>OZ=
MSQ72NB7-NR2*3'(N&4Y!P1T]J 'A@PRI!&<<4M>8>%O%>G>$_!<"3:=J7]G6
MMU<1W-]';YA@_P!(< L20S=1DJ& SUXKKM3\6P6$MU';65Q?_8X1/<FW>,")
M2-P'SLN25&<#MCU&0#H20 23@"D1UD4,C!E/0@Y!K@/$OB :NWA,:?97&H:5
MJ=ZDC&)XPMP@BD?807!^4JK$$8^7!]*T-/O;+07O=.T30[Z:56%[>V<#QXM6
MD .P;G"Y."=B$CJ>-PR =A17+S>/=)2RT2]@2YN;76+@6]O+%'PLA#?*P)!!
MRI&,=?H:5/&2RVUJJ:1?+J5PCR'3YC'%)$B.4+.68* 2.,$YSQQD@ Z>BLOP
M_K]EXETE=0L2X3>T4D<@ >*13AD8 D9!]"16-<^)KY/B3;^'H]-F>V_LY[EW
M#Q_-F6- _)R%7Y\CJ<]#B@#K P)(!!(.#CM2UY=X<\26OA33O$\CZ??36=MK
MUT9Y85!2WCW(-S%V&[Z+N/'2NWU#Q'%:WL-C:6LM_>RPB<0PNB;8R<!BSL ,
MG( Y)P?<T ;55M1T^VU73;K3[V/S+6ZB:&5-Q&Y6&",CD<'M57P_KUCXET:'
M5-.=F@ER-KKAD8'#*P[$$$?XURGB&+2[+XDZ/-?O'#:W=E=&9'<K'-(OE@%E
MSAF"DCD'@>PP ;T'A.!(HK>YU34[VSB8,EK<S*R<$%0Q"AG P.&8CCG-;^Y=
M^S<-V,XSSBN7T:32[J_O]3T/S9UM,V4D,3#9*^V.0,NX@ @/CMGGT%<=ICB_
M\'W_ (HGT&Y;5[2[O;N&^CEA#%DDD106\P$HB@*5/!"\ \4 >LAE)(!!(Z@'
MI67XCT&'Q+HL^DW-Q/#;7 VS>1M#.O\ =RP./J.:XSP\NEZ?IOAW6IM'NX]<
MFLUAA6.6(27Y>,/(S8<!L;2Q+D8Z]2!71P^-]+:SU26Z2>TGTN5(;JVD4-('
M?'EA=I(;?N&W!YSVH Z"WB>&W2.2=YW48,L@4,WN0H _(5(6"C+$ 9QS7,-X
MR*W5_IS:->IJMK9B]6T=XOWL1)7<'#E1@CD$Y] :P5\0P:M\-M(OO$VE7\ZW
M;VKYCV /*TB%&!1_E4,5^]@X'(H ZS2?#%EI.IWNHI-=W-U=RR2;KJ8R"$.V
MXI&.B+G' ]!Z"MJL%_$Z1^+X/#DNFWJ3SQ//%<GR_)=% W$'?NR"0,;<\YZ<
MU$OC&V>&=Q87N];Y["WC C)NI5+!O+PW0;6)+;0,'TH Z.L;5?#EOJFHVVHK
M>7ME?6Z-$D]I(%)1B"5(8%2,J#T[4FB^);76+[4-.\F:UU'3W5;FUGV[E##*
M,"I(*D<Y!]CBL;XG6J2>$)+E"\5U'<VJ1SQN4=0]Q&K#((."&.1T_*@#H=-T
M6'3IY;EKBYN[N50CW%TX9]HR0HP %&23@ =>:TJXWQ?H;:?X8O\ 4]!NKG3]
M2L+=KB)HYV*2; 6VNC$JX(!'([]:FT[QO'J&G:*\&GW%SJ&I6"WYM+<K^ZC^
M4,2SE1PS  9R3[<T =917"ZCXYFO--\-7N@6-U/;ZO>(AD_=!E52S/'M9Q\V
M(V4GH.<'.*V;_P 6)9O=)%I5_=M90B:]$/E_Z."N[:2S@,^WG"D\?49 .AI-
MPW%<C(&2*K:;J5IK&F6VHV$PFM+F,212 $;E/L>1]*PK>_TI?&^L>18WIU2"
MQA-S( =LD>Y]BHN>3G?SC\: .GHKCK?XC:;/IUAJ;:?J46FWDHA^V20A8X79
MRBA\G/)'500,C)%=?(Q2-F5&<@$A%QEO89P/SH <2 "2< =2:0$$ @@@]"*\
MPU;6K_Q)X \:"_TRYM?LOVM(F>6/;%Y: !24?<6SN/0CJ,]*Z'P_XLM/,T/0
MY;*^@DN[(&UN)H@L<YCC4N%YW< YR5 /8T =?17,7GCG3K&W:^FMKS^R5N!;
M-J013"K;MN?O;MH;Y=P4C/MS73YR,CI0 45REEX]TZ]_LR9;.\CL=4N3:V5Z
M_E^7*X#$<!RP!V'&0,^U)<>/K*&[UJVBTS5+F71V7[2L-N.%*[RP)(& O..I
M[ T =917,0>.=-N;S2XXK6_-IJF!:WY@VP.Y4L%R3NR0#_#CWJ:]\6P6SWYM
MM.OM0@T_*W<UH(RL3@ E,,X+,%()"@XSZ\4 =#16%'XJLI]4TJTMX;B>#586
MFM;V/886"KN(/S;@<8_A[_7&?/\ $&PM;'7;F?3M2C.BR".ZB\M';E=P(V.1
MMQ@Y)&,\T =;16!!XLM9]<BTIK&_A>XA>6TFFB"I=!,;@G.01N'W@N:P]"\=
MSR:+K&K:UIUY;6UK?2PH286 Q(L2Q#:^2^X]3\N3][% '=T5E:7K;:C?WEE+
MIMY8W%K'%(RW.PAA)NP5*,P(RC#ZBEU?7+?1Y;&!X9KBYOIO)MX(=@9R%+$Y
M=E   )Z_3- &I17/Q^++=[%)FL+V.ZDNGM(K%E0SO(A.X##%,  G=NQ@9S6'
MXE\?26_AC6I=(L+K^U;!Q;S0RB(-:.^-CL"^&4[@1M+9Z''. #O**K6-Q+=V
M:33V<]G(V<PSE"Z\]]C,O/7@FO/]6U"76?B@-!U#P[=W>FQZ6[K Y@(+--Y9
MGYD^[M! _C&3\O- 'I-%<?9^)-+T'1%2WM]3N=$TX_9GU0E)(T"G:226WLJG
M@L%(&#V!(MZOXXTW1[][)K74+J<637RBTMS()(P0"%.>3SGTQWSQ0!TM ((R
M#FN.T_7[[7=?UO2I](O[>QBBB6.1GC3;N5FW,5DWC=\H  .,<XR165X+\7V&
MF>#/"EI<V]]Y5S%%:"]\D^2DQX",Q(/)&,@$9ZD4 >C4 @]#FD8A5+'. ,\#
M-<3I_B/P]X?\+:[K-K:Z@EG:ZA<-=HR%I#/D;\ G@9..2!0!V]%<_:>+[&\U
MNUTL6M]"]Y T]K//!LCG"@%@N3G(!!Y XZ9J_KVIS:/HEWJ$%C->O!&SB&%E
M!. 3G+$#'KU/H#TH 37](77]$N]*DNI;>&[B:&5X0I8HP((&X$#@]<5;LX'M
MK2*"2=YW1=IE=5!;W(4 ?D!7F^N:G-=:7X$UC48+N&X.I6WF=")2T+$LL<;,
M.6/ Z\5U]CXQTN\75O-6YLI-*8?:XKJ+:ZJPRC #.0PZ <^P- '045@V7BJV
MN=:CTBYL;W3[R>)IK9+M4'GHOWBNUFP1D95MK<]*F\50K+X7U)RTB/#;231O
M%(R,CJA((*D'(H V**\<U?7+6T^%^E7ND^()?^$JDMK1X8HM0:66YF;;N5HB
MQWY)?((]>E>DWWB!=.DL;*2SN+K5+N)I%L[79NPNW><NRJ "PZMSVS0!M45S
MJ^--,FTBSO[>.YG>\N&M8+14"S/,N[<F&("D;&SD@<=>14MMXIM;BSDF:TO(
M9DN_L7V61%\UIMH;:,,5/!SG., G..: -VBLG1_$%KK$]Y:K#/;7UDRK<VEP
MH$D6X94_*2I!&<$$C@UK4 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %<;\3;._U3PDVGZ;IUQ>W$ES!)MBV@
M!4E5VR6('13794F1G&>?2@"".519^>+>2,;2YBV?/],#O7GFB^&M5O/A=K/A
MZXLY+&^GEN9(?M 4HQ>5G3."1CIGZUZ710!Q&A3ZM-):R77@N'29K<%KN4")
MMYV$;8-A)Y;!RV !D<YK$@TK68OA$NBG1KS^T5O?,\@;,E?M?G9SNQ]WWZUZ
ME10!QES;7LGQ2TW5DTZZ-BFE2V\DV!A'=T8 C.>BG) K,T^UO[?PUK-I>^&K
MF]6ZU>25[294S+;RR_>4@[<@9."0>!ZYKT:B@#R^X\+:W_9.M6FF)<RV$$]I
M=Z39:E+N)DB??)%EB3Y9PH&X]<]N:UX;C5IM/NKRV\$Q6,T5C(&M;@0EKF8X
MQ&I0GY.N2V,Y''6NYHH X7PSHMSI7BI6TJ#4;+P^]DYFL;M\QPW&Y=HB!)(X
MWYVG;TQ6EXXTB_U/3M/N=,4R7FEZA#?I;[@OGA"0R9/ )5CC/?'3K7444 <G
M-;SZIXQTW7/L5U#:Z597 _>)AYI)2GRJO7Y1&<GH2PQGFN<ET_59/AA:Z2=(
MU!M034(Y7A94#;5NA,3N!V?<]\9XKTQ)8Y"X1U8HVU@ISM/7!]#R/SI] #5;
MS8@PW+N7/(P1GV[&O.+/2]<M/ASJ'@V;3Y;B]VSV5M<D 0R0R,0LK,#QM5N5
M^]\O .<UZ310!QEG9W5C\0(6%A=O80Z/'8"[V#89 ^[USC'?&/>NSHHH \YB
MTS5'^'EYX2.E7"7MP]Q;B655,(CDE=O-W XP%;..&)&,=Z>-+O/#GBFZ!\,O
MKFEWT$&VXA$1EADCC$95ED8?*0H;((P21S7H=% '#W\6HI>^$7?1Y#+8W+W%
MVMA&!# CPRQX&2-Q!=<[<G@G R!4EA:W_A_QEXAU"2QN+JPU<0W$#VZ[G21(
MPAC9<\9P"#TZY(KLU974,K!@>A!S2T >9+H.I:5I7A9)-.N)9+?69=4NXH '
M6V1Q,=HYYVF51@9)P2,UI^(K'4[3QO:ZY;Z NMZ=/9"TN81Y?FP%7+*Z!R <
M[B"/;M7=4U'61=R,&&2,@YY!P?UH S= 2<6#O/ID&F^9*SI:QA<HO &\K\I8
MXR<=,@<XR<'4K+4K/XGV6N0:=->6DNDO8$PLH\J0S+)E]Q&%V@\C/(QCD5V#
M.J8W,%W' R<9/I3J /,&TW5'\"^-[ :5>K=:I>7<EFGEC,BRC"'KA>G.<$5:
MNK+4K'Q19ZVOAN75K&[TZ.UN(,1^?:21%B" Y (.X@X/;.?7T6B@#,T&.XCT
MW=<V,%BTDC.MK"H'E*3P&(X+8Y)'&3CM6#JL=Z/B3I>H1Z9>3V5M8SP2S1JN
MU7<HPP"03PIY _KCL:* ,&&]N%U9S!I%Q;VCHUQ=SO&-TL@"(BJ 22=HY./X
M .]<UH-IJ5C\+]2TJYTJ]2_;[8$A" E_.DD9,$-CHPSDC'?'6O0Z* /,]1TG
M5)-!\)7]OH37USH<8AN]+N553(&A".5+':2IZ$9!YYJUKVC:EX@\+7C:7H4>
ME7$$]O<V5K<+&CS20OO(?RR0%(^4#.<C)P#7H5% ',V.HZSKT,@FT*?28S;.
ML@NW1G>4C 5-I/RCDECC/&!UKDDM=8?X7:-HK^'[]+NSDLHV4A23Y,B-(W#<
M* AP3][(P*]3HH Y'QIIM_>V>EZYH<!?6=-G66VBD!7>DF$D1^A VMD_[M4_
M$WAZ]L-%T"72-.CU>71I_,DM)MH-RK1LCL">-^6W?7-=U10!SWASS99Y[D>'
MH]&M2BJD<D<:SR-DEBVPD!>F!U)R>*J?$."ZO_#/]FV=A=7<\]S;OB!%(5(Y
MHW8DL0.BG SR?QKJU8,H92"I&00>#2!T9F564LIPP!Y'?F@#EO$\NKZYH<^C
MZ1ILT4E_&8)KNZVHEM&X*NV,Y=@.@'!)'-9DNE7>D:QH^D+IVHW^A6FE);1"
MU9%5IE.T^=E@2-H! )V]>"<8[U65U#*P93R"#D&D#JS,H8%E^\ >10!Y5H.F
MZSH_@7PQ!<Z'?F?1]6>2>&((S.C>>-R#=R 9%].YY%:-Q8WNF^,=4O;SP=_;
M&GZH(9XY(EADFMY5C5&C?S& V_+D$' R>O;T:B@"GI4<T6EVZSVT%K+MRT%O
M]R,DYVCUQGKW//%<W;M<V_Q$UG47T^\-FVG0PQRK"2'>-I68 =3PPQV/:NPH
MH \IO-*U>;X2Z?HJZ1>G4X[N%G@*#("S^83NSM^Z/7KQUKU.*02Q)(%90ZA@
M'4J1GU!Z&GT4 >9W5CJL7A;QQHHTN^>XO)[R6VE6,%)1-_JPISSU(.< 8Y[5
M?D@O6U;P-.-.O?+T^*47?[K_ %1,/EC/J=WIGCGIBN]HH \PT73-0TJTGT"Z
M\$6]W=12R)::DT4+6\L9<LKRDG<I&>0 2?;->FD,(\+MW <=AFG44 >.1:;K
MMWIGA6YNM!U9]5L-7CGU!I2NT ;P1$NX*$Y7D # &23706UK>0ZQ\0+B73;T
MPZD(Q:[8"3-M@$3 #_>/?J.>G->A @]"#VXI: /.8H;Z#PGX%M7TJ_,VF26S
M7B+ 28A' T;'KS\Q&,9SV!J]I*7_ (;NO$5C/IEU=1WE[+?64UM%N$HE&2C'
M/RLK#&6P"",5W%% 'G=GH6H>$M'\%(MC<:@NE))%>+:X9T,D9&57(W .<<=N
M:S+O3=<FL_B&&T2]1]8,8L@FQM_[D)@\\=.3T'.":]7HH XC6DNK[Q_X.U"#
M3[TVEHET;F0PD"+S4"(#[[ASCH.3QS5#3[6]M=#U_2=0\-7%_#)JTTLB.BE+
MB&6X!!3GYB$8MVP5]:]%#*Q.U@<'!P>AHWKM#;AM.,'/!S0!QO@ZPOM.UC48
M89=2?P\8HS:)J6[S(I,MO1"_SE -N-WJ0*N^+[.UU".RM;_2+B]M&D9VGM0W
MFVCA?ED0K\P.>..>?3-=-10!Y3<:%KHTK2]0GT^7Q FF:C<%;6_C3[1<6;KM
M#,&P#(.P(R1BM#6=.N=5\":]_9GA,::+B.(PVGE1Q7-P4?<Q<(2!QPHSGKZ@
M5Z+D9 R,GH* RL2%8$J<'!Z&@"MI]W)>V27$EI/:%R<13X#@9X) )QD<XZ\\
MUR>RX'Q?;4C87OV+^R!8"X\AMGF^=OQTZ8_B^[[UVU% 'FECIFI:7\.]3\%R
MZ;<W5V%N+2TG$68KA)2Q21GY"XW_ # \C;QG(SHZ?8SZ5X]TB(VU]/!:Z%_9
M[WGDL8S('C89;'<*<GIGTKN20H))  [FEH XRT6]TSQCXF:?3KN6VOQ%+%<1
M1;T"K%M(]2VX8V@9YSTKF;BRU!OA?X4TY=+U WEE>6;7$/V5]R+$P+GIT ].
MO;->LT4 ,$@:(288*5W8*G/Y=<^U>3WMCJ-Q\.?&]A'I>H&[U#4KF:UB-JX,
MB2."I''H#UZ=Z];HH X;41<W'C#P3=PV-\;>WCN!<O\ 9F BWQA%#9''S#\.
MIXKJ]9@DNM"U"WB4M)+;2(B@X))4@"KU% 'F=W_:%YI/@?.BZG"=/OH'N%>W
M)942%E9B%)P-QQZGKC'-+K>D:AJ^J>-K:UL)]][:6GV1YX66&>2$LQ3<<#!)
M4=@<FO2Z* .)\/$7VIV-S'X'CT>XB5OMEQ<6T:-&2I&R%EY;+=6Z8]SQO^*7
M9?"^I1QP3SRS6TD4<<$1=F9E( P.G7J>*UZ* /.+I#J'PM@T%_#U_<ZFVF1V
MRP/:,BI.(P 3(^  K<YSVXS4C6FMZ;+X8TS4H=1OK6"P*7-W8$F22Y^4;7?(
M98\9.<C)QGI7H=% 'E6DZ5M\.+H>L^&M2\@ZQ<N)HE(>UR[O'-&R$GC@9'][
MN,TVZT;7QIEK?3V,VNQ:1K#O!;WL2BXN[-H@FY@<;I%+-C< 2%!->KT4 <_X
M<6!Y;FYL_#PTBWD1%_>6R0S2L,_>"_PJ" ,^IQQUZ"BB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0!SQ\#>&6&#I,/3'#,/ZUK6>F66GDFUMUC)C2+=DD[$&%7)[ =O<GJ35NB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC!SD)N).!CDGUK0'@S1TL])MXXYD;1P183K*?-@4C:5#'J-ORX.1@#TKH**
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M7FI6TDM[I%SICK)M6*XDC=F& =V49ACDCKVK1H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X?XM9_X0"?!
M/VRTP2,_\O$==Q63X@\-Z;XGL5LM52:2V#A_+CN'B!8'()V$9P>?K0!1_P"$
M7FO/$UGKFKZ@MS-8Q21VD-O 88XS(,,_+,2V.,Y'TK@=)EO;+X<:MXN34-1N
M-3L#J*0++<,\8'FL 64_>V[0>?3TKUR*W6*T6W5Y2JKM#/(6?'KN/)/OUK-T
M7PQI?A^SGL["*86T[,[Q33O,I+$EL!R<9).<=: .6U:U70D\+:MHM[<2M-?6
M]M.SS.POHIAM+.">6&=X/;!]:JZ5H"^(-6\86UYJVKI%:ZD%MO+OW7R#Y"'<
M"#G@L2 20,=.M=?I_A#1M,-E]G@F*6)8VD<MS)(D!(P=BLQ X) ] 3C&:YG0
M- .I:]XHN-2LM4MH-2N5EA8320++"(E3#*K @Y#<$ XH H>'-5N_$.H^&-)U
MB>22W?03>O\ /C[9,'$>6P>0%^?'JV>W%?6'OX-$^(&C17M\MMI BGL9Q<.'
M021;VBWY)95[*>Q ]*]#OO#6E7\=BDENT9L/^/5[>5X7A&-N%9""!CC'0U#<
M>$='NM%N=)EBG-K=R&2YQ<R"29CUWN&W-V&">@ Z"@#C/'/ARVL)-!N#=7US
M)=^)+'S!/<LRKR0=B]$S@<#T&,8K6F5[3XOZ3:PSW"VK:-.3 9F,8*R( 0I.
M <<9KHM0\,Z;JFC0Z7>I/-! Z212-</YJ.IRKB3.[</7.:C7PII*:S9ZLD=P
MMY9P_9X6%S)A8^ZE=V&SU.0<GF@#@WEGU#X3W7B];R:'7466\6<W#?NF21OW
M.,X"8&W;CN>YS6PEH^K?$8QW-YJ$<$VA17$EM%=21H',W.-IROW<8!&<GK70
M_P#"&Z)YL["V<0W$_P!IFM1,_D22Y!W&/.W.0#TP3R<U8/AS3SXB.O?Z2-0:
M'[.7%P^WR^NW9G:!GG@=>: //M&O)KKP?H5E>ZA?23?VU<6R6\;L\EXD;R@1
MNY880*,DDGA!P:R]12XNO OQ'T_4%PFGS%[>W%P\J09B1]JL<$@'D#& 2>*]
M"3X>^'H]/CLDANUBBNC=PD7LH>*4YW%'W;ESDY /.:FC\">'HVU;;9';JT7E
M7:&5]KKM"D@9X8X&6ZYYS0!B:JCR>/-/\,P2)%8C39;M()I)"L\GF!<'##(4
M9.W./FSC@5T'A2QO-+L+JQO=7&I20W3[6(.Z%& 98F))+8#=2>A%07?@+P]?
MZ79V%W:RS+9N9(9VN9!.K'[Q\T,&Y[\XX'H*V=,TNST>Q2SL8?+A4D\L69F/
M)9F.2S$\DDDF@"2^D@AT^YENEW6Z1,TJ[=V4 .1COQVKRZ_T75OAYHLVJ>'K
MY=5\)JGFW.CZA\_EP'EC"Y[8).T\?6O5+FWCN[6:VE!,<R-&X!QP1@UBQ^#M
M(BL8=/479T^(J5LWNI'B^7&%().5X'RGY?:@#(OK5-7^(UB#<W,-N^BN[)#*
M8VD!E0@$CY@/H1^58VE7,G_"+R:?-J&H2"'Q'+96T<3EIIXT<L(-Y8$#:IR2
MWW5/TKN6\.:>_B!=<;[1]N2(PHPN'"+&<94(#MQD9Z=:SCX!T$Z=)8E+ORGN
M_MV[[7)O6XYS(K[LJ3DYP<<T <A/]OAT+XC6S37%B-/MQ<6D-K>.?LS?9=Y"
MOP<%ADCIDFK6K6,^B7>B+%K-XW]OWD$5Y+=3L4S'"[*J!2-F]@H(4X. /KTQ
M\ ^'B^H-]FG']H0"WN@MU(!*F-I)^;EB."W4COR:NWWA;2=4T :)J-N]Y8J
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MVK3+ZZ-F1=LNP)(  V/OC"XPV1C@ 5Z%8>&+.PEMY1/=W#VL1AM3<S>9Y"D
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MERF(47!;.YAANY.,8&!G/.Z?]HT_X0?\)9%?7C:M#:7$*S23LRJC7)RQ7H6
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MUQGC))/-/\5R336WC74+"XNKF2Q3Y;EKAH4L)(XE;RX0I)9N=S'"CY@,G!P
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MW!0OE@ KCD,2<DDUZF"&4$=",T <7/XP\16D5C)>>$/LXO)XK=%;4D+*[D
M@+V&2<=,?EI>-O%L'@WPY<ZH\!NIHUW1VRN%+\@$D]E&1DX[CUJ&[5M8^(=E
M;X!M-%MS=29Y!N)<I&/JJ"0_\#%>??$6^U&7POXMGU'P[JJRR 6UO=%8OL\-
MLLJ[<'?O^<C<?ESDJ.BB@#VJN3U3Q?J&F3+<-X=G;2/M:6CW9G"R*6D\O>(L
M9*;L#.03D$#'-=#IMY)?V$5S+97%D[YS;W.WS$P2.=I(YZ\$]:Y7XE0ZI%H
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5G:[KEAX;T6YU?4YO*L[90TC!23R0  !U)) _
M&M&N.^*/AB]\7> K[2].*_;"4EB5VVARK [<^XSCWQ0!Q/B+4_MOQ4\!726=
MYIK7SO),C. )T 7RBVTE21R,=1D>U>SUY1JVG^)M<\8>!=77P[<Q0Z6CM>[Y
MH@RLP56 !?D#&0<\\\<<]OH>I>(+SQ!KEMJNDQVFG6TB+I]PK9-PIW9)Y_W>
MPZ]Z .@KS_XP>,KWP;X-6?32%O[R<6T4A&?+R"2P]\#CZ^U>@5Q/Q1\$2>._
M"?V&VF6*^MY1<6S/]TL 05;T!!//KB@"_IG@K3[;2(8;PS7.H^4!-J#SO]H:
M3'S,LF=R\Y. 0!5.TU=?!VE>'_#EYYE_K=TK10PQ/EIMF2TC,QXXY.3U.!5[
M3M;UK^Q(1?\ AZ]&K+&$DB5HS&\@'4.&("D]^H]*PM=\.ZLWQ"\)>*VB^TK9
MPO;7\-N21$61L2(I/(W-@]\ <'L :4OQ%TJ/PO?:[]GN7CTVX-MJ%NH7S;5P
MVUL@G!P2.A.<_6F:?\2=+U#7]&TI;._A.L6OVFSGFB"HX"[BO7.< \XQQZ$&
MN,N/!6N1_#[QLJV$KZAXBU*2YM[-64M&ADW+O.=H.,DX/I^$_P#8>O'Q5\.;
MX:->>1I%CY%\[%?W3%-G][)QC/&>/RH Z7Q)XKL=2M?$FC65K<7;:;:.UY<Q
M8VVLFQF3&2"S KGY<X(]17#Z=J=HG[/FE7/B.]UIK:>Z;SKNQE_?(?-<KDD\
MKD!?Q%;%IX=\0^']1\?VD6D27]OKWFW-E/#(@ =P^4?<01C=[]/>L34_!OB:
M7X!Z;X971)_[6AN]S0B2-ODW,V[=NP!\P&.N<\=Z .N\3^.+W3_'GA;P_I]C
M=RQW0:YDV.FZX3RGVH-S#OR2Q'W1UJUHVHZ7+\5_$$:OJT>HQV<?VF&X=?LR
M( NUD /4@_S]:R/$&B:Z_P 0_!WB*RT>>\MK.R>&:+>B-%(58#=N/ RPR1G@
M'KQET?AS5;[XH^+KBXT^YM]-U;2_L,5YE2NX(JD]<XX."1VH Z*R^(VCWHL+
M@17,6FZA<FTL[^0*(Y91N&W&=RY*D D<TRZ^(]A9^(-3T.73-2:_T^W>Z=(X
ME97B !W!MV,$'/..F.N >-'@W7]1\#>%/"4NGM;3Z7J2S7EPSCRQ%&SX9&_B
M+;N .1WQ6BVD:N/BQXHUM=&NFL+G1FLX)/E_?2@)P 3D [2 2,<9[T >@>'-
M?L_%'A^TUJP$@M;I2R"1<,,,5((^H-:E<+\(M'U+0/AY9Z9JUI):WD,LNZ-R
M#P7+ @@D8P:[J@#C/^%E:/A[LQ3C1DO/L+:H=OE>=Z8SN*YXW8QG\ZY?QMJV
MHWWQ7\/^&VMM1&F7%M<^9#$\:^>3'(!(N6Q\GWANP01D#.*R(_ 7B!/A?<>
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=@DG)78S.NX*.<Y ()R.X]:DU?2X=:TR2PN&=8)63S-C%2RA@Q7(Y&<8X]:
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M<@@UJT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ML-$U:TT[P#JJZ?,T^AVIL[ZR( D"O$J,Z\X;:R X'4$XYKT?SXOW?[U/WO\
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MGG.[L172444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M68OAYC(^^'+ GY&(!!4C&:XZ?P]XAF\-C35T)8W@\1B^58+A-AB\\RG9NV\
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M4'*YV$ >_.#Q71UYKHVCZB?$&CZM9Z->Z'>RMYFN0B55LY@T1R0@9LOOVX(
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M:*$+S@Y +#OV_*MG1CJ6L01P7/A-=#N5C=+NX=8\?,C+^X*$D_,0<G&!ZYH
MRO&^MP:[X=TV>+2KTVLNK6BVMZVU4?\ ?J"<;]VQE#8)&#D>QKL[SQ''!K$N
ME6ME<WMW!;BYF6':!&C$A<EB 6.UL#VKA95\1R^ =.\/2^&;W[?IEQ9QM)$T
M9BE2":/YXV+=U3."!CGTJUJU]>VGQ!OKG3M(U9FETN&*Y>P2&8ARS%-X9U"N
M@S@@L"&Y& ,@'26OC>PO=$L=4@M;LQZA)Y5G&X17G.TL2,MA0 K9+$?=[Y&6
MIX[TS[-J+30W,-SI]Q#;3VK*IDWRE1'MPVTJQ88.<=>E<I/I_G:-X?G\.Z/<
M70\-W#0W.EZBBI.\;QX8X;Y=^&##H#G\*VKD/J.@WLDW@S;IMR887TYXD6ZD
M4OB1R$8@!005&0?E)R.* .GTW5SJ%Y=VDEC<VD]J(RZS;2"'!(VE20>AK2KE
M/!MC?:?<ZG#YU^^B@Q?8$U#/G1G!\Q03\Q0?+C=SP>W-=70 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445R
M?CC4=7LH](ATR- MUJ5O#))YYC?&[<5'RD8.W!/H3Q0!TRWELUV;1;B$W*KO
M,(<;PN<9QUQS4U>=O+<6'Q4NI;'2$GU&YT2%YH8Y BAO.8$M(1S@=\9..E;%
MGXU;4="T>^M-*F-SJ=TUJ+>1\"%TW[R[@'@>6W('/% '645YQXJ\<7Y^'GB>
M^TVV2"\TR:2PG<7&?+;"XDC8#YCB12,[<'Z5Z!:/<2VJ-=P)#,<[HTD\P#GC
MYL#.1@].]  E[:R.$CN868]%60$FIZX3PUIEA!\3_&#Q6-M&Z+9,C)$H*EHW
MW$<<$]_6NGU_6?[$TY+A;26[FEGCMXH8_P")W8*,G!VKSR3TH U**Y(^-)(I
M/$EM)I>^\T*".>2*"X#+,KJ6^5F"X(VMD$=J9:>.)9;K0%O-%FM+76E MYVF
M5B)/+\S:4 R 0" ?;D"@#7AT;3](U&[UI[NX26=1]HDGN3Y9"YVY!^4 9.,8
MZUH_;K3S((_M4&^X&85\P9D&,Y4=^ 3Q7!^.=:_MGP-XG%MI*WNG6D4T#3/(
M QE3(9D0J<A&[Y'(..F:NW4$'_"6^![CRT^T?9[A-^/F*>2#C/IG^= ';T5R
MMSXPG2WU2_M-(>YTS397CGG\\*S^7GS3&F/F"X(Y(R0<5'J/C@P:EIEIIND7
M&I)J=A+>6<T4BHLNU0P7YNF0PY;'4=: .M9E12SL%4#)). !4=O<P7<"SVTT
M<T+9VR1L&4X.#@CWKFY-=N-6AN+&#0DNWBMD.H03SA5BD= WD_=.YL$9Z 9'
MKPOPXP/ASH 52H^QIA3U'M0!T4=U;S7$L$4\3S0X,D:N"R9SC([9P?R-35YK
M:7EQHOQ!\</I.BF]D*64TD<4BQ*/W3DDD_Q'T YKHHO%[7]EH,^E:<UR=8@:
MX7S)?+2!%52V]L'G+ 8 YY]* .HHKDE\=0'P]!J+6RQW$NH'3?(>X78LXD9"
M#)C&WY20<<Y''-;>CZA>WZW@OM-:QEMKDPJOF^8LJ[58.K8'!W8^H- &E17,
MW?BJ[A\3W.@VV@W%S<1VBW44GG(J2*6V\DGY1D'KSQP#4-EX[MK[P[I^HQ6<
MOVR_N6LX;'<"WGJ6#J6'&U=C$MTP/7B@#K**Y@>*KG[7J.F2:9'%K%I;BZ2W
M>Y_=30DXWB0+G (((V\''K3O >I:GJ_@[3;_ %2)%FN+>.42"7>9 RALD;1M
MZ].?K0!TM%<G<^,+Q?%5]X?L_#]S=7-M;)<*_GHBR*Q(')X49'U]JJ1?$0RZ
M'IVMC0;U-,N9DAGFD=5:W9G\O.SJP#<$C'MF@#MZ*Y?6/%TNF2:WY.F&>'1[
M5;BXEDG$0?<"VU,@Y.T$\X&2!]+;^)!-)ID&G6C7-S?P"Z"._EK%#QEW;!QR
MP  !)/L": -B&ZM[AI5@GBE:)MD@1PQ1O0XZ&I:\S\(ZU:>'=%\7ZE>6:V:I
MX@D0VZN@ D9(5"ALA<;CU.!@YXKHM!\<66M>()M$'V8W26JW2O:W:7$3KD!@
M&7&&4D @CH0: .JHK*U75YK'4-.L;:R-U/>NX!,FQ(D1<LS'!]0  ,DFL";X
M@"#PQ_;)TF5_+U#[!<1QSJPC;SA%N#=6!)&,#/TH [2BN7B\57LFM7FC/H4D
M.H):&]M8Y+A-MQ&'V'+#(1@2O'/7K5:R\;W&H^%+76+;1R;BYO?L:637&'#;
MRAW';P0021C@ G- '8T5!=SR6UC-.ENT\D:%A#&P!<@= 6('YUR5C\0H[G0$
MUVYTFXM=*>Q%TMT\B[3(7""+U!R1\QP.IZ#- ':45Q6F_$2VO]:;1UM[>:_>
MV:XMTL;^.X67;U0MP%;H>>,=ZA7XD.-)TS6Y_#]Y#HEV(_.OFD7%N7.!E/O%
M0<#=TYXS0!W=%<I+XPN_[:O],MO#M]<264]O'(RR)CRY?^6G7& .V<^P'-9E
MU\5=(M'6X8VKZ:UP(/.2^C,WW]GF>3UV;AUSG'.,4 =]4%I9V]C;K;VL*Q1
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MW\L#W"')/ZYXRK*=M*^(_B=['17N+V?3[*9K>W*+EBTVXEVPHY([Y.,X.#@
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M-UEMY&=P4#;0-K;  <$^B]:VO!6BWFB0:C#*ES!827.^PM+FX$SV\>T97()
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M=#@@X]Q4U '&V&G:G:_$;7-5;2Y_L,]A!!!()8LR-&6R -^1G<,9QT.<5?\
M MG?:;X3M;'4;.6UN(6D!221'R"[,#E"1T(K>GNK>U56N)XH59@JF1PH))
M&>Y) _&C[3!]I^S>='Y^TOY6\;MHQDXZXY'YB@#D],T[5?#?B/Q!)#ISZA8:
MI-]NA>&5%>.78%:-PY'!V@AAGT-94?AC5='M_!]K;V$EY_9U[+>7LD$D:HID
M67<J!W4D!I...@]>*]&HH *XNZ\)3S>/9[Q=IT74((Y=0B< B6>$[8UQGH0P
M)X.?+ ]J[2B@#@=$\-^(-%\-Z];VTJ"_C62TT9I,86!-S0YY(SER.<<*N1Q5
M&TT'7%\1^%-67PZMN+&.>.^+W<;SR/)$H\QF!.X97KN+<] *],ILDD<,;22N
MJ(HR68X _&@#C/"]CJNF^&]:M;K1[F.:6\N[B"/S86,BRR,R@$/@$!N<D?4U
M6M=-\1VOPBL]*MK&6WU>T@@@>$7"*TB(R>9L=6(&Y P!)!!].M=W%+'/"DT,
MBR1.H9'0Y# \@@CJ*?0!P.FZ5JEAXTGU6'PY]GT^72$MUBBGB,@D5W;#<@%C
MN SN(XR6JI_8FO+X(\%Z<='N'N])N[22Z19H?E6$8.#OP<]OISBO2:* .7TZ
MWU2R\;ZQ,VF[K#41!*MUYR@1[(]C*5^\6R!C'&#U'0T/#^BO;^/-<\IU_LBV
ME6X@@"X$=W-&#+^2X/'_ #V:NNU"PM]4TVYT^[0O;7,30RJ&(RK#!&1R.#46
MD:/8Z%ID6G:= (;:(?*N223W))Y)]S0 [5UEDT>\CA@>>5X718T*@L2,8!8@
M=^Y%<9)H6NS_  NT:PM[1;;7-(2T:."Z=&CED@"@@E&(VM@XY!Z=*[^B@#F+
M"\U^XCDN+SP^+"-+8JUHDT4LLLQ(QM8,%" 9ZD$Y[8YY^VTOQ!;^$_"&G3:3
M=RPV*K;ZG9174:,X6/:ISOPT>>J[AD8R.U>A0W,%P91!/'*8G,<@1PVQAU4X
MZ'D<5+0!Y?#X=U^'PYXOTT:'%$UUJ'VZT6&Y3RY!^Y(1>!C'EG)( S@#-:NJ
MP^(8O$.G^)['P\ET)+9K.]T^2=!-'&)"T;(Q.W=R2RYQVR>M=W4;W$$<T4,D
MT:2RY$:,P#/@9.!WP.: .&U'2_$37^B^)$TV"2[L;F;?ID,J@BWE15/SDA6E
M7:#Z<D \ F_H4>K_ /";:S?W6B/:65]!;^7*]PC,"@<$,JDX/S#H2/?TZZB@
M#EO&EG?SOH%YI]C)>G3]42YEAB=5<IY<B$C<0."X[],U!I<>J6_C;6=4N]&N
M$@N[*VB1XI8W7?%YI8#Y@2#O 4D#..U=A10!Y7:^'?$EIHWAN]M]%5[_ $:>
MY6;3KB:/$\,Y))1]Q (!'7&>?QUO$5KKNM>%+V%/#QADN)K8062R1;PL<@D=
MI&W;0#@@ $]!_>P.^HH XWQ;IVK75[H.OZ7IJWDU@TJ3Z=.Z*TD,H4-@DE=X
MV@CG!Y%5/$&E:UKG@O4D32([.622VDM]/0Q^9MBF61MS [=QP<#.!@<Y)QWM
M% '&/!JMMXRA\2KH]Q);W>G"SN+=)(S-;E)&=&(W8;(<@@$X/K56$ZKX.T'Q
M#X@.DFZN+W46OFLA<(ABAPJY9^5W!4W'&>3C)KO:@NK*VOHEBNX(YXU<.$D7
M*[AT..^#S]: "1Y9;%WML"5XR8]XX#$<9_&O+;31=>:+PK>W/AN\?5;"_$NH
MW4]S"TKY213Y9W_ZO+#C*X 7 ;MZS10!YW#I>K0V'C^,Z3=EM4FE>S&^,^:'
MA6(?Q<<@GG&!BEL[37-%U71=8BT.YNH6TB/3+VU22(36[1L2KKN8!@2S _-T
MP:]#HH X_P !Z?J>FOXC&HZ?):B\UFXO(69T8-&^W'0DYX/:NPHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *Q?$'B*#0VL8#Y+7=]*T<"33>4ORJ69F;!P !Z'D@=ZVJY?QAHVJW<VEZS
MH)A.JZ7*[)#.Y6.>)UVR1DCIG"D''!6@"M%XUO;JPU=[+1X[N^TME,D$%WN2
M>,KN#1/L^8XXP0.01FKFD>+5UVYCETV"";2!:K-<:A]H(6)R"3&!M^9@,$\C
M&><' ,,\WB^32+JZ2QABOYPL,%G'<HRVPYW2EV4!FYX7&.%]ZH:3X?U+P_X@
MO=.L;&23PO?Q@R>9<J7AG(P[H"<E6R"P_O D=<$ O6?B^]O(])OHM#DDTG5)
MQ%#<12EY8T.=DLD>S"H0,YW'&X9YXJEJ/Q'BLK>[OH+*&YLK2Y:WD5+L?:7V
MOL9DBVG(!SU8$@$XZ9;X7T[QEH]A9>'+A+(V-@ZHFJB<EY;=#D)Y6#ABN%R6
MP!D\G&33--\8>'[B_P!(L8+"YTN>YFGM+V2?8UH)&9RK1A?GPQ)&,=>OH 79
MO&&H/XIO- T_0OM4\%HETLKW8C1E8D#.5)'3T/Z9K%U'QW?:EI'AN\TJT^R_
M;=<CT^ZAN)BDD3JS;XSA2,'9@GT/3GA\,][9?&+5!;V4E_\ \2>U60K(B./G
M?#88@$>O/T!I=0\)ZW_8>FSK%!=:G!X@&LSVZ2[5()<%$<@#(5AR1S@^HH ]
M!A,K0H9D1)2HWJC%E![@$@9'O@5Q7Q;N+RV^'FHFV2(HYACD9I"" T\:X VG
M(()!Y&/>NSMS.UM&;E(TG*CS%B8LH;N 2 2/? KE_B-I>IZ]X2GT?2[+SY[A
MXFWM*J(@25'YR<Y(4@8!]\4 227[VGB5;6VT:U?7;RUWRLMRRQ+;Q,0A9]F<
MYD( "GOS@56O/'C67AS5]0DT>5K[2)O)O+)9ERI(!5E8CYE(92#C.#TR,4^[
MTO5$\8V/BNSLB[-8M87UB\JB0('WHR'.TD-G@D<-ZUDZUX8UB^\/>)I(]/23
M4]>N8F%OYX"0)$J*A9L\G"9.,\L!T&: .STN_O;V:^2[TJ6Q2";9 [R*PN(R
MH.\ ?=.200?3KZ1^*-2NM'\+:KJ=G%%)/:6LLZK*Q5?E4MV!STZ=_4=:T;:2
M2:W22:!H)&'S1,P8J?J"0:I>(=.DUCPUJNEQ.L<EY9S6Z.W12Z%03[<T >?Z
MO=7<V@?#S4KRT%Q?'4;8J8I-\DNZUD)RS!<$MUYQQG-=.OC06D6OG6K#[%)H
MRQR2"*;S5E21<IM8A>205QTR.M8DFD^))M#\'0RZ(JRZ/=0S3QI=QLVR.%HS
M@G W$MD#.,=2#P)-4\,:GK^H>*H);%K2VU2W@2UNGEC?9+ 6*LRC)VEBI'4X
M'.#T -K3O%[7'B.#1KJUMUDN87EBEL[K[0@*XRCG8NUL'(Z@X/-=17-:%/XM
MNY+==<L+&P2#)F>WN?-^TG!  7:-B\[CDYR /6NEH X>:QMG^-%O.;:(N-#8
MERHSGSOY\FNKU?45TC2+O4&@FN%MXFD\J!-SO@=%'<UR]U:ZTOQ&77(-$>6S
MCT]K(L;F)7=O,W!@,_=^I!YZ4_6H/%^LZ?K"V &DR?8_*L5:969Y2V68E<[?
ME 5>>"Q- %RP\47-QXC?0[O3HH;S[!]N40W7F#&X+L;*J5;YE[$<]:R++XC7
M-YH.EZV?#LT6GWEXMI([7"EHRTK1A@N/F&X+G.WKQG',>EZ+J^F^)].U6T\+
MV5E:?V;+;36\5VOF1N71\D[<.S%2!SSG+$52L?#WB*T^&5AX=;27:]M[V.:1
MOM4>QD6Y$_WLYR1QT'/MU .LO-:DOKK5--T[2H=2^P*JW2S3"-6=EW"-<JP9
ML;<YP!N'-<58Q+'\-_AM(41Y%O;':VT$J&!SC/\ GBNCL;/Q%HWB34YK/38K
MG3=8E2[/G72QO9S>6J.K  AA\B\J3^/6L:VT'Q-;^"O".ER:/&;G2KJWGG$5
MVA&R+MDX^<Y/ R./O<T ==<:]>RZG?V.C:=%>R6"K]H:6Z\D;V7<(U^5LMM*
MGG ^8<]<9C?$"&73O#^H6.F7%Q;:Q>"S&6"O!)\^0R\\@QL#VX/-2QVFLZ%X
MGU>]M=/DU&PU;RYQ&DT:/;SJBQD$,0"A54.021@\'BL0>$]7T;1_"VG6EI_:
M#:;J;:E=RI*D:DL)=R(&.209>,XX'4$\ '0V/B;4;Z2"P.C)!JYB>:YM9KOY
M+=!(44EPA)WX++\O0&LOX6+MTWQ%F)83_P )#>YA7D1_./EXXX]JO7^G:UIW
MC3^WM(M([V"^M$MKRVEG$1C,9)1U."#]]@1^5+X%T?5M&CUU=4M[>+[9J]Q>
MP^5/YF5D;//RC'08[G/(% '5D @@C(/4&O-/"=_'X>\-^.M7CLUF^Q:WJ,S1
MH0A9$PQ ./05Z3*[1PNZQM(RJ2$4@%CZ#) R?<BO-[/0_$,/A'QEICZ.ZW.M
M7-[/;%;F(JGGC:H8[N"N<G&> <<X! -O_A-KM)M'6;P_<*FL(?LFV96?S F_
M:XQA01D@Y/ .0.E._P"$V>*P\2276EE+S0!ONK>*X#AHS'YBLK$#JO8@<@]:
MISZ?K4EUX.E71I/^)0Q:ZS<1=X7APOS<\D-SCC'?(&7K6FZI91_$S4;G3WCL
MM4TUS!*)4./*MF0[@#D;NHP#QUP>* -VV\<SF;07OM#FM+#6@B079G5PDKH&
M5&4#(#'(![XY IVG>-;K4;NY1="ECMK*_EL[VX>X7$ 1 V_&/F'.#CIQS6=I
M=EJ6OZ!X2MI=-:UM-/\ LMY)</,C";RXP4$84D\L026"X /7-6_#>BZ@UKXF
ML=6TZ6T@U>[N+A'$T;D1RJJ[3M)PXP>F1[T 3?\ ";R1:18:Y=Z1);Z/>RQQ
MI*TN9HUD.$DDCQA5.0>&) (XZXT+7Q'-)XON] N[!;<PVPNHI_/W":,MMR!M
M'3OSQD=<USBZ%X@O_!EKX.U&Q7;'Y4$^HB1/)DMXV!RBAMX<JJC!4 $GDXYU
M?&GAF\UNXTF\TR;R+NVF:&:0'!-K*-DP'N!AA[J* $7QP@M],,UM;PW&IM*U
MLLEX%C,,8R96<KP",8 !)W#ISBE<_$J.V\.WVJ#2999+*_2QFACF!5BS*%D1
M\?.AW<'&?85;\1Z'J]OJ6A:QX:AMY9-*CDMGL)I/+6:!P@(5L'##8I&>./P.
M?XKTWQ3XA\+M;/IL0N9[N"9+:.X0I;)$ZN=TAP69L'H"!Q]2 :J>+=0/B&71
M)/#TT=VUK]KM@;A"'3=M.\CA""1T+=1]*;!X\M3X=_M"[MOLUV+]M,-HTPQ]
MI5RNSS#@8XW;O3/?BFM#JS_$"VUD:+<"R&F&T<F>+>KNZ2?=WXPNTJ2#UZ9&
M">?B\+>))]'O1%:)8ZG#KSZW8FXF5HI-S-^Z<H20=K,#QCD8)YP ;C_$"**/
M7-UDDTFEV?VX&TNEEBN(@#NVO@89<'*D \CKFI;'QI<W5UH"7&AS6T&MQ,8)
M6F#;7$7F;6 ' (#8.<\=!5;4E\5Z_P"%-9AN]%CLY+FPELX;".[25GDD&WS&
MD( 55!X )/+9!X%0-IVMQQ>"L:'*[:,"UUB>+.1 \.U,OSDL&YQQCH>* $TG
MQAJ-O8^+]6UBVC^R:9?RQJD,[.4$<<8"@;!P3EBQQC<<C'-=/I6KW=]?RV\U
MC$D(MXYXKJWN/.BE#%A@-M'(VY[]17,VNG>)=%;Q/#9Z1;W27FH-?0227"A9
ME<QAHRIZ?*'R3@=,9S5KPEH-SI?B&^N;73)]&T66W15TZ2='3S]Q+2(B,RH"
MN!P1D]J .TKE],\6SZLZRVFG1R6?VY[)W6YS+$49E+/'L^4?+TW="*ZBO/5T
M'4;KQ#IVIIH+Z5JJ70:^U"WN(UAN8 6^5U5RSLR[>J\$]>* ,GPUK=SX:T_Q
MM<66AO=6EEKMW-+Y<JQ*D:JF0@YR0 3C 'O7>7'B%_MUK:V-F)O.M#>M//+Y
M4*1@@#+ -\QW#C'0$YXKD;'1]?A\+^-+)]#G$^M7=W/;*;B'Y5F0( Y#X!&,
MG&?;-3KI&OS7^A_;=#2]TZ'35MY+.ZN8PD%TC8\YE!8."H&",D>@.10!2\4:
MU;>*O!'A778K;RO.UNSV*^&:,B?:P##ME>HZC%=$(8D^+QE2-%D?0R78(,M^
M^ Y/T _+VKE1X:\3Q^!='T5M$0SV&KK=_N;N,JT:3M)_$1C(("C)]]M=:MMJ
M3_$9-4;29UL?[-%IYYFBX<N)#E0V<#[N?4'@CF@#JZY:Y\67J^*;SP_9Z!-<
M7,%LERLC7")&ZLQ7)/.T94^I/IWKJ:X^.#5H?B%J.KG1KE[*33DM8V6:'+/&
M\C\ OP&W@#..>H YH FM?&T5]H>BWMMI\[7>K2&*"S9@&5EW;RS<@*NTDGGM
MQDXIEYXPN(8?$5HE@D>K:1:_:A%)-F.6,J2KJP7./E((('(].:YW2?#'B"RT
M;P]=KIWDZEH=W<,]JTL9%U#,6+!&#$!L$?>QR",XYK<ET&_UV^UK5;NT-A)=
M:4VF6D$KJTB@[F9GV,5Y8K@ G@<]<4 :?@B^O]2\%Z/>:BBB>:R@DWB4N9<Q
MJ=[9 P22>.?J:G\76\=UX.UJ*6))5-C-A6 (R$..OO5;P1!JEEX2TW3]5L%L
MYK*UBM0OG+(7V(%+?+P 2.!G..N*U=8LWU'1+^RC*A[BVDA4MT!92.?;F@#C
M]%\82:=I?A>WOM%NK>PU".WLX+QG4_O3&-H9.JAB, _3@5/??$C3[.*ZNT2"
M>RMKG[._EW:^>V&V.Z18RRAL]P2 2!C&8[?2]8UC3- TB^TN;38M+EMY[BX>
M:*19F@P52/8Q;#, 26"X ]3Q'I5EXP\.S7>@V.GVEQI4DTLMCJ37(4VJR,7V
MR1D$N59CC'![D4 =Z"&4,I!!&01WK#UWQ%)HNI:39KID]T-1G-NDL;J C[&8
M CKT0\XP!DDUMQJ4C56=G( !9L9;W..*Y;Q3;ZE-X@\/7-EHT]['IUR]S++'
M-$GRM%)'L4,X);+JW88'7M0!''XY!>&UNK&&PU+[.9[FVOKU(A!\S*J[N=Q8
MJ2,#&,$XR 9--\<VVLZ7I-QI]G,]WJ;2+':2,$,7EG$C.W("J<=,YW+@<U5U
MFT\3:/XNEU[0M/BU:TO;6."ZL&N5@D1T+%9%9AC&&((S3-4L/%5OJ.D^(K6V
MM[^_@6>"ZT])Q&ODRLC 1NP )4QKRW7)Z<4 69_&\MM:^)I)=*Q-X?423H+C
M(E4QF3*-M_NXX(')JX_BO;J?ANT^PDQZY$[I)YO,)6+S"",<\<9!KEK33KWQ
M!>_$C3IEBMKJ^@@A"*^\1EK; !.!D\\XXJ>UT_Q3<77@NXGT&*V&D&2.Y1[Q
M&.# 8MX*Y&W)SCD_3N 6['Q#:Z9I'BS5;'PT\,FGWLK7D*31AYW6-7>0G.!P
M?4].F>*M3>/!9VANM1TB>Q@F:W2SDN9D19VE!/))^3;@EL\X[9XK)?2M;F\.
M^.+&30+G?JT\TEFIG@^?S(EC&?WG&"FXY['C)XK2UW2]=U;PUH][IUL++6]*
MN$NH[6ZE7;(55D>,NA(PRLV#[C.,G  ^Q^(NEW$NM13&(/I423,;6X6X29&S
MCRV&,MG"X(')'K6;JDMU<?$_P5+>Z6+28K>[7659,KY/W&( PPXX&1R<$U;U
M2P\2^,/"]_;7VG0:/(41K:UDN5G+S)(LBL[(,!<H!@$GDD]J@>#Q1K'BGPOJ
MUWX=2R73FN%N0UY&_P#K(@NY=N3MSGWXY X- '?UR$^MZV?B7%H\5K!]ACTY
MKALW)!<-*J[B-AY7:<+GG=U%=?7):C8:O;_$.TUBQTU+NUFT_P"PS/YZQF#]
MZ'W$'EA@G 4$Y_.@ N?&_E:3<:Y;Z8]QH=M(RR7*RXD*HVUY%C(^9 0>=P)
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MCL).,-@\94C/7N]=+U^Q\=:3K#V8OR^AC3[N99518Y1(KLYSR0?FQ@'G'3J
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8*V&SD 8Z@U%8>.QJ6A6EQ;62-J5W>R:?%;"?,;31[BS>8!_JPJ,V[&<=LT
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M;.Y1&50/F7=MR<@\G ..9]9\>II\VI?9(K&XBTQMERDEZ(YI&"ABL2;3N(#
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"-QX!/& !UK%E\)^+?[)U"S\G2KBY;44O!?S3OYMVB7"RI&<+^[VA<9RP &
M.<C=MM&UZP\<7NM10V,T&I6ENMUF9@8GBWY5!M^8-N&"2,<Y'8@%/1O&,4/A
M"6_BT2WM;A]5DL(+"VD55EG,I4?-@#DY)./4ULCQ%>VOB.+0[^R@%S=6CW%G
M+#*?+E=/OQG(RI&0<\@@^HQ7-6O@76V\(W%A++:VNI1:NVK64L<K21[S(7"/
M\H(ZX.,]<CTKHVT[4]2\06&L7UI# NF03>1;I,':29P%)W8 "A00.YW<XQR
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M0R13HPRKHV!GH01C@C%;] !1110 4444 %%%% !1110 4444 %%%% !1110
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MCG&>^,4 5O"&BZCH=OJ<6HR6DC76H3WB-;;AQ(Y;!#=#T[GZFI-=TV_U&Y:
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MPAXE?Q"-5CD-O(VGWGV<3VV1'.NQ6#@$G'WNF3TZUTM !1110 4444 %%%%
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M8Q%H1"5,?EIL')8@Y'7@5A3> -77PM?>&K7Q!"NERR%K8369>6W0N&V;MX#
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MVGA@#U% &!!X;UFVN_$UPEQ8,=:(900X\HA!$,XZ@HN[M@\<CFF+X6UI%\+
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MNK;2+R>RA$]Y' [PQ=I) I*K^)P*XG3/$-]KEC?-9^(8?W>F%I4>U$=U9W(
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M:2V:'YW90H1@PZ8 /'^1M4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4P11K*TJQH)&P&8#DXZ9-/HH **** "BBB@ HHHH ****
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MX.Q7]>F>U '245QNL>(_/\96WARUUJ'3P;.6XEG7RV8R;UC2,;L@'+%B,9.
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@_AQ(;.\ED A2?*F5-W0.55.O]TCVK/&HZ8?AO\ $A8;RW^:]U# #@9+K\N
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MCCL;V^^SW$8BR[8CD?[Q.,':., \=>:U-9LM5U QV]CJ?]FV^"99X8U>8GC
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ML0+N;U..IJ6B@"(VT#7*W#0QF=5VK*4&X#T!ZXI9[>&ZB,5Q#'+&>J2*&!_
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MCIA<8%7:* (;6TMK&V2VM+>*W@082*) BJ/8#@5-110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5F:UJEEI
ML5JFHJGV6\F^S.\F/+3*.V7SQM.W;SW85IT4 >2?#J:+1KI%L+S'A_\ LDW>
MH*TWF06EQOZJ_12R[F* \8_/8L_&?A_5M4AUFYU))"CF#3-/C1C)ERJ[V4C[
M[9P.@521U+8[RTL[>PM8[6UB6*",81%Z =:GH XCQUJ%E9^(/!RW-[;PLNK;
MRLD@4[?(E7=SVR0,^I%;^LZQH%L8M.UF_LX1>1LR)<R!%D52,\GCN._\JV**
M . \)/I_@WPUK]W)-/#X<M]0DELFD5FVP%4SL&"2GF;PO7(P>^:34+C3G\>^
M'_%4\L4VB7FF26L%S(N8XIF=)$8D_=+*&7/'(QWQ7=74,D]M)%%<26[L,"6,
M*67W&X$9^HI+*RM].LH;.U39!"H1%R3@?4\GZT >9Q-J&DZ?\0=8\/1^99SW
M"26#0CS%+;%%Q(B\@X8L>A!*XYI_A2QLM \=6MIX2NS=Z'J5F]Q?HK^:D$JX
M"2;OX2_(*_[)XXX]0HH \V\42Z)XJ;2M0\,7UK=>(8;V'[-+:S?.D8?][O .
M0FS?G=C/ ZD"NNU+4;2_NM0\,0SLFJ2:<TP&QL*C90-NZ?>[9S6W28&[=@9Q
MC- 'CAM["X^%FA:):0QP^);2YM(EM5 6>*YCD42.0.0-H=MQXP<YKJ/$OBO0
MM1U:;PI<:Q:6UNH U)GG",R,#^Y3W.,,>, XZGCO** ,&W\5Z*;71WBE9(=4
ME:"QQ$<2;=V,8& I"Y&<<$5O4A .,CITI: "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH ***RO$HO?^$<OSI]Q#!.('(>:(R  *<\!E
MY]#G\#0!'8>+-"U35/[.L=3AGNMC2*J9(=5;:Q5L;6P>#@G'-;->6? O3PWP
M]TV_N(K.1T,T=M(+;$T2F5]X,A)R"<' "^^:]3H *S]8UO3M LOMFJ7/V:VW
M;3*R,54_[1 .T=LG S@=36A7$_%T _"G7]REAY"\#_?6@#7@\;^&KAK54UBW
M7[7_ ,>[2919?3:S  Y]C6_7SYXPN)+WX,>#+&_M)+#2F%KYVJ/B01;8B!B-
M3N.[G_)KT#Q-XQU?PYXE\(Z7I<5IJ-CK(,0,NX2?+M^?>#C!#@_=/0\4 >AU
M4U/4[/1]/EO[^806L0!DE()"C.,G Z>]<+=>+O$ND3:!H6JP:>->UB_DB$D
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MGP"3@8YSTJK+XTUJR\/K>:GIPLV75!:2W3VLJQK;')%QY9.Y1P 0Q^4\GCJ
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MR19V;(R3@?,V><G<>>F+*:)XAGTR[_M+5[2YU"6V>VB\JW:*",-C<Q7<2S'
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MI6+'<<$\  9Y["K7BW0I_$.A_8[6Z6WN(YXKB(R+OC9HW#!9%_B4XY&?3TH
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M6UN>>8RB%\1>;PPQNYQVK1N/#NLW&M>'-0-W8+_9,<BR((G_ 'I=-AP<_+P
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M&^/Q@UA3>0%O[,M6)-N2?+\Z0E!\_!QQNYZ@X]>LUK5+;PYH,U](BK# JHB
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?D1R(VY2) 6P-I4G[W(]* .^HKB=&U[4I_%\VB"^^V6[Z6+R&\GLC&!)OV$
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MMI5C+>WC.MO$-SLD32;1W)"@G'OVINEZI::Q81WUB\CVTH#1N\+Q[U(R& 8
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MDG>3*>4R]58-@J1QP>>14.E>*-%UN\FL["^62ZA7>\#HT;A<XW;6 )&>XXK
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M-($O^FQVZW+1[3_JV9E!STZJ:N5S,/B"9O%<L,GV9=)&E+?I/M(DP6Q\Y)P
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MY9HO/2YA'(#KD8(8Y&#QTZ5K1Z#JMJ;>2WULS3 2FZ-W"72X9]N#M5E"A=N
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MDG&3@#H *M7'AR[N?[&OI;])-9TR1Y!.8]L<HD!$D94'(4@C')(VKUYST=%
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M1!M# CHN/X0/J35K4-,U2;55O+#58[>(P&&6VGMVFC<Y)# !UVD9(/J.O08
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M*_<23H@SGA>WOSBHM"\(:CIJVUMJ7B.?5-/LQMMK>2W6,C *KYC@YDPI[XY
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MH *8T,3OO:-&;:4W%03M/4?2GT4    P!@4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M WX&3CUXYX[5SWB?X@Z+X=TS3;O[;;3_ -I3QQ6K)("C*6 :3<#C:H))/T%
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MMVMKJUN%*Q[XV?DC*[6SSC)Z=JZ>XUC3+.62&YU&UBEAB,TBRS*I1 0-S9/
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M3>I +9F.?4GG!->CRP0S[/.B238X=-Z@[6'0C/0CUIMW9VM_;/;7EM#<0/\
M>BF0.K?4'@T >3>(=,T#_A%]2DTN=]0BEUNSFEN3L:+SWGC$GE,H !V[=VWC
MG&<Y WKJ#3]%^)4S06ZP6_\ PC4SRP6RA-X28$848!;!;%=G-HFDW-M#;3Z9
M92P0<Q1/;HRQ_P"Z",#\*1=$TE+I;I=+LA<J %F%NF\ #: #C/ )'T- 'FEA
M>V2ZOX QJ&GI9""5([6)U;RHC;' DDS\S9 '103V.,U#+H^F?\(!\0Y?[/MQ
M);7M_P"0WEC,6U59=G]W! /&.17I\'A_1;6***WTBPBCBE\Z-8[9%"28QO
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M% &Z?%6B?V.-774(Y-.+^6+F)6="V<=5![\9Z9XZU7TVZMG\4ZXR^(/M6R.
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MHPN;= FL69<[U7:1OWD_3//U&: /5KCQ1HMKJ!L9M0C2Y$J0%<$@2/C:A(&
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M:55.1(Q.%&00<!<YZ<XJGX-\56TWA[2H]9UB%M5O))E19F5))<32 ?+QCA<
M8'3 J*WU*STOXIZZE_=Q0-=V%E]G60[=X4S[L>N.I/8'FN4BO]$B^#]I+)=V
M(VZQ$[NDBYR-0#$@@YSLR<CG'/2@#T_4O$.D:.X74-0@MVX)#M]T$D!F_NKD
M'DX''6M)65U#*05(R"#P17ETFI:1:^*O$VF^*=3ELHM199K61IO+@NK9HE38
MIQ@D$$$9YW<=Z] \/PPV_A[3X;>"XMX(X$2**X)\Q$ PH;/.<8Z\^O- &)IF
MJW_BS5-6^PWSV&DZ?<FSCE@C1I;B90#(<NK*$!(48&20>12V7B"YTWQE+X:U
MBYCF62T^V6-V5"NZ*2)%EP H*GD$  CWK,\$^3X3U#7/#FH,+;-_+>V4TIVI
M<0R8/RL>"RG(8=N*EB,.N_$M-=MY%.EZ/826S7?2.6:1@2JMT8*HY(X!./7
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M"/85[.DL4T(ECD1XF&0ZL"I'UH YW3-9L;#3M6O[_P 46M]91WLI$[;$6V7
M80Y!^8J#UZG..U:UMK>E7FH2Z?;:E9S7L()DMXYE:1 #@Y4'(P:\HU:ZT]_A
M=\1$CGM67^U+K:JR*1DE,8]\@_E74WDND6_Q%\'BUGM(P;&\C01NN&&(MH_]
M"QZX- '7ZOJEMHVE7%_=2QQI%&S#>P7<0"0HSU)QTKD?"VNO>6F@ZK>>*[5V
MU"V3[182&(9GE 9%C PP(Y&#DD#)Y!KI?%4R0>$M8=Y%C'V*8!F;'.PX_&N
M:XMO^%5^ ;XSQ_9K"YTR2YE!W+$ H4EB/NX+#.>E 'H_]HV=]-=:?::E +^)
M3OCC=6EA[!BASCGU&#7 ZEX@UNV^",&NQZE(FJ#RFDG"(=^Z<(PP1@##=O05
M>LM9TZY^+]Y-#>0O"^@1".7=\DFV:4L5;HP /)&0.1V-<SK%]:R?LY(RW4#9
M^SK\KC&[[2A(Z]< G'H* /9:\_;Q*_B+Q1KNCZ9XEM[!K..W2Q:-HG$TSJSD
MX.2X'RKM&.]=\CK(BNC!D8 JRG((]17FFG77VOQC\2XM+NH'OIK>V%KME'S2
M"U(&,'/#8Z=* .\M]9TY[A+$ZI927W*-&DJ[F=?O +G.1W'4=Z27Q!H\$[02
M:I:+,LL<#1^<NX2.2$0C/WB0>/:O.9;NRU#X2>'K.P*1ZQ'-91VUNQ_?0W*2
MJ)#C[P(Q(22.F<UM:+#I=W\4O%\<T5E+,BV!165&;<JLV<>H8*<]1@>U '8'
M6=+%Y]C.I68NM_E^29UW[NN-N<Y]J+K6=+L9U@N]2L[>9BH$<LZHQ+'"\$YY
M/3UKS3PUJ_AV7PA%H&OIYNO6=^7FT]B5N)KH2[UD49!()(.[IC.> :07&CR7
MGBS0O%6NW%G/<7\SO:NT:BZMW $7E[DW$A J_*<@KQ0!ZU5%=:TIKW[$NIV1
MNMYC\@7"[]X&2NW.<XYQ3]-^72+3,<R8@3Y)CF1?E'#8_B]?>O(SK6FRZ+H-
MU;WMM9VD7B&.3^S]P,EL&N'WO.[DLI)+'^$#./FH ]5N?$6B68E-UK.GP")Q
M'(9;I%V.>BG)X/M5JXO[.SMA<W-W!! V )99 JG/3D\<UYWI=OILWBKXCO<+
M9ER(EWDJ"(_LXSSV&3R?I[54T;6(+&^\ W&HW4<>DOH A@G=AY27FV/(9N@8
MH& R?44 ==X1U>XU34/$*2:C'?6]K?+%;2QA=OEF&-\ KP>6/-=#>7UGI\0E
MO;J"VC+!0\T@0$GMD]ZX_P #7NGS>)/&$=G<V[E]2695C<$LI@B!< =1NSST
MS4/C*_BTOQOX>NM2OKC3],:WN(4O(]FR*=FC(WEE( *J0#QW]30!L>*/&-AH
MO@R]URSOK"X*0.UKFX4I-(!PH(/S<]AS7/:IXFN]&L(;V+QAIU]!?-!:IYGD
MDPRM*BR2(4VAE5')VMG! ).,YSM?@T:U^%OC672+Z>ZM[HO+)=2R*8YIF W>
M65 !Z ''&<CJ#70_$*\M1X>T:87, A;6;!E?<-I43J20?0 9SZ"@#3L-3BTM
M)IM5\56%U87#!K&>>2*-L 8<%EVJWS=,#CO6U/J5A:V:WEQ>VT-JX!6>2550
MYY&&)QS7 :EJ5EI_Q1U&+6]6;3(+W3818SN8Q%(BE_,3=(I ;+ X'48STJI;
MSZ+X6U+P<S/,GAR*&]M[.[O6^6.9F78Y;@!602!">S>] ':ZSXPT;1],MKY[
MZUECNIXX8"DZXDW.%+!LXPN<D]!BMR&:*XA2:"5)8G&Y71@RL/4$=:\ZU4Z+
M!H8FT9 E@?$UG<3W1DW122-<1&1T8DC:#@$CC(;T-=Q#KNE7-_#8P:A;RW,\
M!N8HT<$O$#C>,=1GB@!=334I!:IITT4.9_\ 2)'3>5CVL?E&1R6VCVR3S7,Z
M=J6O:EXG\4:,FHPQC2O(%O(;8$NTL6_Y^<$ \<8X[UVM<+X4EC?XG^/0DB,?
M,L> P/2#!_(\4 2:3XAU./QA?Z?KM[:0P6VEVMPZ@!%BF<L'&X]1D<<UUS7]
MFED+UKN!;5E#"<R (0>AW=,&N+M8;2Y^,NM&X2&5H=(M]H<9V N^>O XQ^=<
MG:7L%AH7@NXN+QK70[;4;Z.:>(*8X'WR+ 7R&4 9(!/0D&@#V&TO;6_@$]G<
MPW,).!)#('7/U%3UR_A2VT:'4=9N-'O9KW[5*DUS.'1X6E((.TH -V "V/5:
MZB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ I" P((!!X(-8]]XL\/Z;=7%M>:O:0SVT8DFC
M:0;HU) &1V)W# ZG-(?%_AT:=:7_ /;%F;6\D$5M() ?-<D#:HZDY//IWH V
M0   !@#H!2UCV_BK1+NQ2]MM0CF@>X:V1HE9B\JYRJ@#+'@G@'@9Z4Y_$VC1
MZ1-JK7\8L8',<TVUL1,#@AQC*X/KB@#5(!&" 1[TM9S:[IJQ:?*UQA-08):L
M8VQ*Q&0!QW )Y[ GH*R=#U/388M?OSXE.H6D=X[RR2L/+LQM7]TK=,#V]?6@
M#IL $D 9/6EK!N_$6D7&G:G'_:HL6MX,S33(T+6X?*J_S@=P<>XJ6UU:PT[P
MYI=Q<:DUQ%-#$D-PR,9+IBF00@!8LP!. ,]: -D    8 HK*/B71ETVZU!]0
MACM;0[;EY24,+>CJ<%3R.",\CUJ.R\6:%J-_#8VFI12W,\?F1( 1O&T,<$C&
M0&!(ZC/(H V:HV.G"SGNKAYY)[BY<%Y' &%'W4 '0 $_B2>]5U\2Z2]ZMHMT
MS2/.;966%RC2C.4#XVEA@Y&>,'/2M:@#G=3T74+WQ=I&L0R6JPZ<DR>6X8O(
M)0@;D<+C9D=<^W6NBK.OM>TW3KD6US<'[1Y1F,4<;2.L8."Y502%SW/%8/C3
MQA%I/P]OM=TFX2=GMBUG-$OF(6. &R 1P3GGTQ0!U]%8>A6#P7$UU%JNH7-I
M+&B"WO%;*2+]YU9P&PV1QTR./2F>+_$T7A309=0>&25]R1Q*L;%2[,%&X@84
M9/?KT'- &]M&XM@;B,$TM<7>ZTMAX\L+BYUB>+2;G3;AEM9D\M1,DL*#"[0[
M,=YP#GVZU8UWQ#HFH^#)KR#Q.--M;@^7'J$#8=74Y*J#R6^4C;C/6@#K**R[
MO7=/TQHH+JXD:9HO,VI \C[!P78(IVKGN<"KUI=07UG!=VT@DMYXUEB<=&5A
MD'\0: )J**XCP]XLN=2\<WUG,I&EWEL)](E.<2K$QCE[=2Q##_9P>] ';U0M
MM,\G4[G4)KB2>>91&@8 +%&"2%4#W/)/)X]!4&H^*-#TB^6RU#5+:VN6B:81
MR/@A!U8^@^O7M5,^._# L#>G6(! LCQ,2&!1EQN#+C(QD9)&!D>M '14@ !)
M '/7WJE=ZS8644#RS[OM',*PHTK2C&<JJ EACG@54;Q7H*Z=::@VJ6XM;N80
M02$_?D+;=@'7.>".V#G&#0!LT5E:5XFT;7+BXM],U"&YEMP&D5,\ YPPSU!P
M>1D5R_BKQ+')>^&_[)UB=%GUB&WD2--L5S&6^;#E?FP0!\C8P3G- '>TA .,
M@''2L.Z\9^'+-KQ9M6MPUDP6Y"Y<Q$YX. >?E.?3OBI5\5:$^H6UBFIP-<7.
M/)4'(<E=P ;IDJ00,YP: ,NQ\/\ B/26N8++7;-[2:XDG5KJR9YDWL6(+"0!
ML9P"1T%;^DZ;%H^E6]A"Q9(5QN( +'J3@  9))P!BJ]]XET?39Y8;N]2-H0I
MF.UBL.[IO8#"9_VB*2Y\3Z)9WTUE/J5NMU"BR21!LLH8@+D#N2PP.ISQ0!K4
M5S&K>-M-L=#T[5+)_ML.H7,4%N\2.R-ND"DDJIQ@$\$9R,8S720RI/"DL>=C
M@,NY2IQ]#R* 'T54OM3M--\D74I5IF*1(B,[N0"2 J@D\ GI5*+Q3HLPLF2^
M7;>RM#;,48"21692@)'W@5;CKQ0!L45E2>)=%@.HB?48(?[-*"\,S;!#O^[N
M)QU[>M5[/QGX;U#4+:PM=8M9+NYC$L,(;#.I7<.#WV\XZT ;M-\M <[%SG=G
M'?&,_E69<^)='L[EX+B]6-HY5A=V5O+21L;4+XVACD<$YY%0W/B_P]9W-Q;W
M&K6R2VTL<,REO]6\A(12>Q.#Q[4 ;0      Z 4,JNI5E# ]B,UE_P#"2Z0;
MR.U%X#+).ULF$8JTJYW(&QM+#!R,\8-$WB71K:Z-O-J$2.)A;EFR$64C(C+X
MVAC_ '2<T :A )!(''3VH  Z #O6%XBURQL[.]LSJ;6MZMJTNZ%=S0+SAVRK
M*@R,9;CK6?X-UX'X>^'[_5[QGN;R!!O8%WFD()P  2QX)P!VH ZW:I8-M&X
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M%0_9;?#CR(L.V]OD'S-ZGU/O5%?$>C/'>NFIVS+92B"Y*R ^7(< (?\ :)(
M'<\=:%\1Z.VGSWW]H0+;6[;9W<[?).?XP>5ZCKCCGI0!;.GV1WYL[?Y_O?NE
M^;G//'//-.%E:"W-N+6$0$Y,?EC:3].E4V\1:.FG0:B=2M_L4[B.*</E'8]
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M6Z06UGXL%U(V[(C@-WD/[*>2#]:]AM;J*]M(KJ!BT,JAT8J5RIZ'!YJ7 QC
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MT&#D]!7;8&<X&?6@JI;<5!.,9QVH \,N+[3F^!4Z+=6Q_P")R05WKU^VAO\
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M;HVHW^J6<=Y;V\EM;0Q1RH)I9=NXYD1<<)PG)YZ\5BO/&_AWXJA&W&XEF\D
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *  !@444 %9GB#1QKVBSZ<;J:
MU,A5EFAP65E8,.""&&0,@C!&16G10!@QZ)JEQ-;G5]92Z@@=95B@M!"'=3E2
MY+,>" <+MZ<YZ5O444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !15'5-8L-&AAEU"Y6%9YTMX@<DO(YPJ@#DG/Z9/05>H
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M3[LB#>"C $CDL,8R#B@#/^$.[_A6>G;\;O.NLXZ9^TR4OCO_ )&+P1_V&?\
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M([B)0F\;,*@)!)SD8/>JC>)?%YB\-I+I]C8WM_=RVES;7 ;.5CD82H0Q^3"
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M",0P8;@.PQS70VNB:C;^,[[6S=VC6UW!%;M (6#JL9<J=V[!.9#GCH!6#<^
M=6GT.\TE=<M5@?4?[0@;[#\^[SO-VRG?\XSQD;3P.<<4 77U?Q)>>,M8T*RF
MTR"*UM89XKB6!Y"-Y;Y2@<9^[UR,>ASQS6J^(-7\0^'/ >IQS0637^KPQSQ+
M$77S%\SG.X97*9Q].>*[&TT#5+7Q5J6M&]M)/MEI';B/R&&UH\X8G=T)8Y'T
MYK%A^'^I0^$M!TE=6M?M>BWZWL%P;9BDF-_#+O!_Y:'H>PH [U!((55W5I H
M#,%P"?7&>/IFO*K6;5;GPU\3Y+Z_CG2*6]AVB#:<K;( 0=QP !C&#ZYKU6%9
M$A199/,D"@,^W;N/<X[5QK>"M0CM_%=I;:I;K::\\TH62V)>)Y8U1LL&P0 ,
M@8!SU- %71=9UFPA\%QS?8VTS5;=+<1)&WFPL+<R*QDW8;(0@C8,9[U%JGC7
M6-*D$MR+-6&K1V;V"PF1U@>3:CM*KE58J0P!'?&*U7\*ZIY'A6-+ZR!T)@S9
M@;$V(FBP/F^7Y6)[\UE7'P\U>30YM)CUNT\A=2&HV[O9'S&?SO,Q,V_YQSC(
M / YP,4 7-$_M.?XH^)3/?Q216MO9HL?D$;8V$K;1\_!SR20<^V*[BN7CT+4
M[#Q/>:U'J=HL%W:PI>*]L=Q>)7 93NPH._)!R>,>]6_",^JW&@(^L3K<W'F.
M%N!;^1YR!OE?9_#D?I@]Z (=?U;4++5K.UAFM;*TFB<_:IXS*SS9 6)(PP))
M&YN,\+6#'X^NW\$:)KMVD&GI>3O#>730O+':[3(H8KD$!F11R?EW<YK>U'0-
M1E\86VNV%]:1A+0VDD5S;&7:I?<6C(9<,>A[<#KBL[P]X6U_0=%L;$:K9S+:
MS7!:-H&"3Q2,6 ?GAP3G(&!DC!ZT ;^@7=Y>V$D]W+:3AIF^SSVG^KEB_A8?
M,W7ZU5U#6+I_$]OX?T]H8IVM'O)IYHRX1 P10%!&26)YSP%Z<\/\+>'D\.:?
M<VR&-1<74ESY,*[8H=V/D0=E&,_4DX&<5%JV@W4OB.R\0:7<11WMO ]M-#,#
MY=Q"Q#!21RI# $'!ZD8YH QY?$6I:AH_BS396MK;5-&5UED6%F26)HB\;JI8
M;21V+'&WWXU?!5K(/"&@RW)MY633H!"R0;&C!C7(R6/7CICI5<>%;Q=/\0.+
MJW.JZ[Q<3%#LA7R_+55 Y8*/4C))Z9K8\/6%WI6AVFG7;P2&TAC@26($>8JH
M!N(/W3D'C)^M &%K\FI?\+$\,VUO>1QV\D%Y+Y;0%@&14&6PPSQ(<=,>^:Y^
MSNM8LO$'Q%N])^QA[:XBG/VE&?S-ML#L 4KC./O9.,]#77Z_H6H7_B#1-6TZ
M[@AEL/.CD6="P:.4*&(P1\PV# /'/M68GA/5HI/%CQW=F6U[[I*N/LYV"/\
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M\HS' H=@/0'<0,#@XP* /2**Y%+W5K;QQ;:3_:OVJP;3VNY6>W0N&5U7!9<
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MWJ .QHKG/!^K:EJ=KJD&K&W:[T[4)+(RP(4655565]I)VDAQQDUT= !1110
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MEJV[<"5QSM&.0.>U=110!P\G@*]/AWP]I$>MQ!=#N([B&5[(L9&B&(PP$@X
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M/+".KR,68J1QP3D<<8[T 43=^)=!O;B_N1=W>APV,T]S]L: 2I(BEAY?E]B
M1@]..:GTJ+Q)>)H.KKK22VU[!YFH6Y1!&@>/<A@(7.0V!\Q.0<^U6M+\'&UB
M@AU36+W6(+:%H8(KM4 564HV[:!O.TXRV>I]:AT3P,-&%K:C6]0N=+LI3+:V
M,VPK&>=H+!=S*N> 3@$#TH J?#BSFACUZ674KNZ/]LW<9$Y0YVN%#$A0=V%
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M+=%:W6 R1KMF<KD2$,QP&R,CC%;\G@EY--\.V?\ :A T*5);=_LX_>%%*('
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M7.I6MP;V'R1*(Y8D'*D-R"6R!GCC.>E-C\3ZO8Z-JUO<7$=UJ,6N+I-I<M$
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MD4ZJ<J2H*G<,D YZ'&#6[10!RLW@L?V3;V%GJ+VY2]&H3W!B#R3W <2;SG@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*.5A#*=V,\$GOCI5]?!D"V&MV7]K:B8M9=Y+G/DY!=0C;?W?&5 '?IZ\T?\
M"&PBZT*Y&JZ@9=%1H[;/E896 5MX"<_* N1C'7K0!DV<NN>)=&O-7T_6EM;Q
M+^2.VA/^HBBBEV,D@P2S,JL2>Q88QBD2UN=1^(7B6*VU.6RC-C9MYMLJ%V)$
MP'+ @#OP,].1WT'^'VF&_P!0GCO=2AM-2E,U[I\<X%O.Y^\2"NX;N^UAGZ5?
MM_#*VVMZCJR:I?"XOHDB=0(MB*A;9M&SMN(Y)SGGM0!!X UJZ\1>!-'U:^*F
MZN(,RLHP&8$J3CMG&?QJGK%]=Z/XXTW[3J4ZZ+JD,T'EG8$AN54,K;L9 *!^
M,XROO6SX9\/P>%M"M]'M+B>:UM\B$S[2RJ3G&5 SR3VI?$/AZQ\3:?%9:@F^
M&.XBN /4HP;'T(R#[&@#A- \1ZEJ5C?Z/)J-X-2EU"#[%<2[%D-G*/-1P N-
MPB23((/*G/<5O65U?W/B_P 6Z5-J-RUK;6=H]N 55H2XE+;6 !YVCDY/O6\_
MA^QD\4P^(6B4WT5HUHK$=$+!OS'(_P"!'UJ*S\-Q6>OZCK'VVZEFU!$CFB?9
MY>U-P0 !01@.>_- 'F,T4O\ PH_PHZW,C32W=@P:;YPK&4=N,C)]?QKNM-FU
M&P^(ESH]QJUQ?6DVF"\1+A$!C<2E#M**ORX(X/I3%^'=F- MM%?5M3-G:SQS
M6ZAH\QB-BR*,H00">O4X&3Q6HOAO'B=-?;4KMKI;86AC*QB,QY#$8"YR6&<Y
M[XZ4 9OQ2#_\*SU]DEEC*VCG]VVW<,8P?;GIWK#UVTG'BKX=007LJ2,;O$[A
M79!]EYQD8SC.,@X]#TKO=:TFVUW1+W2KO=]GNX6A<KU (QD>XZUB)X*0W>BW
MEQK.HS76DAS#(3'AF=-C$C80 5X &,=>O- '/WWB#7-"T_Q-;'4?MD]KJ-K;
MVEQ.L:M&EQY8YP IV[R02,>O KH=*MO$5KXE9KFX#:++;D"&XN!),MQNSE2$
M'RE<Y&>#TI;CP39WW]L1ZA=W-Y;:N!]J@E" !E"A"A505*A1ZYX-6=#\,+HS
M1O-JNI:G+$C1PO?2JYB0D<#"C)X W')X[ XH 3QMJ5WI'A"_OK%S%-$$_>A-
MYB0NJO)CG.U2S<^E9>FW-U/XY:SL-;N+O2%T\7,A5XY569G(4;]I."N6 S_"
M.QJS\1(Y[CPC+:PV][*EQ/#'.]FF^2&+S SN$&2X &-H!SGH1FL_2FU)]9LU
MTO7=9OK-G8W@U&P6)43:1PYB0[]V, 9[Y H @TZ3Q)K'@G7Q8ZS.-9MM1NXK
M2X9(^?+8A$(V[<'&.G?-:&B:W)XEET*:RN[A8/[/%U>,-OS,WR+&WRXW;ED)
MQC[GH:V/#WAY/#T-U%'?75T+JX>Y<W&S(D<Y<C:HX)[=J30O#-GX=AU*/3R8
MS?W<MVY"CY'?L!Z#' H X4:_KS?#/7]1&L3"_LM4G@CG:./E%F$8# +@#!_A
MP?>NGAGU/3O']EIT^JS7EO?:?/.\<B(JQR1O& 4VJ"!AR,$GMWYI@^'UK_PC
MM_H9U;43:7URUS.P\H/O9M[;3LX!;!Z<8J]=>'ICK-MKIU*[FN[*U,,<"K&$
ME!*F0$;>K[%Y!&* .177M4N]#L;Z+6YX=;N-6%I-IX$;>6GGE'C$97@I'\VX
M\\9)QQ7IT2&.)$:1I&50"[8RQ]3@ 9^@KR71([ZTT%6M-9\36FK;'D?36TH.
MJS,Q9D#/%\PW,1O+X/)S7JUG]H^Q0?:]OVGRU\W9TWXYQ[9S0!PT>JZKK?A;
M7]>M-3EM+BTFNDM(4"&-1 S !P5.=VWYN<X;C%5;^YE\1:A\.M6%S<VPOW:?
MRH]N(BUG(W!(Z]1SGC-=&_@V%6U"*SU&[M+'4I'EO+2,(5=G&'*$C*;N^/PV
MGFI=1\*1WM]I=S!?W%DNE _8X8(X]B,4*9.Y22-I(QD?RP ;L<1CMTB\V1BJ
M!?,;!8\8R>,9_"O*[C6/$MKX$\2ZXWB&=[C2M0N8X ((0LB1RJH#C:>P(^7'
M7N:]6VGR]N]LXQNXS]?2N2;P!;2>&=3T*35;YK;4YVGN6VQAMSMND"?+A0Q]
MCB@!8=2NM>\8WVEI>R6=I86<$K1PD"2627+ Y*YVJ% XZD\^E<EK6H:GJWAB
MUMK^]F%WI_BJ#3I9[<!%N )EVN5QCHR\=-PZ=*[F3PIMU&#4[/4[FVU&.#[+
M).$1A/$&R ZXP2.Q&",GUQ3+KP583>'!I$-Q<0,MT+U;L%6E^T"3S/,.1@G=
MVQC'& ,4 -$^H6WCZWLFU">>Q?2Y9S ZI_K%DC4'(4$\,>,UGZ/<:WK7A[3/
M$,.MI 9KCS[F"=%\A;;<P:(8&0RC'S$YR.>.!M1>&WBUV#5CJUY+-# ;=5D$
M95D9E9]WRY))4'(( Z 8JA8> -/TZXD6WU'4UTU[C[3_ &7YR_9E?=NX&W<%
MW<[=V/7(.* ,>.^\3^);36KK1KPP75K?S6MFK.BPH(G"XD7:S$D _@PQ@\UZ
M!;N\EM$\@0.R L$;<N<<X/<>]<Q+X$M#K%[?VFJ:G8Q7[;[RTM9@L4[8PS$$
M$J2,9*D'BNG@ABMK>."%%CBB4(B*,!5 P * /.=3U[6+9I+FWU.XN'CUN.!V
MAB3[(EN\ZQB'<P&Y]K<E-Q5L@D"K\$VLZI\0/$FC?V[=6UE:VUK)#Y,<6]"^
M\D E2,<8Y!/ Y&.;$GP\B;3+C38]<U**R-VMW:PHRXMG$@EX.,N-V3A\@9Z9
M -:-MX4-EK>HZO;:M=_:[Z".&0RI&X C4A"!M'())/KF@#GM$\4:IK=IX0L9
M+GRKG4[.:ZO+J) &(BVKA,@J"S,">. #C&0:U/"<$UOXL\71S74ER1<V^V20
M*&V^0N =H XY[4V/X>6<.F:9:PZG?1W&DNYTZ]79YL"L,,I^7:X/?*^GIFM7
M1O#8TC5=0U$ZG?7<M\4,JSE-N54*" %&#QVP/:@#.\?WVJZ=I>FS:1?BTGDU
M.UMVW1*Z.LDBJ0P/..>Q!Z\U3N+K7=!\4K82:V;VTO\ 3;F>![V%%%M-%M.6
M:-% CPX^]GIUYY=\3W0Z'IMN9GCD?5K1]T0!DC195+2 8.-HYSC [UI-X3M]
M5CNI=6OI=1>[LI+)9 JQB."3[P0+W;C+<_='2@#G-)\0:LOB#PC:27]Q=0ZE
M#.MY-)&@AGD2(/N@PH;;NS@X"E>F:FTK6]4_X2&TTS6=2O+#4OMDQ-M/#&+:
M]AP^T0N$YP-AQN#<'.:TK;P%Y-QH%Q-KVHSS:(2L#.L8S&4V%" O< 9/+=>1
M5FW\'E)--CNM6N;NRTV036MO+&F5D52JDN!D@!C@?3)/< PM/U[5CX@L],U>
M^N].U(:A+^XN(E%K>V_S[5AD"<D*4."P.0<U3O/$NLV:V=U_:3W$C:Y':3R6
MR*;+RGE*")2P#,P7&2N<,""W&*Z:W\%;5TNWO=6N;ZRTV5+BW@FC0$2IG82X
M )"YX'L,DXJ@?AM$-(72TUR_2SM[M;NQCV1D6S"0R=UR_)/WLXS[4 5]9UZ]
M75/%T#ZTVF2:7:1R:?$$0>9F(MYA# ^8"X*8'3:1U.:EBUC79+SP[H\DLQNK
MG36U"]?$<<I8%!Y8!4  %SGC/RCWSB7(F;QEK,TVM:UHUP;J)+=#I@N4G1(@
MH="4;J=QP,8],FNB3PO<^)=+TJ_U>]N[76K%Y&M+^W189A&QP-Z$%060#<N.
M#Z<B@#9\+KKL=C<Q:_(DLZ73BWD!4L\!P4W[0 '&2#@8XSWJM>ZG<7?C>'P]
M#=-:Q1V!OIGCV^9)^\"*HW @+]XGO]WISG5TC24TBU>,7%Q=32OYD]Q<,"\K
MX"Y.  .% P   *J:OX<34=3M-6M;I['5+5&B2YC16W1MU1P?O+GD>AY'?(!R
M-]J>HW_AOQWHEY?3?:-%20+=1JBM/$\!D17&W&0#@E0,X&,5UOA&VDM_"^F&
M2\GN-]I"0)0GR?(.!M4<?7-5IO""2:)J.GIJ$ZS:H[-?W;(K23!DV$ $;5 7
M &!P%'7DUJZ-ITNDZ;%8R7CW20JL<3NBJP15  ..">.N!UH Y37[:XF^*OAU
M$U.]@C>RNWV1E-JE?+' 92.<\]3Z8J:VO=6EU+QM:'5I!]B\K['(8X_W :$2
M$8VX/)/7/&.<\UKZUX835]8TW58[^YLKJQ$D>^W"_O(GQN0[@<?=&".1S^$"
M>%KJ*]UF[BUF59=5 $H-NA6/: JE.^0@QR3GK[4 <>NL^*+;PSX&U9M>,L^K
MW%I:SPO;1^45FC9MYXW[Q@=& )SP*U+OQ'JOAB;Q@ES?-J<>F:;%?VIN(D5@
M[B0;&V!05W1@],X)YK0F\!F31M#TM=9N%AT6:.:T8PH6W1KMCW<8( W>F<^U
M77\(I<:UJM_=WSSPZI;BTN;0Q*J& !@%!'S9^=N<\YQZ8 *&GOXM.JZ3.Q=]
M/9"M^+F2 AMPRKQ>6,\-Q@GD8[\UU&IV]S=Z9<06=X]G<NA$4Z*I*-V.&!!'
MX5@Z#X*&BFWBDUO4KZQLVS9VERR%(>,#)"AGVCIDX'ID CJ: /)Y?%VK'PEX
M<U9-2O5GMYC_ &W"(X6S#%)Y<[-\@P0Q7 7'!/'!(V=8U_4[.2>:WOI!#J.K
MP:18'9&RP$D"24#&200X )(RHXKH(/!^E02^()%A&=<)^U?*/NF,(5'L?F;Z
ML:BC\%::/!=GX9<R?9[2.,1S1X619$((D7J VX9[]>] %*:[U/2_&>GZ))J=
MQ=6>K6DQ2618A+;RQ '<NU ""&_B!Y ]<5AW.OZZGPLLM:759EU!;Y(WEV1-
MYJ&Y\O##9@?+Z $5V-AX>:'58]4U&_DU"^AA:""1XUC$:,06PJ\%B5&3[#&.
M<X<OPWAFTBZT@ZW?KILET+F"W4)_HY\T2G:VW+<YQN) ST/% $ES<I9?%#4+
MN0$I!X=21L G@32$_P JPM4EU;5O 7A_7;O42S7U_IUS+:K&@B1)+B-E5?EW
MY7*\[N?F[&NQ3PU*/%4FMRZI+*)+86CVS0IM:(9(!(&<[F)S[XQ60GPY$>DG
M1X_$6J)I,<\<UK;+Y>;?9() H<J2P!' .0..N* .V8$J0"5)'!':O.M-U+7F
MCUW5;K6Y'M-#U.[1K?[.F;F)(1A6(48(/(*^ISGC'HJ@J@4L6(&-QQD^_%<]
MH7A9](;4TN-2>_M]2FDGGAFA4#S'P&P1_#@8VG/UH Q=-O/%]S+H6HHLKVMP
M4:^CN)+=8O+=?O1;?G!!(P"3D<'GFJUKK^KGQ'!IFJZA=:;J+:B^VWFA1;6Z
MMLMM6&3826V[3@L&SN_#6T;P&ND-#;-KFI7FD6KB2UTZX92L3*05RP 9E4CA
M2<#CT%.A\$N8-/M+_6;B]LK"Z2[@C>)0_F(2R@OU*@GIUX SUR 9,^JZU;^!
M?&5W_:UR;S2KFZ^RSM%%N"QH&52-FT@]^,X/6GWLDD_Q)\#R2.3))IEXS-@#
M)*19/I6CJ'@7[=_;D":W>P:?K".9K150JLC)M+JQ&[' .W."?;BIV\(2G7M$
MU3^V)G?28'@02PJQE5\!BQ&.<*,8 Q[T 9GPXMITG\3S2ZC=7&-<NHRLI0AB
M-@#'"@YPH& 0,=JU/'NH:AI7A@WNFWAMIDNK:-B$5MRR3)&1\P('#'FK&B>&
M/[#U?5+N'4KF2VO[E[K[&X79'(^-[9QN.=HP,X'/UI_BG0)?$NE#3EU!K*,R
MQRNZ1!V)1U=<9.!\RCM0!EWL^M7/Q#;2+;66M=/;2OM!5+=&D1_-"Y5F!'3U
M!'7CD$7/!&JWFJZ!(;^;S[JTO;FS>?8%\WRI60,0. 2 ,X[YJ3_A'[\^)5UO
M^V!Y@L_LGD?91LP2&+=<YW#/7IQ[T[POX=E\-VMW;MJ#7B7%S)=9:((5>1BS
M].V3^% %3Q%?WD&O6=JFHRV]M);R/Y%C&LMU+(&4 A65@(P"<MQR1DU+X!U>
M^UWP3IVH:DP:\D\Q)6"A<E)&3) X!PO..,U)J'AJ:Z\46^N6FK7%C(MJ;2>.
M.-'$L>[<N"P.T@D\X/6G^$O#C^%M%_LPZE/?1++(\33(H**S%MN1R>2<DDY]
MNE %>YU*[U#QG)H%M<M9PVUBEW--%L,CL[LJJ P("@(Q)QG)7IWY#1]7NM#T
M34X8'DEO+[Q;-8I, @8%GRSX;"[MJMCMDCC'%=EJ_A8WOB"UUW3]1ETW4HHC
M;RRQQK()X2P;8RMQP<D$<C-9O_"NK671M4T^ZU2\F^VZ@VHPS (CVDY8L'C(
M&=PXR2><< 9- %S3(_$G]KW-O=R70TR2%)(;F4V_G12ACN3"#:5*XP2,C!]C
M7-^'IK_2OA=I5W!K B$DD<;O=F,"*,SG>4^3+2%3@ YR<<>O4Z?X<U"S#3W.
MO3:AJ*Q^3!<W5NF(4)!8!$VY)P,L3G@>G.;%X"N8/"]AHL6O2(=-N4N;*Y6V
M4,C*6.&7.UAAB,8&/>@#+?Q3J:6/C:)+Z[#Z-9QWMI+<P(DN&B9\.NS&"4/4
M!L'M6U<:OJ4>N^# MW_H^J+(EW 8TPQ%NT@8'&0=P[<?3NL7@8'5M9N[S5[B
MZ@UBR6TNX&AC7?A67=N X^5B !CU.:9;>";U9-!FO/$ES<3:-(QB9;>- Z&,
MQ[2O(SM/+')],9- ',WBW \,_%.2VN)K>1+J=P\6T$A;6,D9(/'TP?0@UZ+X
M?M#9:!8VYN))PD$85I H( 4 #Y0!V]*QH/!CK:>);6ZU,S0Z]YC3!8-AC9T$
M9VG<>-H'![CK5:72==T[_A'+2WUV]N)()Q]H$=FBQ30C8K!ST0!0<#)8LW'3
M@ [-B0I(&3C@5YOI_BK65U'PQ%/>F[DU"Y>"_,=KBT5O+=P(9<#<04QPS9P<
MXKT6X@2YMI8),[)4*-CK@C!KB+7X>W\%AH5L_BB<_P!C3K);F.SB1=@1DV[>
M?FVL1N.1_L]: ,LZYXJFT[QI<IK,$9T*YD$ %FO[P)$K[6Z_*><XYYZCI71V
M^L:AK6L6%A;W LX_[+BU"Z=$5G8R$JB)NR  4<DX/\-1#P3=)9^)K9-7BVZ]
M(\DA:SSY190C ?/S\@ &>_//2@^"KZ*73+ZRUXVNJ65K]A>X6U#1W$ .55XR
MWWAUW ]2>,'% #/AO$\.GZZDTWG3C7;SS9-NW>V\#.!QT Z5VE8/ACPY)X<3
M45?4Y;W[;>R7A\R)4V,YR0-HY_'\ *WJ "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5=1M'OK"6U2YEMC*
M IEA.'"Y&[:>Q(R,CD9SVJU5;4)[FUL)IK2S:\N%7,=NLBIO;L-S< >_\Z .
M&D\,:5H/Q$\.-X<M%L9GCG&H16RX22V"':TG/7S"F"1D\\\5Z%7#:#+XGM[Q
M7O/"S+=WDJ_;+^74(G")G.U57D*H)"J.YR<DDGN: "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
C "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>a106amendmentno12tolease003.jpg
<TEXT>
begin 644 a106amendmentno12tolease003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI" RE6 ((
MP0>]>3RV-E:? JSU>"*.VU2+3H)H;N% LQF^7;\PY)9CCWS0!ZS17G=_XGUM
M;/6]:ANHH8M)OUL_[.,*L)AF,,6?[P8ESMQP..&J[8ZQJE_-+JK:Q!:VJ:N^
MGBQFB4*460Q_>QO\QC@CD#!'% ';TA(52S$  9)/:O/(?%&M2:=X.D%[;K-J
M-M=-=&955&=(&92<?=4,,G&*H7>O:PGA#Q FJ3W)O1H<ERD-U;6[Q,R@AI(G
MCRKQDLN%<9QSSF@#U.BO+]5\1:W_ &3KNKV^L_8FTR_ALH;,0Q%&4F+);<I)
M9MYQ@@ 8XZU;O]8UJ&_O+V/5I5AM_$=MIR6GE1^689/(# G;N)_>$@@C'O0!
MZ(6"C+$#ZFFI+'(2$=6(Z@'.*XKXDQ2S1^&5MX[:2;^VX=J70/E']W)][ -+
MJ+:YI'AO4K@#2+*[\RW6!]-CR1ND56W[Q@\-QQW- ';T5Y[=:MJVA7.J+-JL
MUW::3>6EQ*\RH'-O,&616*@#"D[QP"-H&<"L^3Q#X@U!].BBDO3;:U<W=S;R
M6<D"2I;QE1"B-)\GS+\YZD@GWP >H[@&"Y&XC(&>32UY9=^(-3@@L]6F6&?4
M[*QU8J2T;;O+9-H?RR5W# W*".5/2K&LZIJVA6=[;VWB.:^6323?I>3)&3 X
ME101L4#8P=C@@X"<&@#TNBO-M9U?6= ;5[.UU>;4&,%E,DTHB#0--<&-\' 4
M*5Y4-D ^U;GA*?4X]6U/3+^>6:*&.&:/[3<QS3J7+@@E% "_(",\\GGL #J'
MNK>,2%YXE$9"N2X&TD @'T."/SI(;NVN"1!<12D=0CAL?E7F7B18FO-=\Y%:
M,>*-)W!@,8V6V>O'3-;FL0VB_$'PN-*6-+O=<&[^S!0?LWE'E\=O,\O&>_3O
M0!VDLL<,32RNL<:#<SN<!1ZDU$FH64F=EW VT%CB0' '4]:CL((QI,$!NFU"
M/R@IGF*N9ACJ2  <^PKSV\M(+OPIXU\1"SMX5-I>6-DL2A-L,0=6;(QAFD#Y
M]E3TH ]$CU/3Y;A;>.^MGG<96-95+'Z#.>Q_*K"R1N[HKJS(<. <E3C.#Z<$
M'\:Y[PS:ZH-/L9;JZTY[1K--D=M9M&ZDJN#O,C#&,CIZ5BZ3')X<D\:#2+.>
M^N()H3#"7+O-(;:/EF8\Y)R3GUH [=[RVB\SS+B%/*V^9N<#9NZ9],]J:E]:
M2!C'=0,$&YBL@.T>IKSWP' 8?%/B.TU"UOI+BXM[2ZO)[V%0LDIWY(&Y@!TP
MO8+[55O[87_@V]\0.ENB:OJ%KO,Z?NX;%+A0@(!'RD?.W.#O;/'- 'J$-Q!<
M*6@FCE ."48-C\J(IX9T+PRQR(#@LC C]*\SU+5+_1F\1V%C]BN]8N(+2*UN
MK>$0EY9FD148 D90*7!S]T\]*@^S:EH<.O\ AZSTPZ?'J>CR-IJ"526N(HO*
M8 KP&*"-A[@GUH ](M];TF[G6"VU2RFF89$<=PC,?P!JQ=WEKI]J]U>W,-M;
MQ\O+,X1%YQR3P.:Y(ZGX1;P_X="I!/&\UM_9T%MCS%DR "J@@C;SN] &SZ5=
MU?6+>#39[KQ'H[V]G:31R0;Y4D,TH?\ =A54_>W;2,X'(]#@ U?^$AT3[$;W
M^V-/^R"3RC/]I39O_N[LXS[4U/$N@NDSIK>FLL*>9*PNT(C7.-S<\#)QDUYU
MJJ2?V2FL3W=@E]J.OZ?+)'"ZR0V(5U5 Y##>VT?,<C/0< &M+QG=3W'@?78I
M->TJ]<Q1&%+2':T>)5!9AYC;ADCT_6@#M[+7='U*;R;'5;&ZEQNV07".V/7
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MLK3AN_T"U^<$-^Y7YAD'GCU /X5;HH *9'%'$7,<:(7;>^U0-S>I]3P*?10
MR6*.>)HIHTDC889'7((]P:9-:6UPZ//;Q2M&<HSH&*GVSTJ:B@")[6WEDWR0
M1._]YD!-+)!%,H66)'4<@,H(%244 (R*ZE74,IX((R#2.B2(4=593U##(IU%
M #!#&LK2B-!(PP7"C)_&E6.-#E453C' Q3J* $**Q4LH)4Y!(Z&AE5E*L 0>
MH(ZTM% !@#/'6D"JN=J@9.3@=32T4 ,,49E$IC7S ,!\<X],TXJI() )'0XZ
M4M% ";5((P,'J,4;5W;L#=C&<<XI:* $P-V[ STS0% )( R>I]:6B@ P,YQS
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 17,DL5M))!#YTBC*Q[@N[VR:R/"WB/
M_A*=(CU6&QFM;.8$P^>ZEVPS*V54D#D>O?M6V>017&?"9@WPTTK P%:X7'TG
MD']* .THKA]4NY=>\9PZ3;7*26":=]K"17\EN97,C)G=&-S!=O3(&6YSQBD\
M6IV>G:5HNLZY)=W9U"51;6$[?:+J(1EUC:7*%2H969B1D >O(!Z+17FEBVO7
MOAWQ+I5A/*;RRU98XHKB\8OY!$4C0B;J"5+J&ZC/7^*J4WB)['2-86PEU6RN
M_M-C:3VFI32,VGB1RK.)"7RC#.&!.#SZ"@#UBBN0T?2]7TCQ0'EO8(],NH#&
M+)[^6X<RKR'0R#(^7@@'!X/7KU] !17)>(6:X\6Z=9+--<G['-*=,B;RU8[E
M FD?(PHY &"<MD X..-@GU:;P+X<:XU:]BO8?$?V)Y4N&8L@N73:Q;[^ HP6
M':@#U^L#7?$$^C:QHEFMBLT.I77V8SF;:8CM+?=QSPI[BN.O-4N_"&N^,8;&
MXO+F"UT--1ACNIWN"DP,@R"Y)"G )'M4^HZ1%#)X#OX[JXN)&OXVEF>X=A.7
MA=MQ4DC.>GH#@<4 >DT45XXEI-<^"?'-]+J>JM<Z1J-\+*1;R3,?DJ"A.#\^
M, ?-GB@#V.L[4[C5(+C3UTZQBNHI+@)=L\H0PQ8.7 _B.<<?Y'&W,M]XA\=7
MND2RPB*TTZWF@AEDDCWF0OOD&PC)!" $_=[8))JCJEMJ.DZ?X'M;O79M0O(/
M$$=I/<1RLHE0B0[9!G#$;5&3SQ[F@#T2344>ZN[&S,4NH6\*3&%W** Y8)E@
M#C)1NQZ51\(ZU/XB\+66K7-O';RW(9C%&Y95P[ #) SP!VKG]!TZS3XK>*W2
MW0.D%E,I&?OLLP9OJ17%Z4'L_AIX7\0Q7%R-0CU5+92)W6,1&[9"GE@A2"O7
M(R?6@#V^BO-3::AXLUCQ5 E[:0S6UU]EB,ID\ZS3RU*2( P"Y8EP<<]"3CAD
MMC_;'BO0["[U6XNX[[0;E+N:UG>..X*F)=ZKGY<Y)RN,]\B@#TVN0C\3>(9_
M$^J:+!HFG.UA%'-O;477S$DW[<#R>&^0Y!.!GJ:ZJV@6UM(;=&=UB14#2-N8
M@#&2>Y]ZXFUAOI?BKXE%G=Q6_P#Q+K(,9(/,R29<$?,,$<^O6@#H_#'B.U\4
MZ(FI6L<D7SM%+#(/FBD4X93ZX/>MBO/[CPY8^'-.T'0H)+Z_:74)9V@D<?Z=
M(4=V,S< ("=V,'.U1@US]^EW'\/O&R7%R]M+IVJ,8!:7,@C@!CA8J,XW)F1O
ME8;>3QC% 'JM_J5KIJVYNI GVB=+>(=W=S@ ?J?H":MUYAXQ\,Z;I>J>&IXT
MDFEOO$T#SM<.9"28I,@9Z*2,X'&>V, 7]<>+P7XTAUOR%;3M4MFM&4+DQW*
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M21N&?'13LQGL>M &K<>*;$^&[_5K%GG^R+*K1^2^Y)4!RCKC<O(YR.G/3FN
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M\IWB<DKM(; /(7.W)Z=,=%%X&TN&WTJ&.XU)4TI@]K_ICDJV"N22>?E)7!X
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MR;2,X8%1@[LDYQG& .DUZX3PAXZM=;D6>33]3MY+:10S,([E1N3:N<!I "N
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>'[3=R0-LF^R6TDPB;^ZQ4$;O;K[58TK6;'6[:2XT^8RQ1RM"Y*,A#J<,,,
M>#Q6'\-(8HOASH3Q,':>U2>5QU>1QN<D]SN)Y]JZ&SL(+&2[>!2OVJ<SR#MO
M*JIQ]=H/U)H M45G:Y'J+Z+=_P!DSB'4%C9[<LH96< D*P(Z$X!QS7"?\)IJ
M#:9X-U:.]E-K>;5U:/[.F8QN$;.3CY0)652/3.,8)H [G6=<M=#2U>Z2=A<W
M,=LACC+ .[A%W'H!EAUK2)P">>/2O.?%-WJ-UH&J7HF62"'7;*+3XY0H4&.Y
MB5R2HSCS-Z\Y.%SWK9LK_6H/&]YH%WJ$5S'+I@O;>86X0POYA0C /*\J1DYX
MZT ;VBZM'KFDPZC#;W5NDN[$5U$8Y%P2#E3R.13M7U2#1-)N=2NDF:"WC,CB
M&,NVT#).!["N$TGQKJMSX"\.W4TT!U76M3>Q$[1X6,>=*"P4<$A$P 3UQG/.
M=77[?6[;PYXPCOKJ.ZTPZ9,UI(P F#&)]ZL%4+MSC'?DT =5IM_%JFE6>H0!
MA#=0).@88(5E##/O@U:KS71K_6M(T_P 3?Q2V&I0PVDMJ( -@^S%T8-G.<IR
M<X] *]*H **X;Q1J^JVU]J\=OJ$D+VMD)[&WLXED9V"L6:<LI")D #)7(!P<
MU%=ZUKM]J7A2WM-0BM(]<T^:23$ <PN(E;<N3S@MP#^.>E '?45Y\NI>)-1O
M=6TJVNYWN]&CAB$]LD*+<7#0ARTBN<A"2,!<?Q<GMVFCR:A+HUF^K01P:B8E
M^TQQ-N028YVGTSTH NT444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU^T"8*XQA<<C(+9P.F<CO$UC3I-9?1TO87U&.+SGME;+HF0,L.WWEZ]<U>H
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MH^%KG5-&TA)+R*#5M)F2>VN8HR4WJ"N"I.=K*<$9KIRZJ5#, 6.%!/4XSQ^
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M3DLQ[DDDD^IJ:::*V@DGGE2*&-2[R.P554<DDGH!3@0RAE(((R".] "T444
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M;B2<X6)"3@L#@'. .N<<U0O=.N;[7-=\1QV=TD,NC?V9;Q&%A+.Y9F+%",@
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MYY]12U%U/")%"P@Y"H7)P7)#  <<$D@<UQ5AHNMP^$+@'2+K[5#XD_M-;4E
M\T/V@2?*=V,[>Q(Y%;UK#K&E^,+[6VTF>6RU>UA\V*)D::VEBW!5(W $%6.2
M,X/MS0!T>A:Y:>(=*CU"SWA"S(\<B[7BD4X9&'8@@BL"TUF\UKQOKWAZ]TQ&
MTVWMH%9'D5P1)YI+,,?Q  ;>> /6K_@[1[G2--O&NXUBN+Z_GO7A4@B+>W"\
M<9P!G'&2>O4YT-KJ>D_$36]272[BZLM0M+8)-$Z80Q"3<I!8')W#  P2>HH
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M-^Z:??M#;L9V8^;IG&1C-.31]?A\5Z5?N+:\@L[":UFN99S'+*TC1L6"!"
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M8P,DD;N2Q)Y/H  .N<W6=%U>^\7:1J]M]A%OI@F"I+(X:4RH%.<+A<8]\^U
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M2H(#'M,OWU^\<CT[_6JNA^"[_2TM+.\\276H:79,'MK:2%4;*G,8>0'+A<#
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M552Q))Z*  !T ]!0!;HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MWJ^&PH QG<.0,U5\%FZ/Q$\=_;1"+@26(;R2=I_<<$9Y&1@XYQTR>M '?4A
M(((R#U!JCKFH2:3H5_J,-I)=RVT#RK;Q_>D*C.T?6N9L?$>MW]E/=64^CWUK
M]B-Q#>VZ/Y:RJ06A==Y()4\'/'4CC! .T      '0"EKBKCQC?1Z5X.U%+>W
M\O7+F"VGB.XF,RH7W*<]MI&".XYXYB/B7Q9>ZOXBT_2M+TLOI,R*OGS28E5H
M@X ('+'([ #@9;J #NJ*X.'Q[-K%AI#:7 ;>XOK-KN9I+.6Z$ 5@C((X\%CO
MR,Y48&>>E13>.M=MM"T^\N=!6WFDU9--G6?S(]X9PHDB1E!*L#D;B-O3YL4
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MW#7:>4BEI413U Z N<  ?=&<\U@VEI+!H'Q(G>_N;EC->*RRJAS^X7!)"@G
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M*>%Z\5Z#10!QNH^%=:O8]/U)=6@77K*\:Z1FB8VX5D\MH0N=P3;CG.2V3CG
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MAUF2.TUDLSVYMU81LZA)#D\G(''3!.>>E=2\\44D4<DB*\K%8U8X+D D@>O
M)_"LW1M?@UJYU.WAM[B&33KG[-*)U"DMM5LCD\88<T 8\O@NXE3PX&UDE]";
M=$QMA^](78-W/]PXXQSS[5UIS@X.#VI:* .?T'PW<:/-JC7.J-?QZC.UQ)&\
M"H%=@ =N/X< #!S]:SM'\ C1UBL8M=U"30X)/,ATQQ&44[@P4OMWLH/.,_7/
M.>QHH Y5_!]Q<Q"SOM9DN=-%]]M$#0*'R)?-5-X/W0V.V<#J*P/#\=SJ?B[Q
MI_9VN_9HKBZC*A(UDW+Y$:F2,YZY&W/(X'>NPOO$<%CXFTK0I+:<S:D)3%,
M/+'EIN;/.<].W>KFKW\FEZ3<WT5E<WSPIN%M;+NDD]E'<T <_?\ @&RD72Y=
M*O[O2;W3+?[+;7-N58^5QE'#@AAQGGOS4NH^!K#4M%2SGN[LWD=R+V/42X\]
M;E0 ).FW@ #;C& !BND@D,UO'*T;QEU#%'^\N1T/O4E '+2^"8;W0-3TW5-4
MO;^?4K<037<Q4,JC.W:J@*H!).,<D\YK=TJRET_3HK:>]FO94'S3RA5+?@H
M ]@*L3SQ6MO+<3R+'#$A>1V. J@9)/MBGJP=0RG*D9!H 6BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+=U:+!(Q@D MR>>3ZU%KVD6'AOQ/X3FM;=BDFK3F*&*,'RP]L_[M!V4N-W.
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MR:IIY0SP!_,4HXRCH^!N!'L"""/<MU37[BTU<:98Z=]IN!:M=R/-+Y,2(#M
MW[2"Q/;L.21QFOI&D7$GB_4O$EW ]J9[:*S@@=E+A$)8LVTD9+-P >@&>3@5
M-:T[6KCQE#.VFP:IHPM-D,4DJHEO<;LF216^]QMP0"1@X SD@$D'C>+4="T&
M^TNT,UUKAVVL$S[%0A69][ ' 4*W0')QQW$3^.9(-.\0W%QHLZRZ"#]J1)T*
MN0@?*$X)7:0<D ]L9KC8-%UW1O#/@K06L%.L6%W/*@MKM%E,:(^75F!0*2Z@
MA@<Y'3/&W<0W-WH7B/P\FA7MMK>KV<LQ>XN(9//9E$18NK;5"Y08P..@.#0!
MLGQO)!IZWM[I$EK%<-;)8M)<(%N&E3=R?X N#G/.!G&3BHH?B):0R:M!J4"1
MRZ=;K<E[2<3Q31L=HVOA<-NX(('4<XZ)JF@ZU>^#M"73UAM=:TB2&:.*Z8&-
MVC4HRDKGAE+8/7D=#T74--\2>+/#^H6FH6MKHYDM]MO$LPG;SPP979@N H*C
M@9/)SVH GLO&DDNN_P!C7-E;M=2V[3VQLKP3))M/,;$A=KXY]#SSQ5"#X@WT
MNB:7K;>'I$TV[G6WE;[2&D1FD\M"J@?,-V 22O7C/6M;2KKQ;.8GU;2[6T6W
M1C,EM<"4W3XP N0 B]3R<]!TS7/V_AW7(?AUINA-IH:^M;Z*=C]H39M2Y$V0
M<Y.1\N,=<]L$@'06?BJ?^W[S2M7TW[ \5F;Z%Q.)=\(;:VX ?*P..!D<\$UE
MVOQ&26_TM9;2W^QZI*L5N8+KS9HRXS&94"X4-QT8[20#4U_X?O\ 4_'_ /:,
MMJ8],DT673I&\U=X:1E;. >@ (^OMS3?#UKXVL=.L=&O8M-6*S9(VU&*8LTL
M"8PHC*\.0 "2<#D]<4 17/C[48]+US4(/#P:'1;J2*[\V\53L1%<E< [FPV<
M<#ISUQ)?:OK-S\0-"@T_[,VES6,UT@-S)&9ES$"SKY9Y ?Y5]\DCI527P_KL
M_A;QKI[6*+/K-Q/): SKA5DC5/F/8@J3QGK5V/2-=M]4\,ZA;V=NWV/3Y+"[
MBEN-I3<8OG4@'</W?3@\B@"?3O%U]JM[-]BTZVDL[?46L)_]);SXL-MWM'LP
M 3S][H0?7&OXBUZ/0+"&8PF>XN;B.TM8=P7S)I#A06/0=R>< '@US5SX9U#5
M-5L-1FTVWLM8M=0#MJ<$P!EME<D(P7!;<F%*G@=<]JVO&6@7.OZ5:+82Q17]
MC?0WUL9B1&7C;.&P"<$$CIZ4 -3Q'?0Z]+HE[I\*7CVC7=D\<Y\JX"D!D)*Y
M5E)7/!X.?:J_A/Q1J_B:"POWT-+72[JV>0S?:@[)*K[0NW RI&2#[<XXR]M-
MU*^\20:]=6*0FQL98+>U6<,TDDA4L2V,!0$ '?DYQ@5-X&TJ_P!"\)V>DZC#
M$DUH"FZ&7>C@L3D$@'OCD4 3-K=VOC-="-K#Y,EDUU'<"4[LA@NTIM]3US7.
M?\+"U#_A'#J0T:%IH]:_LF6)+G(SYHCW*2HSDG@''N:UM9TK6%\::;KNE16M
MQ&EG+:3PSS&+;N965P0K9Y4@C'I7/0^"_$47ARYL&&GO/)XA_M56$[HK1B99
M=I&TX8[< <CID\4 ;]KXNNK?7-3TW7[&"R^R6 U)9(+@RJ8<D-NRJ_,"O;CG
M\^=\4W>JZI#X,O[RQMH+:?7;.6-$E+20@[MN\XPV0><8P<<MUK:U/PK?ZQXP
MO;RZCMDTN\T.329=D[&4%V+%@-H&.<=<]ZS;OPYXSOM(T&QN1HTDNCZC!<"Y
M,T@^T)$#ABNSY"0<$<Y.>@H O:OX[FM[O5XM-M$G.E,$DBD23?<R;0Y2,JI"
M\,N"<Y)Z #)+GQGK$NKV.G:;HT#2:CI37UH+F=HV#@I\DBE?DQN/3.3CIS0=
M!\5:'XFU2\\/2Z7<:;JLHN)8+]Y$:";:%+*44[@0HR#CH.>]3'P[K2>-M$U=
MI+:ZM[*PDM;B5Y6261W*DN$VD8&WIN[^W( R3Q=JLVIZCIME;:>=3L!"7TZ6
M8B6<,BN[1GIM&X@<')0]*9IEWK;_ !*\1)//#+:6EI;;(8U;.T^:P"C=C<3U
M/?@8I/%7A75?$UOJ%G-;Z:<W"/IVH/*RSVBX0D@*G4,'Q\PR" :M3:!K<?C#
M5[^SFM$LM4L8X&F+N)X)(U<*54#:>7!SD8Q0!5L_'%Z-:\.:=J%K:17&L"3S
M;1'/G63+'YBA\]>.#PO/K52;QSXACT;Q'J0TG3PFA74L4R-._P"]1%0D(=O7
M!8Y( ' P>345AX/\4V]OX6$BZ)&^B7!9UBEE(G#1,C2%BF=Y+9QCDDY:K#^#
M]<D\.^+]-/\ 9XDUVYDFB87#D1"1 I#?)SC;D8ZYQQC- '0-KUQJ&L0Z9I"Q
M*WV-+Z>XN$++&CDB-0H()9MK]^ O?-<3IVKWNB?#;6=1_LRPN9(M;NOM%O-+
M^[7-R1E>#NPQ! XSCKG KH4\.>(=,U2SU;2'TXW$EE%8ZA:W,K^6PCSLD1PF
M=PW$8(P0?;-4O^$,\0MX'UG0Y)]*>YU"_EN5D7S%1%>7S.A!.>@QVSU..0#:
MU#7]8B\9Q^'[.SLB)[%[J&>65N"KHIWJ , ;CP"<\<KS50>,[V+PT+FXM+<:
MF=6&D!%<^293/Y0?/)VX.['7M[U>DTG5YO&MAKC)9+!!826KQ"9BVYV1B0=G
M(!C YZ@YXZ5R>OZ;J.G>%;C2=2ETI)=:UQ6@W.YB_>2>:T;L0I7A&PPY/ &#
M@T =;9ZUJO\ PEEWHEW':2+;6L=WY\*LK2*Y==H0DX(9.N3D&J/A7Q5J'B06
M-S#-IT]M(76^@AC9)K!PN1&^YSD@_*3M'/08.:J:)_:^D:R-.O(=(-SJ43_Z
M39W<TTZE%.UG$N28QTSG 9@,<U=L_#6J3>(=&UG4XM+BOK&)UNKNT+>9>$QE
M I!5<+D[L$MR!C% %3XG-.A\(-;1++,/$5OL1WV GRY>IP<#\#3YO&>JZ%>:
MS::_86\CVEC]OM);$MMN$W;"A#9*L&*COG.:U_%WA^ZUV'29+*:&.XTW48K]
M%F!V2; PVDCD9W=<'ITJK?>$I?$,FK2ZU*D?VRQ-A!':N6\B,G<S;B!EBP4]
M,?(/>@"&S\1:_/JUE9-9%XKN&3?<_P!F7$*6<H&5#^81YBGID%3D=L\86AZO
MXFM?AMJVMVDEC?7D-[=S>5);NN]4FDWC/F=<#*^@7;SG(Z70=)\5PBS@UW5K
M*:VLP K6D;K)<D#"F4DX'J0!R?;@N\(>'M2\.V]W87-Q:2:?]IGEMDB1M^V2
M0O\ .2<9&XC 'OF@"G<^,9(/%7AFT2\L)--UF$N3Y+B124S&=V\J YR ",\$
M#/4-F\7W\;0JGD2K?WLT=G)%9S2;+>(X=V1"2Y)X&-HP0?:JJ?#8Q>!]0T-+
MX_;&E,FGW>2&M1&Y:W4'&0$XSCU;'6M37?"-Q<6.CMH-\MAJ&C'-HTBEHG4J
M%9)%&"58#MS0!4;Q?J]II]W]MTQA.+R"ULK@6LL<=P)2/G\HY<;/FRN<G P>
M:D_X2+7HCJZ-9B2&VLC=VU[+92V\;,I.Z)E8YSC!!''/MR^_\+:SKFB3+J>L
M)#JQ:*6VELD98;:2)BRL%8DMDG#9/(QP,4O]B^*;W2;H:KJ.GS7SVTEM"ELD
MD4&'P&=P22S8''8<^N: *NF^*->D3PG>WT-A]AUQ$1XX0WF1.T)E5]Q.,':0
M5QQD?,:M?$U[V/P)J#V=VML,(DI,98NC.JE001MR"<GGBH$\,Z]%HWA>Q2;3
M<Z(\;,S>9^]$<;1#''&58GO@CO6[XKT:7Q!X8OM+@F2&:95\MY%RH96##(';
M(H P=:;4X?'_ (82%K62[EL;Z-Y71DB0;H#N" DD\ 8W#.>HJ&W\;:BNAZB)
MX()=4L]9&CAXHV\J1F9 )=F2W"ODJ#R1@$9R-*70]>NO$NA:O<76GYT^*6.:
M-(W'F>;MW[>>-NQ<9SGG.*S%^'][<:?K]K=ZG'$VI:B-3M[BT1E>UG&W;C)P
MP&P>F<GI0!LZ-J.O2>(KBROK0R:9]G$L-]]G,!$F[#1,I8YXP01CN*A\0:UK
M=EXMT71].%B8M2CN#OG1LQ&-5.>#\P^;IQ]15O1-+UU)X[KQ!JT-U/"C111V
M430Q,#C+NI8[GXXZ 9.!S6+XL-U_PL?P:+)[=9A'?\3@E2-D?'!R#[T -M_%
M'B&.W\1:;<PV#:MH\EN?M1_=6\D$ISYI#-QM0.2-W)7 ]*99>,=2N7\4VL$]
MM<-I5G%=VMV]JZ+,&5R05W#(RA 8$#GOBI]0\#7NHV>H7+ZE"FM7MU;7+.(B
MUN! <QQ%"<LO4G)R2<]@*5_!VM-JNN:A_:]FTFL6"6LR-:MA&4.H*X?A</WR
M21U% '.>)]4\4WWPHGUFYO+&VM;RPLW$<$3&4-(Z!P6)Q@ANPSV]SV=[J>J:
M=XK\-Z8]S;36]^+A9F,!61G2,L-I#8 Z<8[=>:J2>#+JZ^&"^$;F]@\V*VBM
MXKE(CM_=E2A*D^JC.#]*FN?#NMWNN>']4N-1L6DTLR/(JVS 2M(NQP/F^4!2
M<9R<]<T 93^+O$5_:W=_HVFR3K#>2016IMLK,D<AC?\ >;QAB58CC P <\U+
MK7BR^M/$5YI37<.ES,D9TH7<'[J]8KEE,F<!MV%QD$=><\6(/!FKZ=J%_%I7
MB$VVBW\KSRVK6X>6%W.7\J3/R@GGD'&3BI=6\*:GJEMJVER:C:OH^H!46*:!
MGEMEV*C;&W8S\I8$CACGF@#IKY+R73YELID@NRG[IY$WJK>XR,C\:\[G\>W\
M/A/P_K#72":2Y$.K0+;AS$%;;,PY&T(Q R<\,.YKTBV@6VM8H%9V6) @9SEB
M ,9)[FN<@\#:;%>>(IY,RIK0*O$V<1*RX<+Z;FRQQCG'I0!G>)O$6M:;HOBS
M5=/GMA%I@"6ZS0;\N(U9^0P[L ,YY!ZTNL_;9/B9X9C2_DC@ELKN01!%*JZB
M,;AD<DAR.>G;J:LW'@EG^&X\(PWP3S+?R9[J1"[.S'=(^-WWF8EN2>M6-0\-
MZA?:GH6J)J4-O?:<DL,S);[EDCD"AMH+?*WR*03D>H- '(VDVKVMY\1KS2KR
MWM7M+QIP98O,\QEMU(4Y("KQR>3SVQSZ-IEY-J>@6=\H2*:ZM4F (+*C,H/3
M() SZBL&#P?=VZ^)0NIPEM=D+L3;']SE0AQ\_/RCVYYZ<5LZ-IEQI'ARTTP7
M,4LMK L$<QB(!"C"EEW'L!GG\J .#L/&'B-?!MWXKO;JRDM[/[7 ;1+<J9I5
ME*1-NW?*,X!'IR22>.CL;GQ5#KL$<MG=W&G20OY\MT+:,Q2@ IL$;DE3R"""
M1P<]:=I/@>"S\(W_ (;U"Y6^LKQYF8B'RV'F,6/\1Y!.0>V!3]-\*ZA;Q00Z
MGXBN=2CM5(M@\*Q%6VE0SLO+, 2 >/7DX( ,/PQXCU;5]1L[*?5O(U5(W;5-
M,N[58VA.P[3%P"Z!R.=S9&.1WIOXB\7P^ I?%?V^RE-A+.TMI]FVK<11S,IR
MV<JVU<C'ISG-=-#X8G2YT6^UK5X[MM$C8Q3^1Y;NQ0H6D8L<C:<G&,GD],5S
M?@[2CXG\#S:<^KQOI<M]<K<V\4?[TK]H=C'Y@;A6&/X<[6X/(- &F_B+6-=O
M]830!=F&SVPV\L,<!C:4QK(3()6#X^8+A0.,G)[6XM7U;5=>M-"G)TNX72EO
MK[R2CN)&;8(T)W+M!#$GG/R^]37O@^X/B2?6M(UZ\TN6[C6.[A2-)8Y=HPK!
M7!"L!@9]!TZTR]\"PF[TZ_TC4KG3-1L;<VJW"*LOG1$Y*R*PPQ+9;/J2: ,'
MQ!;:^UIX,36M3"7XUN.&<607RI/EE9)"&4_-A5..@)/'0CL?%4<Y\'ZJ(+VX
MMIDLY&6XA($@(4G(., G'4#Z8JC?^#OMFFV,*:K<)?6E^NH?;'C1VDE 93N7
M &-K$ #&,#TK=N+!;O2)=.GFED26 P22G =@5VEN!C/?ICVH X72=4N;+P]X
M%T*VO)$FUFU7_2"B9@BCMP[!!@#).T#(.,D]JV=)U6_L_'%YX7O9WO(EL$O[
M6ZD4"0*7,;(Y4 $Y&0<#@\TR'P*%T32;.75IY+W2&5K"]\I T.U=FW;CY@5X
M8$\^W&-?3]"%MJ\^LWDXN=3F@6V,JQ^6BQ*Q8*JY..6)))))]L"@#"\064\W
MQ)\-,FHW<2/;W?[I"FU"JI\P!4\G<03Z=,<YPKB/4_M?Q$N=-U>73C97*W*>
M5"K,[K:1G#%P04.!P #[]J[?6O#QU;4],U"'4;BRN+ R!6A56WI( &4[@1_"
M,'M5-?"#!/$2MJDI_MP?OCY2_NCY8C^3_@  YSSS0!BQ^)M5UZYTBUM8KE!<
M:)#J<XLWB1]TO"@&0_=&&Z#KC/I74>&#K(T5(M>,37T3LA>-@2Z#[C,!P'*D
M9 XSTXK%?X?1BVT4VVM7]G?Z/;?9+>\MP@9X< ;)%(*L/E!Z=:Z72M,CTJS,
M*S2SR.YEFGF(+RN>K-@ >@P    !P* .#DUO5(?$*6.KZK=:1J$FJK]F62,&
MSN[7S1B-'"G#E..2&+>W2Q87VJ3OX\L7U>[QILJ_8YOD\R(>2), [<'GU!XK
M8'@OS;"/3KS5KJZL8[P7BQR(F\$2>8J[\9"AL>^.,XI;SP5'<ZGJ]U#JU]:0
M:L@6\MH!& [!-FX,5W+\N,X(H Y5I[[6-1^%]T]XT=_<V5Q))<>4K'+6REB
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MHCD:)RASM=3@J?<&L_Q-K<?AWP[>:G)MS$H$:LP4-(Q"H"20 "Q')/ YKB/
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M<,GA1G.!CH<T =T2!U-%>7:AKFJZ^_PZOX;M;)-3=I9(5BW@2_9W(/)&0,G
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M(X.:R;#Q5K"ZGX>6YO8KHZE=26]Y;PV^8;9@CL%29<J64K@C<2>3Q0!Z+17
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M'&3VH T:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBJT;AF& "N0>F#[5D2>%]6TKP9X:T:#3VO+FSU*&^N3;NJQ1@2EW5=[ \;L
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MG^?C&.N?E^G-=]10!Q\WAW7[+Q+=:SH=_80C48X_M]I=Q/*GFHNT2(593G&
M0>H _!UQX8U1M<\.7J7<,\>E/-+,\[-YD[S*RO@8(4#<2!T' X KKJ0D#J<4
M <3>^";W5UU^.^NH(5U*XBN[>6WW%[::)46,\\,/W8)Z=Q[U*WAOQ#?>)- U
MK4M1TSS=*2X5H[>VD D\U57J7./N_A[UT,FN6$7B&'0GE8:A-;M<I'L.#&I
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M+=?M#[2&D:<@2; 8F &-P!/7')%=%H,E[IGB5[34M)M8KS45+M=6M^]RS",
M#>'12J\X&.,GIS0!>\5^)CX?DTR!6MH#?SM"+N\)$$)"EOF(QRV,#D?T.7J_
MB/5+32K"YO\ 0[$R/K268\V0E8U,NQ)DROS9'(/&,]ZW=?L]1O9;:&"UL;W3
M761+ZTNVP)%(&W'R-R.>#@<_2N5D\"ZO;^%[;2=/^P[8M8748X);F01V\2RA
MUA0["2./08ST- &[J'B'47UC5=.TB"W,FE6J7$WVD-^^9PQ5$P?EX4Y8YY(&
M*S9?'6I-H_A34;;2+<IKURD7EM<DF)70LO.P#.!SZ=LUF:A;WVL?$#7?L4>F
MSQV]I;VLZ2ZE-:-R&=E;RU)D&''+8 S@?Q5;?3]2\26GAY["QTVTCT+5"9(E
MNF,3")6C"Q,(^5^8\D#!7&.] %V3QM>:/%XB&O6$"S:3##<1_9)2RSI+D(/F
M&00RE2<>^*DL?%U\FKI;ZC9[[&2UDN#>V]K,B6[(,M&^\<Y&2&XSC&WFH=6\
M(:AKU_XB2\:U@LM5M(;:*2*9GDB:(NRN5* $[GZ;N-O4YXMV&D>)K^R6R\37
MFGM;+"\,HL0Q:[#(4R^X +P2=H!YQS@8(!SOB6_UG5=)\*ZE<P6L5E=Z[I\J
M0*&,L*&4%"SYVL2,9  QG&3BO0=8_P"0)?\ _7M)_P"@FN*;PGXKG\/Z5HUQ
M>:0Z:5>VTT-UB3?-'"X*[E  1L #@G/J,UW=U;F[L)K9FVF:)HRP&<9&,T >
M8^&-?USP_P##_P +:@]E8OH M[:"X(E;[2F\A!)C&W:"5R.3C)SVKH8?$^J6
MFN>(K#69-/@33K(7ELT<+YGB.[]X<OT4KM*CN1\W--TWPGJT7A;3/#%[)9?V
M?9-$)+B&1S)<)$P91L*@)DJN?F;C..N1%K4&C^*O&6C)8W27-SI\TJZA]GEW
M!(0,^5+CH3*L9 /78^.AH Z_27OY=)M9-36%+YXPTR0@A%8\[1DD\=,]\9XZ
M5Y_I=QXCLF\82Z!::?*L.MS3.+R1]TW[J(M&@0?*<=&)/4<=Z],KE8=!UC3Y
M-=CL)[+RM5N7N5FD+A[=F1$/RX(? 7(Y')Q0!7T_Q==>)CI4>A?9;<W5@NH7
M$MTAF$2,=HC"JZY8L&YS@;>ASQSGBCQ+K6I>!?$EHTEI9:AI=RMG?!(7=9D=
MDVM&=X*;E?D'<>HXX-=+;>#&T&_T:ZT"2%18V)TZ:&YR//AR&4[E'#A@3G!S
MN/2H;OP/<7?AWQ' UY$NJ:W.+AY0I\N,KM"(!U*@( 3U.2<#I0!GZQ'K$?Q*
M\,(LME-J/]G7J^<8GBA',>#LW,W''&[GU%=/X4U;4-4M;^+58[=;ZPOI+21[
M966.0##*RAB2,JRY&3SFJ<FAZY<>*-$UFYET]VL8)HIE3>F[S2N=H(/W0HZG
MGVJYX<TG4-+NM7EO6M6%_>-=CR"V4)55VG(YX0'/')/% %#4M7\3#QH^B:;'
MI0@?3_M44UQYA,;!PIW*,;AR< $=>3QSGV/C#7+W1'%Q;V-GJ%EJK:=JEP6_
M<0(J[O.0,P)!!0 $]6YSC%6M2:]7XIV?V VID.C2B2.=BNX><F.0"1CG\S44
M_@>_7[)>VFI1#4H]6?5)Q,C-#*[IY>W .0%3:%/^S[T 9]]X[UB#PEXKU"U-
MA/<:+<[(Y'AD19(C&CJ2A.0PWXZX.*3Q?+XF;2[-KV[L(+2XUC3Q$EO&[-L+
MJ65R2,_,%/&,C([U9O? 6KW^G^*[.XU6R8:\8V,JVS*8V5%0\;B",)P.O/6M
MKQ%X>U'6_#5E:1W-M!J%I<P7*N58Q,T3AL>N#B@!)-6U.T\=:5H]P]I):W5C
M/,9$A*N7C,8/5B IWDXYZ5A0^-->U&PMM9TG3IKJVGN=OV+["X(MPY4N)=P!
M? W<9';'<[SZ!JTOBO2=9FO;5Q96TMO(@B9#*)"I9AR0,%!@<_6L_3/!VNZ/
MYVF67B)$\//*SI";=C<P(S9,:2[^!R0&()&>* (+WQ7JZ>)-3TI;BQM+R&:,
M:=97413[="0A=ED9@"WWP .A SFN^KC=:\(:EK^FZCI.H7UM/8W5SYL$K1'S
M[-,@X0]"1@X/&,]\8KH[6WU&/5[V6XO4ET^1(A:VXB :)@#O);^+=\I]L4 7
MZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** *FIZ9:ZQI\UA>K(]M,I61$E>/<IX()4@X(ZC/-.T[3[;2M.@L+-&2VM
MT$<2-(SE5'098DX'3K5FB@ HHHH SM:T'2_$5A]AU>RCN[7S%D\N3.-RG(/'
M^>HJ]%%'!"D,,:QQHH5$08"@= !V%/HH **** "BBB@ HHHH **** *>I:5I
M^L6OV;4K*WNX<[@D\8< ^HST/O3-.T/2](,C:?I]O;/)]]XXP&;TR>IJ_10
M4444 9=_X:T/5;H76H:/8W5P%V^;-;JS8],D9Q[5H0016T"001)%$@VI'&H5
M5'H .E244 %%%% !1110 55M--L;&6XEM+.""2YD,L[11A3*_P#>8CJ?<U:H
MH **** "BBB@ HHHH I'2-,.H#4#I]J;T=+GR5\SIC[V,]*NT44 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX[6!O^647RH.O0=!U/2@#RB]TJRF^&OC'5);=6O[/4]0FM;C)WV[K.2&C/\
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MEM\@^1%D8P=@XQR/RK$T+1-3M;R74-=U.+4;[:T,#QP")88BVXJ!GDG"Y/\
ML+Z$D WRBLA0J"I&"I'&/2O)(= U*]TO4O!4/G1?\(].UW8W>  S']Y:HIY/
MRDL&QC&Q1GDBO7*0* 20!D]3ZT >1Z]J2ZG\'/$7BB[1;*XUJV54B>0955&Q
M8P>^3YC8_P!JMF^U#24\;>!%@O;%,V=RL>V1,%&C0(![$C@#KCBO0O+38$V+
MM'08XH\M,@[%R.G'2@#Q_P -2>'KC0-/T'58]6D\0Z=)&KZ4T\H<3HW$JC.T
M)GYM_0 ^^#I1ZCI$MU\394O[ M*J@2"52646B)U'4!R5X_BR.M>G[1NW8&?6
MD\M/[B_E0!S_ ("G%Q\/O#S"42.-.@21MVXAQ&H8'W!R#[UP"K8ZA\(;KPI$
MT#:[+)-$MAPLXF-P2KLGW@/NMN/&WDG%>P@ # &*3:N[=M&[UQS0!P>CZ@GA
MWQEXCB\0W2VQO7MYK.ZN&V1W""((54DXW!E)V]?FR!6#:P2>'_!/A2?44-M:
MP^(6N#Y@.(()#/Y988^4?.OIC(SBO6BH;J <>M*0",$9% '!Z=?V1^*NL7C3
M*L3Z/;A9)04V[7E+KSC! P2#R.^*E^$LF/AMIT4K8F@:994?AH_WKD @\CY2
M"/;%=O@>E% 'G?A/5["S\6^-9;BZCBCFOXWB=^%D40JI*GHW((XJ7Q'XCBOM
M,M+R.(1V2:TD$>HO;-(8%$;9G52.#OS&&((^;//0]_10!Y+=3V_]G?$2T5[]
MFN[$&"2[BDW39MMN1N QEC@+Q[#%7M;NX&F^'4B2 QQ72M(PZ(! RDMZ#<0.
M>]>F44 >33:@MG\/O%WAG4;6[&L!=19<VCL+L2F22.52H((PP'7Y2N..*OW5
MVK>(_AM*5=1'%,9_-B*F+=;;5W CY<MP,UZ510!YUHDZZ)8>+-*UJ*0W$VH7
M=Q%$59OM<4O*!,#YLYVX'((Q5'3[:?1=5^'-AJ3EKG3[*>*[8 N(6>-%0,P&
M!DC:"?2O4Z* .$L[X^'_ (B^(O[4ANA!J8MGL)X[9Y$8(A5H\H#@ALG!Z[C5
MOX7K)#\/]-MIX)X9H?,5TFA:,@^8Q_B SP>HKL** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBO*;S5]0BETB_MM2NKEY?$4=I->K*5M9X7F9/)CCW8.U< MCJA.XT >K4
M5YTEI?ZOXH\:Z;/KNJI:VR6[6ZP3"-HR\3-P0N0 <8]?XMU-T?7;[Q)!X/TZ
M^N7B&HZ4]]>20NT+S,@C4(&4@J"7+':0?E'0=0#K-&U^35=9UK3I+(VS:9-'
M%EI0QDWH'#8'08(QS^57M5OVTW3WN4MI+EPZ1I#'U9G<(/IRPY]*Y/P7:+8>
M-O&MLLLTJI<6A5YI&=\&W4@%B23CISS7<T <T/$]Z?$#:&-&/VY;,7A_TE=F
MPN4 W8SG*GM6SI5\^I:=%=26SVTC%E>&0@E&5BI&1UY!YKFH_P#DLUQ_V+T7
M_I1)4&M75]J7CU]"B:,P0Z:ER(#?RVID9W=68-&I)VA0,9 &[/T .XHKS.XM
M=9LH?"]C=>))GNDUEK6:2UGW%HS'(ZI)N&&91M&6&>AZFEDNFT2]\<Z6NM7=
MI:6]A#=PW,\K3O;.Z.K%=Q+')52!GJ>.M 'I=%<#I45Q;>.(M/V7]G97NC2M
MY4U\TLA=)$42-R=CX<\JQSD9P16%8P74'@#2=>DU;49+ZWU5(S(]TP3RVOC&
MX9<X8$,<[LGIS@4 >IK>V[ZA)8+(#<Q1+,Z>BL6"G\2K?E4TA=8G,:!W"DJI
M. 3V&>U<)HNE6D7Q<\22HLH=;2SF'[YR-[><"2,X/'8\#M7>T 8GA'79?$OA
MFVU::V6VDF>53"K[PNR1DZX&?N^E;=>+06K6/PMB\0P7EXFH:?J;_9]MPPC0
M-?%&4H,!@0S9+ GGKVK:\9#[9-XOD@GN;N;3M.\Q#YKP1Z<ZQ,XV,I^>1N'Z
M#& ">: /3Z*\RU/?:V'@WQQ<2RLL:6XU4>8P1XY8PHE8 X^1R#TZ,?2F:U-<
MV^CG5HYUL?[?UJ*$RDMM2UP5CY4_*)-BL2"#^]/(Z@ ]0HKDO#^CZAHWB6Y-
MSJEG]GO+;>FFP(X".C -(NYC@8900.,X/UV?$D%Q=>&]0M[6^2QN)83'%<.<
M*C'@9(Y')QD<\\4 7[IITM)GMHUEN%1C%&[;0S8X!/. 3WJ'2Y+Z;2K634X(
MX+YHU,\43;E1\<@'N*X+18HA?ZMI=[I=WH^IKIBF2*WN7-O,BDXEBD!# YX/
M0\\YJM;7$I^%G@>2X::>UDEM!>QQDM).A4X  .7&_82HR2H/;- 'J-%>=#15
M6T\9W4:ZC;:;)!_H,9N)H53;$'<QQY&Q=X'89^8?=.*R]*M19Z-\.=9BGN?M
M]Y);P7$C3DB2-[=B4VGC'RKC XQGJ2: /6:KWTMQ#8SRVD44LZ(61)9"BL?=
M@"1^1KS&#3+CQ3I.KZE)K5IIU]:ZE<E[PP-)<67E2L$4'S  OEJO&W!!R02<
MUKZ6MOXG\0>*O[55+B2Q,=K;1MP(HFA#^8JYRI<NWS=< #/% '3>$M9E\0^$
MM+UB>)(I;R!961,[5)[#-;-<K\- 1\-?#P;J+),TWQDMM=7F@V$HEN)Y;MI8
M;$.J17!1&)\TD'Y%SG&"2<<&@#K**\;U>S:+X:^*(G;RS8ZWBW2VF<1Q*9(?
MD XRHWG@C ]*Z:;3H/#OQ*TUM,24/J&FW;7*M*S^>\1B*,V2<M\S#/O0!L>.
M?$&H>&="34K""UF N(HI1.S<*\BI\H'4_-W(_&NFKQ;6+2PU'X-:=KTD<4^J
M7%S:3SW9QYAE>=-ZD]@"2-O08''%>TT 1W!E%O(8/+\[:?+\PD+N[9QSC-8W
MA#6+K7/"MIJ>H1Q0W$OF>8D8(5-KLN/FYZ#O6+8K;:_\0/$UGJ\,=P+".VCM
M()U#*D;IN9U![LW!/7Y .*X_3KAK;P]\/]-DNH4TRXO+M))+F,R1R2*S^2'&
MY>IR<$]0.M 'H_C76;W0/!NI:QIR023VD)E59@Q4@?[O/O5QY=6DOM)>V%I]
M@D5FO3)N\S[F4\OM][KGM7":WHT6A>"?'EK'J"3^=8M=&SA@\N&U+1LIV LV
M-Q0L5SQ[9%:>KVD:^._ =XJ'S&-Q$[[CC M7(&.GK0!W>Y<9W#&,]>U->6..
M/S'D14_O$X'YUYMJ4*>%/&.IVMG:PI'XFM,6>(AA;M3L93Q]TJZN1G'R/ZU(
M^G6EGXWT[PP1:VVG6VD#^SXKJ,2I*^_$A"D@;\!<YR<$GN: /1RR@ DCGISU
MIKS11QB1Y$5#_$6 'YUY==Z!86UGX<L(+VXO$M?$ @6<'9Y:%6=HE*D90'Y>
M^,$=JM#2],M?'Z>&Q]FMK2'24;3;:ZC,Z/NED,VS<<;A\G')QTXS0!Z2[JBE
MG8*HY))P!7.>'M9O]0\1>(=/NWM7@L)81;O;H5W*\>_YLL<GD#C'3/>N2TZ.
MPLM5\*>'VOSJ6BQ->B*XN&!26Y0X6,CHP0-)CKR!CE:V?"$-K;>/O&T%FL20
MB6S;RX@ %8P_-P.G0<4 =C>BZ-A<"Q:);LQ-Y!F!*!\?+NQSC.,XK).NIH^F
MZ/'KEW:MJ-XT<!,#8224C+,N<';P3]*L>)H([GPMJL4L22J;27Y7 (R%)'7W
MKSV&TBG\%?"V5X(W*W%HK,R@_(;:3(^A..* /5@0P!!!!Y!%+56"^L9)Q:6]
MU;M*L2RB&-U)$9X5L#^$]CTJU0 R82M"XA=4E(^5G7< ?<9&?SKG/!.LZKK^
MDS7^I-9@"ZG@C2VA9.(Y&3<2S-UVDX^E=-7&_#)U/A&0!@=NI7H//3_2)#0!
MUEU>6UC"9KNXAMX@<;Y7"+GZFE-U;B))3/$(Y&"HY<88DX ![DG@5PVJZO9Z
MMXKT$V(Q>F*]-M-=D&V5%*H\FP'+DX^7!7Y68D]JXV!+2Z^&T$9FANA!XL"Q
MR1D?*K7G5,?=!!/3UH ]K@NK>Y,@@GBE,;;'\MPVUO0XZ'VKE/$_BB:QUC0;
M72[ZRE%SJB6=]" ))$5@QSD-\O*XY'?MBN;UF*31/&WB:#P[;1VTC>$O/CAM
MHP@:99)%5@!CY@.!^%0:I=:&VA_#6>TGM %U*U975EW!?*??DDY'S8SGOUYH
M [;1M6U"Z\<>)=*NI8GM;&*TDM@D6TJ)!(6#')W'Y1SQ]*W(M2L9[I[6&]MY
M+B/(>))5+KCKD Y%<-<M>1>*/B%)I*E]1&DV;0+GK($N-N.GM6=JYM)_AAX5
MO=$=%U!;BQ-@T3?.TK,JR*2.3\IDWCV.>E 'I<E_9Q2>7)=P(^Y4VM( =S9V
MC&>IP<#OBN<\>>(WT/PQJ,^G:E90:E;Q[UCE =B/9-PYQSWK&TSP]H]_\3O%
MK7%C;2O%]@GC4K@+(%9M^!_%D#G\*YJ^O[";X':\+Z2W37!),U\DVU9?M8E)
M&1U[+M_V0* /1=0U+6;?7] BM9+&2QNPRW43JWV@_+G>F. HXSGU ZD5LW&J
M:?:3B"YO[6&4X(CDF56.>!P3WIVGRK/IUK,KJX>)3N4Y!X%>:^(?^)=_PD>J
M6CPZKHQNU_M73IODGBF4( T,GT\LA2/7!YH ]3JE<:OIEI<?9[G4;2&8X'ER
M3JK<]."<\U=KS'Q$DEA<>(M4LY+;4]):=/[7TNX79,DBH@#0N.^W80I'4<')
MH ]$&IV!^T8OK8_9SB?$J_NO][GY?QK UW6+NWU?PS)I]]"VF7UXT$^Q5?>O
MDRN"&[+E.2/3ZUEV%W;Z=\5O%0O9XK=;BQLI(A*P7S0/,4E<_>YXX[US6E'3
M;[P-\.(;B2VGMDU0)*)"&4,(9\*P/0YQP?6@#U2+6=*GLI+V'4K.2TC)#SI.
MI12.H+9P,4)K6E27K62:G9M=)'YS0+.I=4Z[BN<X]^E>=:WI]K!KWC6:RBMT
MTIO#VV[" ",W@\S;QTWA-OOROK3-4M-+$GPR58K7RI)@I(48<&WZ'U!8+]3B
M@#T&75;/4]!N[K2M:L@GENJ7T<B2QPOC 8\X.#C@T6>HV]CH&G3:GK%I*TD,
M2F]+I''<N5'S+V^;D@#L>*XN-;/^V/B9!O@$9AA=D.-JG[-@DC/L/2H+**.[
M\*?#\V&M1Z=KD>EH;!IHQ)#+^YC66-QW..F"",'TH [\Z_HPL$OSJUC]C=RB
MW'VA/+9@2" V<$@@\>QJAJU_#>Q:1+8>)K.QAEOHSO#1N+Q5;!@0D]6; RO/
M;VKBK26/5;324M[R'P_X@AO;^2V=/WUI<2*P$^ Q&Y7\S([CG'0YK7VI1:AX
M6\/37%M9V4\'BZ)9O)ES%-(MPWFRQ$X)5F+-SG ^F: /4;[6-,TP@7^HVEH2
MI<">94RHZGD]!ZTL^K:=;/;I/?6T;7)Q &E ,O\ N\\_A7'Z3>PV7Q'\70:S
M)'";B.VEM'N&"K);+&0P4GC"ONR/]JN1EM[>V\/>"(+LQ?8QXF=K1+@#(L]T
MWEYW?P[=I'L5H ]>T[5]-UB)Y=,U"TO8XVV.UM,L@5L9P2I.#BKA( R3@"N/
MTF6U3XH^(H8)8 S:?9%XU8;BX:<=.O VY^HJS\1;;4+OX>:[;Z6&:\DM6"JG
MWF'\0'N5W"@#7L]=TG4+DV]GJ5I//M+>7'*I8J#@L!GD9XR.*Y)_$,WB#QAK
M.B6&OII_V&" 6;P>6_FSR+(26# [@NT#:,=3GG!$.OW5AXA_X0R?P]-&]PFI
M0S1K 1NBM@I\T,H^ZNW"D>NT5+X;O;5OBWXTC6YA+O#8*BB098JDFX =\=_2
M@#NK=94MHEGD$DRH [A=H9L<G';GM5"T\1Z-?7IL[74K:6?G:JN#OQ][:>C8
MQSC..^*OSOY=O*Y1GVH3M7J>.@]Z\?T_6M-=? -R-3MXK=+S8MC%@Q62FWE5
M(W<Y;S,D*=S#<0<** /29?&/AN%-[ZY8!?/^S;O/4@R?*"N?;<N>PSSBMNO)
M[J?2V\(_%!TFLVE>6Z&0REC_ *.@4?\ ?0('O7H^@7*7?A[3ITF68/;1DR*^
M[<=HSS0 X:SIYU2?3!<@WT$7G/ %._9Q\P&.1\P'&>3CK55/%F@/8)?#5;?[
M/)/]F1BV"TN0-@!YW9(R,<=ZQ-9U*PT7XF:9>:E<QVL-QI-Q;I+*VU"XEB?;
MGIG /?G%<#J&HV,W@G6TEGCB(\8%]D_R,5-RK=&P>F2?3!S0!Z_IWB+1]6NK
MFVL-1M[B>U/[Y$?E1TS[C(/(XJ&S\6:'?RK';Z@A+PM<(SJR*\:XW.K, &49
M'(-<MJ6J:<GQ4VM-!,C^')0T:2+ND D#!1SU*Y(]N:K^&;N#3]:TJTM-7M=:
MT1;*5K>>7;]ITU%"\2..-A "_, <J/2@#I_#^H:?8^$OMDGB+^T[*&27.I3N
M#N_>,,;NC8/R@CK@8[5=MO$^B7,TL"ZC#'<1(9)+>X)AE1 ,[F1\,%QSDC&*
M\W6\M/\ A4C20WT<C6>LF6,@[P#]N+1^9CD*V5.[!.&R > >B\/ZYHFI>*[_
M %PZ]I'G/81P"VM[P-MCC9W9WW!><MCIP![T ;L7C;PU/-8Q1:Q;NU\VVW*D
ME7/( W8P"<'&<9[9JQJ7BC1])N&@O;LQ-&H:5Q$[)"#T,CJ"L8/^T17F4=U9
M)\&] 5)X!)'JEL6"D JRW*NQQG((7YCZ#FM3^T-&M=?\2:5XA_M#R]2F-U;O
M"\S0WL#Q1IM79P2,;<4 =]J6MV%@D237$N^X4F(6T+SN5XRX5%8[1D?,1@9&
M>M8OPZOYM2\+RW4U[/>[]0NPD\Y^9T$[A>P &T#@  >@K#TRZM?#/C6-]2MY
M["TOM&M;?3S,2XB,6XO S<_/\P/)Y]S6I\,YEDT+4U59$"ZQ>E4>-DPIF8C@
M@>O\Z .KO[^UTRRDO+V988(Q\SM[G   Y))X ')-5+#Q'I6I0W4L%T4%I_Q\
MI<Q/ \(QNRZ2!648YR1@UB?$(W5KI^DZK!;2W4&F:G%=74$*;G:(!E)4=25+
MAN/2L/Q4T/B[PUKLGAK33--):Q-/=F%HFN1&X?[.,KEB4# ^FY1WX .ST_Q1
MI&I7HLX)YDN&C,J1W-M+ 9$'5D\Q5W@>JYZBL^X^(WA.UC:276$V),89&6&1
MA$PP#OPIV#) RV!UYX-9>M3P>+-5\(RZ-(7EM=06]G."K00"-PRO_=))4;3U
M_"J%G?Z7'I/CFPN5\Z>;4+I?LXB)>XW(H5%Q]XY...GM0!V:>*-(D\0)H:7$
MK:@\/GH@MI=CQ\?.)-NPKR!D'&>.M6].U6SU9+A[-Y'6WG>WD+Q.F)%.& W
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MP(/(P0:\UT6VLIOA[X3TW4HM4M+F)F\N\MXW22QF4,0S C@$$CY@1SSUKK_
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MM?\ M5X;YHO(.9!L,6XL$VXQ@$GW]Z;KOA/2_$%W:7ETMQ%>V9/D75K.T,J
M]1N4]#Z5N44 8$G@[2FBL8D-W"EE,;B$1W+@^:<YD8DY=CN;)8G.3FF7G@K1
M]0O-3N;M)Y6U. 6]TK2G:Z Y4 =MIS@C!YJ3PQKUSKT>IFZL4LY+*_DL]BR^
M9NV!3NS@=<UO4 <]'X-TN.^MK[SM1:\@B:$7#WTI=E8@X8[N0" 0.F>U-;P1
MI#Z$=%8WAL#-Y_EFZ<_/NWYR3G[_ ,^,]?;BNCHH QCX8TUM;CUAA.;Q8DB9
MO/8+*$)*%U!PQ!9L$CO[#&O(GF1LFYEW C*G!'T-.JK;ZC:W5]=V4,FZ>S*"
M=<?=++N SZXP?Q% &,? V@G0GT4PW1TYYO/,/VV;[^[=G.[.-WS8SC/-+<^!
M] O+NYN;BVGD>ZB6&Y!NY=LZJI5?,7=AR <9.37156L;^VU&!YK6021I+)"6
M']]'*,/P92* *"^%])7PS)X=^SLVFR0F!XWE9V*XQ]XDMG &#GC QTJSJ.BZ
M;JVCOI-_9QW%@Z!&A<9&!T]P1@8/6K]% &1H?AC2/#JL--MF1F4(9)9GF?:.
MB[G).T=AG%7=2TZUU?3I["]C,EM.NR1 Q7(^H((_"N6O_&&LZ;8:'<76@6\4
MNK7T=FD#WS!H2X8J7_==<+R.V:Z#3[[4IM2O+2_TQ+9(4C>&XBG,J3!MV1RJ
MX*E>1SU% #%\.:<IF8BY>2:$0-*]W*T@CSG:'+949ZX(SQGI7+>)_",4&DZ+
MIVGZ'+J.BV5RTT]G'=L)U C94$3.PP 6R0&'3 ZFN_HH X?1/#INY'WV&L:9
MI4EL8);*]U-Y6E.5*D!9'V  ,#A@3NP1BML^#M%^Q:?9B&X%OIS;K1%O)AY1
M P",-V!('H#@5NT4 <[=>!/#%YK;ZQ<:/!)?2%6DD);#D8P67.UB,#J*LZCX
M4T35=374;VP26Z$7DE]S+OCSG:X! <>S U<OM5L].N+&WN9=LM[-Y$"#JS;2
MQ_ !35V@"CI&C:=H.GI8:7:I;6J<K&F<?K46L>'],UX6W]HVQE:UE\Z!UD:-
MHWZ9#*01^=0:UJUQ::GI6EV0A%UJ$D@$LREDC1$+,=H(+$\ #(ZY[8-G19-6
MEL#_ &U!;0WBR.O^C.2CH#\K#/(R.<9.* ,[_A!?#0@OK=-*CC@OI$DN8HG>
M-)&7[IPI '//'?GK5U_#FER:K::F\$K7MI'Y<,S7$A*KW'WN<XYSU[YK5SB@
M'(R.E '-2_#_ ,*3S7,LNAVSM<R>=*#G:SY!W;<X!R!R!S71111P0I#"BQQ(
MH5$48"@= !3F8*I9B !U)-+U&10!CZGX5T+6=0AO]1TNWN+N%=B2NO.W.=I_
MO#/8Y%,'@[PVNBR:.NB6(TZ5M[VXA 5FZ[OK[]JVMR[MN1GTS2*Z.6"L"5.#
M@]#0!C0^$/#]MH9T6WTJWBTUCE[>,%5D.,?/@_-^.<X%32^&])F>S>2U+/9*
M%MF,KYA'^R<\''&>I''2L[P?K][K<6M_VB+=7L-6GL4,*E598PN"<D\G)KI-
MZ;]FY=W]W/- $4]E;7,]M/-"CRVSF2%R.48J5)'X$BJFL>'M'\0PQPZQIMM?
M1Q-N03QAMI]O2M 2(9#&'4N!DKGD?A69::[;:EJ6J:;9.K7&G[4=R05\QEW;
M>.> 5S]: $F\,:)<6]E;R:;;F&QQ]E0+@08Z%,?=(QU'-.U;PWHNO10QZOI=
MK?+#_J_M$8<IZX)Y]/RJ72#J$>BVQUF:UDOPG^D26X*Q%O;/:KJ.DB[D967U
M4Y% %"\T#1]1TR/3+S3+2>QCP8[=X@43'3 [8]J2P\/Z/I=RUS8:79VL[1K$
M9(855B@  7('3@<>U7DGADV^7*C;EW+M8'(]1[5)0!#=VEO?VDMI=Q+-;RKM
MDC8<,/0UG/X6T&32/[)DTBS?3MX<6S1 QAAT(7H/PK7J!+VUD:-4N86:7/EA
M9 2^.N/7% $<>EV$.H'4([.!+PPB SJ@#F,'(7/IGM5NJUSJ-E92PQ75Y;P2
M3-MB6655,A]%!/)^E+>:A9:=$LM]=V]K&S;5:>0("<9P"3UX/Y4 27%O#=V\
MEO<1++#(-KHXR&'O62/!_AE49!X=TD(WWE%E'@_48YK6:X@2%YFFC$4:[G<L
M-JC&<D]ACFJT.L:7<64E[!J5G+:19\R=)U:-,=<L#@4 17'AW1;JUM+:XTFR
MEM[,@VT3P*5AP,#:",#BF2^&-!G29)M%TZ59IC<2"2V1M\IZN<CEO?K60?$:
M^)_"5U>>'-:L;*X5R%N)BLJQJKD989XW*I(ST!KHKW4]/TT*;Z^MK4-G:9Y5
M3..N,F@"%-"TA-0_M!=+LA>@ "Y$"^8   !NQGH!3(_#FAQ2RRQZ/8))++Y\
MC+;H"\F"-QXY/S-S[GUJCKGC31=!N=,M[J^MA)J$JI&#.J[4(8^:<G[GRXST
MR:MVQNAXFOA+JL$MLT$9@L%51)"02&<GJ021^5 $\.AZ1;:C)J,&EV45])DO
M<I;HLK9ZY8#)S1;Z)I-I>O>V^F6<-VY):>.!5=B>I+ 9R>_K2QZSI<NH&PCU
M*T>\!(-NLZF3CK\N<\4MSJ^F6:SM=:A:0+;[3,9)E41[L[=V3QG!QGKB@!EO
MH6D6E^]_;:58PWDA)>XCMT61B>N6 R<TLVAZ1<74UU-I5C+<3)LEE>W1GD7C
MAB1DC@<'TJZCK(BNC!D895E.01ZBG4 (B*B*B*%51@*!@ 50.A:.;_[>=*L3
M>[MWV@VZ>9GUW8SGFGW^L:9I7E_VCJ%K:>8<)Y\JIN^F34DNH64,<,DMY B3
MLJQ,T@ D+= OKGMB@"S5"30])FOEOI=+LGNU;>L[6Z&0-TR&QG/ YJ:QU"SU
M.V%S874-U 69?,A<.N0<$9'H13=0U.PTFW%QJ-Y!:0EMH>>0("?09[T 22V-
MI/=174MK!)<0@B*5XP73/7:>HS[4U]/LI;!K&2SMWLV78;=H@8ROIMQC%8^J
M:I!>V^DSZ9XFLK.*6_C&_,<BWBA]KP*2>I/&1R"*T[_6=,TM@M_?VULQ0R8E
MD"G:.K<]O>@"5=.L4LTLTLK=;6/&R$1*$7'3"XP,4?V=8[D;[%;Y084^4ORC
M.>...>:KG7]'!A']JV.9I1#$!<*=[X!VCGDX(./<4ZQUS2=4MI[FPU*TNH("
M5EDAF5UC(&3D@X''- $YT^R)<FT@R_WCY8^;G//'/-(VG6+Q>4UE;M&,_(8E
M(YZ\8JK;>(]%O!(;;5;.;RX?/;9,IQ'_ '_]WCKTK*TCQ]H.IZ++JLE_;6MJ
MEQ)#OEF &%=E5B3C&X+D ^M '0O96DL:1R6T+I&,(K1@A1[#M2O:6TBHKV\3
M*@VH"@(48Q@>G%5Y-9TR+43I\E_;QW@B,WD/( _ECJ^#_#[]*KVOB?0KV>&"
MUU>RFDGC>6)8YE.]$8JS#U ((S['T- &C+;03HJ2P1R(OW5= 0/I1+;03D&:
M&.0@$#>H/'XU2L=?TC4KG[/9:C;S3;/,$:.-S)G&\#NN>-PXK2H B%M )?-$
M,8DR3O"C//7FI:\_\->,+334UF'Q-XC@\V/6KBUMY+QTB)1 F!@8&!GKC&3[
MUV"ZYI;ZQ_9"WT)U'9YGV8'Y]F/O8]/?I0!<2"&.1Y(XD1WY=E4 M]3WI1#$
MI4B- 5)*X4<$]<?6J]CJ=EJ0G-E<)-Y$AAEV_P #CJI]QD5'K%M?7=DL&GWC
M6<K2IOG15++&&!;:&!&2 1R.] %^F+%&H 6-  Q8 #H3U/UY-<3:KJ]SXZU3
M16\2:DMM:65O<1D1V^XLYD!R?*Y'R"MZ'58]%T^TM=<OUDU 0%I&1"S2*G#2
M%57@<C/  )Q0!L^6G]Q>W;TZ4ZLF;Q/H5N]JDNKV:FZA,\&9AAXPI8N#_=P#
MSTI;?Q+HMWI-QJD.I0-8V[,DTQ;:(V7J&ST/(X/J* -0@'&1TZ4M94/B32)S
M=@7JQM9QK+<K.K1-$C D,P< @'!YJ"V\8^'KR:SBM]4AE:\QY!4$JY() W8P
M"0"0"<G% &Y17/:9XKMM3\4ZGHT4<H^Q+"-[0NNYW#L>2,  *N"<9.>M;[N(
MXV<AB%!)VJ2?P Y- &-XFT.YURTM4M-1-E/:W274;&(2([)G =<C(R0>HY /
M:H[+1M5DO[6]UO5(+M[0LT,5K:>2BN5*%CEF).UF&,@<GKQAS>,=!71YM6-\
M180R-%+/Y$FU&7J#\O&#P3TSQUXJQ=Z]ID!@AGNI(&NK=YXW,+J!&JY9BQ7"
M8!'WL8R/6@#5HKS;Q#?RV?POTF^TCQ#>WBI=VRB^+D/=(TP1@YQG!!/3!X'-
M;4]Y<1?%NSLOM5P;6?1Y9?LYD/EAUE0;MOK@D<T =?117.3^/?#%NUXKZJA:
MR<I<K'$[M"0,DL%4D*.[=!W- '1T5GW&MZ=:BS,EQN-X,VRQ(TC2C&255020
M 02<8&:Q]:\;Z=8^#-0\06#27BVRR($C@<E)5!^61<93!Z[L8_*@#ISG!QC/
M;-8?AO0[S1&U$W-[#<B]NGNR(X#'L=_O#ECD<#'?K6M9W*W=JDRB0 Y'[R%X
MCD'!^5P".G>H=2U6STJ.)[N7:9I!%#&JEGE<@G:JCDG )_"@"A<Z!<WGB-+^
MXUBX?3HPCIIGEJ(Q*AR'+?>//..F0#VK<K$C\6Z))IM[?F]"0V,I@NA(C*\4
MF0-A3&[))& !SD8S4MIXCT^[N;BTS/#=V\7GR6TT+))Y?]\+C+#((XSSQ0!K
M45R]M\0O#=W;65U!=S-:WDWV>.?[-((UDW% KMMPA)' ;!Y![U>O_%.F:=<7
M<,S7#FRC$MTT-N\BP*06&X@<9 )QUQ]10!M45SG_  DY;QRV@+:S^7'9B=I/
M(;EF?:,'^Z-K9..3WXYQ5\1Z9X>\(^)-:TR?4]4^SWD[R)<JY,<V 2@W %8U
MR/8<T =[16):^([<SZ99727,5Y?(?+WVSHC,JEF&3P. 3@FJ&J>.;*TTG7Y[
M6"ZFO-&B+7%L8&4H=A=2<\;2!G(SQ0!U5%8&G^)8Y=&TJ>ZAN/MM[$"(([=@
MS,%!9@O9!GJ3CD#.36AI&LV.N6LD]C(S"*5H)4="CQ2+]Y64\@CW[$'H: +]
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %<5KJ+X@\2R:=+I5S?Z?86SQS")HP//F3'.]UY$3-
MV/\ K*[6LS1]$AT470AN+F;[3,9Y#.P8ESU.0![?D,4 <U\/+V:^\+7/A[4&
MN(-1T=S83YD E"8_=ON4D9*$<@GD&N2MCJJ_"[0O$J^(-7;4UNH4W/<ED=7N
M?+*LGW6X;JP)X'..*]$A\(6EOX@OM<@OK^.^OD$<[+*-K*!A?EVX&!T/6JX\
M!Z6/#EOH'VF__LZWE$T<8F (8-N7Y@,X#?-C/6@#'1KKPWX^O+2"^U"]M7T&
M6^,-U<-+F9)0,KG[N0V,* .G%4=#M]>U/PYH/B$:U;P-NCN[FZ-W-(MRC??B
M:,@*H^8@ 9VD8'<UVS>&[5O$$.N-<79O8H/LX/F_(8S@E2N,') )/7(K/T[X
M>>'=*U$W=I!<(GF^<MH;J0VZ2==PB)VYSSTX/(Q0!Q]Q:SW%K\19)-9U3.ER
MO+:*+QU\EEME<'(.2-W\)XXZ5M:9?R^(];T*QU&Y?R_[ BU*2!&*"XE<JI9L
M'D+Z>K@]A6^O@[2UAU>(M=LFKDF]#7#'S<C:?]W*_+QCBF7'@?1;BSTV K=1
MR::GEVES#=/'/$G39YBD$KC P<]/7F@#SNYBFL?ASX\BM+V\AEL]<E\F=9VW
MX)BX9LY88;'/6NEO=*:S^(VCV<>IZIY&IV%R;Q3>/^],31E2.?D/SD?+CCBM
MH_#[P\VFZCI[6]P;;49O/ND^URC>V0>H;(Y SCKCG-7W\,6$NJV.IO)=M>6,
M1B@D-R_"G&X$9P=V!DD=A0!P-SJEUH?A>_T^VNYDMAXF731<23.6M;=V1F^?
M.X ;BH.>-PYX%:]_H=SI1UACK)M;>[TJ799VLDJLDD8R9D9G^4_, >F>,UT2
M>#M%6RU.SD@FGMM38O=Q7%Q)*LC'J0&8[3P.1CH/05%8>!M!TS3[BRM(+E([
MB(0NYO)6D$8Z(LA;<J^RD"@#C[>*73M%^'FL1WM[+?7D]I;SO-<,P>.2!BR[
M<[>H!!QG(R2:W_">E6-KXO\ %KQ0!98[Z/:VYB<-;1$]3SDDFM*7P3HTUCIE
MDXO?L^F,KV:B^F'E,HPIR&R<#@9S@<5=A\.:;!K\VMQQ2K?3*%D;SWV-A0H)
M3.W=M &[&<4 :4T,=Q \,J[HY%*LI[@UX_I'EZ-\+(&LU-LMYKAL[F:)BI2!
MKYD;!'W?E^7/;/K7L=8,'@W0+>#4(!IZO!J#,UQ#*[2(=S%F"JQ(0%CG"XYP
M>PH Q[N(Z%\2/#UOI@:*TU.WNDN[<$^7^Z5620#LV6()[YYKMJRM-\.Z=I<X
MG@CF>=8O)26XG>9TCSG:I<D@9[#K@>@K5H X?XD;O,\';>O_  DMKW_V)*G^
M(=]/:V>BVR3BWM;[5(;:ZF925"$,0K8*G:S!5/(X)'>MC6O"ND^(9H)=3AFG
M,#*\2BYE18W&<.%5@ XR?FZ^]7;W2K'4M+?3+ZW6ZLW0(\<^7W >I/)/&<]<
M\T <%KGA]M&T7Q4R:HD:W.E/-'I]E&]M' T:D>8I#G;G@$# ;'?FF+ID.D:K
MX!U"VDG-Y=M]FNII)F9IHS;,V&!., J" !@=JZNV\#^'+/1[C2K?3O+L[D!9
MU$TFZ11T4ONW%?\ 9SCD\<T^3P=HDL>GI);W#+IW_'I_IDV8>WRG?Z<?3CI0
M!YWJ31FQBU[3XS-%_P )'%MU2=O])D!N@CQ( .(A\R@$\@?=YS6[!H%EK/Q"
M\:6=X]Q-;O:V1,+SL45G67D#/&,9 Z#)P.E=!/\ #_PM<I>)-I$3K=S>?*"[
M\2;MQ9>?D)/7;C-7$\*Z1'?WE]'!-'<WB".>1+J5=ZCH.&P .V.G;% 'F-M%
M#K6E_"J[U.WBN[B=S%+).@D:1!"_#$CD<9P>]>S !0   !P *P!X(\.?V3;:
M4=,5K*UE\VWB>1V\IO\ 9).0.O ..3QS6]'''#$D42*D:*%5%& H'0 =A0!Q
M?B71=-O?'WAIKG2K*X\T77FO+"K%ML0VYR/FQVSTJ#2=/L/$?B#Q;;ZQ;QRR
MVMPEI!!( ?LUOY2E6C_N;BS-D8.0.>!CI;_POI&IZG'J-W;RO>1#$<JW,J&,
M=]NU@%SWQU[T_4/#FDZG=?:KJTW3F/RFD21HV=/[K%2-R]>#D<GUH \NL&N-
M:L?AD^JRRR3RW-S#(YD8--&B2A2V.NY0I)ZG->MZ9IMKH^FP:?91F.V@7;&A
M8MM&<XR>:J7GAC1K^6UDN+%&:S0);;69!"!_<"D!3VR.<<=*UJ .$\27#S?$
MG1=*NI8$LY["=[:.ZA,L4MP&7(*[AE@F<9_O&LZ^\%VUUX+UG2+&]6_O=.NV
MN;17A^2VE 646Z\G]V>!C)P&QVKO-8T+2O$%F+35]/M[V -N"3(&VGU'H?I4
M]AI]GI=E%9V%M%;6T0VI%$@55'T% '!0:IIOB;2M2\:7&Z#3K;2F@@GBC_?1
M$H6G921G()5!Z%7]:S](@:P\5^ S%;P6T%U9W2HL9#32QB%&5IW& SG )P"
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ME6::?(=SVHA7RV.0<[<8Z@'\*>FBZ7'936::?;+;3-NEB$8VR'CEAWZ#KZ4
M>:6&F6EIX1^&NHVT(BO7N+%9+A?]8ZO 0RENI4C VYQP!C@5ZE!?6EU/<06]
MU#++;L$F1'#-&2,@,!T/UJDWAG0FA@A;1[!HK=MT*&W4B,^JC''X5%IF@1V.
MO:EJY6W2:\"H5MX@@*J20SGJSG/)/    ZD@&M<6\-U;R07$4<T,B[7CD4,K
M#T(/!KR'0=/L8_AAX%U(PHMXE_9 7)QYF#-M*[CSMVLPQTY]*]>FABN8'@GC
M26*12KHZY5@>H([UGMX:T)[46K:-IYMP2PA-LFP$XR0N, G _*@#@4CT_5=<
M\:Z5XBU46%Q).?W;^2,V9B0(R%U)QPQ.#P<G@FK,=[%9>-=)E=Y;ZW/AXI%#
M<R1I<1XD7]XP=E7,@P.,'*\C'3N[K1=*O98);O3;.>2# A>6!6,>.FTD<?A7
M-:YX9U"^\6'5#I^C:O8M:+;K:ZB2I@(8DLAV.#NR,Y /RB@#F)M,;PQX,T*-
MT@33I=>2741"0R16[RLR([#[R*QC!)XQQTKI;NU$7Q7TPZ>B"*XTR<ZE&GW6
M567R691P3N+@$]@?2M+P]X8BTV'4#<V5A#_:# S65HF;90 1P"!DD=3@9P..
M.=FSTVQTY66QL[>V5L;A#$J X&!G ["@#R'6%LI/V>+N("W>>W"LR@ M&WVG
M )'4'&1^===J]U92_$&ZMA+;6MU%HX$]S>8=?)>1OE2,D<Y!)8DCA1@YKJ7T
M#1I()('TFP:&63S9(S;(5=_[Q&.3SUZU(-(TQ9K>8:=:"6V7; X@7=$/13CY
M1R>E 'D>EW%D_A7X83R3P-%!>^7+(S+A,0RX5B>G;@UU4XW>-/$LFA"'[;<^
M'(983%A?-E+W&QB1W^YSZ8KLCH^F&T6U.G69ME?S%A,"[ _7<!C&?>GC3+!;
MW[:MC;"[Y_?B)=_(P?FQF@#S*_,5W\%]"GT@$:K')9_8QP)?M?F*)!SR6_UF
M[UY)[UNZ?I.DR?%#Q*TMI:NQL[5V5XU(RWFAFQTR1C)Z\UUT6DZ;#?O?Q:?:
MQWDF=]PL*B1L]<MC)IHT;2Q)+(--LP\H82-Y"Y?=RV3CG/?UH XKX8ZY86'P
MQ\*QZCJ$44MV&M[<2OS(XD8!1^@Q]!7H=8FI>&;+44MX!#;06R2B:14MTW.1
MC #8^7.,$@9QT(K;H XK2IGC^*?B2#4F7=-:6KZ?YF.8 &$@7_@9.[\/:N%N
M((U\"Z5),$-HOBU%T]WQ\MH;@[0A[)@'';&.U>SW5C:7P07=K!<!#E1+&'VG
MU&>E$]A9W.SS[2"78,+YD8;:/09Z4 %G86FG0&"RM8;:$L7\N% B[B<DX'<F
MN<\76J7>IZ*MMJRZ=K43RRZ>TJ[XI2% >-UR,Y5NQ!ZD5U2(L:*B*%51@*!@
M >E0W-E:W@ NK:&<#( EC#8SUZT >6:AJ"WGA719;ZUL[.YMO%L*2>3)NB>0
M769'C)Y )+'GIS6MJ&MVVB_$C6E>:SF-UIEL&CNKM(/**M* HWXRI#$G&2#C
MCFN[;3[)X8X7L[=HHAB-#$I5!Z 8XKE[WPUK$?B&[U"P?1[JVNDC40ZC;L6M
MP@P%C9>-O).,=2>>> #E]>T[3].\'_#_ $_[197D4.M64331[6CD&&#X]5_R
M:L:[<Z;8>)/'@EB26%M @>>VBEV&3'G*P^7D?+M!/4 BNUTGPU:V-M,+J&TN
M)YYVGDV6RI&K$*N$7G PH[DDY)ZUJ_8[7S#)]FAWG.6V#)SUY]Z /.=/U*U;
MXE:!)+K%I<O+I$\(^S$" -YD.(XSU8]<Y)/&<"LRXO;6?X*Z]96\R2W=I+<R
M7$*<M$!=N<L!R. 3]!7K26EM%Y?EV\2>5GR]J ;,]<>F:>L,2;]D:+YAW/A0
M-Q]3ZT >=W6M:7J/Q9\-RVM];W$!TV[3S(W#(6/EG;NZ$X[?XUC:186VH_"#
MQ"^EPV]QJ GU$!H@K28:5LJIZC=& /?CK7K:VT"A0L,8"IL7"#A?0>W XIZQ
MHC%E15+8R0,9QTH \[T'4?"?B/6M'O\ 3-0O]2U* .R1F8YLD9</YB\ #HN#
MG)QCID>C4BJJDE5 +')P.II: /+[%M!AT[Q]!JJ0>9+J=P)(2JF:1&1 @4=6
MR2=OO4VIVM]X7\/^%?$YM9)]2TJT@L=0A#_/+#(JHZY)P6$FUAD]CZUZ08T:
M19"BEU!"L1R >N#^ K O="U'4O$0FO=31]"C\J6+3UA 8S(<@L_4KG#8]0/0
MY +^@Z;)I.BV]I-+YUP 7GE_ORL2SM^+$UI444 <'I6JZ?)\8==@2^MFE?3;
M5%195)9E>7<H&>HR,CMFL[Q%>:9HOQ$N[CQ'>W^G65]9P):7L$\D<19#)NB<
MIT/S;AGU->FT4 >5%=$T[7?A]I]M$+.UAN[UHK>\DS(J/'+L<ACD!F(*@^H'
M7BJ=WK-C:W'Q#:3[-=Q?VA9R".1MR(,1(TQ53DJC@$X[I@XKV&B@#S'2-8TX
M?$Z\NWUA[J&YT&-DNYU$<;!99"VPA0-@'.<GKUK)TN^L+7X1^"U,]K'-#J%H
MS*[ ;&64%RPZC .2?0CL:]DHH X71]0MK/XJ>)+6=RLVHQV<MHH0MYJ+$P9@
M0,;01C)[X]17=444 >;W6A7<OBG6_"P0_P!B:V%U"5P<>4I!2=%]&=Q&1[%S
MU JYX#EN_L=U=ZVPC;1D.DB:5_OB$DO*3T&X;/\ OC)]N\HH \2-U"?@%HEN
M)!Y\5U:H\7\2LLX<@CKPO/TKK[V\MS\:='83(5;1YHPP/REFD1E&>F2 2/6N
M^HH *\MLK^S9?B8_GH1+(Q0E2-X^SJG&>OS KQWKU*B@#RG0+LV5_P"#=?NP
MYTQ] &G23%<BUN,HQWX&5SM*Y.!D =ZDU;3IM3\/?$;4;".5[748E%L@C(\U
MHH0KNJ]3DC ..=N1D8KU*B@"GIFIVVL6*7MF9&MY/N,\31[AZ@, <?A7*>.F
MN],USPWXD2UFNM.TR6=;V.%-[HLJ!!(%')V\YQV)KMZ* /.]9F?6=+76-$T:
M46EMJ=I?R#[*8I[X(W[P[& 9L+L*DX)*D= ,V9IX-7\?Z5KUD\HL-,L+@7=P
M8F56\PKL09&2058D <8&?2N[HH \07S!^S\FFBUO!J OE!M_LLGF9^V>;]W;
MG[@W9K>\3M;R:KK>HZ5+J5AK$=O&%3[,TMKJRF(%$="N&/S%.H(^G3U&B@#B
M(;N:S\>6%QJ%E<13WVC0P%((&DCCE$A+J6 PH7=U)Z"L$6\NK^!_B%86EO=/
M<W-Y=30(]NZ&565=NW<!G)4CC^HKU6B@#@=5U9)F\)^)(['46LK2ZD2<"SD\
MR,/"Z;C'C=M#$#./_KY+V][J%W\4#%IMZIU*PC6T$D)'FD6A7 /3)++P>>>0
M.:]4HH \MOY1,?#'B!]%U&_T:"RDL[F)H'6>W+",B41\,PRFTX';(S7:>%UM
M6M;FXL-&_LRSGD\R,/%Y4DY(&9&7J,\ ;N>.G2MZB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHKS8W=U8^)H8-:DU.)9]4!LM6M+J22TG!D(6VDC#8C.,)RN"03G).0#N
M-.N]1N+S48[[3A:PP3[+643!_M$>T'=@?=YR,&M&O.].N-5CN/B+;Z?=W-Q>
MVL@^PI<3-)Y;&V#*%W9 &XGBHM&CDOM4\(SZ7<ZNT!MGEU;=),(W)B4J9"QQ
MOWXX R1G/ &0#TFBO+XK"6_A\>K-JNJ[;&Z?[*$O9%,3"W1U8$')PQR 25XZ
M5:M=1E\0V_A1YGGO+J[TC[3+IJ.8XB6\O]_*X(P%.0!AB2W X- '>7^H6^FV
MZ3W+[4>:.%<#)+NX11^;"K5>1);MJW@?PW)JTSW5U:^(_LZS-<.YPMT\?W\Y
M;Y1C<>:ZV&W6/XEW5D#.UI+HJ,\32.T>[S2F>6QN*@#.,D#KZ@'845XQ;R74
MGP_T]Q?7B/%XJ$"N+AN(_M> ""<,!@8#<"NANK!K/QC8^%[2Z_T-[2:^CBOY
MYI?-E+@$;MP+!5R0I)QN)]" #T:BL#PA8W.EZ3-I]WJJZC);W+J'!8F%3AEB
M)9B3M# #)Z8K*@(U[XA>(--U-&>UTZVM3:0ERJGS!(7D &,G("[NV"!C)H W
M_$FN1^&_#MYJ\L+SK;("(D."[$A5&>V21S3=,GUW^T[BVU2UM#;"-9(;NV8@
M$DG,91B3E<#YLX.>@Z#R_6VFU#X,:^=4::\ETK4)K.WGE8EY(TN%4$G^(X&,
MG/3UKV&VM8+.$0V\:QQ@D[1ZDYH IG5EFU"_TZQ19KZSBBD=9'V1YD+;5+ ,
M0<(2>.A7UJEX*U^;Q1X/T[6YXHX9+M&<QQDE5P[ #GKP!^-87AC2K"#XF>,)
M(K2%7C-FZL%&59HGW'UR<GGOFN0\-Z>J?"SP3K<;R_;X-0M8UE,K?)&]SY3*
M%S@ JV#QWH ]<A?5#K=VDT5LNEK%&;>16/FM)EMX8=,#Y<?C^%^N)CC$'Q&\
M2!;EX$DT:VE:5Y&;RFWSC<-Q(4 #.!@<?6LOPI9'1?$^FZ?JFD16U^+.58-2
ML6W0:EPA=Y!@,)<*"2V<\\G(H ]*KGK?Q9;7'CF[\,*A$MO:+/YIR [9&Y!V
M) :,G_>K4U?44TC2+J_D1I!!&6$:_>D;^%1[DX ]S7FVMZ7K?AW1-&\07-K9
M-<Z'=/?7\\%RS/,DQ/VD!/+ .0V1D\!!0!ZM17 ^,X;?4_$'@B9)96AN+]L-
M#,RAD,#L",'V'/7WJOIWA'1)?$_B?19; MI*):W"V;2-Y/F.K[F"YZG:.O<9
M]Z /120 23@#J32UXSH>I7>K>'/AY::C=VODWEM.I;4(3-#/,A58D9=R[FQD
MC)Y(S@D"M+7- M[#PGJ>FQZEY\EOK%G/'#:J]NED99HAY:@,1CDL!GY=^>.*
M /5*YOQ7KM]HLNC?8UM7BN]3M[.X\W)95D;&5 Z'&>3^5<W>P)X8\9ZNN@6O
MEW$_AR:\\M<MYT\<F$9LDY;Y\9.2>YJA=6.F?\(MX%UBTBA:\N-4T]YKQ0/,
MF9S\Y=NK$DGJ3@_2@#U5Y$C4L[JH'4L<8H+J'5"P#-G )Y.*X6V\.:5J?C[Q
M3!?V8N+=[>S9H)B6B9F\W+%,X)R,@XX.<8ZUQVC6%O)\+?!VNO'YFJIJ=I&M
M[(2TJQ_:?+V!CR$V\;>GMF@#VIY8XV17D16<X4,<%C[>M*756"LP!() )[#K
M7F+:9:>*?$/C'3]1OK2*\AE"CS[;=-;VWE+L>)V;Y5W$MD#AN<T\:/IM_P"-
M?"J3,=2@ET.X62XFW#[8JF$ R+T8$'/(P<_2@#NM9UVQT/1I-4NI0;==H4HP
M^<L< +D@$DGUK11TD0,C*RGH5.17BUU8VDGP^\5V;6L;0:9XE,%FA4$6\?G0
M':G]U?F/ ]:]DM(K6"V$5E'#' A90D*@*IR<C X'.<^^: .>\*:_?:D=;CUB
M2S26QU5[&)H%**RB.-APQ)W?.>]=&;F 2^49H_,SC9N&<XST^E><VOAK1-93
MQX=;MHFC75)OWLH+"W'V:$^8@)PK<YW#!.!SC%9YLYM-T'P?X_U.V_XF.GV\
M::N\L1,KP.H0R-QN+)PWKC=0!ZO'/#,7$4J.4.&"L#M/H:Y?Q1K&NZ9K^A6E
MA-IZVFIW)MG,]L[O&P1GR") #D+C&./4U?\ "NFBSTV6\DA6.[U*=[V?Y-IR
MYRJGW5=J_4'UK*\:*#XC\%/CYAJ[ 'ZP2_X4 =BNX*-Q!;') P":ABOK2>=X
M(KJ"2:/[\:2 LOU':JFJZO9Z=Y<%Q(ZR3QRLHC +!40LS8]!@#/JRCO7F-@M
MM;77PV>*2RM;8NYM8-P:X:%K>0EY'! ))VE@%QN;J: /5VU"R1BKWENK"40D
M&50?,.,+U^\<CCKS2WMY!90;Y[J"VW'8CSL N\]!R1GZ9KQV31]._P"$/^)S
M+I]MNM+ZZ^RXB'[C]S&W[L8^7D \8Z#T%=7I%]#<>/K2/577[1_8-N^G&4Y\
MPL6^T,N>-W$8(ZX'H30!G3>,_$(^&&I:\ES9_;[34GMBWD?(T8G$7R@MP<'/
M);ICG->D7E_9Z=")KV[@MHB=H>>0(N?3)->0V@LO^%+^)[>V> P1:G<[%1OE
M4?:04QM^@QV_"NS6>0_%Z6WO_P#5?V2K::'^Z3YA\XK_ +7^KSWP!VH ZR6\
MM8+4W4US#';@9,KN F/7)XICZE8QPSS/>VRQ6[;)G,JA8FXX8YX/(X/K7C?B
M2Q\GX<^/D$*G3[+4]VEL5&(#NC\P1?W0KEAQC!W#UKK?$-OIWAWQ?X9 M[>R
MTB\O+B>]E8;8WNA$!"7)XW$[B">K 'K0!K>&=;O=3\4>(;2:^MKRRMEMGM)+
M= %VR*Y/()SRN,Y[5T]Q<06L+37$T<,2_>>1@JC\37%^&9],'Q*\7QV<UKOE
M6S9UB=<LX23<<#J>F:D\:3I!XF\(-?#_ (E1OI%E9ON"<I^XW?\  LX)Z$"@
M#JXM1L9[5KJ*]MY+=20TJRJ4!'4$YQ1;:C8WC[+6\MYV\M9=L4@8[&Y5N.Q[
M'O7GVK65NWC#Q>D")+93:"'U"+ V"Y&[RR>P8H"<GG 4^E;WP[TW3X/!6@ZA
M!:PK=SZ5;":X51OD^0'#-U/)/6@#I;N]M;"'SKRYBMXLA=\KA1D]!D]ZR];\
M5:3HGAF?7I;R"2TCC9HV25<3, <(IZ$DC%8FK3O!\7= ^V!OL$NG7$5HS?<%
MT64GZ,8PP'?!('>N=UV(VWAOXF_8AC3U8/$J?<6;RD,VW'^UR<?Q;N^: .JO
M==N(O%>B-'J<!T:[AN6F5%4JK1J"2TF>@)/3&"*Z.TU33[_3AJ%I?6T]D06^
MT12JT>!U.X''&#7'ZQ+IVL>,O!4GFVMU$K7;*=ZNN]8U''J03^!KE+Z86VF?
M$)(0_P!CMM>MKFXCMT5B(LPM.=I!!RJMD$$'!R.M 'JUMKND7D,TUMJEG+'#
M_K72=2$_WCGBHV\2:$BEGUG3U41K*2UR@^1ONMUZ'L>]<M:R^&-4UEM3L-6D
MU>[ETYXI7CE1XHH1\X\T* %.[[N[GKZ'$'@;PYHNM?"G38WL[;S+S21:33J@
M+X(Y!;KPW.,\$=J .U;6]*2ZM[5M2M%N+A5:&(S+NE!Z%1G)!QVK,UO6+2:S
MF@L?$]AIMU!=1QRRNT;[#N!,95CPS+D>O.:X"2^U_4-"L/$5U$\5WX08B\4+
MEKIE)2Y )[>4 WH2WM6WXC41_#62^OBL%WJ&H6]WB<@,C-<1E%Y[K&%7_@)H
M [B^UK2],D$=_J-K:N4W[9I50[>F>3T]Z+K6M+L8XI+O4;6!)4,D9DE50Z@9
M+#)Y !'/O7&>*)&@U_4]1T?5[2*_MM.0WVGW^!#=09<H0^<H1EQD<9(SZUD1
MZUIMMXK@FUB^NM!M]1T6U:PD=U2,*H8O"S.IPP+ \]?RH ]5BECGA2:&19(I
M%#(Z'(8'D$'N*XZW\2C2_&7B6WUW7;>'3;9+1[4731Q+$9!)N7=P6^Z.O:M;
MP;:Z=9>&;:VTA+A=-C:06QG))9-Y.Y<_P$Y*_P"S@]*P+>33+3XK^(IM1:VA
M:33+41R7!"Y0&3S I8].%R![9H WM6O[:X?17M?$MM8K-=)(BJ4?[?&>/+7)
MZ'(Y7-6;GQ/H-H+HW&L6*?9"%N 9US&QW84C/!.UN.O!KSFV2UTSP;X96>6"
MWMO^$D\[31<'84MC.Y3;NY_U; _1@#71Z=-HS?%'Q--(]CY\6G6BM(Y3<H!F
M\SG.0.$W=.BY[4 =;+JVGPV$=])>P"TE ,<V\%9,\C:1][/;'6N7\(ZU<ZGX
MU\76C:FU[963VHMLA0(]\;,R_*!T/'//'-<-X0U>.Q\/> =1U"[C&BV\E[!-
M,S92WF+.L.\]%&W*@GIN'0&NL\&7]C>?$SQP]E<PS1S?89(WB8,K@0X+ C@C
M)ZT :GC_ %#4])TJSO-,OY;9WOK>VD58HW4I)($)^8'!&>#^E=3!&T,"1O,\
MS*,&23&YO<X 'Y"N*^*=_9VGANT2YNX(7;4[-E620*2JSH6(R>@ )/I6W/XP
MT1;BTM;34K.]O+N=(8K>WN%=CD_,W&>%7+'Z>XH LOXET:.^^Q/J,"S^:(,$
M_+YAZ)NZ;O\ 9SFH[OQ;X>L)KJ&ZUFRBEM0//0RC='G. 1US\I..O%>1:_JU
MA=>$=5:WN4L1#K@:;28AN:,K=+NFG8Y()QD8*KSCDUV^F:AHS_%;Q%<?;; X
MTFUWLTB;@ 92^<\@ ;2WI\N>U '8R:SIL6G1Z@U[!]DEQY4JN&60GH%Q]XGL
M!7$:;KFH:CJ'CY+36)IH;..)[!P(\P$PLQ7!7 PPQAAGCGUKD_"6L6MEX:\
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M?GGO4V@:DVL^'-+U1U5&O+2*X*IG +H&P,\XYJQJ%_;Z782WET^V&(98]SV
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M2\>"-IRV,<G\23UYIUAX=TO39XIK:W</#'Y,)DF>01)@#:@9B%' Z8Z5J44
M4-5T:PUN&*'4(#-'%()47S&7#CD-\I'(/(]*??Z7::GITFGWL;2VLB[)(S(P
MWKC!#$')![YZU<HH PT\'Z%&E@BV;A-/;=:+]HDQ >GRC=QQQ4Z>'-+BOKN]
M2&5;F\7;/(+B0%Q_WUV[8Z=L5J%E! ) )Z#/6LV]?5UUK35M!9_V8WF"],I8
M2YV_)Y>.#SG.>U %4^#?#K:%'HCZ3!)IL;[X[>3++&WJN3E>IZ8ZGUIS^$=!
M?2H=+_LV-;&&3S4A1F5=^<[C@_,<\Y.>>:KZ!K=_J'B+Q%IE[';*-,FA2)H=
MWS*\8?G/?D"MK4;^VTK3;F_NY!';6T;2R-Z*!DT 5ET'35U9-4%N?MR1^4LQ
MD<D)@#;R>G ./49Z\U07P+X61BRZ%9#]\+@#R^%D'<#H.O;BMFTNX[NSMKE0
M4%PBNJ/PPR,X/N/Z5+YT05&\U-KD!#N&&)Z8]: *"^']+2[NKM+7;<72&.:4
M.VYU]"<]!DX].V*K_P#"):!_9L>G#2X!8QN9$MP"(T;KD+T!R,^QYZULE@"
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M*<CG-=1>>+/#]A+=176L6<4EH%,Z&49CSG (]3M/'7B@#7:-&<.R*6 (!(Y
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M[MXC##.85WQIS\JGL.3Q[FJR^$?#B6S6PT.P\AG$C1&!2C, 0"1C!/S'D^M
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M[P]\/=4N;ATTB""XM+FY@;*VDSA0C/U"\!EYZ;J]H$,0Z1H,Y_A'?K^=.V*
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M* .$U*\A\57WA3^SHIA/:WXO+D21,AM8UB=61\CY6+.J[>_)Z UE3RK-X/\
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M!VL C-Y@9CPKE?+)!P2 /3% &Y\/=6O=7T;4);Z_%\T.IW,$4X" -&K87[H
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M6B^'=2TRS6#PW!KCO+*N1&Y>-L3_ .X)&(R>.,],5J^6M_\ $/6+O3"DUO\
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MU=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M (FD$"[I<G/S'&3^- 'E6G7@@B^'O]H:M-IU@^D.D-R=C)]IQ&%!,BLH.S>
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MB.<5M57L[.VLHW2V0*&<NYW%F9NY9CDD].OH* +%%%% !1110 4444 %%%%
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MLJXRP&>!D]:S=7U[3M%T.ZUBZN8A:6\;.6#CYB!]T'."Q/ 'K7GPT'2I=5\
MVJS2:C;0B^MA<S$J\\:(0 2N-R<<=B/8\XWB>PM+'PE\4--M;6**SM;J":"%
M4 6)GBA+%1VYSTZ4 >U0S1W$2RQ.KHW1E.13/MEMN=?M$.Z,9<;QE?KZ4RQ6
MUCMA%:"%8TX*1  *>N,#H><_C7"^(EB\*^-AJD.GI<1^(;8V#P+&,2W:Y:+>
M<=&!=2?8$^P!WAO;58EE-S"(V. YD&"?K6.)=<MX-=EGO-.=HW,E@J1LWE1A
M<@2*""22#T/?\*XKPG97=O>P^!;R*-TT6\^W22K$5CD@8%X=N>XE;&.>(C6S
MX5MX;76_'D<*Q(GVY7VQX !,"D_0YSF@"&Y\5ZS'X.\$:K'-;B75KJPAO<PY
M+";;NV\X7OV/7MBN_<.8V$;*KX.TL,@'MD9&?SKR>[(_X5A\,^?^8CI']*]:
MH YKPGKLU]IC?VO>6OV[^T+NU0(!$)/*F=!L4DD\*.Y-;MWJ%E8",WEW;VPD
M;:AFD";CZ#)Y->43Z)HUS\./%U[-:1/J U'43!.HW3+.+B3R@AQE26V@ =<^
M]7+*6.\\2ZOIGBG4O[/O9M-M457\K9<0F+]YM\U6Z2&3(^F0: /4ZXW5O$WV
MKQ4WA[3]:M+&2.Q:X><LCGS=X1(\-D 9W$CKTQBMKPM%:P>&+""QGN;BSAC\
MJ":Y(+R(I*JQ( !! &#CD8K$C6/_ (7-<#Y"W]@ID=Q^_:@#<L-8@BT*RN=5
MU33/-=522>&8""27'S!"3Z@\=:SKW5]0MOB'HVF+<0MIE_9W$OEB+YM\>S!W
M9Z'?V%<1KEU8P?"CQM9RS6\<XO[Y5@+C=N,I88'7..:Z*2>*;X@>"FAFC=3I
M5X<J0<C$(X_$?H: -'P[XBF>?Q"FN:A:QK8ZJ;2%R!"FSRT=1R>6^8]^U=#_
M &IIX6V;[?:[;HXMSYRXF/HG/S?A7&Z!IMEKS>/-+O$66VN=6>*101G!@B'X
M$$<>XIG@M]4U2]@MM8B D\-J]F\FW FN.BR+[>3M/;F4T =?KT]S:^']0N;2
M98;B&W>1)'C,@!4$_='7I5'POK\&IZ#HWVJ_MGU6YT^"XFA$BAR6C5BVP<@9
M;T[U?UT$^']2 !)-K+P.OW#7F::1I;_#[P+-I<,"ZTLM@]M)",N6)3S]Q')4
M)YA;/3% 'H=C/<1:KK$EYK%I/:*\9@@4*IM%VX(<]R6!/-6XM9TN>[AM8M2M
M)+B:+SHHDG4N\>,[@,Y(P<YKCK2UTYO$'Q M]EKY<D<#S(=NW<83RPSP> >W
M]:QD2RLO!/PQN(([>.5KVPRX(4DO 5<D]SV/X"@#L?&WB&+1_#NIFVUFSL=4
MAM))X%E9&9B%) "$\Y(P/?UZ5+-<W1U7P\!KUM;(Z-]HLY%3S+TF/*[>XP06
M^4>M<3+J=@?!7C_3M7N($U<2WK30SNH=P4/D%1W&P(!C/(K0OKNQN?$OPYOX
MY+5Y)C,OG1E6W#[.1@,#TW<?6@#M+CQ)H5J&-QK.GPA)!"QDN44!R 0IR>N"
M#CWJW=ZC96(C^UW<$'FDB/S) N\@9.,]>.:\Q>'36M_BN_E6QE429; ) -HO
MY?-GZFEM]:M=-O\ P%J=W?6I+Z"T<BW$R1X!6$EU=R%W9 &,YP3[T >F66I6
M&HJS6-[;707&XP2J^/K@^QHO=2L=.6-KV\@MA(VU/-D"[CC.!GKQ7/\ @"UM
M[70)S#>V-TUQ>SW+FRE$L<9D<OLW#K@$#M53Q1J=I:>-M"@EN+;3[AK:Y9-0
MNGPJH6C#1("0I=CM.3G 4\'- '2G7M(%M:W']IV?DW<@CMW$RD3,6VA4.?F.
M3CBC3M<TK5Y;B+3M2M;N2V8+,L$H<QD],X_SP:\JCN=.?P-%8RW<$AMO%@$B
M7!0,4-_GYDP-N5.2,#C/ %;7B"65_'>LVVBW%LFH2>%FC@1'4.9O,8H /8$G
M\10!=\8>*5BU#P[#I&N(&N-9MK6>"%D/FQE_GYQG@@ X/?!ZUWU>0:MKVA7O
MA7P&MA=6ZBTUC3Q+!O&^V"@A@XZK@C!SCI7JFI1RW&D7<=JW[Z2!UB96Q\Q4
MX(/UH KQ>(M&FOUL8]3MC<NQ1(_,&9& R0O]XCN!G'>N2GUMO$7BS6]'MM=E
MTP:;%;_9)K?:RO*ZN[,P(PX 4#:2!U]B,7PM>^&M7T#PW873WTVMZ7+ $TQW
M*RV\\>%+E1CY!R23QM]ZV_#6H60^*?C@&\MP76R*_O!\P2%MV.><=_2@"#0]
M7N/$]U=W*^)I;2YT_4)(U018ADMX=H?>AXRV2=V<KD8Z5V>F^(=)U>>2"QOH
MY9HUWM'RK;>@< X)4]F'!]:\T=_[7^'OC*VTEOMDXUJ><P6[J9)(A.CG:!UR
MH.,=:V+2Z\.>*+A-1\/W%[>:R=.GBBE::3_1 RGY9 3@'=@8P3D9' S0!U]O
MXHT2ZU#[!!J4+W!W;5&<2%>6"-T8CN 3C!STK$LO&5AXCTSQ&@OCI<-K)+;1
MWK@QF-1&@,I+@!2'9L _W0:QO">N:#J&A>&-+ET]VUW36CA^P,C+):2JA1Y&
M!Z*%W')ZY ZD4MAJ>GQ:)X^TZ>=(KF.\O9)8IOE^1U&QN>S9 'KSB@#J+7Q'
MI.F:;H]O=ZP]Q)=V\?V>XEB8-=D@ ,,#&X]<=>_2M)];TZ/4Y].DN0EU!!]I
ME5U952+^\6(VXX/?L?0UQ7]GS:Y\&]%ETJ6-M2L+2UN[1PV0LT2J=I^HW+SZ
MU'JUO?\ B7X9ZUK=K:S"ZU>&*XAM<_O/LZ;66/CNPWMWYDQS0!VVG^(=*U2Z
M-K:78:<1B41NC(S(?XE# ;EY'(R.1ZUIUP&@:GX8UO5M/U'2I-3OKRW23<UQ
M+,?L:LOSA]WRY)"C;R<\CIFNJ\/>(M,\4Z0FIZ3.9K9F9,LA5@P.""#R/\"*
M *EY/:)XWTR-]=FBNGMY532T;*3#KYC#'&,'!./3V,R>+=$?3+S45NV-I92F
M*YD\B3]TX )##;D8!&>.,UEZ]_R4?PCCKY=]Z=/+3\:Y=[^WTW2OB/HUSYB:
MA<SW=S!!L8M)%);J%=>.5RK9/08H [^Y\3:1:BWWW+.;B#[1&L,,DK&+CYR$
M4D+R.3@5ER>.M/?7=&T^S2YN(M2MFNQ.EI*R^5M4J5PO.2PS_=[XR*Y8RV?D
MZ-<VFM2:%K<&AVX2YND!MKF,D_N71L9(93TPWS9&>E21Z@;/5?A_J6HV!T]!
MI=U$UO%$Q"2%(=L:KR<D*=J]>/:@#TV66.")Y975(T4L[L<!0.22?2LG3_%.
MD:I>QVEM<2^=+&TL(FMI(A,@QEHRZ@./F'*D]0:F\1R/%X8U62.Q%^ZV<I6T
M*Y$YV'Y,=\],>]>:Z;?6\OBSP!="XN;A?LL\1=;9EMX6>% L2<<8QW+$ <F@
M#T2U\5Z/>W\=G;W$K2RRO#$QMI5CE= Q8)(5V-@*W0GI5G7);>#0;][J]DLH
M/(</=1'#P@@C>I /(SD>]<!H,B6>JZ&=!O)+G2[NZ<RZ/=1AI=.9HY"SHW!1
M0<K@Y!W':>17=^))4B\,:HTC!0;651GN2I 'US0!RFN^(XM+\!:.-.O]2O%O
MOLL,>H?9YI))(G=%9RRKD2%2<=&)/ S72^'].6S6ZN8-0U2>TNW$D5OJ#2,U
MN0,,%\T>8 <9PQX[8S7 O=PP?!_PC"[ 3QR:<6B*G<OERQ[\@<C;@Y^E>K1R
MI-&LD3JZ,,JRG((H \XT;Q?9Z!J_BY->U:Z:*WU,"%9!).8HC$ASM4':F2><
M 5V]SKVG6L5G(9VE^VC-JL$;2M,-N[*A03C'.>G(KD]&O(-%\1^,TU19$-Q=
MI<0HT3?Z1&8E7"<?.<@C K'\-Z3>^"]5\-W6K1,EC_8\MC(R NEI*TWF@,0.
M 1A,],J!0!UNN>-[#3_!5]XAL?-NU@5U5%MW)64<;9%P"F#C.[&!^%8WB'6!
M:^/O"-_]NOX+">.^\^VD$D:MY<7R_N2 6;).."3QCM65J^BSWFC?$C5+6WE:
MSU2&(VJ;2#*T4?SR*OH3T/?;GIBM76-1@U+XA>!KZU6=[5/MF^4P.H7S(PB$
MY' 9@0,]<4 =?HNOZ=X@MYY].ED=8)F@E66%XGC<8R&5P"."#R.]2ZEJ]GI7
MD+<NYEN7\N"&*-G>5L9P% )X'4]!W(KFO!\Z?\)5XNC"NJSWZ3PED9?,40Q(
MS+D<@,"..]+XA6ZT[Q[H>NR1O+I*6L]I.40M]F=]K"0@=CLVD]OQH V?^$EL
M9M)O[RT,TKV19)8! _FI(!]UDQN'8YQC!SG'-<WX$@_MK3M&\0O>:M'?&U\V
M\5RZPW;2KGD,-K!3G;MZ#':ELX=OB/Q=XB,<G]G7EM!;Q'RG#3NB-EE4#+#Y
ME4$#G''2M3X=L1X T2VDCFBN+:RBBFBFB:-T<* 000#VH 75_%C:=XQTC0DL
MIY!>1S2O(L1/"*" O//+#/85SF@^)[/PW=^+$U.ZU*XAM]5;#8FNVAB$49);
M&XH@R>3@=<9Q6AXK:6Q^(GA7539W<]K'!>0,;:!I2'=4*C '&=IY.!Q6/&DR
MZ5\3E-I>;KR6;[,OV:3,VZW"#9\OS?-QQ0!WU[X@LK.2"%5GNIYH_.2&UB,C
M>7_?('0=@3U/ S5C2M5LM;TR#4=.G$]I.NZ.0 C/.""#R""""#R,5Y=Y0T[5
MM%U;4]%U*_TNYT6"Q8VUM*TMG-$22'C7#;3NZX/*]*]"\*V]O;Z(HL]*.EVC
MR-)#:NNUPIYRR_PL3DX[9YYS0!#?^--'T_5;C2Y?MCW\$:RFWALY'>16) ,8
M"Y<<')7(&.2*=;^,M&O=)L=1LYWN([Z?[-;QHA$CR\Y0JV-I&UB<XQBLBYO(
M=.^+<DLZ3%9M#C0-% \F"L[GG:#CKQ7/B'4=&6.^.F72:=J6NW5Y+);VC375
MK$\>$95 +1ER#N(&5#8X- '8W?CO1;#1+_5;O[9%!83FVN4^RNSQ2  X( (
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MC]^&ZA_[V?>M*.6.5-\<BNO]Y3D5%9W]GJ$;O97<%RB,49H9 X5AU!P>#[4
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M@_+U'?O0!T+ABC!6VL1PV,X-5-.T^/3H'19))I)7,LTTN-\KG R< #H ,
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ML%O8VMI/,@)7<,J 3@@@Y''O61KOQ$M+2S0Z3!<W<[7UK;;OLS^7ME8?.K8
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MAN;*;R+F"0J2C;0PP5)!!!!!!J76=;M]%BMO-22:>[G6WMH(Q\TLA!('/ &
M22>  : -.BN?A\5QF;4+2YT^ZM]0L8!<O:$H6DB.?G1MVUAP0>1@_A2>&O%7
M_"2I#/#I5Y!:3V<=U#=2@>6^[J@[[E]P,]1Q@D Z&BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&K.K1(K,C,2N59 1Z@GI7J=% &+X>6X(N)GT:+2;9RODVVU!*<9RS["5&<@
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MRA\Y@2I"\_-R"..]<?I&J>%->U30M1T_5[K4+Z!&,-NDJ@VD;+B0RJH&U1@
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M+>\EO(+&VBNIO]9.D2J[_5@,G\:M44 4;?1M*M+HW5MIEG#<-G,T<"JYSUY
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY)Z_,,8ZUC>'=?UF[TVPTB&_DDFU+4+IK6]F^>1-.B?_ %G.<L>%4G(Y!YH
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M _9E$=K:1;OEB5NA;<>><C(&!D9C^+W_ "2O7/\ <B_]&I0!V]%%% !1110
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MR3@8Z.B@"*VMXK2UAMH5"Q0HL:*.R@8 _*L_6="AUEK.4W-S:75G*9;>XMF
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5YU\0[+2[&QN-3N]>EL];D95TR62]:);=RP5<(#C8"07)
M!XSGL*]%KE/$=W)K&CZQH@T"^GFECDMXA+$HAE)7 ??G 4$YR>1C@9P* .G@
MW?9XM\@E;8,R 8#''7\:DJCHUBVEZ'I^GO()&M;:.$N!C<54#/Z5>H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>a106amendmentno12tolease004.jpg
<TEXT>
begin 644 a106amendmentno12tolease004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=)CV#1NG_ UK-TW7O$5U?6FI23O%%/JAM'@FNH1$$\TH8Q'MW[P!GKDD>AH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%&
M:* "BC-&: "BBC- !11FB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:Z"1&1NC#!Y
MQ3J:[B-&<YPHR< D_D* .#\,:;'=W'BJ*XNK^2.'47@A!OI<Q($4@(=WR\D]
M*@\">(;^VAT_0_$4[2R7MN)]-O'))N$(RT;,?^6BY_$8-6_"EPUK<>*99[#4
M(1<7\ES$9+20>;&5505&.3D=.M26'A^'Q)\.=.TR\CN;.ZMX(Q'(\31RVTZ
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M[XV_+WQ]* *OAIK*;4_$T&JZS>JMGJCQ6ZRZM,FR+8I ^^,C)/6I=9O;S1_
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MN"TR:-?"GP[CF5XVM[X-*DL94HH20;CD<#+#GIS72:5>6<'CSQC/--$B-%;
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M%D:(RL/F"% !G &?J/>NFH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ML*NNUQ'"JAE]#@<CDU+;6EM91>5:V\4$><[(D"C/T%344 5[JPL[X(+NU@N
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M"A>_<^QKLJ* //[#2]0E^"\^B&RFBU)=,DMC!*NTF0H0 #T.<]:EOIKJ^O\
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MI-C%)#X<DMHKR^6-+>UB4/&K #S90#@="3UP,9YKIZ* "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MNL16B:4LB_V<T1^=EYSNY^G7O0!T-%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <]XR\.7'BO0I
M='2^CM+:XP)F,!D<@,&&WY@!R.^:SH/"6NVGA2/P];^(H([>.V^S+,-/_>A,
M8Z^9C..^*[*B@#AKOX=M<>(TU.+69X(1I?\ 9IMUB5L)C!*DYVYX[9]^:SIO
MA9<S_#NV\'OKP^SPS&0S?9/FQDL% W>I)R<_A7I5% '%P>";U?'5KXIGU:&2
M:&T%HT"VI563')!WG!R2>]9<OPLD31M;T.QUMK?2-3G^T" VP9XG)4D!L\K\
MO3 /3GKGTBB@#@-7^'5SJ6F^';%-96--#=)8G>UW&1DQMW88 # Y]:N7_@>6
M34]8O].U".UDUJU%M?*\!<9"[=Z?,,'!/!R*[.B@#@=<^&HO_#>B:#IVH+9V
M>E2+*ID@,K2.O0GYAU))/U[5L^,?"4?C'PXFG7-R;>YBD2>&XC7(250><$].
M3QGO72T4 <1#X'U!_&]EXJOM;26[M[86[11VNU&&6SCYB1PWJ><]N*UM#T'4
M=,\0:UJ%WK,UY;7TBM;VKCY;8#/ Y]P.,=*Z&B@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MFJQ:RUYK<Z+I^I3VJLD40S''C!;*]?7I0!VE%<+KVHZWIOA2QOXM6#7#WL4
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MP ,FNQLH[J.W5;R>.:?^)XXC&OX D_SH L4444 %%%% !1110 4444 %%%%
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MSS+L$2N=Y+$D+R!]2/6M[^S+ 9Q8VW/7]TO/Z4^*RM(&+16T,9(P2D8&1^%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MCL&A9EA=S<2B,*LOE[,$CDG>X '7RSZBBX69VE% Z44Q!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_*D*;F7. V.HYZ4 :%%9(\068X\C4>/^H=/_ /$4O_"0V?\ SPU'_P %T_\
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M=XQ-;)-O"QGDN[+@8('(/MGT/_A(],_YZS?^ TG_ ,32'Q+I0ZSR#_MWD_\
MB:+!<CT34KW5"9O[,DL=." 0BZ^6=SZE/X5^IR?0=]JLG_A)=*[W#CZPR?\
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M62/%&@'_ )C6G_\ @0G^-'_"3Z!_T&M/_P# E/\ &@#6HK*_X2;0?^@UI_\
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M@$@]\8SWK?HH 1$5$"(H55&  , "EHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]"E9N ROM,0&>S 9.,_TK-FDATW1+RV7$>D+XN\F[5>$CMSAB#Z)O*Y[8)H
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MAE*[<QL53(..IS6GJ>@VMC:>)'_M&*0WND22M9VL!BB4QK\LHPQVGG'OCV-
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MSH<MFD<<5HMTDXEW%P7*XVXXZ'N: 'S>'(+I[<W5Y?7"03),L<DWREE.5)
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MVVKZ7:ZC9OOMKF-98V(QE2,CBK= !1110 4444 %%%% !1110 4444 %%%%
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M4# JS0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MP +^['R@=,<<8JI>>(M(T^Z^SW=_##("H;<>$+?=#'HN>V2*TR>,T 116EM
MY>*"*-SP65 ":1;*U6;SEMH1+DMO"#=D]3FN9T'4[_Q>EQJ=M?O9:1YSQ67V
M=$+SJIVF1BZM@%@<  <#GK5ZTNK[2;C5'UN]#Z?%Y;6]TZ*F%((8-M[@CDX
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M3)ZFJT&N:5=7C65OJ-K+=*NYH4F5G ZY(!R!4]EJ%GJ,32V5S%<1JQ1FB<,
MPZCCN* "WTZRM)7EMK2"&23[[1QJI;ZD#FI+FUM[VW:WNH(YX7^]'(H96^H-
M5=9U--(TJ>\=6<H L<:_>D=CM51[EB!^-9W@O7)=?\,P7-V M_"S6UZF -LZ
M':XP/<9'L10!J'2=.,_G&PM3+C'F>2N[&,8SCTXIG]AZ2('A&F67E.063R%V
ML1TR,=J+C6]+M+DV]SJ-K#,N,I)*JD9Z9STSVI)M>TFW&9=2M$'E--S,OW%Z
MMUZ#UH F&FV*O,XLX TZA)2(QF10, -ZC'&#2K;K8V/DZ?:PH(UQ% N(T^G
MX'X5!-KNDVT<4D^I6D23()(V>95#J>C#)Y'O4MUJ=A911RW5[;P1R?<:24*&
M[\9/- '-^#_"TFE6TPU?3M-:Z^URW,=Q"?,8>8[/C+("",X_PKI;O3;&_""\
MLX+D(<J)HP^WZ9%,;6--6.WD-_:A+D@0-YRXE)Z;>>?PJ(>(M%-M-<C5K$P0
MOLEE^T)M1O0G. : )KC2--NTC2YT^UF2(8C62%6"#T (XITVFV-RD*3V<$JP
M,&B5XPPC(Z%<]"/:E?4+..T6[>Z@6V8 K,T@"$'H0>G-1'6M+%C]M_M&T^R[
MMOG><NS/IG.,^U #X=*T^VNFNH+&VBN'SNE2)0YSUR0,FD@TG3K6Y:XM["VB
MG;.Z2.)58YZ\@9I$U?39)+B--0M6>V&9U6928A_M#/'3O5'PUXFL/$]B]U92
MQL!*ZA0X+;5<J&(Z@';D9H N#0])#S,-,L]TX(E/D+F0$Y(;CG\:L6EE:V$/
MDV=M#;Q9SLA0(N?7 IM[>VMC#ONKN&V5CA7F<*,_CUKF_".ORWMEK=SJ>I03
M06FIRP1W'RH@B4+CD<=^N>] '0+I&FI>&\2PM5NB=QF$2A\],[L9S2/HNE27
M?VM]-LVN<AO.:!2^1WW8S4-SXCTBVTNYU%M1MFM;8$R2)*K!3C..#U]J;IWB
M'3[[0K;56NK>&&:-&8M,N(V90=I.<9YH T+JSMKZVDMKN".>"08>.50RL/<&
MJRZ)I2W"7"Z;:":-0B2"!=RJ!@ '&0,<8J:+4+.>S-W#=P26P!)F20% !U^8
M<<5SEIKTM[\0CI]MJ=M=::=->X\N':VV02(HRP)[$^G6@#=AT/2;>":"'3+.
M.&?B6-(%"R?[P P?QJ:RT^STV#R+&T@M8<Y\N&,(N?7 J6X222!UBE,4A'RO
MM!VGZ&N7\%Z[>:EX8_MG6KRV0-++'P@B1 DC)G))ZX]: *VL^&;^X\276I?V
M3HFLV\\<<:1Z@2CVX7/"G8X())/0'GO@5JZ-X8MK+2[NSN[6S:"\D\R2SBC_
M -'CX VJI[?+DG R23@5JQZII\UJ]S%?6SVZ'#RK*I53[G.!2QZG8RW!MX[R
MW>94\PQK*I8+_>QG..1S0!%%HFEPLK1:=:(RQ>2I6%1B/GY1QTY/'N:CA\.:
M);+ L&DV48MV+PA(%'EL1@D<<$U-_:^FFV:Y&H6GV=6V-+YR[0WH3G&?:G7&
MJ6%HJ/<WMM"L@RADE50P]LGF@".VT32[))DM=.M8$G!$JQQ*HD!Z[@!S^-11
M>&M#@2!(=(L8UMV+1!8% 0D8)''!([U=>]M8_+WW$2^;S'EP-_!/'KP"?PJ*
M'5]-N9$C@U"UE=^45)E8M] #S0!6_P"$9T/[(]I_9%C]F=M[P^0NQF]2,8S4
MDNAZ:TUO<KIUJUU:(5MI'C&8O8'J!]*MV]Y;789K:XBF"-M8QN&VGT..]<YJ
M6OW7_";VWANVF@M?,L7O#-*A<R$-M"*,@<#)/M0!/X?T_5Y+HZOXA2T34C"+
M=(K1F:.),Y.">['&?]T5N75I;WUL]O=0I-"XPT;C(8>XK'\':Y/XB\-P:C<P
M+%*SR1G9G8^URN]<\[3C(K9NIFM[6:98GF:-"PC3[SD#.![F@"O#H^FV^GO8
M0V-NEFX(:W$8\L@]1MZ8J&V\.Z+964UE:Z7:06TW,L44*JK_ % ZUSMUK7BG
M1KK2[G5(M-DL+V[CM9H;=7$EL9#A#N)PX!(!X'M6A)K&HZEK^IZ9I#VT8TV)
M/->XC9P\S@LJ###   )//WAZ4 7Y/"^A2VD%I)I-FUM _F11-$"L;8QE1VIQ
M\.:*8[U#I=IMO1BY'E#]Z,8^;UZ"LZ+Q%=:CX(&NZ9;P&X,#2-#<2%51E!WJ
M2 2<$$>_J*T-(U0S^%;'5KYXXS)9I<3N!M5<H&8^PZT )<^&-"O;*"RN=(LI
MK:W_ -3$\"E8_H,<5+=Z#I-]I\=A=:=:RVD6/+A:(;4QTVCMCVJAHFI:EKZ1
MZFBQV>ER'=;Q21DS3)V9CG" ]0,$X[CI6])(D4;22.J(HRS,< #W- %&QT+2
MM,GDGL=.MK>:0!7>*,*Q   &?3 %+=Z+IE]?V]]=6,$UU;9\F5T!9._!^O-6
M?M=OMD;SXML7^L.\83OSZ4J75O) 9TGC:$ DR!P5P.O- %*7P]I$UV]U)I\#
M32,&D8K]\CH6'0D8')K1(!!!&0>,5&+F%I6B$L9D5=Q4,,@>N/2ECGAFB\V*
M5'CY^96!''7F@#('A#P^L"P+I-LL2R><$5< /_>X[CMZ=JM)H.EQZD=16S3[
M:4\LSDDL5_ND]Q[=*MQ7,-RC&WFCDQP2C!L'\*HZ--?1Z/"VLW5G)>9*R26Q
M(B)W$ #/?H/K0 S3?"^A:1>27>G:3:6MQ)D-)%$%.#UZ=/PJQJ&C:?JCPO>V
MXF:%M\1+$;&_O#!X/OUJXDL<A8(ZL5.& .<'WI([B&5BL<T;L.H5@: ([RRM
MK^SDM+J%98)!M9&Z$5#?:/I^I20R7=LLDL&?*E!*O'GKM88(SWP>:9K1U);)
M3I4MK'.)H]S76=GE[AO''?&<>]7C+&C;6=0<%L$]AWH HR:%I<VD2:5)8PM8
M2 [X-ORMDY)/OGG/7/-5[SPGH&H6$%C=Z3:S6]N28D9/N$]2#U!/?UK85@ZA
ME(*D9!!X-86LZQ-!K6FZ19RPQ3W@E=Y9!N$:1J">,CDEE_#- &O9V5MI]I':
MV<$<%O&,)'&NU5'TK&LM(ETK6+Z.&%9]+U21IYE)'[B4KAN#]Y7QGU!SV/%[
M1I]0;3%.L-:"\5F5VMF/ED;B%(SR,C!Q6;KFM7VG>(O#MI;_ &=K34KAX92R
MDN,1LX*G..WI0!+%X*\-PQP1II%N%MY!)%D$E" 0,$G.,$\=/:K$'AC1K:5)
M(K(#9,9U0R,460DG>%)V[LDG.,YJKI6KW]SXPUS2KH6_V>RBMY(#&I#$2;\[
MLGK\HZ5<\1ZPN@>'[W4V0.;>(LJ$XW-T _,B@"SJ6EV.L63V>HVL=S;L03'(
M,C(Z$>A]Q56Q\,Z+IM[]LM-/BCNO+$1FY+%1G@D\GJ>3S3--DUM-0E&HRV,U
MAY*M'-""C"3^)2I)&.X.:V"RA=Q8;<9SGC% &-I_A#P_I-\UY8:5;6]PQ)WH
MN-I/7:.BY]L5+:^'-+LI[F>VAECENO\ 7N+B3,AQC)^;DXX!ZBM3<ISAAQUY
MZ4!@PR""/44 88\':$--ATX6)%G#+YT4(FD"H^<AA\W!SS]>:M#P_IHU4:IY
M,AO1'Y7FF>0G9_=(+8([XZ9YZUI*P894@CU!I20!DG H P]/\'>'])OC>V.E
MPP3[BP*YPI/4JN<+^ %1W7@CPY>/=M/IB,+P[KA!(X21O[Q4';NX^]C/O6_N
M&W=D8]:7- %=;&W2Q%G&K1P!=@6-V4@>Q!R/SK('@O01IEMIJV<BV=K+YT$2
MW,H$;YR&'S=CR/0D^M,\8:W?:!I45Y8PV\N;F&&3SF/RB214R .OWO45T5 &
M9'H&GQZP=66.;[<8Q$9#<2'*#HI4MC')/3KSUHU+P_IFKW=I=7UMYLUIN\I@
M[+@-C<#@C<#@<'(XK3S7+W^M:Q<:CJMEH4-I)-IL<19+G</.=\ML# @+A0.3
MGD]!B@"\OA7246_58K@#4.;K_2Y?WO '/S>@ X[<=*BN?!6@7EC9V=Q9,\5D
M<VS&>3?#VPK[MP' XSC@52M=>UO52]UI=I:2VD&HM930R,5DVH=LD@;..&SA
M<<@=<G%=8.E %:QT^UTVT6ULX1%"N<*">IY))/))]3S5&Q\,Z9INIW&I6L<Z
MW=R09Y&NI'\W P-P9B#@=..*UZI:?JEKJ;WBVS%OLEPUM(<<;U ) ^F<?4&@
M"'5M L-::W-ZL[?9Y!+%Y=P\>UQT;Y2.1SU]:2W\/:=:ZS/JT23B]G4)+(UQ
M(P=1G *EL8&3CCC-/UC5ETJ"';$9[JYD$-M IP9'()QGL  23V /TJ[!YOV>
M/S]GG;1OV9V[N^,]LT 8UKX0T>T-OY<4[1VTIGAADN)'C23D[@I.,Y8X],\5
M8L/#NG:;JEYJ%K'(D]VYDE'FL4WD ,P4G )P,D#G%:M% &:FAV<>MR:NK7'V
MN1!&Q,[E2@SA=I.  23TZFH-3\,:;J^I6NH7?VDW-IDV[1W+Q^43U("D<D<'
M-5Y]=O(?'5GH1MH?LMQ:2W G$A+Y0J,;< #[WJ?PK7U'4+?2M.N+^[?9;V\9
MD=O8>GJ: ,T>%--#:DP:[#:D,79^U/\ O. OKQ\HQQCBHSX,TDVFF6N;L0Z8
MP:S N7_=$# .<\X!(&<\5T .1FB@#G;KP/H-WJLNHR6TJS3X^T)'<.D=Q@8_
M>("%?\1SWJTGANSCUBXU6.6[6[GB$+L)SMV#.U0O08+$CCO5V?4K:#4;?3V?
M_2KA'DC3U5,;C[?>'YUE^%M>N=>35OM5K';/8ZC)9;8Y"X.P*=V2!UW>E $"
M^!-#71H]*"7/V:&;[1;G[0^^"3))9'SN!))/7N:DC\%:5%)?2J][YU]"L%Q*
MUV[,Z*,<Y/7&>>O)QBNBHH YR3P5IDEEIEH9KT0Z8P>S N#F)@,*<]\ X&<\
M59C\,6*ZK>:@[W$LMY'Y5PDLFZ.1!G"E>F!N./J:VJ* .;TOP1I.C.6L6O$"
MJRP*]T\BVV1@^6K$A3@XSCVIG_""Z6-!?11/?"P>8S-'Y_)8MO/S8S@M\W7K
M6]?ZA;:9:FYNY/+BWHF<9^9F"J./4D"K- &%-X<LAJ<&L2S7K7-M (F*2G]^
MJG<N]5^\0<D#W[U1ATBXOVUO5KZWG6:_M_LD%O"X26.W4-@;B<*[%V;KQP.U
M=745S<0V=K-<SN$AA0R2.>BJ!DG\J ,_PWIL^D>'[.QN)6DDB4C+.7*C)(7<
M>6P"!GOBM6H[>>.YMHIXCF.5 ZG&,@C(J2@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S[3]
M0M=.\9>-X;N=89)VAEC#G&4%N 6]ER,9Z9XK$L;O3K;X=> P;BVC=+VU9QO4
M%2 =Y/IC//UYKUO:I.<#-&U?04 >40W6C1W'B30?$TUXD]Q>S3) KOMO89.4
M\O;]XXPN!Z5Z;;PA]*C@:-X@T(0HS;F7Y<8)[D>M6MH]*6@#S_X?7"^&-&/A
M/6W2UNM.D=(9)3L2ZB9BRNA/!ZX(ZC%5-#TZVN=>\>S6$"20%(XK)XN8\F#Y
MQ&>GWCSCO7I+(CC#J&'H1FE"A1@  >@H \GM]<TV3PI\/84NXW>TN+2.YV\^
M2RP,I5_[ISD8-5M>U6RN?#WB-4N5LC'JF7L$&Z0L)4!FE+9(4X!&-H QR:]@
M$:#HBCG/3O2&*,[LQJ=WWLCK]: N>?VKZ5J7Q<U)7>TN$ET>!45MK!\R,2,'
MKQM/Y5S6NZE93^&?$'D745DR:RKR6"'=)N6YCW2RELE00-PQM &!DU[+Y4>X
M-L7<#D'%(T$+!PT2$/\ >RH^;ZT <5I]QI,_Q0U>Y$UH[?V5:E)"RYQOE+8/
MTVY]L5RFFW=K'\//!LYN(EM[;7U\URX"Q+YDN,GL.1^E>P&"(DDQ(<]<J*0V
MT#(4,,95CDJ5&#0!P_BF2;2M8TOQ9HT/VAKQ/[.F5?\ EH).8'_"3 )]&-=?
MH^G#2=(MK$.9&B3#R'K(YY9C[EB3^-99T/4[OQ(UWJ6HQ3:7;RK-8V:0[61P
MNW+M_%C+$#U.>PKHJ .1U6:77/%MMIFGW]I'_9:_;)Q(GF[I6W+&NT,I^4;V
M//7961IEY_PBWQ+N]+O[VT,6NPB\0QIY2K<+A6&TLV-R@'KR17H*V\*R>8L,
M8?GY@HSSUYI'M;>1F9X(V9NI*@YH \LO+RRGA\7^')-2TR-KZ_?]_=W21-'N
M1-V4/)VX^4C@X'2MW5HM*N?B%X:BE:VFC;3[O:&*D/GR@/KD;L5;M/#6M67V
MJ 76E7D4\TDPN+NU)F7><X(!PV.@Z< "MW2="L]*TVVLTB23R%"B1D&2<YSP
M..3P!P.U '!"?2],\7^(M(UO43I5M<1PBS5C&D,ML(@FQ2RG[IW<#UJ*.YT[
M0?$^D)<WE[I>D2:,MO87-R5&UED8LK,ZG:63RR.G P:]1DMX9BIEB1RARI90
M<'VHEABG39+&DB==KJ"* /*]1LM!MM,\-6]B3+8'Q&C1O<L")0P8LR?[!8GV
M/T(K<TV'3/\ A:GB+<EMN33[4\[>/]8&X^FT'VQ7:RV=K-CS;:&3 P-Z X'I
M2?8+,LS&T@W-G<?+'.>N?K0!Y!I=]#9^&? EY/>20:3!/<Q37$>TK Y++$6R
M" .HR>F:N>*X- _X0KQ-<:;>/>I=W-K+-<M(C1/+YJ ["H W!0-V/4>]>J+9
M6J1O&MM"J2??4( &^H[TC6-H\:1M:PLD?W%,8(7Z#M0!Q\B65K\5M(CMA#$K
M:/<+MCP 1YD948'_  (C\:D^&5W:OX3BM$GC:ZAFN/-B##<G[^3&X=OQKJQI
M]DKJZVD =,;6$8R,<#'TJ2*V@@:1H88XS(V]RB@;F]3ZF@#D=1U&WT_XF6QU
M6:*"VDTUELI)B%3S=X\P GC<5V?@*Y2RU'2XM%UQ5-M(K>*R8RTNV*)BZE))
M,?P97/H>G'6O69[:"Y4+/#'*H.0)%##/KS3'L;22"2![6%H9&W/&T8*L<YR1
MW.>: /-3=0377CV$:C!>7$^E(5,051*PAESL4$Y X'4_6BYU:QAC\$W<NIB#
M2X[9H)+J$HRPW!B39O+ A>-PSCC->F+:6R2F5+>)9"@C+A #M'1<^@R>*:EA
M9QV?V-+2!;;&/)$8">OW>E 'F6K?V586K76G7ES>:5-K=K-JUP65H",'<05
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MD $]^A[UZ*=(TUM-_LUK"V-CMV_9C$#'CTV]*@_X1O1/[,&F_P!DV7V -O\
MLWD+Y>[UVXQF@#D-4T+2HO%_A&)+2-1<1W*3D=9U$:MB0]7&0#ALUGS#3M.M
MO'MG)&Z:<+ZW1;>W81@-)'%P#C"J6/)QT)KO_P#A&M$,MO*=*M/,M@! WE#,
M0!S\I[?A31X8T)5NE&D60%VI2X_<C]\.N&]?QH Y'2(U_P"%F7MK=MIS+-HT
M8DM[5<1C]ZP"MD_,V#UP..PK#>SMI?A3X7#1K\NKVZ*RG#*#<X.".1Q7I:>&
MM#B\GR])LT,,30Q%80-B-U4>@-1'PCX=-HMH=%L?LZ/O6+R1M5O4#H#[T <K
M-9:=IGCK7+:'9IUE+X>$EPT"[0I$C@R8'\0&>:D\-0SZ1XFT_3=4L+,W0T^5
M+/4; ;8YX5,>X2)C*L/D.<D<G%=8WAO17NY+I],MFN)(S$\I0%F0C:5)[C'&
M*DL-#TO2Y/,L;&"!]GEAD7!"YSM'H,]A0!S_ ,1[>*;PY;.\:F2/4;/RV(Y7
M-Q&#C\*I7.CZ=>_%UUN;:.6-]$$CQL,K(WGXRR]&Z#K[5U^I:/IVL1)%J5G#
M=1H=RI*NX ^N/6HAX>T@7XOQ80_; GEB?'S[<8VYZX]J ,+X; 1^&)[="?*M
M]1NX8ESPJ+,P51[ 4S6;"RD^).@&2TMV,EK>,Y:-26(\H GCFNETW1M.T>.2
M/3K.*U21MSK$, GUQZU%<>'M)N]174)[&*2\3[DYSO7Z'L..U '$Q1V,%Y\2
M894@2!?+8QL % -JISCZY_&HK AM-^%6"#\B9_\  -J[FZ\-:+>ZB=0N=,MI
M;PIY9G:,;]N",9^A(I@\*:"JVBKI5L@L_P#CV")M\H^JXZ'WZF@#,T<_\7'\
M3_\ 7M9?REJ/XFV]O-X"U)YH8W:-%*,Z@E274<9Z5OP:'IEKJ<VI06B)>S?Z
MV8$[G^OK[>E.U31].UJW%OJ5I'=0 Y\N3E2?<=#^- '+WL%DOC_2-)N+6%-/
M-C/<6\.P".2X#*"2O0L$)(^I-<EXAMA%X;^(E@BG^S+&:)[( G;%(\:M(J^@
M!;IT&37J4^@Z9<VL%M/:+)';OOAW$EHV]5;.0?H:9/X<T>ZTW^SI[")[/<7:
M$YVNQ.26'\1SSSGGF@#CM<T[3-!\0Z#;LACTS5;YWU!I7+)-.L7[K>3QR><=
MR!5?Q4EAH&FWT.FWCP6USJEK)J (W0VT<AVL !C"G:"PST;WKOKK1-,OM*_L
MN[LXKBQP!Y,HWK@=.OI3+;P]H]II+Z5;Z9:QV#YWVXB&QL]<CO\ C0!AZ)H\
M&F>+)+F+4[=GO+/YK*TM_+B(1AB7 8@'YL>X^E'BXVT^N>'K&16GN99II(+1
MV"P2[8_F,N0>%W @ 'G'U&WH_AW1_#\3Q:3IUO9I(<OY28+'W/>EU;0-*UT0
M#4[**Y^SOOB+YRAZ'!'K0!Y3=VX?X<^,(I'4?9-;985MV*I%EXLA1GI\S<=.
M:Z6XM(M!^)=E_9D3*UUI-T\ZF1F\]T9"I;).3DGGWKI6\%^'&CNHSI%N([MU
M>=%!42%<8R >@P..F>:M'P[I9U&WU!K=FN[=!'%,TSEE7TSGH>_KWH \TO[;
M3KWX6:)K1\N;49[NRFGNB<R-,TR>8I/7 )8;>@VCTKU+6)Y[;1+^XM5WW$5M
M(\2@9RX4D#\ZRYO OAB=IVDT6U;SY!+(NT[2X.=V.@.1SCKWK>CB2*)8HT5(
MU&U548 'I0!YEX>TO[=I/AGQ"FNVD;*\;22PVK>;=-)A7BE;S#N)8GMP1G
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MM,BO-<MYI;BW5HYI75&N $R9,=@0"?05R7V[3RGQ'07-N5Y;:'7'_'JJD_\
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MT!%VN^,\+NB&U3Z$GC!YKM]*UW3-;^U?V==+.;2=K>< $;)%ZCF@"/Q)*(M
MNS_:\>D,T95+V3;B(^N&.#3WU:PTZSM3>ZC#F6,%)'('FX RP'IW]LUF_$!H
MA\/O$'FLB@V$X7>0/FV'&,]\UAW;PW5QHLNFZS%8ZS#I6^$SJ'M[B([=R-R#
MPRKR""/>@#NK2[M[^TBNK69)H)5W1R(<JP]0:Y?Q'JE[IGC7PO$M_P"3IMVU
MR+J-@H4A(6<$L1D<^^.*O^"KQ;_P?IMRMDEFKQG$$9RBX8CY3_=.,CV(K$\7
MM;2?$#P/!<&$J9[IBDA'7R#MX/OT]Z .LL]:TS4+&2^L]0MI[2,D/-'*"BD=
M<GH,4RVU_2+M)W@U*U=8 &E(E'R ]"?0'UKS+6W3[-XV6R)DCAU2TN+B&V(+
MF)1$92!W. <_2MJSG\+:CJ$^KZ?JMQJ=Q_9TD<L[R QQ1=0K\  [N@//6@#L
M;?Q%H]T6$&IVDA2 7+;91Q$>CG_9]Z@GUBUU/2K_ /L?5(3<PQ%M\160QG&0
M2I]?>O.X[:V3X,:'J-E"K>1%:M?26RJ93 KJTJYP<X(R1[5OZ;)H&J:I+J>C
MZI=ZK>-ILD;S"0,D<?55< #YB>@Z\&@#6\(>)K2_\/Z'%?:K;2:Q=6,4[Q-(
MHD<E 2=H_'M6Q:Z_I%[]H^RZE:S_ &8$S^7*&\L#KNQT_&O-H+.RN_AAX1@T
MU(!K!>S:W:$ .DBE3*QQR,*'W5L:]9WVE^+)H-,C(@\30_9Y&3 \FX0<R?\
M?K<?J@]: .[L[VVU"UCNK.>.>WD&4DC8,K#V(J*[U;3[&9(;N^MX)9 2J22!
M20 6)QZ  G\*L001VT$<$*!(HU"HHZ  8 KBO&$=D_CKP8MPL)9KFXR'Q\W[
MDX!]><4 =-+XCT6"S@NY=5LX[>X3?#*TRA77U!SR/>H-1N#)J6CM;ZW;VT3R
MEF@(5C>*4.%4Y[?>R/2N-FGTS1?'FIZ=JE__ &19W%G -.VB-(6B4-YB992
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MKGIWH M:5IL>E:?':Q,SX)9Y&QND=B2S''<DD_C5VL[3M=TS5OM'V*\24VQ
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M&8U 8%L_5<B@!;OPYHM^MNMYI5E<"W&(?.@5_+'H,CBM, *    . !4+WEM
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MX)\/C0Y-%:P\S3I'\PP2RNX5LYRI8DJ<DG(QR30?!6@'1FT@63+8NVZ2-9Y
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MFKE%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW62&.[YVL"RE=I)?!(X)]JZC09O#WA^37-0CU[S[6>:.:ZN99(A;K,WRX4H
MH8_+D>Z^M=4=+L&L?L)LK<V>,?9S$OE^OW<8JEJ?A^UO-#;2;>WL[>V; V&V
M5T49SE4^[N[@G.#V- &NK!U#*05(R".]<9\58()?A_?O-%&[120-&SJ"4/G(
M,CT."1^-=?:VZ6EI#;1 B.%!&N3DX P*CO=.LM2B6*^M(+F-3N"31AP#ZX-
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M=O.+[0>F=O./3FJ'AF6.SU70;;1;Y=2T:8.R6DZ@W&F_(3G<.=O.W#<\C!-
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M6#;"$(#8X)&1FG44 8/AO0;G0O[1\Z]CNA>WCWAVP>7L=\9'WCD<#%;V***
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% $<\T=M;R3S.$BC4N[$\
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ML9BLC DVR'<N5X_UF%&WT+>E &CX-\07NK3:K::H@BO+>X$L<1QD6TH#Q?B
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MD*TA8').,X&, ]ZR->UWQ'I'@C7=3EF2/4-,N76-A;@13QY3:<')^ZW8]0:
M.[6UMDMOLRP1+!C;Y00;<>F.E16FEZ?8%C9V-M;EAAC#$J9^N!6-XENM1TGP
M5>ZA;WY-Y9VS3^8\2D2$*3@KCI],&M;1S<-I-K)=3F>:2-7=]H7DC. !VH D
MM--L; N;.RM[<O\ >,,2IN^N!S41T32C.TYTRS,S$EI# NXD]<G&>:OT4 9G
M_".:'C']C:?_ . J?X5.VE:>UM';&QMC!&"$B,2[5!Z@#&!5RB@"G;Z796,4
MJV-G;6_F#YO+B"AO3.,9JOH.B0Z%8/;PB(&60RR"&(11AC@85!]T  #'MSDU
MJ44 4/[%TO[;]M_LZT^U;MWG^0N_/KNQFGV>DZ=I\LDEG8VUO))]]HHE4M]<
M#FKE% $0MH1=-<B)!.R!&DV_,5!) SZ D_G56[T/2K^X$]WIMI/,!CS)859L
M>F2*OT4 5)],L+FQ%C-9V\EH, 0-&"G!R/EZ<$"K=%% !1110 4444 %%%%
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M FR&-(USG:B@#/X4 24444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MOD,BKRSD'D M@+Z_E18:%%XF^'/AZ2RN5M]6T^S@-I=+]Z"98U!5O8XPR^E
M%_0H=1U"RUI1J]T+B#4I8K:1R&$:IC:I&/F')SGD^N0#6UX9UL:_H<5Z8_*F
M#-#/%G/ERHQ5U_,''MBLGX?2W4^BWT]];BVO)=1N&GA#9".&P0#W'&1]:B^'
M",=,UJZ',%WK=[/ ?5/,*@_FIH [*BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ Q1BBB@ Q1110 8HQ1FB@ Q
M1110 8HQ110 8HHHH *,444 4]1M+B[M&M[>Z-KO.'D1<L%[[<\ ^_./2I;*
MSM].LH;.UB6*WA0)&B] !4]% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@4 =%9^++*\FU:%;>ZCDTH9NEE15VG!8 <X.0,YZ>]2KXEM2ND%K>[3^U21
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M] 778=I,_B"_CNC=:[:6SPW<L"K]D4[E1@ >6'7(_.M5;#7G4,OB"!E(R"+
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M+#+:1B:47,+0_NSG#C<!E?E//M0 W[!X@_Z#EK_X ?\ VRC[#X@_Z#=K_P"
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MO7Y6Z9QBETW5M,T_PSH\@OKBY@N88TM9959Y[G*9!P!N+$#)X]<T 6/LVO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ***3/.* %HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BF1RQR[O+D5]K%6VG.".H/O3Z "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ K'UW4)X!!I]@P&HWI*0MMW")1]^4CT4>O4E1WK8K(U3
MPUI>L7D=Y>0RM<1Q^6KQW$D6%SG'R,,\T 8OPYB6#2M7B5G94UF\4,[;F.).
MI/<UV-<AX$\+'PY%JC2PR12W%],R;KAI 82Y*'!8@'!Z]?6NOH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
K"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>a106amendmentno12tolease005.jpg
<TEXT>
begin 644 a106amendmentno12tolease005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6YVX;<J_,-O'+#IFM.VU_4SXACTJ[TNWB26"22.XBN_,4NA7*$;00</FO/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **,T4 %%&:* "BBB@ HHHH ***:'4L5# D=1Z4 .HHHH ***3(]: %HHHH
M**** "BF22QQ &1U0$A06.,D\ 4^@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ JIJ&GPZG;?9YWG1-P;,$[Q-Q_M(0?UJW10!A
M?\(EIO\ SWU0_P#<5N?_ (Y2'PAI9ZRZI_X-;G_XY6]10!@_\(=I.,%M2/\
MW%+G_P".4?\ "':3_>U'_P &ES_\<K>HH P!X.T@'.=1_P#!G<__ !RE/@[2
M#U^W_P#@RN/_ (Y6]10!A?\ "'Z/W6^/UU&X_P#BZ:?!FB$Y,-V2?^G^?_XN
MM^B@#CKKX;Z+=:C:WGGZC&;5MT<:7;E<G@Y+$GD<=:T3X*T%CDVLY/\ U^3?
M_%UT%% '/_\ "%:#C_CTE_&[F_\ BJ/^$*T#_GSD_P# F7_XJN@HH Y__A"?
M#YZV+'ZW$O\ \52?\(/X=Y_XEW7_ *;2?_%5T-% '.?\('X9_P"@6A^LK_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]<69S+<VT=NT9 P C,0?_'OTKPP^(?B$0?\ BK])'_;];_X5@W7Q!\8KJO\
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MI-6-I2HTL).C&?,VT]GTN?5E%>;?\+P\(>M__P" _P#]>D_X7EX/_P"H@?\
MMW_^O6QY5STJBO-#\<_"(Z+J)_[=Q_\ %4#XY^$2/N:C_P!^!_\ %4#N>ET5
MYE_PO7PEVBU,_P#;!?\ XJD_X7KX4_Y]]4_[\)_\70%STZHKBXAM;>2>>18X
MHU+.['  '4UYI+\<- F1HM/LM1FNV!\M'A 7/JVTD@#N0#5""^T;79H[OQCK
M;7;!MZ:;!;3?9H_0'Y/GXQU'6@#U>POK;4[""^LY1+;3H)(Y!T93T-6*\=T/
MXM>'_#\5SI$D5_,L-[-';>3 JHL1<[%&Y@0 "!R!74GXG60/_(&U'\9;4?\
MM:@#N:*X,_%&R!(.CWXQZSVO_P >K'/Q[\- L/[.U7(.#\D7_P 70!ZI17E1
M^/?AO_H':K_WQ'_\75RQ^,VDZE&[VFEWI"-M;S9[>+GK_%*,T"N>DT5P'_"T
M[3_H%2_^!]I_\>JE?_&G2=,\L7>E7@,F=OE3V\O3KG;(<=:!GIE<=X1 'B_Q
MF!_S_0G_ ,@K7+GX^^'O^@7J9_"/_P"+K"T;XQZ+IFO:]?2:=?M'J$\<L:J$
MW*%C"D'YO44"N>[45Y)_PO\ T+/_ ""-1_./_P"*IH^/^BG_ )@VH?\ ?4?^
M- 7/7:*\B/Q_T7_H#:A_WU'_ (TG_"_]'Q_R!K[_ +[3_&@+GKU%>0'X_P"D
M\8T2]/\ VT2D/Q_TOH-$O"?^NJ4!<]@HKQW_ (: TW&?["N\_P#79:3_ (:
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MD&2W)X#8'X5V5% &?I6BV&BQ21:?;K!$Y!*+G'  'Z 5H444 %%%% !1110
M4444 %> _&/CXF:>?731_P"AO7OU?/WQ?GCG^(FF30RI)$VGD!T8,"1(X(R/
M0UG6_AR]#ORO_?:7JCM_@MSX3U 9/&I2?^@1UZ/L_P!IOSKS;X*$_P#"+ZG_
M -A-_P#T7'7IE.G\",L;_O-3_$_S&[3_ 'C3%7<S@LW!QG/M4M1Q_P"LE_WA
M_(59RCMGN?SKFO&&B:EJD6D2:2;;[18:C'>$7+L%8*&!&0"<_-73T4 (N<#/
M7O2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MT3XA^&?$>J+INEZ@T]TR,X0P2)P.O+*!0!0^*FFRZGX0,<5N\YCG60HJ[B<
MX_7%<UI/P?D?3]+>YUJ5%A=+D6[6<1>-MPD*>9UQN]Z]<HH *Y'Q!--'\0_!
M\:32+'+]M$B*Q"OB)2,CO@UUU><^+O$%C:?$_P *VY^T2W%JEU++%!"SL%>/
M"D #GD'I0!Z-17-GQI9@9_LS6O\ P72_X4@\:V9Z:7K7_@ND_P *!7.EHKFQ
MXSM2.-*UL_\ </>F_P#":VW_ $!]<_\  !Z N=-17-'QG;@X_L;7/_ %J/\
MA,X?^@+KG_@$?\: N=+17*IX_P!*_MRQT>YMM0L[R]SY"W-N4#8[YS[5U6:!
MA17)'XA:6VM:AI-M9ZC=75@P2X$$&0I/N2*MZ?XPM+_6(-+:PU&UN)XWDC-S
M"%5@F-V"">?F% '15QG3XSGWT#^4]=G7&L/^+S(>W]@-_P"CQ0!V5%%86N^*
MK70KZRLI+2\NKF\61XH[95/" %B2S #J* -VBN*U#XE6&E0Q3:AI&K6\4DJP
MJ[)$?F;H,*Y-=H#Q0 M%<GJ_Q!TO2M?AT1;>[O;V9"RK:A"HQG(+,P .!G%(
M?'.!G_A']4_&2V_^.T"N=;17(_\ "=C_ * &I9_Z[6W_ ,=I#X[QS_8&H8]Y
M[4?^UJ N=?17'_\ ">'&?^$?OL>]U:?_ !ZF_P#"?G_H W8^MY:?_'J!W.RH
MKBF^()'_ # Y_P ;ZT'_ +5JM>_$]-.M([JY\/W[0R3"!3;SP3$N02%PCGL#
M0*YWU8^J>*-'T>^M+&\O46[NY5BBA7YG)8X!('0>YXKCH_$WB;QT9+?PY:2:
M):1,JW%Y?*/-R>2L:<@\=S5C4_!6G>'? FO36L<EUJC64LC7T_[R=Y AP0QY
M'X4#.GT7Q7HGB":>'3;Y)9H&*O&05;@XR <$CW'%;5<C>>"=*UK2["0QM9W\
M$*^3=V_[N2,[1U(QGZ&L&;Q9XG\$7$>GZ_I\FN0RAOLMY8I^\8 _\M!T!P1T
M_6@#TPU\L:WD3Z$<?P7V/_ N6O6!\7IBP'_"&:W@^B"O'KN\FU#^RI#I]S!#
M ]W%YLB_*SM*\FT>X!P?H:SK?PV=V6?[[2_Q(]B^"?\ R+6JC_J)O_Z+CKTZ
MO'O@CJJ>9K>B^4WF)*MWYF>"&55QCU^7]:]AIT_@1&/5L54_Q/\ ,*8@P\GN
M1_*GTQ/]9)]1_*K.0?117(?$"YO8;/18+*^GLC>:O!;2S0$!@C;L@9'L* .O
MHI%&U0,DX[FEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ KPOQW<7]CK?BJ]M#;F*U:RN)EE#
M$OLDC90N.GS 9]J]TKP[XA_?\>C_ *=K4_\ D2.LJF\?7_,]#!?PZ_\ @_\
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M<^7#*1P1SE1_C6G0,Y\>!O"P.1H%@#_UQ%+_ ,(1X7X_XD.G\# _<+TK?HH
MY*U\$>&+K[0SZ'9?+.RC:F.!TZ5XAXLTO1[3XUQZ;-9^7I32PQO# "O#+UX]
MSFOHS25$<5Q$H.([AUSZ]_ZUXAK<2R_M*VL<@!5W0'_OR:!'?Q_!KP8F"+*=
MN<Y,[&C_ (4UX,SG[%<?3[0U;W@^]=M,;2KDJ+[2V^S2INRVP<1N?]Y &_&M
M/6]4CT71+W4I49TMH6E*IU; Z#W-%@/FKXM>'](\.ZE;6^AVC1VXWI+,92^Z
M48)3GH0"#^->^V/@WPY+IUM(VBV19XD9CY(Y.!7BOQ<L)K#PKX7%T=UY=/<W
M=R^""TC[#R#T."!CVKV75O%6D^%8-/@U/4)+82VI>/" A@@4$#CK\PP*'N"9
M/I?A?0)+5_,T/3OEFD09MT/ <@=O05>_X1;P^>NB:=_X#)_A6A:0+!!M5F;<
MQ<ENI).3_.I))(XP/,=5SP,G&:!F/_PC_AG_ *!.E<?].\?^%3+X:T X9=&T
MX@CJ+9/\*2SVM:*TMTJR$MD87U..U6-+N#+:*)&7S<MQQT!./Z4 0CPUH0.1
MHNG_ /@,G^%8WC#0M)M_!.NS0:791RII\[*RVZ@@B,X(XKK:PO&G_(BZ_P#]
M@ZX_]%M0!R_PHTC3+SX9:+-<:=:32%),O) K$_O&'4BH/$OAZQ\$Z[:>-M*L
MECAAD9=3C3/,4F S@9_AXX'Y5I_!W_DE>B_[LO\ Z->KNJ>*X3+>:9+X;UVY
MCRT+NEEF*0="0V>1[T =5'(LL22(P9& 92.A!K#\8^)5\)>&+K66MFN1 4'E
M*VTL68+U_&L;X7M<Q^';BPFN8)X;*Y:"V$<H=HHP!B-^!AEJ/XQ2O!\,=4DC
M;:RM"0?^VJ4 ;WA'Q)'XK\.6^KI;O;^:SJT3]5*L5(_2O'OB7"LWQQ\/0R%O
M+G:VBD"L5W(TF",CGD$BN9L-=\01^'+^:PUB_MTBD!6&WPJ1AD+L<9Z9XSGO
M6_XNG:[^)WP_O)"3+/%8R.Q/))<'^M CUBX^'GA:.WED72LNJD@&XEZX_P!Z
MO+=*\+^+M4TJVOK;PWX?,,\8==\TH;!]1YO!]J]_KC[>UOO"6L71@MVNM!O)
M6G*Q#,MK,QRQQWC/7V]Z .(T'X9ZY=^*;2Y\06.GV>EVT;%K>SE<K<,> &!8
M],YS[5WY^'7A,YSHT//^V_\ C5FU\;>'+V^MK*WU6%[FY9DAC (+E>H''M6_
M0,Y@?#OPD/\ F"0?BS?XU!?> /"L.G74D>B6P=87*GDX.#[UUU5[Z-I=/N8T
M&6:)E ]210!Y?X T33=?CNO[4LXKIUTO38T>5=S*I@!.">G(S6[-IWB;P>IE
MTB>36M+7YGM+MR9XU'7RV_BXSA<5!\+]/U.R@NSJ6F7%BPM;.W438RYBC*L1
M@GC->A4 <1H'A33-<T:'5?$.@6XU6\W2SK-'\RY8X!_#%<9I3_V!XGFNX+">
M6QL]6U*W$=LJGR@R0E0 2 !P:]JKQG3+"SU'XCM;7UK%<P-K6J$QS(&7/E0D
M'!H$<=9S^/HY8/MEYK+1!F,H340&9<?*!EL#!KJ? .M7UIXST&S\0"[?4[C3
MKFU$LKK(7;SO-&3DG 48Y[\5ZC_PAGAG_H7],_\  9/\*X+Q!96'AOXK:3J-
MEIL45K8Z7+//%:PC<P+>6-JCJV7'X9H&>M9KQ/X@>(;;Q#JVKVU@DN[1-+O8
MKJ1MH4F0(%V\Y/0UV$NG^)/&T;+J$K:)HKD;;:+FYF7/\;=$S_LGO7*_$+0-
M,\/06UGIEJEO$-%U$$J/F?"H<L>I/?F@1U>J^ ='NO"C#2M)LK74/*CEAGCM
MU#AE*MP>N3C'XU';IXL\:*#?"3P]I#+S%$W^E2GCJP^XOTYKMM/.=-M3_P!,
M4_D*LT#/)?BKX9TG0OA-/!I]C%']GEB*R;09,E@"Q;J21U-=AH_@_P ,S:+8
M2R>'],9WMHRS-:(23M'M5?XI:)?^(? 5[IVFP^==.T;+'D#.&!/6NET>&6WT
M6P@G7;-';QHZ^C!0#^M &>?!GA<<GP[I7_@''_A6)<'X:6=S';3P>'4ED. I
MABZ\]>..G>J'Q?U^]L=$M-!TJ-VU'6Y#;Q,IQM *YY[$Y _.N2U"S'@6\;1M
M'T&VOF:&%KJ>XM);F20N'#ME3A0"HX_VJ!'0^(O 4VK:W9ZIX/\ [ M[-;1H
MG#6Z2(YWYR%"E?3GK6'JO@GQ=I.E7>HW%WX:$-M$TK[=+BR0!G _=U1$\'PM
M\=:%>0![/2M6L0UY8MN<P' SC/.0V/R-=M<^)M$\4WEL;O7M,M-&MY4N$C>\
M027+J<KN&?E4'J#R: -OPUX4L%\.6!U;2M)N+\Q!II8[*-58GG@;1VQVKEKR
MVM[#XA+;VEO#!"NK6!$<2!5&;><'@5V__":^%5'_ ",>D_\ @9'_ (UYWJOB
M'19?'PNXM6L7@_M.P;S5G4KM$4X)SGH,C\Z8'L6*,9KGSXY\*#/_ !4>E\?]
M/:?XTG_">>$O^ADTO_P*3_&D,Z&BN=_X3WPE_P!#'IG_ ($K_C2?\)]X2SC_
M (2+3?PN%H Z*O KQ@? NDKC_F.WV<]^)J]:_P"$_P#"7_0PZ=Z?Z\5XK>ZQ
MI[^$;"W@NH9IDUV\D\I6R=C>9AOI\P_.HJ? SJP-WBJ=NZ_,V?@CQXSUX9_Y
M=(OYU[K7S_\ "34+32?%?B"]O[F.WM8K.(/+(<!<N ,_C7K1^(7A$?\ ,?LO
M^^Z5+X$5F/\ O=3_ !/\SIJC0_O)!GN/Y5SO_"PO"1Z:[:'Z,3_2K5EXIT.\
MN;9+;4H97OMWV95S^\V_>QQVP:T.,W*X7XI"(Z+HXGMWN8?[8M?,@C7+2#<?
ME [DUW5<;\1_.&F:,UNJ-.NM6AC61MJEM_&2 <#\* .PCQY:X4J,# /:G4B9
MVC< &QS@YI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUOXL!+B.&-6N;VZ_=@_>9%0CD],(* /H&N-F_P"2QVG_ & I/_1RUV5<;/\
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M\*\XUNUMT^(21K;Q!1J6G *$& #'<9'Z5ZI7E^MNK_$;Y6!VZEI@.#T.RYH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4"%^&^E6VA:MXJTJS39;6MW J#U/D)D_B>:] KBO"CK#XP\<-(P5%O8&+$X
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MS$*0L%&6( ]ZS;+7;2_UC4]+A$GVG33&)P5X^==RX/?BN;^*+6G_  BML;_
MLAJ5K]HW9 \OS1NS[8H [>BH[?ROL\?D;?)VC9MZ;<<8_"I* "BBB@ HHHH
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M_G736%A;:9806-G$(K:!!'%&O15'05SG_"S/!W;78/\ OA_\*/\ A9G@[/\
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M$$XV_+P3TKN?^%R:J6PO@R])],M_\32_\+BUCH/!5Z3C/WF_^(I!='BZ-J:
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MLRN@\6'R]V,O'L0!L>AQ7T!+X:T,1.PTBRR >?(7/\J^;[9=GQ2T)0,!=2
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8YX4FB</&ZAE8="#T-/J*VE\^VBE\MXMZ!O+D&&7(Z$=B*EH **** "BBB@
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M%-+!!<7 9(0"YW!E& 2,\D5A/^+%^IZV%E_L%>/G%_B>V:\0/BAX1]X+T?\
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MT_[Y%+Y,?_/-?R%/HH 9Y4?]Q?RH\J/_ )YK^5/HH 9Y2?W%_*G!5'0 4M%
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MR#_VSKJ:* ,_0M(BT'0K'28)'DBM(5B5W^\P'<UH444 <6O_ "6I^.OA\?\
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M;5CB/X3/2R?_ 'V'J:G@*]N8=*01'>\'B.S>&.1\(&9)E//;MGZ"O2_$PO\
MP4VCW$&JI'J.LZFL>HZA-%O!7!(0 @[5'  %><^&]+N-!\2V/A/7+/$VH:E:
M7HPX9?+42C!([DD8^E>M:CI=I#?V>D^*HOMNDK<B;3+R1F_<R#I'*1]< G@]
M#R:U6QY\_B9H>$1CQCXU'_3]"?\ R M=E7&>$B?^$V\:J?\ G[MR/^_*_P"%
M=G3)"H;JTM[ZV>VNX(YX'&'CE4,K?4&IJ"0,9[T -CC2&)8HD5(T 5548"@=
M !3J** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1ONGZ5\^)9P7WQ*\+6
M]U%YD1OKMBISR58L.GH0#7T&WW37@EGQ\4_"V>OV^]'\ZRE\<?F=]#_=:OK'
M]3WRBBBM3@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JL+"U&HG4!!'
M]L,0A,V/FV YVY],G-6:* "BBB@ HHHH **** "BBB@ HHK&\6:M/H7A+5-5
MMD1Y[2V>5%DSM) [XH Y;Q./^$Q\967A6$AK#3V6]U1U]0?W<6<]^2?I7H72
MN)^%EI_Q1L6L3/YM]K#M>W4I !9V.,?0 #]:[:@ HHHH *\H^*Z(VJPED5BN
MCW3*2.A$L'->KUY1\6"1JT'H='O,_P#?<)H ]4AYA0_[(KSRPO\ 6[+QOXM7
M2M$CU%&N8"[->+#M/DKQ@J<ULZQXDU6QUW3-$TC3+:[GNK1[@M<7)B"A"HQP
MK?WJYW0+SQ:GBGQ2UOHNEO<-<0&='OV"H?*& #Y?S<?2@#H_[;\9$?\ (G6X
M^NK)_P#$4?VWXS_Z$ZV_\&R__$4O]H>.NV@:-^.I/_\ &J07WCOOH6B?^#&3
M_P"-4  UKQH?^90M!]=67_XW2_VQXT_Z%.R_\&P_^-T"]\=GKHFAC_N(R?\
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M$\5'PSJ]I8*K6OGK<1!][>5P1\IQQ0!U(T/QAW\8)G_L'1TIT+Q=_P!#B/\
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M^;IFNVMG:; /)EL?-.[G)W;A[4 ;]%<I_9'C3OXJLOPTH?\ QRC^Q_&6<_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=R +$[@JTA(.5!% '5GP'8$<ZIKO_@TF_P#BJP?$^AIX;;0KNQU'5C)+K-K
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M"]_:_BO./^$7T$#_ +"H_P#C=!UCQ4>OAS0![_VM_P#:ZI_\*J7_ )_=,_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.XQ+7751 44C9"DCKBO+O#5MXHU[P7%KS^,[Z&26.5_*6VA*@JS #)7_ &:
M/4J*Y_P/J-UJW@C1[^^E,MU/;*TLA &YO7 XKH* "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH #TKYC^),:#4+>0(H=M7N S8Y(&S'\S7TY7S+\3OEGC;TU
MBXZ_1*SG\43OPW^[UO1?F?3)K"E_M?[09(UD6)9?NL5RR]S6Z.5%+BK:N<E.
MIR=$_4P[P:HTLOV=)=C !"&7@GO@^GI3XTU(6&) [S>;P-P!V^YK9Q1BERE^
MWT2Y4<_##K6T/*5R1\RJ_/7\J;-;ZV9LQ%A&6(P7&0M=%BBDX>92Q+O?E7W&
M!=0ZRUC:K#@7"EO,^< ?[.?6IM/;5/M2QW4#+&L8W2F12';V Z5LT4^76]R7
M7O'EY49,%E>*8WFDW2>:2=K'[G/7GGM6KBEHII65C*<W-W8F*6BBF2%%%% !
M1110 5QM]_R6#2/^P/<_^C(Z[*N,O^/C!HWOI-S_ .C(Z .SHHHH **** "B
MBB@ HHHH HZW_P @'4?^O67_ -!->&?""&:V\'ZAKEFH-S87RO*O_/6 1C>O
M'7 +,!_> KW36/\ D"7_ #C_ $:3G_@)KPCX17$]WX/U'0; _P"E7U\BS-_S
MRMS&-['TR%91[D4".G\3:D/$W]C^((&)TF#6;*.P(X\TE_WCD=>N% /]TGO4
MWB@8^)#'_IZT;_T=,*A\6:8OA==*T>V5O[*NM8LGLT!)%NZO^\4GT/##/=FJ
M;Q8<?$4CN;C1C_Y,RC^M 'J]%%% PKQ+]HI?^)7H39X$TP_\=%>VUXI^T5QH
M^A_]=Y?_ $$4 >OZ3_R!K'_KWC_]!%7*I:/SHEA_U[Q_^@BKM !7F?Q=_P!;
MX//IKL'\Z],KS/XP':GA-_[NNP?UH L^&O!ND:WH[W]^MU)<2WEUO874BYQ/
M(!P#Z 5'X@\*Z7X>N_#UUIL<\4SZS;1N3<.V5).0035^RT#QII4<UKI^KZ.M
MI]HFEB$UH[.%>1GP2& _BIUQX=\5ZI>::=6U;2I+:SO8KLI;VCHS%#G )8T
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUGIN@HLBAC')=2[TR,@$!3C((/7O0!Z#1573FOFT^!M22".\*_O5@8L@;V)
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M/_CE+_PE&I\X\(:Q^+0?_'* .FKYF^+'W9?;5YO_ $!*]R_X2C5B./!VK?\
M?R#_ ..5X-\19+G4&ORUL;>."^,\B2L-ZEP%VX!.>1VK*;]Z/]=#T,)%RP]:
MW1+\SZ=BYA0_[(I]>;^"_B'K7B/0&O?^$8FN-D[1!K.6,)@ ==[@YYKH1XEU
MLX_XH[4OQN(/_BZU//.GHKF?^$CUS_H3[_\ \"8/_BZ/^$BUWMX/O?\ P*A_
M^*H Z:BN8_X2+7_^A/O/_ N'_P"*I/\ A(/$>./!UQG_ *_8?\: .HHKE_\
MA(/$F?\ D3I__ Z'_&@Z_P")<<>#Y<^]_%0!U%%<J=?\4=O!S_\ @PBKHK&:
MXN+&&6[MOLMPZ R0;P^P]QN'!H L445SM[J_B2#4[B"T\,K<VB$>7<&^1/,X
M&?E()&#D4 =%17*?VYXO)X\'Q8]]33_XFKVE:EXANKX1ZCX?BL;;829EO5E.
M[L-H4?G0!NT452U6>_MM.EETVR2\NUQL@>7R@W(S\V#C R?PH NUQ6KC_B[O
MALGH=/NP/S2LKQIXQ\9>'_"MSJ9T*QL_)>,>:;SS\ L!C9M&>N.M<E>:_P"-
MK/XC^%Y-5M-.FN)XG2V\G<D<B28W*6YPPP.W?WH ]WHKE3JOC3MX8T[_ ,&A
M_P#C=)_:GC;'_(LZ9_X-#_\ &Z .KKQ7XQG01J=Q#<&_;6;C3@+=(D!CPKL1
MD_7.?:N_.I^-^WAO2_\ P9G_ .-UYGXJ&NS?%W0+Z^T&$W:11K!!#=LT;-YC
M8)?R^ ,Y(QTH BTG7H=2\<V=M#.9$?7(IDQ"RY40NI.XGD#Z"O?*X_[5XT5P
M4\-Z(#ZC4&X_\AU)_:'CO/\ R =& _["#_\ QN@#K**Y/[=X[[:+H@_[?I/_
M (BC[;X\/_,'T,?]OLG_ ,10!TE__P @ZY_ZY/\ R->"_!V^FC\&:OI]B ]]
M?7J01+_SS#1_-(?0!0QSZ@#O7J<L_CN:%XFTK0U#J5)^V2'&1_N5Y?I?P:\9
M:,YDT[6X;25DV.\$SH6&<XR* .@\0:<?".DVWAW>7TV;4K*33F*Y*MYRF5&/
M<YRP/OBK7C,8\>N?^P.?_)UZQ)OA=X^NY;=KOQ.+@6\RS1K//)(JNIR#@\=:
M=?V^O6WB>X3Q'>V]W>E])9)((PBB/[:<#'KG- CVZBBN8NI?&_VRX^R6^A?9
MO,/D&627>4[;L#&?I0,Z>O%_VBA_Q(=%/_3S)_Z!7>A_'W>+PZ/^!35Y5\78
M?&&J/86.J6MB(5:1X#:L0'*QEW)+'/"@_E0![=X?.?#>EG_ITB_] %:5>.Z6
M_C>31M/>V'B+R#;1F/RS8!=NT8QGG&/7FDU _%4>5_9(U4')\S[:;(C';&V@
M#V.O+OCB4'A_0C('*#6(=VS.[&U\XQSGZ5@;?C:P^\P_\!O\*S-7\.?%S7HK
M>+4XC.EM<+<1 R0+MD7.#QCU/%%P.TDF\&[V+77BC)/./MW^%()?!AX\WQ0W
MX7W^%<Z8/C<?^6K?@UM_A0+7XV'.ZY9 .Y>W_P *!6.A#^#<?\S21Z;;ZL7Q
M=<>'X?#=P^DS>)+>[WQJ)I!> ("Z@G+<=,UQ4/CGXEW+;8;^_D8PFXPELAS&
M"1OX7ID'FMAM+^*WB_P[&9+@W>F7T:R!3+"NX9!'3!'04#,[6WAAT+5[O2_$
MOBF:2PD2&-YO-6)R2-V3_"1DC!QT'K7?Z6_A:71["2\MO$CW#VT32LB7A!8H
M"2".#SZ5YO>?#+QS8Z3?2W5NR62HT\Z?;%(; W$D!N3Q6A-??%'2M.T98[ZY
M:"_B L8K81NS((PP& ,\+_*@#T-?^$-##%CXFS_URO:Y[0+G3CHM];FVU<?8
MM=N[FW6.QFDW95E57;!P?GYSSZUS7]K?%XG)77\C_IT_^QK,TS4_']GXA3P_
M;WE[8ZAJ,YG:&4",L[Y)<Y'&<$T =YXJMI[/X>_#B"XA>*:*]LU='!!4A>A'
M:O7]5U?3]#L'OM2NHK:V3J\C8'T'J?:O!?B-I/B#2UTNUO?%[:I>/?1_9[5@
M%:-SG:_MS78:-X$\7S&#5-=U.PNM17(6._A,ZP<D?+M8#D8/3O0!J:CXI\3Z
MC87>IZ/I;6>F68\Y);I3YMXJ\E53@J#_ 'CFNUOI%FT.YD4@J]NQ'XJ:PFT[
MQF\3QOJVCE"I4JMB_(QT_P!97GFF>$_B):Z9':79U&4H-B^3KBQ($Q@+MV-T
M'O0!+X ADD^#VC7 @>Y@M-2:>>W1=QD0.W;O@D-_P&NO\27MIXH73+/0IX[F
M]BOX9C-"<_9D5@SEB/NY4%<=\XKC[#P3XLTFQ2RTZPU*UME)(BB\1!5!/7@1
M513P9\5HY)##JLT*,QVK_: ) SP"1C- '8>(]!C\3^+_ !#HTK[!<Z%;A6QG
M:PFD*G\"!7)-XC?3(=.M_'*ZKINHV$4MK;WMH XND8*&)SW&T<UFW_PM^(6K
M7:W-_=K<3!/+\R6[RVT$D#/IDFGV?P@U]8BNHZ1!?2AB5E&JF+"X'&-C>_-
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MCY>@VC ^M>Q53FU2SM]3M=.EF"W=TKO#'@Y<)C=^610!<HHHH *3 SG%+10
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M_'5O-# J/%;6R>6K#J%RN<5[-10%CQW5%N[G1;Z"*;Q]-++;R1I'/;IL8E2
M&PO2MHQ26VI?#"&>-HIHX9$=&&"K"TP01]:](K%U[PS9^()K&:YGNX)K)V>&
M2UF,3*67:>1STH&8_AY]>_X2G61J#77V'[=(MJ'7Y?+V(1@]AG./?->7_%6"
MZA\>WNO6=V]M<Z:ME'$4'.9?,^;/MM/YUZS_ ,(-;9S_ &[XB_\ !I)_C7 ?
M%GPY9^'O"'VBVFO)Y[W4+9)I;NX:5BJ!RHRWIDT 7IOA!JUYJ,5[>>+I;HBY
MBN766VSO,?3G=QQD5ZU2)]P?2EH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?-GQ8'[B]/_
M %&6_P#1=?29Z5\W_%O M[X?]1@_^BJRG\4?7]#OPO\  K>B_-'T5:G-I"?5
M%_E4U067_'C;_P#7-?Y"IZU. **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "N-USCXH^$O>VOO_04KLJXW7O^2H>$/^N%]_Z E '94444 %%%% !1110
M4444 %%%% !7E?C_ (\8Y_Z=M._]+Q7JE>5_$#_D;S[6=@WY7Z_XT >J44#I
M10 5X[^T/_R*VE=/^/P_^@&O8J\>_:&_Y%32^/\ E]_]D:@#TKPJ<^#]$_Z\
M(/\ T6M:]8_A(Y\&Z&?^H?!_Z+6MB@ HHHH **** "BBB@ HHHH *\O^._\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQJ%1 %4 < "@#D1X]D/_ #*'B?\ \ E_^+I?^$\G)P/!WB;\;1/_ (NNPHH
MX_\ X3NX[>#?$W_@-'_\72GQQ>9X\&>)#_VPB_\ CE=?10!Q_P#PG%[NV_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM=W\$$8B3:1(S84DXZ>M>ZUQOQ%_X]?#W_8?LO\ T90!U\2%(40]54"GT44
M%%%% !1110 4F!G.*6B@!-B[@V!D=#Z4M%% !1110 4444 %%%% !7@7Q"FE
M?X]Z+"TCM&@@V(6)5<DYP.V:]]KY_P#B#@?M :+D=?LO_H34/9E0^)';>%C_
M ,3[PI[Z)=C_ ,BP5Z57FOA;_D.^$L?] :\_]&05Z544_@7H;XS_ 'FI_B?Y
MA1115G,%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%  :^=?C!_
MQ[ZIZ_VK%_Z*:OHJOG;XP_ZG5?\ L)P_^BGK*IO'U_0[L)_"K?X?_;D>]Z-S
MH>GG_IVC_P#015ZJ&B<Z#IW_ %ZQ_P#H(J_6IPA1110 4444 %%%% !1110
M4444 %%%% !1110 5QWB8?\ %P?!1_Z:W@_\@UV-<AXF'_%>>"SW$]U_Z(-
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MBB122SL%'YFN2\+_ !"B\2W>GQ+I-S:Q7\,LUO,\J,K>60&!"G(/S#K3]/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MGA;Q+]?L/_V58,OQ%\6K-(L7P\U!X@Q",TI!9<\$C:<'IQ0%STRBO)-1\?\
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M.JEOAR^.@NHL_F:]+K@?B]8/JG@ZWTZ)E66[U&W@1FZ*6?&30!E^ M,\6S^
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M!CI3E'F2L".IMN;B;KCC!]:JZKK*Z9/!']FFF$F2[1KGRU'<_G65_;OB7/\
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M/PA>>'!I5E9>+]?FOM2N1#!Y]T5B7&-Q8@\<'@=Z])\OQ_\ \_?AO_P'G_\
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MHHKECX(@((.O>(>?^HD]=.B[(U7).T 98Y)^M #J*** "BBB@ HHHH ****
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M[JRE#Q8)R_)/YUQ/Q6 _LS3L]YG'_CAK2CN)G1ZMJL^C^'8+JW@69\1KM9L
M CK5NPUFVN=.MKBXFAMY)HED,;R $9^M8GB^5H?!MN52-]S1*0[8&,5R.M6P
M:5H4MW:1+"WQM4G8,-FAK4$>LHZ2(KHP96&0P.013JRO#'/A;2\G/^BQ\_\
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M?BNJKF/A]_R*$/\ U\W7_H^2NGH **** "BBB@ HHHH \\^-PS\+M0]I8?\
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MP0?6N\K@_C)G_A6&JX]8O_1BT 3?"-F?X8:,[L69EE)).23YK\UVU<1\(?\
MDEVC?[LO_HUZ[>@ HHHH **** "BBB@#S_XU?\DMU3_>A_\ 1BUUGAL?\4KI
M'_7E#_Z *Y7XS_\ )+-6^L/_ *-6NI\,?\BGHW_7C!_Z * +EG86>GP^39VT
M4$><[8U"BN;^)O\ R3S5O]V/_P!&+76UR?Q,_P"2>:O_ +B?^C%H ZM?NBEI
M%^Z/I2T %%%% !1110 4444 %%%% !1110 4444 %%%% !7@OQPX\>^&6_V%
M_P#1HKWJO OCTC-XP\.[&V.T.U6QT/F#!H&MSUKP9_R![C_K]G_]&&NCKE_
M221>'6CFE\V9+J99'_O,'.3745G2^!'3CO\ >9^H4445H<H4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MT?A,Y\&Z&?73X/\ T6M<=\6M:TN[^'FOZ?!J%O)>1+$7@20%U_>(1D?2NO\
M"'_(E:%_V#K?_P!%K0!M5RGQ+X^'6M'_ *8C_P!"%=77*?$L9^'.N?\ 7O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(Z;]M\<Y_P"0+H@_[B$G_P :H ZFO&/C%G.IX_Z!\7_HX5WIN_'7;2-"_P#
M^3_XW7F?Q%FU&74UCU^WMK<2VI5X[6Y8HX!)7YBH(.['&*SJ*]O5?F>AE\>:
M51?W)?D=GX#N'E^'6BR$#<8"#CC&&(_I6Z\4=Q%F6,'RG1UY. 0>#7GG@#Q'
MK4^@PVRZ9]J2WBVJBY0C!/))Z_2NJ35]<:',?AQAD\[I<]*^5Q,?WLNFK,8[
M(Z_Y<=J9'@J<X^\?YURC:MXA!'_%/#)_VA3CJGB0GY?#Z#TRXK(#IX<>9/D_
MQ\?D*@G@AN+V)945Q'B101G# \'ZUSIU7Q(6*_V F>N-XIZ:GXD5]_\ 8*9
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M!-1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@QDB)_@EZE?Q[?2MV\ADGLY(XGV2,/E;.,&L/2[.77=&T^\U*Z:?>D<ZHJA
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M_P#!3_\ ;*8'IQD3^^OYUYMJ5W%\._'*Z@,MHGB"01SI'SY%UV<#T89S4?\
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M?_X[7.^*+VWT^73Q>0K<M-.(XP3@J3WIV\@+UWXGLK:2YCDBNS]G;9)(L)*
MX!Z_B*UK0;;=1]:XN]UB&WU+5X&L,M'@9W']^<+QC'O^E=I:?\>ZT*[>H="?
MM2445IU$%<#XRAEF^('A)8)/+DWRG=^%=]7 >-H99_'/A-('"2>9(=Q..,5T
M81VJIWL3/X6>B:?#+;VBQSOOD!.6]>:M53TV":VLDCG</("<D'/>KE?52^)G
M-#X4%%%(S!5+'@ 9-24+7EGB;CX_^$3ZV4H_22NIB\0W7B9=OAL;;,CYM3E7
M"K_US4CYB"""#@4/X$L;^^T_4]8N;B]U6QC"1W:N83P<DX0CKD_G0!U5%%%
M!7E7QS_Y _AUL\#5X_\ T%J[[Q1/JMMX;OY]%B274$B+0JW<^WJ?05Q@\.0_
M$OP?HMU/K]S*8IUNF<Q)D.!@QLHP 0210!Z51110 4444 %>3?'"^;2XO"VI
M(H=[34Q,J,<!BH#8_2O6:\;_ &AE+>']% _Y_&_] - '9?"N3S?AMH\AP"ZR
M/CTS(QKL<CUKQ3PGX.N/$7A33]4M;#0X(9T)6)C=97#$=I<=036S_P *RO\
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M_P#:U'_"IYSU/AH@]<Z0_P#\=I@=-X)FB2+7@TB+_P 3JZQDC^\#73_:[?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5Y%\8!\MV<?\PM__ $8M>NUY)\7L;;OU_LJ3'_?Q
M:SJ;?-?F=V ^.7^&7Y&S\*)9)OAOICR<MF49QU D8"NSKB_A.\DGPWTMILER
M9>6&"1YC8_2NTKYG$QM6EZF,=BM)LCN 7&58=>O-"AC.)4!VD8(/%2@9F;=V
MZ"LS6_$-GH:J)_,>5P3'&BYW>V>@Z]ZYE%LHNY=)FDD0D=!CGBB("2Y>0?=
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ME"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !16%KFH^(;.ZACT?0H
M=0B9"9))+P0[&SP,%3FJ^F:IXKN-3ABU'PW;6=FV[S)TU 2E,#CY=HSDX% '
M2T45EZY=:Q:V<;Z+IT-_<&0*T<L_E!4P<MG![XX]Z -2BN/_ +6\=?\ 0K:;
M_P"#/_["D?5O'H0[/#&F%L<?\3+O_P!\4 =C14=NTSVT37"+',4!D13D*V.0
M#WYJ2@ HKE;J_P#&RWEPMKHNE/;K(1"\EXP9T[$@+P:B-_X]QQHFC9][Q_\
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MP@2]_$WB3_P9/0!U]%<C_P (%'CGQ)XD/_<3DI!X AS_ ,C'XD/_ '%)/\:
M.OHKD/\ A7UOG/\ PD/B/_P:2?XT'X?VQZZ]XB_\&DG^- '7UXI^T*1/INB0
M1,'F%Q(/+4Y;)48XZUWH^']GWUKQ ?8ZI+_C7C'Q-\)W'A#Q)!KS3M/9RW2>
M2KW+M.VQ026?J.01D'B@:/8?A]<Q7EOJ5Q X>-YDP1QTC4']:[2O)O!'@^'4
M;"[6^N]0AECF#;;6]D0?.H;D@C<>>IKJ_P#A7>E]]1UL_74Y?\:RHWY=?/\
M,[,P45B&HNZLOR1UU%<B/AUI0_YB&M'_ +B4O^-'_"N](Q@WFL'W.I2_XUJ<
M1UU%<E_PKK1N]SJQ^NH2_P"-='IVGPZ7I\-E;F0Q0KM4RR%VQ[L>30!:HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ KRSXL#B7_L%W']*]3KRWXL#.
M[_L&7/7\*BI\/S7YG=E_\5_X9?DRS\'Y))/AS9&7)82R@$]2-YQ7=5PGP?:1
MOAW:&7.?.E R,<;CBN[KYG%K]])>?0PC\* G R335</TJ%@QN=I/RD9%(-L-
MQPWRL,'GO7(Y%V)V=5QDXS2@@\@YJN2LLY!.%48'/>DC5EO"H/RA<T<P6+5%
M%8WBK5;C1O#\U]:A#*CH '&1@L ?YU:701LT5D^&;N>^\-6%U<OOGEB#NV,9
M)K6HV8!1112N,*XOXEG;H>GMDC&I0'(^IKM*XOXF''A^Q/IJ,'\S5T[<R$SM
M#55]-M'O8KUH$^T19VN!@C(P:M45-E<!",J1TS7 ZIH-WH?@RZMWN[62W$8C
M?;;D,P+ ==W7FN_KGO'!QX.U _[*?^AK5+5I 2VNG:S:6<%M#J-H(H8U1=UJ
M2< 8_OU-]FUSK_:=KGVM#_\ %UJC[H^E+47 ROLVM_\ 03MO_ 3_ .RI/LFM
M_P#05MQ_VZ?_ &5:U%&HS+%IK(;)U6 CT^R?_94GV/6CG_B;PC_MT'_Q5:M%
M%V!D_8]9P?\ B<19_P"O0?\ Q55XM$U.*_N+U-8433JB.?LHQA<XP,^YK>HI
MQ;N!C:#H T22_D-R9Y+V?SY"4"X;&#@"M2XMH+J+R[B))4R#M<9&1TJ6BB6H
MA H50J@ #@ 5Y]\1+<W/B;P;$LBQM_:&0Q/TZ>]>A5YS\1K4W7BWP4@F$7^G
M'DGGJG3WKJP.F(B[V(J? SU"VB:&VCC9MS*N"?6I:BMHC#;1QERY5<;B>M2U
M]0]S!;!7.^/.? .O_P#7C-_Z":Z*N>\=C/@'7Q_TX3?^@FDAGBOPM3Q0WA:8
MZ(VH_9OM3;A;/;JN[:N?]8"<XQ[5MKX,\1++=R_V1J+R7<C33/(]DQ9VZG)0
MX_"MC]GW_D1+SGC^T'_]%I7K%(#PT>!->73XK!-'U!88E4*1-9!AM((^;R]V
M<@=ZG;PEXIDO[J^ETS49;FZ*F:22YLV+%5PN,QG''I7M=%,#PK_A -?.GRV'
M]C7WV>7=N'VNSR=Q)/S>5D=3]*DU_P '^--=T9=-N+;4I8X65H4GU"V**R\
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M SX;U0>MI+_Z : *G@MBW@?02>IT^#_T6*W:Y_P*<^ ?#Q_ZAT'_ *+%=!0
M4444 %%%% !1110 4444 %%%% !1110 4444 %>._M#?\BSI'_7Z?_1;5[%7
MCO[0P_XI?22>GVT_^BVH ZKX='-O>GU%N?\ R"E=Q7GWPKAGM],NHKF<SR@0
MDR$8R#$I _ 8%>@UE1^'YO\ ,[,=I6^4?_24%%%%:G&%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !7E_Q7SD8Z_V;=?^@BO4*\M^+1MQ=Z5]
MKD>.U9)%G9,Y\LCYNG/2LZGP_=^9Z&6KFKM?W9?^DLD^#/F?\*[M_-+$BXE
MW>F>*] K@/@VKI\/H0^<?:9=F?[N>*[\U\YBU^^EMOT.:'PHKR(XG\P>E(FZ
M6<2-C"C''K5BN;U#Q;!:7MY90V\DL]LC$G'R[@H;&?H17)RZEW-R4,DRR(.H
MP:<B,TGF,><8KE?#?C&YUO5DLI[6"-6B:0-&Q)XQZ_6NQH<-17$KF/B#_P B
M7>=OGB_]&+73US'Q Q_PA5]G^]%_Z,6JIKW@+/@L_P#%'Z;_ -<OZFMZL'P5
M_P B?IN#G]V?YFMZDUJ!Y7/I4U_XZU"WMW0,[L^7X X [5VOA30[C0K.YAN)
M(W:6;S 8\X V@=_I6RMI;K<M<+#&)F&"X49/XU-2U;U&%<7\3O\ D5X"3TOH
M#_X]7:5Q7Q0R/"<>.OVV#_T*KIOWT)G:TA91P2,TO856N OF\]P!^HJ9.P(D
MDE.Y5C*DD\\]*R/$GEP:)=W-VOG01IEH@/O#(XK1,:Q7L008!!S67XV!;P;J
M@'7R?ZBIBN:5F,UC;>:%9W/3C%*+4 8+N1[FID_U:_04ZDXH+D7V>+^X*?L7
M&-HQ3Z2JY4@$V@= *6BBG9 %%%%+J!4@CCS*& R&/6I+4_*:BC">?-O(^]QF
MK,0CQ^[QCVJ8IW!CZ\V^(5BM_P"+/"2&?RMNH9!QR>4]Z])KS+XC68O/%GA%
M#.D0_M$?>/7)3I[UVX)VQ$'>Q%17@SUB!/*@1-V[:,9]:\5UXR/^T'%'@!%L
MRY9N3@02# ].OZ5[5!&(H$C!R%&,UYAK'A_4)OC':ZO%93?9QY4+3(@ ,;1R
M!\G/(!VC)Y':OJ'N<ZV/./ 5_#-K7@ZW%A%%.+TM]J2,!Y5",&#-GGDBO>_&
MXSX$UX?]0^;_ - -9&E?"KPSHVHV-]:1W8EL7+P![EF52>O!X[UL^,QGP1K@
M_P"G";_T TEN,\^_9Y.?!FI#_J('_P!%I7KU>0?L\?\ (G:G_P!?Y_\ 1:5Z
M_0 4444 %%%% !1110 4444 %9^NC/A[4A_TZR_^@&M"J.M#=H6H#UMI/_03
M0!E^ N?A]X=_[!T'_HL5T5<YX _Y)[X=_P"P=!_Z *Z.@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *\?\ V@U+>&=(4*6+7Q  ZDF-J]@KR;X\7;6&
MBZ!>(H9K?5$E"D\$JK''Z4 ;?PRN(KJRNY86W+LMU)QC!$*@C\""*[ZN ^&)
MG>'59[E8UENIDNBL9RJB50X'/LU=_65'X?F_S.S'I*NTMK1_])04445J<844
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M$5/A9[LHPH%+2+]T4M?2F(5C^*_^10UG_KQF_P#0#6Q61XJ7=X1U@>ME-_Z
M: /-?V>/^12U3_K^_P#::5[#7CO[/'_(J:J/^GT?^BUKV*@ HHHH **** "B
MBB@ HHHH *I:OSHM_P#]>\G_ *":NU3U;_D#7W_7O)_Z": ,;X>_\D[\/?\
M8/A_] %=+7-?#W_DG?A[_KPA_P#0172T %%%% !1110 4444 %%%% !1110
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M>N:=;&'_ (2XW@+%A)=:2789[9$HXH]I#N']F8S_ )]L]LHKQT>.M<)Y\10
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M\_']YRW_  @&A;P_DS;AT/G/Q^M//@/0F0*T$C >LSG^M=-12]E#L'U_%?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ+\/+71_$\>OMJ=W=7:6[6X61(D3:3GHB+0!V5%%% '&^$0!XR\:8_Y_8?\
MT2M.\+#_ (GGC4?]1)?_ $GBJWX?TF]L/$WB:]N8PL%]<1/;D,#N58PIX[<T
M_0M)N['5_$UQ.BK%?7BRP$,#N40HI/MRI'X4 5/AA_R3;0_^N!_]":NMKGO
MNEWFB^"=+TZ_C$=U!$5D0,& .XGJ/8UT- !1110 4444 %%%% !1110 4444
M %)M7T'Y4M% ";5_NC\J\N^)_AW7$U?3_&/A_$EWI:8:')9G4G!"KC'1CGVK
MU*B@#R3P_P"-?!%GIMS(VB7&F7LBF2>S^R-FX8CG;CAN_7%<U&U[KWB3PYXA
M_L^32-'LM6MK#3[!UP,,Q+.!@8Z"O=Y-/LYKI+J2UA>= 0LC("P'UK'\4Z%<
M:V-%%L\:"QU2"\D#]T0G('OS0(Z&BBB@84444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !3)&=2FQ-V6PW.,#UI]% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
)44 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>a106amendmentno12tolease006.jpg
<TEXT>
begin 644 a106amendmentno12tolease006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M *2%+%F.<?<%6;K6QKT?AW5I)-5AT2\M)"XTTRAUNB4VI)Y7S8&)!TQD<]J
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M*[NZG:#S[T =/1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC7.U!P  ,D].2<G-:]% %&TTJVL]2U"_CWFXOG1I68YP$4*JCT'!/U8UD_\
M"%6$:G[)=W]F_G3RJ]O,%*B8AI$'!&TL ?4'D$5TE% '/CP=IL3V+6<MY9"R
MM3:0BWFVXC+*Q!)!))*CDFM#2-%LM$MYHK-9,SRM/-)+(TCRR'&69F.2< #V
MQ6A10!2TG3+?1=(M-,M2Y@M8A%&7.6P.F363)X-LWN=1E74-4A349#+<0PW.
MQ&)0(<8&1P!T.>*Z.B@#)_X1S3%ETAHH/)CTDL;2&([40E"G3OA68?C2:GX>
M@U'4;?44NKNROH$,2W%JX5F0D':P8%6&1G!!QS6O10!SB>"M,@M+>*VDNH+F
M"Z:\6]20&=IG!#NQ8$-N!(((QC'' Q"W@/3_ /1&BOM0AEMKB:Z\U)$+23R\
M-*P92-W)Q@ #. ,5U-% &%+X965;1_[7U1;RV61%NQ*GF.DA!96&S:1PN/ER
M-HP:C;P=8QVMG;V-U?:>+6W:V5[64!GC;E@Q8'))YW?>R2<\UT-% '/3>#[$
MQV\=G=7VGQPV@LMMI*%WPCHI+ G(Y^8$,,GGFKT^A64UGIUHJM%!I\L4MND9
MP!Y8PHY[8K3HH SVTB!O$,>M,\AN([5K54R-@5F#$XQG.5'?I52Z\,P2ZQ/J
MMI?7NG7ES$L5P]JR8F"_=+*ZL,C) ( .#C-;=% ',GP/IT=MI$5G<WMDVE/)
M)!+#(I=G<$.SEU8,6RQ)(ZDUI:3H-MI$UU<)-<W-W=;?/N;F3>[A00H[  9;
M   RQ/>M2B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/&?Q)LKD,T-Q<-%(H)7*M),#R.1P:U?BK''!X]^&$$2A$CU(JJCH )( !^E
M'IND^(-+UQ[E-.NA,]L5692C(4)&0"& /(JIJOC+0-$OX['4M06VNI1F.)XW
MS)SCY>/FY],UJQV-O%?SWJ)B>=$CD;/W@F[;QZ_,>?IZ5Y=\6'>+Q_\ #F2-
M'D<7\N$1@I/,70G'\Z /1=,\2:-K%S+;6&H0S7,0#209VR(#W*'!'Y5J5X_&
MR7W[1=M<:D3I5Y;V!6UM,AVO 5?+%ERHP"W!Y^05[!0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MVDYLR8LA19VQ@B5<\ (6;'YU?HH **** "BBB@ HHHH **** "BBB@ HHHH
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MPMLE$,JOY;>C8/!]C5N@ HHHH **** "BBB@ HHJIJ>IV6CZ=-J&H7"6]I"
M9)7Z*,X_F10!;HIJ.LB*Z,&1AE64Y!'J*=0 451N-8TVUU.VTV>]A2^NL^3;
MEOG< $DA>N.#STIUOJMA=ZC>Z?;W4<EY9;/M,*GYHMXW+GZCF@"Y1110 444
M4 %%%-DD2*-I)'5$499F. !ZDT .HJIIVIV.KV8N].NX;JV+,JRPL&4D'!P1
MP>15N@ HHJF=5T]=572S>P?;VC,HMO,'F;!U;;UQS0!<HHHH **** "BBB@
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M59U4L<*"<9^E #J*8)HB<"5#DX^\.M/H **** "BBB@ HHJ-9X7FDA25&EC
M+H&!9<],CMF@"2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H(!&#THHH XWQI;1VUMX4
MMK91##%KEHJ(@P%4!N![8&*J_%J"-/ U[<QQ+]H>XLD+$XW!;E2H)] 6;\S6
MWXFT._UN?2OLUU;V\5C>Q7I\R)G:1DS\O!& 0>O/TJ/QCX>OO%'AU=*BN;>V
M9Y8I99'1G *.KX49&<E<<GI0!67Q%JNG^+;G3=62S:S&E2:BCVRL&C\MPK(<
MGYN&!SA?I56Q\5:_=IHU['I;RP7\J?:;86<J-9Q.,J_FM\K[<C=@<YXZ5H77
MAV_OO%::M/)9?9CIS:?+;A6W,LC*SD/VP5P!CN>E5/#_ (6\1:/9P:/<>(HK
MG2+8KY3BV9+HHK B,R;]NW VD[<X[B@#KKA9VMW6VDCCF(^1Y(RZ@^Z@@G\Q
M7FWAC4KK0/ASIMQ(MI>R3WIM[&#R3&?M$MRZY9RS<?,3P <9KTFX,XMW-LL;
M38^02,0I/N0":XY?!5]<>"XM!N[^&*XM9EN+2^MD.8Y5D,BL4;TX'7GGI0!H
M?VYJ.F^+=.T34T@FBU*&1K>Z@0Q[98QN:-E+-G*\@@]CP>M</!_R1_Q__P!?
MVJ?^AFN]CT74+W7+'5M6DM/-T^*1;:&W#;3(X :0EN1\H( '3<>3VPH?!.K)
MX*\0Z"]S9>9JT\\HE&_$7G,2PQCG;D8Z9]J -<:S=?VKI.@:?]G2>33_ +9-
M-.K.$C4J@"J",DEO48 )YZ5ES^+==.D>)8;2ULWUW0&S)"8W,=S&4WHR -E2
MRYXRW*D=\C3E\/:BFIZ5K-I-:IJ-I:M97$3[C%/"2#@'JI#*"#@]Q[U>T70S
M87NJ:C=2)+>ZG*KS;!\B*B!$1<\D #J>I)X'0 &%<>,[B/5_"GE7-C)IFLQJ
M97\A]\99,H<ABJAV^4!N0<_>YQ%KOBO5++1KO4HHK">T&K1V5MOB<'9YBQLY
MRQ#$/N (P/ESSG%"_#H1>#-7T1+S=<7+,;.=AC[,BN7@08Y 0G/U)^E7O$7A
M*XU#PC8Z%ILL"?9IH)#+<$_,(F#=@>6(Y/N: '7OB'6?^$\D\-V%M8E?[,^V
MK/,[Y0F38,J!R.#P"/J.]6W\:7K>%S=2VL!U)=7.D-M)$/F^?Y7F<G.W'.,Y
MSQGO5]=$U;_A/AXA9K/[,=-%B8 [;@=^\L#MQUXQZ#/M7):UI=YH7A6;2M0N
M]-C?6M>$L;2%O*)DE,S1N2!MX4@,#DG&,'% '7Z?K&K/XSO-"NTM'AM[6*Z%
MQ#&Z%ED+KM(+$ @H>_(IOQ&D\OX;>)&QG.G3+TSU0C^M4-"N+_3?$4%C<II-
MR^H1M)++932R2H$7Y7?>6^3^$?,,%AC.3C8\8Z/>>(?"M_H]F\$;WL+0M+,3
MA >X !S^E '#?$6\NKCP=I=M-HM[I<$5U:R/J<PB=+$*0=X$;LV1]W[H'/6N
MRU_7;ZQOHX;>:PL[9K<RK=WBM(LTN?EB1%923@%B1DXQP:@US0]?\1>'YM$G
MFTZQM[F,13S0!Y6V?Q!58*!D<9R<4@\,:A8^*(+_ $R>S%C'IR6*1W,;.]L$
M/6/!YW#@@X^ZO- %!O'=P?#WAO49EM=.35@1/>7"/)!:L!P",KC<W +,,>]6
M6\6:FCZ=I\MM"FHWSW,B2Q0O<1"VB.%EVH<G>&CP,C[QYZ II/AWQ#I>CZ=I
MTLVEWUK;1S0SVTB,J7"D@QMDAL,"#GC'S8YQFJ$/P]U#3+33;G1]2M[;5-/N
MKF:%)(F>V$4QR8, AMBX7'/4=!G@ Z?PUJ^H:I'>QZE8/;RVMP8DE\B2)+E,
M B15<9'4@C)P1U.17/\ C:;[/X[\"2B&68B[N@(XE!8Y@89Y(Z=?I75Z3;:C
M$LT^JW44UU,1\D *Q1*!@!03GU))Y)/H!6/XAT+5-3\3:#JMI]C5-(EED"2R
M,#-YD>PCA?EQD\\]J ,KPLBZ_P"/]5\7VB+;6:VW]E- W$TLT<F6DE7^$@84
M Y..> 13KCQKJ\MC?ZEI6EO>0VMV]M'9):3-+<A)-C,LH&Q>0V!@].3S@:,W
MAN_TWQ=-KV@26RI>Q!=0LIRRI,Z_=E4@':^,J3@@CMGFJEEX9\3Z/=:A::9K
M%F-(O9Y+A1/$[36;2,6<1D'##))&>AH E/B76[OQC?Z!865E&(+&*[CFN6?(
MWL1AE SGCH/S[5BZAXCU?7/#W@N_MVAL6U#6(H;F HS?,AD)PV1\NZ+IC)XY
M'.>@M- U2S\:ZCKJFUDBGL([2*-YFWDQDE68[>Y;GKCWK&C\$ZY;^$="TZ*?
M3VO=&U07T3,S>7,N9"0?ERI_>GU^Z.F> #T#]\MM_P LWG">ZJ6Q^) S]:\^
M/CW75\(S^)7TJR%K:7LD$\"S,9)%6?RLQG  (]6ZD=%KT#]^EITCEN G;**S
MX_$J"?KCWK@F\%ZVW@"[\-^98"6ZO'G,_F/M16F,Q&-O)!^7MQS[4 ;=IKVK
MIXQ31-3LK1(KFRDN[>2VD9BFQU4H^0,G#J<C ZCGK64GCJ^ANM#CO[6UAEU2
M]-I)8!C]HL\AS&7YP<A5)&%QNXS6M<:3J\_C&QUG99QPP6$EI(@G8OF1T9F7
MY,?+Y8QGKGM7,P>!_$J:-X;LFET99-&U!+EG029N<!@9'/\ ?.[)'.3D[ATH
M T=+U+7+>7QKJ,SVMX]C<^7% -\:X2WC? .6P/G/;)/IP!5OO%NOO\/[OQ#<
M^']-DL6TJ&\2*:<L'+#+JRX/ &"!W!Y.<XTY= UZ.X\4PVQTXV6KDRPL[.LB
M2-"D+!L C V!@>2>G&<B.\\-:U<_"V/PJJ6(NC8I8/,9VV*JQA=X^3).0/EX
MZ]: +_B+Q'=^&M1TZ:[AM_[!F8Q7=YR&MG(^0D?W6; SVS[UJZ)<:E=V'VC4
MX(H'D8F*) P81Y^4N#T8C!([=,FLG4M)U37M1M+?5;2Q;0Q;.UU:BX+&6X/"
M@@H,HHR1R/F(./E%3>#K#7=*T=-.UN6WN/( 6"=)F=RG9'RJY*C W_Q=2 :
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M$4A"6&V-5R<<Y/?%:<NE:X?B!%X@CL[$VR:4UD4-VP?>SK)G_5XP"N/QS[4
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M$ZMC?M&,[?3BDO\ 2O$&H>,_#.L26-G'#IB3BX"W1)/G +A/EYV!023C.>*
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M=M>DR7P4OEBVPE>&'!SQP ,"M?7/#FJ:[<O,VF0V>K07B_8M8MYPKI;A]WS
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M2:>\>G7-I#:12>:A.8RQW%0V=IW8'?U KI=4M7OM(O;2,@// \2D] 64C^M
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH IZAI.G:LD*:C8V]VD,@EC6>,.%<9 8 ]^35RBB@ HHHH **** "LV#0
M=,MM6EU6&VVWTW^MFWMEQT //('8=!VK2HH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH QM2\-6>JZQ8ZI<3W:W%B2;?RIBJH2"&.
M!UR"0<]JV:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "@YQQUHHH Y
MC0/#NHZ3XFUW5)[RUEAU:6.4PQQ,K1%$"#YBQSP!V%6/$6BZAJU]I%Q9W5K
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MXHTK4_)MXK#4["\DL95ES-$)$QEAC:64YXZ&J_A77M<\4>&;;6D&G6HD>53
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MQ1)X@76+5+-;74]+N&MIH7DWQEL95@X )4_0'VK!U2TU*[^*VHII6H_8;O\
MX1N+RI#$KKO\^7;N!!X!]*O?#>73Y-)O%CMS;ZVER1K,<K%I3<]V)/56ZKCC
M'3O0!-X=\1:YXDT.ZO[>QT^&2*YDMXHWG=ED,;%6;<%X!(XX/%1Z)XVFU+PY
MJ^I:A:0:;=Z=(\,MD\C.T<BC@-\HSNR-NT'.1C)IOPR;'A:[=SC_ (FM\3N/
M3]^]<UKL;_V\OQ%L;(S:/;2(EW" V;N%,_Z6%S@^63\F0<@%LXQ0!Z-H=SJM
MYI\=QJUC#8S2*K"WCF,ACR.0QP!GZ5IU#9WEOJ%G#=VDR3V\R!XY8SE64]"#
M4U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5'/!'<P/#,NZ-QAESC(
MJ2B@##B\&^&X8_+CT6S6/O&(AM.>N5Z'/?UJY>:%I5_:V]K=:?;R6]N0T,10
M!8R.A4#@8[5H44 5;W3K/4;0VEY;I/;G[T4@RK>Q'<?6J(\)^'UMX;<:/9^3
M 6:*/RAMC+8R5'\)X'(K8HH H6^BZ;:&<V]G%&\ZA)74?,Z@8 +=<"J</A#P
M];*RP:3;1!B2P1=N2>I./6MNB@"O8V-KIMG'9V5O';VT>=D4:X5<G)P/J2:J
MP^']*@U-]3BLHUOG^]<<[V'/!/<<GBM*B@#,D\/:1+J,VH-80_;)@!).HVNX
M P 2.O'%0P>%-"MK;[-!ID$4'/[J,%5YZ\#CG)K9HH RAX;T<&T*V$2?8T"6
MVS*^2OHF#\OX=:NW=C;7\:1W4*2I'*DR!A]UT8,K#W! -6** *6IZ38:S:FU
MU&V6YMS]Z)R=C?[PZ$>QJ:SLK?3[5+:U3RX4X1-Q(4>@ST'H.@J>B@#/U#1-
M.U6:":]M_-DMSNA8NP\ML$;EP>&P3SUYJP;"U^TS7(MXUN)HQ%),HP[(,X!8
M<\;CCZU8HH PX_!^@16EU:KIL?D79W7*%V(G;.27R?F)[DY)[UI#3[==.^P*
M)!;[=@ E<,![-G</SJU10!FZ3X?TK0H'M]+M%M(7',<3,%[\@9P#SR1R>]-T
MSPYI6CW,US86S133Y,S^:[&0\<MDG<>!R>:U** ,I?#FEKJYU402?;SP9_/D
MW%<YV_>^YDD[?N^U+-X<TF;5'U,VGEWSJ$>XAD:)W Z!BI&X?7^E:E% &'!X
M0T.VL)K"&S9+2=MTL*W$FQR<YR-W.<G/KWS5O^PM._L0:-Y+_P!GB/RO)\Y_
MN?W<YSCMC.,<=*T:* ,_2-#T[0;8VVF6WV:WXQ$KL47_ '020OX8K0HHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **YOQ-)=/JV@6%MJ%S9+>7,J226VS<0L+N
M!\ZL,97TJ1O#]T"P'B;7"0N=H,'T'/E?YZGUH Z"BN?'A^^4LH\3ZX0 #D_9
M>?;_ %7^<T+X=O4^4>*=<(.3N/V8X_\ (- '045@'0;W+ >*=:+ 9P!;?_&:
M#X>O@"1XIULGK@"V_P#C- &_17/-X=O@!CQ5KG)':W/_ +1I3X>O0>/%.ND\
M=/LWT_YXT =!16!_PCUXGS?\)5K?'_7M_P#&:%\/7W4^*M:R<]K;_P",T ;]
M%<^-!OOX/%.MG (R1;8STY_<_P"<4XZ!>E@/^$IUOC)R!;>W!_<T ;U%<_\
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MCRO%).3>Z0HR.!:R'CO_ ,M* -RBL?RO$G_/WI/_ ("R?_'*/*\2?\_>D_\
M@+)_\<H V**Q=#U*^N[_ %:QOQ;F6QF2,20(RJX:-7Z$GGYB.O:MJ@ HHHH
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M'[SG/. . *TK[0+CP[\0_$FL+9W=Q::WI3)&UM"TI^T< H0H.W.,@GCKR,4
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M]>E*0Q8_-@$8  Z'UI2"3C/RX.1W_.@!-N(]BDKQ@$ <?TI#Q]TC+-W/YX_
M4XYR, >](/D4#KVX%  ,"1ANRQP<9Z#Z4@PY8'H/EZ]>!1RJ@ ')/.3G'>C
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M6EQ\^<'D8Z\?E2'YE^8E0<J0#C/;KUH/4@;LGY<CMQG/- "GYL948SW_ $-
MY<G(..  >G3J/6D)&TGYSGY@ ,=.W_ZZ&R5< -R<#].GM0 JX(W @Y_B'<=J
M0#/*A",Y7'ZFG$@ DD #J336Y.&((# X _+/XT *!AF)QD_R_P YI&!=67D
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MZAT." O0J1C\1WK,_LW6/^@^_P#X"1TU+#5G7='XA++R,K:QD<<4 ;(W9&<
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MY35=)"^ATV0G_P!'TTVWBK8H&K:/N'4_V;)@_AY_% &[16&+;Q2.NJZ.>/\
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M2\8M=:1>?9]3NUEBNRI\D1*'8G=W.60!1ZGT-=P+;Q5GG5-'(S_T#I>G_?\
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M0TG'_7C)_P#':00^)\C-]I&,G/\ H<OX?\M: -JBL+RO%>1_IFC8[_Z)+_\
M'*3RO%F#_I>B_P#@++_\<H WJ*PS'XJ .+O1B>W^C2C_ -J4NSQ2).9]',>W
M_GC*"3_WUTH VZ*P]OBK'^LT8'U\N4_U^E*?^$H ( T=CCALRK^G/\Z -NBL
M,GQ5O7 T8KCD9ER30#XJ[KHW_?4O^% &Y16&3XIQPFC ^[R_X?6C/BK ^31O
M?YI?3Z>M &Y16(3XI[)H_3^_+_A2 ^*MW*Z-C'3=+U_*@#<II^^ORY[Y]*Q]
MWB;=_J](QCIYDG7_ +YH#>)]W,>D%<= \N<_E0!M45C[O$G_ #QTG_O[)_\
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M7&!CN>U;E8GA  >%+!0RMM0J2O3(8@T ;=%%% !1110 4444 %%%% !1110
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M<'8#C/4GUKK:P](T6>WUK4=:U!H3>WJQQ!(22L,2#A0Q )RS,Q.!U [9.Y0
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MO3?!]KJ%W-=:C=ZU?3+;ZE?VT5NS@QM&)BBAAC)*[#@Y[^G%-^)F/[#TG/\
MT&[''3_GLM &I_P@WA?_ * =GZ_<]\_SK-U31?!&CRQB[T:(S2(S!8+229]B
M]6(0$A1D<GCFNQWJ'";AN(R!GFLW5;J/34>Z@M%N-1G40PQK@/,1DJI/91N8
MD] ,F@#GFTOP$-'MM433[*:SNF46[0Q-(9F8\!5&23U. .,$GH:#IW@4:8E^
M--MVA>5H%5+9VD,@R"@C W;AM;(QG@UD_P!FMHVN?#[3WGBGAM[B\6Y>/ C%
MRT+L !U')DP.N*N^%KBTLY_%NI72*;>#7)O(<1[FW%(U8( ,EBWRX'4\4 7+
M'2O NHZ9<:C;V-E]FMF=;AI(VC,#)]Y75L%2.X(!I=(T;P5KD<DEAI,3K&0&
M,EI)%R?]\#/X4_3_  ]%?Z3K5KJF+:?6;C[7<VUM+L>%6"H@)4_>*Q#)'!;=
MC(J;PI)J-M?:QHU]?RZBEA+'Y%Y,JAV5TW;'*X!9?7 X9: +/_"$^&O^@-:?
M]\4A\%^&5!)T:T '))6K<FIWZ32HFA7<B(Q"R":$!QZ@%\X^M6!<>;I<DU[:
MRVZ[&,D+D,P49S]PG.1Z4 <I;V?@.ZEM$BTR(B];;:RFTD$<QVEOE<KM/ )Z
M\XXK9_X0GPU_T!K3_OBN4LQJ/@M-%M;RYBUOPU+<Q0V-TPV7%D6^6(''$BX.
M,C!Y]*=I&JZ[JC6VL?;[2W@_M>2UGBDNG/R>:T0A$0CP'^Z0V[DC/0\ '4_\
M(3X:_P"@-:?]\4Q/!_A61Y$32;)FC;:X49*G .#Z'!!^A%<78WNNQ^'8_$)\
M0W]Q+;ZR;0VDR1JDT1N_)VN H(?#9R#@8 Q1;WESH^E:[/:WDHFG\2_8I)IY
MR B,Z+N+8.TXPN[!QD>@H [8^"?#)(_XDUKQ_LT?\(3X9SG^QK7_ +YKFKYO
M$6F1&WDUM4;^U[(0)&_GND$LBHR2,R+N!(8C&#V)(K/UBYUS2[#QA*GB6_(T
M)X[FV,HC)D)C20HY"<J3E0  !NYSQ@ Z*VT'P7=:W>:/%I,?VRSCCEE5HW4;
M7+!<$]?NGIQ6B/ WA@;?^)-;_+TZ_KSS7.7EE=:C\1?$*66LW&FRKH]HWFVZ
MHQ#;IL!MRGCO@8)]:H:3X@\1>+H[2VBN%L[LZ'#>(WGF 232%@9<"-MRJ57Y
M>GS\]L '9'P-X98<Z1 >,9);.,8]:HZEX8\%:1;B6]TV&-';:H42.['&<*JY
M8\ G@=B:IV?]MZIXB2T?Q'(L8TJRO7-K&AB>4R,'V$KG8XCZ9S\W4=*[.[BD
M>(R6RP"[52(GF3<%SC/3!QQV- ')KHO@0Z(-:6*V.G2 $7 F<AB3M ZY+9)7
M'7)Q[5/I_A3P=J,;RV6G)^[<Q2#=+&Z,,':RD@@\@\CH0?2N0@:X7PKX2MI;
M=(?LOBD6]Z5.8Y)%EE!D7/9I<$#L3CM74^&FE/Q)\;C)-N#8[0#P)/).[\<;
M,_A0!H77AGPS86LEU=0K!!"-[RR7,BJH'/)W=.3^=9^G:;X*UU[BWM$,KVP
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M8+B*5TRJM\QX7-;IO[,7GV,W< NL9\GS!OQC/W<YZ4 <UIWB'PMI4<J6,%[
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MM5E,9P"P8.F!@')QBM;2;G4[Q&N+^SBLXI%5HH?,+2KGJ)., ].!GZT 4O\
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M^!"6\#Z0Q# M &.XY.223GWH D_X37PW_P!!BV_,_P"%'_":^&_^@Q;?F?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#E-:_Y*-X4_Z][_\
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MIS3M-U=O#VDZYJTMG.7U35I9K*+R9&+IA$5V"*Q5?E+9QG!&,G%=1]I\3_\
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M=:V<C:?=Z2VH>>P"L/GC5<@L"H 9L@C.2,=#5JV\7:?>M8J8+N*VU-C'973
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MPUTE<WX>_P"1J\7?]?L'_I+#724 %%%% !1110 4444 %%%% !1110 4444
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M)?*2W_"4ZN !SE+7'_HFL*/4M7/CVV^W7,5M#!H!N+FS0,Z"0RKO(;(!(V$
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M:;J7@DZE9Z_:R:EMBUJXCGEQ ,Q[ B@*<]UC7K[GC-:O_")>&_\ H7M)_P#
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MW-?3D_GOH VJ*Q1X4TE0 %O=HZ+_ &A/CUZ;\4-X5TIUVNMZP/7-_.2?QWT
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MS_U%9_\ XKWH Z&BN?\ ^$1M?^@IKG?_ )BDW?\ X%2?\(A:[@W]J:YD'/\
MR%)_3']Z@#H:*P/^$3MLY_M36\_]A.;_ .*H_P"$3M@2?[4UOG_J)S?_ !5
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MWR;"<#\]E)_PE6D[2=]WCU^PS\_3Y.: -JBL0^+-' R9;GOTLICT_P" 4O\
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MMY8=EW, &QDXSZ#.* (;?1=3N_#N@:U:VB27AU0ZU=6LKA6D657&T$\;D1T
MS@?(.:Q"TU]?ZE?26SP:9?>*[*)HW(<.8PJL3@E<&144D$\J?2N[OO$7A^^M
M7M9KZY2(C$@BBFC)7'(RJ@@?0BJTVJ^#IM%_L5]HT_8$6W2VE0*H/&W"@C!'
M!'((H GT? \?^)P@.TPV9<@\;]K_ *[=OX8KIZYG3M7\,:7YXM[ID>XD\R62
M82,\KX R689/  'L.*M#QAH!Z:BAZD_(W '<\<"@#<HK&_X2SP^" VKVBYZ;
MI ,_G2'Q?X=&/^)S9<G'^M% &U16&/&7AP_\QFTZ9^_3CXO\.@X.LV73/$H/
M^>E &U16+_PE_AW<%_MFRR?^FHQW[_A3O^$L\/?]!JQ_[_K_ (T ;%%8_P#P
MEGA[_H-6/_?]?\:/^$L\/?\ 0:L?^_Z_XT ;%%8__"6>'O\ H-6/_?\ 7_&C
M_A+/#W_0:L?^_P"O^- &Q16/_P )9X>_Z#5C_P!_U_QI#XM\.@@'6[#GI^_7
M_&@#9HK%_P"$O\.8S_;FGXSC/VA>N<8Z^M'_  F'ALG']NZ?UQ_Q\+U_/WH
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M@:'_ ->JUTE<W\/O^1 T/_KU6@#I**** "BBB@ HHHH **** "BBB@ HHHH
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M$2,!$JH HE4]&$@('0XSC@5LZE>:!X@LM*\56>LM;FQED-K<(AS*"=DD7ED
MMN( P!G(7% &C9>,;&70;S4KU#:O8W+V=U I\UEG5@H1=HRY;*[0!D[AQFG7
MGB*[TO1?M^I::L,TTT<%I9QSAY))';:JL<8!R<G!8  \G%</)X>NM/T;3-2U
MWS5AG\0MJNIHQP8%9&2,L4X 4B(MV!SS@<M G9-2U.!I;OP]8>(K:]M7#F0>
M4$ F9"<DHK.6XXX;% 'HFC:V^I7>HV-U:BUOM/E5)8EE\Q65E#(ZM@<$9Z@$
M%36O7*^&IX]2\4^(M6M'6;3YA;00W"/N25D1BQ4]"!Y@&1QD'T-=50 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 8'I1@>E%% '.>%HWC
MU#Q.'<,3J[,,'. 8(2!71UAZ ,:GXD^__P A,?>'_3M!^E;E !1110 4444
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M_/N?I6GKVHKHGA[4-3CA9S;6S3!3R&(7@'_@74CU]>@!?36_%+>6?*T@"09
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MYS@$J/F&1R!3K7Q?<Q)JMYK%E-'%#?R6-N(RA\PJZ1@'Y_OEMWL!_%0!T_\
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MLV_@C2(H]'M) +==A-U("R]C@0G&?Q_*NBA5BEN0T89G!;"_7C_Z]8/@S<?
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M_P#3/)''7Z^V43Q1J[,Q_L6VVJ,G_36SU&.L>/KS2>?$DAE3*Q[=I4CV]O\
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MXE&,G=>XQ^&S-(T@D+,%)#9 !'W>.?UYX_\ KU$<KNQO7'5F''N>/R[]R<T
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M?[V5U!6)@P480]3QN. ,<9I__"+:&6XTO3B00,?9(NAXP.#U Y_'I5/5-/\
M#&DRVL5[IENK3R)!&JV"N"[-A1G8<9SWZ8)'N 79-2U"+Q+96L9C-E+#+YA
M9I(V )#$X"[#P #@Y/M4'B.PU/5;FWM[9[ Z;N+S12LY^TG.0K;5/R#J1GYC
M],5,/#&BN1&-+M"T:AG06Z#<.W&.G_UAZUF:E:^&M(N42YL80?)\YDBL3*R(
M"=SLB(2%X^\< G.#GH /O--U"5M-U.2ZLY-3T^>64!%9(F212CID@D';M.2.
MH'&"34NFZ9JVDV\HMC8SW5WJ3WEV'=TB&X8VH=K' "I@D<X.<=!5:W\)'28+
M_P"R6<MM>%4@$-N)#*SCA551DD@,<8R,'..:?Y'A46%O>FSA\J60IA+)G9F!
M*L@0+OW#:> ,@!LC@D &KH-A<Z1I^H2S&.2YN+V2[:)6*Q@L!\J\,0, #)&3
MR<"JO@_2[W0/#UGI%RL33VJ[?-A?<'!8MT(!&,C\LY.:HQ+X4;2(M3CLX)+.
M1V08M"9'?)!0(%+AAAN.3\I],U+I5CX7UJW>>QM(&2-VCD+6^PI(,?*RL 5Z
M\@@=O6@#4G\,Z5/-)+-IMLTLC%B?+!+,?O9XSG)]O7L*DETF&'0;RSTZ.&VD
MDCD2$Q+LVN0</QC/(!]:JMX3TD)@Z?"N.C-" 3\I([>V>]"^'-$\MI1IEMP,
M_,JX'7/.W''].AH HMHNKZC<Z*VH0644FFSI<"\@9GE8HIRJJR#:KYR1E@,=
M,X(ATOP]KND/_9L-S:C2!=/*CB-C/L+E_+(/RGD_?SG'09QB.VA\)7<ELD5G
MO-Y\ML38R(LV 6.QBNT\#.0>1TSU.LOA?0B(PEG#SE6.T#D#GYL>O! Y&: .
M7\.Z-?ZUH,5OY-LMA%JTMP\HD<R/LN6;;C;M!)&,ALX7Z8T[SPMKDD6HP(;2
M.4ZBVJ6DQR_[TMG:X('RD%EX/1B>V*UD\)Z!%#(L.DVOEQM\I5!DG@G.,<]3
M^-!\.: 7D18;9BA'F8#<$CH0#]X@CCJ0??- %"[T;Q#?06,MPMDTD.H6]TJ(
M[")4B.2H8*6);(Z@ 8_$T]7\+ZWJ6G>([94M(GU9H"C&=OW02)$)8>7UPF>/
M7C/?<'AC2HPN^R53MWEB>6YSV[<DY]Z8/"VD<(^E1<G.QLY 'MD>YSVSSQG
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M^U:EO)PRKK%T<'IP/,YZ_P O44 7X\;)ANW.0NY2#\WRG(/(]>>/UIRN!M5
MT;$?(X!.T;<Y_KCGZUFIH-L(SY=SK C(^9AJMWT."/XSZ=OSYIJZ'9[D5K[5
M2J#Y@VJ7)P,<]9<#@CC_ .L: -!3Q&PA<X<[=AQCI[]P?\YJ12C&<Y(._=C=
MR,GC'//>LA/#]HZ92[U0CLQU&Z/8YQ\^.#_3OBI(_#EJV6AO=28'(<_VM<G;
MQT;]Y[T :N\>9A=Y).=N!\V?XCSP3T^O:FPQY@C"J1\V6PA^4^W4]AW_ $K'
M70K=D#+=ZIN"C_F+W+;?7'[SI][OVJPV@6L3LK7FJL =TF_4KDG\C(<_=_\
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MW[<-'ORV\X/X8]\?@3^(1+EE#,I*@D' /7H<?A^?L,X$GB-I'+?V3JXSG?\
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MB?3-8">*+<.2=/UG) 5RFD70]>OR=?\ Z].E\50\K_9^M;1\B+_8]R-O8?\
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M2RDFE>(/?S)+=D9&\?*RJ6/3+#KSC.:[GP]/8WN@Z:VFQK';/"CVZ$D-$,<
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MSGWP 3SQU/(Z $;JQD+JJLJ%E;'5VY&?U!P?0^PI-P-LDC']Z/E7:"H7TX[
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M8*G#8'?!/Y?UJ&]NKR!+4P6SW#22QP%8RH\H'.Z3YB-VT#[HR3G\:2S@8:;
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MJ%Z[5=5W>J'TY .IM])FG(\GQ)JSK%D,J2V[E".Q_<=>.] TF8*T47B+5&V
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MGGM[4 97V/6!&KQ:[<2(A "M'"">.0<1^F/7\,YH6SU1_P!V=:NR9,@$10$
MYVG^#KWQ^%:VW>C$D,CG'S/O"@'&<=N<?KZTP&16C0A2I!;@ ]#V].G3@$#O
M0!E_9M5)9DUFZC!)(8P0]^Q.PX/J3['ZO>TU4@JVNW1(S]^WA&WKC!V#.1G/
M''3WK2C4J,X&X$L 02 0>Q_+D5/Y>WEGRSJVX#^+D<<=/\^M &&UCJ14!M7D
M;* $B&+^Z,X&WG\L=.*9!!<3QEH-=$L:2,I\J&-@&_B&0.""#G/<]L<V/$5A
M-JOA?4--M+DVTEQ"R),RD>6WN<D[>H_D#7$^$8K#5+R\MS;II>KK]MM[BTMT
M0*T;R@;D?;APA 4,.AR.!C(!V7V;59"K?VR27QCY4/..@('''U]/2J]OHMY8
M0&W@U,QQQG[HA4J2S$EB>IR3G)]\YXK%M=&TS3O&L%MI>FI;_P!E6<DTLD9.
M2\S>4@;N?E$K<^H]!5SQC/>_:M(T.QWNFIF5[F02>6WDQ*K. QSC.Y1GDCYL
M=<T ;,=AJMPNQ-5DW8W,#;J?R.,]N^*A6#4P[.NL\\[O]'3C\<^N/3^@Y;4+
MBTN_"$O]E:?':S6NIQV\VG2  7$L<BDVYV\.')3!YSGDXW8F\,6MEJWA[4Q,
M)4M9M2DE;3D 7R0NW]PR\ \@,5 "_-D#% '1Q6NK[E(U48'(984; _\ U=\\
M5)Y.LH=C:KEBHVD6D9&>WM@>N<^PK&\#E1;:E;"WDMA#JLV;.X3FW4E2L?7I
MMPP'(^8X.*Z;R_W0;=LVY8<DMQVSG./;Z4 9BVVM%'\K4TP>H-DN3_='WL$^
MO Z?6IEAUH90:G;@<*,V.2?KAOPX]\5H1;3)L)4D<;2,Y&<9W'IU]>,]:D$C
MR8P?W9R5"XR2,]\\].#B@#(*ZV&!75H0C_(=]D%_(;O;CH*61-;"@+JT2[
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M>^E\\&",@[E25D!Q]XCY#R0.AZ5KF[TLWGV/[7:&Y3YS"67?MX(XX.-N?UH
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M4PI+%1U&  <#.1QL2PJ\;LBY7)!;&0WH<]^!D=>GMB@#.C\2Z:JDR7D9<9X
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M7:-\KB2,,%R4*Y /!08.>F]9>*;RXU*RLKK1]2LWO@_D---$4Q&H9MP5R5[
M\=2 >IK0UK7QHT5K"PN+FXO9Q!!%&V!O(+'+$C"@*22,GI0!RBQ>'5TE(HO$
M=BM_]O&IK<F:,C[5C!)CSC9M^7;GH>N>3-8W%A91W4EMXQTJ._O+T74UR1$T
M;#9M";#)P, <YZCDFM3_ (2R1M*6\CT_4+BZ-Q):-;189TE1F5MQW;."N22<
M<KR2:2'Q=#+9:G<75O>V$>FA1,)F0[B5#!5*,P+$%>,]Z #2=2T#34O99/$>
MG7-W=S^=/(UQ$ Y$:J J@_*H"@ 9)QU)/-7%\2:#&S;=;TW[I7F\3CGUS[GK
MZT_2-4N-5C>673;ZQ*?*/M#H6/7) 5F QWSR*TAG;_KF?HH56.?QY_#ZB@#+
M/B/0FSOUW3\'.-UY&2/<X/UZ4C^(]"9U UW2!@'+O<1DGCCG/X<^G8UI*[?O
M)?.<D 8RQ!(/I@_3_P"O2X"X9-V6PS*&Y'KP?0G/T_*@#.7Q%X>D1=VL:4&#
M;B!?0]".O+<'C^G4TK>)=$1IRVLV&0V0?M<(!SD=SCN3Z>YQSI(D;.[!&*JH
MPQ([]\#CJ.GZ=:;'%$/+/E@[CEQGD8Y]<8^GTH H+XBT-9H\ZUI>%&P WL1Z
M=23GZ]<=/;%1CQ%H?E!?[?T@?,V0+Z)L?+V);!/^-:,2PE#\IY =2"" O\\_
M7-.2"(RE41V"C.<=SU'/_P"KB@"D?$^@<M_;NEELY(^W1A0<],$_X'CI49\2
M:$9EVZWI:C(8 W4>>>W7J?\  \]M06]L#$H0$X]3SQ_];]#3?LT?)V)@8"L7
MQV)_SW_#H 9Z>)- 6$>=JVELRC);[5'DD9/<\?\ ZZD7Q%H:R835K($-@#[2
MF5/X'GI^E7&ACC,BC:S9\O.>_P"H'Y=QFHFA^21L+DXP$&=G'7/0_P">E %;
M^W](<N!J^GA2"I4W*'&<@9&?4Y_"E&L:0\84ZIIX>,;QF=""W/OWP.]63$-X
MPN> 2"I R?H!]?S'L06ULF5:U!C)(4;%PQZ=L\8..W'X  %277=(=)$35=.&
MX Y-PC'=GO\ YSD_A4O]NZ()E<:E:!_* 8^>@&/IU')Q_C4DEK;RYB$<3)P/
M+8 *,<# ^OX9Z#@4?98 ,-"JL &=<#YF!Y)[9X)SCG'7% %==<T80@'5;(CG
M[LZ]>N3SZ?Y]72:YI"Y\O4;/<PP5693W'H0#VXJ:2VBC"1Q0Q\.RA50 +TY]
MNI&0,Y-*ME;M)(FV$_P*&50/;H.G+ ?4]: &+K.EDJPU"U48/S>>N?O$X([8
M]_YTP:SIB,H^WVN <@+(OR]3S]/KW_.5])T\@-_9L#'A0QB4=L_7@TK:78+Y
MF;.%BB$AB@&>,\>E #8]4TQERU_;[3R,S*=H (.1P>II_P#:FG [EU"USR #
M*IX''KZ#]:#I&G$1JNFVRJ0Q*"!.#N'J,?Y-,&BZ<T;/]@LPS.$)\A/G7<?8
MY'?'XT 3?#B1)8/$3QNLB'69,,IR"/)AKM:XKX;P16UOXAA@CCCB76'VI&@1
M1^YA/ ' _"NUH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ KG_ !Y_R3SQ+_V"KK_T4U=!6#XX3S/
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M!Q ]/^>F>G'6D/AK7#TUZT!(QG^SCQ]/WM $%O:I:1QP0VX2&.-4547:B
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MV" ?O#S)>?\ QVC^RO&7RG&A[E_B,TQX_P"^?K0!9 C$@)Q@YW<]3GMZ\&E
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MC_GAZ#UI?LWC#YS_ &-I7*]#JKD\GI_J.V/Y4 7EV$Q\F0X;YO7D?RI@,/E
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MP:'?W9;0;/5_#\\*P7)MY6PEQ;NQ(/EEF7#;7'0,,Y[UZ'0!RFM?\E&\*?\
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MJ>7NBE+JX['E1CKT[8ZUNT %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% '*>"_P#C\\5_]AR7_P!%0UU=<IX+_P"/SQ7_ -AR7_T5
M#75T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5A^-"1X$\0D=?[-N/_1;5N5@^-_^1"\1?]@RY_\
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M*]<Y!7;Z\5PVA0G2[?POX?\ %=]-8P'0W\H23M"/M!<94GIO1" N2<<G (H
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M, M@GC<,8XJIJ]I=Z=I7BV>VUC50-(U6W%B'O7(B#+!(X)))<'S6&'R,'\:
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M3_Z%C1?_   B_P#B:/\ A"?"?_0L:+_X 1?_ !-;M% &%_PA/A/_ *%C1?\
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MR<#(R<8&1ZUQW@&WN]+\1:!%JC27%M=:.YT.3S<FWAW*[0R  ;G"&+Y^!\N
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M &'_ ,(=H.,?8!_W]?/_ *%1_P (AH>0?LCY'0_:),],?WJW** ,3_A$M'P
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M7X:G<_\ QRD_X1;3?^>FI=_^8I<]_P#MI6U10!A_\(GIF"/-U3G_ *BMU_\
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M/B'[6MH)(M9BTBUC#/<7;(C,H&, ;P5 ZY)!Z8'7( *L[ZE<6 LY_"MK-;L
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M=W)A/EVR/)M>3;GHH[DX[GTI;7Q?JKZ&[*(9Y[C6!INFWGE'R[B)B")L _,
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M^']9&?6*/C_Q^E_X2*7_ * &L=O^64?_ ,7VK;HH Q!XBE)Q_8&L#ISY4?\
M\71_PD,N[']@ZQC/7R4QW_V_;]1[UMT4 8O_  D,N"?[!U?(&<>2G/M]^G?V
M\_\ T!=6_P"_*_\ Q5;%% &/_;S_ /0%U;_ORO\ \51_;S_] 75O^_*__%5L
M44 8_P#;S_\ 0%U;_ORO_P 52'Q X(']B:MR<<0+_P#%5LT4 <AX#F-Q)XHE
M,4D1;7)3LD&&7]U%U%=?7*>"_P#C\\5_]AR7_P!%0UU= !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5UH6N/;W$;0RH;)QN1@01D<C(/;F@# T]]6\,ZCH6C>(;:#4-+2<0:5JMO\
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M2_$.ZWEEF@A;3;LQP/)]]E79C)RWKC+8QGG8;QGIZY!T_7B1V&B79_#/EXH
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MIU#*#T/3D8K$TQO#=A+-<ZCJE[J5S+%/;AWL9$5(9)-[($2,#DE<L1DX[ 8
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MD$;RT;%N2"<]3G.<&@"_X$T\VT>LW\5I]BL=1OS<6=J%V;8@B('V\;2Y4OC
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M*^&L]Q)X9L(YIM4=$T^VVK>VR(B_)_RS=5&\8QU)(P,]:[6D      '0"EH
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M*1K'YKJ<%%R&8Y P ">M '8ZE<7=M9E[&T%W<EE1(FDV+R0"6;!P ,D\$\<
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ME/!?_'YXK_[#DO\ Z*AKJZY;P6/](\4. =KZY-@GOB.)3C\01^%=30 4444
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MJS_'3S_\<K9HH Q?L/B+C_B>673G_B7'G_R+2"Q\1X&=<LB?;3C_ /':VZ*
M,0V/B3 QKMCG')_LT]?^_M(;'Q)VUVQ'/?33T_[^UN44 8?V'Q)D_P#$]L<?
M]@T__':/L/B7 _XGMAGO_P 2P_\ QVMRB@##^P^)>?\ B>V'M_Q+3Q_Y%H%C
MXF[Z[IY_[AC?_'JW** ,-;+Q*$PVN:>6]?[,8?\ M:F_8/%'_0?T_P#\%;?_
M !ZMZB@##6R\3!\MKFG$>G]F,/\ VM1]B\3X _MS3.G)_LM^3Q_TW^M;E% &
M&MGXG# G6]+*XY']EOR?^_\ 34L/$D2A8]7TA%Y.U=)<#)[_ .O]<G\:WJ*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
00 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Aug. 01, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ARROWHEAD PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-0408024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">177 E. Colorado Blvd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Pasadena<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">91105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">304-3400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ARWR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138,257,550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000879407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--09-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 129,793<span></span>
</td>
<td class="nump">$ 102,685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">9,699<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available-for-sale securities, at fair value</a></td>
<td class="nump">770,579<span></span>
</td>
<td class="nump">578,276<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">23,692<span></span>
</td>
<td class="nump">9,537<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">13,160<span></span>
</td>
<td class="nump">4,973<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">946,923<span></span>
</td>
<td class="nump">695,471<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">381,048<span></span>
</td>
<td class="nump">386,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">7,286<span></span>
</td>
<td class="nump">8,562<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">44,002<span></span>
</td>
<td class="nump">45,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,353<span></span>
</td>
<td class="nump">4,482<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">1,380,612<span></span>
</td>
<td class="nump">1,139,802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">33,050<span></span>
</td>
<td class="nump">11,388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">64,818<span></span>
</td>
<td class="nump">63,017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll and benefits</a></td>
<td class="nump">19,298<span></span>
</td>
<td class="nump">21,989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">7,010<span></span>
</td>
<td class="nump">6,342<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">22,979<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LinesOfCreditCurrent', window );">Credit facility</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other liabilities</a></td>
<td class="nump">7,375<span></span>
</td>
<td class="nump">432<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">194,530<span></span>
</td>
<td class="nump">103,168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-term liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, net of current portion</a></td>
<td class="nump">105,690<span></span>
</td>
<td class="nump">111,027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_RoyaltiesLiabilityNoncurrent', window );">Liability related to the sale of future royalties</a></td>
<td class="nump">360,254<span></span>
</td>
<td class="nump">341,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Credit facility, net of current portion</a></td>
<td class="nump">200,332<span></span>
</td>
<td class="nump">393,183<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long-term liabilities</a></td>
<td class="nump">666,276<span></span>
</td>
<td class="nump">845,571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Noncontrolling interest and stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value: Authorized 290,000 shares; issued and outstanding 138,144 and 124,376 shares</a></td>
<td class="nump">230<span></span>
</td>
<td class="nump">217<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">2,120,130<span></span>
</td>
<td class="nump">1,806,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">5,357<span></span>
</td>
<td class="nump">4,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,603,404)<span></span>
</td>
<td class="num">(1,625,523)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders&#8217; equity</a></td>
<td class="nump">522,313<span></span>
</td>
<td class="nump">185,444<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="num">(2,507)<span></span>
</td>
<td class="nump">5,619<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total noncontrolling interest and stockholders&#8217; equity</a></td>
<td class="nump">519,806<span></span>
</td>
<td class="nump">191,063<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities, Noncontrolling Interest and Stockholders&#8217; Equity</a></td>
<td class="nump">$ 1,380,612<span></span>
</td>
<td class="nump">$ 1,139,802<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_RoyaltiesLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties, Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_RoyaltiesLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LinesOfCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LinesOfCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481573/470-10-45-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481573/470-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 42: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 47: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 51: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 52: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 54: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 55: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">290,000<span></span>
</td>
<td class="nump">290,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">138,144<span></span>
</td>
<td class="nump">124,376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">138,144<span></span>
</td>
<td class="nump">124,376<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive (Loss) Income - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 27,767<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 572,976<span></span>
</td>
<td class="nump">$ 3,551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">162,368<span></span>
</td>
<td class="nump">152,431<span></span>
</td>
<td class="nump">432,472<span></span>
</td>
<td class="nump">370,044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">30,949<span></span>
</td>
<td class="nump">23,710<span></span>
</td>
<td class="nump">86,264<span></span>
</td>
<td class="nump">72,384<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">193,317<span></span>
</td>
<td class="nump">176,141<span></span>
</td>
<td class="nump">518,736<span></span>
</td>
<td class="nump">442,428<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating (loss) income</a></td>
<td class="num">(165,550)<span></span>
</td>
<td class="num">(176,141)<span></span>
</td>
<td class="nump">54,240<span></span>
</td>
<td class="num">(438,877)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterestAndDividend', window );">Interest income</a></td>
<td class="nump">11,019<span></span>
</td>
<td class="nump">6,498<span></span>
</td>
<td class="nump">28,236<span></span>
</td>
<td class="nump">15,550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(24,382)<span></span>
</td>
<td class="num">(5,094)<span></span>
</td>
<td class="num">(67,667)<span></span>
</td>
<td class="num">(17,705)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="num">(176)<span></span>
</td>
<td class="nump">760<span></span>
</td>
<td class="nump">603<span></span>
</td>
<td class="nump">1,370<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other (expense) income</a></td>
<td class="num">(13,539)<span></span>
</td>
<td class="nump">2,164<span></span>
</td>
<td class="num">(38,828)<span></span>
</td>
<td class="num">(785)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">(Loss) income before income tax expense and noncontrolling interest</a></td>
<td class="num">(179,089)<span></span>
</td>
<td class="num">(173,977)<span></span>
</td>
<td class="nump">15,412<span></span>
</td>
<td class="num">(439,662)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="num">(437)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,419<span></span>
</td>
<td class="num">(3,313)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income including noncontrolling interest</a></td>
<td class="num">(178,652)<span></span>
</td>
<td class="num">(173,977)<span></span>
</td>
<td class="nump">13,993<span></span>
</td>
<td class="num">(436,349)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interest, net of tax</a></td>
<td class="num">(3,411)<span></span>
</td>
<td class="num">(3,184)<span></span>
</td>
<td class="num">(8,126)<span></span>
</td>
<td class="num">(7,392)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income attributable to Arrowhead Pharmaceuticals, Inc.</a></td>
<td class="num">$ (175,241)<span></span>
</td>
<td class="num">$ (170,793)<span></span>
</td>
<td class="nump">$ 22,119<span></span>
</td>
<td class="num">$ (428,957)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Net (loss) income per share attributable to Arrowhead Pharmaceuticals, Inc.:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (1.26)<span></span>
</td>
<td class="num">$ (1.38)<span></span>
</td>
<td class="nump">$ 0.17<span></span>
</td>
<td class="num">$ (3.63)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (1.26)<span></span>
</td>
<td class="num">$ (1.38)<span></span>
</td>
<td class="nump">$ 0.17<span></span>
</td>
<td class="num">$ (3.63)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted-average shares used in calculating</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">139,039<span></span>
</td>
<td class="nump">124,199<span></span>
</td>
<td class="nump">132,385<span></span>
</td>
<td class="nump">118,260<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">139,039<span></span>
</td>
<td class="nump">124,199<span></span>
</td>
<td class="nump">133,352<span></span>
</td>
<td class="nump">118,260<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Other comprehensive income (loss), net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gains on available-for-sale securities</a></td>
<td class="nump">$ 876<span></span>
</td>
<td class="nump">$ 249<span></span>
</td>
<td class="nump">$ 1,022<span></span>
</td>
<td class="nump">$ 2,374<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="nump">91<span></span>
</td>
<td class="num">(141)<span></span>
</td>
<td class="num">(415)<span></span>
</td>
<td class="num">(139)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive (loss) income</a></td>
<td class="num">$ (177,685)<span></span>
</td>
<td class="num">$ (173,869)<span></span>
</td>
<td class="nump">$ 14,600<span></span>
</td>
<td class="num">$ (434,114)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterestAndDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterestAndDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Non- controlling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,312,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Sep. 30, 2023</a></td>
<td class="nump">$ 287,162<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 1,300,395<span></span>
</td>
<td class="num">$ (3,222)<span></span>
</td>
<td class="num">$ (1,026,030)<span></span>
</td>
<td class="nump">$ 15,819<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">19,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="nump">58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gains (losses) on available-for-sale securities</a></td>
<td class="nump">1,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(135,376)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(132,864)<span></span>
</td>
<td class="num">(2,512)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="nump">173,714<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">1,320,356<span></span>
</td>
<td class="num">(1,255)<span></span>
</td>
<td class="num">(1,158,894)<span></span>
</td>
<td class="nump">13,307<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,312,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Sep. 30, 2023</a></td>
<td class="nump">287,162<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">1,300,395<span></span>
</td>
<td class="num">(3,222)<span></span>
</td>
<td class="num">(1,026,030)<span></span>
</td>
<td class="nump">15,819<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(139)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gains (losses) on available-for-sale securities</a></td>
<td class="nump">2,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(436,349)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,227,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2024</a></td>
<td class="nump">338,974<span></span>
</td>
<td class="nump">$ 217<span></span>
</td>
<td class="nump">1,786,304<span></span>
</td>
<td class="num">(987)<span></span>
</td>
<td class="num">(1,454,987)<span></span>
</td>
<td class="nump">8,427<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">173,714<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">1,320,356<span></span>
</td>
<td class="num">(1,255)<span></span>
</td>
<td class="num">(1,158,894)<span></span>
</td>
<td class="nump">13,307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">17,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">1,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">723,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,790,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued, net of offering costs</a></td>
<td class="nump">429,265<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">429,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(56)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(56)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gains (losses) on available-for-sale securities</a></td>
<td class="nump">216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(126,996)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(125,300)<span></span>
</td>
<td class="num">(1,696)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,133,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2024</a></td>
<td class="nump">495,405<span></span>
</td>
<td class="nump">$ 217<span></span>
</td>
<td class="nump">1,768,866<span></span>
</td>
<td class="num">(1,095)<span></span>
</td>
<td class="num">(1,284,194)<span></span>
</td>
<td class="nump">11,611<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">17,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(141)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(141)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gains (losses) on available-for-sale securities</a></td>
<td class="nump">249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(173,977)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(170,793)<span></span>
</td>
<td class="num">(3,184)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,227,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2024</a></td>
<td class="nump">338,974<span></span>
</td>
<td class="nump">$ 217<span></span>
</td>
<td class="nump">1,786,304<span></span>
</td>
<td class="num">(987)<span></span>
</td>
<td class="num">(1,454,987)<span></span>
</td>
<td class="nump">8,427<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Sep. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,376,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Sep. 30, 2024</a></td>
<td class="nump">191,063<span></span>
</td>
<td class="nump">$ 217<span></span>
</td>
<td class="nump">1,806,000<span></span>
</td>
<td class="nump">4,750<span></span>
</td>
<td class="num">(1,625,523)<span></span>
</td>
<td class="nump">5,619<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">15,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of pre-funded warrants</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(106)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(106)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gains (losses) on available-for-sale securities</a></td>
<td class="num">(507)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(507)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(175,218)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(173,085)<span></span>
</td>
<td class="num">(2,133)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,655,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2024</a></td>
<td class="nump">56,075<span></span>
</td>
<td class="nump">$ 217<span></span>
</td>
<td class="nump">1,846,843<span></span>
</td>
<td class="nump">4,137<span></span>
</td>
<td class="num">(1,798,608)<span></span>
</td>
<td class="nump">3,486<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Sep. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,376,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Sep. 30, 2024</a></td>
<td class="nump">$ 191,063<span></span>
</td>
<td class="nump">$ 217<span></span>
</td>
<td class="nump">1,806,000<span></span>
</td>
<td class="nump">4,750<span></span>
</td>
<td class="num">(1,625,523)<span></span>
</td>
<td class="nump">5,619<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">458,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">$ (415)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gains (losses) on available-for-sale securities</a></td>
<td class="nump">1,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">13,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138,144,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2025</a></td>
<td class="nump">519,806<span></span>
</td>
<td class="nump">$ 230<span></span>
</td>
<td class="nump">2,120,130<span></span>
</td>
<td class="nump">5,357<span></span>
</td>
<td class="num">(1,603,404)<span></span>
</td>
<td class="num">(2,507)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,655,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2024</a></td>
<td class="nump">56,075<span></span>
</td>
<td class="nump">$ 217<span></span>
</td>
<td class="nump">1,846,843<span></span>
</td>
<td class="nump">4,137<span></span>
</td>
<td class="num">(1,798,608)<span></span>
</td>
<td class="nump">3,486<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">16,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">353,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">2,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,128,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,926,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued, net of offering costs</a></td>
<td class="nump">241,387<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">241,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gains (losses) on available-for-sale securities</a></td>
<td class="nump">653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">367,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">370,445<span></span>
</td>
<td class="num">(2,582)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138,062,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2025</a></td>
<td class="nump">684,225<span></span>
</td>
<td class="nump">$ 230<span></span>
</td>
<td class="nump">2,106,864<span></span>
</td>
<td class="nump">4,390<span></span>
</td>
<td class="num">(1,428,163)<span></span>
</td>
<td class="nump">904<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">13,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gains (losses) on available-for-sale securities</a></td>
<td class="nump">876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(178,652)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(175,241)<span></span>
</td>
<td class="num">(3,411)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138,144,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2025</a></td>
<td class="nump">$ 519,806<span></span>
</td>
<td class="nump">$ 230<span></span>
</td>
<td class="nump">$ 2,120,130<span></span>
</td>
<td class="nump">$ 5,357<span></span>
</td>
<td class="num">$ (1,603,404)<span></span>
</td>
<td class="num">$ (2,507)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 42: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 47: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 51: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 52: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 54: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 55: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 13,993<span></span>
</td>
<td class="num">$ (436,349)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash flow from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">44,279<span></span>
</td>
<td class="nump">54,494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">17,542<span></span>
</td>
<td class="nump">13,570<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">(Accretion) amortization of note premiums/discounts</a></td>
<td class="num">(4,545)<span></span>
</td>
<td class="nump">7,886<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Realized loss on investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(80)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties', window );">Non-cash interest expense on liability related to the sale of future royalties</a></td>
<td class="nump">18,893<span></span>
</td>
<td class="nump">17,705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest expense on credit facility</a></td>
<td class="nump">48,774<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(9,841)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(22,342)<span></span>
</td>
<td class="num">(1,746)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">21,662<span></span>
</td>
<td class="nump">2,785<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">7,956<span></span>
</td>
<td class="nump">13,086<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">22,979<span></span>
</td>
<td class="num">(866)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease, net</a></td>
<td class="num">(3,417)<span></span>
</td>
<td class="nump">3,880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other</a></td>
<td class="nump">3,128<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="nump">159,061<span></span>
</td>
<td class="num">(325,635)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(15,177)<span></span>
</td>
<td class="num">(117,180)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(774,616)<span></span>
</td>
<td class="num">(428,611)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Proceeds from sales and maturities of investments</a></td>
<td class="nump">587,880<span></span>
</td>
<td class="nump">348,642<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(201,913)<span></span>
</td>
<td class="num">(197,149)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercises of stock options</a></td>
<td class="nump">3,476<span></span>
</td>
<td class="nump">2,166<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock, net of offering costs</a></td>
<td class="nump">241,388<span></span>
</td>
<td class="nump">429,265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ProceedsFromSaleOfFutureRoyalties', window );">Proceeds from the sales of future royalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from the issuance of warrants</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs</a></td>
<td class="num">(5,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayments of credit facility</a></td>
<td class="num">(201,625)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from Visirna credit agreement</a></td>
<td class="nump">7,098<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">70,337<span></span>
</td>
<td class="nump">481,431<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">27,485<span></span>
</td>
<td class="num">(41,353)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate on cash, cash equivalents and restricted cash</a></td>
<td class="num">(377)<span></span>
</td>
<td class="num">(139)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract', window );"><strong>CASH, CASH EQUIVALENTS AND RESTRICTED CASH:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">BEGINNING OF PERIOD</a></td>
<td class="nump">102,685<span></span>
</td>
<td class="nump">110,891<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">END OF PERIOD</a></td>
<td class="nump">129,793<span></span>
</td>
<td class="nump">69,399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplementary disclosure of cash flows:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="num">(19)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes paid</a></td>
<td class="num">(81)<span></span>
</td>
<td class="num">(3,062)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CashFlowNoncashInvestingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Capital expenditures included in accrued expenses</a></td>
<td class="nump">$ 346<span></span>
</td>
<td class="nump">$ 6,909<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CashFlowNoncashInvestingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Flow, Noncash Investing Activities Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CashFlowNoncashInvestingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Interest Expense, Liability Related To Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ProceedsFromSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ProceedsFromSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization and Significant Accounting Policies</a></td>
<td class="text">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Recent Developments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Arrowhead Pharmaceuticals, Inc. and its subsidiaries (referred to herein collectively as the &#8220;Company&#8221;) are primarily engaged in developing medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, the Company&#8217;s therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference (&#8220;RNAi&#8221;) is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. The Company&#8217;s RNAi-based therapeutics may leverage this natural pathway of gene silencing to target and shut down specific disease-causing genes. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s current pipeline:</span><span style="color:#ee2724;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:28.035%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Therapeutic Area</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Name</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Stage</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Product Rights</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Cardiometabolic</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">plozasiran</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Phase 3</span></div></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">zodasiran</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Phase 3</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">olpasiran</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Phase 3</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Amgen</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">ARO-PNPLA3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">GSK-4532990</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Phase 2b</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">GSK</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">ARO-INHBE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">ARO-ALK7</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Pulmonary</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">ARO-RAGE</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></div></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">SRP-1002 (ARO-MMP7)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Sarepta</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Liver</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">fazirsiran</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Phase 3</span></div></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Takeda and Arrowhead</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">GSK5637608</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Phase 2</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">GSK</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Neuromuscular</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">SRP-1001 (ARO-DUX4)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Sarepta</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">SRP-1003 (ARO-DM1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Sarepta</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Central Nervous System (CNS)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">SRP-1004 (ARO-ATXN2)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Sarepta</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Other</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">ARO-C3</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">ARO-CFB</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates lab facilities in California and Wisconsin, where its research and development activities, including the development of RNAi therapeutics, take place. The Company also operates an active pharmaceutical ingredient manufacturing and supporting laboratory facility in Verona, Wisconsin. The Company&#8217;s principal executive offices are located in Pasadena, California.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the first three quarters of fiscal 2025, the Company has continued to develop and advance its pipeline and partnered candidates. The following is a summary of select significant developments affecting our business that have occurred since the filing of our Annual Report on Form 10-K for the fiscal year ended September 30, 2024:  </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Triggered a $100.0 million milestone payment from Sarepta Therapeutics, Inc., which was triggered on July 27, 2025, when the Company reached the first of two prespecified enrollment targets and subsequent authorization to dose escalate in a Phase 1/2 clinical study of ARO-DM1, an investigational RNAi therapeutic for the treatment of type 1 myotonic dystrophy (DM1);</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Announced the signing of an asset purchase agreement between Sanofi and Visirna Therapeutics, a majority-owned subsidiary of the Company, created to develop and commercialize four of the Company&#8217;s investigational cardiometabolic candidates in Greater China. Under the terms of the agreement, Sanofi will acquire rights to develop and commercialize investigational plozasiran, the Company's first-in-class RNAi therapeutic candidate designed to reduce production of apolipoprotein C-III (APOC3) as a potential treatment for familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia (SHTG), in Greater China;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Initiated and dosed the first subject in the YOSEMITE Phase 3 clinical trial of zodasiran, the Company&#8217;s investigational RNAi therapeutic being developed as a potential treatment for homozygous familial </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">hypercholesterolemia (HoFH), a rare genetic condition that leads to severely elevated LDL-cholesterol and early onset cardiovascular disease; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10pt">Completed enrollment of SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 clinical trials of plozasiran. The Company&#8217;s global Phase 3 clinical studies are designed to support regulatory submissions for approval of investigational plozasiran in the treatment of severe hypertriglyceridemia. The Company previously submitted a New Drug Application to the U.S. Food and Drug Administration (&#8220;FDA&#8221;) on November 16, 2024 for plozasiran based on positive Phase 3 PALISADE study results in patients with familial chylomicronemia syndrome, which the FDA accepted on January 17, 2025, with a Prescription Drug User Fee Act (PDUFA) action date of November 18, 2025, and indicated it is not currently planning to hold an advisory committee meeting;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Initiated a Phase 1/2a clinical trial of ARO-ALK7 for the treatment of obesity. ARO-ALK7 is the first RNAi-based therapy designed to silence adipocyte expression of  the </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ACVR1C </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">gene to reduce the production of Activin receptor-like kinase 7 (ALK7), which acts as a receptor in a pathway that regulates energy homeostasis in adipose tissue;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Announced Topline results from Part 2 of a Phase 1/2 clinical study of ARO-C3, the Company&#8217;s investigational RNAi therapeutic designed to reduce liver production of complement component 3 (C3) as a potential therapy for various complement mediated diseases. ARO-C3 achieved reductions in alternative pathway complement activity and proteinuria;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Entered into a global licensing and collaboration agreement with Sarepta Therapeutics, Inc (&#8220;Sarepta&#8221;) on November 25, 2024, which closed on February 7, 2025. Closing of the transaction was subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary conditions. Upon closing, the Company received $325.0 million through the purchase of 11,926,301 shares of Company common stock by Sarepta, at a price per share of $27.25, and received $500.0 million as an upfront payment on February 24, 2025. The Company will also receive $250.0 million to be paid in equal installments over five years and is eligible to receive an additional $300.0 million in near-term payments. Additionally, the Company is eligible to receive royalties on commercial sales and up to approximately $10.0 billion in future potential milestone payments;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">GSK dosed its fifth patient in a Phase 2 trial in December 2024, triggering a $2.5 million milestone payment to the Company which was paid in the second quarter of fiscal 2025;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.7pt">Announced that the Company dosed the first subjects in a Phase 1/2a clinical trial of ARO-INHBE; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Presented interim results from a Phase 1/2a clinical study of ARO-CFB at the 8th Complement-Based Drug Development Summit. The study resulted in multiple findings including: (1) ARO-CFB led to dose dependent reductions in circulating CFB protein by up to 90% with greater than 3 months duration, (2) single and multiple doses of ARO-CFB led to near complete inhibition of alternative pathway activity based on Wieslab AP, and (3) single and multiple doses of ARO-CFB led to near complete inhibition of alternative pathway hemolytic activity, measured by AH50.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation and Basis of Presentation </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The interim Consolidated Financial Statements include the accounts of Arrowhead Pharmaceuticals, Inc. and its subsidiaries (wholly-owned subsidiaries and a variable interest entity for which the Company is the primary beneficiary). Subsidiaries refer to Arrowhead Madison, Inc., Arrowhead Australia Pty Ltd., Arrowhead Pharmaceuticals Ireland Limited, Arrowhead Pharmaceuticals NZ Limited and Visirna Therapeutics, Inc. (&#8220;Visirna&#8221;). For subsidiaries in which the Company owns or is exposed to less than 100% of the economics, the Company records net loss attributable to noncontrolling interests in its consolidated statements of operations equal to the percentage of the economic or ownership interests retained in such entity by the respective noncontrolling party.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The interim Consolidated Financial Statements have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). The financial data of the Company included herein are unaudited. In the opinion of management, all material adjustments of a normal recurring nature have been made to present fairly the Company&#8217;s financial position as of June&#160;30, 2025 and the results of operations and cash flows for the periods presented. All intercompany transactions and balances have been eliminated. Certain prior period amounts have been reclassified to conform with the current period presentation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certain financial information that is normally included in annual financial statements prepared in accordance with GAAP, but that is not required for interim reporting purposes, has been omitted from the accompanying interim consolidated financial statements and related notes. Readers are urged to review the Company&#8217;s Annual Report on Form </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10-K for the fiscal year ended September&#160;30, 2024 for more complete descriptions and discussions. Operating results and cash flows for the nine months ended June&#160;30, 2025 are not necessarily indicative of the results that may be expected for the fiscal year ending September&#160;30, 2025.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s primary sources of financing have been through the sale of its equity securities, credit facility, revenue from its licensing and collaboration agreements and the sale of certain future royalties. Research and development activities have required significant investment since the Company&#8217;s inception and are expected to continue to require significant cash expenditure in the future, particularly as the Company&#8217;s pipeline of drug candidates and its headcount have both expanded. Additionally, significant investment will be required as the Company&#8217;s pipeline matures into later stage clinical trials and commercialization efforts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, the Company had $129.8 million in cash, cash equivalents and restricted cash ($2.2 million in restricted cash) and $770.6 million in available-for-sale securities to fund operations. During the nine months ended June&#160;30, 2025, the Company&#8217;s cash, cash equivalents and restricted cash and investments balance increased by</span><span style="color:#ee2724;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$219.4 million, which was primarily due to the $500.0 million as an upfront payment under the Sarepta agreement and $325.0 million in the form of an equity investment under the Sarepta agreement, and $25.0 million in the form of pre-funded warrants, partially offset by ongoing expenses related to the Company&#8217;s research and development programs, $201.6 million payments on its credit facility, and $28.2 million interest income earned on investments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In total, the Company is eligible to receive up to $13.3 billion in additional developmental, regulatory and sales milestones, and may receive various royalties on net sales from its licensing and collaboration agreements, subject to the terms and conditions of those agreements. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Significant Accounting Policies </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes to the significant accounting policies disclosed in the Company&#8217;s most recent Annual Report on Form 10-K for the fiscal year ended September&#160;30, 2024.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In January 2025, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standard Update (&#8220;ASU&#8221;) 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">in November 2024, and ASU 2025-01,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Clarifying the Effective Date</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. These updates require entities to provide disaggregated disclosures of income statement expenses. The ASUs do not affect the expense captions presented on the face of the income statement but instead require the disaggregation of certain expense captions into specified categories within the footnotes to the financial statements. The ASUs will become effective for the Company beginning October 1, 2027, and the Company is currently evaluating the impact on its consolidated financial statements and related disclosures.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, to improve its income tax disclosure requirements. Under the guidance, entities must annually (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold. This ASU will become effective for the Company beginning October 1, 2025, and is not expected to have a material impact on its consolidated financial statements and related disclosures.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, which is intended to improve reportable segment disclosure requirements, primarily through additional disclosures about significant segment expenses. This ASU requires public companies with a single reportable segment to provide all disclosures required under ASC 280. In addition, this ASU requires public companies to include in interim reports all disclosures related to a reportable segment&#8217;s profit or loss and assets that are currently required in annual reports. While the ASU implements further segment disclosure requirements, it does not change how an entity identifies its operating or reportable segments and it will have no impact on the Company&#8217;s consolidated financial condition, results of operations or cash flows. The Company plans to adopt the ASU's in connection with our Annual Report on Form 10-K for the fiscal year ending September 30, 2025, as required and will be applied retrospectively to all periods presented. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On July 4, 2025, the One Big Beautiful Bill Act (&#8220;OBBBA&#8221;) was signed into law, which enacts significant changes to U.S. tax and related laws. Some of the provisions of the new tax law affecting corporations include but are not limited to expensing of domestic research expenses, reinstate the limit of the deduction of interest expense to thirty percent of EBITDA, and one hundred percent bonus depreciation on eligible property acquired after January 19, 2025. The Company is currently evaluating the impact the new tax law will have on its financial condition and results of operations.  </span></div>Preliminarily, the Company does not anticipate a material change to its effective income tax rate and its net deferred federal income tax assets as the Company maintains a full valuation allowance.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CollaborationAndLicenseAgreementsAbstract', window );"><strong>Collaboration And License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration and License Agreements</a></td>
<td class="text">COLLABORATION AND LICENSE AGREEMENTS<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of revenue recognized:</span></div><div style="margin-top:6pt;text-align:center;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.878%"><tr><td style="width:1.0%"></td><td style="width:27.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.775%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">GSK</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2,646&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2,685&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Takeda</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">866&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Sarepta</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">27,624&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">570,330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">27,767&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">572,976&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">3,551&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balance of receivables and contract liabilities related to the Company&#8217;s collaboration and license agreements:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.787%"><tr><td style="width:1.0%"></td><td style="width:61.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.153%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">June 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Receivables included in accounts receivable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">9,699&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Contract liabilities included in deferred revenue</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">22,979&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GlaxoSmithKline Intellectual Property (No. 3) Limited (&#8220;GSK&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">GSK-HSD License Agreement</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On November 22, 2021, GSK and the Company entered into an Exclusive License Agreement (the &#8220;GSK-HSD License Agreement&#8221;). Under the GSK-HSD License Agreement, GSK has received an exclusive license for GSK-4532990 (formerly ARO-HSD). The exclusive license is worldwide with the exception of greater China. GSK is wholly responsible for all clinical development and commercialization of GSK-4532990 in its territory. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has completed its performance obligation related to this agreement, and the upfront payment of $120.0&#160;million was fully recognized in the year ended September 30, 2022. Further, GSK dosed the first patient in a Phase 2b trial in March 2023 and paid a $30.0&#160;million milestone payment to the Company in the third quarter of fiscal 2023. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is eligible for an additional payment of $100.0&#160;million upon achieving the first patient dosed in a Phase 3 trial. Furthermore, should the Phase 3 trial read out positively, and the potential new medicine receives regulatory approval in major markets, the deal provides for commercial milestone payments to the Company of up to $190.0&#160;million at first commercial sale, and up to $590.0&#160;million in sales-related milestone payments. The Company is further eligible to receive tiered royalties on net product sales in a range of mid-teens to twenty percent. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">GSK-HBV Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On December 11, 2023, the Company entered into an Amended and Restated License Agreement with GSK (the &#8220;GSK-HBV Agreement&#8221;) pursuant to which GSK received a worldwide, exclusive license to develop and commercialize daplusiran/tomligisiran (GSK5637608, formerly JNJ-3989), the Company&#8217;s third-generation subcutaneously administered RNAi therapeutic candidate being developed as a potential therapy for patients with chronic hepatitis B virus infection. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the GSK-HBV Agreement, the Company received $2.7&#160;million in December 2023, upon signing the amended GSK-HBV Agreement. Further, GSK dosed the fifth patient in a Phase 2 trial in December 2024, triggering a $2.5&#160;million milestone payment to the Company which was paid in the second quarter of fiscal 2025. The Company is eligible to receive up to $830.0&#160;million in development and sales milestone payments under the GSK-HBV Agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, the Company had no contract assets and liabilities recorded.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, Takeda and the Company entered into an Exclusive License and Co-Funding Agreement (the &#8220;Takeda License Agreement&#8221;). Under the Takeda License Agreement, Takeda and the Company will co-develop the Company&#8217;s fazirsiran program (formerly TAK-999 and ARO-AAT), the Company&#8217;s second-generation subcutaneously administered RNAi therapeutic candidate being developed as a treatment for liver disease associated with alpha-1 antitrypsin deficiency. Within the United States, fazirsiran, if approved, will be co-commercialized under a </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">50/50 profit </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">sharing</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> structure. Outside the United States, Takeda received an exclusive license to commercialize fazirsiran and will lead the global commercialization strategy, while the Company will be eligible to receive tiered royalties of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20%</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">25%</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> on net sales. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the key deliverables included the license and certain research and development services including the Company&#8217;s responsibilities to complete the initial portion of the SEQUOIA study, to complete the ongoing Phase 2 AROAAT2002 study, and to ensure certain manufacturing of fazirsiran drug product is completed and delivered to Takeda (the &#8220;Takeda R&amp;D Services&#8221;). Due to the specialized and unique nature of these Takeda R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represent one distinct bundle and, thus, one performance obligation. Takeda is responsible for managing clinical development and commercialization outside the United States. Within the United States, the Company and Takeda are responsible in the co-development and co-commercialization efforts. The Company considers the collaborative activities, including the co-development and co-commercialization, to be a separate unit of account within Topic 808, and as such, these co-funding amounts are recorded as research and development expenses or general and administrative expenses, as appropriate. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Takeda License Agreement, the Company received $300.0&#160;million as an upfront payment in January 2021 and an additional $40.0&#160;million upon Takeda&#8217;s initiation of a Phase 3 REDWOOD clinical study of fazirsiran in March 2023, and is eligible to receive up to $527.5&#160;million in additional potential development, regulatory and commercial milestones. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocated the total $300.0&#160;million initial transaction price to its one distinct performance obligation for the fazirsiran license and the associated Takeda R&amp;D Services. The Company has substantially completed its performance obligation under the Takeda License Agreement by December 31, 2023. As such, all revenue has been fully recognized as of December 31, 2023. There were no further deferred revenue and contract liabilities as of June&#160;30, 2025.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded $24.6&#160;million as accrued expenses as of June&#160;30, 2025 that was primarily driven by co-development and co-commercialization activities.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Janssen Pharmaceuticals, Inc. (&#8220;Janssen&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On April 7, 2023, Janssen voluntarily terminated its collaboration agreement with the Company and the Company regained full rights to ARO-PNPLA3, formerly called JNJ-75220795. There are no currently active trials for ARO-PNPLA3.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Further, on December 11, 2023, the Company entered into the GSK-HBV Agreement, as discussed above, pursuant to which GSK received an exclusive license for JNJ-3989 (formerly ARO-HBV). JNJ-3989 had previously been licensed to Janssen in October 2018.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Amgen Inc. (&#8220;Amgen&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In September 2016, Amgen and the Company entered into two collaboration and license agreements and a common stock purchase agreement. Under the Second Collaboration and License Agreement (the &#8220;Olpasiran Agreement&#8221;), Amgen received a worldwide, exclusive license to the Company&#8217;s novel RNAi olpasiran (previously referred to as AMG- 890 or ARO-LPA) program. These RNAi molecules are designed to reduce elevated lipoprotein(a), which is a genetically validated, independent risk factor for atherosclerotic cardiovascular disease. Under the Olpasiran Agreement, Amgen is wholly responsible for clinical development and commercialization.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has substantially completed its performance obligations under the Olpasiran Agreement. There were no contract assets and liabilities recorded as of June&#160;30, 2025. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, Royalty Pharma Investments 2019 ICAV (&#8220;Royalty Pharma&#8221;) and the Company entered into a Royalty Purchase Agreement with Royalty Pharma (the &#8220;Royalty Pharma Agreement&#8221;). In consideration for the payments under the Royalty Pharma Agreement, Royalty Pharma is entitled to receive all royalties otherwise payable by Amgen to the Company under the Olpasiran Agreement. The Company remains eligible to receive up to an additional $485.0&#160;million in remaining development, regulatory and sales milestone payments payable from Amgen and Royalty Pharma. See Note 11.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Sarepta Therapeutics, Inc. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On November 25, 2024, the Company entered into an Exclusive License and Collaboration Agreement (the &#8220;Sarepta Collaboration Agreement&#8221;) with Sarepta for the development and commercialization of multiple clinical and preclinical programs in rare, genetic diseases of the muscle, central nervous system, and lungs. The Company concurrently entered into a Stock Purchase Agreement (the &#8220;Stock Purchase Agreement&#8221;) with Sarepta (see Note 6). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the Sarepta Collaboration Agreement, Sarepta received an exclusive sublicensable worldwide license to </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">SRP-1001 (formerly ARO-DUX4), SRP-1003 (formerly ARO-DM1), SRP-1002 (formerly ARO-MMP7), and SRP-1004 (formerly ARO-ATXN2) clinical stage programs (the &#8220;C1&#8221; programs). Sarepta also received an exclusive sublicensable worldwide license to the Company&#8217;s ARO-HTT, ARO-ATXN1, and ARO-ATXN3 preclinical stage programs (the &#8220;C2&#8221; programs). The Company will perform certain research and development activities for the C1 and C2 programs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Further, Sarepta may select up to six gene targets for which the Company will perform discovery, optimization and preclinical development activities to identify RNAi compounds against each selected target (the &#8220;C3&#8221; programs). Upon target acceptance, Sarepta will receive an exclusive license to the Company&#8217;s intellectual property rights to exploit compounds directed to those targets and is wholly responsible for clinical development and commercialization of each compound after the Company delivers a Clinical Trial Application ready data package (the "CTA package").</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company identified 17 performance obligations under the Sarepta Collaboration Agreement. The four C1 licenses are distinct performance obligations from the four C1 research and development performance obligations since the customer can use and benefit from the licenses separately. The performance obligations for the licenses were satisfied in the second quarter of fiscal 2025 upon delivery, and the research and development performance obligations will be satisfied as the work is performed. The remaining nine performance obligations include three C2 preclinical stage program licenses and research and development activities, and six C3 unidentified discovery target licenses and research and development activity. Each of the three C2 programs and the six C3 programs were determined to represent one performance obligation, as the customer cannot benefit from the use of the product license at the point of transfer until the specified research and development activities are performed. As such, each of the C2 and C3 product licenses and respective research and development work will be combined to form one performance obligation. For these nine performance obligations, revenue is recognized over time as the work is performed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For performance obligations recognized over time, the estimated performance period over which revenue will be recognized is determined to be the period over which the Company estimates it will perform the research and development activities. The Company determined that the most appropriate method of measuring progress for these performance obligations is an input method based on research and development costs in the program budget. Accordingly, the Company has estimated the total cost required to complete its obligation and recognized an amount of revenue equal to the proportion of services performed, which is reassessed on an ongoing basis as the program progresses. In the period an agreement expires or is terminated, remaining deferred revenue, if any, is recognized as revenue.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Sarepta Collaboration Agreement, the Company received an upfront payment of $500.0&#160;million on February 14, 2025. In addition, on February 7, 2025, the Company received $325.0&#160;million in the form of an equity investment under the Stock Purchase Agreement. Based upon the Company's share price on February 7, 2025, (the &#8220;Closing Date&#8221;), the difference between the $325.0&#160;million and the fair value of the shares on the Closing date resulted in a premium of $83.6&#160;million. The premium is included as part of the total consideration of the Sarepta Collaboration Agreement for revenue recognition purposes. The Company is entitled to receive $250.0&#160;million to be paid in annual installments of $50.0&#160;million over the first five years of the agreement. The Company is also eligible receive reimbursement of certain costs related to carrying out the research and development activities for the C1 programs. The fixed consideration of $833.6&#160;million and an estimated variable consideration of $71.2&#160;million were allocated to all performance obligations based on their relative standalone selling price. Standalone selling prices for the product licenses were determined using an adjusted market-based approach through the net present value of the expected future cash flows for each program. The standalone selling prices for the research and development work were determined based on an expected cost plus margin approach. The fixed and estimated variable consideration of $904.9&#160;million was allocated in accordance to the following table:</span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:48.939%"><tr><td style="width:1.0%"></td><td style="width:57.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.696%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">June 30, 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Upfront payment</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">500,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Annual fees</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">250,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Equity premium</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">83,612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Fixed consideration</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">833,612&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Estimated variable consideration</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">71,243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Total transaction price</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">904,855&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the stand-alone selling price for each distinct performance obligation, which involves assumptions that may require significant judgment. The Company&#8217;s estimates of the stand-alone selling price for license-related performance obligations includes forecasted revenues and expenses, phase dates, probability of success, development timelines, and the discount rate. The estimates of the stand-alone selling price for research and development </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">or other service-related performance obligations generally include forecasting the expected costs of satisfying a performance obligation at market rates. The Company identified a discount based on the difference between the aggregate stand-alone selling price and the transaction price for accounting revenue recognition purposes. The Company allocated the discount proportionally to each of the performance obligations based upon their standalone selling price. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company receives reimbursement of certain costs related to carrying out the research and development activities for the C1 programs and may receive development milestone payments of up to $300.0&#160;million</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Further, for each of the 13 programs, the Company is eligible to receive regulatory milestone payments between $110.0&#160;million and $180.0&#160;million per program. Variable consideration associated with the milestones that may be achieved will be allocated to the performance obligation to which it is determined to be related, which will be the respective development work that is being reimbursed and the respective programs to which the milestones relate. ARO-DM1 development milestones were allocated between the license and development work based on the allocation of the standalone selling price. The Company will recognize the ARO-DM1 development milestones and other development milestones as revenue in the periods the underlying milestone events are achieved as achievement of the milestone events are highly susceptible to factors outside of the entity's influence and therefore there is a possibility that the milestone event will not be achieved.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also eligible to receive sales milestone payments between $500.0&#160;million and $700.0&#160;million per program as well as tiered royalties on net sales of licensed products of up to the low double digits, subject to the terms and conditions of the Sarepta Collaboration Agreement. The Company has applied the sales-based scope exception to the sales milestones and the royalty-based payments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Sarepta Collaboration Agreement commenced in February 2025 and may be terminated by either party in the event of a material breach as defined therein. In addition, Sarepta may voluntarily terminate the Sarepta Collaboration Agreement with 30 days' written notice to the Company if terminated prior to any regulatory approval of a licensed product. Unless earlier terminated, the Sarepta Collaboration Agreement expires on a product-by-product and country-by-country basis, upon the date of expiration of the relevant royalty term for such product in such country.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, the Company recorded $570.3&#160;million in revenue from Sarepta, $9.7&#160;million in accounts receivable and $23.0&#160;million in deferred revenue. The recognition of the remaining revenue for the performance obligations is dependent upon the time it takes to complete the respective research and development activities and in consideration of the timing of the selection of the C3 programs.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration and license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Accounts<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Accounts</a></td>
<td class="text">BALANCE SHEET ACCOUNTS<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s major classes of property, plant and equipment:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">June 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Land</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">2,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">2,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Buildings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">249,245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">75,988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Research equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">59,561&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">65,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Manufacturing equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">16,548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Furniture</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">5,594&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">5,594&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Computers and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">1,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">981&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">104,403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">104,410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">15,872&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">188,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">455,278&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">444,053&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(74,230)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(58,021)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Property, plant and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">381,048&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">386,032&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense for property, plant and equipment for the three months ended June&#160;30, 2025 and 2024 was $5.8&#160;million and $4.4&#160;million, respectively. Depreciation and amortization expense for property, plant and equipment for the nine months ended June&#160;30, 2025 and 2024 was $16.2&#160;million and $12.3&#160;million, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of fiscal 2025, the Company substantially completed the build out of its manufacturing facility in Verona, Wisconsin, leading to the reclassification of $162.7&#160;million from construction in progress to buildings and $2.6&#160;million from construction in progress to manufacturing equipment. The Company subsequently incurred and capitalized $10.6&#160;million to buildings and $13.9&#160;million to manufacturing equipment during the second and third quarters of fiscal 2025. Furthermore, the Company began depreciating the newly completed manufacturing facility over a 39-year period and the manufacturing equipment over 7- or 10-year periods.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of fiscal 2024, the Company completed the build out of its laboratory and office facilities in Verona, Wisconsin, which resulted in the reclassification of $71.8&#160;million from construction in progress to buildings. The Company subsequently incurred and capitalized $4.2&#160;million from construction in progress to buildings in fiscal 2024.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#242424;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following as of:</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">June 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Accrued research and development expenses</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">31,708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">28,069&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Accrued research and development expenses; co-development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">24,627&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">23,351&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Accrued capital expenditures</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">4,206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">8,137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">7,391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Total accrued expenses</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">64,818&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">63,017&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, the Company&#8217;s accrued research and development expenses was primarily attributable to ongoing clinical trial operations, preclinical animal studies, and associated toxicology assessments. In addition, accrued research and development expenses; co-development relates to the co-development and co-commercialization activities under the Takeda License Agreement (see Note 2).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments</a></td>
<td class="text">INVESTMENTS<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investments consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.787%"><tr><td style="width:1.0%"></td><td style="width:33.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.237%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.237%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.237%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">As of June 30, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Adjusted Basis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Available-for-sale securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">768,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">1,938&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(105)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">770,579&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Total current investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">768,746&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">1,938&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(105)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">770,579&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.787%"><tr><td style="width:1.0%"></td><td style="width:33.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.237%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.237%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.241%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">As of September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Adjusted Basis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Available-for-sale securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">577,465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">578,276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Total current investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">577,465&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">837&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(26)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">578,276&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the contract maturity of the available-for-sale securities as of:</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">   </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.484%"><tr><td style="width:1.0%"></td><td style="width:51.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.440%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">June 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Within one year</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">224,571&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">578,276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">After one to two years</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">450,889&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">After two to three years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">95,119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">770,579&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">578,276&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div>As of June&#160;30, 2025 and September&#160;30, 2024, the gross unrealized losses were immaterial. The Company has determined that the available-for-sale securities that were in an unrealized loss position did not have any credit loss impairment as of June&#160;30, 2025 and 2024.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/940-320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph b<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
<td class="text">INTANGIBLE ASSETS<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets subject to amortization include patents and a license agreement capitalized as part of the Novartis RNAi asset acquisition in March 2015. The following table presents the components of intangible assets: </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.361%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross Carrying Amount</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Impairment</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Useful Lives</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">As of June 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Patents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">21,728&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">16,037&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">5,691&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">14</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">License</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">3,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">1,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">1,595&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">21</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Total intangible assets, net</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">24,857&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">17,571&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">7,286&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">As of September 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Patents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">21,728&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">14,873&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">6,855&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">14</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">License</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">3,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">1,422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">1,707&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">21</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Total intangible assets, net</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">24,857&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">16,295&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">8,562&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are reviewed annually for impairment and more frequently if potential impairment indicators exist. No impairment indicators were identified during the nine months ended June&#160;30, 2025 and 2024.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with definite useful lives are amortized on a straight-line basis over their useful lives. Intangible assets amortization expense was $0.4 million for the three months ended June&#160;30, 2025 and 2024, and $1.3 million for each of the nine months ended June&#160;30, 2025 and 2024. None of the intangible assets with definite useful lives are anticipated to have a residual value.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the estimated future amortization expense related to intangible assets as of June&#160;30, 2025:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.727%"><tr><td style="width:1.0%"></td><td style="width:72.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.505%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.552%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amortization Expense</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Year Ending September 30, </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2025 (remainder)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">424&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">1,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">1,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">1,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2030 and thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">967&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">7,286&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s shares of common stock and preferred stock:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"><tr><td style="width:1.0%"></td><td style="width:30.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.049%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Par Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Authorized</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Issued</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">As of June 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Common stock </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">290,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">138,144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">138,144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Preferred stock</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">0.001&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">5,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">As of September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">290,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">124,376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">124,376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Preferred stock</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">0.001&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">5,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;(1) Does not include shares of common stock into which the Avoro Pre-Funded Warrants may be exercised.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2025 and September&#160;30, 2024, respectively, 10,081,964 and 11,492,293 shares of common stock were reserved for issuance upon exercise of options and vesting of restricted stock units granted or available for grant under the Company&#8217;s 2013 and 2021 Incentive Plans, as well as for other inducement grants made to new employees under Rule 5635(c)(4) of the Nasdaq Listing Rules.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On November 25, 2024, the Company entered into a Securities Purchase Agreement (the &#8220;Securities Purchase Agreement&#8221;) with an institutional and accredited investor for a private placement of pre-funded warrants to purchase shares of common stock with an exercise price of $0.001 per share (&#8220;Avoro Pre-Funded Warrants&#8221;). Pursuant to the Securities Purchase Agreement, the Company sold pre-funded warrants to purchase up to 917,441 shares of common stock at a purchase price of $27.25 per pre-funded warrant, for an aggregate value of approximately $25.0 million. The outstanding Avoro Pre-Funded Warrants are exercisable at any time and do not have an expiration date. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the Avoro Pre-Funded Warrants are freestanding financial instruments because they (i) are immediately exercisable, (ii) do not embody an obligation for the Company to repurchase its shares, (iii) permit the holders to receive a fixed number of shares of common stock upon exercise, and (iv) are indexed to the Company&#8217;s common stock. As such, the Company evaluated the Avoro Pre-Funded Warrants to determine whether they represent instruments that require liability classification pursuant to the guidance in ASC 480. However, the Company concluded that the Avoro Pre-Funded Warrants are not a liability within the scope of ASC 480 due to their characteristics. Further, the Company determined that the Avoro Pre-Funded Warrants do not meet the definition of a derivative under ASC 815 because they do not meet the criteria regarding no or little initial net investment. Accordingly, the Company assessed the Avoro Pre-Funded Warrants relative to the guidance in ASC 815-40, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts in Entity's Own Equity</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, to determine the appropriate treatment. The Company concluded that the Avoro Pre-funded Warrants are both indexed to its own stock and meet all other conditions for equity classification. Accordingly, the Company has classified the Avoro Pre-funded Warrants as permanent equity. As of June&#160;30, 2025, no shares underlying the Avoro Pre-Funded Warrants had been exercised. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Sarepta Collaboration Agreement, on November 25, 2024, the Company entered into the Stock Purchase Agreement with an affiliate of Sarepta for a private placement of shares of common stock of the Company (the &#8220;Private Placement&#8221;). Pursuant to the Stock Purchase Agreement, the Company sold 11,926,301 shares of common stock, at a price per share of $27.25, for an aggregate value of approximately $325.0&#160;million. The Private Placement closed on February 7, 2025.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On December 2, 2022, the Company entered into an open market sale agreement (the &#8220;Open Market Sale Agreement&#8221;), pursuant to which the Company may, from time to time, sell up to $250,000,000 in shares of the Company&#8217;s common stock through Jefferies LLC, acting as the sales agent and/or principal, in an at-the-market offering (&#8220;ATM Offering&#8221;). The Company is not required to sell shares under the Open Market Sale Agreement. The Company will pay Jefferies LLC a commission of up to 3.0% of the aggregate gross proceeds received from all sales of the common stock under the Open Market Sale Agreement. Unless otherwise terminated, the ATM Offering shall terminate upon the earlier of (i) the sale of all shares of common stock subject to the Open Market Sale Agreement and (ii) the termination of the Open Market Sale Agreement as permitted therein. The Company and Jefferies may each terminate the Open Market Sale Agreement at any time upon prior notice. As of June&#160;30, 2025, no shares have been issued under the Open Market Sale Agreement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be subject to various claims and legal proceedings in the ordinary course of business. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount is reasonably estimable, the Company will accrue a liability for the estimated loss. There were no contingent liabilities recorded as of June&#160;30, 2025. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company owns land in the Verona Technology Park in Verona, Wisconsin, where it has constructed an approximately 160,000 square foot drug manufacturing facility and an approximately 140,000 square foot laboratory and office facility to support manufacturing process development and analytical activities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, the build-out of these facilities was substantially completed, with total costs incurred of $293.2 million. These costs included (i) $76.0 million capitalized to building, related to the laboratory and office facility, and (ii) $11.5 million capitalized to research equipment, $173.3 million capitalized to building, $16.5 million capitalized to manufacturing equipment, and $15.9 million in construction in progress, related to the drug manufacturing facility. The Company has an expected outstanding balance of approximately $3.3 million remaining to be settled.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">LEASES<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Pasadena, California</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: The Company leases 49,000 square feet of office space located at 177 East Colorado Blvd. for its corporate headquarters from 177 Colorado Owner, LLC, which lease expires on April&#160;30, 2027. The lease contains an option to renew for one additional five-year term. The Company is not reasonably certain that it will exercise this option to renew and therefore it is not included in right-of-use assets and liabilities as of June&#160;30, 2025.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">San Diego, California</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: The Company leases 144,000 square feet of office and research and development laboratory space located at 10102 Hoyt Park from 11404 &amp; 11408 Sorrento Valley Owner, LLC, which lease expires on April&#160;30, 2038. Pursuant to the lease, within twelve months of the expiration of the initial 15-year term, the Company has the option to extend the lease for up to one additional ten-year term, with certain annual increases in base rent. The Company is not reasonably certain that it will exercise this option to renew and therefore it is not included in right-of-use assets and liabilities as of June&#160;30, 2025.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The lease agreement, as amended, granted the Company the right to receive an Additional Tenant Improvement Allowance (&#8220;ATIA&#8221;) funded by the lessor. The Company received $30.8&#160;million in ATIA, including a final payment of $3.1 million during the first quarter of fiscal 2024. As a result, the Company remeasured its lease liability and right-of-use assets to reflect these additional allowances and the related increased lease payments. The Company has further concluded that these ATIAs have no effects on the classification of the lease.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Madison, Wisconsin</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: The Company leases 110,956 square feet space, which it increased from 107,000 square feet on June&#160;30, 2025, located at 502 South Rosa Road for its office and laboratory facilities, which lease expires on September&#160;30, 2031. The lease contains options to renew for two terms of five years. The Company is not reasonably certain that it will exercise this option and therefore it is not included in right-of-use assets and liabilities as of June&#160;30, 2025.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease assets and liabilities along with their classification on the Company&#8217;s consolidated balance sheets were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.144%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Lease Assets and Liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">44,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">45,255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Current operating lease liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">7,010&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">6,342&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">105,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">111,027&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:16.493%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.569%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.982%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.982%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.982%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.988%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Lease Cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2,233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2,965&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">7,754&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">8,531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">General and administrative expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">449&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">537&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">1,442&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">1,504&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Variable lease cost </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">863&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2,830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">General and administrative expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">3,575&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">4,365&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">12,026&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">12,513&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(1) Variable lease cost is primarily related to operating expenses associated with the Company&#8217;s operating leases.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There was no short-term lease cost during the three and nine months ended June&#160;30, 2025 and 2024, respectively. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents maturities of operating lease liabilities on an undiscounted basis as of June&#160;30, 2025:</span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"><tr><td style="width:1.0%"></td><td style="width:83.996%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.804%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amounts</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">2025 (remainder)</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">3,902&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">15,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">14,974&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">13,619&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">2029</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">13,905&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">2030 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">114,790&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">176,989&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Less imputed interest</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(64,289)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Total operating lease liabilities (includes current portion)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">112,700&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow and other information related to leases was as follows:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.079%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.079%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Cash received for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">3,099&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Right-of-use assets obtained in exchange for amended operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(64)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">3,875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">3,204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">11,554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">7,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">11.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">12.8</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Weighted-average discount rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">8.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">8.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">STOCK-BASED COMPENSATION<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has three plans that provide for equity-based compensation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2013 Incentive Plan (the &#8220;2013 Plan&#8221;), 2,350,117 awards are granted and outstanding, relating to stock options and restricted stock awards to employees and directors as of June&#160;30, 2025. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2021 Incentive Plan (the &#8220;2021 Plan&#8221;), 8,000,000 shares (subject to certain adjustments) of the Company&#8217;s common stock are authorized for grants of stock options, stock appreciation rights, restricted and unrestricted stock, performance awards, cash awards and other awards convertible into or otherwise based on shares of the Company&#8217;s common stock. The maximum number of shares authorized under the 2021 Plan will be (i) reduced by any shares subject to awards made under the 2013 Plan after January 1, 2021, and (ii) increased by any shares subject to outstanding awards under the 2013 Plan as of January 1, 2021 that, after January 1, 2021, are canceled, expired, forfeited or otherwise not issued under such awards (other than as a result of being tendered or withheld to pay the exercise price or withholding taxes in connection with any such awards) or settled in cash. As of June&#160;30, 2025, 6,215,559 shares have been granted under the 2021 Plan. The total number of shares available for issuance was 2,308,495 shares, which includes 170,898 and 353,156 shares that were forfeited under the 2013 and 2021 Plans, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">s Inducement Plan (the &#8220;Inducement Plan&#8221;), 832,950 shares of the Company&#8217;s common stock are authorized for issuance pursuant to grants of stock options, stock appreciation rights, restricted and unrestricted stock, stock units (including restricted stock units), performance awards, cash awards, and other awards convertible into or otherwise based on shares of the Company&#8217;s common stock. Awards under the Inducement Plan may only be granted to new employees of the Company in accordance with the provisions of Rule 5635(c)(4) of the Nasdaq Listing Rules. As of June&#160;30, 2025,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">607,340 shares have been granted under the Inducement Plan. The total number of shares remaining available for issuance was 307,924 shares.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, prior to adoption of the Inducement Plan, the Company previously granted stand-alone inducement awards in the form of stock options and restricted stock units outside of the Company</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">s equity plans to new employees under Rule 5635(c)(4) of the Nasdaq Listing Rules. As of June&#160;30, 2025, there were 602,355 and 138,775 shares underlying outstanding stand-alone inducement options and restricted stock units, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of awards outstanding attributable to Arrowhead Pharmaceuticals, Inc.:</span></div><div style="margin-top:6pt;text-align:center;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.036%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.036%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.036%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.041%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2013 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2021 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Inducement Awards</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Granted and outstanding awards:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">850,117&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">32,151&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">602,355&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">1,484,623&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">1,500,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">3,888,660&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">592,262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">5,980,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2,350,117&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">3,920,811&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">1,194,617&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">7,465,545&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock-based compensation expenses included in operating expenses attributable to Arrowhead Pharmaceuticals, Inc.:</span></div><div style="margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.939%"><tr><td style="width:1.0%"></td><td style="width:43.769%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.226%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Nine Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">6,898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">6,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">21,008&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">21,634&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">5,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">8,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">20,242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">27,350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">11,993&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">14,711&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">41,250&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">48,984&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Awards</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">            The following table presents a summary of the stock option activity for the nine months ended June&#160;30, 2025:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Exercise<br/>Price<br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at September&#160;30, 2024</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">1,978,516</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">23.39&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Cancelled or expired</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(35,341)</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">45.92&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Exercised</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(458,552)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">7.55&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">1,484,623</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">27.75&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">3.5</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">5,750,674&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Exercisable at June&#160;30, 2025</span></div></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">1,484,623</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">27.75&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">3.5</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">5,750,674&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic values represent the amount by which the market price of the underlying stock exceeds the exercise price of the option. The total intrinsic value of the options exercised during the three months ended June&#160;30, 2025 and 2024 was $0.3 million and $0.7 million, respectively. The total intrinsic value of the options exercised during the nine months ended June&#160;30, 2025 and 2024 was $4.9 million and $3.8 million, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June&#160;30, 2025, there was no stock-based compensation expense related to stock options outstanding, while $0.4 million was recorded for the same period in 2024. Stock-based compensation expense related to stock options outstanding for the nine months ended June&#160;30, 2025 and 2024, was $0.1 million and $2.5 million, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, the pre-tax compensation expense for all outstanding unvested stock options is considered nominal. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which do not have vesting restrictions and are fully transferable. The determination of the fair value of each stock option is affected by the Company&#8217;s stock price on the date of grant, as well as assumptions regarding a number of highly complex and subjective variables. No options were granted during the nine months ended June&#160;30, 2025 and 2024.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Visirna ESOP</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: On October 1, 2023, Visirna, a subsidiary of the Company, granted 7,500,000 stock options to its employees from the Employee Stock Option Plan (the &#8220;Visirna ESOP&#8221;), which authorizes 20,000,000 shares for issuance. The Visirna ESOP is independently managed by Visirna, including the valuation process. For the three months ended June&#160;30, 2025 and 2024, stock-based compensation expense related to the Visirna ESOP was $1.1&#160;million and $2.3 million, respectively. For the nine months ended June&#160;30, 2025 and 2024, stock-based compensation expense related to the Visirna ESOP was $3.0&#160;million and $5.5&#160;million, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restricted Stock Units (&#8220;RSUs&#8221;), including market-based, time-based and performance-based awards, have been granted under the Company&#8217;s 2013 and 2021 Plans, the Inducement Plan, and as inducements awards granted outside of the Company&#8217;s equity-based compensation plans. At vesting, each outstanding RSU will be exchanged for one share of the Company&#8217;s common stock. RSU awards generally vest subject to the satisfaction of service requirements or the satisfaction of both service requirements and achievement of certain performance targets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity of the Company&#8217;s RSUs:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Grant<br/>Date<br/>Fair Value<br/>Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at September&#160;30, 2024</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">4,913,312</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">49.61&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">2,711,009</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">19.49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Vested</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(1,383,568)</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">43.96&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(259,831)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">32.96&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">5,980,922</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">37.97&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of RSUs was determined based on the closing price of the Company&#8217;s common stock on the grant date, with consideration given to the probability of achieving service and/or performance conditions for awards.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June&#160;30, 2025 and 2024, the Company recorded $11.9 million and $14.3 million of expense related to RSUs, respectively. For the nine months ended June&#160;30, 2025 and 2024, the Company recorded $41.1 million and $46.5 million of expense related to RSUs, respectively. As of June&#160;30, 2025, there was $85.8&#160;million of total unrecognized compensation cost related to RSUs that is expected to be recognized over a weighted-average period of 1.7 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company employs a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The Company&#8217;s valuation techniques and inputs used to measure fair value and the definition of the three levels (Level 1, Level 2, and Level 3) of the fair value hierarchy are disclosed in Note 10 - Fair Value Measurements of Notes to Consolidated Financial Statements of Part IV, &#8220;Item 15. Exhibits and Financial Statement Schedules&#8221; of its Annual Report on Form 10-K for the fiscal year ended September&#160;30, 2024.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses prices and inputs that are current as of the measurement date, including during periods of market disruption. In periods of market disruption, the ability to observe prices and inputs may be reduced for many instruments. This condition could cause an instrument to be reclassified from Level 1 to Level 2, or from Level 2 to Level 3. The Company recognizes transfers between levels at either the actual date of the event or a change in circumstances that caused the transfer. As of June&#160;30, 2025 and September&#160;30, 2024, the Company did not have any financial assets or financial liabilities based on Level 3 measurements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present information about the Company&#8217;s assets and liabilities measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques utilized by the Company:  </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.449%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Available-for-sale securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">221,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">221,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">7,019&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">7,019&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Commercial notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">26,449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">26,449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">515,234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">515,234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Total available-for-sale securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">770,579&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">770,579&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Money market instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">81,283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">81,283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Term deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">11,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">11,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">7,960&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">7,960&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Commercial notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">23,770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">23,770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Total cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">81,283&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">42,779&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">124,062&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Total financial assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">81,283&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">813,358&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">894,641&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.449%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Available-for-sale securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">160,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">160,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Commercial notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">179,714&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">179,714&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">237,839&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">237,839&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Total available-for-sale securities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">578,276&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">578,276&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Money market instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">66,966&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">66,966&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Total cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">66,966&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">66,966&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Total financial assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">66,966&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">578,276&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">645,242&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability Related to the Sale of Future Royalties<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract', window );"><strong>Liability Related To The Sale Of Future Royalties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock', window );">Liability Related to the Sale of Future Royalties</a></td>
<td class="text">LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, the Company and Royalty Pharma entered into the Royalty Pharma Agreement, pursuant to which Royalty Pharma agreed to pay up to $410.0&#160;million in cash to the Company in consideration for the Company&#8217;s future royalty interest in olpasiran, originally developed by the Company and licensed to Amgen in September 2016 under the Olpasiran Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Royalty Pharma Agreement, Royalty Pharma paid $250.0 million upfront and agreed to pay up to an additional $160.0&#160;million in aggregate one-time milestone payments due if and when the following milestone events occur: (i) $50.0&#160;million on completion of enrollment in the OCEAN Phase 3 clinical trial for olpasiran, (ii) $50.0&#160;million upon receipt of FDA approval of olpasiran for an approved indication (reduction in the risk of myocardial infarction, urgent coronary revascularization, or coronary heart disease death in adults with established cardiovascular disease and elevated Lp(a)), and (iii) $60.0&#160;million upon Royalty Pharma&#8217;s receipt of at least $70.0&#160;million of royalty payments under the Royalty Pharma Agreement in any single calendar year. During the third quarter of fiscal 2024, Amgen completed enrollment of the Phase 3 OCEAN(a) outcomes trial of olpasiran, which triggered a $50.0&#160;million milestone payment that the Company received in the same quarter. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for the payment of the foregoing amounts under the Royalty Pharma Agreement, Royalty Pharma is entitled to receive all royalties otherwise payable by Amgen to the Company under the Olpasiran Agreement. The Company remains eligible to receive any milestone payments potentially payable by Amgen under the Olpasiran Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated the terms of the Royalty Pharma Agreement and concluded, in accordance with the relevant accounting guidance, that the Company accounted for the transaction as debt and the funding of $250.0&#160;million and $50.0&#160;million from Royalty Pharma were recorded as liabilities related to the sale of future royalties on its consolidated balance sheets. The Company is not obligated to repay these funds received under the Royalty Pharma Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company records the obligations at their carrying value using the effective interest method. In order to amortize the sale of future royalties, the Company utilizes the prospective method to estimate the future royalties to be paid by the Company to the counterparty over the life of the arrangement. Under the prospective method, a new effective interest rate is determined based on the revised estimate of remaining cash flows. The new rate is the discount rate that equates the present value of the revised estimate of remaining cash flows with the carrying amount of the debt, and it will be used to recognize non-cash interest expense for the remaining periods. The Company periodically assesses the amount and the timing of expected royalty payments using a combination of internal projections and forecasts from external sources. The estimates of future net product sales (and resulting royalty payments) are based on key assumptions including population, penetration, probability of success and sales price, among others. To the extent such payments are greater or less than the Company&#8217;s initial estimates or the timing of such payments is different than its original estimates, the Company will prospectively adjust the amortization of the royalty financing obligations and the effective interest rate. As of June&#160;30, 2025, the estimated effective interest rate was 9.1%. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the activity with respect to the liability related to the sale of future royalties.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.574%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.577%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Beginning carrying value</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">341,361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">268,326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Milestone payment received</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">50,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Non-cash interest expense recognized</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">18,893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">23,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Ending carrying value</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">360,254&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">341,361&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability Related To The Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability Related To The Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financing Agreement<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Financing Agreement</a></td>
<td class="text">FINANCING AGREEMENT <div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On August 7, 2024 (the &#8220;Closing Date&#8221;), the Company entered into a Financing Agreement with the guarantors party thereto, the lenders party thereto (the &#8220;Lenders&#8221;), and Sixth Street Lending Partners (&#8220;Sixth Street&#8221;), as the administrative agent and collateral agent for the Lenders (the &#8220;Financing Agreement&#8221;). The Financing Agreement establishes a senior secured term loan facility of $500.0&#160;million (the &#8220;Credit Facility&#8221;), consisting of $400.0&#160;million funded on the Closing Date and an additional $100.0&#160;million available at the Company&#8217;s option, subject to mutual agreement with Sixth Street. The loans under the Credit Facility bear interest at an annual rate of 15.0%, which is paid in kind and added to the outstanding principal balance of the Credit Facility each period. The outstanding principal balance of this Credit Facility, including amounts representing accrued but unpaid interest previously paid in kind, is due and payable on August </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7, 2031.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is permitted to use the net proceeds for working capital, capital expenditures and general corporate purposes of the Company and its subsidiaries.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company will have the right to prepay loans under the Credit Facility at any time. The Company is required to partially repay loans under the Credit Facility with proceeds from certain asset sales, condemnation events and extraordinary receipts, subject, in some cases, to reinvestment rights. If the Company repays in full the aggregate principal outstanding under the Credit Facility and such payment in full occurs on or prior to August 7, 2028, the Company will be required to make an additional payment to the lenders under the Credit Facility on such date in an amount necessary for the lenders to achieve a two times multiple of invested capital (&#8220;MOIC&#8221;) of the aggregate principal amount funded on the Closing Date (the &#8220;MOIC Payment&#8221;). If such payment in full occurs after August 7, 2028, the Company will be required to make a payment to the lenders under the Credit Facility on such date in an amount necessary for the lenders to achieve the greater of the MOIC Payment and the present value of all interest payments that would have been payable from such date through the maturity date of the Credit Facility discounted at the Treasury Rate (as defined in the Financing Agreement) plus 0.5%; provided that such payment amount in this instance will not exceed the amount necessary for the lenders to achieve a 2.5 times MOIC. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On November 26, 2024, the Company entered into an amendment to the Financing Agreement (the "Amendment") to modify, amongst other things, some of the prepayment terms of the loans under the Credit Facility, including, the prepayment terms related to the Sarepta Collaboration Agreement. The Amendment was effective on February 14, 2025, following the closing of the Sarepta Collaboration Agreement and receipt of the $500.0&#160;million upfront payment from Sarepta. The Amendment added an additional prepayment clause that requires certain contractual prepayments of principle and MOIC payments throughout the life of the loans under the Credit Facility. Additionally, any prepayment will be split with 50% of any such prepayment paying down the principle balance of the loans under the Credit Facility and the other 50% being applied to prepay the MOIC Payment. In the event the prepayment amounts result in fees being prepaid in excess of the actual amounts required to be paid, the excess fees shall be reallocated and applied to reduce the amount of the principal balance upon repayment in full of the loans under the Credit Facility. As of June 30, 2025, the Company has paid $100.0&#160;million in MOIC payments of which $25.3&#160;million is expected to be applied to principal upon repayment in full. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has paid $201.6&#160;million of the loans under the Credit Facility during fiscal 2025. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Amendment was accounted for as a debt modification under ASC 470-50, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Debt&#8212;Modification and extinguishments</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; since the Amendment did not result in substantially different terms. In connection with the Amendment, the Company did not incur significant third-party fees.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All obligations under the Financing Agreement are secured on a first-priority basis by security interests in substantially all assets of the Company and material subsidiaries of the Company, including its intellectual property, subject to certain exceptions, and is guaranteed by material subsidiaries of the Company, including foreign subsidiaries, subject to certain exceptions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Financing Agreement contains customary covenants, including, without limitation, a financial covenant to maintain liquidity (cash, cash equivalents and investments) of at least $100.0&#160;million if the Company</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">s market capitalization is above $1.5 billion, and negative covenants that, subject to certain exceptions, restrict indebtedness, liens, investments (including acquisitions), fundamental changes, asset sales and licensing transactions, dividends, modifications to material agreements, payment of subordinated indebtedness, distributions from certain parties, and other matters customarily restricted in such agreements. The Company is subject to restrictions on sales and licensing transactions with respect to certain core intellectual property, subject to certain exceptions, including certain transactions related to areas outside the United States, United Kingdom, European Union, Japan and China.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Financing Agreement contains certain embedded features that were identified and evaluated as not material to the consolidated financial statements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The outstanding balance of the Credit Facility consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Initial Term Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">400,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">400,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated interest on the Initial Term Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">53,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">9,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated accretion of the MOIC Payment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2,787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Less: Unamortized debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(14,284)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(15,817)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Less: Current portion of credit facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(40,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Less: Payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(201,625)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Credit facility, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">200,332&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">393,183&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth total interest expense recognized related to the Credit Facility:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.540%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of debt issuance costs</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">420&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">1,533&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Accretion of the MOIC Payment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2,218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2,787&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Contractual interest expense</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">13,766&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">44,454&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;Total interest expense</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">16,404&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">48,774&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The amounts shown in the table below, related to the Credit Facility, represent the expected repayments of principle and accrued interest balance as of June 30, 2025 as well as any mandatory prepayments that the Company is obligated to make to the Lenders during the indicated periods. The principal balance will increase from accrued paid in kind interest and the table does not include MOIC payments beyond those contractually determined. Actual payments on current principal may vary from the amounts presented in the table. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"><tr><td style="width:1.0%"></td><td style="width:78.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.933%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Year</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amounts</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2025 (remainder)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">40,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">40,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">15,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">15,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Thereafter</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">216,503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">326,503&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In May 2025, Visirna entered into the Revolving Credit Agreement with Bank of Zhejiang. The maximum aggregate credit facility is 73.0&#160;million Chinese Yuan ($10.0&#160;million) bearing an annual interest rate of 4.1%. The term of each loan is twelve months. The amount outstanding as of June 30, 2025 was 50.8&#160;million Chinese Yuan ($7.1&#160;million) on the credit facility which was classified as other current liabilities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net (Loss) Income Per Share</a></td>
<td class="text">NET (LOSS) INCOME PER SHARE<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the computation of basic and diluted net (loss) income per share for the three and nine months ended June&#160;30, 2025 and 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">                            </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.545%"><tr><td style="width:1.0%"></td><td style="width:43.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.146%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Nine Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands, except per share amounts)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Net (loss) income attributable to Arrowhead Pharmaceuticals, Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(175,241)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(170,793)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">22,119&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(428,957)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Weighted-average basic shares outstanding</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">139,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">124,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">132,385&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">118,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Effect of dilutive securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">967&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Weighted-average diluted shares outstanding </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">139,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">124,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">133,352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">118,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Basic net (loss) income per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(1.26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(1.38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">0.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(3.63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Diluted net (loss) income per share</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(1.26)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(1.38)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">0.17&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(3.63)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(1) Includes shares of common stock into which the Avoro Pre-Funded Warrants may be exercised. See Note 6.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net (loss) income per share because to include them would be anti-dilutive.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.545%"><tr><td style="width:1.0%"></td><td style="width:43.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.146%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Nine Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">768&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">753&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">711&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">5,178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">3,976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">4,770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">4,060&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">5,946&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">4,729&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">5,526&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">4,771&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">INCOME TAXES<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company's estimated annual effective tax rate significantly fluctuates for fiscal 2025 with small changes to the Company&#8217;s estimated income. For the three months ended June&#160;30, 2025, the Company has recorded a discrete income tax benefit of $0.4&#160;million. The income tax provision for the three months ended June&#160;30, 2024, resulted in no tax expense. For the nine months ended June&#160;30, 2025, the Company has recorded a discrete income tax expense of $1.4&#160;million, and for the nine months ended June&#160;30, 2024, the Company has recorded a discrete income tax benefit of $3.3&#160;million. Income tax expense for the three and nine months ended June&#160;30, 2025 was based on actual year to date income recorded and statutory tax rates. </span></div>The Company does not anticipate any changes in its unrecognized tax benefits over the next 12 months. Due to the presence of net operating loss carryforwards, all of the income tax years remain open for examination domestically. The Company has not been notified that it is under audit by the Internal Revenue Service or foreign taxing authorities; however, the Company has been notified of an income tax examination by the State of California. There are no other audits in any other jurisdictions.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">SUBSEQUENT EVENTS<span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Visirna</span><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">On August 1, 2025, Visirna Therapeutics HK Limited (&#8220;Visirna HK&#8221;), a wholly owned subsidiary of Visirna Therapeutics, Inc, a majority owned subsidiary of the Company, entered into an Asset Purchase Agreement (the &#8220;Asset Purchase Agreement&#8221;) with Genzyme Corporation (&#8220;Sanofi&#8221;), a wholly owned subsidiary of Sanofi S.A., pursuant to which Visirna HK sold all of its assets and rights in investigational plozasiran to Sanofi, which included an assignment of Visirna HK&#8217;s rights (as successor by assignment from Visirna) to develop and commercialize investigational plozasiran in Greater China pursuant to that certain License Agreement by and between the Company and Visirna dated, April 25, 2022 (the &#8220;Visirna License Agreement&#8221;).  The Asset Purchase Agreement is scheduled to close during the second half of the </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">year.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Asset Purchase Agreement, the Company consented to the partial assignment of the Visirna License Agreement by Visirna HK to Sanofi (as so assigned, the &#8220;Sanofi License Agreement&#8221;), amongst other agreements between the Company and Visirna, effective as of the closing of the Asset Purchase Agreement. After giving effect to the Asset Purchase Agreement, Visirna HK retains rights to develop and commercialize in Greater China three other cardiometabolic drugs licensed to it pursuant to the Visirna License Agreement.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Upon closing of the Asset Purchase Agreement, Visirna will receive an upfront payment of $130.0&#160;million from Sanofi and is eligible to receive further milestone payments of up to $265.0&#160;million upon approval of plozasiran across various indications in mainland China. The Company is also eligible to receive royalties from Sanofi on net commercial product sales in Greater China under the Sanofi License Agreement. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Sarepta DM1 Milestone</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">On July 27, 2025, the Company triggered a $100.0&#160;million milestone payment from Sarepta. The Company reached the first of two prespecified enrollment targets and subsequent authorization to dose escalate in a Phase 1/2 clinical study of ARO-DM1, an investigational RNAi therapeutic for treatment of type 1 myotonic dystrophy (DM1), as outlined in the Sarepta Collaboration Agreement, triggering the milestone. The Company is eligible to receive up to an additional $200.0&#160;million in near-term milestone payments associated with the continued enrollment of certain cohorts of a Phase 1/2 study of ARO-DM1.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In January 2025, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standard Update (&#8220;ASU&#8221;) 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">in November 2024, and ASU 2025-01,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Clarifying the Effective Date</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. These updates require entities to provide disaggregated disclosures of income statement expenses. The ASUs do not affect the expense captions presented on the face of the income statement but instead require the disaggregation of certain expense captions into specified categories within the footnotes to the financial statements. The ASUs will become effective for the Company beginning October 1, 2027, and the Company is currently evaluating the impact on its consolidated financial statements and related disclosures.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, to improve its income tax disclosure requirements. Under the guidance, entities must annually (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold. This ASU will become effective for the Company beginning October 1, 2025, and is not expected to have a material impact on its consolidated financial statements and related disclosures.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, which is intended to improve reportable segment disclosure requirements, primarily through additional disclosures about significant segment expenses. This ASU requires public companies with a single reportable segment to provide all disclosures required under ASC 280. In addition, this ASU requires public companies to include in interim reports all disclosures related to a reportable segment&#8217;s profit or loss and assets that are currently required in annual reports. While the ASU implements further segment disclosure requirements, it does not change how an entity identifies its operating or reportable segments and it will have no impact on the Company&#8217;s consolidated financial condition, results of operations or cash flows. The Company plans to adopt the ASU's in connection with our Annual Report on Form 10-K for the fiscal year ending September 30, 2025, as required and will be applied retrospectively to all periods presented. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On July 4, 2025, the One Big Beautiful Bill Act (&#8220;OBBBA&#8221;) was signed into law, which enacts significant changes to U.S. tax and related laws. Some of the provisions of the new tax law affecting corporations include but are not limited to expensing of domestic research expenses, reinstate the limit of the deduction of interest expense to thirty percent of EBITDA, and one hundred percent bonus depreciation on eligible property acquired after January 19, 2025. The Company is currently evaluating the impact the new tax law will have on its financial condition and results of operations.  </span></div>Preliminarily, the Company does not anticipate a material change to its effective income tax rate and its net deferred federal income tax assets as the Company maintains a full valuation allowance.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ScheduleOfCurrentProductsTableTextBlock', window );">Schedule of Company's Current Pipeline</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s current pipeline:</span><span style="color:#ee2724;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:28.035%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Therapeutic Area</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Name</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Stage</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Product Rights</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Cardiometabolic</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">plozasiran</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Phase 3</span></div></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">zodasiran</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Phase 3</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">olpasiran</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Phase 3</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Amgen</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">ARO-PNPLA3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">GSK-4532990</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Phase 2b</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">GSK</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">ARO-INHBE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">ARO-ALK7</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Pulmonary</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">ARO-RAGE</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></div></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">SRP-1002 (ARO-MMP7)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Sarepta</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Liver</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">fazirsiran</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Phase 3</span></div></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Takeda and Arrowhead</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">GSK5637608</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Phase 2</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">GSK</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Neuromuscular</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">SRP-1001 (ARO-DUX4)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Sarepta</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">SRP-1003 (ARO-DM1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Sarepta</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Central Nervous System (CNS)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">SRP-1004 (ARO-ATXN2)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Sarepta</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Other</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">ARO-C3</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">ARO-CFB</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ScheduleOfCurrentProductsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Current Products</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ScheduleOfCurrentProductsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CollaborationAndLicenseAgreementsAbstract', window );"><strong>Collaboration And License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Revenue</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of revenue recognized:</span></div><div style="margin-top:6pt;text-align:center;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.878%"><tr><td style="width:1.0%"></td><td style="width:27.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.775%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">GSK</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2,646&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2,685&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Takeda</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">866&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Sarepta</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">27,624&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">570,330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">27,767&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">572,976&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">3,551&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Receivables and Contract Liabilities</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balance of receivables and contract liabilities related to the Company&#8217;s collaboration and license agreements:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.787%"><tr><td style="width:1.0%"></td><td style="width:61.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.153%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">June 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Receivables included in accounts receivable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">9,699&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Contract liabilities included in deferred revenue</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">22,979&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule of Fixed and Estimated Variable Consideration</a></td>
<td class="text">The fixed and estimated variable consideration of $904.9&#160;million was allocated in accordance to the following table:<div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:48.939%"><tr><td style="width:1.0%"></td><td style="width:57.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.696%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">June 30, 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Upfront payment</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">500,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Annual fees</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">250,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Equity premium</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">83,612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Fixed consideration</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">833,612&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Estimated variable consideration</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">71,243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Total transaction price</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">904,855&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration and license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Accounts (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s major classes of property, plant and equipment:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">June 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Land</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">2,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">2,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Buildings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">249,245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">75,988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Research equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">59,561&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">65,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Manufacturing equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">16,548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Furniture</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">5,594&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">5,594&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Computers and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">1,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">981&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">104,403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">104,410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">15,872&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">188,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">455,278&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">444,053&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(74,230)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(58,021)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Property, plant and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">381,048&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">386,032&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#242424;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following as of:</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">June 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Accrued research and development expenses</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">31,708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">28,069&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Accrued research and development expenses; co-development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">24,627&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">23,351&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Accrued capital expenditures</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">4,206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">8,137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">7,391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Total accrued expenses</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">64,818&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">63,017&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock', window );">Schedule of Short-term and Long-term Investments and Marketable Securities</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investments consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.787%"><tr><td style="width:1.0%"></td><td style="width:33.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.237%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.237%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.237%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">As of June 30, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Adjusted Basis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Available-for-sale securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">768,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">1,938&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(105)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">770,579&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Total current investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">768,746&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">1,938&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(105)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">770,579&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.787%"><tr><td style="width:1.0%"></td><td style="width:33.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.237%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.237%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.241%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">As of September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Adjusted Basis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Available-for-sale securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">577,465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">578,276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Total current investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">577,465&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">837&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(26)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">578,276&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of Contract Maturity of Available for Sale Securities</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the contract maturity of the available-for-sale securities as of:</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">   </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.484%"><tr><td style="width:1.0%"></td><td style="width:51.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.440%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">June 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Within one year</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">224,571&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">578,276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">After one to two years</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">450,889&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">After two to three years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">95,119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">770,579&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">578,276&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Held to maturity securities and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets</a></td>
<td class="text">The following table presents the components of intangible assets: <div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.361%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross Carrying Amount</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Impairment</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Useful Lives</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">As of June 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Patents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">21,728&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">16,037&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">5,691&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">14</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">License</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">3,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">1,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">1,595&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">21</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Total intangible assets, net</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">24,857&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">17,571&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">7,286&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">As of September 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Patents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">21,728&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">14,873&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">6,855&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">14</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">License</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">3,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">1,422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">1,707&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">21</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Total intangible assets, net</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">24,857&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">16,295&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">8,562&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Intangible Assets Future Amortization Expense</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the estimated future amortization expense related to intangible assets as of June&#160;30, 2025:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.727%"><tr><td style="width:1.0%"></td><td style="width:72.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.505%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.552%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amortization Expense</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Year Ending September 30, </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2025 (remainder)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">424&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">1,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">1,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">1,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2030 and thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">967&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">7,286&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of Shares of Common Stock and Preferred Stock</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s shares of common stock and preferred stock:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"><tr><td style="width:1.0%"></td><td style="width:30.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.049%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Par Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Authorized</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Issued</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">As of June 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Common stock </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">290,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">138,144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">138,144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Preferred stock</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">0.001&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">5,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">As of September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">290,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">124,376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">124,376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Preferred stock</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">0.001&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">5,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;(1) Does not include shares of common stock into which the Avoro Pre-Funded Warrants may be exercised.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-5<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481142/505-10-45-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-10<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Assets and Liabilities and Lease Cost</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease assets and liabilities along with their classification on the Company&#8217;s consolidated balance sheets were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.144%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Lease Assets and Liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">44,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">45,255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Current operating lease liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">7,010&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">6,342&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">105,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">111,027&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:16.493%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.569%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.982%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.982%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.982%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.988%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Lease Cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2,233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2,965&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">7,754&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">8,531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">General and administrative expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">449&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">537&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">1,442&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">1,504&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Variable lease cost </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">863&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2,830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">General and administrative expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">3,575&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">4,365&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">12,026&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">12,513&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(1) Variable lease cost is primarily related to operating expenses associated with the Company&#8217;s operating leases.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Operating Lease Liabilities on an Undiscounted Basis</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents maturities of operating lease liabilities on an undiscounted basis as of June&#160;30, 2025:</span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"><tr><td style="width:1.0%"></td><td style="width:83.996%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.804%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amounts</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">2025 (remainder)</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">3,902&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">15,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">14,974&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">13,619&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">2029</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">13,905&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">2030 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">114,790&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">176,989&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Less imputed interest</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(64,289)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Total operating lease liabilities (includes current portion)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">112,700&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow and other information related to leases was as follows:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.079%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.079%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Cash received for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">3,099&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Right-of-use assets obtained in exchange for amended operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(64)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">3,875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">3,204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">11,554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">7,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">11.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">12.8</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Weighted-average discount rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">8.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">8.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule of Awards Outstanding</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of awards outstanding attributable to Arrowhead Pharmaceuticals, Inc.:</span></div><div style="margin-top:6pt;text-align:center;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.036%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.036%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.036%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.041%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2013 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2021 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Inducement Awards</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Granted and outstanding awards:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">850,117&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">32,151&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">602,355&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">1,484,623&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">1,500,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">3,888,660&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">592,262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">5,980,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2,350,117&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">3,920,811&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">1,194,617&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">7,465,545&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Share-Based Payment Arrangement, Expensed</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock-based compensation expenses included in operating expenses attributable to Arrowhead Pharmaceuticals, Inc.:</span></div><div style="margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.939%"><tr><td style="width:1.0%"></td><td style="width:43.769%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.226%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Nine Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">6,898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">6,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">21,008&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">21,634&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">5,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">8,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">20,242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">27,350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">11,993&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">14,711&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">41,250&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">48,984&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Summarized Information about Stock Options</a></td>
<td class="text">The following table presents a summary of the stock option activity for the nine months ended June&#160;30, 2025:<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Exercise<br/>Price<br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at September&#160;30, 2024</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">1,978,516</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">23.39&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Cancelled or expired</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(35,341)</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">45.92&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Exercised</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(458,552)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">7.55&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">1,484,623</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">27.75&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">3.5</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">5,750,674&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Exercisable at June&#160;30, 2025</span></div></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">1,484,623</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">27.75&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">3.5</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">5,750,674&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Share Activity Related to RSUs</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity of the Company&#8217;s RSUs:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Grant<br/>Date<br/>Fair Value<br/>Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at September&#160;30, 2024</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">4,913,312</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">49.61&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">2,711,009</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">19.49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Vested</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(1,383,568)</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">43.96&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(259,831)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">32.96&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at June&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">5,980,922</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">37.97&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present information about the Company&#8217;s assets and liabilities measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques utilized by the Company:  </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.449%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Available-for-sale securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">221,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">221,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">7,019&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">7,019&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Commercial notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">26,449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">26,449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">515,234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">515,234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Total available-for-sale securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">770,579&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">770,579&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Money market instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">81,283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">81,283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Term deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">11,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">11,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">7,960&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">7,960&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Commercial notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">23,770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">23,770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Total cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">81,283&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">42,779&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">124,062&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Total financial assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">81,283&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">813,358&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">894,641&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.449%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Available-for-sale securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">160,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">160,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Commercial notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">179,714&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">179,714&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">237,839&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">237,839&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Total available-for-sale securities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">578,276&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">578,276&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Money market instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">66,966&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">66,966&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Total cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">66,966&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">66,966&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Total financial assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">66,966&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">578,276&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">645,242&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability Related to the Sale of Future Royalties (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract', window );"><strong>Liability Related To The Sale Of Future Royalties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock', window );">Schedule of Liability Related to the Sale of Future Royalties</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the activity with respect to the liability related to the sale of future royalties.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.574%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.577%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Beginning carrying value</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">341,361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">268,326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Milestone payment received</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">50,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Non-cash interest expense recognized</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">18,893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">23,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Ending carrying value</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">360,254&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">341,361&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability Related To The Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Liability Related To The Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financing Agreement (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock', window );">Schedule of Line of Credit Facilities</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The outstanding balance of the Credit Facility consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Initial Term Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">400,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">400,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated interest on the Initial Term Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">53,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">9,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated accretion of the MOIC Payment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2,787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Less: Unamortized debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(14,284)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(15,817)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Less: Current portion of credit facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(40,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Less: Payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(201,625)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Credit facility, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">200,332&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">393,183&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_SummaryOfInterestExpenseRecognizedRelatedToCreditFacilityTableTextBlock', window );">Schedule of Interest Expense Recognized Related To Credit Facility</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth total interest expense recognized related to the Credit Facility:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.540%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of debt issuance costs</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">420&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">1,533&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Accretion of the MOIC Payment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2,218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2,787&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Contractual interest expense</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">13,766&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">44,454&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;Total interest expense</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">16,404&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">48,774&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Maturities of Long-Term Debt</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The amounts shown in the table below, related to the Credit Facility, represent the expected repayments of principle and accrued interest balance as of June 30, 2025 as well as any mandatory prepayments that the Company is obligated to make to the Lenders during the indicated periods. The principal balance will increase from accrued paid in kind interest and the table does not include MOIC payments beyond those contractually determined. Actual payments on current principal may vary from the amounts presented in the table. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"><tr><td style="width:1.0%"></td><td style="width:78.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.933%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Year</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amounts</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2025 (remainder)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">40,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">40,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">15,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">15,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Thereafter</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">216,503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">326,503&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_SummaryOfInterestExpenseRecognizedRelatedToCreditFacilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary Of Interest Expense Recognized Related To Credit Facility</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_SummaryOfInterestExpenseRecognizedRelatedToCreditFacilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the computation of basic and diluted net (loss) income per share for the three and nine months ended June&#160;30, 2025 and 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">                            </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.545%"><tr><td style="width:1.0%"></td><td style="width:43.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.146%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Nine Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands, except per share amounts)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Net (loss) income attributable to Arrowhead Pharmaceuticals, Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(175,241)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(170,793)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">22,119&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(428,957)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Weighted-average basic shares outstanding</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">139,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">124,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">132,385&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">118,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Effect of dilutive securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">967&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Weighted-average diluted shares outstanding </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">139,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">124,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">133,352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">118,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Basic net (loss) income per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(1.26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(1.38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">0.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(3.63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Diluted net (loss) income per share</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(1.26)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(1.38)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">0.17&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(3.63)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(1) Includes shares of common stock into which the Avoro Pre-Funded Warrants may be exercised. See Note 6.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net (loss) income per share because to include them would be anti-dilutive.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.545%"><tr><td style="width:1.0%"></td><td style="width:43.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.146%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Nine Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">768&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">753&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">711&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">5,178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">3,976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">4,770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">4,060&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">5,946&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">4,729&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">5,526&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">4,771&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 27, 2025</div></th>
<th class="th"><div>Feb. 24, 2025</div></th>
<th class="th"><div>Feb. 07, 2025</div></th>
<th class="th"><div>Nov. 25, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 129,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69,399<span></span>
</td>
<td class="nump">$ 129,793<span></span>
</td>
<td class="nump">$ 69,399<span></span>
</td>
<td class="nump">$ 102,685<span></span>
</td>
<td class="nump">$ 110,891<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">770,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">770,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 578,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_IncreaseDecreaseInCashAndInvestments', window );">Increase (decrease) in cash and investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from the issuance of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayments of credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">201,625<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterestAndDividend', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,498<span></span>
</td>
<td class="nump">28,236<span></span>
</td>
<td class="nump">$ 15,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development regulatory and sales milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_SareptaMember', window );">Sarepta | Sarepta Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares of common stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,926,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock sold price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ProceedsFromCollaborationArrangements', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_AdditionalCashReceivableUnderCollaborationAgreement', window );">Annual fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod', window );">Annual installments period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_EnrollmentRelatedMilestonePayments', window );">Enrollment related milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_FuturePotentialMilestonePayments', window );">Future potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_SareptaMember', window );">Sarepta | Sarepta Collaboration Agreement | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DevelopmentMilestonePayments', window );">Development milestone payments</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_FuturePotentialMilestonePayments', window );">Future potential milestone payments</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember', window );">GSK | GSK-HBV Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DevelopmentMilestonePayments', window );">Development milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_AdditionalCashReceivableUnderCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Cash Receivable Under Collaboration Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_AdditionalCashReceivableUnderCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Receivable Under Collaboration Agreement, Annual Installments Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DevelopmentMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DevelopmentMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development regulatory and sales milestones payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DevelopmentRegulatoryAndSalesMilestonesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_EnrollmentRelatedMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Enrollment Related Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_EnrollmentRelatedMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_FuturePotentialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future Potential Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_FuturePotentialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_IncreaseDecreaseInCashAndInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in cash and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_IncreaseDecreaseInCashAndInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ProceedsFromCollaborationArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Collaboration Arrangements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ProceedsFromCollaborationArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterestAndDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterestAndDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arwr_SareptaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arwr_SareptaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_SareptaCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_SareptaCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_GSKHBVAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_GSKHBVAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 27,767<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 572,976<span></span>
</td>
<td class="nump">$ 3,551<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember', window );">GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">143<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,646<span></span>
</td>
<td class="nump">2,685<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember', window );">Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">866<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=arwr_SareptaTherapeuticsIncMember', window );">Sarepta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 27,624<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 570,330<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=arwr_SareptaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=arwr_SareptaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration and License Agreements - Receivables and Contract Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CollaborationAndLicenseAgreementsAbstract', window );"><strong>Collaboration And License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Receivables included in accounts receivable</a></td>
<td class="nump">$ 9,699<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities included in deferred revenue</a></td>
<td class="nump">$ 22,979<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration and license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479196/954-310-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - GlaxoSmithKline Intellectual Property (No. 3) Limited (&#8220;GSK&#8221;) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 22, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 11, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,979,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember', window );">GSK | GSK-HSD License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_InitialTransactionPrice', window );">Initial transaction price</a></td>
<td class="nump">$ 120,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceivable', window );">Milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree', window );">Milestone payment receivable upon achievement of phase two and first patient dosed in phase three</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember', window );">GSK | GSK-HSD License Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CommercialMilestonePaymentsAtFirstCommercialSale', window );">Commercial milestone payments at first commercial sale</a></td>
<td class="nump">190,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_SalesRelatedMilestonePayments', window );">Sales-related milestone payments</a></td>
<td class="nump">$ 590,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember', window );">GSK | GSK-HBV Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_InitialTransactionPrice', window );">Initial transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DevelopmentMilestonePayments', window );">Development milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember', window );">GSK | GSK-HBV Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DevelopmentAndSalesMilestonesPayments', window );">Development and sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 830,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CommercialMilestonePaymentsAtFirstCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commercial milestone payments at first commercial sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CommercialMilestonePaymentsAtFirstCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DevelopmentAndSalesMilestonesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development And Sales Milestones Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DevelopmentAndSalesMilestonesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DevelopmentMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DevelopmentMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_InitialTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_InitialTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment receivable upon achievement of phase two and first patient dosed in phase three.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_SalesRelatedMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales-related milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_SalesRelatedMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_GSKHSDLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_GSKHSDLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_GSKHBVAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_GSKHBVAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Takeda Pharmaceutical Company Limited (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>bundle</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development regulatory and sales milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,979,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,818,000<span></span>
</td>
<td class="nump">$ 63,017,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember', window );">Takeda | License and Co-Funding Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfDistinctBundle', window );">Number of distinct bundle | bundle</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_InitialTransactionPrice', window );">Initial transaction price</a></td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentEarned', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember', window );">Takeda | License and Co-Funding Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales', window );">Percentage of eligible to receive tiered royalties on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember', window );">Takeda | License and Co-Funding Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales', window );">Percentage of eligible to receive tiered royalties on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development regulatory and sales milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 527,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development regulatory and sales milestones payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DevelopmentRegulatoryAndSalesMilestonesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_InitialTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_InitialTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment earned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfDistinctBundle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of distinct bundle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfDistinctBundle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of eligible to receive tiered royalties on net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_LicenseAndCoFundingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_LicenseAndCoFundingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration and License Agreements - Amgen, Inc (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>agreement</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">$ 22,979,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_AmgenIncorporatedMember', window );">Amgen Incorporated | Olpasiran Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfAgreements', window );">Number of agreements | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_AmgenIncorporatedMember', window );">Amgen Incorporated | Olpasiran Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments', window );">Additional remaining development regulatory and sales milestones payments</a></td>
<td class="nump">$ 485,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional remaining development regulatory and sales milestones payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arwr_AmgenIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arwr_AmgenIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_OlpasiranAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_OlpasiranAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Sarepta Therapeutics, Inc. (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 14, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 07, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 25, 2024 </div>
<div>USD ($) </div>
<div>obligation </div>
<div>program</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,767<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 572,976<span></span>
</td>
<td class="nump">$ 3,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities included in deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_SareptaTherapeuticsIncMember', window );">Sarepta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">570,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities included in deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_SareptaTherapeuticsIncMember', window );">Sarepta | Sarepta Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfPerformanceObligations', window );">Number of performance obligations | obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ProceedsFromCollaborationArrangements', window );">Upfront payment</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_SaleOfStockPremiumOnIssuanceOfShares', window );">Equity premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_AdditionalCashReceivableUnderCollaborationAgreement', window );">Annual fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallments', window );">Annual installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod', window );">Annual installments period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CollaborationArrangementFixedConsideration', window );">Fixed consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">833,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CollaborationArrangementConsideration', window );">Total transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 904,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_EnrollmentRelatedMilestonePayments', window );">Enrollment related milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfCollaborationPrograms', window );">Number of collaboration programs | program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CollaborationArrangementTerminationNoticePeriodPriorToRegulatoryApproval', window );">Collaboration agreement termination notice period prior to any regulatory approval of a licensed product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_SareptaTherapeuticsIncMember', window );">Sarepta | Sarepta Collaboration Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfNewTargetPrograms', window );">Number of new target programs | program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_RegulatoryMilestonePayments', window );">Regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_SalesRelatedMilestonePayments', window );">Sales-related milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_SareptaTherapeuticsIncMember', window );">Sarepta | Sarepta Collaboration Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_RegulatoryMilestonePayments', window );">Regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_SalesRelatedMilestonePayments', window );">Sales-related milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_AdditionalCashReceivableUnderCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Cash Receivable Under Collaboration Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_AdditionalCashReceivableUnderCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Receivable Under Collaboration Agreement, Annual Installments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CashReceivableUnderCollaborationAgreementAnnualInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Receivable Under Collaboration Agreement, Annual Installments Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CollaborationArrangementConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CollaborationArrangementConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CollaborationArrangementFixedConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Fixed Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CollaborationArrangementFixedConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CollaborationArrangementTerminationNoticePeriodPriorToRegulatoryApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Termination Notice Period Prior To Regulatory Approval</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CollaborationArrangementTerminationNoticePeriodPriorToRegulatoryApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_EnrollmentRelatedMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Enrollment Related Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_EnrollmentRelatedMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfCollaborationPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Collaboration Programs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfCollaborationPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfNewTargetPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of New Target Programs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfNewTargetPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Performance Obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ProceedsFromCollaborationArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Collaboration Arrangements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ProceedsFromCollaborationArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_RegulatoryMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Regulatory Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_RegulatoryMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_SaleOfStockPremiumOnIssuanceOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Premium On Issuance Of Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_SaleOfStockPremiumOnIssuanceOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_SalesRelatedMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales-related milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_SalesRelatedMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arwr_SareptaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arwr_SareptaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_SareptaCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_SareptaCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Sarepta Therapeutics, Inc. Consideration Components (Details) - Sarepta - Sarepta Collaboration Agreement - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 14, 2025</div></th>
<th class="th"><div>Feb. 07, 2025</div></th>
<th class="th"><div>Nov. 25, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ProceedsFromCollaborationArrangements', window );">Upfront payment</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_AdditionalCashReceivableUnderCollaborationAgreement', window );">Annual fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_SaleOfStockPremiumOnIssuanceOfShares', window );">Equity premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,612<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CollaborationArrangementFixedConsideration', window );">Fixed consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">833,612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CollaborationArrangementVariableConsideration', window );">Estimated variable consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,243<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CollaborationArrangementConsideration', window );">Total transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 904,855<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_AdditionalCashReceivableUnderCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Cash Receivable Under Collaboration Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_AdditionalCashReceivableUnderCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CollaborationArrangementConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CollaborationArrangementConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CollaborationArrangementFixedConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Fixed Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CollaborationArrangementFixedConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CollaborationArrangementVariableConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Variable Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CollaborationArrangementVariableConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ProceedsFromCollaborationArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Collaboration Arrangements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ProceedsFromCollaborationArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_SaleOfStockPremiumOnIssuanceOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Premium On Issuance Of Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_SaleOfStockPremiumOnIssuanceOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arwr_SareptaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arwr_SareptaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_SareptaCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_SareptaCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Accounts - Property, Plant and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 455,278<span></span>
</td>
<td class="nump">$ 444,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation and amortization</a></td>
<td class="num">(74,230)<span></span>
</td>
<td class="num">(58,021)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">381,048<span></span>
</td>
<td class="nump">386,032<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">2,996<span></span>
</td>
<td class="nump">2,996<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">249,245<span></span>
</td>
<td class="nump">75,988<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchEquipmentMember', window );">Research equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">59,561<span></span>
</td>
<td class="nump">65,353<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ManufacturingEquipmentMember', window );">Manufacturing equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">16,548<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">5,594<span></span>
</td>
<td class="nump">5,594<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ComputerAndSoftwareMember', window );">Computers and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">1,059<span></span>
</td>
<td class="nump">981<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">104,403<span></span>
</td>
<td class="nump">104,410<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 15,872<span></span>
</td>
<td class="nump">$ 188,731<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ManufacturingEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ManufacturingEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ComputerAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ComputerAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Accounts - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense for property and equipment</a></td>
<td class="nump">$ 5.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.2<span></span>
</td>
<td class="nump">$ 12.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ConstructionInProgressReclassifiedToBuildingMember', window );">Construction In Progress Reclassified To Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges', window );">Property, plant and equipment, reclassification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (162.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (10.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges', window );">Property, plant and equipment, reclassification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71.8<span></span>
</td>
<td class="nump">10.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ConstructionInProgressReclassifiedToManufacturingEquipmentMember', window );">Construction In Progress Reclassified To Manufacturing Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges', window );">Property, plant and equipment, reclassification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ManufacturingEquipmentMember', window );">Manufacturing equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges', window );">Property, plant and equipment, reclassification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ManufacturingEquipmentMember', window );">Manufacturing equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ManufacturingEquipmentMember', window );">Manufacturing equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember', window );">Manufacturing Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">39 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">39 years<span></span>
</td>
<td class="text">39 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges', window );">Property, plant and equipment, reclassification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (71.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4.2)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of physical assets used in the normal conduct of business and not intended for resale, from reclassification, impairment, donation, or changes classified as other. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTransfersAndChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ConstructionInProgressReclassifiedToBuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ConstructionInProgressReclassifiedToBuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ConstructionInProgressReclassifiedToManufacturingEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ConstructionInProgressReclassifiedToManufacturingEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ManufacturingEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ManufacturingEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Accounts - Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_AccruedResearchAndDevelopmentExpenseCurrent', window );">Accrued research and development expenses</a></td>
<td class="nump">$ 31,708<span></span>
</td>
<td class="nump">$ 28,069<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent', window );">Accrued research and development expenses; co-development</a></td>
<td class="nump">24,627<span></span>
</td>
<td class="nump">23,351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_AccruedCapitalExpenditureCurrent', window );">Accrued capital expenditures</a></td>
<td class="nump">346<span></span>
</td>
<td class="nump">4,206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">8,137<span></span>
</td>
<td class="nump">7,391<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 64,818<span></span>
</td>
<td class="nump">$ 63,017<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_AccruedCapitalExpenditureCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Capital Expenditure, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_AccruedCapitalExpenditureCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Research And Development Co-Development Expense, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_AccruedResearchAndDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Research And Development Expense, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_AccruedResearchAndDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Schedule of Short-term, Long-term Investments and Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems', window );"><strong>Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Current investments, Adjusted Basis</a></td>
<td class="nump">$ 768,746<span></span>
</td>
<td class="nump">$ 577,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent', window );">Current investments, Gross Unrealized Gains</a></td>
<td class="nump">1,938<span></span>
</td>
<td class="nump">837<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent', window );">Current investments, Gross Unrealized Losses</a></td>
<td class="num">(105)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Current investments, Fair Value</a></td>
<td class="nump">770,579<span></span>
</td>
<td class="nump">578,276<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember', window );">Available-for-sale securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems', window );"><strong>Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Current investments, Adjusted Basis</a></td>
<td class="nump">768,746<span></span>
</td>
<td class="nump">577,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent', window );">Current investments, Gross Unrealized Gains</a></td>
<td class="nump">1,938<span></span>
</td>
<td class="nump">837<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent', window );">Current investments, Gross Unrealized Losses</a></td>
<td class="num">(105)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Current investments, Fair Value</a></td>
<td class="nump">$ 770,579<span></span>
</td>
<td class="nump">$ 578,276<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of held to maturity securities and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Schedule of Contract Maturity of Available for Sale (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue', window );">Within one year</a></td>
<td class="nump">$ 224,571<span></span>
</td>
<td class="nump">$ 578,276<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo', window );">After one to two years</a></td>
<td class="nump">450,889<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree', window );">After two to three years</a></td>
<td class="nump">95,119<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">$ 770,579<span></span>
</td>
<td class="nump">$ 578,276<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, After Year One Through Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, After Year Two Through Three</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 7,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=arwr_NovartisMember', window );">Novartis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">24,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">17,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_FiniteLivedIntangibleAssetsImpairment', window );">Impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">7,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,562<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=arwr_NovartisMember', window );">Novartis | Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">21,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,728<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">16,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,873<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_FiniteLivedIntangibleAssetsImpairment', window );">Impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 5,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,855<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Lives (in years)</a></td>
<td class="text">14 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">14 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">14 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=arwr_NovartisMember', window );">Novartis | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 3,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">1,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_FiniteLivedIntangibleAssetsImpairment', window );">Impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 1,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Lives (in years)</a></td>
<td class="text">21 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">21 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">21 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_FiniteLivedIntangibleAssetsImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Assets, Impairment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_FiniteLivedIntangibleAssetsImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-29<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-29<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 24: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 26: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 27: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 28: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=arwr_NovartisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=arwr_NovartisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets - Schedule of Expected Future Amortization (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2025 (remainder)</a></td>
<td class="nump">$ 424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2026</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2027</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2028</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2029</a></td>
<td class="nump">795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour', window );">2030 and thereafter</a></td>
<td class="nump">967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 7,286<span></span>
</td>
<td class="nump">$ 8,562<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Asset, Expected Amortization, after Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Shares of Common Stock and Preferred Stock (Details) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">290,000<span></span>
</td>
<td class="nump">290,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">138,144<span></span>
</td>
<td class="nump">124,376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">138,144<span></span>
</td>
<td class="nump">124,376<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 25, 2024</div></th>
<th class="th"><div>Dec. 02, 2022</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock, share reserve for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,308,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants (in shares)</a></td>
<td class="nump">917,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights', window );">Warrants purchase price (in dollars per share)</a></td>
<td class="nump">$ 27.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from the issuance of warrants</a></td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ClassOfWarrantOrRightNumberOfWarrantsExercised', window );">Number of warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares of common stock issued (in shares)</a></td>
<td class="nump">11,926,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock sold price (in dollars per share)</a></td>
<td class="nump">$ 27.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from sale of stock</a></td>
<td class="nump">$ 325,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=arwr_AtTheMarketAgreementMember', window );">At The Market Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued to institutional investors (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | At The Market Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance', window );">Common stock shares value reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock', window );">Percentage of commission to sales agent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember', window );">2013 and 2021 Incentive Plans and other inducement grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock, share reserve for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,081,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,492,293<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ClassOfWarrantOrRightNumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Number Of Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ClassOfWarrantOrRightNumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Purchase Price of Warrants or Rights</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock, capital shares value reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CommonStockCapitalSharesValueReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of commission on aggregate gross proceeds from sale of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=arwr_AtTheMarketAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=arwr_AtTheMarketAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> ft&#178; in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Contingent liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_DrugManufacturingFacilityMember', window );">Drug Manufacturing Facility | Wisconsin</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Planned area of the site (in sq ft) | ft&#178;</a></td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_LaboratoryAndOfficeFacilityMember', window );">Laboratory and Office Facility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CommitmentsCapitalExpendituresIncurredToDate', window );">Capital expenditures incurred</a></td>
<td class="nump">$ 76,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_LaboratoryAndOfficeFacilityMember', window );">Laboratory and Office Facility | Wisconsin</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Planned area of the site (in sq ft) | ft&#178;</a></td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_FacilitiesMember', window );">Facilities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CommitmentsCapitalExpendituresIncurredToDate', window );">Capital expenditures incurred</a></td>
<td class="nump">$ 293,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_AmountIntendsToInvestForBuildoutOfFacilities', window );">Amount intends to invest for buildout of the facilities</a></td>
<td class="nump">3,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchEquipmentMember', window );">Research equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CommitmentsCapitalExpendituresIncurredToDate', window );">Capital expenditures incurred</a></td>
<td class="nump">11,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CommitmentsCapitalExpendituresIncurredToDate', window );">Capital expenditures incurred</a></td>
<td class="nump">173,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ManufacturingEquipmentMember', window );">Manufacturing equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CommitmentsCapitalExpendituresIncurredToDate', window );">Capital expenditures incurred</a></td>
<td class="nump">16,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CommitmentsCapitalExpendituresIncurredToDate', window );">Capital expenditures incurred</a></td>
<td class="nump">$ 15,900,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_AmountIntendsToInvestForBuildoutOfFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount intends to invest for buildout of facilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_AmountIntendsToInvestForBuildoutOfFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CommitmentsCapitalExpendituresIncurredToDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments, Capital Expenditures Incurred To Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CommitmentsCapitalExpendituresIncurredToDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_DrugManufacturingFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_DrugManufacturingFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_WI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_WI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_LaboratoryAndOfficeFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_LaboratoryAndOfficeFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_FacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_FacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ManufacturingEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ManufacturingEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">15 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>option</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>option</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 29, 2025 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_CorporateHeadquartersInPasadenaMember', window );">Corporate Headquarters In Pasadena | California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Office space leases (in sq ft) | ft&#178;</a></td>
<td class="nump">49,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_CorporateHeadquartersInPasadenaMember', window );">Corporate Headquarters In Pasadena | California | Colorado Owner, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfOptionsToRenew', window );">Number of options to renew | option</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInSanDiegoMember', window );">Research Facility in San Diego | California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Office space leases (in sq ft) | ft&#178;</a></td>
<td class="nump">144,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease renewal term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ProceedsFromTenantImprovementAllowance', window );">Proceeds from additional tenant improvement allowance | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInSanDiegoMember', window );">Research Facility in San Diego | California | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfOptionsToRenew', window );">Number of options to renew | option</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInMadisonMember', window );">Research Facility in Madison | Wisconsin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Office space leases (in sq ft) | ft&#178;</a></td>
<td class="nump">110,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfOptionsToRenew', window );">Number of options to renew | option</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfOptionsToRenew">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options to renew.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfOptionsToRenew</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ProceedsFromTenantImprovementAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Tenant Improvement Allowance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ProceedsFromTenantImprovementAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LandSubjectToGroundLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land subject to a ground lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LandSubjectToGroundLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_CorporateHeadquartersInPasadenaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_CorporateHeadquartersInPasadenaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arwr_ColoradoOwnerLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arwr_ColoradoOwnerLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInSanDiegoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInSanDiegoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInMadisonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInMadisonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_WI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_WI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Components of Lease Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAndLiabilitiesLesseeAbstract', window );"><strong>Lease Assets and Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 44,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">7,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,342<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, net of current portion</a></td>
<td class="nump">105,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total</a></td>
<td class="nump">3,575<span></span>
</td>
<td class="nump">$ 4,365<span></span>
</td>
<td class="nump">12,026<span></span>
</td>
<td class="nump">$ 12,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">2,233<span></span>
</td>
<td class="nump">2,965<span></span>
</td>
<td class="nump">7,754<span></span>
</td>
<td class="nump">8,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">893<span></span>
</td>
<td class="nump">863<span></span>
</td>
<td class="nump">2,830<span></span>
</td>
<td class="nump">2,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">449<span></span>
</td>
<td class="nump">537<span></span>
</td>
<td class="nump">1,442<span></span>
</td>
<td class="nump">1,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAndLiabilitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAndLiabilitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2025 (remainder)</a></td>
<td class="nump">$ 3,902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">15,799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="nump">14,974<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2028</a></td>
<td class="nump">13,619<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2029</a></td>
<td class="nump">13,905<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive', window );">2030 and thereafter</a></td>
<td class="nump">114,790<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">176,989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(64,289)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities (includes current portion)</a></td>
<td class="nump">$ 112,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability payments due year five and after year five.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Cash Flow and Other Information Related to Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract', window );"><strong>Cash received for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,099<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for amended operating lease liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(64)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 3,875<span></span>
</td>
<td class="nump">$ 3,204<span></span>
</td>
<td class="nump">$ 11,554<span></span>
</td>
<td class="nump">$ 7,221<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (in years)</a></td>
<td class="text">11 years 10 months 24 days<span></span>
</td>
<td class="text">12 years 9 months 18 days<span></span>
</td>
<td class="text">11 years 10 months 24 days<span></span>
</td>
<td class="text">12 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Flow, Operating Activities, Lessee, Cash Received For Amounts Included In Measurement Of Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Cash Received For Amounts Included In Measurement Of Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right-Of-Use Asset Adjustment In Exchange For Operating Lease Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowOperatingActivitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2023</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock, share reserve for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,308,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,308,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,484,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,484,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,978,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,993<span></span>
</td>
<td class="nump">$ 14,711<span></span>
</td>
<td class="nump">$ 41,250<span></span>
</td>
<td class="nump">$ 48,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based payment award (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,980,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,980,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,913,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,900<span></span>
</td>
<td class="nump">14,300<span></span>
</td>
<td class="nump">$ 41,100<span></span>
</td>
<td class="nump">46,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized pre-tax compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period to recognize pre-tax compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="nump">$ 4,900<span></span>
</td>
<td class="nump">3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember', window );">2013 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserve for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,350,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,350,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">850,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">850,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember', window );">2013 Plan | Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based payment award (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember', window );">2021 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,215,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">353,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember', window );">2021 Plan | Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based payment award (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,888,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,888,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_InducementPlanMember', window );">Inducement Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">832,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">832,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">607,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock, share reserve for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">307,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">307,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">602,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">602,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_InducementPlanMember', window );">Inducement Awards | Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based payment award (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_VisirnaESOPMember', window );">Visirna ESOP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_InducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_InducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_VisirnaESOPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_VisirnaESOPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Granted and Outstanding Shares (Details) - shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options (in shares)</a></td>
<td class="nump">1,484,623<span></span>
</td>
<td class="nump">1,978,516<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding', window );">Total (in shares)</a></td>
<td class="nump">7,465,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock units (in shares)</a></td>
<td class="nump">5,980,922<span></span>
</td>
<td class="nump">4,913,312<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember', window );">2013 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options (in shares)</a></td>
<td class="nump">850,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding', window );">Total (in shares)</a></td>
<td class="nump">2,350,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember', window );">2013 Plan | Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock units (in shares)</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember', window );">2021 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options (in shares)</a></td>
<td class="nump">32,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding', window );">Total (in shares)</a></td>
<td class="nump">3,920,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember', window );">2021 Plan | Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock units (in shares)</a></td>
<td class="nump">3,888,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_InducementAwardsMember', window );">Inducement Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options (in shares)</a></td>
<td class="nump">602,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding', window );">Total (in shares)</a></td>
<td class="nump">1,194,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_InducementAwardsMember', window );">Inducement Awards | Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock units (in shares)</a></td>
<td class="nump">592,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_InducementAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_InducementAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Expenses Included in Operating Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">$ 11,993<span></span>
</td>
<td class="nump">$ 14,711<span></span>
</td>
<td class="nump">$ 41,250<span></span>
</td>
<td class="nump">$ 48,984<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">6,898<span></span>
</td>
<td class="nump">6,221<span></span>
</td>
<td class="nump">21,008<span></span>
</td>
<td class="nump">21,634<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">$ 5,095<span></span>
</td>
<td class="nump">$ 8,490<span></span>
</td>
<td class="nump">$ 20,242<span></span>
</td>
<td class="nump">$ 27,350<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Information about Stock Options (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">1,978,516<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Cancelled or expired (in shares)</a></td>
<td class="num">(35,341)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(458,552)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">1,484,623<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options Outstanding, Exercisable (in shares)</a></td>
<td class="nump">1,484,623<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 23.39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Cancelled or expired (in dollars per share)</a></td>
<td class="nump">45.92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">7.55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">27.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Exercisable (in dollars per share)</a></td>
<td class="nump">$ 27.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Contractual Term (Years)</a></td>
<td class="text">3 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term, Exercisable</a></td>
<td class="text">3 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="nump">$ 5,750,674<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">$ 5,750,674<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of RSUs Activity (Details) - Restricted stock units<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning of period (in shares) | shares</a></td>
<td class="nump">4,913,312<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">2,711,009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(1,383,568)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(259,831)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">End of period (in shares) | shares</a></td>
<td class="nump">5,980,922<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- Average Grant Date Fair Value Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 49.61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">19.49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">43.96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">32.96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 37.97<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">$ 770,579<span></span>
</td>
<td class="nump">$ 578,276<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">770,579<span></span>
</td>
<td class="nump">578,276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">124,062<span></span>
</td>
<td class="nump">66,966<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">894,641<span></span>
</td>
<td class="nump">645,242<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Money market instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">81,283<span></span>
</td>
<td class="nump">66,966<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Term deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">11,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">7,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Commercial notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">23,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">221,877<span></span>
</td>
<td class="nump">160,723<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">7,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Commercial notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">26,449<span></span>
</td>
<td class="nump">179,714<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">515,234<span></span>
</td>
<td class="nump">237,839<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">81,283<span></span>
</td>
<td class="nump">66,966<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">81,283<span></span>
</td>
<td class="nump">66,966<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Money market instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">81,283<span></span>
</td>
<td class="nump">66,966<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Term deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Commercial notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Commercial notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">770,579<span></span>
</td>
<td class="nump">578,276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">42,779<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">813,358<span></span>
</td>
<td class="nump">578,276<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Money market instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Term deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">11,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">7,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Commercial notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">23,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">221,877<span></span>
</td>
<td class="nump">160,723<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">7,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Commercial notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">26,449<span></span>
</td>
<td class="nump">179,714<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">515,234<span></span>
</td>
<td class="nump">237,839<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Money market instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Term deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Commercial notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Commercial notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=arwr_CommercialNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=arwr_CommercialNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=arwr_CommercialNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=arwr_CommercialNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability Related to the Sale of Future Royalties - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties', window );">Milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arwr_RoyaltyPharmaAgreementMember', window );">Royalty Pharma Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties', window );">Upfront payment received</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceivable', window );">Milestone payment receivable</a></td>
<td class="nump">160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceivableUponFDAApproval', window );">Milestone payment receivable upon FDA approval</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments', window );">Milestone payment receivable upon receipt of royalty payments</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_RoyaltyPaymentThreshold', window );">Royalty payment threshold</a></td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties', window );">Milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_LiabilitySaleOfFutureRoyaltiesInterestRate', window );">Liability related to the sale of future royalties, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arwr_RoyaltyPharmaAgreementMember', window );">Royalty Pharma Agreement | Amgen Incorporated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial', window );">Milestone payment receivable upon achievement of enrollment in phase 3 clinical trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arwr_RoyaltyPharmaAgreementMember', window );">Royalty Pharma Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_InitialTransactionPrice', window );">Initial transaction price</a></td>
<td class="nump">$ 410,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_InitialTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_InitialTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_LiabilitySaleOfFutureRoyaltiesInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability, Sale Of Future Royalties, Interest Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_LiabilitySaleOfFutureRoyaltiesInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment Receivable, Upon Achievement of Enrollment in Phase 3 Clinical Trial</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceivableUponFDAApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment Receivable, Upon FDA Approval</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceivableUponFDAApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment Receivable, Upon Receipt Of Royalty Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment Received, Liability Related To Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_RoyaltyPaymentThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Payment Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_RoyaltyPaymentThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront Payment Received, Liability Related To Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_RoyaltyPharmaAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_RoyaltyPharmaAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arwr_AmgenIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arwr_AmgenIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability Related to the Sale of Future Royalties - Activity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_LiabilitySaleOfFutureRoyaltiesRollForward', window );"><strong>Liability, Sale Of Future Royalties [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_RoyaltiesLiabilityNoncurrent', window );">Beginning carrying value</a></td>
<td class="nump">$ 341,361<span></span>
</td>
<td class="nump">$ 268,326<span></span>
</td>
<td class="nump">$ 268,326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties', window );">Milestone payment received</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties', window );">Non-cash interest expense recognized</a></td>
<td class="nump">18,893<span></span>
</td>
<td class="nump">$ 17,705<span></span>
</td>
<td class="nump">23,035<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_RoyaltiesLiabilityNoncurrent', window );">Ending carrying value</a></td>
<td class="nump">$ 360,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 341,361<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_LiabilitySaleOfFutureRoyaltiesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability, Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_LiabilitySaleOfFutureRoyaltiesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment Received, Liability Related To Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Interest Expense, Liability Related To Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_RoyaltiesLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties, Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_RoyaltiesLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financing Agreement - Narrative (Details)<br> $ in Thousands, &#165; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 24, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Nov. 26, 2024</div></th>
<th class="th">
<div>Aug. 07, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>May 31, 2025 </div>
<div>CNY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayments of credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 201,625<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LinesOfCreditCurrent', window );">Credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_SareptaMember', window );">Sarepta | Sarepta Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ProceedsFromCollaborationArrangements', window );">Upfront payment</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=arwr_FinancingAgreementMember', window );">Financing Agreement | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Financing Agreement | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Long-term line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Line of credit facility, remaining borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtInstrumentCovenantMultipleOfInvestCapital', window );">Multiple of invested capital rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayments of credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">201,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtInstrumentCovenantMinimumLiquidityIfCapitalizationIsAboveThreshold', window );">Debt instrument, covenant, minimum liquidity cash, cash equivalents and investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtInstrumentCovenantMarketCapitalizationThreshold', window );">Market capitalization threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LinesOfCreditCurrent', window );">Credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Financing Agreement, Initial Term Loan | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtInstrumentPrepaymentPercentage', window );">Debt instrument, prepayment percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Financing Agreement, MOIC Payment | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtInstrumentCovenantMultipleOfInvestCapital', window );">Multiple of invested capital rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtInstrumentPrepaymentPercentage', window );">Debt instrument, prepayment percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayments of credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtInstrumentMultipleOfInvestmentCapitalExpectedToBeAppliedToPrincipalUponRepayment', window );">MOIC payments expected to be applied to principal upon repayment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 73.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LinesOfCreditCurrent', window );">Credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 50.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DebtInstrumentCovenantMarketCapitalizationThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Market Capitalization, Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DebtInstrumentCovenantMarketCapitalizationThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DebtInstrumentCovenantMinimumLiquidityIfCapitalizationIsAboveThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Minimum Liquidity If Capitalization Is Above Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DebtInstrumentCovenantMinimumLiquidityIfCapitalizationIsAboveThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DebtInstrumentCovenantMultipleOfInvestCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Multiple Of Invest Capital</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DebtInstrumentCovenantMultipleOfInvestCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DebtInstrumentMultipleOfInvestmentCapitalExpectedToBeAppliedToPrincipalUponRepayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Multiple Of Investment Capital Expected To Be Applied To Principal Upon Repayment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DebtInstrumentMultipleOfInvestmentCapitalExpectedToBeAppliedToPrincipalUponRepayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DebtInstrumentPrepaymentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DebtInstrumentPrepaymentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ProceedsFromCollaborationArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Collaboration Arrangements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ProceedsFromCollaborationArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LinesOfCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LinesOfCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arwr_SareptaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arwr_SareptaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_SareptaCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_SareptaCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=arwr_FinancingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=arwr_FinancingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=arwr_FinancingAgreementInitialTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=arwr_FinancingAgreementInitialTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=arwr_FinancingAgreementMOICPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=arwr_FinancingAgreementMOICPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financing Agreement - Schedule of Outstanding Balance of Credit Facility (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LinesOfCreditCurrent', window );">Less: Current portion of credit facility</a></td>
<td class="num">$ (40,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (40,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Less: Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(201,625)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Financing Agreement | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Initial Term Loan</a></td>
<td class="nump">326,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">326,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Accumulated accretion of the MOIC Payment</a></td>
<td class="nump">2,218<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,787<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Less: Unamortized debt issuance costs</a></td>
<td class="num">(14,284)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,284)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,817)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LinesOfCreditCurrent', window );">Less: Current portion of credit facility</a></td>
<td class="num">(40,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Less: Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(201,625)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Credit facility, net of current portion</a></td>
<td class="nump">200,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">393,183<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Financing Agreement, Initial Term Loan | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Initial Term Loan</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Financing Agreement, Initial Term Loan Interest | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Initial Term Loan</a></td>
<td class="nump">$ 53,454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LinesOfCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LinesOfCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=arwr_FinancingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=arwr_FinancingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=arwr_FinancingAgreementInitialTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=arwr_FinancingAgreementInitialTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=arwr_FinancingAgreementInitialTermLoanInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=arwr_FinancingAgreementInitialTermLoanInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financing Agreement - Schedule of Interest Expense Recognized Related to Credit Facility (Details) - Secured Debt - Financing Agreement - Line of Credit - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">$ 420<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,533<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Accretion of the MOIC Payment</a></td>
<td class="nump">2,218<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,787<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual interest expense</a></td>
<td class="nump">13,766<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">44,454<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total interest expense</a></td>
<td class="nump">$ 16,404<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 48,774<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=arwr_FinancingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=arwr_FinancingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financing Agreement - Principal Repayment Related to Credit Facility (Details) - Financing Agreement - Secured Debt - Line of Credit<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2025 (remainder)</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2026</a></td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2027</a></td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2028</a></td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2029</a></td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_LongTermDebtMaturityAfterYearFour', window );">Thereafter</a></td>
<td class="nump">216,503<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total</a></td>
<td class="nump">$ 326,503<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_LongTermDebtMaturityAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt, Maturity, After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_LongTermDebtMaturityAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=arwr_FinancingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=arwr_FinancingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income attributable to Arrowhead Pharmaceuticals, Inc.</a></td>
<td class="num">$ (175,241)<span></span>
</td>
<td class="num">$ (170,793)<span></span>
</td>
<td class="nump">$ 22,119<span></span>
</td>
<td class="num">$ (428,957)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average basic shares outstanding (in shares)</a></td>
<td class="nump">139,039<span></span>
</td>
<td class="nump">124,199<span></span>
</td>
<td class="nump">132,385<span></span>
</td>
<td class="nump">118,260<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Effect of dilutive securities (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">967<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average diluted shares outstanding (in shares)</a></td>
<td class="nump">139,039<span></span>
</td>
<td class="nump">124,199<span></span>
</td>
<td class="nump">133,352<span></span>
</td>
<td class="nump">118,260<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net (loss) income per share (in dollars per share)</a></td>
<td class="num">$ (1.26)<span></span>
</td>
<td class="num">$ (1.38)<span></span>
</td>
<td class="nump">$ 0.17<span></span>
</td>
<td class="num">$ (3.63)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net (loss) income per share (in dollars per share)</a></td>
<td class="num">$ (1.26)<span></span>
</td>
<td class="num">$ (1.38)<span></span>
</td>
<td class="nump">$ 0.17<span></span>
</td>
<td class="num">$ (3.63)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income Per Share - Schedule of Antidilutive Securities (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from computation of diluted earnings per share (in shares)</a></td>
<td class="nump">5,946<span></span>
</td>
<td class="nump">4,729<span></span>
</td>
<td class="nump">5,526<span></span>
</td>
<td class="nump">4,771<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from computation of diluted earnings per share (in shares)</a></td>
<td class="nump">768<span></span>
</td>
<td class="nump">753<span></span>
</td>
<td class="nump">756<span></span>
</td>
<td class="nump">711<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from computation of diluted earnings per share (in shares)</a></td>
<td class="nump">5,178<span></span>
</td>
<td class="nump">3,976<span></span>
</td>
<td class="nump">4,770<span></span>
</td>
<td class="nump">4,060<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="num">$ (437)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,419<span></span>
</td>
<td class="num">$ (3,313)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">5 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 27, 2025</div></th>
<th class="th"><div>Feb. 07, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_SareptaMember', window );">Sarepta | Sarepta Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_FuturePotentialMilestonePayments', window );">Future potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Visirna Therapeutics, Inc. | Sanofi License Agreement | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_InitialTransactionPrice', window );">Initial transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_FuturePotentialMilestonePayments', window );">Future potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 265.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Sarepta | Sarepta Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_FuturePotentialMilestonePayments', window );">Future potential milestone payments</a></td>
<td class="nump">$ 200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DevelopmentMilestonePayments', window );">Development milestone payments</a></td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DevelopmentMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DevelopmentMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_FuturePotentialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future Potential Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_FuturePotentialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_InitialTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_InitialTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arwr_SareptaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arwr_SareptaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_SareptaCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_SareptaCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arwr_VisirnaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arwr_VisirnaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_SanofiLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_SanofiLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>320</ContextCount>
  <ElementCount>337</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>83</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>9952151 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952152 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952153 - Statement - Consolidated Statements of Operations and Comprehensive (Loss) Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive (Loss) Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952154 - Statement - Consolidated Statements of Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952155 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952156 - Disclosure - Organization and Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies</Role>
      <ShortName>Organization and Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreements</Role>
      <ShortName>Collaboration and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Balance Sheet Accounts</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/BalanceSheetAccounts</Role>
      <ShortName>Balance Sheet Accounts</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Liability Related to the Sale of Future Royalties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyalties</Role>
      <ShortName>Liability Related to the Sale of Future Royalties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Financing Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/FinancingAgreement</Role>
      <ShortName>Financing Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - Net (Loss) Income Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/NetLossIncomePerShare</Role>
      <ShortName>Net (Loss) Income Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9952170 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - Organization and Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - Organization and Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesTables</Role>
      <ShortName>Organization and Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - Collaboration and License Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTables</Role>
      <ShortName>Collaboration and License Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - Balance Sheet Accounts (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/BalanceSheetAccountsTables</Role>
      <ShortName>Balance Sheet Accounts (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/BalanceSheetAccounts</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/Investments</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/IntangibleAssets</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/StockholdersEquity</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/Leases</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/StockBasedCompensation</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/FairValueMeasurements</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - Liability Related to the Sale of Future Royalties (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesTables</Role>
      <ShortName>Liability Related to the Sale of Future Royalties (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyalties</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - Financing Agreement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/FinancingAgreementTables</Role>
      <ShortName>Financing Agreement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/FinancingAgreement</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - Net (Loss) Income Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/NetLossIncomePerShareTables</Role>
      <ShortName>Net (Loss) Income Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/NetLossIncomePerShare</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - Organization and Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Organization and Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - Collaboration and License Agreements - Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails</Role>
      <ShortName>Collaboration and License Agreements - Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - Collaboration and License Agreements - Receivables and Contract Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsReceivablesandContractLiabilitiesDetails</Role>
      <ShortName>Collaboration and License Agreements - Receivables and Contract Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - Collaboration and License Agreements - GlaxoSmithKline Intellectual Property (No. 3) Limited (???GSK???) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedGSKDetails</Role>
      <ShortName>Collaboration and License Agreements - GlaxoSmithKline Intellectual Property (No. 3) Limited (???GSK???) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - Collaboration and License Agreements - Takeda Pharmaceutical Company Limited (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails</Role>
      <ShortName>Collaboration and License Agreements - Takeda Pharmaceutical Company Limited (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - Collaboration and License Agreements - Amgen, Inc (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails</Role>
      <ShortName>Collaboration and License Agreements - Amgen, Inc (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - Collaboration and License Agreements - Sarepta Therapeutics, Inc. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails</Role>
      <ShortName>Collaboration and License Agreements - Sarepta Therapeutics, Inc. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - Collaboration and License Agreements - Sarepta Therapeutics, Inc. Consideration Components (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncConsiderationComponentsDetails</Role>
      <ShortName>Collaboration and License Agreements - Sarepta Therapeutics, Inc. Consideration Components (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - Balance Sheet Accounts - Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/BalanceSheetAccountsPropertyPlantandEquipmentDetails</Role>
      <ShortName>Balance Sheet Accounts - Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - Balance Sheet Accounts - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/BalanceSheetAccountsNarrativeDetails</Role>
      <ShortName>Balance Sheet Accounts - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - Balance Sheet Accounts - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails</Role>
      <ShortName>Balance Sheet Accounts - Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - Investments - Schedule of Short-term, Long-term Investments and Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/InvestmentsScheduleofShorttermLongtermInvestmentsandMarketableSecuritiesDetails</Role>
      <ShortName>Investments - Schedule of Short-term, Long-term Investments and Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - Investments - Schedule of Contract Maturity of Available for Sale (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/InvestmentsScheduleofContractMaturityofAvailableforSaleDetails</Role>
      <ShortName>Investments - Schedule of Contract Maturity of Available for Sale (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets - Schedule of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9955538 - Disclosure - Intangible Assets - Schedule of Expected Future Amortization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofExpectedFutureAmortizationDetails</Role>
      <ShortName>Intangible Assets - Schedule of Expected Future Amortization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9955539 - Disclosure - Stockholders' Equity - Schedule of Shares of Common Stock and Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockholdersEquityScheduleofSharesofCommonStockandPreferredStockDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Shares of Common Stock and Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9955540 - Disclosure - Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9955541 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/CommitmentsandContingencies</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9955542 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9955543 - Disclosure - Leases - Schedule of Components of Lease Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/LeasesScheduleofComponentsofLeaseAssetsandLiabilitiesDetails</Role>
      <ShortName>Leases - Schedule of Components of Lease Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9955544 - Disclosure - Leases - Schedule of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails</Role>
      <ShortName>Leases - Schedule of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9955545 - Disclosure - Leases - Schedule of Cash Flow and Other Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/LeasesScheduleofCashFlowandOtherInformationRelatedtoLeasesDetails</Role>
      <ShortName>Leases - Schedule of Cash Flow and Other Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9955546 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9955547 - Disclosure - Stock-Based Compensation - Schedule of Granted and Outstanding Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofGrantedandOutstandingSharesDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Granted and Outstanding Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9955548 - Disclosure - Stock-Based Compensation - Schedule of Expenses Included in Operating Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofExpensesIncludedinOperatingExpensesDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Expenses Included in Operating Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9955549 - Disclosure - Stock-Based Compensation - Schedule of Information about Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofInformationaboutStockOptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Information about Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9955550 - Disclosure - Stock-Based Compensation - Schedule of RSUs Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofRSUsActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of RSUs Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9955551 - Disclosure - Fair Value Measurements - Schedule of Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9955552 - Disclosure - Liability Related to the Sale of Future Royalties - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails</Role>
      <ShortName>Liability Related to the Sale of Future Royalties - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9955553 - Disclosure - Liability Related to the Sale of Future Royalties - Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesActivityDetails</Role>
      <ShortName>Liability Related to the Sale of Future Royalties - Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9955554 - Disclosure - Financing Agreement - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails</Role>
      <ShortName>Financing Agreement - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9955555 - Disclosure - Financing Agreement - Schedule of Outstanding Balance of Credit Facility (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/FinancingAgreementScheduleofOutstandingBalanceofCreditFacilityDetails</Role>
      <ShortName>Financing Agreement - Schedule of Outstanding Balance of Credit Facility (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9955556 - Disclosure - Financing Agreement - Schedule of Interest Expense Recognized Related to Credit Facility (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/FinancingAgreementScheduleofInterestExpenseRecognizedRelatedtoCreditFacilityDetails</Role>
      <ShortName>Financing Agreement - Schedule of Interest Expense Recognized Related to Credit Facility (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9955557 - Disclosure - Financing Agreement - Principal Repayment Related to Credit Facility (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails</Role>
      <ShortName>Financing Agreement - Principal Repayment Related to Credit Facility (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9955558 - Disclosure - Net (Loss) Income Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/NetLossIncomePerShareScheduleofBasicandDilutedNetLossPerShareDetails</Role>
      <ShortName>Net (Loss) Income Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/NetLossIncomePerShareTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9955559 - Disclosure - Net (Loss) Income Per Share - Schedule of Antidilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/NetLossIncomePerShareScheduleofAntidilutiveSecuritiesDetails</Role>
      <ShortName>Net (Loss) Income Per Share - Schedule of Antidilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/NetLossIncomePerShareTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9955560 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/IncomeTaxes</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="arwr-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9955561 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/SubsequentEvents</ParentRole>
      <Position>73</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="arwr-20250630.htm">arwr-20250630.htm</File>
    <File>arwr-20250630.xsd</File>
    <File>arwr-20250630_cal.xml</File>
    <File>arwr-20250630_def.xml</File>
    <File>arwr-20250630_lab.xml</File>
    <File>arwr-20250630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="853">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>97
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "arwr-20250630.htm": {
   "nsprefix": "arwr",
   "nsuri": "http://www.arrowheadresearch.com/20250630",
   "dts": {
    "inline": {
     "local": [
      "arwr-20250630.htm"
     ]
    },
    "schema": {
     "local": [
      "arwr-20250630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "arwr-20250630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "arwr-20250630_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "arwr-20250630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "arwr-20250630_pre.xml"
     ]
    }
   },
   "keyStandard": 266,
   "keyCustom": 71,
   "axisStandard": 24,
   "axisCustom": 0,
   "memberStandard": 38,
   "memberCustom": 38,
   "hidden": {
    "total": 5,
    "http://xbrl.sec.gov/dei/2025": 5
   },
   "contextCount": 320,
   "entityCount": 1,
   "segmentCount": 83,
   "elementCount": 646,
   "unitCount": 11,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 853,
    "http://xbrl.sec.gov/dei/2025": 30,
    "http://xbrl.sec.gov/ecd/2025": 4
   },
   "report": {
    "R1": {
     "role": "http://www.arrowheadresearch.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
     "longName": "9952151 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "9952152 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R4": {
     "role": "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome",
     "longName": "9952153 - Statement - Consolidated Statements of Operations and Comprehensive (Loss) Income",
     "shortName": "Consolidated Statements of Operations and Comprehensive (Loss) Income",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity",
     "longName": "9952154 - Statement - Consolidated Statements of Stockholders\u2019 Equity",
     "shortName": "Consolidated Statements of Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-47",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-54",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows",
     "longName": "9952155 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies",
     "longName": "9952156 - Disclosure - Organization and Significant Accounting Policies",
     "shortName": "Organization and Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreements",
     "longName": "9952157 - Disclosure - Collaboration and License Agreements",
     "shortName": "Collaboration and License Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.arrowheadresearch.com/role/BalanceSheetAccounts",
     "longName": "9952158 - Disclosure - Balance Sheet Accounts",
     "shortName": "Balance Sheet Accounts",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.arrowheadresearch.com/role/Investments",
     "longName": "9952159 - Disclosure - Investments",
     "shortName": "Investments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.arrowheadresearch.com/role/IntangibleAssets",
     "longName": "9952160 - Disclosure - Intangible Assets",
     "shortName": "Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.arrowheadresearch.com/role/StockholdersEquity",
     "longName": "9952161 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.arrowheadresearch.com/role/CommitmentsandContingencies",
     "longName": "9952162 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.arrowheadresearch.com/role/Leases",
     "longName": "9952163 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.arrowheadresearch.com/role/StockBasedCompensation",
     "longName": "9952164 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.arrowheadresearch.com/role/FairValueMeasurements",
     "longName": "9952165 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyalties",
     "longName": "9952166 - Disclosure - Liability Related to the Sale of Future Royalties",
     "shortName": "Liability Related to the Sale of Future Royalties",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "arwr:LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "arwr:LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.arrowheadresearch.com/role/FinancingAgreement",
     "longName": "9952167 - Disclosure - Financing Agreement",
     "shortName": "Financing Agreement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.arrowheadresearch.com/role/NetLossIncomePerShare",
     "longName": "9952168 - Disclosure - Net (Loss) Income Per Share",
     "shortName": "Net (Loss) Income Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.arrowheadresearch.com/role/IncomeTaxes",
     "longName": "9952169 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.arrowheadresearch.com/role/SubsequentEvents",
     "longName": "9952170 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies",
     "longName": "9955511 - Disclosure - Organization and Significant Accounting Policies (Policies)",
     "shortName": "Organization and Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesTables",
     "longName": "9955512 - Disclosure - Organization and Significant Accounting Policies (Tables)",
     "shortName": "Organization and Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "arwr:ScheduleOfCurrentProductsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "arwr:ScheduleOfCurrentProductsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTables",
     "longName": "9955513 - Disclosure - Collaboration and License Agreements (Tables)",
     "shortName": "Collaboration and License Agreements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.arrowheadresearch.com/role/BalanceSheetAccountsTables",
     "longName": "9955514 - Disclosure - Balance Sheet Accounts (Tables)",
     "shortName": "Balance Sheet Accounts (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.arrowheadresearch.com/role/InvestmentsTables",
     "longName": "9955515 - Disclosure - Investments (Tables)",
     "shortName": "Investments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.arrowheadresearch.com/role/IntangibleAssetsTables",
     "longName": "9955516 - Disclosure - Intangible Assets (Tables)",
     "shortName": "Intangible Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.arrowheadresearch.com/role/StockholdersEquityTables",
     "longName": "9955517 - Disclosure - Stockholders' Equity (Tables)",
     "shortName": "Stockholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.arrowheadresearch.com/role/LeasesTables",
     "longName": "9955518 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.arrowheadresearch.com/role/StockBasedCompensationTables",
     "longName": "9955519 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.arrowheadresearch.com/role/FairValueMeasurementsTables",
     "longName": "9955520 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesTables",
     "longName": "9955521 - Disclosure - Liability Related to the Sale of Future Royalties (Tables)",
     "shortName": "Liability Related to the Sale of Future Royalties (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "arwr:ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "arwr:ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.arrowheadresearch.com/role/FinancingAgreementTables",
     "longName": "9955522 - Disclosure - Financing Agreement (Tables)",
     "shortName": "Financing Agreement (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.arrowheadresearch.com/role/NetLossIncomePerShareTables",
     "longName": "9955523 - Disclosure - Net (Loss) Income Per Share (Tables)",
     "shortName": "Net (Loss) Income Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails",
     "longName": "9955524 - Disclosure - Organization and Significant Accounting Policies - Narrative (Details)",
     "shortName": "Organization and Significant Accounting Policies - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "arwr:IncreaseDecreaseInCashAndInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails",
     "longName": "9955525 - Disclosure - Collaboration and License Agreements - Revenue (Details)",
     "shortName": "Collaboration and License Agreements - Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-93",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsReceivablesandContractLiabilitiesDetails",
     "longName": "9955526 - Disclosure - Collaboration and License Agreements - Receivables and Contract Liabilities (Details)",
     "shortName": "Collaboration and License Agreements - Receivables and Contract Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AccountsReceivableNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AccountsReceivableNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedGSKDetails",
     "longName": "9955527 - Disclosure - Collaboration and License Agreements - GlaxoSmithKline Intellectual Property (No. 3) Limited (\u201cGSK\u201d) (Details)",
     "shortName": "Collaboration and License Agreements - GlaxoSmithKline Intellectual Property (No. 3) Limited (\u201cGSK\u201d) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-105",
      "name": "arwr:InitialTransactionPrice",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
     "longName": "9955528 - Disclosure - Collaboration and License Agreements - Takeda Pharmaceutical Company Limited (Details)",
     "shortName": "Collaboration and License Agreements - Takeda Pharmaceutical Company Limited (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "arwr:DevelopmentRegulatoryAndSalesMilestonesPayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-114",
      "name": "arwr:NumberOfDistinctBundle",
      "unitRef": "bundle",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
     "longName": "9955529 - Disclosure - Collaboration and License Agreements - Amgen, Inc (Details)",
     "shortName": "Collaboration and License Agreements - Amgen, Inc (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-119",
      "name": "arwr:NumberOfAgreements",
      "unitRef": "agreement",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails",
     "longName": "9955530 - Disclosure - Collaboration and License Agreements - Sarepta Therapeutics, Inc. (Details)",
     "shortName": "Collaboration and License Agreements - Sarepta Therapeutics, Inc. (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-129",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncConsiderationComponentsDetails",
     "longName": "9955531 - Disclosure - Collaboration and License Agreements - Sarepta Therapeutics, Inc. Consideration Components (Details)",
     "shortName": "Collaboration and License Agreements - Sarepta Therapeutics, Inc. Consideration Components (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-124",
      "name": "arwr:ProceedsFromCollaborationArrangements",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-127",
      "name": "arwr:CollaborationArrangementVariableConsideration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.arrowheadresearch.com/role/BalanceSheetAccountsPropertyPlantandEquipmentDetails",
     "longName": "9955532 - Disclosure - Balance Sheet Accounts - Property, Plant and Equipment (Details)",
     "shortName": "Balance Sheet Accounts - Property, Plant and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.arrowheadresearch.com/role/BalanceSheetAccountsNarrativeDetails",
     "longName": "9955533 - Disclosure - Balance Sheet Accounts - Narrative (Details)",
     "shortName": "Balance Sheet Accounts - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails",
     "longName": "9955534 - Disclosure - Balance Sheet Accounts - Accrued Expenses (Details)",
     "shortName": "Balance Sheet Accounts - Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "arwr:AccruedResearchAndDevelopmentExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "arwr:AccruedResearchAndDevelopmentExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.arrowheadresearch.com/role/InvestmentsScheduleofShorttermLongtermInvestmentsandMarketableSecuritiesDetails",
     "longName": "9955535 - Disclosure - Investments - Schedule of Short-term, Long-term Investments and Marketable Securities (Details)",
     "shortName": "Investments - Schedule of Short-term, Long-term Investments and Marketable Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.arrowheadresearch.com/role/InvestmentsScheduleofContractMaturityofAvailableforSaleDetails",
     "longName": "9955536 - Disclosure - Investments - Schedule of Contract Maturity of Available for Sale (Details)",
     "shortName": "Investments - Schedule of Contract Maturity of Available for Sale (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails",
     "longName": "9955537 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details)",
     "shortName": "Intangible Assets - Schedule of Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "us-gaap:AmortizationOfIntangibleAssets",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofExpectedFutureAmortizationDetails",
     "longName": "9955538 - Disclosure - Intangible Assets - Schedule of Expected Future Amortization (Details)",
     "shortName": "Intangible Assets - Schedule of Expected Future Amortization (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.arrowheadresearch.com/role/StockholdersEquityScheduleofSharesofCommonStockandPreferredStockDetails",
     "longName": "9955539 - Disclosure - Stockholders' Equity - Schedule of Shares of Common Stock and Preferred Stock (Details)",
     "shortName": "Stockholders' Equity - Schedule of Shares of Common Stock and Preferred Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails",
     "longName": "9955540 - Disclosure - Stockholders' Equity - Narrative (Details)",
     "shortName": "Stockholders' Equity - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-172",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesDetails",
     "longName": "9955541 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails",
     "longName": "9955542 - Disclosure - Leases - Narrative (Details)",
     "shortName": "Leases - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ShortTermLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:ShortTermLeaseCost",
       "us-gaap:ShortTermLeaseCost",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ShortTermLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:ShortTermLeaseCost",
       "us-gaap:ShortTermLeaseCost",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.arrowheadresearch.com/role/LeasesScheduleofComponentsofLeaseAssetsandLiabilitiesDetails",
     "longName": "9955543 - Disclosure - Leases - Schedule of Components of Lease Assets and Liabilities (Details)",
     "shortName": "Leases - Schedule of Components of Lease Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:LeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.arrowheadresearch.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails",
     "longName": "9955544 - Disclosure - Leases - Schedule of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Details)",
     "shortName": "Leases - Schedule of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.arrowheadresearch.com/role/LeasesScheduleofCashFlowandOtherInformationRelatedtoLeasesDetails",
     "longName": "9955545 - Disclosure - Leases - Schedule of Cash Flow and Other Information Related to Leases (Details)",
     "shortName": "Leases - Schedule of Cash Flow and Other Information Related to Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "arwr:OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "arwr:OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
     "longName": "9955546 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-224",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofGrantedandOutstandingSharesDetails",
     "longName": "9955547 - Disclosure - Stock-Based Compensation - Schedule of Granted and Outstanding Shares (Details)",
     "shortName": "Stock-Based Compensation - Schedule of Granted and Outstanding Shares (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofExpensesIncludedinOperatingExpensesDetails",
     "longName": "9955548 - Disclosure - Stock-Based Compensation - Schedule of Expenses Included in Operating Expenses (Details)",
     "shortName": "Stock-Based Compensation - Schedule of Expenses Included in Operating Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-191",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofInformationaboutStockOptionsDetails",
     "longName": "9955549 - Disclosure - Stock-Based Compensation - Schedule of Information about Stock Options (Details)",
     "shortName": "Stock-Based Compensation - Schedule of Information about Stock Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofRSUsActivityDetails",
     "longName": "9955550 - Disclosure - Stock-Based Compensation - Schedule of RSUs Activity (Details)",
     "shortName": "Stock-Based Compensation - Schedule of RSUs Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-222",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-223",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.arrowheadresearch.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
     "longName": "9955551 - Disclosure - Fair Value Measurements - Schedule of Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "shortName": "Fair Value Measurements - Schedule of Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-246",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails",
     "longName": "9955552 - Disclosure - Liability Related to the Sale of Future Royalties - Narrative (Details)",
     "shortName": "Liability Related to the Sale of Future Royalties - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "arwr:MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "arwr:ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-284",
      "name": "arwr:UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesActivityDetails",
     "longName": "9955553 - Disclosure - Liability Related to the Sale of Future Royalties - Activity (Details)",
     "shortName": "Liability Related to the Sale of Future Royalties - Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "arwr:RoyaltiesLiabilityNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-289",
      "name": "arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "arwr:ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails",
     "longName": "9955554 - Disclosure - Financing Agreement - Narrative (Details)",
     "shortName": "Financing Agreement - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RepaymentsOfLinesOfCredit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-291",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.arrowheadresearch.com/role/FinancingAgreementScheduleofOutstandingBalanceofCreditFacilityDetails",
     "longName": "9955555 - Disclosure - Financing Agreement - Schedule of Outstanding Balance of Credit Facility (Details)",
     "shortName": "Financing Agreement - Schedule of Outstanding Balance of Credit Facility (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LinesOfCreditCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-305",
      "name": "us-gaap:DeferredFinanceCostsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.arrowheadresearch.com/role/FinancingAgreementScheduleofInterestExpenseRecognizedRelatedtoCreditFacilityDetails",
     "longName": "9955556 - Disclosure - Financing Agreement - Schedule of Interest Expense Recognized Related to Credit Facility (Details)",
     "shortName": "Financing Agreement - Schedule of Interest Expense Recognized Related to Credit Facility (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-306",
      "name": "us-gaap:AmortizationOfFinancingCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "arwr:SummaryOfInterestExpenseRecognizedRelatedToCreditFacilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-306",
      "name": "us-gaap:AmortizationOfFinancingCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "arwr:SummaryOfInterestExpenseRecognizedRelatedToCreditFacilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails",
     "longName": "9955557 - Disclosure - Financing Agreement - Principal Repayment Related to Credit Facility (Details)",
     "shortName": "Financing Agreement - Principal Repayment Related to Credit Facility (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-299",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-299",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.arrowheadresearch.com/role/NetLossIncomePerShareScheduleofBasicandDilutedNetLossPerShareDetails",
     "longName": "9955558 - Disclosure - Net (Loss) Income Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details)",
     "shortName": "Net (Loss) Income Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.arrowheadresearch.com/role/NetLossIncomePerShareScheduleofAntidilutiveSecuritiesDetails",
     "longName": "9955559 - Disclosure - Net (Loss) Income Per Share - Schedule of Antidilutive Securities (Details)",
     "shortName": "Net (Loss) Income Per Share - Schedule of Antidilutive Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.arrowheadresearch.com/role/IncomeTaxesDetails",
     "longName": "9955560 - Disclosure - Income Taxes (Details)",
     "shortName": "Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R73": {
     "role": "http://www.arrowheadresearch.com/role/SubsequentEventsDetails",
     "longName": "9955561 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-89",
      "name": "arwr:FuturePotentialMilestonePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-320",
      "name": "arwr:InitialTransactionPrice",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250630.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r836"
     ]
    },
    "us-gaap_AccountsReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableNet",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsReceivablesandContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivables included in accounts receivable",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business."
       }
      }
     },
     "auth_ref": [
      "r673",
      "r725",
      "r856",
      "r1101",
      "r1102"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "arwr_AccruedCapitalExpenditureCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "AccruedCapitalExpenditureCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued capital expenditures",
        "label": "Accrued Capital Expenditure, Current",
        "documentation": "Accrued Capital Expenditure, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued research and development expenses; co-development",
        "label": "Accrued Research And Development Co-Development Expense, Current",
        "documentation": "Accrued Research And Development Co-Development Expense, Current"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_AccruedResearchAndDevelopmentExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "AccruedResearchAndDevelopmentExpenseCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued research and development expenses",
        "label": "Accrued Research And Development Expense, Current",
        "documentation": "Accrued Research And Development Expense, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsPropertyPlantandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Accumulated depreciation and amortization",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r123",
      "r616"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r16",
      "r65",
      "r131",
      "r612",
      "r636",
      "r637",
      "r1069"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r8",
      "r16",
      "r449",
      "r452",
      "r520",
      "r632",
      "r633",
      "r972",
      "r973",
      "r974",
      "r986",
      "r987",
      "r988",
      "r989"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "arwr_AdditionalCashReceivableUnderCollaborationAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "AdditionalCashReceivableUnderCollaborationAgreement",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncConsiderationComponentsDetails": {
       "parentTag": "arwr_CollaborationArrangementFixedConsideration",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncConsiderationComponentsDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Annual fees",
        "label": "Additional Cash Receivable Under Collaboration Agreement",
        "documentation": "Additional Cash Receivable Under Collaboration Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r650",
      "r986",
      "r987",
      "r988",
      "r989",
      "r1070",
      "r1136"
     ]
    },
    "arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional remaining development regulatory and sales milestones payments",
        "label": "Additional Remaining Development Regulatory And Sales Milestones Payments",
        "documentation": "Additional remaining development regulatory and sales milestones payments."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of pre-funded warrants",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r33",
      "r87"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net income (loss) to net cash flow from operating activities",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r872",
      "r882",
      "r892",
      "r924"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r875",
      "r885",
      "r895",
      "r927"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r876",
      "r886",
      "r896",
      "r920",
      "r928",
      "r932",
      "r940"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofExpensesIncludedinOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "verboseLabel": "Total",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r405",
      "r406"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_AmgenIncorporatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "AmgenIncorporatedMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amgen Incorporated",
        "label": "Amgen Incorporated [Member]",
        "documentation": "Amgen Incorporated."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/FinancingAgreementScheduleofInterestExpenseRecognizedRelatedtoCreditFacilityDetails": {
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementScheduleofInterestExpenseRecognizedRelatedtoCreditFacilityDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementScheduleofOutstandingBalanceofCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated accretion of the MOIC Payment",
        "verboseLabel": "Accretion of the MOIC Payment",
        "label": "Amortization of Debt Discount (Premium)",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r72",
      "r315",
      "r1083"
     ]
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/FinancingAgreementScheduleofInterestExpenseRecognizedRelatedtoCreditFacilityDetails": {
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementScheduleofInterestExpenseRecognizedRelatedtoCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt issuance costs",
        "label": "Amortization of Debt Issuance Costs",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r315",
      "r977",
      "r1083"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization expense",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r147",
      "r265",
      "r272",
      "r742",
      "r747",
      "r748",
      "r750",
      "r752"
     ]
    },
    "arwr_AmountIntendsToInvestForBuildoutOfFacilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "AmountIntendsToInvestForBuildoutOfFacilities",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount intends to invest for buildout of the facilities",
        "label": "Amount Intends To Invest For Buildout Of Facilities",
        "documentation": "Amount intends to invest for buildout of facilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.arrowheadresearch.com/role/NetLossIncomePerShareScheduleofAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potentially dilutive securities excluded from computation of diluted earnings per share (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/NetLossIncomePerShareScheduleofAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/NetLossIncomePerShareScheduleofAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/NetLossIncomePerShareScheduleofAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "us-gaap_AreaOfLand": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AreaOfLand",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Planned area of the site (in sq ft)",
        "label": "Area of Land",
        "documentation": "Area of land held."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedGSKDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncConsiderationComponentsDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "us-gaap_AssetAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Acquisition",
        "label": "Asset Acquisition [Axis]",
        "documentation": "Information by asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r640",
      "r1063"
     ]
    },
    "us-gaap_AssetAcquisitionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Acquisition",
        "label": "Asset Acquisition [Domain]",
        "documentation": "Asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r640",
      "r1063"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r107",
      "r126",
      "r156",
      "r158",
      "r159",
      "r195",
      "r200",
      "r207",
      "r208",
      "r247",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r437",
      "r441",
      "r490",
      "r600",
      "r601",
      "r609",
      "r678",
      "r759",
      "r760",
      "r768",
      "r836",
      "r850",
      "r851",
      "r863",
      "r1023",
      "r1024",
      "r1089"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsAndLiabilitiesLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAndLiabilitiesLesseeAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesScheduleofComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Assets and Liabilities",
        "label": "Assets and Liabilities, Lessee [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r134",
      "r156",
      "r158",
      "r159",
      "r247",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r437",
      "r441",
      "r490",
      "r836",
      "r1023",
      "r1024",
      "r1089"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total financial assets",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r464",
      "r465",
      "r823"
     ]
    },
    "arwr_AtTheMarketAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "AtTheMarketAgreementMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At The Market Agreement",
        "label": "At The Market Agreement [Member]",
        "documentation": "At-the-market agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsScheduleofContractMaturityofAvailableforSaleDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsScheduleofContractMaturityofAvailableforSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Within one year",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Remainder of Fiscal Year",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.arrowheadresearch.com/role/InvestmentsScheduleofContractMaturityofAvailableforSaleDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.arrowheadresearch.com/role/InvestmentsScheduleofContractMaturityofAvailableforSaleDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Available-for-sale securities",
        "totalLabel": "Total",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r255",
      "r464",
      "r485",
      "r486",
      "r487",
      "r488",
      "r597",
      "r740",
      "r823",
      "r826",
      "r833",
      "r997",
      "r1074",
      "r1075",
      "r1076"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsScheduleofShorttermLongtermInvestmentsandMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/InvestmentsScheduleofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Available-for-sale securities, at fair value",
        "verboseLabel": "Current investments, Fair Value",
        "label": "Debt Securities, Available-for-Sale, Current",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r255"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofGrantedandOutstandingSharesDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofRSUsActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "us-gaap_BankTimeDepositsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BankTimeDepositsMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term deposit",
        "label": "Bank Time Deposits [Member]",
        "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_BuildingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BuildingMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsNarrativeDetails",
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsPropertyPlantandEquipmentDetails",
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Buildings",
        "label": "Building [Member]",
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "stpr_CA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2025",
     "localname": "CA",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "California",
        "label": "CALIFORNIA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital expenditures included in accrued expenses",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r24"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Axis]",
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r487",
      "r488",
      "r1072",
      "r1073"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, cash equivalents and restricted cash",
        "periodStartLabel": "BEGINNING OF PERIOD",
        "periodEndLabel": "END OF PERIOD",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r77",
      "r155"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH:",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation",
        "documentation": "Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r77"
     ]
    },
    "arwr_CashFlowNoncashInvestingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "CashFlowNoncashInvestingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of non-cash investing activities:",
        "label": "Cash Flow, Noncash Investing Activities Disclosure [Abstract]",
        "documentation": "Cash Flow, Noncash Investing Activities Disclosure"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashFlowOperatingActivitiesLesseeAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesScheduleofCashFlowandOtherInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:",
        "label": "Cash Flow, Operating Activities, Lessee [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesScheduleofCashFlowandOtherInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash received for amounts included in the measurement of lease liabilities:",
        "label": "Cash Flow, Operating Activities, Lessee, Cash Received For Amounts Included In Measurement Of Lease Liabilities [Abstract]",
        "documentation": "Cash Flow, Operating Activities, Lessee, Cash Received For Amounts Included In Measurement Of Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_CashReceivableUnderCollaborationAgreementAnnualInstallments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "CashReceivableUnderCollaborationAgreementAnnualInstallments",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual installment",
        "label": "Cash Receivable Under Collaboration Agreement, Annual Installments",
        "documentation": "Cash Receivable Under Collaboration Agreement, Annual Installments"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual installments period",
        "label": "Cash Receivable Under Collaboration Agreement, Annual Installments Period",
        "documentation": "Cash Receivable Under Collaboration Agreement, Annual Installments Period"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class Of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r129",
      "r130",
      "r197",
      "r324",
      "r330",
      "r331",
      "r332",
      "r334",
      "r337",
      "r342",
      "r344",
      "r447",
      "r642",
      "r643",
      "r644",
      "r645",
      "r769",
      "r950",
      "r979",
      "r981"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant exercise price (in dollars per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r161",
      "r345"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of securities called by warrants (in shares)",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "arwr_ClassOfWarrantOrRightNumberOfWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "ClassOfWarrantOrRightNumberOfWarrantsExercised",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of warrants exercised (in shares)",
        "label": "Class Of Warrant Or Right, Number Of Warrants Exercised",
        "documentation": "Class Of Warrant Or Right, Number Of Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants purchase price (in dollars per share)",
        "label": "Class of Warrant or Right, Purchase Price of Warrants or Rights",
        "documentation": "Class of Warrant or Right, Purchase Price of Warrants or Rights"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "arwr_CollaborationAndLicenseAgreementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "CollaborationAndLicenseAgreementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration And License Agreements [Abstract]",
        "label": "Collaboration And License Agreements [Abstract]",
        "documentation": "Collaboration and license agreements."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_CollaborationArrangementConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "CollaborationArrangementConsideration",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncConsiderationComponentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncConsiderationComponentsDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total transaction price",
        "totalLabel": "Total transaction price",
        "label": "Collaboration Arrangement, Consideration",
        "documentation": "Collaboration Arrangement, Consideration"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_CollaborationArrangementFixedConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "CollaborationArrangementFixedConsideration",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncConsiderationComponentsDetails": {
       "parentTag": "arwr_CollaborationArrangementConsideration",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncConsiderationComponentsDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed consideration",
        "totalLabel": "Fixed consideration",
        "label": "Collaboration Arrangement, Fixed Consideration",
        "documentation": "Collaboration Arrangement, Fixed Consideration"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_CollaborationArrangementTerminationNoticePeriodPriorToRegulatoryApproval": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "CollaborationArrangementTerminationNoticePeriodPriorToRegulatoryApproval",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration agreement termination notice period prior to any regulatory approval of a licensed product",
        "label": "Collaboration Arrangement, Termination Notice Period Prior To Regulatory Approval",
        "documentation": "Collaboration Arrangement, Termination Notice Period Prior To Regulatory Approval"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_CollaborationArrangementVariableConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "CollaborationArrangementVariableConsideration",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncConsiderationComponentsDetails": {
       "parentTag": "arwr_CollaborationArrangementConsideration",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncConsiderationComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated variable consideration",
        "label": "Collaboration Arrangement, Variable Consideration",
        "documentation": "Collaboration Arrangement, Variable Consideration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration and License Agreements",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r433",
      "r434"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedGSKDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncConsiderationComponentsDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "arwr_ColoradoOwnerLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "ColoradoOwnerLLCMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Colorado Owner, LLC",
        "label": "Colorado Owner L L C [Member]",
        "documentation": "Colorado Owner, LLC."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_CommercialMilestonePaymentsAtFirstCommercialSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "CommercialMilestonePaymentsAtFirstCommercialSale",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedGSKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial milestone payments at first commercial sale",
        "label": "Commercial Milestone Payments At First Commercial Sale",
        "documentation": "Commercial milestone payments at first commercial sale."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_CommercialNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "CommercialNotesMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial notes",
        "label": "Commercial Notes [Member]",
        "documentation": "Commercial Notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 7)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r97",
      "r610",
      "r664"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r283",
      "r284",
      "r726",
      "r1016",
      "r1021"
     ]
    },
    "arwr_CommitmentsCapitalExpendituresIncurredToDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "CommitmentsCapitalExpendituresIncurredToDate",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital expenditures incurred",
        "label": "Commitments, Capital Expenditures Incurred To Date",
        "documentation": "Commitments, Capital Expenditures Incurred To Date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares reserve for issuance (in shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "arwr_CommonStockCapitalSharesValueReservedForFutureIssuance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "CommonStockCapitalSharesValueReservedForFutureIssuance",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock shares value reserved for future issuance",
        "label": "Common Stock Capital Shares Value Reserved For Future Issuance",
        "documentation": "Common stock, capital shares value reserved for future issuance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r853",
      "r854",
      "r855",
      "r857",
      "r858",
      "r859",
      "r860",
      "r986",
      "r987",
      "r989",
      "r1070",
      "r1133",
      "r1136"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.arrowheadresearch.com/role/StockholdersEquityScheduleofSharesofCommonStockandPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.arrowheadresearch.com/role/StockholdersEquityScheduleofSharesofCommonStockandPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r665"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.arrowheadresearch.com/role/StockholdersEquityScheduleofSharesofCommonStockandPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.arrowheadresearch.com/role/StockholdersEquityScheduleofSharesofCommonStockandPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r59",
      "r665",
      "r684",
      "r1136",
      "r1137"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.001 par value: Authorized 290,000 shares; issued and outstanding 138,144 and 124,376 shares",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r322",
      "r327",
      "r611",
      "r836"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss), net of tax:",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive (loss) income",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r92",
      "r139",
      "r141",
      "r145",
      "r598",
      "r624"
     ]
    },
    "arwr_ComputerAndSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "ComputerAndSoftwareMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computers and software",
        "label": "Computer And Software [Member]",
        "documentation": "Computer And Software"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsNarrativeDetails",
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsPropertyPlantandEquipmentDetails",
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction in progress",
        "label": "Construction in Progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_ConstructionInProgressReclassifiedToBuildingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "ConstructionInProgressReclassifiedToBuildingMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction In Progress Reclassified To Building",
        "label": "Construction In Progress Reclassified To Building [Member]",
        "documentation": "Construction In Progress Reclassified To Building"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_ConstructionInProgressReclassifiedToManufacturingEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "ConstructionInProgressReclassifiedToManufacturingEquipmentMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction In Progress Reclassified To Manufacturing Equipment",
        "label": "Construction In Progress Reclassified To Manufacturing Equipment [Member]",
        "documentation": "Construction In Progress Reclassified To Manufacturing Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Receivables and Contract Liabilities",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability."
       }
      }
     },
     "auth_ref": [
      "r1026"
     ]
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerAssetNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedGSKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract assets",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r349",
      "r350",
      "r354"
     ]
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsReceivablesandContractLiabilitiesDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract liabilities included in deferred revenue",
        "label": "Contract with Customer, Liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r348",
      "r350",
      "r354"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedGSKDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r348",
      "r350",
      "r354"
     ]
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate debt securities",
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r778",
      "r780",
      "r782",
      "r823",
      "r837",
      "r852",
      "r1130"
     ]
    },
    "arwr_CorporateHeadquartersInPasadenaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "CorporateHeadquartersInPasadenaMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate Headquarters In Pasadena",
        "label": "Corporate Headquarters In Pasadena [Member]",
        "documentation": "Corporate Headquarters in Pasadena"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedGSKDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncConsiderationComponentsDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r156",
      "r163",
      "r164",
      "r303",
      "r332",
      "r521",
      "r541",
      "r608",
      "r744",
      "r745",
      "r746",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r1065",
      "r1066",
      "r1067",
      "r1068"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementScheduleofInterestExpenseRecognizedRelatedtoCreditFacilityDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementScheduleofOutstandingBalanceofCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Axis]",
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r1022"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementScheduleofInterestExpenseRecognizedRelatedtoCreditFacilityDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementScheduleofOutstandingBalanceofCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Domain]",
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r1022"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementScheduleofInterestExpenseRecognizedRelatedtoCreditFacilityDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementScheduleofOutstandingBalanceofCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r49",
      "r50",
      "r95",
      "r96",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r834",
      "r979",
      "r980",
      "r982",
      "r985",
      "r1017",
      "r1018",
      "r1019",
      "r1082",
      "r1084",
      "r1098"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis spread on variable rate",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementScheduleofOutstandingBalanceofCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Initial Term Loan",
        "totalLabel": "Total",
        "label": "Long-Term Debt, Gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r96",
      "r317"
     ]
    },
    "arwr_DebtInstrumentCovenantMarketCapitalizationThreshold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "DebtInstrumentCovenantMarketCapitalizationThreshold",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market capitalization threshold",
        "label": "Debt Instrument, Covenant, Market Capitalization, Threshold",
        "documentation": "Debt Instrument, Covenant, Market Capitalization, Threshold"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_DebtInstrumentCovenantMinimumLiquidityIfCapitalizationIsAboveThreshold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "DebtInstrumentCovenantMinimumLiquidityIfCapitalizationIsAboveThreshold",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, covenant, minimum liquidity cash, cash equivalents and investments",
        "label": "Debt Instrument, Covenant, Minimum Liquidity If Capitalization Is Above Threshold",
        "documentation": "Debt Instrument, Covenant, Minimum Liquidity If Capitalization Is Above Threshold"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_DebtInstrumentCovenantMultipleOfInvestCapital": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "DebtInstrumentCovenantMultipleOfInvestCapital",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Multiple of invested capital rate",
        "label": "Debt Instrument, Covenant, Multiple Of Invest Capital",
        "documentation": "Debt Instrument, Covenant, Multiple Of Invest Capital"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r301"
     ]
    },
    "arwr_DebtInstrumentMultipleOfInvestmentCapitalExpectedToBeAppliedToPrincipalUponRepayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "DebtInstrumentMultipleOfInvestmentCapitalExpectedToBeAppliedToPrincipalUponRepayment",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MOIC payments expected to be applied to principal upon repayment",
        "label": "Debt Instrument, Multiple Of Investment Capital Expected To Be Applied To Principal Upon Repayment",
        "documentation": "Debt Instrument, Multiple Of Investment Capital Expected To Be Applied To Principal Upon Repayment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementScheduleofInterestExpenseRecognizedRelatedtoCreditFacilityDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementScheduleofOutstandingBalanceofCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r834",
      "r979",
      "r980",
      "r982",
      "r985",
      "r1017",
      "r1018",
      "r1019",
      "r1082",
      "r1084",
      "r1098"
     ]
    },
    "arwr_DebtInstrumentPrepaymentPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "DebtInstrumentPrepaymentPercentage",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, prepayment percentage",
        "label": "Debt Instrument, Prepayment, Percentage",
        "documentation": "Debt Instrument, Prepayment, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentTerm",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument term",
        "label": "Debt Instrument, Term",
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsScheduleofShorttermLongtermInvestmentsandMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsScheduleofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current investments, Gross Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, Current",
        "documentation": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, Current"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsScheduleofShorttermLongtermInvestmentsandMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsScheduleofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Current investments, Gross Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Current",
        "documentation": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsScheduleofShorttermLongtermInvestmentsandMarketableSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsScheduleofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Current investments, Adjusted Basis",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Current",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r998"
     ]
    },
    "arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsScheduleofContractMaturityofAvailableforSaleDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsScheduleofContractMaturityofAvailableforSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "After one to two years",
        "label": "Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, After Year One Through Two",
        "documentation": "Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, After Year One Through Two"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsScheduleofContractMaturityofAvailableforSaleDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsScheduleofContractMaturityofAvailableforSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "After two to three years",
        "label": "Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, After Year Two Through Three",
        "documentation": "Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, After Year Two Through Three"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsScheduleofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Available-for-sale securities",
        "label": "Debt Securities [Member]",
        "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r855",
      "r1138"
     ]
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredFinanceCostsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementScheduleofOutstandingBalanceofCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: Unamortized debt issuance costs",
        "label": "Debt Issuance Costs, Gross",
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r1082",
      "r1084"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r27"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization expense for property and equipment",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r148",
      "r195",
      "r204",
      "r208",
      "r747",
      "r759",
      "r760"
     ]
    },
    "arwr_DevelopmentAndSalesMilestonesPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "DevelopmentAndSalesMilestonesPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedGSKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development and sales milestone payments",
        "label": "Development And Sales Milestones Payments",
        "documentation": "Development And Sales Milestones Payments"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_DevelopmentMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "DevelopmentMilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedGSKDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development milestone payments",
        "label": "Development Milestone Payments",
        "documentation": "Development Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_DevelopmentRegulatoryAndSalesMilestonesPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "DevelopmentRegulatoryAndSalesMilestonesPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development regulatory and sales milestones payments",
        "label": "Development Regulatory And Sales Milestones Payments",
        "documentation": "Development regulatory and sales milestones payments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Line Items]",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r353",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r353",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenue",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r1027"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r371",
      "r400",
      "r401",
      "r403",
      "r784"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_DrugManufacturingFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "DrugManufacturingFacilityMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Drug Manufacturing Facility",
        "label": "Drug Manufacturing Facility [Member]",
        "documentation": "Drug manufacturing facility."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome",
      "http://www.arrowheadresearch.com/role/NetLossIncomePerShareScheduleofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in dollars per share)",
        "verboseLabel": "Basic net (loss) income per share (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r146",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r184",
      "r186",
      "r188",
      "r189",
      "r190",
      "r194",
      "r320",
      "r404",
      "r429",
      "r432",
      "r461",
      "r462",
      "r599",
      "r625",
      "r756"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome",
      "http://www.arrowheadresearch.com/role/NetLossIncomePerShareScheduleofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in dollars per share)",
        "verboseLabel": "Diluted net (loss) income per share (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r146",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r186",
      "r188",
      "r189",
      "r190",
      "r194",
      "r320",
      "r404",
      "r429",
      "r432",
      "r461",
      "r462",
      "r599",
      "r625",
      "r756"
     ]
    },
    "us-gaap_EarningsPerShareReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareReconciliationAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net (loss) income per share attributable to Arrowhead Pharmaceuticals, Inc.:",
        "label": "Earnings Per Share Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/NetLossIncomePerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net (Loss) Income Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r191",
      "r192",
      "r193"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate on cash, cash equivalents and restricted cash",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued payroll and benefits",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofExpensesIncludedinOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1057"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average period to recognize pre-tax compensation expense",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized pre-tax compensation expense",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r1058"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/NetLossIncomePerShareScheduleofAntidilutiveSecuritiesDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056"
     ]
    },
    "arwr_EnrollmentRelatedMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "EnrollmentRelatedMilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Enrollment related milestone payments",
        "label": "Enrollment Related Milestone Payments",
        "documentation": "Enrollment Related Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r945"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r945"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r945"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity [Abstract]",
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r112",
      "r114",
      "r115",
      "r142",
      "r143",
      "r144",
      "r166",
      "r167",
      "r168",
      "r170",
      "r177",
      "r179",
      "r181",
      "r196",
      "r248",
      "r249",
      "r279",
      "r319",
      "r346",
      "r404",
      "r419",
      "r420",
      "r426",
      "r427",
      "r428",
      "r430",
      "r431",
      "r432",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r460",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r502",
      "r505",
      "r520",
      "r622",
      "r632",
      "r633",
      "r634",
      "r650",
      "r703"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r872",
      "r882",
      "r892",
      "r924"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r869",
      "r879",
      "r889",
      "r921"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "arwr_FacilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "FacilitiesMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Facilities",
        "label": "Facilities [Member]",
        "documentation": "Facilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r464",
      "r465",
      "r475",
      "r823"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r464",
      "r465",
      "r475",
      "r823"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r463",
      "r465",
      "r466",
      "r467",
      "r468",
      "r474",
      "r475",
      "r477",
      "r486",
      "r528",
      "r529",
      "r530",
      "r740",
      "r764",
      "r765",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r823",
      "r826",
      "r833"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r464",
      "r465",
      "r466",
      "r468",
      "r823",
      "r1075",
      "r1078"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r466",
      "r470",
      "r472",
      "r473",
      "r474",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r596",
      "r823",
      "r827"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r356",
      "r361",
      "r362",
      "r465",
      "r475",
      "r486",
      "r528",
      "r740",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r823",
      "r833"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r356",
      "r361",
      "r362",
      "r364",
      "r465",
      "r466",
      "r475",
      "r486",
      "r529",
      "r740",
      "r764",
      "r765",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r823",
      "r833"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r465",
      "r466",
      "r467",
      "r468",
      "r475",
      "r486",
      "r530",
      "r740",
      "r764",
      "r765",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r823",
      "r826",
      "r833"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r464",
      "r465",
      "r466",
      "r468",
      "r823",
      "r1075",
      "r1078"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r463",
      "r465",
      "r466",
      "r467",
      "r468",
      "r474",
      "r475",
      "r477",
      "r486",
      "r528",
      "r529",
      "r530",
      "r740",
      "r764",
      "r765",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r823",
      "r826",
      "r833"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Measurements, Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r823",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1078"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.arrowheadresearch.com/role/InvestmentsScheduleofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r256",
      "r257",
      "r258",
      "r316",
      "r342",
      "r447",
      "r458",
      "r482",
      "r489",
      "r492",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r607",
      "r623",
      "r762",
      "r823",
      "r824",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r837",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1071",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080"
     ]
    },
    "arwr_FinancingAgreementInitialTermLoanInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "FinancingAgreementInitialTermLoanInterestMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementScheduleofOutstandingBalanceofCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing Agreement, Initial Term Loan Interest",
        "label": "Financing Agreement, Initial Term Loan Interest [Member]",
        "documentation": "Financing Agreement, Initial Term Loan Interest"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_FinancingAgreementInitialTermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "FinancingAgreementInitialTermLoanMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementScheduleofOutstandingBalanceofCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing Agreement, Initial Term Loan",
        "label": "Financing Agreement, Initial Term Loan [Member]",
        "documentation": "Financing Agreement, Initial Term Loan"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_FinancingAgreementMOICPaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "FinancingAgreementMOICPaymentMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing Agreement, MOIC Payment",
        "label": "Financing Agreement, MOIC Payment [Member]",
        "documentation": "Financing Agreement, MOIC Payment"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_FinancingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "FinancingAgreementMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementScheduleofInterestExpenseRecognizedRelatedtoCreditFacilityDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementScheduleofOutstandingBalanceofCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing Agreement",
        "label": "Financing Agreement [Member]",
        "documentation": "Financing Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofExpectedFutureAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofExpectedFutureAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2030 and thereafter",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Four",
        "documentation": "Finite-Lived Intangible Asset, Expected Amortization, after Year Four"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Useful Lives (in years)",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r261",
      "r271",
      "r742"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofExpectedFutureAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofExpectedFutureAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r739",
      "r742"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofExpectedFutureAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofExpectedFutureAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025 (remainder)",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r1139"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofExpectedFutureAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofExpectedFutureAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r739",
      "r742"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofExpectedFutureAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofExpectedFutureAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r739",
      "r742"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofExpectedFutureAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofExpectedFutureAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r739",
      "r742"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r266",
      "r267",
      "r268",
      "r270",
      "r271",
      "r274",
      "r275",
      "r560",
      "r561",
      "r640",
      "r739",
      "r742",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Carrying Amount",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r271",
      "r561",
      "r742"
     ]
    },
    "arwr_FiniteLivedIntangibleAssetsImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "FiniteLivedIntangibleAssetsImpairment",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment",
        "label": "Finite-Lived Intangible Assets, Impairment",
        "documentation": "Finite-Lived Intangible Assets, Impairment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite Lived Intangible Assets [Line Items]",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r271",
      "r274",
      "r275",
      "r277",
      "r560",
      "r739",
      "r742",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r266",
      "r267",
      "r268",
      "r270",
      "r271",
      "r274",
      "r275",
      "r640",
      "r739",
      "r742",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofExpectedFutureAmortizationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofExpectedFutureAmortizationDetails",
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Net Carrying Amount",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r560",
      "r1011"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r876",
      "r886",
      "r896",
      "r928"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r876",
      "r886",
      "r896",
      "r928"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r876",
      "r886",
      "r896",
      "r928"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r876",
      "r886",
      "r896",
      "r928"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r876",
      "r886",
      "r896",
      "r928"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_FuturePotentialMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "FuturePotentialMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future potential milestone payments",
        "label": "Future Potential Milestone Payments",
        "documentation": "Future Potential Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_GSKHBVAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "GSKHBVAgreementMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedGSKDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GSK-HBV Agreement",
        "label": "GSK-HBV Agreement [Member]",
        "documentation": "GSK-HBV Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_GSKHSDLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "GSKHSDLicenseAgreementMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedGSKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GSK-HSD License Agreement",
        "label": "GSK-HSD License Agreement [Member]",
        "documentation": "GSK-HSD License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r687"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesScheduleofComponentsofLeaseAssetsandLiabilitiesDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofExpensesIncludedinOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative expense",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "arwr_GlaxosmithklineIntellectualPropertyLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "GlaxosmithklineIntellectualPropertyLimitedMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedGSKDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GSK",
        "label": "Glaxosmithkline Intellectual Property Limited [Member]",
        "documentation": "Glaxosmithkline Intellectual Property Limited."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Short-term and Long-term Investments and Marketable Securities",
        "label": "Held To Maturity Securities And Marketable Securities Table [Table Text Block]",
        "documentation": "Held to maturity securities and marketable securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "(Loss) income before income tax expense and noncontrolling interest",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r100",
      "r106",
      "r600",
      "r602",
      "r618",
      "r749",
      "r751",
      "r753",
      "r758",
      "r759",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesScheduleofComponentsofLeaseAssetsandLiabilitiesDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofExpensesIncludedinOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r281",
      "r282",
      "r443",
      "r444",
      "r445",
      "r446",
      "r469",
      "r471",
      "r476",
      "r491",
      "r492",
      "r493",
      "r629",
      "r631",
      "r688",
      "r739",
      "r740",
      "r787",
      "r788",
      "r821",
      "r822",
      "r825",
      "r833",
      "r1061",
      "r1062",
      "r1104"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesScheduleofComponentsofLeaseAssetsandLiabilitiesDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofExpensesIncludedinOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r282",
      "r443",
      "r444",
      "r445",
      "r446",
      "r469",
      "r471",
      "r476",
      "r491",
      "r492",
      "r493",
      "r629",
      "r631",
      "r688",
      "r739",
      "r740",
      "r787",
      "r788",
      "r821",
      "r822",
      "r825",
      "r833",
      "r1061",
      "r1062",
      "r1104"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r160",
      "r409",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r421",
      "r423",
      "r424",
      "r425",
      "r606",
      "r639",
      "r647",
      "r786"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome",
      "http://www.arrowheadresearch.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax (benefit) expense",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r109",
      "r156",
      "r180",
      "r181",
      "r195",
      "r205",
      "r208",
      "r410",
      "r411",
      "r422",
      "r627",
      "r749",
      "r751",
      "r753",
      "r786"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Income taxes paid",
        "label": "Income Taxes Paid, Net",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r154",
      "r417",
      "r418"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "arwr_IncreaseDecreaseInCashAndInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "IncreaseDecreaseInCashAndInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) in cash and investments",
        "label": "Increase (Decrease) In Cash And Investments",
        "documentation": "Increase decrease in cash and investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r558",
      "r976"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, net",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r953",
      "r976"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r876",
      "r886",
      "r896",
      "r920",
      "r928",
      "r932",
      "r940"
     ]
    },
    "arwr_InducementAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "InducementAwardsMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofGrantedandOutstandingSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inducement Awards",
        "label": "Inducement Awards [Member]",
        "documentation": "Inducement Awards"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_InducementPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "InducementPlanMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inducement Awards",
        "label": "Inducement Plan [Member]",
        "documentation": "Inducement Plan"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_InitialTransactionPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "InitialTransactionPrice",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedGSKDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial transaction price",
        "label": "Initial Transaction Price",
        "documentation": "Initial transaction price."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r868",
      "r944"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r868",
      "r944"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r868",
      "r944"
     ]
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets",
        "label": "Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r276",
      "r278",
      "r738",
      "r739"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/FinancingAgreementScheduleofInterestExpenseRecognizedRelatedtoCreditFacilityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementScheduleofInterestExpenseRecognizedRelatedtoCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total interest expense",
        "label": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r313",
      "r318",
      "r766",
      "r767",
      "r1135"
     ]
    },
    "us-gaap_InterestExpenseDebtExcludingAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseDebtExcludingAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/FinancingAgreementScheduleofInterestExpenseRecognizedRelatedtoCreditFacilityDetails": {
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementScheduleofInterestExpenseRecognizedRelatedtoCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual interest expense",
        "label": "Interest Expense, Debt, Excluding Amortization",
        "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r314",
      "r766",
      "r767"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r749",
      "r753",
      "r975"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest paid",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activity",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r152",
      "r153"
     ]
    },
    "us-gaap_InvestmentIncomeInterestAndDividend": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeInterestAndDividend",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Investment Income, Interest and Dividend",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r70"
     ]
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "(Accretion) amortization of note premiums/discounts",
        "label": "Investment Income, Net, Amortization of Discount and Premium",
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Contract Maturity of Available for Sale Securities",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]",
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Investments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r111",
      "r214",
      "r216",
      "r483",
      "r484",
      "r1097"
     ]
    },
    "arwr_LaboratoryAndOfficeFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "LaboratoryAndOfficeFacilityMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory and Office Facility",
        "label": "Laboratory And Office Facility [Member]",
        "documentation": "Laboratory and office facility."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LandMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LandMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Land",
        "label": "Land [Member]",
        "documentation": "Part of earth's surface not covered by water."
       }
      }
     },
     "auth_ref": [
      "r1027",
      "r1028"
     ]
    },
    "us-gaap_LandSubjectToGroundLeases": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LandSubjectToGroundLeases",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office space leases (in sq ft)",
        "label": "Land Subject to Ground Leases",
        "documentation": "Area of land subject to a ground lease."
       }
      }
     },
     "auth_ref": [
      "r1085"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesScheduleofComponentsofLeaseAssetsandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesScheduleofComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r510",
      "r835"
     ]
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesScheduleofComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Cost",
        "label": "Lease, Cost [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Lease Assets and Liabilities and Lease Cost",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1087"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r518"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Abstract]",
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee Lease Description [Line Items]",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r509",
      "r519"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee Lease Description [Table]",
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r509",
      "r519"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Maturities of Operating Lease Liabilities on an Undiscounted Basis",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1088"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.arrowheadresearch.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r517",
      "r980",
      "r985",
      "r1098"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r517",
      "r980",
      "r985",
      "r1098"
     ]
    },
    "arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2030 and thereafter",
        "label": "Lessee Operating Lease Liability Payments Due Year Five And After Year Five",
        "documentation": "Lessee operating lease liability payments due year five and after year five."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r517",
      "r980",
      "r985",
      "r1098"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r517",
      "r980",
      "r985",
      "r1098"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r517",
      "r980",
      "r985",
      "r1098"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025 (remainder)",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r1088"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r517"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease renewal term",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1086"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease term",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1086"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities, Noncontrolling Interest and Stockholders\u2019 Equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r99",
      "r615",
      "r836",
      "r850",
      "r851",
      "r979",
      "r984",
      "r1003",
      "r1081"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES, NONCONTROLLING INTEREST AND STOCKHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r120",
      "r156",
      "r158",
      "r159",
      "r247",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r438",
      "r441",
      "r442",
      "r490",
      "r836",
      "r1023",
      "r1089",
      "r1090"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total long-term liabilities",
        "label": "Liabilities, Noncurrent",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r54",
      "r55",
      "r56",
      "r57",
      "r156",
      "r158",
      "r159",
      "r247",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r438",
      "r441",
      "r442",
      "r490",
      "r1023",
      "r1089",
      "r1090"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term liabilities:",
        "label": "Liabilities, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability Related To The Sale Of Future Royalties [Abstract]",
        "documentation": "Liability Related To The Sale Of Future Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyalties"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability Related to the Sale of Future Royalties",
        "label": "Liability Related To The Sale Of Future Royalties [Text Block]",
        "documentation": "Liability Related To The Sale Of Future Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_LiabilitySaleOfFutureRoyaltiesInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "LiabilitySaleOfFutureRoyaltiesInterestRate",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability related to the sale of future royalties, interest rate",
        "label": "Liability, Sale Of Future Royalties, Interest Rate",
        "documentation": "Liability, Sale Of Future Royalties, Interest Rate"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_LiabilitySaleOfFutureRoyaltiesRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "LiabilitySaleOfFutureRoyaltiesRollForward",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability, Sale Of Future Royalties [Roll Forward]",
        "label": "Liability, Sale Of Future Royalties [Roll Forward]",
        "documentation": "Liability, Sale Of Future Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_LicenseAndCoFundingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "LicenseAndCoFundingAgreementMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License and Co-Funding Agreement",
        "label": "License And Co Funding Agreement [Member]",
        "documentation": "License and co-funding agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicensingAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LicensingAgreementsMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License",
        "label": "Licensing Agreements [Member]",
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory)."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r803",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1011",
      "r1013",
      "r1014",
      "r1015",
      "r1060"
     ]
    },
    "us-gaap_LineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term line of credit",
        "label": "Long-Term Line of Credit",
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r96",
      "r1100"
     ]
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementScheduleofInterestExpenseRecognizedRelatedtoCreditFacilityDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementScheduleofOutstandingBalanceofCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit Facility [Line Items]",
        "label": "Line of Credit Facility [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r979",
      "r982",
      "r1022"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum borrowing capacity",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r53"
     ]
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of credit facility, remaining borrowing capacity",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r53",
      "r290"
     ]
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementScheduleofInterestExpenseRecognizedRelatedtoCreditFacilityDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementScheduleofOutstandingBalanceofCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit Facility [Table]",
        "label": "Line of Credit Facility [Table]",
        "documentation": "Disclosure of information about short-term and long-term contractual arrangements with lender under which borrowing can occur up to maximum amount. Includes, but is not limited to, letter of credit, standby letter of credit, and revolving credit arrangement."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r53",
      "r290",
      "r979",
      "r982",
      "r1022"
     ]
    },
    "us-gaap_LineOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementScheduleofInterestExpenseRecognizedRelatedtoCreditFacilityDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementScheduleofOutstandingBalanceofCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit",
        "label": "Line of Credit [Member]",
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LinesOfCreditCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LinesOfCreditCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementScheduleofOutstandingBalanceofCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit facility",
        "negatedTerseLabel": "Less: Current portion of credit facility",
        "label": "Line of Credit, Current",
        "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r95"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Long-Term Debt, Maturity, Year One",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r157",
      "r165",
      "r311",
      "r604"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Long-Term Debt, Maturity, Year Four",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r157",
      "r165",
      "r311",
      "r604"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Long-Term Debt, Maturity, Year Three",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r157",
      "r165",
      "r311",
      "r604"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Long-Term Debt, Maturity, Year Two",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r157",
      "r165",
      "r311",
      "r604"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025 (remainder)",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r980",
      "r985"
     ]
    },
    "arwr_LongTermDebtMaturityAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "LongTermDebtMaturityAfterYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Long-Term Debt, Maturity, After Year Four",
        "documentation": "Long-Term Debt, Maturity, After Year Four"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementScheduleofOutstandingBalanceofCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit facility, net of current portion",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "us-gaap_LongTermDebtTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing Agreement",
        "label": "Long-Term Debt [Text Block]",
        "documentation": "The entire disclosure for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_LongTermLineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermLineOfCredit",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit facility, net of current portion",
        "label": "Long-Term Line of Credit, Noncurrent",
        "documentation": "The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r30",
      "r31"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementScheduleofInterestExpenseRecognizedRelatedtoCreditFacilityDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementScheduleofOutstandingBalanceofCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r1017",
      "r1018",
      "r1019"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementScheduleofInterestExpenseRecognizedRelatedtoCreditFacilityDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementScheduleofOutstandingBalanceofCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r32",
      "r1017",
      "r1018",
      "r1019"
     ]
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingencyAccrualAtCarryingValue",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent liabilities",
        "label": "Loss Contingency Accrual",
        "documentation": "Amount of loss contingency liability."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r951"
     ]
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Axis]",
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r212",
      "r770",
      "r773",
      "r846",
      "r849",
      "r1103",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1131",
      "r1132"
     ]
    },
    "arwr_ManufacturingEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "ManufacturingEquipmentMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsNarrativeDetails",
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsPropertyPlantandEquipmentDetails",
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Manufacturing equipment",
        "label": "Manufacturing Equipment [Member]",
        "documentation": "Manufacturing Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ManufacturingFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ManufacturingFacilityMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Manufacturing Facility",
        "label": "Manufacturing Facility [Member]",
        "documentation": "Structure used in the manufacturing of goods."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsNarrativeDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedGSKDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r199",
      "r286",
      "r287",
      "r288",
      "r289",
      "r365",
      "r395",
      "r396",
      "r397",
      "r407",
      "r468",
      "r557",
      "r628",
      "r630",
      "r638",
      "r656",
      "r657",
      "r708",
      "r710",
      "r712",
      "r713",
      "r715",
      "r720",
      "r721",
      "r723",
      "r724",
      "r736",
      "r737",
      "r761",
      "r769",
      "r783",
      "r787",
      "r789",
      "r790",
      "r826",
      "r827",
      "r831",
      "r832",
      "r847",
      "r1025",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "arwr_MilestonePaymentEarned": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "MilestonePaymentEarned",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment",
        "label": "Milestone Payment Earned",
        "documentation": "Milestone payment earned."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_MilestonePaymentReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "MilestonePaymentReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedGSKDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment receivable",
        "label": "Milestone Payment Receivable",
        "documentation": "Milestone Payment Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment receivable upon achievement of enrollment in phase 3 clinical trial",
        "label": "Milestone Payment Receivable, Upon Achievement of Enrollment in Phase 3 Clinical Trial",
        "documentation": "Milestone Payment Receivable, Upon Achievement of Enrollment in Phase 3 Clinical Trial"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedGSKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment receivable upon achievement of phase two and first patient dosed in phase three",
        "label": "Milestone Payment Receivable Upon Achievement Of Phase Two And First Patient Dosed In Phase Three",
        "documentation": "Milestone payment receivable upon achievement of phase two and first patient dosed in phase three."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_MilestonePaymentReceivableUponFDAApproval": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "MilestonePaymentReceivableUponFDAApproval",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment receivable upon FDA approval",
        "label": "Milestone Payment Receivable, Upon FDA Approval",
        "documentation": "Milestone Payment Receivable, Upon FDA Approval"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "MilestonePaymentReceivableUponReceiptOfRoyaltyPayments",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment receivable upon receipt of royalty payments",
        "label": "Milestone Payment Receivable, Upon Receipt Of Royalty Payments",
        "documentation": "Milestone Payment Receivable, Upon Receipt Of Royalty Payments"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesActivityDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment received",
        "label": "Milestone Payment Received, Liability Related To Sale Of Future Royalties",
        "documentation": "Milestone Payment Received, Liability Related To Sale Of Future Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsNarrativeDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r199",
      "r286",
      "r287",
      "r288",
      "r289",
      "r365",
      "r395",
      "r396",
      "r397",
      "r407",
      "r468",
      "r557",
      "r628",
      "r630",
      "r638",
      "r656",
      "r657",
      "r708",
      "r710",
      "r712",
      "r713",
      "r715",
      "r720",
      "r721",
      "r723",
      "r724",
      "r736",
      "r737",
      "r761",
      "r769",
      "r783",
      "r787",
      "r789",
      "r790",
      "r826",
      "r827",
      "r831",
      "r847",
      "r1025",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096"
     ]
    },
    "us-gaap_MinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MinorityInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling interest",
        "label": "Equity, Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r98",
      "r156",
      "r158",
      "r159",
      "r247",
      "r291",
      "r293",
      "r294",
      "r295",
      "r298",
      "r299",
      "r614",
      "r667",
      "r1081"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market instruments",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r1029",
      "r1030"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "us-gaap_MunicipalBondsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MunicipalBondsMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Municipal securities",
        "label": "Municipal Bonds [Member]",
        "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments."
       }
      }
     },
     "auth_ref": []
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Domain]",
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r212",
      "r770",
      "r773",
      "r846",
      "r849",
      "r1103",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1131",
      "r1132"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r78",
      "r79"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome",
      "http://www.arrowheadresearch.com/role/NetLossIncomePerShareScheduleofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (loss) income attributable to Arrowhead Pharmaceuticals, Inc.",
        "terseLabel": "Net (loss) income attributable to Arrowhead Pharmaceuticals, Inc.",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r79",
      "r101",
      "r115",
      "r118",
      "r138",
      "r140",
      "r144",
      "r156",
      "r158",
      "r159",
      "r162",
      "r169",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r180",
      "r181",
      "r187",
      "r247",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r320",
      "r323",
      "r325",
      "r328",
      "r404",
      "r429",
      "r432",
      "r462",
      "r490",
      "r621",
      "r685",
      "r701",
      "r702",
      "r749",
      "r751",
      "r753",
      "r861",
      "r1023"
     ]
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss attributable to noncontrolling interest, net of tax",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r93",
      "r138",
      "r140",
      "r177",
      "r180",
      "r181",
      "r620",
      "r974"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/NetLossIncomePerShareScheduleofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numerator:",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash interest expense on liability related to the sale of future royalties",
        "verboseLabel": "Non-cash interest expense recognized",
        "label": "Non-Cash Interest Expense, Liability Related To Sale Of Future Royalties",
        "documentation": "Non-Cash Interest Expense, Liability Related To Sale Of Future Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r876",
      "r886",
      "r896",
      "r920",
      "r928"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non- controlling Interest",
        "label": "Noncontrolling Interest [Member]",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r346",
      "r986",
      "r987",
      "r988",
      "r989",
      "r1136"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other (expense) income",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other (expense) income:",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_NovartisMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "NovartisMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Novartis",
        "label": "Novartis [Member]",
        "documentation": "Novartis."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_NumberOfAgreements": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "NumberOfAgreements",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of agreements",
        "label": "Number Of Agreements",
        "documentation": "Number of agreements."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_NumberOfCollaborationPrograms": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "NumberOfCollaborationPrograms",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of collaboration programs",
        "label": "Number Of Collaboration Programs",
        "documentation": "Number Of Collaboration Programs"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_NumberOfDistinctBundle": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "NumberOfDistinctBundle",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of distinct bundle",
        "label": "Number Of Distinct Bundle",
        "documentation": "Number of distinct bundle."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_NumberOfNewTargetPrograms": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "NumberOfNewTargetPrograms",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of new target programs",
        "label": "Number Of New Target Programs",
        "documentation": "Number Of New Target Programs"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_NumberOfOptionsToRenew": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "NumberOfOptionsToRenew",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of options to renew",
        "label": "Number Of Options To Renew",
        "documentation": "Number of options to renew."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_NumberOfPerformanceObligations": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "NumberOfPerformanceObligations",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of performance obligations",
        "label": "Number Of Performance Obligations",
        "documentation": "Number Of Performance Obligations"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_OlpasiranAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "OlpasiranAgreementMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Olpasiran Agreement",
        "label": "Olpasiran Agreement [Member]",
        "documentation": "Olpasiran agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating (loss) income",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r749",
      "r753",
      "r758",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995"
     ]
    },
    "arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesScheduleofCashFlowandOtherInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash flows from operating leases",
        "label": "Operating Lease, Cash Received For Amounts Included In Measurement Of Lease Liabilities",
        "documentation": "Operating Lease, Cash Received For Amounts Included In Measurement Of Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesScheduleofComponentsofLeaseAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesScheduleofComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease cost",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r511",
      "r835"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total operating lease liabilities (includes current portion)",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/LeasesScheduleofComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/LeasesScheduleofComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities, net of current portion",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesScheduleofCashFlowandOtherInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash flows from operating leases",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r508",
      "r514"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/LeasesScheduleofComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r506"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesScheduleofCashFlowandOtherInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r516",
      "r835"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesScheduleofCashFlowandOtherInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining lease term (in years)",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r515",
      "r835"
     ]
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeasedAssetsLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesScheduleofComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leased Assets [Line Items]",
        "label": "Operating Leased Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization and Significant Accounting Policies",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r961",
      "r978"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r836"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Line Items]",
        "label": "Other Commitments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitmentsTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Table]",
        "label": "Other Commitments [Table]",
        "documentation": "Disclosure of information about obligations resulting from other commitments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Unrealized gains on available-for-sale securities",
        "terseLabel": "Unrealized gains (losses) on available-for-sale securities",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r136",
      "r137",
      "r622"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation adjustments",
        "verboseLabel": "Foreign currency translation adjustments",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r622"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r836"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r820"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r874",
      "r884",
      "r894",
      "r926"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r877",
      "r887",
      "r897",
      "r929"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r877",
      "r887",
      "r897",
      "r929"
     ]
    },
    "us-gaap_PaidInKindInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaidInKindInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash interest expense on credit facility",
        "label": "Paid-in-Kind Interest",
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_PatentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PatentsMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patents",
        "label": "Patents [Member]",
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law."
       }
      }
     },
     "auth_ref": [
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1009",
      "r1011",
      "r1014",
      "r1015"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payments of debt issuance costs",
        "label": "Payments of Debt Issuance Costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of investments",
        "label": "Payments to Acquire Investments",
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of commission to sales agent",
        "label": "Percentage Of Commission On Aggregate Gross Proceeds From Sale Of Common Stock",
        "documentation": "Percentage of commission on aggregate gross proceeds from sale of common stock."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of eligible to receive tiered royalties on net sales",
        "label": "Percentage Of Eligible To Receive Tiered Royalties On Net Sales",
        "documentation": "Percentage of eligible to receive tiered royalties on net sales."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofGrantedandOutstandingSharesDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofGrantedandOutstandingSharesDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityScheduleofSharesofCommonStockandPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r330"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityScheduleofSharesofCommonStockandPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r665"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityScheduleofSharesofCommonStockandPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r330"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityScheduleofSharesofCommonStockandPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r665",
      "r684",
      "r1136",
      "r1137"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses",
        "label": "Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r259",
      "r260",
      "r743"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement",
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_ProceedsFromCollaborationArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "ProceedsFromCollaborationArrangements",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncConsiderationComponentsDetails": {
       "parentTag": "arwr_CollaborationArrangementFixedConsideration",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncConsiderationComponentsDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront payment",
        "label": "Proceeds From Collaboration Arrangements",
        "documentation": "Proceeds From Collaboration Arrangements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the issuance of common stock, net of offering costs",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the issuance of warrants",
        "label": "Proceeds from Issuance of Warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromLinesOfCredit",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from Visirna credit agreement",
        "label": "Proceeds from Lines of Credit",
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r979",
      "r982"
     ]
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sales and maturities of investments",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "arwr_ProceedsFromSaleOfFutureRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "ProceedsFromSaleOfFutureRoyalties",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the sales of future royalties",
        "label": "Proceeds From Sale Of Future Royalties",
        "documentation": "Proceeds From Sale Of Future Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the exercises of stock options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r12"
     ]
    },
    "arwr_ProceedsFromTenantImprovementAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "ProceedsFromTenantImprovementAllowance",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from additional tenant improvement allowance",
        "label": "Proceeds From Tenant Improvement Allowance",
        "documentation": "Proceeds From Tenant Improvement Allowance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (loss) income including noncontrolling interest",
        "terseLabel": "Net income (loss)",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r118",
      "r138",
      "r140",
      "r150",
      "r156",
      "r158",
      "r159",
      "r162",
      "r169",
      "r177",
      "r180",
      "r181",
      "r247",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r320",
      "r404",
      "r429",
      "r432",
      "r436",
      "r439",
      "r440",
      "r462",
      "r490",
      "r600",
      "r602",
      "r619",
      "r649",
      "r685",
      "r701",
      "r702",
      "r818",
      "r819",
      "r862",
      "r974",
      "r1023"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsNarrativeDetails",
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsPropertyPlantandEquipmentDetails",
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesDetails",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r518"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsPropertyPlantandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment, gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r122",
      "r617"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsNarrativeDetails",
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r518"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsPropertyPlantandEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsPropertyPlantandEquipmentDetails",
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment, net",
        "totalLabel": "Property, plant and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r518",
      "r605",
      "r617",
      "r836"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property, Plant and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTransfersAndChanges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTransfersAndChanges",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment, reclassification",
        "label": "Property, Plant and Equipment, Transfers and Changes",
        "documentation": "Amount of increase (decrease) of physical assets used in the normal conduct of business and not intended for resale, from reclassification, impairment, donation, or changes classified as other. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsNarrativeDetails",
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsPropertyPlantandEquipmentDetails",
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesDetails",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r518"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Useful life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsNarrativeDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedGSKDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r199",
      "r286",
      "r287",
      "r288",
      "r289",
      "r355",
      "r365",
      "r395",
      "r396",
      "r397",
      "r403",
      "r407",
      "r468",
      "r531",
      "r540",
      "r557",
      "r628",
      "r630",
      "r638",
      "r656",
      "r657",
      "r708",
      "r710",
      "r712",
      "r713",
      "r715",
      "r720",
      "r721",
      "r723",
      "r724",
      "r736",
      "r737",
      "r761",
      "r769",
      "r783",
      "r787",
      "r789",
      "r790",
      "r826",
      "r827",
      "r831",
      "r832",
      "r847",
      "r855",
      "r1020",
      "r1025",
      "r1075",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsNarrativeDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedGSKDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r199",
      "r286",
      "r287",
      "r288",
      "r289",
      "r355",
      "r365",
      "r395",
      "r396",
      "r397",
      "r403",
      "r407",
      "r468",
      "r531",
      "r540",
      "r557",
      "r628",
      "r630",
      "r638",
      "r656",
      "r657",
      "r708",
      "r710",
      "r712",
      "r713",
      "r715",
      "r720",
      "r721",
      "r723",
      "r724",
      "r736",
      "r737",
      "r761",
      "r769",
      "r783",
      "r787",
      "r789",
      "r790",
      "r826",
      "r827",
      "r831",
      "r832",
      "r847",
      "r855",
      "r1020",
      "r1025",
      "r1075",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096"
     ]
    },
    "us-gaap_RealizedInvestmentGainsLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RealizedInvestmentGainsLosses",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Realized loss on investments",
        "label": "Realized Investment Gains (Losses)",
        "documentation": "Amount of realized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r626"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r869",
      "r879",
      "r889",
      "r921"
     ]
    },
    "arwr_RegulatoryMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "RegulatoryMilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Regulatory milestone payments",
        "label": "Regulatory Milestone Payments",
        "documentation": "Regulatory Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfLinesOfCredit",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementScheduleofOutstandingBalanceofCreditFacilityDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayments of credit facility",
        "terseLabel": "Repayments of credit facility",
        "negatedTerseLabel": "Less: Payments",
        "label": "Repayments of Lines of Credit",
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r979",
      "r982"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedGSKDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncConsiderationComponentsDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r156",
      "r163",
      "r164",
      "r303",
      "r332",
      "r521",
      "r541",
      "r608",
      "r744",
      "r745",
      "r746",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r1065",
      "r1066",
      "r1067",
      "r1068"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "documentation": "Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r1059"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesScheduleofComponentsofLeaseAssetsandLiabilitiesDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofExpensesIncludedinOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_ResearchEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "ResearchEquipmentMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsPropertyPlantandEquipmentDetails",
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research equipment",
        "label": "Research Equipment [Member]",
        "documentation": "Research Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_ResearchFacilityInMadisonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "ResearchFacilityInMadisonMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research Facility in Madison",
        "label": "Research Facility In Madison [Member]",
        "documentation": "Research facility in Madison."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_ResearchFacilityInSanDiegoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "ResearchFacilityInSanDiegoMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research Facility in San Diego",
        "label": "Research Facility In San Diego [Member]",
        "documentation": "Research Facility in San Diego."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r870",
      "r880",
      "r890",
      "r922"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r871",
      "r881",
      "r891",
      "r923"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r878",
      "r888",
      "r898",
      "r930"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash and Cash Equivalent, Current",
        "documentation": "Amount of cash and cash equivalent restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r121",
      "r155"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Domain]",
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/NetLossIncomePerShareScheduleofAntidilutiveSecuritiesDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofGrantedandOutstandingSharesDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock units",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r87",
      "r613",
      "r635",
      "r637",
      "r646",
      "r666",
      "r836"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r114",
      "r115",
      "r166",
      "r167",
      "r168",
      "r170",
      "r177",
      "r179",
      "r181",
      "r248",
      "r249",
      "r279",
      "r319",
      "r404",
      "r419",
      "r420",
      "r426",
      "r427",
      "r428",
      "r430",
      "r431",
      "r432",
      "r448",
      "r450",
      "r451",
      "r453",
      "r460",
      "r502",
      "r505",
      "r632",
      "r634",
      "r650",
      "r1136"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r105",
      "r195",
      "r201",
      "r202",
      "r206",
      "r208",
      "r209",
      "r210",
      "r212",
      "r351",
      "r352",
      "r353",
      "r559",
      "r749",
      "r753"
     ]
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevolvingCreditFacilityMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revolving Credit Facility",
        "label": "Revolving Credit Facility [Member]",
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesScheduleofCashFlowandOtherInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets obtained in exchange for amended operating lease liabilities",
        "label": "Right-Of-Use Asset Adjustment In Exchange For Operating Lease Liability",
        "documentation": "Right-Of-Use Asset Adjustment In Exchange For Operating Lease Liability"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_RoyaltiesLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "RoyaltiesLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability related to the sale of future royalties",
        "periodStartLabel": "Beginning carrying value",
        "periodEndLabel": "Ending carrying value",
        "label": "Royalties, Liability, Noncurrent",
        "documentation": "Royalties, Liability, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_RoyaltyPaymentThreshold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "RoyaltyPaymentThreshold",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty payment threshold",
        "label": "Royalty Payment Threshold",
        "documentation": "Royalty Payment Threshold"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_RoyaltyPharmaAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "RoyaltyPharmaAgreementMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty Pharma Agreement",
        "label": "Royalty Pharma Agreement [Member]",
        "documentation": "Royalty Pharma Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of stock",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares of common stock issued (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_SaleOfStockPremiumOnIssuanceOfShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "SaleOfStockPremiumOnIssuanceOfShares",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncConsiderationComponentsDetails": {
       "parentTag": "arwr_CollaborationArrangementFixedConsideration",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncConsiderationComponentsDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Equity premium",
        "label": "Sale Of Stock, Premium On Issuance Of Shares",
        "documentation": "Sale Of Stock, Premium On Issuance Of Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock sold price (in dollars per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_SalesRelatedMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "SalesRelatedMilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedGSKDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales-related milestone payments",
        "label": "Sales Related Milestone Payments",
        "documentation": "Sales-related milestone payments."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_SanofiLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "SanofiLicenseAgreementMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi License Agreement",
        "label": "Sanofi License Agreement [Member]",
        "documentation": "Sanofi License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_SareptaCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "SareptaCollaborationAgreementMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncConsiderationComponentsDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sarepta Collaboration Agreement",
        "label": "Sarepta Collaboration Agreement [Member]",
        "documentation": "Sarepta Collaboration Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_SareptaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "SareptaMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sarepta",
        "label": "Sarepta [Member]",
        "documentation": "Sarepta"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_SareptaTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "SareptaTherapeuticsIncMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncConsiderationComponentsDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sarepta",
        "label": "Sarepta Therapeutics, Inc [Member]",
        "documentation": "Sarepta Therapeutics, Inc"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forecast",
        "label": "Forecast [Member]"
       }
      }
     },
     "auth_ref": [
      "r366"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Domain]",
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r116",
      "r117",
      "r182",
      "r366",
      "r951"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Expenses",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/NetLossIncomePerShareScheduleofAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/NetLossIncomePerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedGSKDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncConsiderationComponentsDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fixed and Estimated Variable Consideration",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r1064"
     ]
    },
    "arwr_ScheduleOfCurrentProductsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "ScheduleOfCurrentProductsTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Company's Current Pipeline",
        "label": "Schedule of Current Products [Table Text Block]",
        "documentation": "Schedule of Current Products"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/NetLossIncomePerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r990"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofExpensesIncludedinOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-Based Payment Arrangement, Expensed",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1072",
      "r1073"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Finite Lived Intangible Assets [Table]",
        "label": "Intangible Asset, Finite-Lived [Table]",
        "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r271",
      "r274",
      "r275",
      "r277",
      "r560",
      "r739",
      "r742",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finite-Lived Intangible Assets",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r742",
      "r1010"
     ]
    },
    "arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsScheduleofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]",
        "label": "Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]",
        "documentation": "Schedule of held to maturity securities and marketable securities."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsScheduleofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Held To Maturity Securities And Marketable Securities [Table]",
        "label": "Schedule Of Held To Maturity Securities And Marketable Securities [Table]",
        "documentation": "Schedule of held to maturity securities and marketable securities."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Liability Related to the Sale of Future Royalties",
        "label": "Schedule Of Liability Related To The Sale Of Future Royalties [Table Text Block]",
        "documentation": "Schedule Of Liability Related To The Sale Of Future Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfLineOfCreditFacilitiesTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Line of Credit Facilities",
        "label": "Schedule of Line of Credit Facilities [Table Text Block]",
        "documentation": "Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r53"
     ]
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Maturities of Long-Term Debt",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesScheduleofComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Operating Leased Assets [Table]",
        "label": "Schedule of Operating Leased Assets [Table]",
        "documentation": "Disclosure of information about long-lived, depreciable assets that are subject to operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsNarrativeDetails",
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r518"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Awards Outstanding",
        "label": "Share-Based Payment Arrangement, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r11",
      "r89"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofGrantedandOutstandingSharesDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r370",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r403"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share Activity Related to RSUs",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Summarized Information about Stock Options",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r11",
      "r88"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Stock By Class [Table]",
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r85",
      "r86",
      "r87",
      "r128",
      "r129",
      "r130",
      "r197",
      "r330",
      "r331",
      "r332",
      "r334",
      "r337",
      "r342",
      "r344",
      "r447",
      "r642",
      "r643",
      "r644",
      "r645",
      "r769",
      "r950",
      "r979",
      "r981"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockByClassTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Shares of Common Stock and Preferred Stock",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r34",
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r58",
      "r59",
      "r85",
      "r86",
      "r87"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Intangible Assets Future Amortization Expense",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r742",
      "r1012"
     ]
    },
    "us-gaap_SecuredDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SecuredDebtMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementScheduleofInterestExpenseRecognizedRelatedtoCreditFacilityDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementScheduleofOutstandingBalanceofCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Secured Debt",
        "label": "Secured Debt [Member]",
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesDetails",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r198",
      "r210",
      "r211",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r600",
      "r601",
      "r602",
      "r603",
      "r653",
      "r654",
      "r655",
      "r709",
      "r711",
      "r714",
      "r716",
      "r720",
      "r722",
      "r723",
      "r724",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r741",
      "r757",
      "r770",
      "r772",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r848",
      "r855",
      "r1103",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1131",
      "r1132"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r386"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r386"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "calculation": {
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofGrantedandOutstandingSharesDetails": {
       "parentTag": "arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofGrantedandOutstandingSharesDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment award (in shares)",
        "verboseLabel": "Restricted stock units (in shares)",
        "periodStartLabel": "Beginning of period (in shares)",
        "periodEndLabel": "End of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r384"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of RSUs",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in dollars per share)",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r384"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Grant Date Fair Value Per Share",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofGrantedandOutstandingSharesDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r370",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r403"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares authorized (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, share reserve for issuance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding",
     "calculation": {
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofGrantedandOutstandingSharesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofGrantedandOutstandingSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total (in shares)",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Outstanding",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options Outstanding, Exercisable (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Exercise Price Per Share, Exercisable (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intrinsic value of options exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cancelled or expired (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r381"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted (in shares)",
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r379"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "calculation": {
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofGrantedandOutstandingSharesDetails": {
       "parentTag": "arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofGrantedandOutstandingSharesDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of options outstanding (in shares)",
        "verboseLabel": "Options (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r376"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in dollars per share)",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r376"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Exercise Price Per Share",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofGrantedandOutstandingSharesDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofRSUsActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cancelled or expired (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r379"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Remaining Contractual Term, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Remaining Contractual Term (Years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesIssued",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued to institutional investors (in shares)",
        "label": "Shares, Issued",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermDebtTypeAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-Term Debt, Type [Axis]",
        "label": "Short-Term Debt, Type [Axis]",
        "documentation": "Information by type of short-term debt arrangement."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r1017",
      "r1018",
      "r1019"
     ]
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermDebtTypeDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-Term Debt, Type [Domain]",
        "label": "Short-Term Debt, Type [Domain]",
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r1017",
      "r1018",
      "r1019"
     ]
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term lease cost",
        "label": "Short-Term Lease, Cost",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r512",
      "r835"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r59",
      "r62",
      "r63",
      "r112",
      "r114",
      "r115",
      "r142",
      "r143",
      "r144",
      "r166",
      "r167",
      "r168",
      "r170",
      "r177",
      "r179",
      "r181",
      "r196",
      "r248",
      "r249",
      "r279",
      "r319",
      "r346",
      "r404",
      "r419",
      "r420",
      "r426",
      "r427",
      "r428",
      "r430",
      "r431",
      "r432",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r460",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r502",
      "r505",
      "r520",
      "r622",
      "r632",
      "r633",
      "r634",
      "r650",
      "r703"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesDetails",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r198",
      "r210",
      "r211",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r600",
      "r601",
      "r602",
      "r603",
      "r653",
      "r654",
      "r655",
      "r709",
      "r711",
      "r714",
      "r716",
      "r720",
      "r722",
      "r723",
      "r724",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r741",
      "r757",
      "r770",
      "r772",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r848",
      "r855",
      "r1103",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1131",
      "r1132"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r167",
      "r168",
      "r196",
      "r321",
      "r322",
      "r324",
      "r326",
      "r505",
      "r559",
      "r641",
      "r651",
      "r652",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r665",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r674",
      "r675",
      "r676",
      "r677",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r686",
      "r687",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r703",
      "r751",
      "r753",
      "r856",
      "r1134"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Axis]",
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r116",
      "r117",
      "r182",
      "r366",
      "r951",
      "r952"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r167",
      "r168",
      "r196",
      "r213",
      "r321",
      "r322",
      "r324",
      "r326",
      "r505",
      "r559",
      "r641",
      "r651",
      "r652",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r665",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r674",
      "r675",
      "r676",
      "r677",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r686",
      "r687",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r703",
      "r751",
      "r753",
      "r856",
      "r1134"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r873",
      "r883",
      "r893",
      "r925"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued, net of offering costs (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r58",
      "r59",
      "r87",
      "r642",
      "r703",
      "r717"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock - restricted stock units vesting (in shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r87"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options (in shares)",
        "negatedLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r58",
      "r59",
      "r87",
      "r380"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued, net of offering costs",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r58",
      "r59",
      "r87",
      "r650",
      "r703",
      "r717",
      "r862"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock - restricted stock units vesting",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r58",
      "r59",
      "r87"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r59",
      "r62",
      "r63",
      "r87"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Stockholders\u2019 equity",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r62",
      "r63",
      "r80",
      "r667",
      "r684",
      "r704",
      "r705",
      "r836",
      "r863",
      "r979",
      "r983",
      "r984",
      "r1003",
      "r1081",
      "r1136"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total noncontrolling interest and stockholders\u2019 equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r43",
      "r44",
      "r112",
      "r113",
      "r114",
      "r115",
      "r143",
      "r166",
      "r167",
      "r168",
      "r170",
      "r177",
      "r179",
      "r248",
      "r249",
      "r279",
      "r319",
      "r346",
      "r404",
      "r419",
      "r420",
      "r426",
      "r427",
      "r428",
      "r430",
      "r431",
      "r432",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r460",
      "r495",
      "r496",
      "r500",
      "r503",
      "r520",
      "r633",
      "r634",
      "r648",
      "r667",
      "r684",
      "r704",
      "r705",
      "r718",
      "r850",
      "r851",
      "r862",
      "r979",
      "r983",
      "r984",
      "r1003",
      "r1081",
      "r1136"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling interest and stockholders\u2019 equity:",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r329",
      "r331",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r343",
      "r346",
      "r447",
      "r459",
      "r706",
      "r707",
      "r719"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Line Items]",
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r501",
      "r523"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r501",
      "r523"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Table]",
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r501",
      "r523"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r501",
      "r523"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r501",
      "r523"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events [Abstract]",
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r522",
      "r524"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_SummaryOfInterestExpenseRecognizedRelatedToCreditFacilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "SummaryOfInterestExpenseRecognizedRelatedToCreditFacilityTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Interest Expense Recognized Related To Credit Facility",
        "label": "Summary Of Interest Expense Recognized Related To Credit Facility [Table Text Block]",
        "documentation": "Summary Of Interest Expense Recognized Related To Credit Facility"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccounts"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Accounts",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r962"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplementary disclosure of cash flows:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Takeda",
        "label": "Takeda Pharmaceuticals United States Of America Incorporated [Member]",
        "documentation": "Takeda Pharmaceuticals United States of America Incorporated."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.arrowheadresearch.com/role/InvestmentsScheduleofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r316",
      "r342",
      "r447",
      "r458",
      "r482",
      "r489",
      "r492",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r607",
      "r623",
      "r823",
      "r824",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r837",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1071",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r942"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r942"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r943"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "arwr_TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2013 and 2021 Incentive Plans and other inducement grants",
        "label": "Two Thousand Thirteen Equity Incentive Plan, Two Thousand Twenty One Equity Incentive Plan And Inducement Grants [Member]",
        "documentation": "Two Thousand Thirteen Equity Incentive Plan, Two Thousand Twenty One Equity Incentive Plan And Inducement Grants"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_TwoThousandTwentyOneIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "TwoThousandTwentyOneIncentivePlanMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofGrantedandOutstandingSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 Plan",
        "label": "Two Thousand Twenty One Incentive Plan [Member]",
        "documentation": "Two thousand twenty one incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_TwoThousandsThirteenIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "TwoThousandsThirteenIncentivePlanMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofGrantedandOutstandingSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2013 Plan",
        "label": "Two Thousands Thirteen Incentive Plan [Member]",
        "documentation": "Two thousands thirteen incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedGSKDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncConsiderationComponentsDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. government and agency securities",
        "label": "US Government Agencies Debt Securities [Member]",
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)."
       }
      }
     },
     "auth_ref": [
      "r754",
      "r755",
      "r778",
      "r780",
      "r1099"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Treasuries",
        "label": "US Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r754",
      "r755",
      "r778",
      "r780",
      "r782",
      "r823",
      "r1099"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "arwr_UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront payment received",
        "label": "Upfront Payment Received, Liability Related To Sale Of Future Royalties",
        "documentation": "Upfront Payment Received, Liability Related To Sale Of Future Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesScheduleofComponentsofLeaseAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesScheduleofComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease cost",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r835"
     ]
    },
    "arwr_VisirnaESOPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "VisirnaESOPMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Visirna ESOP",
        "label": "Visirna ESOP [Member]",
        "documentation": "Visirna ESOP"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_VisirnaTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250630",
     "localname": "VisirnaTherapeuticsIncMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Visirna Therapeutics, Inc.",
        "label": "Visirna Therapeutics, Inc. [Member]",
        "documentation": "Visirna Therapeutics, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "stpr_WI": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2025",
     "localname": "WI",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesDetails",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Wisconsin",
        "label": "WISCONSIN"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "calculation": {
      "http://www.arrowheadresearch.com/role/NetLossIncomePerShareScheduleofBasicandDilutedNetLossPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/NetLossIncomePerShareScheduleofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of dilutive securities (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation."
       }
      }
     },
     "auth_ref": [
      "r990"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.arrowheadresearch.com/role/NetLossIncomePerShareScheduleofBasicandDilutedNetLossPerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome",
      "http://www.arrowheadresearch.com/role/NetLossIncomePerShareScheduleofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Weighted-average diluted shares outstanding (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r190"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.arrowheadresearch.com/role/NetLossIncomePerShareScheduleofBasicandDilutedNetLossPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome",
      "http://www.arrowheadresearch.com/role/NetLossIncomePerShareScheduleofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted-average basic shares outstanding (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r190"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome",
      "http://www.arrowheadresearch.com/role/NetLossIncomePerShareScheduleofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average shares used in calculating",
        "verboseLabel": "Denominator:",
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "320",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-13"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-14"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479024/942-230-45-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/942-320/tableOfContent"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "b",
   "Publisher": "SEC"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481003/205-10-S50-2"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SAB Topic 1.B.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-7"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-4"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-3"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-11"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "805",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478072/944-805-50-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479196/954-310-45-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-18"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/210/tableOfContent"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/940-320/tableOfContent"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>98
<FILENAME>0001628280-25-038858-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-25-038858-xbrl.zip
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M%D\PT8I[QGH2D767B2F %9K!1JCG%L7<5CDP@2#YQ=258NT3K>^D5N_426:
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M,;S/X?/&IR8(_UU"B?724SU&"SW>P<BM?,?@([?N-?^?%*T7%).U'SFLAN7
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M&:2H\'I<[[K@P64NU22Y!U==!A< B6J>=8,"G A?C)(B\:=,4PV-2 37PBU
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M<)WFY[6W*GZ(,2+S_FUCE&.>1004-RV"/XJ,[N^YA\Z@@VY,%6E 7'!4"Q&
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M'35\23F.%C=TZUOIK@#8'N_<F9  JT"AMTV>^;RJGN677MM^8?X'4$L#!!0
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MXWKE*)B5[4W9/0+#+BUJ>^,N;@FPK'C?XP*67,9LN8-%R;(B*GA$BRH#>%+
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MNA>*=^XB,9GHSK;6.QQB%-C#^17BH)Z[2 ?OU"\4^]Q%$K)3_P?RI@-D1].
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M)X\;_3]W$N^7R:/T6J>MJLKNL3<.N/YA=PI03G<#C%;>V:AUFK1W\>H;?\Q
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M-],HC)!':9.$D;)5'S5I@QV]+2LIHY2$-6L 6#LUC2P76+35C&;(:AN =73
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M"HWLS]IZD S@>QSP!6T$[ 1V CN!G;QY[&N'K#FW%5H;;04A?/GRA>9D6L;
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MI -C@#%59>?*5,%JN@J&_%R9^;G#*PM-(>0E.)!<AAS(P$'D"A@#C '& &.
M,8?TMK=,V-U_>+RNU3IZ2Y$-(W<=,F"&KW2ZOC:Z=4/B)@=Z=-J#Q[36CT1
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M;71XF 99EX+Y0-GD(XK%4'HB'Y/7.IE..X=T-K/,\#5:M8Z1V^&$L^V<[K7
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MA&MM<$YSD*"Q;4A1WD&"9C)(4#4$;81>('@J"DE6)A="-E$ODBC"*8DT:^Q
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M5/'L2 0!$N[ 3F GA^S,M UO:;_*V_0>BY:%M>26N9ZO O@>!WQ!&P$[@9W
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MO^Y][^::5>7W>]^O>]]ZY]WK>ZE[?G[S\_J>%G??WESUSGN7_9F)DKS_&Z5
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MY-*"*AR?I21&-!4KPNNQ[^"D.?F(O%[P*K/'++V5VOK,7C@@S@%]-+&M'W'
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MB^/L?/[R57'7 W?ER+TL1>@/+$U&R,8K9_4E- K]Q8*1%S^$7+K2,X(\[C'
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M?C7BIB^P27C2WT-[+JD]61 A<&TG0XD>,[!S2(J,L<'+JTO=-7BO$NRWZWA
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M8,?PA\ =_X'S($ AY\"X%V^[=1X3^!6%,GIG%QV ^I)01O#LN>$35W!C]R_
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MZ:CT:19ZR+J!+V,U#AV:*_)M2-&.)#*A2<R"X1$9SENX5NXQ)I<9KH2FQ(+
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M0"*Y)\>AB)12GK0]8"^&'?)P'$$%+AD'L<%5*0">.L2CMV72&?ZB#AD%02P
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M# MHJRH8NTO & ^N%7-K$[.Q,B1QZ/9J0,8#:V.\R :*(J!BJW\3!QIY2-6
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M/&/&PH"&.3HFC>N21@RED5@T;A"G("32@M\T)SXO!)48ZS9^!I48'O7,\/,
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M&JT.K_+"<1!ZK"7=AH&/,;D"3B#XZ?*0(/#]K+F?8J7Q&&D;?;3XAB?;'='
MW,4 ':P(7OHTIRG)8C)XAH$#XUG/CS8Y.#94JO*!D0 2-J_U9>PX-6.*W'%_
M']#C[>1*P./1Y?Y_]DC N(]@<>N EDK62JSJ(24)LNJV<:I/3K7[S[?"23C4
MHS^XSEX.#AMMY(WO-SLXX;DFH_3(75]IYX+)T/UE.>3),?@\\#\8?DZ:UT(Q
M Y^$GJB\8^;A_.)D?#I^F+;C884O<'WTB,C%M*A1QGD/D67%^2V%]_FT<NXC
MDV:N%V4ZX,</5__GQ^WU$& 7FCC@>>$NUWER\961,PK46M!JU79;C>X@+=H%
M!1]' <?; >"&$P-%AY@3G^+VIA<^Q?$+*YV%P/=.8.,)!T*R%)@ ]_]E3&>_
M?)$>!'@2"^!+R"('DC]CL>Y)(2;'^A.^=0P4:0("?FPI+#XR,A LU)Y!C@0\
M%0*GM#];LR0Y11SGPG3L/%;X+(L3'HZJ]_&,2_G'"-@9QN,6^8=68NX3![DA
MIG,[^0+V R!-\%D\)&7=GX,!@JZG5S"^804%%GY7/;MP'9:WZ$WQ5(FO#8&$
M.P]!#SC$;71*ME&<[-**<,'R<YE$<*WQA-A<)9VH3&E:9EBET0@?&YFK'LNL
M2=R<&*RI=9SGE\(FL(G%X.,8'P8VF2\>E1KU+2&D7HB7R N\9\U7$C<9X5!X
MG\T,&O:.&(%T)^JYB(9@'X_N#*S:/L9W\&%@Q/KA^%D61 //G@BO@#'E96 <
M%MQU)%$V6@GW9#]G2)N@[GD2M[9M_@IA7XN]1I?)9$"C)3OST$@^<C%5$J$I
M]XS4$*A1]I#*U<4.!VODE.!A.KGL-$"XOX-XPC'FF&?)\2&3C%-QQU6RKJX,
M#V1"Y0WK9Q?:FCDTB7>1% ,N]R.1G^3.W%]]^>?M[9>$FY$\7Q#5F;PT3IQU
MQE*6I2ZE8BGW<?)-?5&5;O?L0E=[*X-35C9+*P[\IIB,G,D.RLB!)/9R2AJO
M8=ONF.>$(FO!)I6'R"1ZZS&)2#$.DO>!=@HO1(3&O-A#5&OZJ[2SDF1>5&0H
MWIS0>-H:H>!UXB$N48RS.L0SB>N1'QA$&?9\O;3B<*6C7AK-DYAW1^2\M*1A
MI!U@:K<HH:-%C!AS\IF[!HF]@N? 'D"+>,4?U7"W7W>L;8WS+HZWQ9ECBR6%
MY3U;C)( Z7&'?1^S>@O7"RNRI))4PE2UK1>RN%$0P+(P;+J:+_70GZ:URAJM
MI747_LI$B2T[/&YB4H*$9V%''R !TP.Q[" -K6LA) K_\49CV]B@![0['^AH
M(1P+ROVU,V[%45AQU4F$86\=:0A';TN]*#,P@L&+:X/%Q%&">R2,B#$O]&?*
M9@0N&J%9R^#)(,\&,EN)ZO3(WX0QS[N;NV_#3BI/#R!OPZ68KM?3 >Z]@1[Q
M7K3B'%<:<SK"J.>8K#'*>.*YT\DCCYM!Q6E?;K4\SI*$.J!TD/3C$#O$27"&
M+TQ>F9E95J<5)5(N%FE]_OUC*_D24V9F(%TL'I\F62N>0IZZ"-^L=$* TC]R
M3C*</L&>,FR#/CH)IG'MI(J8X+"ZLL3WNS1YHU2HQ@PD+UH'ZRC$,7K[%96C
MGG)V$;P6:$?K-*#CUC^9;!1==,=_("6-R4HVDKS-Q)7RP/,.+W,/7UZ >6O/
M#*YPY[)6(KA7R*(N"@$XP 9LGBSBQB_[D"):+](2,0?'EX;??SV7^H.V)/CL
MM[OAQRBKA5@TO(J>-G5M-@ZI%:"'/FQ,=>5/@8>%8PRXLA<2*[8U<^$) ;.<
M#\9'6? A+!HD[QO)85C("Y "IJ^8Z%DTV8P1&8 D\?^0,&H "Z(**629KC^V
MX2=/>_%,RWTQ@/'91IS2DCZ; B!'P"TO$5W?G]N23L>(W\QL2Z>.%@![<ZM*
M;>\UP[*G5LRPW&A]6V18]CHU9UB66W['C=/7Z=+Y-A;/\_#X7*C_(+U?F!]P
M9@]2;B!=7PY_C\5Y]N*XS&5Y_F+RBDA2+-33+"PA+0<6OBI(880=17&9K-.F
M('V[[&DY**#;%E/\[(AQ<[<M^5"2G!ADN*_ 5O%5U%P5S$?./A=2\E=S@92U
M, 5K89G7>!OGNZHL\20.XZ?>TR(LYVG';N6>=G:A]?5UDO6]:$E+?<FE*?S1
M"4T\=YK2V[+'W@)MA0%]! R,C>/5Q14U&9I)$D8DPD8F_<XS6HI7=-R,,]-S
M1)>CJJ(-DK;3BG"Q\AN=7<FU,=LEYAE='+&]M;IV3$-@8:"^)-H<=5$ 1A/]
M+31;*I;U#"P5%RIII$C&\=%IB#JG+&$>ED<EX=X+:-"2/_?!6N)A,#MTGO+!
M],25L2 P'LBP*! 7&2B57%0,G@]^1-K=CT<NPU/&U7)$D>,+BOT:H-!R(XE8
M8])()F4Y->G=A4<P.(;T[DYA>K>V77KW'H#[<'^'8[R5!1?;EQ__5P,C67S;
M6?SVNY)\J2Y\^?W[7>\CYT3B"FWABN'C_[U1/Z;#^W!X"1-,\YU+17"8^&M@
M*!&A@5[E;DYM17X*\BX^/LKQ,A4Y*9F!/SL9MKULW6K!NM,<F1+"A2&[.M,R
MB7_$HN>29X=<JO$;3L0-'9WNU)A+/L,6<T(7+U6^!0#R"KBZCG,/EOX(\&'!
MG8!C51^??G;A6S_SYB_*<"F@1_-CXRZG7%E A 7H-@>MQYO+DCL+K&D<_%K0
M%DH0 U,"\/S@.+EO#)TFF'2.?;'0S DD9L#[.4S1UJ*E9=&V4X"VV(\GNM@8
M8[<S]+PD!T6;B*VVD@*+(FJSTCT$9U$/P21HPW[.;-<*4AOAR:Y1QR_73^ K
M\G^V]J.AHD5@BEXJD3A92*"E5%ET'5Y&#WZD4OCA; 9[CIJ3&29<:P"$9L;X
M#V05!.JSR\=A],G9Q^,FVDPE.T<^BRTI8$Z\=7EB[:Q#K'>)Z^\V\?P5467W
M[$+)]TM8PW>X0L_C;'SBAAZR8('APOV\/,/%YP9QD+J]E.&7/<&W\!/*=!6.
M/*RXE$)A\(R Y6"A8/RB>'U1GJL]YQLH7:(0+_&-Y"_UX5N?CG:=#@<\V4]0
M2:J35>7=1E53R>L-G@X,W/@/)'=Q(S/YIA*_A8,MLLH>*RH>X$EPIER"E@CU
MU/DZYCKBF6\6Q(%TV4&T3V@BYNX1*ZWT:#BU*^1*P@Q,K5PH'Q&,Q:OCS^GX
MTAG_;BJYWRT%DAQ!.HUFCAOD,0Q13ZPJ*IR(0UF!:&!F\>YQE,8V@6>% !0[
M*8,@^*RC^R"1I8X\3K=B*=  4$@OZBPN)P;TC/%8?ND;";N24N'I*((<B>ER
MH+6DKYQZ8._+$%".<Z$L/YT/AN@A@>!GY6A^U-("H5-&DT5@X"X?!LN?4@@O
M?2_\;KGB6JY713"-#B[=(M-?(($1YZ'YAV1\3.+%P#""K*:VE)FE<I4R&G]1
M,=;4!:TLE=0O31FH-29YC9CA\Q(EHF7FQ[S97\+9**O<<F9A$#UJ9& :A+O$
MN!C#(OR(L4>,;Q2:P*2 QL88HX%E8$O";*,2/W4T2;8M/@W>]6=HB7!N7+2%
MH;M4EB6GQB09TA$E%'S&&S]+> RFO[K1TE(58G'Q64P<J9@NZ%YB2*%$;XJ+
MQ0 :EA^15[37",!X8M=.&C.,=/(1J*.P)ZK7L/Q4QI*<\9=GLQUY_P$'8)<E
M=2H,H2N.FZ1+RCA6^LH*JSD*"B(J]QQ5M25!%[#PQHR9/A]QF5K:T*,.A9O%
M57K8I6%U,C?\\Y6-/"KN4+0HP'F=!)CDS"6]HNY &Q:^J"4Y[5& &"-,MQ/R
M\5ZFPWNBM->\=5(9[Y7ATS^[Z*AKQ9VX:HPR=D*&)#"1 'OQ1E'2M)9>XI!N
M29^)X9$*F@+=?X.N\$SZ ^7/%T(Z8PG;KH\$_04H/$F&(9^_-0$:9\AZ1RQX
MQ6PS_/B83F2PWHE$.N7$L#Q,C EC38] 20T_"<0"5M3V!3X/[2!JAPN:YM0*
MIQO0\;(RC!1T[O@+;IUK'U,,Q_@Y+:XJ4/IM[&6V*O=9&$]B5U:J>II:P'E!
MK*$+89@.EJ_''$G,1P)0B Q>^1%Z,]=?5"M*HN<5H;VL3BP)55\:_G.J3S,2
M8Y:-)GEV%8%/_0!6\U"NND6M]L B":G_(-ALMLUCS]41K;.L/?&Z&Q[24JY3
M*ZD, A7%R&HI\B(8(&]7O'S,,!YK/;NY(WTH[QDU0R_VC$8;Z9Q=3! %L2.]
MOSCY)"("HS@C Y4S].K'&1D1/GO,FHY"SV>16A#YS+GVFIH$,#8\;TZE_6&P
MKJ:>]JK'[G3NZ,%,J#P=5\2Q9=6$98K(5WQSAOE71BD-6=I*GA95F2;:_(L!
MU@A"_RWV_;MX^79;U\\N>DI+7350@7+]DYI!E[*.RJRKV)3BG1>B<"NZC!S3
ML-$QX#-X,-ELH&6TL&Z^\)L$X7).BD6'34BBE?*04.W'MMW4T_V<KX:,1X,L
M5\\-G[@%R[MP<Q]/1FYCN0[YSR<A]9D8 T>0)K;[RA=$?I1TFFWIUI(-K/"B
M+.PF!B'%"<1BR&3$!LL2-WGB3;56\+><UC1^9F:(NL%ENE] 6KL?.N:-ZXQ+
MODXI57[)N/5^-Q_I[7=Q+=DA[ GS0, <"&UM1U-@Z S:6JMLYEMZ2DE"4V)$
MKF<2.0E3?F':^Z?<?*R,35P2=2>H+[.8Q1RO<YSQ!@9M?VTC>K_3V[5^:] 9
M5)W>KO=:2ENK95"ZUFYU!]UM!J67=KA:=X3XJOL/?2YV^6CUMX+<1K/&ETY#
MW%-6T":#R!=R=?8XC1S@FTX=VM_ Q1]93UD!!)JARR<V-W-1YG=VY=Q,9FCV
M^^3<E&'[QS&(>1-)<E!TS6UO:<*87TS3\:;5:ILNI._3)(6=>:Q2A#$@CU4=
MA%&,H+LGC",3>%<\&B!\KUO0QKJR[S1IHS[?>4(, _*=RUVES-_2"(EZT>%K
MWBM940&L9"6<CFI8;=NGSPWJ=CZG>()"SN<ZF$)5B[81G8NB<X7WL1&F-9//
M%C&,% 6I&,.05:W32-6]X,4CQ>QSS1:WDJS"$=R9X93@$"F/.-;[EKO; >7]
MLI7MV$F'PC=R7R]K+/L6I[DQ'_H;Q5O6*I8]AD3*=!)$DG@<1"'8\X(8;!*R
M75%X$B?&.B^N_4+-&OUP.N-!;<I%QEH[D;/+IX5. /!.(/T[-)]R21IQ_5:R
MSB@M;.E218@['C^]HCR#0LQL;%#,6^1#\1S^I"7ZC)+_3-Z<?N:Y(]'4AA*$
M0Q![/GR>#DIC6CD"WT^J4J@P _../>JJ_IA*.5]S8Z4A\*:@NQ#7E?8Q5'0?
M?NTVH!ZUQ8ERX5=2EA@S8,_C$JB(Q*+Y"9F<#$)_7GLUY[-\2QHF$P?!I!2B
MH<4$Q:0&RDB(+9U+4Y92:SP]83_/8!G]152<;Y%-;=KX, >\?/V,RFP/\7C%
M2?D!01#K4U-E1\MSAJ)L9,M;DBRTNT* MQQ M=#_&)/Y_#?(YJ/+N9CC"87I
M6PMZ&,&:-ID;L#2;],KQ7)Y/><\WN/44Z\%ZTR;>:*Q6:J1XK*H(<JE>R[]6
M>7!&<4[J^7/5P0,=I%#>K(ZQ)5MU43)7(M4.JP"!(D96$7]*6GW3+I.N8-LC
M#I9'*VN,*7$JUYHLF^!>YPYZL(/^ZAT 8TY2&G\O3KY;G#Q+I7EQP[5$1<:)
M0>-GB[TP,RXSS&2/EDN"I/6Q%136(PJ>%^GJT>,%RXMJ5G,)EK0VRQ?3=F.^
M:J:+KJ.;8UX8KV5AHWP-K:C'2S&/]!>S9M,B.SVQ(;?6C,P7]Z?J(LHE8ZYQ
M2EQ)1S>N6"ZNA>M)91?$Q7AQ%22ENW/[BVJ.;))!"9GCY6+84XP1U!:??H^D
M6@:\Z7N>@4N"#N&'/K;3B!@+[R_KQZ.YHJ1=+._  B;+F=@A:4GB<#V&^AO_
MC;>R!75&#-J;IZI,LTO@(.3%W/'J3ZE_;*Z((,6T2YL6[H!?4^/&VD1]?[TR
MPYHY=KU[&)Q=]-;80XIG(U6] C>@FMW<H-S4V$ZDEKCKN\BJ3ZEQQ)S<U\A#
M90)F!"#F_7#T;^PP)*[@1:QB0@G/(5FWIC4_><; 9C#"BJ EBI1]L"=F:&D1
MZ;MQ_](%S$Q:.O#]SL7=$<(>=]WPXQIU<-2;![@=Y9#'U9K48"12YD<L/3EB
M-)>818P>*_'F$3/G3(\FC*%3AQKUH%\!;0B?)LKSFGQ +LM9J,A--Z,JG%>Q
M5D4?*14K2K76\P _BO?"IS?8>)SQPJP[^.'A*-ZX;2R-O$<B+*C8,HUY1)+
M4=""R%5IP27^?TNOGA4$P!,=>M5BHUUKD@;^#)? 6^;.,YUBQ4KX 2Q2*'9(
MM[&W =AT0"Q>IJQ^'=#&1?F\VI0>>CZ:GT=U-9R6X=R\.7XL?N5] .2D2IA*
M5['U$SXNHY5XU$$>W8.B?2VND.P9[#V2#(MU^-_B!<=-G<.2?MRY8O1-IAFI
M@^6ES_=<%>-IK/G&Y=3I%<,'0]'AX='X65$.Z6T%9&FOW2H+K&9:(7/%D/K=
M"&24*^ZXTUXYOXEFAR:)BF6-X]?8FGIV,6CE&U_E1P>*EPK-B*RBZKK#JJTM
M;3U?>6^=LPNULTXC@<4V'%%[J,3U%U-WU+DC/NBH,*^\Q4HR%B+F']2U!RR[
MP/BC8,#U.DV'TFV.'!)YA<7CV!>0CZWF;;BP?5[JZU3KIU83?2B./BCET0=<
M*2*;->J;1D?OJ6-5Z6OCB3Y0S)ZN*(-NUQRPP5CY5Z=W]E8ABV)AHO1W*RER
M93@$S)O;QRNI4[E.,P35F.2W87\V;*2QAV?&@B^6/[9=G-;NYPHO];:6*[R$
MS_*%EY^'WX8WEU?2PV]75X_2\/+R]L?-X\,F%8;\\0<0!5J_'3T=RIUHI2E+
M=[8A&EUB]O0L7RA4Z=BBY])3AXX9/[/@L/3%8SDV'>@Q7Z8*&MX41QC^)2+S
MB_'PJ?%OZC5*O:>0(\_B@YC%!\$BH'VJW2NOK+6QM?P\BOH&A; *N@8X&ZQ2
M"=OMM0:#XJ^J5L(J6JNM%]]2]JCRS[7V\IK:2HOJ;%.>NV8MZ?$7VVZU_6PZ
MT_I%LP<%FV1LG@"05J4:>2FD!HN0JE9;?%!@RI8/2U5@5&\V^'Y3%+_!=K<J
MHSV9A-23K1'N*,6)I2N5N%\]UZ]:^:6WNV"2RX-!68NA?:>H;TBR:7[7T,-I
MT8.Z5WKH'18][+5D8[]8\#FT;%RC7ZH!ONL"^4YGKWC?![S7!K*JU55<L"])
ML$Z[G?>-2-I>$0E3!'1YT.\?"!Z=L#5P'\4B6,XYV)2 IBE WR<%*.VS"WT@
MZUWE0'2(&G3J!H\(C[I[Q2/E[**KRQW]798/[Q<-OAM.B-F;?&#'=NST]!6*
MDM+7'9&!>G:A=&5=.Q2%HE%,Z\*C?GUX1)UZS_]BGEN$0IVS"PKRJ;\<" Z=
ML%+Z-?3@T$./-;IH(=(/]LH\-=!%97V@'8@*T:BB-:&1UMXK&NF'A48GK(EB
M3DH8T'!:'$3I3H)78T->>O(*A+;74)F")9=R6R]KG]_HH<>*1EM&F/*8@H,6
M^EN[?QI=<V4Z!#-\]NS:IF1-L4J%]\AN%,]"+-]K/$GI8YL83=;:A^*]:E3/
MNA!IK_$D92 027F7#>SWK7PZ?N"%' DL)QZLVZB?A82PU["2V@9"T.5^KZYV
MO(W^>2AXM->PDJI@WY6^W.N<BH*ZJ8C>HH?KL>+:7G5 53V[T'1=5GM;AVXJ
MG=@1:(?O$/7VJC6J'4 ]39/;M07/#ZAY_?'HD]] =_PD#<?C<!KRCH FFWD,
M6W5%K6Z,*?9D_"O;QO[4U<P/-?+L%'2_I( +O]N,FH\XYC %XU(ZJTQBVME%
M3Y/53MXN^]BHHD>*:RN8])OA&L:?^G);S:NL>\>UFMRI'&T&A\FW[Y;5/<O8
MLVM#\=E,4Z@=*(?*=_9AEMRPZJRD>W;1Z2MR>_M\LAI/\4!+Y1JJ;:BV?HMN
M$ZKM(=5VY7:GK@F%!S;[)-W9)M_10ZP2>ZT<0^N5+\N,O&CZ!S7J6MI@)6[E
M%3Q[C$E3>.^S+V'G+K.@MQW=B_T2I%?#K]8%35_> VT=5;=J*S05N\&VRD30
MQKU@NV^PD\'9A=8JRPP3.Y%3+=3L>4NJ&T,<P,$=(HBR?[!V,-S3;96QNXTQ
MI/<&6\&(@[JJ6>,"BJQJ<G1L+)%7EB"N3BS/#Z0_0\,+F(==IB86@JR@0:<?
MCK"G>F#1P)*H(R%O*CS"ZFD:J@%/L )L7I4N88'?>!-QRY%^9Y[K&++T3YR$
MXO@6@-IFADGK<45_0VIZ15.CHFZ$U0A$6X%7Y:W'<.[+A'D^?'CYC&URJW:E
MUCMJU8!;KNDWSLR"W_:ZZ@X2N%K0ZG,%R5,GTW%)I)Z&$42%]1OT ]56-'?=
M*42TBN>HYYJ7OL4YZF<7:BO?+V+;4YP6EZ1EVY0CAX"OX',^$RJDIJG4,]F8
M4;_!ORKW]]5STNXMH-JMB@LE3?#WLE@<9=*NC@-;TJJ>FU7T%@?5KWI0VAL>
M%":3=5KY#.[5!U5"CI*9"':?X= !T?;?\LQ(QOL+0CX>JP0Z%<M*_!%[,IQ4
MD$P\V6&O&06@1-:[8'5*QHI>KOKZ$/_ALTEH?[,FK+ -_9P97@Q:#?O0#Q9M
MV7.\1DQCB><AE(&2EK]B\=W=+!XTU%YN[9*[<CF]W2Q'Y3,6RV'IKS'NY20U
M9"U++RMT8C%Q@,88X!"AR80&"W)ZP4[=Q=HQGZT$@CBT SZ]HAXE63\$O5/K
M5&78;Z@2:AAD5@K\)+7IR+O7I[J'H*5J>L53[Z[P>>QTL5UT*>5='_491O!%
MBJ>L->P#.RH?:+_PX7CLA8"75V*N\A8MPA_&S\P,;78[$0^-ACT MWQ$IW6^
M53B:_BM;A>] &*D:_G\WPBB":#2IFL]RH$G68E!#TEK<0/WNTV;2N!RIFL[=
M*Q_5=.ZND3#>2>?N'<+FE#IW[Q!,!].Y.Y[44L?>UXNN1V*E=(@0*Y3@3:?O
M4^QL7)+T1.,#!:)$#1Y!E?Z28(E0\RH-&$M2*;3^V45'D7OMNO*?CB"/J7;"
MV"&/>$/"V.&N:L@KVCEA#,XNU+[<[F[=X.,8"XT/61K^ ML_3WU1+!U/-H-_
M+T+ETJV-D/0V]A*7NVK9%,NF/.2=,>8ZD4O!&:)R1S^5ZN5CX=+" <Z9LDD=
M'DO,E*9-RGJ,^))#]"H!:$P3>;1706O7#F4JR='WTCD>AKH$22HR3BR)EM7V
MH>#0J6NWMYCAT6BJF]9\$?CR,:A-D5\[N^C+2J?12-\% ]T1$NEG%SVY,WBO
MFN="J.(<+UXRMGR'*/+HHB9J+ 1I-W.:-S6.38WC-LTW:N(MW;.+KB;WE:8J
M^7@H]I"B &]/L<>A$M1'L3V@V([<5K;6*8^Q(OF@4XF'E'&?KP#-Y [30)C>
M+WZL1JP,0U#=Z,P#?/!@N9(1!)XU"GFB5N!*KO/D8C[8&!:$@);@:_B):9*4
M+^S+$J;U1]\:#B(60"4T 0EE7@7K^R[F_6,^L_O30E ]S?%3YOO4VKHE73L2
MGG= %9-K+WTQ@@)W8!<?/RH 7/B6$EY=P,\I(  LR(XJ<Q'!7WCJ-" PX\6W
MC\8?S#2D;]:8JG:'3QZC1MS2!Y\QZ<8-F*1^7,BQ1 Q#NK6<T."YG2D<$X>I
M8>K:S/5ILY]HQ=8+2S+6_C.KE@K":2>W&",@DS HOR67([-_7%74!<"D?N)*
MD=M8H[YI=/2>.E:5OC:>Z /%[.F*,NAVS0$;C)5_8?6%N.G92_3T)W8^\ICQ
MQ[DQ@<U],NQ78^XCS:<)&J@Y#?!%6'&(7/S/R$->D5]J2;9LJ5E0#S"+$V%O
M;A^O)*VUHFIC421<.R_,#XB^KITO;(3IS-\-[P]&I(V)S<'\@8U#CQ ?TYJ!
ME1J6\^A1$>T0R#/POUC^V';]T"O(D,6\?X'LS!P&XC-<2#9O]OKF]ZN'Q^]7
M-X\/.1:\F-*;)I[D/?C,@C<E!;(K0$*>Q]^8;3ZZWPTLT%G8>0*6Y&.>%ER<
M&XRU RMS@P]:ECP62 PK09@EB<$K4X*C!."]9_L.^JU>OU<UV;?3:?6[@[KR
M:M5.KY9D7WB%6ENR;[.HM1>EJ3M+BU:5-T@,WHB'K)?QFJBCQ:G3]<)JUZG!
M.P14-C6X-ACM*,U^-X#@!HR) A!DRF<#A$M]>?;'LG_J^4P:YP\']%=>=?<K
MJ%P-+#@LOKE^VN'];H#QU; \Z7?##ED1=UBP'[D)4D=ARA*>NB9@F_>4O6<%
M9X]T7K!=6/G[WN-5M38B[AQB[(K+PA?#LM'2.9^XWKEOV-1H0]B>6^7*'V[0
MCC9^<A4RM*MJ1>@K)C.BLR;EGX@PY:OK/0">B)YUS+QT_6!#+W^W?7;1Z_;E
MWBGEWC54\BZHA)QY*T@D:>A/>F:B8J*VO2G-8+]'>=!I"LP:BMG;KBJ-N=@-
MR:!15I[!W:6F3OH6 RP:<FC(X4W4K$422(@C2RJ;RHL.Z%B]MJSWCJ3R\NUM
MOT.]JJ:D_K6'X^R<NHK=4#S_=,S1/1T.K)H"?/3II159:+5MGP)S79% N@<+
M5JO-@JUT>F]4%M%07$-QAV4-ZS59PPWU'0HVOC?JJV-<Z2XMZ^ZVEG5#6H>"
M:N^-M.JL1=JQE=ZKS4K?.;GM(Q]@L4!C9P'T=_BBQO^R&__+VR_P4*]J -<
M[@T ERV[:TH$4I\?:.)[NZ\=WJ+J@Y32KZV=NZHM?WE3(K!8(K###N*G4B?
M_1%-G4!3)]#4"31U DV=P/MY3V-H-'4"39U D\!6F,#V]ED6_;,+O=>3M6X^
M#M5D/1\ /C544DHE]65&Y,EB<';1W[[K:D,2#4GLJ!!@_^D*/1R/D<_%:^H
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M/7B\R1QKZ.;@/-8[HYO^D:63K9L5=9SB=(@C2$F:XLS95Y>$JE\L56/@J-6
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M%]&E),6UWRW E&X>4XH226<>\PD@/(UT.G,=^A/V;"T"]Y.T&6IU*Z/6WIN
M Q-JM3DCJI+=J>JU)5(J:FLPJ-:1NOP56K>FAMO-HHYY48-6I[N[SN0[RLW=
M36)ETCA8NC0\;XX<<#@%^RQ8(T=WK>3;@TG@W2$ 4^7,TC E7AL8K@_#Z]B6
M::"V/M1N0-FJ3K@GQK]^^&P2VA+JAGYMF?/O95["2I?35M1UY#"C%(9*\R5J
MSXC?;U O<9Y5*=;9+.[>W/_^[E^3(Q])TM,=]YJ4Q#I.(<9V<@$SI;LB9+;$
MST1V4N50&19O*')/K3C^>S?AY251Y 9=3PQ=4U9IVBBMC,#]LPNE*[>KMK5K
M$+A!X"4(3"F&2[ W\0=421$<;)@BV"!K@ZS;<=L;5KG1VJ!]=J'+W4'%JL[]
MX>I!^H0J'7M)F!'/>=V3Y=ZE;]8DFZM\[K/Q)S/TT$60G*@"LE(K#0?6Z#\X
M=-/H&P\A-^4?A6Q&WZ\-,E#/+CJRHC;5&PTBU6P=##K \62]HS6H]3Y0:R=Z
M^T [M-*>!H_>GD5MHE+KQ(X&)S2#L:8@TS%IY_J.M/,NNF*WT<Z/<CI1+F%1
MEAR62Q.H%+<]5H_%.ZH,4KK=/1L9&.C0Y+Y>=?S)GBOLEA72-<C?(']=AA&&
M37H;]&QKR*$AAWV1PVZ,N4V#, WJ-ZA_2)*@NOW9;;?/+GJRVJ]:%GT F+_.
M9<6UU(I^HL74S8NV:E]]$KFP*YJSOW5"97/_<=_?),0>YD[>4<Y+;Z]^HFY;
M:1)B&W1]"W2MQ[/3;:N8Y"/W>YT&@1L$K@V!=^&+Z;8[34)L@ZQOPFTW\9YH
M9Q==N:]7C-X?A(_DR$/NO9V$W+MMO4F(;1)B5[.9_IYMD&Z3$-L@TFZL@QYF
MH&FJVJ#6^T"MW>CM_28A]IWAT8Y4Z@&RHUZ[:E+6,:#1^TF([>]&.U?:34)L
MDQ#[;C)!!OLU,A2E28@]""QID'\KY*_),%)4ZB.B5J[-:<BA(8=]D<-.C#EE
MTR!,@_H-ZA^2)-C _E2TLXN^K'>KNL,. /,W3XAM\F'?Q8N*L2$_?.FHARWE
M9XD8'I,\]F*Q5QP&XL#&;'N.;"$SC\@Q)5 6F33QV)\A? *76!-IYF*"H(5&
M>'(M[ ](-7 ]7V(_+3]H23=NR?=\9!*"PYI8\'HS]"P<VO',) >6#J]T@F=X
M#$#,7#$-2?"=)2-TCNA,7JW@&;CZA'BW%/*&V#8VQ*;C$C-? "8@'0Q8J6?@
MX\[QT=+(\"U?<E]P?C.\QLO<WI(*$" ]08;]G-&LF%?#E_ZCBB#*UF7D2K[3
MIL;M9%$2Q9*FFT@:O9H@U.M^?_?LHMW*]T')?2 !,MBX.B09Q%P^+GM=U)7I
MMTJ@5NK>:J\:J'MUOQ]K*UOY]+OEH&;&^#D:6E2-60 _@LO%K3GOX4KB V8U
MMF8T'2)PQ20WX*"^90+KE%YPB/("/]IH1I*[;$;2US (/9:&]!4GW.+A25UE
ML#@FZ=B8Y,JQ3@Q6.J53F1!PBOD:3;WC)Y<_^;*I>Y_6$2^*6A20V/N,IT&O
MU5-[54<\]=26KG5J&NRCM^L9%J5V6KJN[G&RS\'GAJTYOR:-^((O;!$%VKOQ
MO]XN<?J\=.7@2A>JNNH;F7(:8R]*1H6<2KE?L;P@D?_!8U,#Q9:WUI24*F'K
MK3,>#@A6ZX_D+MK<*;C1.IN'4_(ZV'V$=#CF$K7=_Z4H?<Z9IK;/+C3U4%HM
M5F8'"Y/L#QO%@1UT-V(!"[NLG !5 *632H"JE7)NX+F/K\Q^8=_)F*OJGE85
MGA[5KFF,_=YIZMA$;&]GU?/O.:FP5II"X?/XZE8F);4F4FK$TWJDU&_$TU&0
M$GIW*Q-3IY%+>R6F02.7CH&8OKIAH6&DG5WT#J;I\ZE+GDZ;0B/!,_.8,0F8
MUPBB_='.B@PUI)7Q0J;F$,]H&?7H9Q>#[M85(H<E:@ZG'GA)*<*^?8PGGL6W
MY;9/F&OL)KE/[6[6[7*[<]J"J2SDZ2G:]HEZ.TA**TDCRY1HK9E6AC%F@:\7
M_S/R_G91&I@6(-$P9CQS?0N?^HF"WX L(E2LM D=4W>)0',[N<48P;&%0?DM
M11'O/:<&*%H6#.F?N%)$;VO4-XV.WE/'JM+7QA-]H)@]75$&W:XY8(.Q\B\-
ML%_<].PEZ/#$SD>@%_UQ3JK1)\-^->8^'FOZA.!XT@!?A%7YB2U-*.CO-L^B
M6)#=W#Y>2=V65#%I)7#'?SR[-A"%?_5G: 7S&S=@7RQ_;+M^Z!5DI*@]SNL
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MHU+JL [*\(,;@NIP[_H&_##,V$&04K53&G42M2K5A N;@'240H] U-!A.W_
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MBXZL]^K*5JWCP XTPZ\AT(9 RPETA8&V.8'VSBXTN5-;.GE#H V!ODL"71'
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M;7XHDK'M8K+,[01G#C/')Z2\YYW<</ZJ__!L>.PSL  S<IT^LL59HEJ;,Q=
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M8:^N@VPWOE<P95'$BR>1$RG%7CTN(M!<1P]YEG>^4TV(APBB ,*B>.&T7H_
MX(-_N>I].(2>]['?B!AX10K'LOXV>JT+[,Z-["U]5UM>&7"X06W'![+9$!0J
M3M7NR[V"JM!('!!BV7/$F[3WK(3@5Q/U4B.M4J3S8?S,3$!EP?OS ,9W /P>
M41[D YQZ9S&4>6RL_)%X*L[AXGX]E-3 FWW$%,F0_' Z11\E$+G@PQGW9P"'
M,PKY7<!. !W=UV=FF-(=0'-JC%E(N1AP8-?.N+7)H"^1FOWF<[Z4=KO5YBD
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MLR2Z8A[+6)(<&B7'9Z:PP#!^Y'>;_*2S\L/QOYFLPU ]"Z?DMZ0[-V;N5]S
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M@<?,@0<Z@!D,CT<1GC:TZE594-6W.H[B^?T__TY2-[ZZ#EE(,]W[00+)<OS
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ME2R$"1*%;F:RL6*<%GQ0'FU,8>.@V4]W:1 QA\$3)3D \1NS4AN]WL+,(!C
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M<,YWRS^T*YHJ:X-NH_E'**8M&&M#7X#=,E8'&$L9R&KO2&K(C^N0['HR(4:
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M&D=GA<H#1K#A;RT)US UN[GGOE@^SF52@8H=&:CFAS9;!:D*67K+9-F"&@5
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M:10^PW D)3)\.#VH< )#@!]O^-(?_Y"^6#,+C;]S-,O5]J?HOC_^07]0/GT
M=2>]3EVL779?'4R. H:T3$N'#0HDO^C%,FZA^-Q,_S>JG>(G4^I'EFC]!#5"
M02,#L4:^#VKX6^B!FH?]=_0,^RXV4I'.\3$^V%4W14-GSLCOQ/EK,<-O>7/7
M8^L<3?=1=]R)57*J[&;IL35JR=(\]/P0MB0I+M9/2(>A S/:)5#QZ3ZM",?=
MG48*V*[EO.!N\$Q'!&I\;KM_Z? *F#V\DWU,YN_F)=QH(.#+@-TH,5+T9PM&
M'2O^B7-0Z7YH&,3W84< C9UZD%:6\T<_4&L$M@3;G=,A(AH!0@H 6_]%U@T3
M)O&[1V +\*2K*6P-&:+0S<L@7H#;X1?8EYS,.N)X'"Q$#UYQVTGO1?A[-"VT
MDDQ9&LT]"QS,+F5G-<,$T9VY3T2KVI+H5KN2HV!W]3G"@8D#QW #D4S8GK">
M?THK]5T8TE2W)Q'?5C#'N&1VL+8]W\*%%Q*WJ5&4>HJ'J-K)(_H8N"H,5C^2
M*T?:OUF7JG]CA$G]>QK#HL_U9W(Q!L;Y<:%/8)P?=?M57_@8*$OOU[!9IVFW
M/.W58:Z-JGVC#M^_RD;C<34(0R-WF5L'-TB',#^/JMI@C9QE[4UXTD<F-6,+
M7/<0(6-)N^&5E0*..B2E=&.ER32?RU^%ZB.E+O@M*[4%[ '@'SS#WLE-U^@&
M?Y.NDE-Q,]V/1H_:!!4)_^LJZK2D$8J"]&R]X-WL31%M5I,T-7UPRD'3QMI_
M@TY?4MS,KV4S!F?'M,#H#_2Q"\:69'KALR_9C&!TO< 'R6KZ-8N49^JU\>E&
M<_SW.3!ZR05-UN;5 D, G%-"&<.1PCGLOD"YN;Z(V+Q2U$13V\7A)=U[]3[>
MPI.PRD^P/_OL9=_ L">58R4:]O[1VJU5*5L\6L(L"2Y4R&BPFQ)8-@M/58 W
MHGE/0H\R%SP&UH3KD&CZ5%#".=Y;(Q5NPB#TR+<(=^=K]-5O_*/5R:' [M;K
M;B1'B"RBSS$:JU/S+V4NZ8:'P807W;/<$$U \'[IWD3-00P;V$A!*I'9\  0
M%6;I%E+6<Q>Z36&$TDL!H\ X1B+V&" V0] I/DS-SVL %F"@3OT*#;D<A#K$
M45-Y+Y *[*/ND7F@2Y^_*E+, R>DD,#1^WL(WHK:+PIP![ 5/%.O2J\F6X/!
M&M'ZS'85Y(@:Q I;^+0W:YF<VHB8G:YO5EB K=&<IZ286)[/#(E7EP;YYC 6
M&MXBC@>.'GU5H'O/D7OFQ]&6*&CV%S,?<3]%OP #*C8+W0)9OU&EK_RJPK9@
M.1C9@]4/3>HNCA[N+X#Q9!9&RSI1#W<C"P<8N<PLP(P"&5L^BSF\6)HM7)@V
M[L(+/_#<^70AG<-+T4RA72F1)^C1#9-<QNY7"+DUCGS=M 7&.")R;&*JYK1-
MD:)A2AKUF&E:?![UL57]&EM#*(G-K&6AIM2]"U"%LZ+M":Q(%Q0HFJJQC1L'
MAM)LA#A^W-TU7. <MK6E>629-0I ^G)N9"GE]*Y\S-YJ'[-"RH1V=BC'='5,
M.LHS87UP^VIT>L/WF O\9?]QZ]NGZZ^2VF)2D__WU]'=Z/?KK]=W3SP ]2A]
MOGV\^O[X>'M_)XWN/L/_1U_^]7C[*-W?2#>W=Z.[J]O1%^GJ_N[S[5-TS\/U
MX_<O3_26^V_7#R.\\%AP!%! .'5> ,6R?S+=W#_\<_3P^>++_?T_;N]^EQZ?
M1D^4+(_;8RON!]YRI5&U*GD$-HC_#L%?)Q[8'@]D#KH.#<X;4-"2TK[X;ZH?
MJ3,:*41^=G9AN^X/W'WPC)-[U:A4^?XU([K#7:M''E90^Z/(TTK2SJ210=6M
M,M0TNA'"-H)'L.RH.WY4N2YX]/HG.SA,O:.3?\<K[N^P%?$S.#\TINOF,"9H
M./P[Y;+[^H1(4]V#71BH0"UM:I%X9+R(DA: C.!&@_(E,CT72[V0$S#:VC<2
MG/PT8.>G5@3<'(#9@J:(Y; ]DUI0#"S61%. .O%CLF9&+>F?%D((!>#WSZP@
M,AB>B0,FBTTC^HRR>-#X[,)U67IU/=-GI )R\G +?%;FH97X)^2EY1_125[^
M#0_?C=R=8[!-P 1=_CDY'8ZNU-VGFRJ:;02F]H[A6XLNI]6SJ^>)#<ROO[C>
M\N]8$Y^G-A..Y5_GX+_F?O/<?Q>LHH$PM+DQ\(RPY=^9@5Z*CY ?#=W/_1Y#
M\,870%3BL3!K+G6%I0L\4_N)LSK8<(S#X3(+E*$CS_UW*MEP'UPST(KV*"(N
MFI26 PO]O*#GX8QJ/(:&.AU4_%HAO$V,[9R*H(K)(Q-"LTDXF>E@<!RA)TVH
M10TND*,[+ ) /*H/'(.@*P!#H7$ O'<<^L LOB\GLP,UB08SB3P@^E[^3O+"
M(C=PE^49X0Q;N!K LSC)=?-YHF1<HTCY.9<, PIX"@%7091J<OI>\'#@)I:$
M@3$O1B7@(*J-@"#@]_C\T(WFN,64 4<PXZ[AOD"#I-&/P//@H["M !_ [!#=
M0\4&/YB) \R^HL^0;J$G,87%J05Z$0.I,#_X$X(W8T9/'!E"39V-RTJV'CKP
MB4S,Z-.Z]V:@I5/Y+I,XH [:VI]:<YE';VDJB&/^2KDT[2)21/'GB*XX:<H"
M(/M [6?P/G,W!$E\T<?=DJ)79PYQX2.XY]#?V"]\EV<\Q&9&E?F$O7+-+'6:
M/LX^3-<WQ8NQRR;S4-@BX>'8B6.'D1'TM<D2?S!/AB%L6Y[)#B!(E&E#?L(V
M2ND5Q_\_Q>P0Z:GT,/EH/):+X\NK>8;GE,$MACY'U0VW_B>TO!1UDW&[V=&]
M :>[H;9D&75@2JA>,>""P.91/AV8=%Y$SYAON(3#*/5G?D@4Y]^]Z)9-]7+:
M+J(Q:^?%M3$X+SFT1S6^Q;/\'VPQ0"J9%8L+$"=_L7-Y')!I32:6 ?H%&<J:
M@3WG1Z$34#28X23I!@P69F4OF$Z9T32H]$O&9.%R[L+MR'/MEC1BUA33+3Q[
M,-9D'D9_,#?+7Q*+R.3F.AIE$$>(L7<,]S(4>L[W]*#;\HW0]]'RY9L(,X(C
M<\JDTV*Q:F:/XN#7:?F;U0L:J?1GL&;A$X2D=Y74_A2+VO*T)U%J'BRVG-K;
M\(3>BA<4+ "PUVWW=<7\88SP8C3-J6+ >QA:OLO);\'^0U>0FK/L>4*WN(T[
MU!)5:6C?13;!\SFTR2.SXQ:( GZU]#7FU?_K2Y_9<]%$1HYN+WR+3OPFGNQ5
M9K(/"6WN8]K$MLQ$^@:J0[JEMZ:_K(Q:T@,P>42*W!.W;"?9Z'OHN '8=LKH
M9^]O2;]QJR)Z-0YA=[9P&<NW,99XN27(+5H_S2YQPL_.F.8VUJ>N']! ,"C4
M$2L2R;/"/V V1(?=$UN;T+W6  &9A*AP8%^T@(S,CJ:Z54XS#MWDD[ R4[XF
M\0V01"9#;$,W7; V6=@ +5O0LDR363.6RHO_C:.T*:\?IQQ[_E=@<UF,7.E$
MHL?KJR1E""QO&Y<KLJ92]2^KM@88)6Y3F%'D1+YQ1@^FMYVEG4V.DHGMT.=-
M/JCF23_":<K2A+GE@6<[,!3X&\M@#N+TW)#N$4FZ+2RRC\<8<3@C4JGT>!K[
M@1A3]*MY ,3C"XD:#E0COI6P;^.V9NN@HL%0"G$<MD4U-HZP*$R2FD*+)0S/
M^,9DDO2^GJ1,F#RIF!W@V/%A^T9-E*S\]14[S5DBF8TG/^R(E@7GT:5*3GSP
MPRWD$XREZ'&#'6Z>F4A66W^5D?=0O]NZ-:.OH'Y=P,Y*7BR?%*Y^872'SY\^
M.;$Q?K32M:+I(3%Y$G\S]2Q>=0UF%[%<]M!);^3LW04V9,F8>:]$7G430K'W
M?UX__'E[_<^F&\ME:_0B]P$X$NU)W%.9(-,30V0_]-2I:0M\2<#@]9%7?="/
MH/M3L;O($6*=@:9DUI*^,Z]0&GNN#FX&R-3$M2T7F>?A;B09<).%,2"N1 G:
MNA9R^\PUF?5F@EB]$&^1.7R.]R9VR$F['+'#1WH7/?]$L?&X804S0^UL^3/6
ML<@,X3=\$/2120A+8C)#%E?YX;C&#]-]I7J2!8?8]%K\Q:@2DQ=RU8AJV6;I
M509L.YP6H+2ML16P+0A<"8P9< VL2_RXV*!OEZ/X+<@BS?.*7'"66)%_""X$
M(-UL4!?,#PG2^=>H7VRLQ8 -G>DW1P=+&$,U>C!]U:F/@)].+Z4;S9@IN!!K
MF($2\5<Y!US@(N,#G# G(PL\_LN7[^G!^EJW4==K=4N,JN"@%6EXH;4*NECA
MXN,+8"JU#[<D#27BH/ LL:!+/2.?,J&=BB;IY@OL'#H66-'ZJ;EGP5[#XO_,
MT^;1JSEA@@#21B.=U$=FU@U6S /GSN8V2[F T8<3=.@\'HB"C0OE'-_C8WQE
M!@:)-;<QIRD,F'+13?!K+1J(2LPFNIV&8R.$O9&P5"H>_.3N_%3'B6:?_<2,
MS+%%CR\2,8H_&H!-B(&AQ3QV\V@!F$6+I>P0HXJXHR&A@ PO^&%_X:-9?GYU
M]_A!AE>!44"8 :6;%I[L\+<RWR<;L)NP<($']#7I>5&PR! %S4Q:0$#5.VBL
MT-8Q4FO99CB7DP9O<;G5A+RBE\L3-X,H(XP68^,4Z%+@'2Y8"Z%]2EHAWF[F
MUIP*6F1@^Q_+3C%S]JZ5F/3P$'.F'DIOAW[L6HV7)I%*%=W9Y1\@+Q[N[?8"
MG"'+!'M!ER[2>8_GZ !0HQWS7D;?[J^T#Y]6+HM8ARW7P9VY?RV>42O1SZ&*
MF>+:&%,7(^3$@__@VIS_X=[\\0&6Z"_7+%ZAN]_% M6_0%<TK_Y%]PVJR+F=
M!NO@VO/\.GS]71H,V^C@X9)\^3;",'!PD4[#'\U@/UZS4.\J*ZS?G,HC(2MO
MEI5;9V+KLQD[-)V']LQUL @SCO+[(#8H%P^CWZ^%IJJ=^J"GT -%'S:F_<0:
M>RY&E2^DQX=OV()>7=HWOG[]UL]K*9Z47'9#Z:N;E^FBFKTYPD,?()#N^!<G
MLT9?H_JL"W/A3T*'NS])LC+L^" ^4P(+"2+C2^=?1X]TV__]\1\7G:ZF#F%[
MR2[@'X^?Z?I1S99>0WCD8 ;!2:[>R)Y/]0N%'K,&WF+N6XYD$A9:,Q;2^6CT
M]!G7:J+_97F%-MKH":O5LVD<-/[]I/\@IA"WNHVWJ4?+,/Z(Y>DWZ<7R0E2'
MIC['8QM8I%_!<L+*";9B5-2Z/:W?:P]2R_?WN[]?:,/!D)W5H=C]]F=>;5*1
M6^V?"YFKOH0NAC]H3@B&T:F2C,/ES)RXTN)%N;KY38A00W8L7(]O=]^^C+0E
M,>IW5;7='W8C-PE^4X3FJW?9[L?$QX@I6X;;NS]^NXZ%1!I]^4=?Z*CZB'VC
M&Y:+D$VA[4X1DTFW:52910SB$L#8!%>6S(+/W_^G<WHF.*UU/=ABP==7*+2H
M-O-SO#!/K&J3K@\LC[:\/%^558M#3PB.4I0:NCJ/<\MQ#3RP)39*CXY8>+JD
M)L+36;:IG_[G3ETM/8W/O2U]A,I2*.&UX#N BV'@D1A+8$H!^5$E_T_+1Z06
M3%!ZI>=,>%*^,K,9\\%?K"![!,AR5E)WL<R"3/DSW!^ V\(2BS+%R,G!C@=O
MM.:(3OR3&"$OS "/B9<=V&Z<G_I-]W6@M"ZG80E/9O&B:I4,Q LOV8CJ%PQ8
M&<M,\)E9?NU2>4-+NBJX'VD9X'&!R?(S')HOS$XO/3=\GDJ_NZXI?6%>)X;G
MOM&Z:H-(Y[]_^89@8C\M@]6\Q+45 0J5;YE$LJ/G,)E=^NR%SW%:+ALKS2%;
M4Y1!!T@L!B82'RAG1QME\>I&##!D>>8%YM OT@]Y?K;PG3C/],0[?7OTHH3K
M7>]9=^*BF/.KAWN?0JBQG//\>+&<T/5^8-H7SUV&-5MPH.PP]T*TB6E2)&:U
MTS/P[!M3N>UI*</:*\R8!,:5,7V$YNAXQ/!"6KX7H0#;MOLJA?.H%"=:%GH
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M@@:+VP]]3H0(&<',WQ=-PW6>7?SDX_5_?[^_'44-($>C)Q7[@"\#/']@U(]
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M/?;F>'6]:>=5,NI&J;9VLN]U;\?FW<&R)^>KC7S5'-P-4VP)"Q6(MX^(5ZW
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M![25%B;,E4Q6^'\)V H,ZG!$[*'7*JF=*; A[<K\R/L^ZTZDTP_I28^4P-\
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M(>I.LAD@VQ4>,!"RU4JKF(UG,^3DDJO];ID]C/#L2;+$9./QXGPV]-H<]QF
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M6D=W0K K-Q"L3A$(FOZ543(?S#4B/%_=N5X2(K(9$9X?@,?>O=_YT-&1\6Q
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MT^4 -'Q>?O^'5]'H'\]^2+^ZF/QET?W[M[,4EIV"'IS"#RM_H_X-+GX-ZK>
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MI)K5T"%:%K#::'J-:E;]/%F$(QKPJ /QKIP/>4G$B$FQP!0D:34H75L?%B:
M)<=1!B:<:VUF/(1ITX-QQ>>?Y3=XFTJTL:X'1YMKM ZBUP;0.N:D"(4W#YVZ
M#\^VZCTUY<'-0ZV9P/>A&M/?PG_/YJ].:1L]P?E9C_IBLXV:,R"CCO90GB1X
MQBRDA$GZY*-V+6HQW1YY5WE%[10Z:R;8QC5R:CV(=^4:IO,8]SZ@&E906@ED
M^Q63-M70;"SQ;DWWBH=,!E--GK:!N$W>7?#<@>6*Y1QM#J)7SL=^Z?R>^D=;
M4?D0J;;.%1]<LX5,\>"U]5!X$J!$/0B3JQVVDG>*C&CF?2^'9K_+Y332UD;E
M<8:(NG7NSZ?P3\SA_><P/PD)3Y>3%(X7OTTG73NBL*SW/ <D$_IV==3G7ZH9
M_QUXUB%&;@BIKX&5@AEP/I&';B)G66B11;_HL4U0/'J^;$T%(]6?^/09Y^%+
M!WQ!",^!^5B?YA,#J6N'OF1('%8PR$RG6)@4^F;[Y/L+3]PYRJ/7?3,1CI 7
M<6[MGH553Y?SD);_H$WM8NJ__'%>(/Q@L4#Z7ZZ-!&C^0B-M92(K"\J'3()@
M 5AQEHM<@D^MJ[BO 7/[EV:C^IUC*VKEF;.CZ[#N@/U8#]C_6G7 _CJ3YV?L
M7S_^UYCW9NMBV>H%6Q.![6/U>!V3-[5;E)*%?'!;'\"E"5!BBCZY5%3S[>:)
M5X_/S-O(Z,Q!C;G6N"G@8TVOTB1.G4O)N7E*Y4OU^*%<WD+U^"%$V(?[RCLK
M&%L?78S,@_?.U]0(!P%M J&TD(S,JB1ZE49ZWM7C!U'AH>KQ0U2RLWK@?4 ^
MX^KQ@W2X5F'P=12P,[:HDJ,R7D!$;FA5&%_!>G VY:!53<;BCY\E0ZO'CT^2
M(7+?^7VJ-B('1ENGM"K76H0,O' 9N)-!NEBLMNPA;^01W*>.I+V-[E>'B'Z$
M0CHKBM2Z$K)G]8Z(U7R"%,C<R[KFLA3+G$#R_!L;VD^]_/@Z=DH[)>U#^?$>
M<%_*CV^DY$W+CZ^AH3TH/ZZ8<US% (1:@:(3'"(S!JSP*L6@5&*M:P#N!:'6
M*S^^13X-44QS$^CC?_WGQY]O7C9>U#,,UBEC:"^6GH1@/.W%SD30TELII5'>
M]2M?<M\H^U^!>I!^;E:@;B+<[50:#\PJ+A%!2:%!)2L)D27.6X9><*6\[E?I
MZ)%6&M](SYN)L[7;6V=Y'@"#Q1//()10<X*D :]0@?#TC4Q[F=1-FJ)=#/C,
M+='UA=^PN-EW$!>A*3U@M+P(NQQZ^U==:PK_IOHVD-P82_D"CN/!2L?!>E_3
MBK4#C['42L-,2\:4MN8Q*/">6ZC&^AL@L,9Z^UOX8W)R>G(1X4.0;7$2"O)4
MJ]<Q<$87T,*&HJR*(O1ZD7LPZOK*H%N^,UI7[+,6,FMM(+VIH@K'5PZ%KFSE
M85",)9H"&6U8RU7Z#-&9 #6)&VT44F"_@,H5 SSR3+!UGC^;R;LU!VX66+HL
M\';HHB-^9P_<&Z(ULXGV)N/ >5F4B=P84WK18/48SY4)C:3>VD]>#>NW+Z24
M]'F"7SMQO"OOZ\7YI]]G)+;7D_EB^9XD1C_XN3ZAOYF>_91(@8?:VLAKL=M$
M7Q&YBP8ZUB+8P+B@^9 #TB_R=@1P+_3;C9X;7D"?5::<G9R0%W57O;B#90?[
M\C=JVNVAX=*FDA"P)/):BR*OQT<+@E8:)]8%3#V+B0X<^;DR;E0-M2Z9W65F
MKZQ/R8R6M#>3Q293J 5(& 3&&"2K$_?>D#G7[[[PWF&>*U':R;YU:>Q[.Z (
MENK17%,L:W4 1\Z<YQ%!6V:1YINQ9U/V)]Q[9FU.-)-\ZZK65X#=4] A,UDO
M5BT8Y&31N8P0@C9@LTY$@&(B]HNGZ#7<"TE:Z:)A!>I+4=U.>JBY#LM?<?GJ
M=#XGC(?.(_G]SD!6O);_MPP<>8& 0?N,*@6O6M?B[ 'K&=)J+*4U+%I]'\2W
MDQ GQY/EMPN,P@KOBR#/LI:348:.T: "<1]URE&7(F/KI_$^N%Z8U4YM*PM>
M[RC_Z:Z$43+TOX3I1>#;F!E/_4??:H[3FD+9QZPF+I5/F27()?M:641 B"(
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MO2#4>IE/6^33$,6T-I,N+A^G^=7L]>FTJZUU(X-#"\&<#;0%^^) *94A&EE
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MF1/,!#(L"%WB17%=DC+]WDAVK<!["ORVU=\0@376V]](4B>G)Q?&?T0N@\G
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M-IG7*DB^,A=!A2(AL,S I*RMCH9+;!V3N0>9!F/I>(@T=Y4''VP2F:4$$M&
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M5$8ST.[!M?T+HN8*[4&8C;0Q0MK*E47S_<O_G."\>HW?WM:*5=VZB<8F:V0
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M5Q"PWH)J-_]IH-@B.>*'H:1;8\^5A5-6;Z4KJ;YTG>I0CT-E/7IQZ+6*X?@
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M097ZNRHD,:D"ZUHNS#FNZUSD*C?\"RX60IK:BTKR<_'/1?Z\D6T;)JF(XH#
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MM^$6INC!EN#2/[IIQ'?='U51J3XNT>&N-BBIJPUM/Y%I][)!07>VL>&G+>-
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MO&SG\4MFP5MN-Y\ F_R><NOO<BKU-,-[39"IM7$(^;9O\\;/-\U77H'F*R[
M]DLCQ26, )^K< :7K$T;!3$"J#O!$V/0L'3[Y47>\,^2$+N2IFCQF),Y[[:&
MS7CF/G/HFG]O'K[Q^0O_4A;-UWJ&>80CGD4P]%,/(H)2F,4H@2K5.XNR+(C3
MP,@U>!([(RMI^2F/#3V'IZ&KZ5V<##-##V3+%VP9 VO..H.S2T9KZV1O,MD7
MT+TI'%:8<8./*R?F:<Q,Z^AT MR.,]3-J#8Q+3MWDI<+Y8N]*U_Q7,4_STC
M T^$,21))M59@"DD*$80!QX7F2#,TPOOUB,W=CS*U@6\-$WZ*)12 -$R JHE
M)R9A$4=!U/ 7.87&3"OMCQ'IR(.[40 QB0)Q"8QEC,=I !F&;NC*.QR8<724
M"<,N="7:#JK0?LL\M%::C2PO'N]?GT@YGV5AFJ0B\2 +O1@B0832;O(+(PD)
MJ(<9TJJ*N#/RR-JLIP4Z8OI!L]O2#^NFDV0R4T.:XAB%P^YEW2H$=GNDR<)>
M]PJP&>JZ_X'Q&X"TK2F]D' _RA ,(Q]#Q!(&TR21:RC&V M0) 0VJQUNR,#X
MIYMLO/8?&@U/I\#%;)%:-?]PT^[S5##>H?7'=)U#3P7GE,8?)W07U:YF>:B8
M9=? ^:JHFZHU[.K6X?CP%1=]F<O?>-VH8]7>"I>_R/&;3[CAESBO?L/S!9]1
M$N$P] +H>X1"%!(,28 83'PFS002"I(:M33Z820;65=VW$Q3+7FR#X.>=OYA
M^!U/[>O45SY27KD3%FQ(NWDYL"J^W'^.ANHNMX(#)3E0HH-6]@G++T\]G5/5
M99Y,KA^K8//4TVE<R7ER!LWV\+IJ9O?\47'P"R\?*_S\-:=X_JE\PGDQ8RC#
M49IQB.4.*@_720 SY/DP]4,4A"1"&6$Z^^D@E9'WMDV"X/>.I.95\C XP_N+
M,Y'-=+V9M-KJ54N:(54G!]A0<_*GM8H;'GL2=:,EWG+IZSUL[M>Z*!JI$<X9
MD]-;?Y3?WE0/Y;=B%OH"QSSV(1;"AXAC'Y(HP##+0A'$29!&GE;:Z0"-D9=@
M1Q7T9,^ (JRZ="C2^IZO0_@<]X$YD-IL%5H);.0;.R*2E9?LT)B3^<N."+7I
M.3OVJ.U)MJR:!UX]J?I+*B:[5_4DQ2G#00R#($DA0EZF*N8B&+*4>C0C(L-:
M2_ (G9&784L5*K)M%:^S/I;?:$L\AI3NH>MD^4V/0%:B6QP_!@5S=AC83V5B
MTWQ0U%U#>?AQNP5[S1O5D/ZV*E]RQMF'UU]K93.O7%_GM,E?NL+=?;OZ&6:$
MA)QB2'F&Y'8:,T@$)Y!1A"G*D')_FZQE<Q;&CKT\O_\;N/Q\\_=[<'EW\P7<
MW%[<G3]<7?\"SC\^7/UV]7!U<?]7L]5N ;.>(A@7/#,=H1@!2TZ4/^0GQ0S(
MBS]O.,Q[AE[/5&G4^:*]\VI+8\K]J%C(Q_M'RP+\OF39H7ZQQ\N1ZK%@8%*M
M9 _06X5UPDB6I1JK1USTT4*J-7,YSUGG36A+KM;+R(<;T;4RS/'\7OZFB[14
MG\%Y67<YF??Y8Y$+>2@IFG/:5FV5_-[*\:CD=IUQ3R(OC,,40RS/^1!YB8"I
M\&/H>9B':40B/S%J*#BU "/KT4UQVM#H#:[ FBVPY,NPVN34LZVGD'_D.313
MYYN2G($M698%JU?2J!BRE3Q@+1!82Z3S"7!<'.*]Y\15 <^IV9^V).@[3<Y.
MD='WXL,B</5.LB/?^+ILL'U5W./B4\X?RSYMU4\1R2@5T,<^@8B)&&(O]6%$
M<,@H]D.A=][6HC;R-K(DOV[JGA= <@!:%@P",X^B-JSAG6-AIHYW8;C:@,$F
MX_DH'@9QJBYQL0M3'?Z8N"HMIBOG8'CJT4&FBT[5E6<K.%7[):O>DB]\7CZK
M^;_CCZHQ6%F]*J6J0M6_Y/)+4Q:\7@;AS#R.(X%I!),8<6F#9RF4NH]!+TP(
MHI$?^8%6H68;XB,KO@UN0+5BI[6CNL#]IQ5'X+EGR:A?H1G2&MIQ1/S,E.4F
M=&M.VM39EA>P9F89J3$F=$9M'4>#T+:%H_FGT)6VM03C2%-&LS&G;,!H)>V;
M9HMV8]BVTMK.UUJ;P>MCLR<"CWIA"EG,5 @$3:$T30.8DBB+0Y_Z&36*DM:@
M.;)>?INZ:-P$ZSAH>KX&QU"8J=@=%#;/^N.<XPWD==;!ZCC%B3M6:4.PVZ%*
M_U4[=7 A!*?-C;CX3K^J\*T[>3R^*9036/VO K9>I!J2:D<:D$V5JV1?]0>I
MGK9_L?'DS N%YV<\A1X2 B(>)9#@B,$HCF*/A"3#J5$-D!%X'#OXH^58>=AX
MSS.H5/1G60 J&3EKOP*^YJ?=FZL5M^W?S534&!.II]+>>7K,5.!Z9I;L@KM^
M9CZV,]/>B*U9.0-K)OLGU%2]^>76"Q^[>S'E)%U=C+E3J".B[4@!C\'AI I[
M1(C?*O@Q25F<Y%4ST05G2V>!)+-AG'XL-W[H4_N7C<*\,$8XBV,89@GM5#X.
MO 1F*<8$>Y[\!=4^TMMR,;)2[]E2:KKS6BE%P#:.6KSCIOX?@)9PXP\&IU3K
M"= XZ4\!JYDR7B*Z\@.JP_[FX?5C"3=_[/DZWMW-(; &?H I +9S"(P&M)EO
MX%2 !IT$UH-/YRTX5?XMM\')@YDW;K@NBUM>7O/R_.51I7Z<TV:!Y_-7E3E[
M_M3H-G X,LS(:EQ2A[<7-^!:_K],T-K.$.O9:1."566CA:ZFT<%H6%$[AL=,
M';M%QJ@?A*;,5GTACHT]67\(32$W^T3HOF)AZSU\*Q^^EHM:6C$/7_.JX;Q8
MYF>IWC#Y"[^5GX[-I[[)7[_>%'S/8U+[7!5L0=NK]391:UF-.>5)%!(D[4&<
MAA!AU4",!B%D)!,D##//(UJ^Q EY'ED!!9X?MK:C_)3Z8,424#QUCH"R33/-
M5\R!QY8[ W-GHLG5L#I_O"DS4XJ2,[!D#2PE6.<&;T[>&=A^N!5$U<';_WAK
MA*W%Z;*$K>J@3S3;!J;PCS?K=H;SU+/OR-">%OY!LWPB5J8SXJ?%=LODGYBT
MW8W"VC'5]HG[M<B;^N[^UV5K#AY' 4LHI$AD$$4<01+&#$8)BOT,(\I1:'(W
M,$AM_"BWI1.X[84(%HJZF=M^&"T]![PS#,QVQ@WQN\[=+6'PDR1=_WF$)E5:
M8CKR80_3FM0;K27V6[^RWDNV$02T?.*K0-K/:N+DGMHG0ZKJ"0*)!'*:$8AB
M%$""PQAZ?NR1-$E]CQLUFAND-GK4@**]CHT'2^J6":3#R.D&$#C"PVRQKS$H
M!>AQ6=(^ Q^P?)B.D5RJ):ZSR($A6A/'#&B(O1LMH/.299.04ZZD5FF#G_+Z
MN:SQ_)>J7#PKC^5&%N'JKG2=3QDAA"-?6@=9H.*0DI3##'O*BX"SB%$41LPH
M!?T]A!A91:G$US/0IK]>_.]?KWX[_WQQ_7 /SJ\_@;N+^X>[JX\/%Y_:OQNF
MO[[+A.NIP!]]&LTTJZNP@W?)S7W/J7#5YN0]1)BV'<H[3M).VY3WY,7\QNNM
MS_VWKF39%XZW@S\U;[XTAQM[SSA\I_-2_Z4O<MCSI'_QI0O5\0NP$5 R5,D&
M (W0'-U0?JM+,5T:DUV.&0J]>4EF^NH47996];)1)L(,B0B*F'D017$BK5DN
M((\)2I%@<1P;!</:L3'ZE99IW7%+-/4,Q/$Q,M,G)W11<EN)_#1@WJ5]TOM4
M)3\-J-/:)9U8H7Q=*>[BB5>/TEJ25M*WYJO2DKAXG2%!H\ G/J0\\"'R,R$5
M$N(PC(*,A9S'J1^;E5;<2V?L"/NNVN"2-.AH@YZX:8'%_4@-*QN'\IMI$TO1
M+4HM#@IV0KG%_>-.7')Q4+C=LHO#CUNV+RF+QV5YN"^X651M::4[OLS)O!&W
M55[0_!G/KPJE%AXDZ'S&TR .(QS  *4)1(FOXJP3#GWBQ3%":20B(Y/"CHWQ
M38K4L)6)'9IZ)L7X&)DI <7/9FW'GJ?7WFQHJ3OL8'*2]*[ZF-@Q,6TWDY.
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MCR\5^X^J+Q>AFX5D.?[(NN]CYV67%O<ESBL@N5NHVR?UJ?Z-UZW/_5-;JEF
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M>TV-\#ON-QT+.L.3D!UJ(_A2;?"P\J8:$9K,GVHC_J9'U>I]ZQ 2RCFK+Z4
M;5F'OL/;Q7=>T;SF;(:H+WCLA3 *?*)Z.P0P"T0(@]CS,R%HC+G6#:XVQ9%U
MRY(^4'/6^EAX3[E6'I:VY HH.YZ,PRR.8*GG5'&*D)D*V0:G*[#44P<K\DZC
M+?0D=1>$<83>U+$9>N+O"=G0?-'B#/.QG,OOR^IMMTCE*LY97\=WQF@L_!"E
M,$T#3YYH,(,D1 2F<2A0&#$_3?4#.[1(CJP7'E3LVDFG&SW@B$@]1,,4DB0)
M5&7+ *9)%L-,'@A3QH/ %YY.I-Y(P)E'\$T%G,8AT3D<I@;8!OG-]C7=%=V*
M ^?0&)PGG4-D=[H\&2JSLZ:1U(,G3[V1ICN'&DFV=2HU>].\]>9'U3"PXKAK
MMHG#-)3[!:2)BK]-TQ1F@A 8,]4*P@LI2CW=9IN; X]]$&U;3$I:AMTTMV0?
M5ERG2&2HGO2$,6J0N8]SJY:86P--U@1S'_N;;2_W_MW<7=-&Q3T\/?ZM_/:E
M>,X_%C63/YLZ:(9'&7DEM,3!0_Z4%X]G0+( OES?7JV4]<"IP!2-X^X6=T"8
M+:"C&(S@2M&3U<IY<F3HR=PE>B)N.D@TWS@IC%TE5?;W@5Z6L B%/@Q\::VC
M0&Y>A& J37;&28:PSZA6*XF#%$:_NG$1PKX!B(8I?JJ89BMS0T)%[K3@]0U!
MK4+7[00^.7!=D74>MKXKBV;0^L:+[Q&ROLOW@8#U/0]:[.]S=;G35EU8V]'+
M] ?=W7U@C+'W]GE[S=E5_=@@;K"E#P&@L:$[DMUP.S\@MN.BMCK"V>W?0P-/
MMWMKB+>U=^L\;[X$+_XI+?5O<F\[9_^X+(QMZP.OC[SP5.2).I-U&5<;19;/
MP&59-D5ITD;^$ +'EY\#X<U6GH;<(YC21\2T6H.'QIQL^1T1:G/E'7O4?-&U
MKM^V$/S7<BY?N6N*W^I;SJM?JG+Q;+P(-8>;Y")@@PUPQYM%58#?:J"8 2TW
M^NM2%Z3CZW0$?,S6K1XT(RQ=0\FMEK(NC<F6MJ'0FTO=]-63BLQ_[M,17OM.
M[0_EPU?>=8*Y7,B/![\K7_%<!7&_J08N)/R1'Z4P351S=2%G) UC BGU/!_[
M891%@47]>5M^1M8KFW7$5RR"GD=5W$#%(BQ[&W6,@A6G5K78K2=&XWP_+=QF
M:FJ%],T^I!]*\+!$^F87:5>%\*W!MZJ1/\4DG%@^WV8RG-?7/Q4GS=+[UF3>
MHRK_J9@<*-A_\K!V$6WGE%8+SCZO<^26%:(I5XW N-QD,KG3("^.(29^!),L
M39+4B],H2$TBV0Y2&MM=T]%=%K(UC%([C$\D*$IB(2#G$AJ$?(F/3S.8L2A#
M44Q%[,4F-:3<X&,;D()'0FEX;W0JNZ$[JQ=X@^8(Y<*/"N8H5.\PG4E#](Z*
M^S8T[_@+EAU/E3'_ =>J//@ZS'O#A?;A=?W(+7Y=%6/I?"WKGJSUC;0SJX>O
MN.B#!J_+MFH_9]>+KF13Z"<>"R,8,*RZ%6215)A9 @G/(L:(AU&@%:HQ.>=C
MV^^*24@4E^"Y8Q/@]D;8NB/C=).*4Q(+A!,8T(Q 1#T.<>K++P&6_\4XB[-T
M]L(K4OZAIW53 NV)505,JKQ-B>BBOQ=%WM1_A%EE2>B',>40^4$ $5-152@.
MH.>)@(=9R)% LV=>Y26[;W#5_(%G]JT4VK/[@3_F1:'N>.2QNAOECS"U4LD*
M+\I"&-)0&JL)P3"->0(Y0B(6:<I$1/JIO2C8'WYBES+H7R$4[(\UH7IVXP\Y
M18;>EW:?;!D$VREI:RD >06;S_62=#="9Z"_']J0!K3B@$;*LTQ(.0,KD>2W
MK5 .>X!//0^N6HE/QO>T'<FGGHZ=QN:3,V!95ZE\>LJ[N]3S@JG^-W+GXP65
MYY!/>4WGI4H>7!7YX9C1( X$I"&15J&/$,01E7N.ES(J$(D\:M30T(CZR.;Z
M!B]M2;0M;L":'9W"0 Z@UE/_HP%HIL)=8F=>5,D& U>%E8QH3UM<R0:6G0)+
M5H/8JJ*N^=;?\^;KQX4\63WQZKRNN>I4LO(-O[G[\&./!2'&T N8/-70*()9
M*@^LA$8BBQ,:<JX5:7L"#Q/> MYQRO,717V]S!2WFRX\4YUDCKFN9AH525/]
MU /U37(#ENR<K0%L.3O;!?3UK 5Z#;S);9^%)K/&S)D^,^=@8JUF#=&N;K,?
MRBI-^NE)95OC^9=<+N"F+'AO]]7GS65>U<WZ"77K-0MXC*.,<I@@'T,DDA02
MG&70IS%-XHP$8:9? \J4^@3&5D<,/"WY63I)I6YK@% L ;I^K)9,&>7!&J*M
M$<(P)H;F]E:/RXJ5Y9FX!N<-:+D!&X_=CPR?44;Q>##:)A?;?!I=U;6RQ>-(
MVK'AH%-F(-O)^R89V7(0.]OTFC>JUNAM5;[DC+,/K[_*8_M5<=4>Q;?JCJX.
M<(@3[.'8@Y@$""(L(I@*3J&?) B%"8VRU#<Q3<U9&%N'G]__#5Q^OOG[/;B\
MN_D"KJY_N[A_N+K^!9Q_?+CZ[>KAZN+>L-RP!<QZUNBXX!DJ;U6 >,F)<FS^
MI)@!>?%GL.)G69#X=;/)D3IQM2<P=6O?E[PMBU'.U/9X.3)$+1B8U ZU!^BM
M&7K"2':Z[!=>R(_.7%JYY^PI+W(UJ"3!^Z; L]1+_13)DW28*"=?J!J>$1)
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MIMB7>=.CQU,[8\IP1G,9Y#R+ \_(63>B-K$Z-M3P6N+G2MC5G8Q"9;9;.@,
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MJ<"I%_ DRT6:,:-6#',Q//7]D":*=,>B>HWJ/];H53$ F<P[QS<;-QCO\4L
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M- @Q21A5ILF+L. R#8+,S\)0 *I]3&A"5,BN-W.K)$\M Y!.A":(&83V7*,
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MYS$H=0=$?>JM?&=^>45;9:LT;T!C!(+4T!)-!130#'6H=+U\=EA!/2]ZCMJ
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M^"KJ.WE/_]P4AX69'T=)E&'F2]U7)I(XE3+&^O07)*E' A%#M-R YM0;=Y-
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M7'E[ABSGEVX5LFIGI-+MWPS:H%5=+9HO(B_B),-9KF=>^)SK;4Q@/_="&I.
M)J$/&F@*HS_QYC.81_0B=G+CF]$O@__=WHS6ZCN@W9=@G?MM/X/9IC(AN+"M
M8 Y<X4-6[=!Q-7452'W>,:QVT!S,9;5<QK*]ZW->B7\]JZ4_ONCUU2K7?Q;5
M0D34DQ$1. G\')/(DYC2B.&$IM*/>:Y,%P<U<CU.9V+3M*6*&K)(TT6_:\I
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MX[M)'.QB5WX09['/8AS[7HX)BW.<)S''<2)R+X_",$^,;M -Z4T=Z6L9:'[
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MQE["<@&['0&1G]@,:&;TCY\U["#9\7.%RIXCE/<L(=;Q!+P_@<%M>&$R&8C
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M09+MG.EA;]KY+<W$]>NG;6I%F\?YX_K[#_,N/L:+31U8U/31D($N8QG]HGB
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MTE^OK[]M&E\.>##/D#< 9%QCW6,!4]HQ&!P'TF"B6N7.&RP_6P:]N:C#/'K
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MO8/: MOF)2?H>2PBE64B08HE'&$2*\2H23"%5!22AGD4QI") '[8 KD@^""
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M+RH-GOL&R^\K"6Y/>-YL.%@A1VEQ^ KPP_$'+=]F+1T+-T^_/?5]/JAH\XR
ME\_%U\L&W-I;>E,7:HZ+Y71(/K/D;,?D<9&&!^4+3SK4T'PT"2IY!J>EM^!?
MMO(?DI8?EL]2F^VMTC_T_9\7><:+C!8APB11!G(0(QVC%TB)K""Y(%%46.&%
M>N%F8LN-PR1L-J#ZNRPE-90!E2=7JWK<YF=7(/#PWG!V'M8IV.W^FKW \!,8
MA@+-8="PN/^[.74.* B:4_=N-4/=-]@<PI %J]TW>.J_@=#?X,7H6YEO8'[D
MFY_V_=_]NZ?Z(E]*&RU!NIK(?%5*OO1Q4,CD;=$KBJ>K=^W,R44>*B;RE"-2
M1%(?].(8%8SD>L/(L1(L2@7)(;!;!ZN#-@!7]*Q^@"AM*#M42^]T87<V<Y80
M>+71D+D)WOD>#GJ2?Y]UT+NUYR]_?BW6R:KGHX<< K7?EBM9U3KXZ^Q5QX!R
M^6Q*'WY_VJP__')[^_14;I[I:J$(+@CF"DG)"H2SN$ L*3(D(L)#3,(P"W/K
MB,R:[,2AUXZ/?H\*RATGP5:S$FA> MHQ X@0[/5J$7Y-HBV8%>\5U2,=[YFX
M"7[O-74[I:8 0=,D&G.+CGQI#A8 @14P&NG8KS9?2 .6\"!V@;]]39"B(Y\^
M,%K*JHV;=A<K*N(L3I,,J0(+A/.<(49"@JC(8Y4F3.C_ W=[C9*<^B*Y"?];
M-IH@?\"(2U@SJCU(K.-+)RX!T&M%&-2.YM@TQ265O;A>XZ51@F\01-DHX'1D
M9?4F?#;.%X.BW@R $6'*$L$E2K%*$(XI1103C(J481R'.%.A51O&P:H3V[49
M9[*LZB77AY7?M(UORW84 G0DSEX+X\;K+!O,/AW% DW".1+CBNDW^[5FFWAS
MQ/YPRLWQ/\+O6]Y]-ZB:'\R%\;TR6 %B_4W;X._KYZH6[_]9O]S^68KJUW)=
MB[OUY[+\1PFL6'0F,+%-F5P(,EEWU.0AWWTWRC1 ]8.2AHT*6HS2H)OF^6M)
MUP9"<VGZ\I:;-H=9!0_?:1T8$)DAP(79=K24.MB1POYZR/U[7+Y!FN53P%S
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MC]>?U4#/BO?:#L\_""\K^K)=R2AD::1/#0_EX[H6'U;TFVU1T>FW)P[)#='
M4$710?.@&4V]7%,0?NL9\<?-RH_D,+NZ+'3PA^' 4SG1N'A.Q41GEIRME&A<
MI&$AT84GK[\A7"1QFL0%X4CJWR!,(XJ*PH"*9D48%SA4A02-UAXN/O6!V$R!
M-X/(@U5W^<4;LNYW?@Y7?!.>;G=#[C\>W.U-<XLWX:7=V]W1V5S)76E,._#
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M6+ \PC2%>(&+%"?V =J[EEN]BS[1%[W$JKDE9W(MU=)V"(&][NP<@5>-P-Q
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MW?5;TYWWIAZJCJ-[=O "#C'%5UIJ6>@A[&KOA?J*P40IR46&LH@(A!L0?7V
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M^M@HY/:5)CY3OW=1)P7S%!4>KCUKY'=2K-?1W>F''$][6U8U-]+U^V<#PM*
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M.;<]+!^;VI7?/GV^&P[ M<]PC2CC<E[+CQY@9F6K G_]<W:2NL\ /KWLO(.
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MT+-B((@_3*XS *C?5+IS0_>S_MG;_]SY0C5V4<0H]A]HP?E  %WD/$ #=%K
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M2^__DB5?5H:3]G9K$<<*DZP(4<8)19A1'9WQ.$$JCF61Q#2A$0PCW3>'$[O
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M>F^ TGFSE5U9G75FR3<JS.JX:<!Z]OSXJ<@ZI[QQ9S^AWH"^W:_*KB[ NJ
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M3#(96@V1OT!G5J_034]8-I3=L2+.J0SL EP5<8W9MS1O@I;J)'9^2BS_MGU
MY:WL^92H(S9\\G$WNS4SB,PP;M/!\!NMM^6R7LKJB^Q0HJI[];E<KOGRB:[N
MUOO<?!%%F!*%DD3DIGI.(EJ$ K%(J8*()),9Z 3EQ,7DB?FX@!FTFR[MS'UR
M#<&<03.ZRO#3M+[<!!U++S<^L[U>9/?D,=QXF-6?7*6FU][FNL4F&'O\19IB
MQ/X?#6O1(DIRG(9Y@C(22H0IQXBP+$%%*K-,931-N;^QQR<8F-@#'0UO*GL6
M@I7A(:B- 9KXXT5_ &CX =:VG:.:4H<P'W5Y$/*.G?:)P# TTQCD$4W,,0;Y
M%/D?9PSRB') 8Y#'UGF;.LI?&S#FNW4[:^37<E-5BS2/,,<Q15AD^A<L%6+:
MKVE_5@BNBCRGF,-FT$W )<1,G2;5-32O.4Y-\6D**O572"@**=6?)HIS1*(,
M(QD569JE:1$KT.GUC3^,PQ[T0WZ6B2\$_"A[YAN"06%BRWB@OUC+NOD;S?P/
M<&UP6;-O?8\PPN&_QL7"917[KB,<(^6VR]YIEZ-MI>YND(>-O0N<1I1AKE!<
MI G"*BM0D:018AF+E0@S8D;?KN4WD^!\L/?,(R2MC+YHC?Z(L+4#Z!D(NHY[
MF)<=TYB=M[Q6 4Y>;R=T1_4F&-+UY[ LA//D>,8HS>I +$1^[0AL7H&7>#V4
MU)08:W_2]+A95G$=OC5QD-,1&^ZUED 7)P0<-[?K9(-9UPFQO#7OG9?#J2;J
MU5*SE3V=%F%8V73F"0<[V-1TU6RDWS<K_<J7>@VH:CS]]M1V88@& ZK!%UEO
MRS6X4O&,[!:F<K780)-QE!AF-Z-"N=G/Z27GLZ-1D0[L:?Q)AR:37[_^YW_\
M_+?;;Z5L7-QOLL$8R5BJ<(8QRE,I$)98(1I& A4B%G&A8A$R^_:1DR2F/GE_
M_4^DB08[JH"6A=,J&3<W/X+"S.U(QN"/EJ1ED>&(L(#.BZN%=NNIL/_ L/Z(
M47%&.Q].OSE?3\,HYP?="N-/^L'EW^->YPE6,B81RCF-$"9*(()#@81@D4H+
MRG@.&\E\CM+$+N4(GOXZ.'[PV&0?8@/3:L> _-.,/+XDVD28_&\UMOB2N)=0
M^7UABS<HA29MI<,)?69=/LL6^>WCIJH^;$JY_+9NI\/Q%QW(KRO*F]S66C1_
M:@%A;\5_;:O:N)%/LKY7#_2O193$,DP906EN\&EH&"*6)0E*0QY3'@G"<JN9
M;].R.;&WZ!@+>,=94.^9">B.&Z 3F>B+B43A)*0IRD)9Z"]&&"I8R%">"1'G
M:4+S(H==HKW]-W.Z1_N7^FIV^\;;?PG8IM-"IQXPO$,.-3S_VTW0?Z6>[V#
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MN%2T]BV319YC59_%L]<C,NFY-VDYY%990PNNWA#'359FT5N5S4QWVJQ89M:
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M<8] \U_KL*P3!DN&.QA6>PQ$8F3PA4'T25BIK'2Y=;+=CKVK^9-XO=J3Y2,
MR]T4"I553AXU&)\K'QA"+-4FCUXD%%F&T+H>8<\4EJ?Q3'20  Y\W7\YSV/*
M8&'2BN1%!LD, ^6M V)?-;9#Y%'(9$4OD<SC9+#PI_-H=%Q1-P7YL9LA/ ^K
MS[_.%K^M;N[FL!X(5Q]ZG-8']VRB?<>#RX6NFMEAR459"R[;2%Z&*E!G+H%-
M1J-TD>7<6P> +?0TZ-U?/Y,,ACI7,?_R_6^K.MK\<F;L,_*]OIX9HI<MUK+&
M7.=B6%;G#4>C(#@>("EC'=?%Z.81]-VI'$G:\J$(VC(*H$]QC<  O&:Z\D+?
MUM5J];Y23MK9Z4B_1+1DS4I/S!K86^@+0'W+^7Y_81>FCP N-^*F%^W(\<;$
MC(^+G5GI@B"O6H,SCNQ<'@QXGSAH'UW6.1$O6\=3^MC'P)-<CPOAP8$P@L-P
M,7CA9D+JQ-FL=%8&(O?Z_"U+> 7&>,XL=TGQYKV9ME(RK$X='B';7.W#Q#4"
MT+U 6CF=3X"8YV<GU>OZ[[.MI.B8LY(#CXZ#<MR 4ZD 63@V:%;0I=:*] %R
MAM6'HX-?*\&- (.W!\835Z]OI_8+7Z7%Z;Q.D'^WQ)/IZ<E$DOF=BA=@'"./
M/UDZ9E(E8%*D$KFTH;3.Q-B#S&$K+D:'V;X%?>A@]T9=+L)L^M^5C1>;_7.8
MSE>5VS4M2N0DBR?ZT=0.M62E!\$EN*)5L=9);5J_>#](T+ 5%*-#:#OA'8K%
MCP>KUQH K!T<*O\N(J7G<W1?3T.<SFH<%S=]9CXNZK/EV_+KZ?ITB>\7W\.L
MLG126!3!E@(FZD0^9:$-%Q' 62N4-<49><L"N!MU/)R,86LH1H/1(\MS!(;!
M6?[47Z;S?!GIUX@BN21!&)'I.I %?+(6(L. 0EM?8FMOZ"X5PU9*C :0C<0T
M J#=??*ZY-5Y]MXEHZQPR2?F@1%7:&>9UW8Z''(0 8-C*C0OY^E.W;#VYI%C
M1CT);91P?)8V=O&*CCM.OVY:]1@E/"O<0PRUKY.T"EP2'#"%HHU%D3WK'8AW
MZ1I;OY VF'@4>@<*:!2>R]U=D1/VA93[BW.*SJT-\LXVV7#/R"A>KR9)";4I
M\D"K+.TS*]+UD0ZR"-E$E%*PUEUJ]J-T;)U!C@3-YD(<*5@OCN"[\'US_BS3
M4>><P3#C064D&P1%A*R9C+5")#;O#?@H46-KP7%D[;B/:,9Z'R]/B8YSOZOZ
M5CQ$QM#3GA3+M>#20+0Q PM)J*A2LJYU8D47NL;6(N-XB#M$0*,$W?.:^4:L
M^OMT_?DYN8#D["TO/?])5H$S[SP8P10H8UQ-3*EJG!<931(2^W=,'B1Q;+TP
MC@3%=F(;)2HON?BZ_OUJ8\8IEGPH4*?$TG$+# )/J@8#3&9"Y/;#"SH3-[96
M%T="8@M1C1.#U9*]S<0WN)YD<K9X,@&804X[$TC>&)TS1,.5-U[KTK\->!]U
M8VMA<2P4MA#6\,\KNT>])AA=CMP;.F>U8W9*=92V$\ $-\(KE\CM&BSW=EA#
M\<BQPYZ$UFS(8G,XGCUH;F>DU9Z\,4/JG_%(OG\D;ZR>N^"CBZ%@+*;UF\KN
M5(ZD3?J14L);B6L$MS7Y_!>-$=)_G4Z72'NE8[;^_FX6-ID>M>[G2_V12:"+
MQ%A?K8^:ZU&*@! LTLG#H@)M3C:?!-*=NE&FE#?#R9TGO5Z$-HK(X9V]725[
MK":RSKKDPI*I0YQ3N:9O6KI>G.1"*97)%&K=4_(A>D:9!'XTT.TKF'' ;+E(
MB'GU*[&U9F/\-:QK4X#O='B>+V8SW+3%6+TMUS=)AH7W19MJ 2/=)"C V>(
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M;N^T!Y/2";'V:2/VN/(<6J>^G-.G;:@_+VZ_&V"@2T!SY &T=8&V(Y',DE!
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MJZ]%K-8YI@!.9ET+=(ME3B!+O\_L.=8EV4Y4(\#;KL,?%'..JQB =J= T54
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M?H/KYZ?+*IV)\ZBL<@:RXG56F&7@R#L'#-IG5"EXU;JS? >RGM#,F'T@V9<
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M#I1PM3V)RF"-LTH'8XILT4]R9&EN.PGKOC2W'3@WJC0WPR)REAA8)^M(/F&
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M>N99X +!H.>@4'D(OI8X&6539%YFW7IN[V/T3)MH-+:V:2:)B3MJ;%M+;YL
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MW25RSS:F;5]VJL>C$2Q>P,EX?[Y9;W"1YHO/%SIC9F4.6L4,*E<&&*W FQ!
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M/S_Z-)5(!R#[6UZ0T7]&.WJ5OLX7\VJ2U&2DVYOB*D9>;('" ZOO6:3LC>+
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M',^NWZ^V=@0OB"9'#T'6F>Z6V!.\5<0C:P39&#*'YM[I_:1T JIIW8,&4NH
M;)]6N%C3RI6-'_/J^SP2B]Z7>W:WKCW6UO?_:'> '9FR2B>R='5MKLHM<2&)
M #I('LC63;YY#\:6]$]LY;4 U+(3Z7: [+]__-OR>UXMMHS\G&E3>?UK#IN/
M51'L=,5%JQ>7)%T"=?H-*F(P_>$Q".!2)IFL+"JW1NU0VJ9%Y'3H63Z#*#N
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MH@],0*@Y1 H=[4]Z!U$K,E"$C-*;8[#XV.+#@'="CP3/(H4.C,+;6ZQI!;/
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M6- 8J^.'MI+<(V)$& .M3OG*20D+4@INC]<#]0&Z,%/9SL%4G#MJ0B!G)42
M&,3#<NT@,"+^& O.X&M<[_Q<>CW0J%4J&0,EF-.SZ_N_J7;13-J)FS]O#O$L
M01.G7V LUJS,C9K^X51S19EER$?\2#Q3P)(!@;0&3%7,.$N89Z=8V,;H7-ZI
M\4#S.="*X>1<OBW;_33[XOYN+_]RTSOW6SUK?\ROK+$J=BL$W)H*$$H\4 %B
M0"P,0&O!H#Q%'#]8X?).G5[=:D>R^-9,-L[)R[_J*XY\Y257H((5C,6K!"@C
M*F"L1 QIA*@XQ0V4OGJ6MR/-8*!#.'N3=AD,S5TI9Z4WR "L8K,,) W0U#O
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MLQ]CNXMSOQ[$K\TL*O[NKK%_-#&7;F?79S/[^^QNWMH$!C#XHV5,_7[\UNG
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MW/WW?_P_4$L! A0#%     @ E( '6[UG9IAY 0    @  !P
M ( !     &$Q,#9A;65N9&UE;G1N;S$R=&]L96%S92YH=&U02P$"% ,4
M" "4@ =;*Q_ 8L8'  #[)   &               @ &S 0  87)W<BTP-C,P
M,C R-7AE>'@S,3$N:'1M4$L! A0#%     @ E( '6S_X.&*D!P  VB0  !@
M             ( !KPD  &%R=W(M,#8S,#(P,C5X97AX,S$R+FAT;5!+ 0(4
M Q0    ( )2 !UO-LM4*E00  " 0   8              "  8D1  !A<G=R
M+3 V,S R,#(U>&5X>#,R,2YH=&U02P$"% ,4    " "4@ =;Y4NY%U4$  !H
M#@  &               @ %4%@  87)W<BTP-C,P,C R-7AE>'@S,C(N:'1M
M4$L! A0#%     @ E( '6][+4B"28@$ A!45 !$              ( !WQH
M &%R=W(M,C R-3 V,S N:'1M4$L! A0#%     @ E( '6]"'W/6I%@  OP8!
M !$              ( !H'T! &%R=W(M,C R-3 V,S N>'-D4$L! A0#%
M  @ E( '6]+)RG@Y(P  XUT! !4              ( !>)0! &%R=W(M,C R
M-3 V,S!?8V%L+GAM;%!+ 0(4 Q0    ( )2 !UN:Y'PL46X  *(/!0 5
M          "  >2W 0!A<G=R+3(P,C4P-C,P7V1E9BYX;6Q02P$"% ,4
M" "4@ =;6!X/[@(A 0 Z5 L %0              @ %H)@( 87)W<BTR,#(U
M,#8S,%]L86(N>&UL4$L! A0#%     @ E( '6ZHR4_ZGNP  Q> ( !4
M         ( !G4<# &%R=W(M,C R-3 V,S!?<')E+GAM;%!+!08     "P +
+ .P"  !W P0    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>arwr-20250630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:arwr="http://www.arrowheadresearch.com/20250630"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="arwr-20250630.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2025-08-01</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SareptaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SareptaCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-27</startDate>
            <endDate>2025-07-27</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SareptaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SareptaCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-07</startDate>
            <endDate>2025-02-07</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SareptaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SareptaCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-07</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SareptaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SareptaCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-24</startDate>
            <endDate>2025-02-24</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:GSKHBVAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:GSKHSDLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-22</startDate>
            <endDate>2021-11-22</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:GSKHSDLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:GSKHSDLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-22</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:GSKHSDLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-22</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:GSKHBVAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:GSKHBVAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-11</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:GSKHBVAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-30</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SareptaCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SareptaCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SareptaCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-14</startDate>
            <endDate>2025-02-14</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SareptaCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-07</startDate>
            <endDate>2025-02-07</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SareptaCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-25</startDate>
            <endDate>2024-11-25</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SareptaCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SareptaCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ComputerAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ComputerAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ConstructionInProgressReclassifiedToBuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ConstructionInProgressReclassifiedToManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ConstructionInProgressReclassifiedToBuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ConstructionInProgressReclassifiedToManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2024-11-25</startDate>
            <endDate>2024-11-25</endDate>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-25</startDate>
            <endDate>2024-11-25</endDate>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-02</instant>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-02</startDate>
            <endDate>2022-12-02</endDate>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:DrugManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:LaboratoryAndOfficeFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:FacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:LaboratoryAndOfficeFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:CorporateHeadquartersInPasadenaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:ColoradoOwnerLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:CorporateHeadquartersInPasadenaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-25</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInMadisonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInMadisonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-29</instant>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:InducementAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:InducementAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:VisirnaESOPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-01</endDate>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:VisirnaESOPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-01</instant>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:VisirnaESOPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:VisirnaESOPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:VisirnaESOPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:VisirnaESOPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="c-284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="c-285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="c-286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-07</instant>
        </period>
    </context>
    <context id="c-291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-07</instant>
        </period>
    </context>
    <context id="c-292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-07</startDate>
            <endDate>2024-08-07</endDate>
        </period>
    </context>
    <context id="c-293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementMOICPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-07</startDate>
            <endDate>2024-08-07</endDate>
        </period>
    </context>
    <context id="c-294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementInitialTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-26</startDate>
            <endDate>2024-11-26</endDate>
        </period>
    </context>
    <context id="c-295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementMOICPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-26</startDate>
            <endDate>2024-11-26</endDate>
        </period>
    </context>
    <context id="c-296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementMOICPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-07</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementMOICPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementInitialTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementInitialTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementInitialTermLoanInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementInitialTermLoanInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-31</instant>
        </period>
    </context>
    <context id="c-310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-05-31</endDate>
        </period>
    </context>
    <context id="c-311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:VisirnaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SanofiLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="bundle">
        <measure>arwr:bundle</measure>
    </unit>
    <unit id="agreement">
        <measure>arwr:agreement</measure>
    </unit>
    <unit id="program">
        <measure>arwr:program</measure>
    </unit>
    <unit id="obligation">
        <measure>arwr:obligation</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="option">
        <measure>arwr:option</measure>
    </unit>
    <unit id="cny">
        <measure>iso4217:CNY</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-26">0000879407</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-27">--09-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-28">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-29">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-30">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2025-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-38042</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">ARROWHEAD PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">46-0408024</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">177 E. Colorado Blvd</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-10">Suite 700</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">Pasadena</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">91105</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-14">626</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">304-3400</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">ARWR</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-19">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-20">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-21">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-22">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-23">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-24">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-25" unitRef="shares">138257550</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-31" unitRef="usd">129793000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-32" unitRef="usd">102685000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-3" decimals="-3" id="f-33" unitRef="usd">9699000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-4" decimals="-3" id="f-34" unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-3" decimals="-3" id="f-35" unitRef="usd">770579000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-4" decimals="-3" id="f-36" unitRef="usd">578276000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-3" decimals="-3" id="f-37" unitRef="usd">23692000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-4" decimals="-3" id="f-38" unitRef="usd">9537000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-3" decimals="-3" id="f-39" unitRef="usd">13160000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-40" unitRef="usd">4973000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-3" decimals="-3" id="f-41" unitRef="usd">946923000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-42" unitRef="usd">695471000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-43" unitRef="usd">381048000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-44" unitRef="usd">386032000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-3" decimals="-3" id="f-45" unitRef="usd">7286000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-4" decimals="-3" id="f-46" unitRef="usd">8562000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="-3" id="f-47" unitRef="usd">44002000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-48" unitRef="usd">45255000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-3" decimals="-3" id="f-49" unitRef="usd">1353000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-50" unitRef="usd">4482000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-3" decimals="-3" id="f-51" unitRef="usd">1380612000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-52" unitRef="usd">1139802000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-3" decimals="-3" id="f-53" unitRef="usd">33050000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-54" unitRef="usd">11388000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-55" unitRef="usd">64818000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-56" unitRef="usd">63017000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-57" unitRef="usd">19298000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-58" unitRef="usd">21989000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-59" unitRef="usd">7010000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-60" unitRef="usd">6342000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-3" decimals="-3" id="f-61" unitRef="usd">22979000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-4" decimals="-3" id="f-62" unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LinesOfCreditCurrent contextRef="c-3" decimals="-3" id="f-63" unitRef="usd">40000000</us-gaap:LinesOfCreditCurrent>
    <us-gaap:LinesOfCreditCurrent contextRef="c-4" decimals="-3" id="f-64" unitRef="usd">0</us-gaap:LinesOfCreditCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-65" unitRef="usd">7375000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-66" unitRef="usd">432000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-67" unitRef="usd">194530000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-68" unitRef="usd">103168000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-69" unitRef="usd">105690000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-70" unitRef="usd">111027000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <arwr:RoyaltiesLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-71" unitRef="usd">360254000</arwr:RoyaltiesLiabilityNoncurrent>
    <arwr:RoyaltiesLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-72" unitRef="usd">341361000</arwr:RoyaltiesLiabilityNoncurrent>
    <us-gaap:LongTermLineOfCredit contextRef="c-3" decimals="-3" id="f-73" unitRef="usd">200332000</us-gaap:LongTermLineOfCredit>
    <us-gaap:LongTermLineOfCredit contextRef="c-4" decimals="-3" id="f-74" unitRef="usd">393183000</us-gaap:LongTermLineOfCredit>
    <us-gaap:LiabilitiesNoncurrent contextRef="c-3" decimals="-3" id="f-75" unitRef="usd">666276000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-76" unitRef="usd">845571000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:CommitmentsAndContingencies contextRef="c-3" id="f-77" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-78" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-79"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-80"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="-3" id="f-81" unitRef="shares">290000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="-3" id="f-82" unitRef="shares">290000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="-3" id="f-83" unitRef="shares">138144000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="-3" id="f-84" unitRef="shares">138144000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="-3" id="f-85" unitRef="shares">124376000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="-3" id="f-86" unitRef="shares">124376000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-3" decimals="-3" id="f-87" unitRef="usd">230000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-88" unitRef="usd">217000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-3" decimals="-3" id="f-89" unitRef="usd">2120130000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-4" decimals="-3" id="f-90" unitRef="usd">1806000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-3" decimals="-3" id="f-91" unitRef="usd">5357000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-3" id="f-92" unitRef="usd">4750000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-3" id="f-93" unitRef="usd">-1603404000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-94" unitRef="usd">-1625523000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-95" unitRef="usd">522313000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-96" unitRef="usd">185444000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest contextRef="c-3" decimals="-3" id="f-97" unitRef="usd">-2507000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="c-4" decimals="-3" id="f-98" unitRef="usd">5619000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-3" decimals="-3" id="f-99" unitRef="usd">519806000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-4" decimals="-3" id="f-100" unitRef="usd">191063000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-3" decimals="-3" id="f-101" unitRef="usd">1380612000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-102" unitRef="usd">1139802000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-5" decimals="-3" id="f-103" unitRef="usd">27767000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="-3" id="f-104" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-105" unitRef="usd">572976000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-7" decimals="-3" id="f-106" unitRef="usd">3551000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-5" decimals="-3" id="f-107" unitRef="usd">162368000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-6" decimals="-3" id="f-108" unitRef="usd">152431000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-1" decimals="-3" id="f-109" unitRef="usd">432472000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-7" decimals="-3" id="f-110" unitRef="usd">370044000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-5" decimals="-3" id="f-111" unitRef="usd">30949000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-6" decimals="-3" id="f-112" unitRef="usd">23710000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-113" unitRef="usd">86264000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-7" decimals="-3" id="f-114" unitRef="usd">72384000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-5" decimals="-3" id="f-115" unitRef="usd">193317000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-6" decimals="-3" id="f-116" unitRef="usd">176141000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-117" unitRef="usd">518736000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-7" decimals="-3" id="f-118" unitRef="usd">442428000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-5" decimals="-3" id="f-119" unitRef="usd">-165550000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-6" decimals="-3" id="f-120" unitRef="usd">-176141000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-121" unitRef="usd">54240000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-7" decimals="-3" id="f-122" unitRef="usd">-438877000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterestAndDividend contextRef="c-5" decimals="-3" id="f-123" unitRef="usd">11019000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend contextRef="c-6" decimals="-3" id="f-124" unitRef="usd">6498000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend contextRef="c-1" decimals="-3" id="f-125" unitRef="usd">28236000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend contextRef="c-7" decimals="-3" id="f-126" unitRef="usd">15550000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InterestExpenseNonoperating contextRef="c-5" decimals="-3" id="f-127" unitRef="usd">24382000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-6" decimals="-3" id="f-128" unitRef="usd">5094000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-1" decimals="-3" id="f-129" unitRef="usd">67667000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-7" decimals="-3" id="f-130" unitRef="usd">17705000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-5" decimals="-3" id="f-131" unitRef="usd">-176000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-6" decimals="-3" id="f-132" unitRef="usd">760000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-133" unitRef="usd">603000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-7" decimals="-3" id="f-134" unitRef="usd">1370000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-5" decimals="-3" id="f-135" unitRef="usd">-13539000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-6" decimals="-3" id="f-136" unitRef="usd">2164000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-137" unitRef="usd">-38828000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-7" decimals="-3" id="f-138" unitRef="usd">-785000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-5" decimals="-3" id="f-139" unitRef="usd">-179089000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-6" decimals="-3" id="f-140" unitRef="usd">-173977000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-141" unitRef="usd">15412000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-7" decimals="-3" id="f-142" unitRef="usd">-439662000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-5" decimals="-3" id="f-143" unitRef="usd">-437000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-144" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-145" unitRef="usd">1419000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-7" decimals="-3" id="f-146" unitRef="usd">-3313000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss contextRef="c-5" decimals="-3" id="f-147" unitRef="usd">-178652000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-6" decimals="-3" id="f-148" unitRef="usd">-173977000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-149" unitRef="usd">13993000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-7" decimals="-3" id="f-150" unitRef="usd">-436349000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-5" decimals="-3" id="f-151" unitRef="usd">-3411000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-6" decimals="-3" id="f-152" unitRef="usd">-3184000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-153" unitRef="usd">-8126000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-7" decimals="-3" id="f-154" unitRef="usd">-7392000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-155" unitRef="usd">-175241000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-156" unitRef="usd">-170793000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-157" unitRef="usd">22119000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-158" unitRef="usd">-428957000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-5"
      decimals="2"
      id="f-159"
      unitRef="usdPerShare">-1.26</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-6"
      decimals="2"
      id="f-160"
      unitRef="usdPerShare">-1.38</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-161"
      unitRef="usdPerShare">0.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-7"
      decimals="2"
      id="f-162"
      unitRef="usdPerShare">-3.63</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-5"
      decimals="2"
      id="f-163"
      unitRef="usdPerShare">-1.26</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-6"
      decimals="2"
      id="f-164"
      unitRef="usdPerShare">-1.38</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-165"
      unitRef="usdPerShare">0.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-7"
      decimals="2"
      id="f-166"
      unitRef="usdPerShare">-3.63</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="-3" id="f-167" unitRef="shares">139039000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-6" decimals="-3" id="f-168" unitRef="shares">124199000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-169" unitRef="shares">132385000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-7" decimals="-3" id="f-170" unitRef="shares">118260000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="-3" id="f-171" unitRef="shares">139039000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-6" decimals="-3" id="f-172" unitRef="shares">124199000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-173" unitRef="shares">133352000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-7" decimals="-3" id="f-174" unitRef="shares">118260000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-5" decimals="-3" id="f-175" unitRef="usd">876000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-6" decimals="-3" id="f-176" unitRef="usd">249000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-1" decimals="-3" id="f-177" unitRef="usd">1022000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-7" decimals="-3" id="f-178" unitRef="usd">2374000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-5" decimals="-3" id="f-179" unitRef="usd">91000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-6" decimals="-3" id="f-180" unitRef="usd">-141000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-1" decimals="-3" id="f-181" unitRef="usd">-415000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-7" decimals="-3" id="f-182" unitRef="usd">-139000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-5" decimals="-3" id="f-183" unitRef="usd">-177685000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-6" decimals="-3" id="f-184" unitRef="usd">-173869000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-185" unitRef="usd">14600000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-7" decimals="-3" id="f-186" unitRef="usd">-434114000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding contextRef="c-8" decimals="-3" id="f-187" unitRef="shares">124376000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-8" decimals="-3" id="f-188" unitRef="usd">217000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-9" decimals="-3" id="f-189" unitRef="usd">1806000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-10" decimals="-3" id="f-190" unitRef="usd">4750000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-11" decimals="-3" id="f-191" unitRef="usd">-1625523000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-12" decimals="-3" id="f-192" unitRef="usd">5619000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-4" decimals="-3" id="f-193" unitRef="usd">191063000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-13" decimals="-3" id="f-194" unitRef="usd">15209000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-14" decimals="-3" id="f-195" unitRef="usd">15209000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-15" decimals="-3" id="f-196" unitRef="shares">70000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-13" decimals="-3" id="f-197" unitRef="usd">634000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-14" decimals="-3" id="f-198" unitRef="usd">634000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="c-15" decimals="-3" id="f-199" unitRef="shares">209000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c-13" decimals="-3" id="f-200" unitRef="usd">25000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c-14" decimals="-3" id="f-201" unitRef="usd">25000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-16" decimals="-3" id="f-202" unitRef="usd">-106000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-14" decimals="-3" id="f-203" unitRef="usd">-106000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-16" decimals="-3" id="f-204" unitRef="usd">-507000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-14" decimals="-3" id="f-205" unitRef="usd">-507000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ProfitLoss contextRef="c-17" decimals="-3" id="f-206" unitRef="usd">-173085000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-18" decimals="-3" id="f-207" unitRef="usd">-2133000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-14" decimals="-3" id="f-208" unitRef="usd">-175218000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding contextRef="c-19" decimals="-3" id="f-209" unitRef="shares">124655000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-19" decimals="-3" id="f-210" unitRef="usd">217000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-20" decimals="-3" id="f-211" unitRef="usd">1846843000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-21" decimals="-3" id="f-212" unitRef="usd">4137000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-22" decimals="-3" id="f-213" unitRef="usd">-1798608000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-23" decimals="-3" id="f-214" unitRef="usd">3486000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-24" decimals="-3" id="f-215" unitRef="usd">56075000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-25" decimals="-3" id="f-216" unitRef="usd">16027000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-26" decimals="-3" id="f-217" unitRef="usd">16027000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-27" decimals="-3" id="f-218" unitRef="shares">353000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-25" decimals="-3" id="f-219" unitRef="usd">2619000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-26" decimals="-3" id="f-220" unitRef="usd">2619000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="c-27" decimals="-3" id="f-221" unitRef="shares">1128000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-27" decimals="-3" id="f-222" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-26" decimals="-3" id="f-223" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-27" decimals="-3" id="f-224" unitRef="shares">11926000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-27" decimals="-3" id="f-225" unitRef="usd">12000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-25" decimals="-3" id="f-226" unitRef="usd">241375000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-26" decimals="-3" id="f-227" unitRef="usd">241387000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-28" decimals="-3" id="f-228" unitRef="usd">-400000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-26" decimals="-3" id="f-229" unitRef="usd">-400000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-28" decimals="-3" id="f-230" unitRef="usd">653000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-26" decimals="-3" id="f-231" unitRef="usd">653000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ProfitLoss contextRef="c-29" decimals="-3" id="f-232" unitRef="usd">370445000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-30" decimals="-3" id="f-233" unitRef="usd">-2582000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-26" decimals="-3" id="f-234" unitRef="usd">367863000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding contextRef="c-31" decimals="-3" id="f-235" unitRef="shares">138062000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-31" decimals="-3" id="f-236" unitRef="usd">230000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-32" decimals="-3" id="f-237" unitRef="usd">2106864000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-33" decimals="-3" id="f-238" unitRef="usd">4390000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-34" decimals="-3" id="f-239" unitRef="usd">-1428163000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-35" decimals="-3" id="f-240" unitRef="usd">904000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-36" decimals="-3" id="f-241" unitRef="usd">684225000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-37" decimals="-3" id="f-242" unitRef="usd">13043000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-5" decimals="-3" id="f-243" unitRef="usd">13043000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-38" decimals="-3" id="f-244" unitRef="shares">36000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-37" decimals="-3" id="f-245" unitRef="usd">223000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-5" decimals="-3" id="f-246" unitRef="usd">223000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="c-38" decimals="-3" id="f-247" unitRef="shares">46000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-39" decimals="-3" id="f-248" unitRef="usd">91000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-5" decimals="-3" id="f-249" unitRef="usd">91000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-39" decimals="-3" id="f-250" unitRef="usd">876000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-5" decimals="-3" id="f-251" unitRef="usd">876000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ProfitLoss contextRef="c-40" decimals="-3" id="f-252" unitRef="usd">-175241000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-41" decimals="-3" id="f-253" unitRef="usd">-3411000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-5" decimals="-3" id="f-254" unitRef="usd">-178652000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding contextRef="c-42" decimals="-3" id="f-255" unitRef="shares">138144000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-42" decimals="-3" id="f-256" unitRef="usd">230000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-43" decimals="-3" id="f-257" unitRef="usd">2120130000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-44" decimals="-3" id="f-258" unitRef="usd">5357000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-45" decimals="-3" id="f-259" unitRef="usd">-1603404000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-46" decimals="-3" id="f-260" unitRef="usd">-2507000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-3" decimals="-3" id="f-261" unitRef="usd">519806000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding contextRef="c-47" decimals="-3" id="f-262" unitRef="shares">107312000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-47" decimals="-3" id="f-263" unitRef="usd">200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-48" decimals="-3" id="f-264" unitRef="usd">1300395000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-49" decimals="-3" id="f-265" unitRef="usd">-3222000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-50" decimals="-3" id="f-266" unitRef="usd">-1026030000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-51" decimals="-3" id="f-267" unitRef="usd">15819000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-52" decimals="-3" id="f-268" unitRef="usd">287162000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-53" decimals="-3" id="f-269" unitRef="usd">19694000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-54" decimals="-3" id="f-270" unitRef="usd">19694000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-55" decimals="-3" id="f-271" unitRef="shares">34000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-53" decimals="-3" id="f-272" unitRef="usd">267000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-54" decimals="-3" id="f-273" unitRef="usd">267000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="c-55" decimals="-3" id="f-274" unitRef="shares">154000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-56" decimals="-3" id="f-275" unitRef="usd">58000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-54" decimals="-3" id="f-276" unitRef="usd">58000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-56" decimals="-3" id="f-277" unitRef="usd">1909000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-54" decimals="-3" id="f-278" unitRef="usd">1909000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ProfitLoss contextRef="c-57" decimals="-3" id="f-279" unitRef="usd">-132864000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-58" decimals="-3" id="f-280" unitRef="usd">-2512000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-54" decimals="-3" id="f-281" unitRef="usd">-135376000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding contextRef="c-59" decimals="-3" id="f-282" unitRef="shares">107500000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-59" decimals="-3" id="f-283" unitRef="usd">200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-60" decimals="-3" id="f-284" unitRef="usd">1320356000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-61" decimals="-3" id="f-285" unitRef="usd">-1255000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-62" decimals="-3" id="f-286" unitRef="usd">-1158894000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-63" decimals="-3" id="f-287" unitRef="usd">13307000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-64" decimals="-3" id="f-288" unitRef="usd">173714000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-65" decimals="-3" id="f-289" unitRef="usd">17750000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-66" decimals="-3" id="f-290" unitRef="usd">17750000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-67" decimals="-3" id="f-291" unitRef="shares">120000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-65" decimals="-3" id="f-292" unitRef="usd">1512000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-66" decimals="-3" id="f-293" unitRef="usd">1512000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="c-67" decimals="-3" id="f-294" unitRef="shares">723000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-67" decimals="-3" id="f-295" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-65" decimals="-3" id="f-296" unitRef="usd">-1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-66" decimals="-3" id="f-297" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-67" decimals="-3" id="f-298" unitRef="shares">15790000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-67" decimals="-3" id="f-299" unitRef="usd">16000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-65" decimals="-3" id="f-300" unitRef="usd">429249000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-66" decimals="-3" id="f-301" unitRef="usd">429265000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-68" decimals="-3" id="f-302" unitRef="usd">-56000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-66" decimals="-3" id="f-303" unitRef="usd">-56000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-68" decimals="-3" id="f-304" unitRef="usd">216000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-66" decimals="-3" id="f-305" unitRef="usd">216000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ProfitLoss contextRef="c-69" decimals="-3" id="f-306" unitRef="usd">-125300000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-70" decimals="-3" id="f-307" unitRef="usd">-1696000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-66" decimals="-3" id="f-308" unitRef="usd">-126996000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding contextRef="c-71" decimals="-3" id="f-309" unitRef="shares">124133000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-71" decimals="-3" id="f-310" unitRef="usd">217000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-72" decimals="-3" id="f-311" unitRef="usd">1768866000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-73" decimals="-3" id="f-312" unitRef="usd">-1095000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-74" decimals="-3" id="f-313" unitRef="usd">-1284194000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-75" decimals="-3" id="f-314" unitRef="usd">11611000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-76" decimals="-3" id="f-315" unitRef="usd">495405000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-77" decimals="-3" id="f-316" unitRef="usd">17050000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-6" decimals="-3" id="f-317" unitRef="usd">17050000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-78" decimals="-3" id="f-318" unitRef="shares">43000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-77" decimals="-3" id="f-319" unitRef="usd">388000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-6" decimals="-3" id="f-320" unitRef="usd">388000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="c-78" decimals="-3" id="f-321" unitRef="shares">51000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-79" decimals="-3" id="f-322" unitRef="usd">-141000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-6" decimals="-3" id="f-323" unitRef="usd">-141000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-79" decimals="-3" id="f-324" unitRef="usd">249000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-6" decimals="-3" id="f-325" unitRef="usd">249000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ProfitLoss contextRef="c-80" decimals="-3" id="f-326" unitRef="usd">-170793000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-81" decimals="-3" id="f-327" unitRef="usd">-3184000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-6" decimals="-3" id="f-328" unitRef="usd">-173977000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding contextRef="c-82" decimals="-3" id="f-329" unitRef="shares">124227000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-82" decimals="-3" id="f-330" unitRef="usd">217000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-83" decimals="-3" id="f-331" unitRef="usd">1786304000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-84" decimals="-3" id="f-332" unitRef="usd">-987000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-85" decimals="-3" id="f-333" unitRef="usd">-1454987000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-86" decimals="-3" id="f-334" unitRef="usd">8427000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-87" decimals="-3" id="f-335" unitRef="usd">338974000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-336" unitRef="usd">13993000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-7" decimals="-3" id="f-337" unitRef="usd">-436349000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-338" unitRef="usd">44279000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-7" decimals="-3" id="f-339" unitRef="usd">54494000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationAndAmortization contextRef="c-1" decimals="-3" id="f-340" unitRef="usd">17542000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-7" decimals="-3" id="f-341" unitRef="usd">13570000</us-gaap:DepreciationAndAmortization>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium contextRef="c-1" decimals="-3" id="f-342" unitRef="usd">4545000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium contextRef="c-7" decimals="-3" id="f-343" unitRef="usd">-7886000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:RealizedInvestmentGainsLosses contextRef="c-1" decimals="-3" id="f-344" unitRef="usd">0</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses contextRef="c-7" decimals="-3" id="f-345" unitRef="usd">80000</us-gaap:RealizedInvestmentGainsLosses>
    <arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties contextRef="c-1" decimals="-3" id="f-346" unitRef="usd">18893000</arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties>
    <arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties contextRef="c-7" decimals="-3" id="f-347" unitRef="usd">17705000</arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties>
    <us-gaap:PaidInKindInterest contextRef="c-1" decimals="-3" id="f-348" unitRef="usd">48774000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest contextRef="c-7" decimals="-3" id="f-349" unitRef="usd">0</us-gaap:PaidInKindInterest>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-350" unitRef="usd">9841000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-7" decimals="-3" id="f-351" unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-352" unitRef="usd">22342000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-7" decimals="-3" id="f-353" unitRef="usd">1746000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-354" unitRef="usd">21662000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-7" decimals="-3" id="f-355" unitRef="usd">2785000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-1" decimals="-3" id="f-356" unitRef="usd">7956000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-7" decimals="-3" id="f-357" unitRef="usd">13086000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-1" decimals="-3" id="f-358" unitRef="usd">22979000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-7" decimals="-3" id="f-359" unitRef="usd">-866000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-360" unitRef="usd">-3417000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-7" decimals="-3" id="f-361" unitRef="usd">3880000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="c-1" decimals="-3" id="f-362" unitRef="usd">-3128000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="c-7" decimals="-3" id="f-363" unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-364" unitRef="usd">159061000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-7" decimals="-3" id="f-365" unitRef="usd">-325635000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-366" unitRef="usd">15177000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-7" decimals="-3" id="f-367" unitRef="usd">117180000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments contextRef="c-1" decimals="-3" id="f-368" unitRef="usd">774616000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments contextRef="c-7" decimals="-3" id="f-369" unitRef="usd">428611000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments contextRef="c-1" decimals="-3" id="f-370" unitRef="usd">587880000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments contextRef="c-7" decimals="-3" id="f-371" unitRef="usd">348642000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-372" unitRef="usd">-201913000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-7" decimals="-3" id="f-373" unitRef="usd">-197149000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-3" id="f-374" unitRef="usd">3476000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-7" decimals="-3" id="f-375" unitRef="usd">2166000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-7" decimals="-3" id="f-376" unitRef="usd">429265000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <arwr:ProceedsFromSaleOfFutureRoyalties contextRef="c-1" decimals="-3" id="f-377" unitRef="usd">0</arwr:ProceedsFromSaleOfFutureRoyalties>
    <arwr:ProceedsFromSaleOfFutureRoyalties contextRef="c-7" decimals="-3" id="f-378" unitRef="usd">50000000</arwr:ProceedsFromSaleOfFutureRoyalties>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c-1" decimals="-3" id="f-379" unitRef="usd">25000000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c-7" decimals="-3" id="f-380" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-1" decimals="-3" id="f-381" unitRef="usd">5000000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-7" decimals="-3" id="f-382" unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-3" id="f-383" unitRef="usd">241388000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:RepaymentsOfLinesOfCredit contextRef="c-1" decimals="-3" id="f-384" unitRef="usd">201625000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit contextRef="c-7" decimals="-3" id="f-385" unitRef="usd">0</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit contextRef="c-1" decimals="-3" id="f-386" unitRef="usd">7098000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit contextRef="c-7" decimals="-3" id="f-387" unitRef="usd">0</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-388" unitRef="usd">70337000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-7" decimals="-3" id="f-389" unitRef="usd">481431000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-390" unitRef="usd">27485000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c-7" decimals="-3" id="f-391" unitRef="usd">-41353000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-1" decimals="-3" id="f-392" unitRef="usd">-377000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-7" decimals="-3" id="f-393" unitRef="usd">-139000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-394" unitRef="usd">102685000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-52" decimals="-3" id="f-395" unitRef="usd">110891000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-396" unitRef="usd">129793000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-87" decimals="-3" id="f-397" unitRef="usd">69399000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-3" id="f-398" unitRef="usd">19000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-7" decimals="-3" id="f-399" unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-1" decimals="-3" id="f-400" unitRef="usd">81000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-7" decimals="-3" id="f-401" unitRef="usd">3062000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-402" unitRef="usd">346000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-7" decimals="-3" id="f-403" unitRef="usd">6909000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-404">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;General and Recent Developments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Arrowhead Pharmaceuticals, Inc. and its subsidiaries (referred to herein collectively as the &#x201c;Company&#x201d;) are primarily engaged in developing medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, the Company&#x2019;s therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference (&#x201c;RNAi&#x201d;) is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. The Company&#x2019;s RNAi-based therapeutics may leverage this natural pathway of gene silencing to target and shut down specific disease-causing genes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s current pipeline:&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.035%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Therapeutic Area&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Stage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Product Rights&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Cardiometabolic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;plozasiran&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;zodasiran&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;olpasiran&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amgen&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-PNPLA3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;GSK-4532990&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 2b&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;GSK&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-INHBE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1/2a&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-ALK7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1/2a&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Pulmonary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-RAGE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1/2a&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;SRP-1002 (ARO-MMP7)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1/2a&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Sarepta&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Liver&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;fazirsiran&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Takeda and Arrowhead&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;GSK5637608&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;GSK&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Neuromuscular&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;SRP-1001 (ARO-DUX4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1/2a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Sarepta&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;SRP-1003 (ARO-DM1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1/2a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Sarepta&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Central Nervous System (CNS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;SRP-1004 (ARO-ATXN2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1/2a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Sarepta&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-C3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1/2a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-CFB&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1/2a&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates lab facilities in California and Wisconsin, where its research and development activities, including the development of RNAi therapeutics, take place. The Company also operates an active pharmaceutical ingredient manufacturing and supporting laboratory facility in Verona, Wisconsin. The Company&#x2019;s principal executive offices are located in Pasadena, California.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the first three quarters of fiscal 2025, the Company has continued to develop and advance its pipeline and partnered candidates. The following is a summary of select significant developments affecting our business that have occurred since the filing of our Annual Report on Form 10-K for the fiscal year ended September 30, 2024:  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Triggered a $100.0 million milestone payment from Sarepta Therapeutics, Inc., which was triggered on July 27, 2025, when the Company reached the first of two prespecified enrollment targets and subsequent authorization to dose escalate in a Phase 1/2 clinical study of ARO-DM1, an investigational RNAi therapeutic for the treatment of type 1 myotonic dystrophy (DM1);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Announced the signing of an asset purchase agreement between Sanofi and Visirna Therapeutics, a majority-owned subsidiary of the Company, created to develop and commercialize four of the Company&#x2019;s investigational cardiometabolic candidates in Greater China. Under the terms of the agreement, Sanofi will acquire rights to develop and commercialize investigational plozasiran, the Company's first-in-class RNAi therapeutic candidate designed to reduce production of apolipoprotein C-III (APOC3) as a potential treatment for familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia (SHTG), in Greater China;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Initiated and dosed the first subject in the YOSEMITE Phase 3 clinical trial of zodasiran, the Company&#x2019;s investigational RNAi therapeutic being developed as a potential treatment for homozygous familial &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;hypercholesterolemia (HoFH), a rare genetic condition that leads to severely elevated LDL-cholesterol and early onset cardiovascular disease; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10pt"&gt;Completed enrollment of SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 clinical trials of plozasiran. The Company&#x2019;s global Phase 3 clinical studies are designed to support regulatory submissions for approval of investigational plozasiran in the treatment of severe hypertriglyceridemia. The Company previously submitted a New Drug Application to the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) on November 16, 2024 for plozasiran based on positive Phase 3 PALISADE study results in patients with familial chylomicronemia syndrome, which the FDA accepted on January 17, 2025, with a Prescription Drug User Fee Act (PDUFA) action date of November 18, 2025, and indicated it is not currently planning to hold an advisory committee meeting;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Initiated a Phase 1/2a clinical trial of ARO-ALK7 for the treatment of obesity. ARO-ALK7 is the first RNAi-based therapy designed to silence adipocyte expression of  the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ACVR1C &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;gene to reduce the production of Activin receptor-like kinase 7 (ALK7), which acts as a receptor in a pathway that regulates energy homeostasis in adipose tissue;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Announced Topline results from Part 2 of a Phase 1/2 clinical study of ARO-C3, the Company&#x2019;s investigational RNAi therapeutic designed to reduce liver production of complement component 3 (C3) as a potential therapy for various complement mediated diseases. ARO-C3 achieved reductions in alternative pathway complement activity and proteinuria;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Entered into a global licensing and collaboration agreement with Sarepta Therapeutics, Inc (&#x201c;Sarepta&#x201d;) on November 25, 2024, which closed on February 7, 2025. Closing of the transaction was subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary conditions. Upon closing, the Company received $325.0 million through the purchase of 11,926,301 shares of Company common stock by Sarepta, at a price per share of $27.25, and received $500.0 million as an upfront payment on February 24, 2025. The Company will also receive $250.0 million to be paid in equal installments over five years and is eligible to receive an additional $300.0 million in near-term payments. Additionally, the Company is eligible to receive royalties on commercial sales and up to approximately $10.0 billion in future potential milestone payments;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;GSK dosed its fifth patient in a Phase 2 trial in December 2024, triggering a $2.5 million milestone payment to the Company which was paid in the second quarter of fiscal 2025;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.7pt"&gt;Announced that the Company dosed the first subjects in a Phase 1/2a clinical trial of ARO-INHBE; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Presented interim results from a Phase 1/2a clinical study of ARO-CFB at the 8th Complement-Based Drug Development Summit. The study resulted in multiple findings including: (1) ARO-CFB led to dose dependent reductions in circulating CFB protein by up to 90% with greater than 3 months duration, (2) single and multiple doses of ARO-CFB led to near complete inhibition of alternative pathway activity based on Wieslab AP, and (3) single and multiple doses of ARO-CFB led to near complete inhibition of alternative pathway hemolytic activity, measured by AH50.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Consolidation and Basis of Presentation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interim Consolidated Financial Statements include the accounts of Arrowhead Pharmaceuticals, Inc. and its subsidiaries (wholly-owned subsidiaries and a variable interest entity for which the Company is the primary beneficiary). Subsidiaries refer to Arrowhead Madison, Inc., Arrowhead Australia Pty Ltd., Arrowhead Pharmaceuticals Ireland Limited, Arrowhead Pharmaceuticals NZ Limited and Visirna Therapeutics, Inc. (&#x201c;Visirna&#x201d;). For subsidiaries in which the Company owns or is exposed to less than 100% of the economics, the Company records net loss attributable to noncontrolling interests in its consolidated statements of operations equal to the percentage of the economic or ownership interests retained in such entity by the respective noncontrolling party.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interim Consolidated Financial Statements have been prepared in conformity with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;). The financial data of the Company included herein are unaudited. In the opinion of management, all material adjustments of a normal recurring nature have been made to present fairly the Company&#x2019;s financial position as of June&#160;30, 2025 and the results of operations and cash flows for the periods presented. All intercompany transactions and balances have been eliminated. Certain prior period amounts have been reclassified to conform with the current period presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain financial information that is normally included in annual financial statements prepared in accordance with GAAP, but that is not required for interim reporting purposes, has been omitted from the accompanying interim consolidated financial statements and related notes. Readers are urged to review the Company&#x2019;s Annual Report on Form &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10-K for the fiscal year ended September&#160;30, 2024 for more complete descriptions and discussions. Operating results and cash flows for the nine months ended June&#160;30, 2025 are not necessarily indicative of the results that may be expected for the fiscal year ending September&#160;30, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s primary sources of financing have been through the sale of its equity securities, credit facility, revenue from its licensing and collaboration agreements and the sale of certain future royalties. Research and development activities have required significant investment since the Company&#x2019;s inception and are expected to continue to require significant cash expenditure in the future, particularly as the Company&#x2019;s pipeline of drug candidates and its headcount have both expanded. Additionally, significant investment will be required as the Company&#x2019;s pipeline matures into later stage clinical trials and commercialization efforts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2025, the Company had $129.8 million in cash, cash equivalents and restricted cash ($2.2 million in restricted cash) and $770.6 million in available-for-sale securities to fund operations. During the nine months ended June&#160;30, 2025, the Company&#x2019;s cash, cash equivalents and restricted cash and investments balance increased by&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$219.4 million, which was primarily due to the $500.0 million as an upfront payment under the Sarepta agreement and $325.0 million in the form of an equity investment under the Sarepta agreement, and $25.0 million in the form of pre-funded warrants, partially offset by ongoing expenses related to the Company&#x2019;s research and development programs, $201.6 million payments on its credit facility, and $28.2 million interest income earned on investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In total, the Company is eligible to receive up to $13.3 billion in additional developmental, regulatory and sales milestones, and may receive various royalties on net sales from its licensing and collaboration agreements, subject to the terms and conditions of those agreements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Summary of Significant Accounting Policies &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no changes to the significant accounting policies disclosed in the Company&#x2019;s most recent Annual Report on Form 10-K for the fiscal year ended September&#160;30, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2025, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standard Update (&#x201c;ASU&#x201d;) 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in November 2024, and ASU 2025-01,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Clarifying the Effective Date&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. These updates require entities to provide disaggregated disclosures of income statement expenses. The ASUs do not affect the expense captions presented on the face of the income statement but instead require the disaggregation of certain expense captions into specified categories within the footnotes to the financial statements. The ASUs will become effective for the Company beginning October 1, 2027, and the Company is currently evaluating the impact on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to improve its income tax disclosure requirements. Under the guidance, entities must annually (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold. This ASU will become effective for the Company beginning October 1, 2025, and is not expected to have a material impact on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the FASB issued ASU 2023-07, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which is intended to improve reportable segment disclosure requirements, primarily through additional disclosures about significant segment expenses. This ASU requires public companies with a single reportable segment to provide all disclosures required under ASC 280. In addition, this ASU requires public companies to include in interim reports all disclosures related to a reportable segment&#x2019;s profit or loss and assets that are currently required in annual reports. While the ASU implements further segment disclosure requirements, it does not change how an entity identifies its operating or reportable segments and it will have no impact on the Company&#x2019;s consolidated financial condition, results of operations or cash flows. The Company plans to adopt the ASU's in connection with our Annual Report on Form 10-K for the fiscal year ending September 30, 2025, as required and will be applied retrospectively to all periods presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 4, 2025, the One Big Beautiful Bill Act (&#x201c;OBBBA&#x201d;) was signed into law, which enacts significant changes to U.S. tax and related laws. Some of the provisions of the new tax law affecting corporations include but are not limited to expensing of domestic research expenses, reinstate the limit of the deduction of interest expense to thirty percent of EBITDA, and one hundred percent bonus depreciation on eligible property acquired after January 19, 2025. The Company is currently evaluating the impact the new tax law will have on its financial condition and results of operations.  &lt;/span&gt;&lt;/div&gt;Preliminarily, the Company does not anticipate a material change to its effective income tax rate and its net deferred federal income tax assets as the Company maintains a full valuation allowance.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <arwr:ScheduleOfCurrentProductsTableTextBlock contextRef="c-1" id="f-405">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s current pipeline:&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.035%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Therapeutic Area&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Stage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Product Rights&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Cardiometabolic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;plozasiran&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;zodasiran&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;olpasiran&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amgen&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-PNPLA3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;GSK-4532990&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 2b&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;GSK&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-INHBE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1/2a&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-ALK7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1/2a&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Pulmonary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-RAGE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1/2a&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;SRP-1002 (ARO-MMP7)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1/2a&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Sarepta&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Liver&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;fazirsiran&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Takeda and Arrowhead&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;GSK5637608&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;GSK&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Neuromuscular&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;SRP-1001 (ARO-DUX4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1/2a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Sarepta&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;SRP-1003 (ARO-DM1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1/2a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Sarepta&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Central Nervous System (CNS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;SRP-1004 (ARO-ATXN2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1/2a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Sarepta&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-C3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1/2a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-CFB&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1/2a&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</arwr:ScheduleOfCurrentProductsTableTextBlock>
    <arwr:DevelopmentMilestonePayments contextRef="c-88" decimals="-5" id="f-406" unitRef="usd">100000000.0</arwr:DevelopmentMilestonePayments>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-89" decimals="-5" id="f-407" unitRef="usd">325000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-89"
      decimals="INF"
      id="f-408"
      unitRef="shares">11926301</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-90"
      decimals="2"
      id="f-409"
      unitRef="usdPerShare">27.25</us-gaap:SaleOfStockPricePerShare>
    <arwr:ProceedsFromCollaborationArrangements contextRef="c-91" decimals="-5" id="f-410" unitRef="usd">500000000.0</arwr:ProceedsFromCollaborationArrangements>
    <arwr:AdditionalCashReceivableUnderCollaborationAgreement contextRef="c-89" decimals="-5" id="f-411" unitRef="usd">250000000.0</arwr:AdditionalCashReceivableUnderCollaborationAgreement>
    <arwr:CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod contextRef="c-89" id="f-412">P5Y</arwr:CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod>
    <arwr:EnrollmentRelatedMilestonePayments contextRef="c-90" decimals="-5" id="f-413" unitRef="usd">300000000.0</arwr:EnrollmentRelatedMilestonePayments>
    <arwr:FuturePotentialMilestonePayments contextRef="c-89" decimals="-8" id="f-414" unitRef="usd">10000000000.0</arwr:FuturePotentialMilestonePayments>
    <arwr:DevelopmentMilestonePayments contextRef="c-92" decimals="-5" id="f-415" unitRef="usd">2500000</arwr:DevelopmentMilestonePayments>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-5" id="f-416" unitRef="usd">129800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-5" id="f-417" unitRef="usd">2200000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-3" decimals="-5" id="f-418" unitRef="usd">770600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <arwr:IncreaseDecreaseInCashAndInvestments contextRef="c-1" decimals="-5" id="f-419" unitRef="usd">219400000</arwr:IncreaseDecreaseInCashAndInvestments>
    <arwr:ProceedsFromCollaborationArrangements contextRef="c-91" decimals="-5" id="f-420" unitRef="usd">500000000.0</arwr:ProceedsFromCollaborationArrangements>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-89" decimals="-5" id="f-421" unitRef="usd">325000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c-1" decimals="-5" id="f-422" unitRef="usd">25000000.0</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:RepaymentsOfLinesOfCredit contextRef="c-1" decimals="-5" id="f-423" unitRef="usd">201600000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:InvestmentIncomeInterestAndDividend contextRef="c-1" decimals="-5" id="f-424" unitRef="usd">28200000</us-gaap:InvestmentIncomeInterestAndDividend>
    <arwr:DevelopmentRegulatoryAndSalesMilestonesPayments contextRef="c-3" decimals="-8" id="f-425" unitRef="usd">13300000000</arwr:DevelopmentRegulatoryAndSalesMilestonesPayments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-426">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2025, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standard Update (&#x201c;ASU&#x201d;) 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in November 2024, and ASU 2025-01,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Clarifying the Effective Date&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. These updates require entities to provide disaggregated disclosures of income statement expenses. The ASUs do not affect the expense captions presented on the face of the income statement but instead require the disaggregation of certain expense captions into specified categories within the footnotes to the financial statements. The ASUs will become effective for the Company beginning October 1, 2027, and the Company is currently evaluating the impact on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to improve its income tax disclosure requirements. Under the guidance, entities must annually (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold. This ASU will become effective for the Company beginning October 1, 2025, and is not expected to have a material impact on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the FASB issued ASU 2023-07, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which is intended to improve reportable segment disclosure requirements, primarily through additional disclosures about significant segment expenses. This ASU requires public companies with a single reportable segment to provide all disclosures required under ASC 280. In addition, this ASU requires public companies to include in interim reports all disclosures related to a reportable segment&#x2019;s profit or loss and assets that are currently required in annual reports. While the ASU implements further segment disclosure requirements, it does not change how an entity identifies its operating or reportable segments and it will have no impact on the Company&#x2019;s consolidated financial condition, results of operations or cash flows. The Company plans to adopt the ASU's in connection with our Annual Report on Form 10-K for the fiscal year ending September 30, 2025, as required and will be applied retrospectively to all periods presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 4, 2025, the One Big Beautiful Bill Act (&#x201c;OBBBA&#x201d;) was signed into law, which enacts significant changes to U.S. tax and related laws. Some of the provisions of the new tax law affecting corporations include but are not limited to expensing of domestic research expenses, reinstate the limit of the deduction of interest expense to thirty percent of EBITDA, and one hundred percent bonus depreciation on eligible property acquired after January 19, 2025. The Company is currently evaluating the impact the new tax law will have on its financial condition and results of operations.  &lt;/span&gt;&lt;/div&gt;Preliminarily, the Company does not anticipate a material change to its effective income tax rate and its net deferred federal income tax assets as the Company maintains a full valuation allowance.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c-1" id="f-427">COLLABORATION AND LICENSE AGREEMENTS&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a summary of revenue recognized:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.878%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:27.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.419%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.419%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.844%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.419%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.775%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;GSK&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Takeda&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Sarepta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;27,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;570,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;27,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;572,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the balance of receivables and contract liabilities related to the Company&#x2019;s collaboration and license agreements:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.787%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.413%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.153%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(in thousands) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Receivables included in accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;9,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Contract liabilities included in deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;22,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;GlaxoSmithKline Intellectual Property (No. 3) Limited (&#x201c;GSK&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline"&gt;GSK-HSD License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 22, 2021, GSK and the Company entered into an Exclusive License Agreement (the &#x201c;GSK-HSD License Agreement&#x201d;). Under the GSK-HSD License Agreement, GSK has received an exclusive license for GSK-4532990 (formerly ARO-HSD). The exclusive license is worldwide with the exception of greater China. GSK is wholly responsible for all clinical development and commercialization of GSK-4532990 in its territory. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has completed its performance obligation related to this agreement, and the upfront payment of $120.0&#160;million was fully recognized in the year ended September 30, 2022. Further, GSK dosed the first patient in a Phase 2b trial in March 2023 and paid a $30.0&#160;million milestone payment to the Company in the third quarter of fiscal 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is eligible for an additional payment of $100.0&#160;million upon achieving the first patient dosed in a Phase 3 trial. Furthermore, should the Phase 3 trial read out positively, and the potential new medicine receives regulatory approval in major markets, the deal provides for commercial milestone payments to the Company of up to $190.0&#160;million at first commercial sale, and up to $590.0&#160;million in sales-related milestone payments. The Company is further eligible to receive tiered royalties on net product sales in a range of mid-teens to twenty percent. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline"&gt;GSK-HBV Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 11, 2023, the Company entered into an Amended and Restated License Agreement with GSK (the &#x201c;GSK-HBV Agreement&#x201d;) pursuant to which GSK received a worldwide, exclusive license to develop and commercialize daplusiran/tomligisiran (GSK5637608, formerly JNJ-3989), the Company&#x2019;s third-generation subcutaneously administered RNAi therapeutic candidate being developed as a potential therapy for patients with chronic hepatitis B virus infection. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the GSK-HBV Agreement, the Company received $2.7&#160;million in December 2023, upon signing the amended GSK-HBV Agreement. Further, GSK dosed the fifth patient in a Phase 2 trial in December 2024, triggering a $2.5&#160;million milestone payment to the Company which was paid in the second quarter of fiscal 2025. The Company is eligible to receive up to $830.0&#160;million in development and sales milestone payments under the GSK-HBV Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2025, the Company had no contract assets and liabilities recorded.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Takeda Pharmaceutical Company Limited (&#x201c;Takeda&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020, Takeda and the Company entered into an Exclusive License and Co-Funding Agreement (the &#x201c;Takeda License Agreement&#x201d;). Under the Takeda License Agreement, Takeda and the Company will co-develop the Company&#x2019;s fazirsiran program (formerly TAK-999 and ARO-AAT), the Company&#x2019;s second-generation subcutaneously administered RNAi therapeutic candidate being developed as a treatment for liver disease associated with alpha-1 antitrypsin deficiency. Within the United States, fazirsiran, if approved, will be co-commercialized under a &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;50/50 profit &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;sharing&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; structure. Outside the United States, Takeda received an exclusive license to commercialize fazirsiran and will lead the global commercialization strategy, while the Company will be eligible to receive tiered royalties of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on net sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that the key deliverables included the license and certain research and development services including the Company&#x2019;s responsibilities to complete the initial portion of the SEQUOIA study, to complete the ongoing Phase 2 AROAAT2002 study, and to ensure certain manufacturing of fazirsiran drug product is completed and delivered to Takeda (the &#x201c;Takeda R&amp;amp;D Services&#x201d;). Due to the specialized and unique nature of these Takeda R&amp;amp;D Services and their direct relationship with the license, the Company determined that these deliverables represent one distinct bundle and, thus, one performance obligation. Takeda is responsible for managing clinical development and commercialization outside the United States. Within the United States, the Company and Takeda are responsible in the co-development and co-commercialization efforts. The Company considers the collaborative activities, including the co-development and co-commercialization, to be a separate unit of account within Topic 808, and as such, these co-funding amounts are recorded as research and development expenses or general and administrative expenses, as appropriate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Takeda License Agreement, the Company received $300.0&#160;million as an upfront payment in January 2021 and an additional $40.0&#160;million upon Takeda&#x2019;s initiation of a Phase 3 REDWOOD clinical study of fazirsiran in March 2023, and is eligible to receive up to $527.5&#160;million in additional potential development, regulatory and commercial milestones. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company allocated the total $300.0&#160;million initial transaction price to its one distinct performance obligation for the fazirsiran license and the associated Takeda R&amp;amp;D Services. The Company has substantially completed its performance obligation under the Takeda License Agreement by December 31, 2023. As such, all revenue has been fully recognized as of December 31, 2023. There were no further deferred revenue and contract liabilities as of June&#160;30, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded $24.6&#160;million as accrued expenses as of June&#160;30, 2025 that was primarily driven by co-development and co-commercialization activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%"&gt;Janssen Pharmaceuticals, Inc. (&#x201c;Janssen&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 7, 2023, Janssen voluntarily terminated its collaboration agreement with the Company and the Company regained full rights to ARO-PNPLA3, formerly called JNJ-75220795. There are no currently active trials for ARO-PNPLA3.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Further, on December 11, 2023, the Company entered into the GSK-HBV Agreement, as discussed above, pursuant to which GSK received an exclusive license for JNJ-3989 (formerly ARO-HBV). JNJ-3989 had previously been licensed to Janssen in October 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%"&gt;Amgen Inc. (&#x201c;Amgen&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2016, Amgen and the Company entered into two collaboration and license agreements and a common stock purchase agreement. Under the Second Collaboration and License Agreement (the &#x201c;Olpasiran Agreement&#x201d;), Amgen received a worldwide, exclusive license to the Company&#x2019;s novel RNAi olpasiran (previously referred to as AMG- 890 or ARO-LPA) program. These RNAi molecules are designed to reduce elevated lipoprotein(a), which is a genetically validated, independent risk factor for atherosclerotic cardiovascular disease. Under the Olpasiran Agreement, Amgen is wholly responsible for clinical development and commercialization.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has substantially completed its performance obligations under the Olpasiran Agreement. There were no contract assets and liabilities recorded as of June&#160;30, 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2022, Royalty Pharma Investments 2019 ICAV (&#x201c;Royalty Pharma&#x201d;) and the Company entered into a Royalty Purchase Agreement with Royalty Pharma (the &#x201c;Royalty Pharma Agreement&#x201d;). In consideration for the payments under the Royalty Pharma Agreement, Royalty Pharma is entitled to receive all royalties otherwise payable by Amgen to the Company under the Olpasiran Agreement. The Company remains eligible to receive up to an additional $485.0&#160;million in remaining development, regulatory and sales milestone payments payable from Amgen and Royalty Pharma. See Note 11.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Sarepta Therapeutics, Inc. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 25, 2024, the Company entered into an Exclusive License and Collaboration Agreement (the &#x201c;Sarepta Collaboration Agreement&#x201d;) with Sarepta for the development and commercialization of multiple clinical and preclinical programs in rare, genetic diseases of the muscle, central nervous system, and lungs. The Company concurrently entered into a Stock Purchase Agreement (the &#x201c;Stock Purchase Agreement&#x201d;) with Sarepta (see Note 6). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Sarepta Collaboration Agreement, Sarepta received an exclusive sublicensable worldwide license to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SRP-1001 (formerly ARO-DUX4), SRP-1003 (formerly ARO-DM1), SRP-1002 (formerly ARO-MMP7), and SRP-1004 (formerly ARO-ATXN2) clinical stage programs (the &#x201c;C1&#x201d; programs). Sarepta also received an exclusive sublicensable worldwide license to the Company&#x2019;s ARO-HTT, ARO-ATXN1, and ARO-ATXN3 preclinical stage programs (the &#x201c;C2&#x201d; programs). The Company will perform certain research and development activities for the C1 and C2 programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Further, Sarepta may select up to six gene targets for which the Company will perform discovery, optimization and preclinical development activities to identify RNAi compounds against each selected target (the &#x201c;C3&#x201d; programs). Upon target acceptance, Sarepta will receive an exclusive license to the Company&#x2019;s intellectual property rights to exploit compounds directed to those targets and is wholly responsible for clinical development and commercialization of each compound after the Company delivers a Clinical Trial Application ready data package (the "CTA package").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company identified 17 performance obligations under the Sarepta Collaboration Agreement. The four C1 licenses are distinct performance obligations from the four C1 research and development performance obligations since the customer can use and benefit from the licenses separately. The performance obligations for the licenses were satisfied in the second quarter of fiscal 2025 upon delivery, and the research and development performance obligations will be satisfied as the work is performed. The remaining nine performance obligations include three C2 preclinical stage program licenses and research and development activities, and six C3 unidentified discovery target licenses and research and development activity. Each of the three C2 programs and the six C3 programs were determined to represent one performance obligation, as the customer cannot benefit from the use of the product license at the point of transfer until the specified research and development activities are performed. As such, each of the C2 and C3 product licenses and respective research and development work will be combined to form one performance obligation. For these nine performance obligations, revenue is recognized over time as the work is performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For performance obligations recognized over time, the estimated performance period over which revenue will be recognized is determined to be the period over which the Company estimates it will perform the research and development activities. The Company determined that the most appropriate method of measuring progress for these performance obligations is an input method based on research and development costs in the program budget. Accordingly, the Company has estimated the total cost required to complete its obligation and recognized an amount of revenue equal to the proportion of services performed, which is reassessed on an ongoing basis as the program progresses. In the period an agreement expires or is terminated, remaining deferred revenue, if any, is recognized as revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Sarepta Collaboration Agreement, the Company received an upfront payment of $500.0&#160;million on February 14, 2025. In addition, on February 7, 2025, the Company received $325.0&#160;million in the form of an equity investment under the Stock Purchase Agreement. Based upon the Company's share price on February 7, 2025, (the &#x201c;Closing Date&#x201d;), the difference between the $325.0&#160;million and the fair value of the shares on the Closing date resulted in a premium of $83.6&#160;million. The premium is included as part of the total consideration of the Sarepta Collaboration Agreement for revenue recognition purposes. The Company is entitled to receive $250.0&#160;million to be paid in annual installments of $50.0&#160;million over the first five years of the agreement. The Company is also eligible receive reimbursement of certain costs related to carrying out the research and development activities for the C1 programs. The fixed consideration of $833.6&#160;million and an estimated variable consideration of $71.2&#160;million were allocated to all performance obligations based on their relative standalone selling price. Standalone selling prices for the product licenses were determined using an adjusted market-based approach through the net present value of the expected future cash flows for each program. The standalone selling prices for the research and development work were determined based on an expected cost plus margin approach. The fixed and estimated variable consideration of $904.9&#160;million was allocated in accordance to the following table:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:48.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.104%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.696%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Upfront payment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Annual fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;250,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Equity premium&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;83,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Fixed consideration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;833,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Estimated variable consideration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;71,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Total transaction price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;904,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the stand-alone selling price for each distinct performance obligation, which involves assumptions that may require significant judgment. The Company&#x2019;s estimates of the stand-alone selling price for license-related performance obligations includes forecasted revenues and expenses, phase dates, probability of success, development timelines, and the discount rate. The estimates of the stand-alone selling price for research and development &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;or other service-related performance obligations generally include forecasting the expected costs of satisfying a performance obligation at market rates. The Company identified a discount based on the difference between the aggregate stand-alone selling price and the transaction price for accounting revenue recognition purposes. The Company allocated the discount proportionally to each of the performance obligations based upon their standalone selling price. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company receives reimbursement of certain costs related to carrying out the research and development activities for the C1 programs and may receive development milestone payments of up to $300.0&#160;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Further, for each of the 13 programs, the Company is eligible to receive regulatory milestone payments between $110.0&#160;million and $180.0&#160;million per program. Variable consideration associated with the milestones that may be achieved will be allocated to the performance obligation to which it is determined to be related, which will be the respective development work that is being reimbursed and the respective programs to which the milestones relate. ARO-DM1 development milestones were allocated between the license and development work based on the allocation of the standalone selling price. The Company will recognize the ARO-DM1 development milestones and other development milestones as revenue in the periods the underlying milestone events are achieved as achievement of the milestone events are highly susceptible to factors outside of the entity's influence and therefore there is a possibility that the milestone event will not be achieved.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also eligible to receive sales milestone payments between $500.0&#160;million and $700.0&#160;million per program as well as tiered royalties on net sales of licensed products of up to the low double digits, subject to the terms and conditions of the Sarepta Collaboration Agreement. The Company has applied the sales-based scope exception to the sales milestones and the royalty-based payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Sarepta Collaboration Agreement commenced in February 2025 and may be terminated by either party in the event of a material breach as defined therein. In addition, Sarepta may voluntarily terminate the Sarepta Collaboration Agreement with 30 days' written notice to the Company if terminated prior to any regulatory approval of a licensed product. Unless earlier terminated, the Sarepta Collaboration Agreement expires on a product-by-product and country-by-country basis, upon the date of expiration of the relevant royalty term for such product in such country.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2025, the Company recorded $570.3&#160;million in revenue from Sarepta, $9.7&#160;million in accounts receivable and $23.0&#160;million in deferred revenue. The recognition of the remaining revenue for the performance obligations is dependent upon the time it takes to complete the respective research and development activities and in consideration of the timing of the selection of the C3 programs.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c-1" id="f-428">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a summary of revenue recognized:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.878%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:27.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.419%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.419%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.844%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.419%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.775%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;GSK&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Takeda&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Sarepta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;27,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;570,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;27,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;572,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-93" decimals="-3" id="f-429" unitRef="usd">143000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-94" decimals="-3" id="f-430" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-95" decimals="-3" id="f-431" unitRef="usd">2646000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-96" decimals="-3" id="f-432" unitRef="usd">2685000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-97" decimals="-3" id="f-433" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-98" decimals="-3" id="f-434" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-99" decimals="-3" id="f-435" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-100" decimals="-3" id="f-436" unitRef="usd">866000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-101" decimals="-3" id="f-437" unitRef="usd">27624000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-102" decimals="-3" id="f-438" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-103" decimals="-3" id="f-439" unitRef="usd">570330000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-104" decimals="-3" id="f-440" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-5" decimals="-3" id="f-441" unitRef="usd">27767000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="-3" id="f-442" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-443" unitRef="usd">572976000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-7" decimals="-3" id="f-444" unitRef="usd">3551000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock contextRef="c-1" id="f-445">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the balance of receivables and contract liabilities related to the Company&#x2019;s collaboration and license agreements:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.787%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.413%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.153%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(in thousands) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Receivables included in accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;9,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Contract liabilities included in deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;22,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:AccountsReceivableNet contextRef="c-3" decimals="-3" id="f-446" unitRef="usd">9699000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet contextRef="c-4" decimals="-3" id="f-447" unitRef="usd">0</us-gaap:AccountsReceivableNet>
    <us-gaap:ContractWithCustomerLiability contextRef="c-3" decimals="-3" id="f-448" unitRef="usd">22979000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-4" decimals="-3" id="f-449" unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <arwr:InitialTransactionPrice contextRef="c-105" decimals="-5" id="f-450" unitRef="usd">120000000</arwr:InitialTransactionPrice>
    <arwr:MilestonePaymentReceivable contextRef="c-106" decimals="-5" id="f-451" unitRef="usd">30000000</arwr:MilestonePaymentReceivable>
    <arwr:MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree contextRef="c-107" decimals="-5" id="f-452" unitRef="usd">100000000</arwr:MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree>
    <arwr:CommercialMilestonePaymentsAtFirstCommercialSale contextRef="c-108" decimals="-5" id="f-453" unitRef="usd">190000000</arwr:CommercialMilestonePaymentsAtFirstCommercialSale>
    <arwr:SalesRelatedMilestonePayments contextRef="c-108" decimals="-5" id="f-454" unitRef="usd">590000000</arwr:SalesRelatedMilestonePayments>
    <arwr:InitialTransactionPrice contextRef="c-109" decimals="-5" id="f-455" unitRef="usd">2700000</arwr:InitialTransactionPrice>
    <arwr:DevelopmentMilestonePayments contextRef="c-92" decimals="-5" id="f-456" unitRef="usd">2500000</arwr:DevelopmentMilestonePayments>
    <arwr:DevelopmentAndSalesMilestonesPayments contextRef="c-110" decimals="-5" id="f-457" unitRef="usd">830000000</arwr:DevelopmentAndSalesMilestonesPayments>
    <us-gaap:ContractWithCustomerAssetNetCurrent contextRef="c-111" decimals="INF" id="f-458" unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-111" decimals="INF" id="f-459" unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales contextRef="c-112" decimals="2" id="f-460" unitRef="number">0.20</arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales>
    <arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales contextRef="c-113" decimals="2" id="f-461" unitRef="number">0.25</arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales>
    <arwr:NumberOfDistinctBundle
      contextRef="c-114"
      decimals="INF"
      id="f-462"
      unitRef="bundle">1</arwr:NumberOfDistinctBundle>
    <arwr:NumberOfDistinctBundle
      contextRef="c-114"
      decimals="INF"
      id="f-463"
      unitRef="bundle">1</arwr:NumberOfDistinctBundle>
    <arwr:InitialTransactionPrice contextRef="c-115" decimals="-5" id="f-464" unitRef="usd">300000000</arwr:InitialTransactionPrice>
    <arwr:MilestonePaymentEarned contextRef="c-116" decimals="-5" id="f-465" unitRef="usd">40000000</arwr:MilestonePaymentEarned>
    <arwr:DevelopmentRegulatoryAndSalesMilestonesPayments contextRef="c-117" decimals="-5" id="f-466" unitRef="usd">527500000</arwr:DevelopmentRegulatoryAndSalesMilestonesPayments>
    <arwr:InitialTransactionPrice contextRef="c-115" decimals="-5" id="f-467" unitRef="usd">300000000</arwr:InitialTransactionPrice>
    <arwr:NumberOfDistinctBundle
      contextRef="c-114"
      decimals="INF"
      id="f-468"
      unitRef="bundle">1</arwr:NumberOfDistinctBundle>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-118" decimals="INF" id="f-469" unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-118" decimals="-5" id="f-470" unitRef="usd">24600000</us-gaap:AccruedLiabilitiesCurrent>
    <arwr:NumberOfAgreements
      contextRef="c-119"
      decimals="INF"
      id="f-471"
      unitRef="agreement">2</arwr:NumberOfAgreements>
    <us-gaap:ContractWithCustomerAssetNetCurrent contextRef="c-120" decimals="INF" id="f-472" unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-120" decimals="INF" id="f-473" unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <arwr:AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments contextRef="c-121" decimals="-5" id="f-474" unitRef="usd">485000000</arwr:AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments>
    <arwr:NumberOfNewTargetPrograms
      contextRef="c-122"
      decimals="INF"
      id="f-475"
      unitRef="program">6</arwr:NumberOfNewTargetPrograms>
    <arwr:NumberOfPerformanceObligations
      contextRef="c-123"
      decimals="INF"
      id="f-476"
      unitRef="obligation">17</arwr:NumberOfPerformanceObligations>
    <arwr:ProceedsFromCollaborationArrangements contextRef="c-124" decimals="-5" id="f-477" unitRef="usd">500000000</arwr:ProceedsFromCollaborationArrangements>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-125" decimals="-5" id="f-478" unitRef="usd">325000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-125" decimals="-5" id="f-479" unitRef="usd">325000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <arwr:SaleOfStockPremiumOnIssuanceOfShares contextRef="c-125" decimals="-5" id="f-480" unitRef="usd">83600000</arwr:SaleOfStockPremiumOnIssuanceOfShares>
    <arwr:AdditionalCashReceivableUnderCollaborationAgreement contextRef="c-126" decimals="-5" id="f-481" unitRef="usd">250000000</arwr:AdditionalCashReceivableUnderCollaborationAgreement>
    <arwr:CashReceivableUnderCollaborationAgreementAnnualInstallments contextRef="c-123" decimals="-5" id="f-482" unitRef="usd">50000000</arwr:CashReceivableUnderCollaborationAgreementAnnualInstallments>
    <arwr:CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod contextRef="c-126" id="f-483">P5Y</arwr:CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod>
    <arwr:CollaborationArrangementFixedConsideration contextRef="c-127" decimals="-5" id="f-484" unitRef="usd">833600000</arwr:CollaborationArrangementFixedConsideration>
    <arwr:CollaborationArrangementVariableConsideration contextRef="c-127" decimals="-5" id="f-485" unitRef="usd">71200000</arwr:CollaborationArrangementVariableConsideration>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock contextRef="c-1" id="f-486">The fixed and estimated variable consideration of $904.9&#160;million was allocated in accordance to the following table:&lt;div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:48.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.104%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.696%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Upfront payment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Annual fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;250,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Equity premium&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;83,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Fixed consideration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;833,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Estimated variable consideration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;71,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Total transaction price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;904,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <arwr:CollaborationArrangementConsideration contextRef="c-127" decimals="-5" id="f-487" unitRef="usd">904900000</arwr:CollaborationArrangementConsideration>
    <arwr:ProceedsFromCollaborationArrangements contextRef="c-127" decimals="-3" id="f-488" unitRef="usd">500000000</arwr:ProceedsFromCollaborationArrangements>
    <arwr:AdditionalCashReceivableUnderCollaborationAgreement contextRef="c-127" decimals="-3" id="f-489" unitRef="usd">250000000</arwr:AdditionalCashReceivableUnderCollaborationAgreement>
    <arwr:SaleOfStockPremiumOnIssuanceOfShares contextRef="c-127" decimals="-3" id="f-490" unitRef="usd">83612000</arwr:SaleOfStockPremiumOnIssuanceOfShares>
    <arwr:CollaborationArrangementFixedConsideration contextRef="c-127" decimals="-3" id="f-491" unitRef="usd">833612000</arwr:CollaborationArrangementFixedConsideration>
    <arwr:CollaborationArrangementVariableConsideration contextRef="c-127" decimals="-3" id="f-492" unitRef="usd">71243000</arwr:CollaborationArrangementVariableConsideration>
    <arwr:CollaborationArrangementConsideration contextRef="c-127" decimals="-3" id="f-493" unitRef="usd">904855000</arwr:CollaborationArrangementConsideration>
    <arwr:EnrollmentRelatedMilestonePayments contextRef="c-123" decimals="-5" id="f-494" unitRef="usd">300000000</arwr:EnrollmentRelatedMilestonePayments>
    <arwr:NumberOfCollaborationPrograms
      contextRef="c-123"
      decimals="INF"
      id="f-495"
      unitRef="program">13</arwr:NumberOfCollaborationPrograms>
    <arwr:RegulatoryMilestonePayments contextRef="c-128" decimals="-5" id="f-496" unitRef="usd">110000000</arwr:RegulatoryMilestonePayments>
    <arwr:RegulatoryMilestonePayments contextRef="c-122" decimals="-5" id="f-497" unitRef="usd">180000000</arwr:RegulatoryMilestonePayments>
    <arwr:SalesRelatedMilestonePayments contextRef="c-128" decimals="-5" id="f-498" unitRef="usd">500000000</arwr:SalesRelatedMilestonePayments>
    <arwr:SalesRelatedMilestonePayments contextRef="c-122" decimals="-5" id="f-499" unitRef="usd">700000000</arwr:SalesRelatedMilestonePayments>
    <arwr:CollaborationArrangementTerminationNoticePeriodPriorToRegulatoryApproval contextRef="c-123" id="f-500">P30D</arwr:CollaborationArrangementTerminationNoticePeriodPriorToRegulatoryApproval>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-129" decimals="-5" id="f-501" unitRef="usd">570300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-130" decimals="-5" id="f-502" unitRef="usd">9700000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ContractWithCustomerLiability contextRef="c-130" decimals="-5" id="f-503" unitRef="usd">23000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="c-1" id="f-504">BALANCE SHEET ACCOUNTS&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s major classes of property, plant and equipment:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(in thousands) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;249,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;75,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Research equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;59,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;65,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;16,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;5,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;5,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Computers and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;1,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;104,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;104,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;15,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;188,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;455,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;444,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(74,230)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(58,021)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;381,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;386,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expense for property, plant and equipment for the three months ended June&#160;30, 2025 and 2024 was $5.8&#160;million and $4.4&#160;million, respectively. Depreciation and amortization expense for property, plant and equipment for the nine months ended June&#160;30, 2025 and 2024 was $16.2&#160;million and $12.3&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the first quarter of fiscal 2025, the Company substantially completed the build out of its manufacturing facility in Verona, Wisconsin, leading to the reclassification of $162.7&#160;million from construction in progress to buildings and $2.6&#160;million from construction in progress to manufacturing equipment. The Company subsequently incurred and capitalized $10.6&#160;million to buildings and $13.9&#160;million to manufacturing equipment during the second and third quarters of fiscal 2025. Furthermore, the Company began depreciating the newly completed manufacturing facility over a 39-year period and the manufacturing equipment over 7- or 10-year periods.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the first quarter of fiscal 2024, the Company completed the build out of its laboratory and office facilities in Verona, Wisconsin, which resulted in the reclassification of $71.8&#160;million from construction in progress to buildings. The Company subsequently incurred and capitalized $4.2&#160;million from construction in progress to buildings in fiscal 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consisted of the following as of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(in thousands) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;31,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;28,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Accrued research and development expenses; co-development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;24,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;23,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Accrued capital expenditures&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;4,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;8,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;7,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Total accrued expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;64,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;63,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2025, the Company&#x2019;s accrued research and development expenses was primarily attributable to ongoing clinical trial operations, preclinical animal studies, and associated toxicology assessments. In addition, accrued research and development expenses; co-development relates to the co-development and co-commercialization activities under the Takeda License Agreement (see Note 2).&lt;/span&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-505">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s major classes of property, plant and equipment:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(in thousands) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;249,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;75,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Research equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;59,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;65,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;16,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;5,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;5,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Computers and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;1,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;104,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;104,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;15,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;188,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;455,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;444,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(74,230)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(58,021)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;381,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;386,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-131" decimals="-3" id="f-506" unitRef="usd">2996000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-132" decimals="-3" id="f-507" unitRef="usd">2996000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-133" decimals="-3" id="f-508" unitRef="usd">249245000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-134" decimals="-3" id="f-509" unitRef="usd">75988000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-135" decimals="-3" id="f-510" unitRef="usd">59561000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-136" decimals="-3" id="f-511" unitRef="usd">65353000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-137" decimals="-3" id="f-512" unitRef="usd">16548000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-138" decimals="-3" id="f-513" unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-139" decimals="-3" id="f-514" unitRef="usd">5594000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-140" decimals="-3" id="f-515" unitRef="usd">5594000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-141" decimals="-3" id="f-516" unitRef="usd">1059000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-142" decimals="-3" id="f-517" unitRef="usd">981000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-143" decimals="-3" id="f-518" unitRef="usd">104403000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-144" decimals="-3" id="f-519" unitRef="usd">104410000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-145" decimals="-3" id="f-520" unitRef="usd">15872000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-146" decimals="-3" id="f-521" unitRef="usd">188731000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-3" decimals="-3" id="f-522" unitRef="usd">455278000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-4" decimals="-3" id="f-523" unitRef="usd">444053000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-3" decimals="-3" id="f-524" unitRef="usd">74230000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-525" unitRef="usd">58021000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-526" unitRef="usd">381048000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-527" unitRef="usd">386032000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-5" decimals="-5" id="f-528" unitRef="usd">5800000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-6" decimals="-5" id="f-529" unitRef="usd">4400000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-5" id="f-530" unitRef="usd">16200000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-7" decimals="-5" id="f-531" unitRef="usd">12300000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentTransfersAndChanges contextRef="c-147" decimals="-5" id="f-532" unitRef="usd">162700000</us-gaap:PropertyPlantAndEquipmentTransfersAndChanges>
    <us-gaap:PropertyPlantAndEquipmentTransfersAndChanges contextRef="c-148" decimals="-5" id="f-533" unitRef="usd">-162700000</us-gaap:PropertyPlantAndEquipmentTransfersAndChanges>
    <us-gaap:PropertyPlantAndEquipmentTransfersAndChanges contextRef="c-149" decimals="-5" id="f-534" unitRef="usd">2600000</us-gaap:PropertyPlantAndEquipmentTransfersAndChanges>
    <us-gaap:PropertyPlantAndEquipmentTransfersAndChanges contextRef="c-150" decimals="-5" id="f-535" unitRef="usd">-2600000</us-gaap:PropertyPlantAndEquipmentTransfersAndChanges>
    <us-gaap:PropertyPlantAndEquipmentTransfersAndChanges contextRef="c-151" decimals="-5" id="f-536" unitRef="usd">-10600000</us-gaap:PropertyPlantAndEquipmentTransfersAndChanges>
    <us-gaap:PropertyPlantAndEquipmentTransfersAndChanges contextRef="c-152" decimals="-5" id="f-537" unitRef="usd">10600000</us-gaap:PropertyPlantAndEquipmentTransfersAndChanges>
    <us-gaap:PropertyPlantAndEquipmentTransfersAndChanges contextRef="c-153" decimals="-5" id="f-538" unitRef="usd">-13900000</us-gaap:PropertyPlantAndEquipmentTransfersAndChanges>
    <us-gaap:PropertyPlantAndEquipmentTransfersAndChanges contextRef="c-154" decimals="-5" id="f-539" unitRef="usd">13900000</us-gaap:PropertyPlantAndEquipmentTransfersAndChanges>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-155" id="f-540">P39Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-156" id="f-541">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-157" id="f-542">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentTransfersAndChanges contextRef="c-158" decimals="-5" id="f-543" unitRef="usd">-71800000</us-gaap:PropertyPlantAndEquipmentTransfersAndChanges>
    <us-gaap:PropertyPlantAndEquipmentTransfersAndChanges contextRef="c-159" decimals="-5" id="f-544" unitRef="usd">71800000</us-gaap:PropertyPlantAndEquipmentTransfersAndChanges>
    <us-gaap:PropertyPlantAndEquipmentTransfersAndChanges contextRef="c-160" decimals="-5" id="f-545" unitRef="usd">-4200000</us-gaap:PropertyPlantAndEquipmentTransfersAndChanges>
    <us-gaap:PropertyPlantAndEquipmentTransfersAndChanges contextRef="c-161" decimals="-5" id="f-546" unitRef="usd">4200000</us-gaap:PropertyPlantAndEquipmentTransfersAndChanges>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-547">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consisted of the following as of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(in thousands) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;31,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;28,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Accrued research and development expenses; co-development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;24,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;23,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Accrued capital expenditures&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;4,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;8,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;7,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Total accrued expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;64,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;63,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <arwr:AccruedResearchAndDevelopmentExpenseCurrent contextRef="c-3" decimals="-3" id="f-548" unitRef="usd">31708000</arwr:AccruedResearchAndDevelopmentExpenseCurrent>
    <arwr:AccruedResearchAndDevelopmentExpenseCurrent contextRef="c-4" decimals="-3" id="f-549" unitRef="usd">28069000</arwr:AccruedResearchAndDevelopmentExpenseCurrent>
    <arwr:AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent contextRef="c-3" decimals="-3" id="f-550" unitRef="usd">24627000</arwr:AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent>
    <arwr:AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent contextRef="c-4" decimals="-3" id="f-551" unitRef="usd">23351000</arwr:AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent>
    <arwr:AccruedCapitalExpenditureCurrent contextRef="c-3" decimals="-3" id="f-552" unitRef="usd">346000</arwr:AccruedCapitalExpenditureCurrent>
    <arwr:AccruedCapitalExpenditureCurrent contextRef="c-4" decimals="-3" id="f-553" unitRef="usd">4206000</arwr:AccruedCapitalExpenditureCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-554" unitRef="usd">8137000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-555" unitRef="usd">7391000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-556" unitRef="usd">64818000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-557" unitRef="usd">63017000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="c-1" id="f-558">INVESTMENTS&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s investments consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.787%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.237%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.026%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.237%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.026%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.237%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.026%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.242%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;As of June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Adjusted Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Available-for-sale securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;768,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;770,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total current investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;768,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;770,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.787%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.237%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.026%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.026%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.237%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.241%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;As of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Adjusted Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Available-for-sale securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;577,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;578,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total current investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;577,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;578,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the contract maturity of the available-for-sale securities as of:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;   &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.484%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.207%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.438%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.440%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Within one year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;224,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;578,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;After one to two years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;450,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;After two to three years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;95,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;770,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;578,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;As of June&#160;30, 2025 and September&#160;30, 2024, the gross unrealized losses were immaterial. The Company has determined that the available-for-sale securities that were in an unrealized loss position did not have any credit loss impairment as of June&#160;30, 2025 and 2024.</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock contextRef="c-1" id="f-559">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s investments consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.787%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.237%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.026%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.237%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.026%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.237%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.026%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.242%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;As of June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Adjusted Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Available-for-sale securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;768,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;770,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total current investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;768,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;770,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.787%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.237%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.026%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.026%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.237%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.241%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;As of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Adjusted Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Available-for-sale securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;577,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;578,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total current investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;577,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;578,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent contextRef="c-162" decimals="-3" id="f-560" unitRef="usd">768746000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent contextRef="c-162" decimals="-3" id="f-561" unitRef="usd">1938000</arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent>
    <arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent contextRef="c-162" decimals="-3" id="f-562" unitRef="usd">105000</arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-162" decimals="-3" id="f-563" unitRef="usd">770579000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent contextRef="c-3" decimals="-3" id="f-564" unitRef="usd">768746000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent contextRef="c-3" decimals="-3" id="f-565" unitRef="usd">1938000</arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent>
    <arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent contextRef="c-3" decimals="-3" id="f-566" unitRef="usd">105000</arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-3" decimals="-3" id="f-567" unitRef="usd">770579000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent contextRef="c-163" decimals="-3" id="f-568" unitRef="usd">577465000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent contextRef="c-163" decimals="-3" id="f-569" unitRef="usd">837000</arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent>
    <arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent contextRef="c-163" decimals="-3" id="f-570" unitRef="usd">26000</arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-163" decimals="-3" id="f-571" unitRef="usd">578276000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent contextRef="c-4" decimals="-3" id="f-572" unitRef="usd">577465000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent contextRef="c-4" decimals="-3" id="f-573" unitRef="usd">837000</arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent>
    <arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent contextRef="c-4" decimals="-3" id="f-574" unitRef="usd">26000</arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-4" decimals="-3" id="f-575" unitRef="usd">578276000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock contextRef="c-1" id="f-576">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the contract maturity of the available-for-sale securities as of:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;   &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.484%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.207%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.438%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.440%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Within one year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;224,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;578,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;After one to two years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;450,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;After two to three years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;95,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;770,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;578,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue contextRef="c-3" decimals="-3" id="f-577" unitRef="usd">224571000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue contextRef="c-4" decimals="-3" id="f-578" unitRef="usd">578276000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue>
    <arwr:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo contextRef="c-3" decimals="-3" id="f-579" unitRef="usd">450889000</arwr:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo>
    <arwr:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo contextRef="c-4" decimals="-3" id="f-580" unitRef="usd">0</arwr:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo>
    <arwr:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree contextRef="c-3" decimals="-3" id="f-581" unitRef="usd">95119000</arwr:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree>
    <arwr:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree contextRef="c-4" decimals="-3" id="f-582" unitRef="usd">0</arwr:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-3" decimals="-3" id="f-583" unitRef="usd">770579000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-4" decimals="-3" id="f-584" unitRef="usd">578276000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="c-1" id="f-585">INTANGIBLE ASSETS&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets subject to amortization include patents and a license agreement capitalized as part of the Novartis RNAi asset acquisition in March 2015. The following table presents the components of intangible assets: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.361%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Useful Lives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;License&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;24,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;License&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;24,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are reviewed annually for impairment and more frequently if potential impairment indicators exist. No impairment indicators were identified during the nine months ended June&#160;30, 2025 and 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets with definite useful lives are amortized on a straight-line basis over their useful lives. Intangible assets amortization expense was $0.4 million for the three months ended June&#160;30, 2025 and 2024, and $1.3 million for each of the nine months ended June&#160;30, 2025 and 2024. None of the intangible assets with definite useful lives are anticipated to have a residual value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the estimated future amortization expense related to intangible assets as of June&#160;30, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.727%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.505%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.552%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortization Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ending September 30, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2025 (remainder)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2030 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="c-1" id="f-586">The following table presents the components of intangible assets: &lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.361%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Useful Lives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;License&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;24,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;License&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;24,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-164" decimals="-3" id="f-587" unitRef="usd">21728000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-164" decimals="-3" id="f-588" unitRef="usd">16037000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <arwr:FiniteLivedIntangibleAssetsImpairment contextRef="c-164" decimals="-3" id="f-589" unitRef="usd">0</arwr:FiniteLivedIntangibleAssetsImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-164" decimals="-3" id="f-590" unitRef="usd">5691000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-164" id="f-591">P14Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-165" decimals="-3" id="f-592" unitRef="usd">3129000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-165" decimals="-3" id="f-593" unitRef="usd">1534000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <arwr:FiniteLivedIntangibleAssetsImpairment contextRef="c-165" decimals="-3" id="f-594" unitRef="usd">0</arwr:FiniteLivedIntangibleAssetsImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-165" decimals="-3" id="f-595" unitRef="usd">1595000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-165" id="f-596">P21Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-166" decimals="-3" id="f-597" unitRef="usd">24857000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-166" decimals="-3" id="f-598" unitRef="usd">17571000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <arwr:FiniteLivedIntangibleAssetsImpairment contextRef="c-166" decimals="-3" id="f-599" unitRef="usd">0</arwr:FiniteLivedIntangibleAssetsImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-166" decimals="-3" id="f-600" unitRef="usd">7286000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-167" decimals="-3" id="f-601" unitRef="usd">21728000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-167" decimals="-3" id="f-602" unitRef="usd">14873000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <arwr:FiniteLivedIntangibleAssetsImpairment contextRef="c-167" decimals="-3" id="f-603" unitRef="usd">0</arwr:FiniteLivedIntangibleAssetsImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-167" decimals="-3" id="f-604" unitRef="usd">6855000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-167" id="f-605">P14Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-168" decimals="-3" id="f-606" unitRef="usd">3129000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-168" decimals="-3" id="f-607" unitRef="usd">1422000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <arwr:FiniteLivedIntangibleAssetsImpairment contextRef="c-168" decimals="-3" id="f-608" unitRef="usd">0</arwr:FiniteLivedIntangibleAssetsImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-168" decimals="-3" id="f-609" unitRef="usd">1707000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-168" id="f-610">P21Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-169" decimals="-3" id="f-611" unitRef="usd">24857000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-169" decimals="-3" id="f-612" unitRef="usd">16295000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <arwr:FiniteLivedIntangibleAssetsImpairment contextRef="c-169" decimals="-3" id="f-613" unitRef="usd">0</arwr:FiniteLivedIntangibleAssetsImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-169" decimals="-3" id="f-614" unitRef="usd">8562000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-6" decimals="-5" id="f-615" unitRef="usd">400000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-5" decimals="-5" id="f-616" unitRef="usd">400000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-5" id="f-617" unitRef="usd">1300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-7" decimals="-5" id="f-618" unitRef="usd">1300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="c-1" id="f-619">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the estimated future amortization expense related to intangible assets as of June&#160;30, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.727%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.505%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.552%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortization Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ending September 30, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2025 (remainder)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2030 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear contextRef="c-3" decimals="-3" id="f-620" unitRef="usd">424000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c-3" decimals="-3" id="f-621" unitRef="usd">1700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c-3" decimals="-3" id="f-622" unitRef="usd">1700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c-3" decimals="-3" id="f-623" unitRef="usd">1700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c-3" decimals="-3" id="f-624" unitRef="usd">795000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <arwr:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour contextRef="c-3" decimals="-3" id="f-625" unitRef="usd">967000</arwr:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-3" decimals="-3" id="f-626" unitRef="usd">7286000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-627">STOCKHOLDERS&#x2019; EQUITY&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s shares of common stock and preferred stock:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.310%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.049%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Par Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Common stock &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;290,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;138,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;138,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;290,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;124,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;124,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;(1) Does not include shares of common stock into which the Avoro Pre-Funded Warrants may be exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2025 and September&#160;30, 2024, respectively, 10,081,964 and 11,492,293 shares of common stock were reserved for issuance upon exercise of options and vesting of restricted stock units granted or available for grant under the Company&#x2019;s 2013 and 2021 Incentive Plans, as well as for other inducement grants made to new employees under Rule 5635(c)(4) of the Nasdaq Listing Rules.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 25, 2024, the Company entered into a Securities Purchase Agreement (the &#x201c;Securities Purchase Agreement&#x201d;) with an institutional and accredited investor for a private placement of pre-funded warrants to purchase shares of common stock with an exercise price of $0.001 per share (&#x201c;Avoro Pre-Funded Warrants&#x201d;). Pursuant to the Securities Purchase Agreement, the Company sold pre-funded warrants to purchase up to 917,441 shares of common stock at a purchase price of $27.25 per pre-funded warrant, for an aggregate value of approximately $25.0 million. The outstanding Avoro Pre-Funded Warrants are exercisable at any time and do not have an expiration date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that the Avoro Pre-Funded Warrants are freestanding financial instruments because they (i) are immediately exercisable, (ii) do not embody an obligation for the Company to repurchase its shares, (iii) permit the holders to receive a fixed number of shares of common stock upon exercise, and (iv) are indexed to the Company&#x2019;s common stock. As such, the Company evaluated the Avoro Pre-Funded Warrants to determine whether they represent instruments that require liability classification pursuant to the guidance in ASC 480. However, the Company concluded that the Avoro Pre-Funded Warrants are not a liability within the scope of ASC 480 due to their characteristics. Further, the Company determined that the Avoro Pre-Funded Warrants do not meet the definition of a derivative under ASC 815 because they do not meet the criteria regarding no or little initial net investment. Accordingly, the Company assessed the Avoro Pre-Funded Warrants relative to the guidance in ASC 815-40, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contracts in Entity's Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to determine the appropriate treatment. The Company concluded that the Avoro Pre-funded Warrants are both indexed to its own stock and meet all other conditions for equity classification. Accordingly, the Company has classified the Avoro Pre-funded Warrants as permanent equity. As of June&#160;30, 2025, no shares underlying the Avoro Pre-Funded Warrants had been exercised. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Sarepta Collaboration Agreement, on November 25, 2024, the Company entered into the Stock Purchase Agreement with an affiliate of Sarepta for a private placement of shares of common stock of the Company (the &#x201c;Private Placement&#x201d;). Pursuant to the Stock Purchase Agreement, the Company sold 11,926,301 shares of common stock, at a price per share of $27.25, for an aggregate value of approximately $325.0&#160;million. The Private Placement closed on February 7, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 2, 2022, the Company entered into an open market sale agreement (the &#x201c;Open Market Sale Agreement&#x201d;), pursuant to which the Company may, from time to time, sell up to $250,000,000 in shares of the Company&#x2019;s common stock through Jefferies LLC, acting as the sales agent and/or principal, in an at-the-market offering (&#x201c;ATM Offering&#x201d;). The Company is not required to sell shares under the Open Market Sale Agreement. The Company will pay Jefferies LLC a commission of up to 3.0% of the aggregate gross proceeds received from all sales of the common stock under the Open Market Sale Agreement. Unless otherwise terminated, the ATM Offering shall terminate upon the earlier of (i) the sale of all shares of common stock subject to the Open Market Sale Agreement and (ii) the termination of the Open Market Sale Agreement as permitted therein. The Company and Jefferies may each terminate the Open Market Sale Agreement at any time upon prior notice. As of June&#160;30, 2025, no shares have been issued under the Open Market Sale Agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ScheduleOfStockByClassTextBlock contextRef="c-1" id="f-628">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s shares of common stock and preferred stock:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.310%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.049%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Par Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Common stock &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;290,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;138,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;138,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;290,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;124,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;124,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;(1) Does not include shares of common stock into which the Avoro Pre-Funded Warrants may be exercised.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-629"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="-3" id="f-630" unitRef="shares">290000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="-3" id="f-631" unitRef="shares">138144000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="-3" id="f-632" unitRef="shares">138144000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-633"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-3" decimals="-3" id="f-634" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c-3" decimals="-3" id="f-635" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-3" decimals="-3" id="f-636" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-637"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="-3" id="f-638" unitRef="shares">290000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="-3" id="f-639" unitRef="shares">124376000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="-3" id="f-640" unitRef="shares">124376000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-641"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-4" decimals="-3" id="f-642" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c-4" decimals="-3" id="f-643" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-4" decimals="-3" id="f-644" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-170"
      decimals="INF"
      id="f-645"
      unitRef="shares">10081964</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-171"
      decimals="INF"
      id="f-646"
      unitRef="shares">11492293</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-172"
      decimals="INF"
      id="f-647"
      unitRef="usdPerShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-172"
      decimals="INF"
      id="f-648"
      unitRef="shares">917441</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <arwr:ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights
      contextRef="c-173"
      decimals="2"
      id="f-649"
      unitRef="usdPerShare">27.25</arwr:ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c-173" decimals="-5" id="f-650" unitRef="usd">25000000.0</us-gaap:ProceedsFromIssuanceOfWarrants>
    <arwr:ClassOfWarrantOrRightNumberOfWarrantsExercised contextRef="c-3" decimals="INF" id="f-651" unitRef="shares">0</arwr:ClassOfWarrantOrRightNumberOfWarrantsExercised>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-174"
      decimals="INF"
      id="f-652"
      unitRef="shares">11926301</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-175"
      decimals="2"
      id="f-653"
      unitRef="usdPerShare">27.25</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-174" decimals="-5" id="f-654" unitRef="usd">325000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <arwr:CommonStockCapitalSharesValueReservedForFutureIssuance contextRef="c-176" decimals="INF" id="f-655" unitRef="usd">250000000</arwr:CommonStockCapitalSharesValueReservedForFutureIssuance>
    <arwr:PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock contextRef="c-177" decimals="3" id="f-656" unitRef="number">0.030</arwr:PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock>
    <us-gaap:SharesIssued
      contextRef="c-178"
      decimals="INF"
      id="f-657"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-658">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may be subject to various claims and legal proceedings in the ordinary course of business. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount is reasonably estimable, the Company will accrue a liability for the estimated loss. There were no contingent liabilities recorded as of June&#160;30, 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company owns land in the Verona Technology Park in Verona, Wisconsin, where it has constructed an approximately 160,000 square foot drug manufacturing facility and an approximately 140,000 square foot laboratory and office facility to support manufacturing process development and analytical activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2025, the build-out of these facilities was substantially completed, with total costs incurred of $293.2 million. These costs included (i) $76.0 million capitalized to building, related to the laboratory and office facility, and (ii) $11.5 million capitalized to research equipment, $173.3 million capitalized to building, $16.5 million capitalized to manufacturing equipment, and $15.9 million in construction in progress, related to the drug manufacturing facility. The Company has an expected outstanding balance of approximately $3.3 million remaining to be settled.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyAccrualAtCarryingValue contextRef="c-3" decimals="INF" id="f-659" unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:AreaOfLand contextRef="c-179" decimals="-3" id="f-660" unitRef="sqft">160000</us-gaap:AreaOfLand>
    <us-gaap:AreaOfLand contextRef="c-180" decimals="-3" id="f-661" unitRef="sqft">140000</us-gaap:AreaOfLand>
    <arwr:CommitmentsCapitalExpendituresIncurredToDate contextRef="c-181" decimals="-5" id="f-662" unitRef="usd">293200000</arwr:CommitmentsCapitalExpendituresIncurredToDate>
    <arwr:CommitmentsCapitalExpendituresIncurredToDate contextRef="c-182" decimals="-5" id="f-663" unitRef="usd">76000000.0</arwr:CommitmentsCapitalExpendituresIncurredToDate>
    <arwr:CommitmentsCapitalExpendituresIncurredToDate contextRef="c-135" decimals="-5" id="f-664" unitRef="usd">11500000</arwr:CommitmentsCapitalExpendituresIncurredToDate>
    <arwr:CommitmentsCapitalExpendituresIncurredToDate contextRef="c-133" decimals="-5" id="f-665" unitRef="usd">173300000</arwr:CommitmentsCapitalExpendituresIncurredToDate>
    <arwr:CommitmentsCapitalExpendituresIncurredToDate contextRef="c-137" decimals="-5" id="f-666" unitRef="usd">16500000</arwr:CommitmentsCapitalExpendituresIncurredToDate>
    <arwr:CommitmentsCapitalExpendituresIncurredToDate contextRef="c-145" decimals="-5" id="f-667" unitRef="usd">15900000</arwr:CommitmentsCapitalExpendituresIncurredToDate>
    <arwr:AmountIntendsToInvestForBuildoutOfFacilities contextRef="c-181" decimals="-5" id="f-668" unitRef="usd">3300000</arwr:AmountIntendsToInvestForBuildoutOfFacilities>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-669">LEASES&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Pasadena, California&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The Company leases 49,000 square feet of office space located at 177 East Colorado Blvd. for its corporate headquarters from 177 Colorado Owner, LLC, which lease expires on April&#160;30, 2027. The lease contains an option to renew for one additional five-year term. The Company is not reasonably certain that it will exercise this option to renew and therefore it is not included in right-of-use assets and liabilities as of June&#160;30, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;San Diego, California&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The Company leases 144,000 square feet of office and research and development laboratory space located at 10102 Hoyt Park from 11404 &amp;amp; 11408 Sorrento Valley Owner, LLC, which lease expires on April&#160;30, 2038. Pursuant to the lease, within twelve months of the expiration of the initial 15-year term, the Company has the option to extend the lease for up to one additional ten-year term, with certain annual increases in base rent. The Company is not reasonably certain that it will exercise this option to renew and therefore it is not included in right-of-use assets and liabilities as of June&#160;30, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The lease agreement, as amended, granted the Company the right to receive an Additional Tenant Improvement Allowance (&#x201c;ATIA&#x201d;) funded by the lessor. The Company received $30.8&#160;million in ATIA, including a final payment of $3.1 million during the first quarter of fiscal 2024. As a result, the Company remeasured its lease liability and right-of-use assets to reflect these additional allowances and the related increased lease payments. The Company has further concluded that these ATIAs have no effects on the classification of the lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Madison, Wisconsin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The Company leases 110,956 square feet space, which it increased from 107,000 square feet on June&#160;30, 2025, located at 502 South Rosa Road for its office and laboratory facilities, which lease expires on September&#160;30, 2031. The lease contains options to renew for two terms of five years. The Company is not reasonably certain that it will exercise this option and therefore it is not included in right-of-use assets and liabilities as of June&#160;30, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease assets and liabilities along with their classification on the Company&#x2019;s consolidated balance sheets were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.657%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.144%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Lease Assets and Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;44,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;45,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;105,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;111,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.493%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.569%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.401%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.982%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.401%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.982%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.401%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.982%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.401%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.988%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Lease Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;General and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Variable lease cost &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;General and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(1) Variable lease cost is primarily related to operating expenses associated with the Company&#x2019;s operating leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There was no short-term lease cost during the three and nine months ended June&#160;30, 2025 and 2024, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents maturities of operating lease liabilities on an undiscounted basis as of June&#160;30, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.996%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.804%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2025 (remainder)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;3,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;15,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;14,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;13,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;13,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2030 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;114,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;176,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(64,289)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Total operating lease liabilities (includes current portion)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;112,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow and other information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.079%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.079%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash received for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;3,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Right-of-use assets obtained in exchange for amended operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;3,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;3,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;11,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;7,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;11.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;12.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LandSubjectToGroundLeases contextRef="c-183" decimals="-3" id="f-670" unitRef="sqft">49000</us-gaap:LandSubjectToGroundLeases>
    <arwr:NumberOfOptionsToRenew
      contextRef="c-184"
      decimals="INF"
      id="f-671"
      unitRef="option">1</arwr:NumberOfOptionsToRenew>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-184" id="f-672">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LandSubjectToGroundLeases contextRef="c-185" decimals="-3" id="f-673" unitRef="sqft">144000</us-gaap:LandSubjectToGroundLeases>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-185" id="f-674">P15Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <arwr:NumberOfOptionsToRenew
      contextRef="c-186"
      decimals="INF"
      id="f-675"
      unitRef="option">1</arwr:NumberOfOptionsToRenew>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-185" id="f-676">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <arwr:ProceedsFromTenantImprovementAllowance contextRef="c-187" decimals="-5" id="f-677" unitRef="usd">30800000</arwr:ProceedsFromTenantImprovementAllowance>
    <arwr:ProceedsFromTenantImprovementAllowance contextRef="c-188" decimals="-5" id="f-678" unitRef="usd">3100000</arwr:ProceedsFromTenantImprovementAllowance>
    <us-gaap:LandSubjectToGroundLeases contextRef="c-189" decimals="0" id="f-679" unitRef="sqft">110956</us-gaap:LandSubjectToGroundLeases>
    <us-gaap:LandSubjectToGroundLeases contextRef="c-190" decimals="0" id="f-680" unitRef="sqft">107000</us-gaap:LandSubjectToGroundLeases>
    <arwr:NumberOfOptionsToRenew
      contextRef="c-189"
      decimals="INF"
      id="f-681"
      unitRef="option">2</arwr:NumberOfOptionsToRenew>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-189" id="f-682">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LeaseCostTableTextBlock contextRef="c-1" id="f-683">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease assets and liabilities along with their classification on the Company&#x2019;s consolidated balance sheets were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.657%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.144%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Lease Assets and Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;44,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;45,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;105,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;111,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.493%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.569%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.401%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.982%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.401%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.982%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.401%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.982%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.401%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.988%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Lease Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;General and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Variable lease cost &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;General and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(1) Variable lease cost is primarily related to operating expenses associated with the Company&#x2019;s operating leases.&lt;/span&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="-3" id="f-684" unitRef="usd">44002000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-685" unitRef="usd">45255000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-686" unitRef="usd">7010000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-687" unitRef="usd">6342000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-688" unitRef="usd">105690000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-689" unitRef="usd">111027000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseCost contextRef="c-191" decimals="-3" id="f-690" unitRef="usd">2233000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-192" decimals="-3" id="f-691" unitRef="usd">2965000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-193" decimals="-3" id="f-692" unitRef="usd">7754000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-194" decimals="-3" id="f-693" unitRef="usd">8531000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-195" decimals="-3" id="f-694" unitRef="usd">449000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-196" decimals="-3" id="f-695" unitRef="usd">537000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-197" decimals="-3" id="f-696" unitRef="usd">1442000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-198" decimals="-3" id="f-697" unitRef="usd">1504000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-191" decimals="-3" id="f-698" unitRef="usd">893000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-192" decimals="-3" id="f-699" unitRef="usd">863000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-193" decimals="-3" id="f-700" unitRef="usd">2830000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-194" decimals="-3" id="f-701" unitRef="usd">2478000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-195" decimals="-3" id="f-702" unitRef="usd">0</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-196" decimals="-3" id="f-703" unitRef="usd">0</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-197" decimals="-3" id="f-704" unitRef="usd">0</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-198" decimals="-3" id="f-705" unitRef="usd">0</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost contextRef="c-5" decimals="-3" id="f-706" unitRef="usd">3575000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-6" decimals="-3" id="f-707" unitRef="usd">4365000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-1" decimals="-3" id="f-708" unitRef="usd">12026000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-7" decimals="-3" id="f-709" unitRef="usd">12513000</us-gaap:LeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-1" decimals="INF" id="f-710" unitRef="usd">0</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-6" decimals="INF" id="f-711" unitRef="usd">0</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-5" decimals="INF" id="f-712" unitRef="usd">0</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-7" decimals="INF" id="f-713" unitRef="usd">0</us-gaap:ShortTermLeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-714">&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents maturities of operating lease liabilities on an undiscounted basis as of June&#160;30, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.996%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.804%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2025 (remainder)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;3,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;15,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;14,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;13,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;13,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2030 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;114,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;176,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(64,289)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Total operating lease liabilities (includes current portion)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;112,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow and other information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.079%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.079%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash received for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;3,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Right-of-use assets obtained in exchange for amended operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;3,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;3,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;11,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;7,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;11.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;12.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="c-3" decimals="-3" id="f-715" unitRef="usd">3902000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-3" decimals="-3" id="f-716" unitRef="usd">15799000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-3" decimals="-3" id="f-717" unitRef="usd">14974000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-3" decimals="-3" id="f-718" unitRef="usd">13619000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-3" decimals="-3" id="f-719" unitRef="usd">13905000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <arwr:LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive contextRef="c-3" decimals="-3" id="f-720" unitRef="usd">114790000</arwr:LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-3" decimals="-3" id="f-721" unitRef="usd">176989000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-3" decimals="-3" id="f-722" unitRef="usd">64289000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-3" decimals="-3" id="f-723" unitRef="usd">112700000</us-gaap:OperatingLeaseLiability>
    <arwr:OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities contextRef="c-5" decimals="-3" id="f-724" unitRef="usd">0</arwr:OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities>
    <arwr:OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities contextRef="c-6" decimals="-3" id="f-725" unitRef="usd">0</arwr:OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities>
    <arwr:OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities contextRef="c-1" decimals="-3" id="f-726" unitRef="usd">0</arwr:OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities>
    <arwr:OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities contextRef="c-7" decimals="-3" id="f-727" unitRef="usd">3099000</arwr:OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities>
    <arwr:RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability contextRef="c-5" decimals="-3" id="f-728" unitRef="usd">0</arwr:RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability>
    <arwr:RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability contextRef="c-6" decimals="-3" id="f-729" unitRef="usd">0</arwr:RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability>
    <arwr:RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-730" unitRef="usd">0</arwr:RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability>
    <arwr:RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability contextRef="c-7" decimals="-3" id="f-731" unitRef="usd">-64000</arwr:RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeasePayments contextRef="c-5" decimals="-3" id="f-732" unitRef="usd">3875000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-6" decimals="-3" id="f-733" unitRef="usd">3204000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-3" id="f-734" unitRef="usd">11554000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-7" decimals="-3" id="f-735" unitRef="usd">7221000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-3" id="f-736">P11Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-87" id="f-737">P12Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-3" decimals="3" id="f-738" unitRef="number">0.080</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-87" decimals="3" id="f-739" unitRef="number">0.080</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-740">STOCK-BASED COMPENSATION&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has three plans that provide for equity-based compensation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the 2013 Incentive Plan (the &#x201c;2013 Plan&#x201d;), 2,350,117 awards are granted and outstanding, relating to stock options and restricted stock awards to employees and directors as of June&#160;30, 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the 2021 Incentive Plan (the &#x201c;2021 Plan&#x201d;), 8,000,000 shares (subject to certain adjustments) of the Company&#x2019;s common stock are authorized for grants of stock options, stock appreciation rights, restricted and unrestricted stock, performance awards, cash awards and other awards convertible into or otherwise based on shares of the Company&#x2019;s common stock. The maximum number of shares authorized under the 2021 Plan will be (i) reduced by any shares subject to awards made under the 2013 Plan after January 1, 2021, and (ii) increased by any shares subject to outstanding awards under the 2013 Plan as of January 1, 2021 that, after January 1, 2021, are canceled, expired, forfeited or otherwise not issued under such awards (other than as a result of being tendered or withheld to pay the exercise price or withholding taxes in connection with any such awards) or settled in cash. As of June&#160;30, 2025, 6,215,559 shares have been granted under the 2021 Plan. The total number of shares available for issuance was 2,308,495 shares, which includes 170,898 and 353,156 shares that were forfeited under the 2013 and 2021 Plans, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Company&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s Inducement Plan (the &#x201c;Inducement Plan&#x201d;), 832,950 shares of the Company&#x2019;s common stock are authorized for issuance pursuant to grants of stock options, stock appreciation rights, restricted and unrestricted stock, stock units (including restricted stock units), performance awards, cash awards, and other awards convertible into or otherwise based on shares of the Company&#x2019;s common stock. Awards under the Inducement Plan may only be granted to new employees of the Company in accordance with the provisions of Rule 5635(c)(4) of the Nasdaq Listing Rules. As of June&#160;30, 2025,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;607,340 shares have been granted under the Inducement Plan. The total number of shares remaining available for issuance was 307,924 shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, prior to adoption of the Inducement Plan, the Company previously granted stand-alone inducement awards in the form of stock options and restricted stock units outside of the Company&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s equity plans to new employees under Rule 5635(c)(4) of the Nasdaq Listing Rules. As of June&#160;30, 2025, there were 602,355 and 138,775 shares underlying outstanding stand-alone inducement options and restricted stock units, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of awards outstanding attributable to Arrowhead Pharmaceuticals, Inc.:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.673%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.036%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.036%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.036%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.041%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2013 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Inducement Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Granted and outstanding awards:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;850,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;32,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;602,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,484,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,888,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;592,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,980,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,350,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,920,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,194,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,465,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock-based compensation expenses included in operating expenses attributable to Arrowhead Pharmaceuticals, Inc.:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.769%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.412%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.412%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.412%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.226%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Nine Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;27,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;41,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;48,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Option Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;            The following table presents a summary of the stock option activity for the nine months ended June&#160;30, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;br/&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Outstanding at September&#160;30, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;1,978,516&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;23.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Cancelled or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(35,341)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;45.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(458,552)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;7.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Outstanding at June&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;1,484,623&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;27.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;3.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;5,750,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Exercisable at June&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;1,484,623&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;27.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;3.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;5,750,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic values represent the amount by which the market price of the underlying stock exceeds the exercise price of the option. The total intrinsic value of the options exercised during the three months ended June&#160;30, 2025 and 2024 was $0.3 million and $0.7 million, respectively. The total intrinsic value of the options exercised during the nine months ended June&#160;30, 2025 and 2024 was $4.9 million and $3.8 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended June&#160;30, 2025, there was no stock-based compensation expense related to stock options outstanding, while $0.4 million was recorded for the same period in 2024. Stock-based compensation expense related to stock options outstanding for the nine months ended June&#160;30, 2025 and 2024, was $0.1 million and $2.5 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2025, the pre-tax compensation expense for all outstanding unvested stock options is considered nominal. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which do not have vesting restrictions and are fully transferable. The determination of the fair value of each stock option is affected by the Company&#x2019;s stock price on the date of grant, as well as assumptions regarding a number of highly complex and subjective variables. No options were granted during the nine months ended June&#160;30, 2025 and 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Visirna ESOP&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: On October 1, 2023, Visirna, a subsidiary of the Company, granted 7,500,000 stock options to its employees from the Employee Stock Option Plan (the &#x201c;Visirna ESOP&#x201d;), which authorizes 20,000,000 shares for issuance. The Visirna ESOP is independently managed by Visirna, including the valuation process. For the three months ended June&#160;30, 2025 and 2024, stock-based compensation expense related to the Visirna ESOP was $1.1&#160;million and $2.3 million, respectively. For the nine months ended June&#160;30, 2025 and 2024, stock-based compensation expense related to the Visirna ESOP was $3.0&#160;million and $5.5&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted Stock Units (&#x201c;RSUs&#x201d;), including market-based, time-based and performance-based awards, have been granted under the Company&#x2019;s 2013 and 2021 Plans, the Inducement Plan, and as inducements awards granted outside of the Company&#x2019;s equity-based compensation plans. At vesting, each outstanding RSU will be exchanged for one share of the Company&#x2019;s common stock. RSU awards generally vest subject to the satisfaction of service requirements or the satisfaction of both service requirements and achievement of certain performance targets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity of the Company&#x2019;s RSUs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of&lt;br/&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant&lt;br/&gt;Date&lt;br/&gt;Fair Value&lt;br/&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Outstanding at September&#160;30, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;4,913,312&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;49.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2,711,009&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;19.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(1,383,568)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;43.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(259,831)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;32.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Outstanding at June&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;5,980,922&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;37.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of RSUs was determined based on the closing price of the Company&#x2019;s common stock on the grant date, with consideration given to the probability of achieving service and/or performance conditions for awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended June&#160;30, 2025 and 2024, the Company recorded $11.9 million and $14.3 million of expense related to RSUs, respectively. For the nine months ended June&#160;30, 2025 and 2024, the Company recorded $41.1 million and $46.5 million of expense related to RSUs, respectively. As of June&#160;30, 2025, there was $85.8&#160;million of total unrecognized compensation cost related to RSUs that is expected to be recognized over a weighted-average period of 1.7 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding
      contextRef="c-199"
      decimals="INF"
      id="f-741"
      unitRef="shares">2350117</arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-199"
      decimals="INF"
      id="f-742"
      unitRef="shares">2350117</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-200"
      decimals="INF"
      id="f-743"
      unitRef="shares">8000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-201"
      decimals="INF"
      id="f-744"
      unitRef="shares">6215559</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="c-3" decimals="INF" id="f-745" unitRef="shares">2308495</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c-202"
      decimals="INF"
      id="f-746"
      unitRef="shares">170898</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c-201"
      decimals="INF"
      id="f-747"
      unitRef="shares">353156</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-203"
      decimals="INF"
      id="f-748"
      unitRef="shares">832950</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-204"
      decimals="INF"
      id="f-749"
      unitRef="shares">607340</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-203"
      decimals="INF"
      id="f-750"
      unitRef="shares">307924</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-203"
      decimals="INF"
      id="f-751"
      unitRef="shares">602355</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-205"
      decimals="INF"
      id="f-752"
      unitRef="shares">138775</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="c-1" id="f-753">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of awards outstanding attributable to Arrowhead Pharmaceuticals, Inc.:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.673%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.036%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.036%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.036%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.041%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2013 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Inducement Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Granted and outstanding awards:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;850,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;32,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;602,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,484,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,888,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;592,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,980,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,350,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,920,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,194,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,465,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-199"
      decimals="INF"
      id="f-754"
      unitRef="shares">850117</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-206"
      decimals="INF"
      id="f-755"
      unitRef="shares">32151</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-207"
      decimals="INF"
      id="f-756"
      unitRef="shares">602355</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-3" decimals="INF" id="f-757" unitRef="shares">1484623</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-208"
      decimals="INF"
      id="f-758"
      unitRef="shares">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-209"
      decimals="INF"
      id="f-759"
      unitRef="shares">3888660</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-210"
      decimals="INF"
      id="f-760"
      unitRef="shares">592262</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-211"
      decimals="INF"
      id="f-761"
      unitRef="shares">5980922</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding
      contextRef="c-199"
      decimals="INF"
      id="f-762"
      unitRef="shares">2350117</arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-199"
      decimals="INF"
      id="f-763"
      unitRef="shares">2350117</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding
      contextRef="c-206"
      decimals="INF"
      id="f-764"
      unitRef="shares">3920811</arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding>
    <arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding
      contextRef="c-207"
      decimals="INF"
      id="f-765"
      unitRef="shares">1194617</arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding>
    <arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding contextRef="c-3" decimals="INF" id="f-766" unitRef="shares">7465545</arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-767">&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock-based compensation expenses included in operating expenses attributable to Arrowhead Pharmaceuticals, Inc.:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.769%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.412%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.412%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.412%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.226%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Nine Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;27,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;41,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;48,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-191" decimals="-3" id="f-768" unitRef="usd">6898000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-192" decimals="-3" id="f-769" unitRef="usd">6221000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-193" decimals="-3" id="f-770" unitRef="usd">21008000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-194" decimals="-3" id="f-771" unitRef="usd">21634000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-195" decimals="-3" id="f-772" unitRef="usd">5095000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-196" decimals="-3" id="f-773" unitRef="usd">8490000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-197" decimals="-3" id="f-774" unitRef="usd">20242000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-198" decimals="-3" id="f-775" unitRef="usd">27350000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-5" decimals="-3" id="f-776" unitRef="usd">11993000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-6" decimals="-3" id="f-777" unitRef="usd">14711000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-778" unitRef="usd">41250000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-7" decimals="-3" id="f-779" unitRef="usd">48984000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-780">The following table presents a summary of the stock option activity for the nine months ended June&#160;30, 2025:&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;br/&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Outstanding at September&#160;30, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;1,978,516&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;23.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Cancelled or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(35,341)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;45.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(458,552)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;7.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Outstanding at June&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;1,484,623&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;27.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;3.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;5,750,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Exercisable at June&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;1,484,623&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;27.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;3.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;5,750,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-4" decimals="INF" id="f-781" unitRef="shares">1978516</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-782"
      unitRef="usdPerShare">23.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-783" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-784"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="c-1" decimals="INF" id="f-785" unitRef="shares">35341</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-786"
      unitRef="usdPerShare">45.92</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="INF" id="f-787" unitRef="shares">458552</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-788"
      unitRef="usdPerShare">7.55</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-3" decimals="INF" id="f-789" unitRef="shares">1484623</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-3"
      decimals="2"
      id="f-790"
      unitRef="usdPerShare">27.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-791">P3Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-3" decimals="0" id="f-792" unitRef="usd">5750674</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c-3" decimals="INF" id="f-793" unitRef="shares">1484623</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-3"
      decimals="2"
      id="f-794"
      unitRef="usdPerShare">27.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-795">P3Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-3" decimals="0" id="f-796" unitRef="usd">5750674</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-212" decimals="-5" id="f-797" unitRef="usd">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-213" decimals="-5" id="f-798" unitRef="usd">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-214" decimals="-5" id="f-799" unitRef="usd">4900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-215" decimals="-5" id="f-800" unitRef="usd">3800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-212" decimals="-5" id="f-801" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-213" decimals="-5" id="f-802" unitRef="usd">400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-214" decimals="-5" id="f-803" unitRef="usd">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-215" decimals="-5" id="f-804" unitRef="usd">2500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-216"
      decimals="INF"
      id="f-805"
      unitRef="shares">7500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-217"
      decimals="INF"
      id="f-806"
      unitRef="shares">20000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-218" decimals="-5" id="f-807" unitRef="usd">1100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-219" decimals="-5" id="f-808" unitRef="usd">2300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-220" decimals="-5" id="f-809" unitRef="usd">3000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-221" decimals="-5" id="f-810" unitRef="usd">5500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="c-1" id="f-811">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity of the Company&#x2019;s RSUs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of&lt;br/&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant&lt;br/&gt;Date&lt;br/&gt;Fair Value&lt;br/&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Outstanding at September&#160;30, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;4,913,312&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;49.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2,711,009&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;19.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(1,383,568)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;43.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(259,831)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;32.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Outstanding at June&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;5,980,922&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;37.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-222"
      decimals="INF"
      id="f-812"
      unitRef="shares">4913312</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-222"
      decimals="2"
      id="f-813"
      unitRef="usdPerShare">49.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-223"
      decimals="INF"
      id="f-814"
      unitRef="shares">2711009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-223"
      decimals="2"
      id="f-815"
      unitRef="usdPerShare">19.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-223"
      decimals="INF"
      id="f-816"
      unitRef="shares">1383568</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-223"
      decimals="2"
      id="f-817"
      unitRef="usdPerShare">43.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-223"
      decimals="INF"
      id="f-818"
      unitRef="shares">259831</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-223"
      decimals="2"
      id="f-819"
      unitRef="usdPerShare">32.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-211"
      decimals="INF"
      id="f-820"
      unitRef="shares">5980922</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-211"
      decimals="2"
      id="f-821"
      unitRef="usdPerShare">37.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-224" decimals="-5" id="f-822" unitRef="usd">11900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-225" decimals="-5" id="f-823" unitRef="usd">14300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-223" decimals="-5" id="f-824" unitRef="usd">41100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-226" decimals="-5" id="f-825" unitRef="usd">46500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c-211" decimals="-5" id="f-826" unitRef="usd">85800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-223" id="f-827">P1Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-828">FAIR VALUE MEASUREMENTS&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company employs a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The Company&#x2019;s valuation techniques and inputs used to measure fair value and the definition of the three levels (Level 1, Level 2, and Level 3) of the fair value hierarchy are disclosed in Note 10 - Fair Value Measurements of Notes to Consolidated Financial Statements of Part IV, &#x201c;Item 15. Exhibits and Financial Statement Schedules&#x201d; of its Annual Report on Form 10-K for the fiscal year ended September&#160;30, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses prices and inputs that are current as of the measurement date, including during periods of market disruption. In periods of market disruption, the ability to observe prices and inputs may be reduced for many instruments. This condition could cause an instrument to be reclassified from Level 1 to Level 2, or from Level 2 to Level 3. The Company recognizes transfers between levels at either the actual date of the event or a change in circumstances that caused the transfer. As of June&#160;30, 2025 and September&#160;30, 2024, the Company did not have any financial assets or financial liabilities based on Level 3 measurements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present information about the Company&#x2019;s assets and liabilities measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques utilized by the Company:  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Available-for-sale securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;221,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;221,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Commercial notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;26,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;26,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;515,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;515,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total available-for-sale securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;770,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;770,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Money market instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;81,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;81,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Term deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Commercial notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;23,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;23,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;81,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;42,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;124,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;81,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;813,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;894,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Available-for-sale securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;160,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;160,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Commercial notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;179,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;179,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;237,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;237,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total available-for-sale securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;578,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;578,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Money market instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;66,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;66,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;66,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;66,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;66,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;578,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;645,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-829">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present information about the Company&#x2019;s assets and liabilities measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques utilized by the Company:  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Available-for-sale securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;221,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;221,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Commercial notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;26,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;26,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;515,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;515,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total available-for-sale securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;770,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;770,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Money market instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;81,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;81,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Term deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Commercial notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;23,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;23,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;81,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;42,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;124,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;81,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;813,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;894,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Available-for-sale securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;160,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;160,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Commercial notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;179,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;179,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;237,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;237,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total available-for-sale securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;578,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;578,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Money market instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;66,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;66,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;66,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;66,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;66,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;578,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;645,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-227" decimals="-3" id="f-830" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-228" decimals="-3" id="f-831" unitRef="usd">221877000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-229" decimals="-3" id="f-832" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-230" decimals="-3" id="f-833" unitRef="usd">221877000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-231" decimals="-3" id="f-834" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-232" decimals="-3" id="f-835" unitRef="usd">7019000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-233" decimals="-3" id="f-836" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-234" decimals="-3" id="f-837" unitRef="usd">7019000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-235" decimals="-3" id="f-838" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-236" decimals="-3" id="f-839" unitRef="usd">26449000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-237" decimals="-3" id="f-840" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-238" decimals="-3" id="f-841" unitRef="usd">26449000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-239" decimals="-3" id="f-842" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-240" decimals="-3" id="f-843" unitRef="usd">515234000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-241" decimals="-3" id="f-844" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-242" decimals="-3" id="f-845" unitRef="usd">515234000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-243" decimals="-3" id="f-846" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-244" decimals="-3" id="f-847" unitRef="usd">770579000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-245" decimals="-3" id="f-848" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-246" decimals="-3" id="f-849" unitRef="usd">770579000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-247" decimals="-3" id="f-850" unitRef="usd">81283000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-248" decimals="-3" id="f-851" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-249" decimals="-3" id="f-852" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-250" decimals="-3" id="f-853" unitRef="usd">81283000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-251" decimals="-3" id="f-854" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-252" decimals="-3" id="f-855" unitRef="usd">11049000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-253" decimals="-3" id="f-856" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-254" decimals="-3" id="f-857" unitRef="usd">11049000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-255" decimals="-3" id="f-858" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-256" decimals="-3" id="f-859" unitRef="usd">7960000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-257" decimals="-3" id="f-860" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-258" decimals="-3" id="f-861" unitRef="usd">7960000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-259" decimals="-3" id="f-862" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-260" decimals="-3" id="f-863" unitRef="usd">23770000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-261" decimals="-3" id="f-864" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-262" decimals="-3" id="f-865" unitRef="usd">23770000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-243" decimals="-3" id="f-866" unitRef="usd">81283000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-244" decimals="-3" id="f-867" unitRef="usd">42779000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-245" decimals="-3" id="f-868" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-246" decimals="-3" id="f-869" unitRef="usd">124062000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-243" decimals="-3" id="f-870" unitRef="usd">81283000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-244" decimals="-3" id="f-871" unitRef="usd">813358000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-245" decimals="-3" id="f-872" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-246" decimals="-3" id="f-873" unitRef="usd">894641000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-263" decimals="-3" id="f-874" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-264" decimals="-3" id="f-875" unitRef="usd">160723000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-265" decimals="-3" id="f-876" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-266" decimals="-3" id="f-877" unitRef="usd">160723000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-267" decimals="-3" id="f-878" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-268" decimals="-3" id="f-879" unitRef="usd">179714000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-269" decimals="-3" id="f-880" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-270" decimals="-3" id="f-881" unitRef="usd">179714000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-271" decimals="-3" id="f-882" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-272" decimals="-3" id="f-883" unitRef="usd">237839000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-273" decimals="-3" id="f-884" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-274" decimals="-3" id="f-885" unitRef="usd">237839000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-275" decimals="-3" id="f-886" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-276" decimals="-3" id="f-887" unitRef="usd">578276000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-277" decimals="-3" id="f-888" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-278" decimals="-3" id="f-889" unitRef="usd">578276000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-279" decimals="-3" id="f-890" unitRef="usd">66966000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-280" decimals="-3" id="f-891" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-281" decimals="-3" id="f-892" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-282" decimals="-3" id="f-893" unitRef="usd">66966000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-275" decimals="-3" id="f-894" unitRef="usd">66966000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-276" decimals="-3" id="f-895" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-277" decimals="-3" id="f-896" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-278" decimals="-3" id="f-897" unitRef="usd">66966000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-275" decimals="-3" id="f-898" unitRef="usd">66966000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-276" decimals="-3" id="f-899" unitRef="usd">578276000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-277" decimals="-3" id="f-900" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-278" decimals="-3" id="f-901" unitRef="usd">645242000</us-gaap:AssetsFairValueDisclosure>
    <arwr:LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock contextRef="c-1" id="f-902">LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2022, the Company and Royalty Pharma entered into the Royalty Pharma Agreement, pursuant to which Royalty Pharma agreed to pay up to $410.0&#160;million in cash to the Company in consideration for the Company&#x2019;s future royalty interest in olpasiran, originally developed by the Company and licensed to Amgen in September 2016 under the Olpasiran Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Royalty Pharma Agreement, Royalty Pharma paid $250.0 million upfront and agreed to pay up to an additional $160.0&#160;million in aggregate one-time milestone payments due if and when the following milestone events occur: (i) $50.0&#160;million on completion of enrollment in the OCEAN Phase 3 clinical trial for olpasiran, (ii) $50.0&#160;million upon receipt of FDA approval of olpasiran for an approved indication (reduction in the risk of myocardial infarction, urgent coronary revascularization, or coronary heart disease death in adults with established cardiovascular disease and elevated Lp(a)), and (iii) $60.0&#160;million upon Royalty Pharma&#x2019;s receipt of at least $70.0&#160;million of royalty payments under the Royalty Pharma Agreement in any single calendar year. During the third quarter of fiscal 2024, Amgen completed enrollment of the Phase 3 OCEAN(a) outcomes trial of olpasiran, which triggered a $50.0&#160;million milestone payment that the Company received in the same quarter. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In consideration for the payment of the foregoing amounts under the Royalty Pharma Agreement, Royalty Pharma is entitled to receive all royalties otherwise payable by Amgen to the Company under the Olpasiran Agreement. The Company remains eligible to receive any milestone payments potentially payable by Amgen under the Olpasiran Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has evaluated the terms of the Royalty Pharma Agreement and concluded, in accordance with the relevant accounting guidance, that the Company accounted for the transaction as debt and the funding of $250.0&#160;million and $50.0&#160;million from Royalty Pharma were recorded as liabilities related to the sale of future royalties on its consolidated balance sheets. The Company is not obligated to repay these funds received under the Royalty Pharma Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records the obligations at their carrying value using the effective interest method. In order to amortize the sale of future royalties, the Company utilizes the prospective method to estimate the future royalties to be paid by the Company to the counterparty over the life of the arrangement. Under the prospective method, a new effective interest rate is determined based on the revised estimate of remaining cash flows. The new rate is the discount rate that equates the present value of the revised estimate of remaining cash flows with the carrying amount of the debt, and it will be used to recognize non-cash interest expense for the remaining periods. The Company periodically assesses the amount and the timing of expected royalty payments using a combination of internal projections and forecasts from external sources. The estimates of future net product sales (and resulting royalty payments) are based on key assumptions including population, penetration, probability of success and sales price, among others. To the extent such payments are greater or less than the Company&#x2019;s initial estimates or the timing of such payments is different than its original estimates, the Company will prospectively adjust the amortization of the royalty financing obligations and the effective interest rate. As of June&#160;30, 2025, the estimated effective interest rate was 9.1%. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the activity with respect to the liability related to the sale of future royalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.345%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.574%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.577%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Beginning carrying value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;341,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;268,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Milestone payment received&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-cash interest expense recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;18,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;23,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Ending carrying value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;360,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;341,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</arwr:LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock>
    <arwr:InitialTransactionPrice contextRef="c-283" decimals="-5" id="f-903" unitRef="usd">410000000</arwr:InitialTransactionPrice>
    <arwr:UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties contextRef="c-284" decimals="-5" id="f-904" unitRef="usd">250000000.0</arwr:UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties>
    <arwr:MilestonePaymentReceivable contextRef="c-285" decimals="-5" id="f-905" unitRef="usd">160000000</arwr:MilestonePaymentReceivable>
    <arwr:MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial contextRef="c-286" decimals="-5" id="f-906" unitRef="usd">50000000</arwr:MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial>
    <arwr:MilestonePaymentReceivableUponFDAApproval contextRef="c-285" decimals="-5" id="f-907" unitRef="usd">50000000</arwr:MilestonePaymentReceivableUponFDAApproval>
    <arwr:MilestonePaymentReceivableUponReceiptOfRoyaltyPayments contextRef="c-285" decimals="-5" id="f-908" unitRef="usd">60000000</arwr:MilestonePaymentReceivableUponReceiptOfRoyaltyPayments>
    <arwr:RoyaltyPaymentThreshold contextRef="c-285" decimals="-5" id="f-909" unitRef="usd">70000000</arwr:RoyaltyPaymentThreshold>
    <arwr:MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties contextRef="c-287" decimals="-5" id="f-910" unitRef="usd">50000000</arwr:MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties>
    <arwr:UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties contextRef="c-284" decimals="-5" id="f-911" unitRef="usd">250000000</arwr:UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties>
    <arwr:MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties contextRef="c-287" decimals="-5" id="f-912" unitRef="usd">50000000</arwr:MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties>
    <arwr:LiabilitySaleOfFutureRoyaltiesInterestRate contextRef="c-288" decimals="3" id="f-913" unitRef="number">0.091</arwr:LiabilitySaleOfFutureRoyaltiesInterestRate>
    <arwr:ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock contextRef="c-1" id="f-914">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the activity with respect to the liability related to the sale of future royalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.345%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.574%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.577%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Beginning carrying value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;341,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;268,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Milestone payment received&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-cash interest expense recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;18,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;23,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Ending carrying value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;360,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;341,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</arwr:ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock>
    <arwr:RoyaltiesLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-915" unitRef="usd">341361000</arwr:RoyaltiesLiabilityNoncurrent>
    <arwr:RoyaltiesLiabilityNoncurrent contextRef="c-52" decimals="-3" id="f-916" unitRef="usd">268326000</arwr:RoyaltiesLiabilityNoncurrent>
    <arwr:MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties contextRef="c-1" decimals="-3" id="f-917" unitRef="usd">0</arwr:MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties>
    <arwr:MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties contextRef="c-289" decimals="-3" id="f-918" unitRef="usd">50000000</arwr:MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties>
    <arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties contextRef="c-1" decimals="-3" id="f-919" unitRef="usd">18893000</arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties>
    <arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties contextRef="c-289" decimals="-3" id="f-920" unitRef="usd">23035000</arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties>
    <arwr:RoyaltiesLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-921" unitRef="usd">360254000</arwr:RoyaltiesLiabilityNoncurrent>
    <arwr:RoyaltiesLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-922" unitRef="usd">341361000</arwr:RoyaltiesLiabilityNoncurrent>
    <us-gaap:LongTermDebtTextBlock contextRef="c-1" id="f-923">FINANCING AGREEMENT &lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 7, 2024 (the &#x201c;Closing Date&#x201d;), the Company entered into a Financing Agreement with the guarantors party thereto, the lenders party thereto (the &#x201c;Lenders&#x201d;), and Sixth Street Lending Partners (&#x201c;Sixth Street&#x201d;), as the administrative agent and collateral agent for the Lenders (the &#x201c;Financing Agreement&#x201d;). The Financing Agreement establishes a senior secured term loan facility of $500.0&#160;million (the &#x201c;Credit Facility&#x201d;), consisting of $400.0&#160;million funded on the Closing Date and an additional $100.0&#160;million available at the Company&#x2019;s option, subject to mutual agreement with Sixth Street. The loans under the Credit Facility bear interest at an annual rate of 15.0%, which is paid in kind and added to the outstanding principal balance of the Credit Facility each period. The outstanding principal balance of this Credit Facility, including amounts representing accrued but unpaid interest previously paid in kind, is due and payable on August &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7, 2031.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is permitted to use the net proceeds for working capital, capital expenditures and general corporate purposes of the Company and its subsidiaries.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will have the right to prepay loans under the Credit Facility at any time. The Company is required to partially repay loans under the Credit Facility with proceeds from certain asset sales, condemnation events and extraordinary receipts, subject, in some cases, to reinvestment rights. If the Company repays in full the aggregate principal outstanding under the Credit Facility and such payment in full occurs on or prior to August 7, 2028, the Company will be required to make an additional payment to the lenders under the Credit Facility on such date in an amount necessary for the lenders to achieve a two times multiple of invested capital (&#x201c;MOIC&#x201d;) of the aggregate principal amount funded on the Closing Date (the &#x201c;MOIC Payment&#x201d;). If such payment in full occurs after August 7, 2028, the Company will be required to make a payment to the lenders under the Credit Facility on such date in an amount necessary for the lenders to achieve the greater of the MOIC Payment and the present value of all interest payments that would have been payable from such date through the maturity date of the Credit Facility discounted at the Treasury Rate (as defined in the Financing Agreement) plus 0.5%; provided that such payment amount in this instance will not exceed the amount necessary for the lenders to achieve a 2.5 times MOIC. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 26, 2024, the Company entered into an amendment to the Financing Agreement (the "Amendment") to modify, amongst other things, some of the prepayment terms of the loans under the Credit Facility, including, the prepayment terms related to the Sarepta Collaboration Agreement. The Amendment was effective on February 14, 2025, following the closing of the Sarepta Collaboration Agreement and receipt of the $500.0&#160;million upfront payment from Sarepta. The Amendment added an additional prepayment clause that requires certain contractual prepayments of principle and MOIC payments throughout the life of the loans under the Credit Facility. Additionally, any prepayment will be split with 50% of any such prepayment paying down the principle balance of the loans under the Credit Facility and the other 50% being applied to prepay the MOIC Payment. In the event the prepayment amounts result in fees being prepaid in excess of the actual amounts required to be paid, the excess fees shall be reallocated and applied to reduce the amount of the principal balance upon repayment in full of the loans under the Credit Facility. As of June 30, 2025, the Company has paid $100.0&#160;million in MOIC payments of which $25.3&#160;million is expected to be applied to principal upon repayment in full. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date, the Company has paid $201.6&#160;million of the loans under the Credit Facility during fiscal 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Amendment was accounted for as a debt modification under ASC 470-50, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;Debt&#x2014;Modification and extinguishments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d; since the Amendment did not result in substantially different terms. In connection with the Amendment, the Company did not incur significant third-party fees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All obligations under the Financing Agreement are secured on a first-priority basis by security interests in substantially all assets of the Company and material subsidiaries of the Company, including its intellectual property, subject to certain exceptions, and is guaranteed by material subsidiaries of the Company, including foreign subsidiaries, subject to certain exceptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Financing Agreement contains customary covenants, including, without limitation, a financial covenant to maintain liquidity (cash, cash equivalents and investments) of at least $100.0&#160;million if the Company&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s market capitalization is above $1.5 billion, and negative covenants that, subject to certain exceptions, restrict indebtedness, liens, investments (including acquisitions), fundamental changes, asset sales and licensing transactions, dividends, modifications to material agreements, payment of subordinated indebtedness, distributions from certain parties, and other matters customarily restricted in such agreements. The Company is subject to restrictions on sales and licensing transactions with respect to certain core intellectual property, subject to certain exceptions, including certain transactions related to areas outside the United States, United Kingdom, European Union, Japan and China.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Financing Agreement contains certain embedded features that were identified and evaluated as not material to the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The outstanding balance of the Credit Facility consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.719%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Initial Term Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;400,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;400,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accumulated interest on the Initial Term Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;53,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accumulated accretion of the MOIC Payment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Less: Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(14,284)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(15,817)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Less: Current portion of credit facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(40,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Less: Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(201,625)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Credit facility, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;200,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;393,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth total interest expense recognized related to the Credit Facility:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.293%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.540%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accretion of the MOIC Payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Contractual interest expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;44,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;Total interest expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;48,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amounts shown in the table below, related to the Credit Facility, represent the expected repayments of principle and accrued interest balance as of June 30, 2025 as well as any mandatory prepayments that the Company is obligated to make to the Lenders during the indicated periods. The principal balance will increase from accrued paid in kind interest and the table does not include MOIC payments beyond those contractually determined. Actual payments on current principal may vary from the amounts presented in the table. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.226%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.933%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amounts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2025 (remainder)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;40,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;40,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;216,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;326,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2025, Visirna entered into the Revolving Credit Agreement with Bank of Zhejiang. The maximum aggregate credit facility is 73.0&#160;million Chinese Yuan ($10.0&#160;million) bearing an annual interest rate of 4.1%. The term of each loan is twelve months. The amount outstanding as of June 30, 2025 was 50.8&#160;million Chinese Yuan ($7.1&#160;million) on the credit facility which was classified as other current liabilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-290" decimals="-5" id="f-924" unitRef="usd">500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCredit contextRef="c-290" decimals="-5" id="f-925" unitRef="usd">400000000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity contextRef="c-290" decimals="-5" id="f-926" unitRef="usd">100000000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-291" decimals="3" id="f-927" unitRef="number">0.150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <arwr:DebtInstrumentCovenantMultipleOfInvestCapital
      contextRef="c-292"
      decimals="INF"
      id="f-928"
      unitRef="number">2</arwr:DebtInstrumentCovenantMultipleOfInvestCapital>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="c-292" decimals="3" id="f-929" unitRef="number">0.005</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <arwr:DebtInstrumentCovenantMultipleOfInvestCapital
      contextRef="c-293"
      decimals="INF"
      id="f-930"
      unitRef="number">2.5</arwr:DebtInstrumentCovenantMultipleOfInvestCapital>
    <arwr:ProceedsFromCollaborationArrangements contextRef="c-91" decimals="-5" id="f-931" unitRef="usd">500000000</arwr:ProceedsFromCollaborationArrangements>
    <arwr:DebtInstrumentPrepaymentPercentage contextRef="c-294" decimals="2" id="f-932" unitRef="number">0.50</arwr:DebtInstrumentPrepaymentPercentage>
    <arwr:DebtInstrumentPrepaymentPercentage contextRef="c-295" decimals="2" id="f-933" unitRef="number">0.50</arwr:DebtInstrumentPrepaymentPercentage>
    <us-gaap:RepaymentsOfLinesOfCredit contextRef="c-296" decimals="-3" id="f-934" unitRef="usd">100000000</us-gaap:RepaymentsOfLinesOfCredit>
    <arwr:DebtInstrumentMultipleOfInvestmentCapitalExpectedToBeAppliedToPrincipalUponRepayment contextRef="c-297" decimals="-3" id="f-935" unitRef="usd">25300000</arwr:DebtInstrumentMultipleOfInvestmentCapitalExpectedToBeAppliedToPrincipalUponRepayment>
    <us-gaap:RepaymentsOfLinesOfCredit contextRef="c-298" decimals="-5" id="f-936" unitRef="usd">201600000</us-gaap:RepaymentsOfLinesOfCredit>
    <arwr:DebtInstrumentCovenantMinimumLiquidityIfCapitalizationIsAboveThreshold contextRef="c-299" decimals="-5" id="f-937" unitRef="usd">100000000</arwr:DebtInstrumentCovenantMinimumLiquidityIfCapitalizationIsAboveThreshold>
    <arwr:DebtInstrumentCovenantMarketCapitalizationThreshold contextRef="c-299" decimals="-8" id="f-938" unitRef="usd">1500000000</arwr:DebtInstrumentCovenantMarketCapitalizationThreshold>
    <us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock contextRef="c-1" id="f-939">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The outstanding balance of the Credit Facility consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.719%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Initial Term Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;400,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;400,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accumulated interest on the Initial Term Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;53,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accumulated accretion of the MOIC Payment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Less: Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(14,284)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(15,817)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Less: Current portion of credit facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(40,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Less: Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(201,625)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Credit facility, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;200,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;393,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-300" decimals="-3" id="f-940" unitRef="usd">400000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-301" decimals="-3" id="f-941" unitRef="usd">400000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-302" decimals="-3" id="f-942" unitRef="usd">53454000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-303" decimals="-3" id="f-943" unitRef="usd">9000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-298" decimals="-3" id="f-944" unitRef="usd">2787000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-304" decimals="-3" id="f-945" unitRef="usd">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:DeferredFinanceCostsGross contextRef="c-299" decimals="-3" id="f-946" unitRef="usd">14284000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DeferredFinanceCostsGross contextRef="c-305" decimals="-3" id="f-947" unitRef="usd">15817000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:LinesOfCreditCurrent contextRef="c-299" decimals="-3" id="f-948" unitRef="usd">40000000</us-gaap:LinesOfCreditCurrent>
    <us-gaap:LinesOfCreditCurrent contextRef="c-305" decimals="-3" id="f-949" unitRef="usd">0</us-gaap:LinesOfCreditCurrent>
    <us-gaap:RepaymentsOfLinesOfCredit contextRef="c-298" decimals="-3" id="f-950" unitRef="usd">201625000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit contextRef="c-304" decimals="-3" id="f-951" unitRef="usd">0</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-299" decimals="-3" id="f-952" unitRef="usd">200332000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-305" decimals="-3" id="f-953" unitRef="usd">393183000</us-gaap:LongTermDebtNoncurrent>
    <arwr:SummaryOfInterestExpenseRecognizedRelatedToCreditFacilityTableTextBlock contextRef="c-1" id="f-954">&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth total interest expense recognized related to the Credit Facility:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.293%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.540%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accretion of the MOIC Payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Contractual interest expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;44,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;Total interest expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;48,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</arwr:SummaryOfInterestExpenseRecognizedRelatedToCreditFacilityTableTextBlock>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-306" decimals="-3" id="f-955" unitRef="usd">420000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-307" decimals="-3" id="f-956" unitRef="usd">0</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-298" decimals="-3" id="f-957" unitRef="usd">1533000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-308" decimals="-3" id="f-958" unitRef="usd">0</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-306" decimals="-3" id="f-959" unitRef="usd">2218000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-307" decimals="-3" id="f-960" unitRef="usd">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-298" decimals="-3" id="f-961" unitRef="usd">2787000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-308" decimals="-3" id="f-962" unitRef="usd">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="c-306" decimals="-3" id="f-963" unitRef="usd">13766000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="c-307" decimals="-3" id="f-964" unitRef="usd">0</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="c-298" decimals="-3" id="f-965" unitRef="usd">44454000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="c-308" decimals="-3" id="f-966" unitRef="usd">0</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebt contextRef="c-306" decimals="-3" id="f-967" unitRef="usd">16404000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-307" decimals="-3" id="f-968" unitRef="usd">0</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-298" decimals="-3" id="f-969" unitRef="usd">48774000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-308" decimals="-3" id="f-970" unitRef="usd">0</us-gaap:InterestExpenseDebt>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="c-1" id="f-971">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amounts shown in the table below, related to the Credit Facility, represent the expected repayments of principle and accrued interest balance as of June 30, 2025 as well as any mandatory prepayments that the Company is obligated to make to the Lenders during the indicated periods. The principal balance will increase from accrued paid in kind interest and the table does not include MOIC payments beyond those contractually determined. Actual payments on current principal may vary from the amounts presented in the table. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.226%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.933%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amounts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2025 (remainder)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;40,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;40,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;216,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;326,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear contextRef="c-299" decimals="-3" id="f-972" unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c-299" decimals="-3" id="f-973" unitRef="usd">40000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c-299" decimals="-3" id="f-974" unitRef="usd">40000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="c-299" decimals="-3" id="f-975" unitRef="usd">15000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="c-299" decimals="-3" id="f-976" unitRef="usd">15000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <arwr:LongTermDebtMaturityAfterYearFour contextRef="c-299" decimals="-3" id="f-977" unitRef="usd">216503000</arwr:LongTermDebtMaturityAfterYearFour>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-299" decimals="-3" id="f-978" unitRef="usd">326503000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-309" decimals="-5" id="f-979" unitRef="cny">73000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-309" decimals="-5" id="f-980" unitRef="usd">10000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-309" decimals="3" id="f-981" unitRef="number">0.041</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentTerm contextRef="c-310" id="f-982">P12M</us-gaap:DebtInstrumentTerm>
    <us-gaap:LinesOfCreditCurrent contextRef="c-311" decimals="-5" id="f-983" unitRef="cny">50800000</us-gaap:LinesOfCreditCurrent>
    <us-gaap:LinesOfCreditCurrent contextRef="c-311" decimals="-5" id="f-984" unitRef="usd">7100000</us-gaap:LinesOfCreditCurrent>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-985">NET (LOSS) INCOME PER SHARE&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the computation of basic and diluted net (loss) income per share for the three and nine months ended June&#160;30, 2025 and 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;                            &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.545%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Nine Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands, except per share amounts)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net (loss) income attributable to Arrowhead Pharmaceuticals, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(175,241)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(170,793)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;22,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(428,957)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted-average basic shares outstanding&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;139,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;124,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;132,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;118,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Effect of dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted-average diluted shares outstanding &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;139,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;124,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;133,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;118,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Basic net (loss) income per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1.26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1.38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3.63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Diluted net (loss) income per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1.26)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1.38)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3.63)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(1) Includes shares of common stock into which the Avoro Pre-Funded Warrants may be exercised. See Note 6.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net (loss) income per share because to include them would be anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.545%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Nine Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-986">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the computation of basic and diluted net (loss) income per share for the three and nine months ended June&#160;30, 2025 and 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;                            &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.545%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Nine Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands, except per share amounts)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net (loss) income attributable to Arrowhead Pharmaceuticals, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(175,241)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(170,793)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;22,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(428,957)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted-average basic shares outstanding&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;139,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;124,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;132,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;118,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Effect of dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted-average diluted shares outstanding &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;139,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;124,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;133,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;118,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Basic net (loss) income per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1.26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1.38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3.63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Diluted net (loss) income per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1.26)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1.38)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3.63)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(1) Includes shares of common stock into which the Avoro Pre-Funded Warrants may be exercised. See Note 6.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-987" unitRef="usd">-175241000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-988" unitRef="usd">-170793000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-989" unitRef="usd">22119000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-990" unitRef="usd">-428957000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="-3" id="f-991" unitRef="shares">139039000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-6" decimals="-3" id="f-992" unitRef="shares">124199000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-993" unitRef="shares">132385000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-7" decimals="-3" id="f-994" unitRef="shares">118260000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="c-5" decimals="-3" id="f-995" unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="c-6" decimals="-3" id="f-996" unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="c-1" decimals="-3" id="f-997" unitRef="shares">967000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="c-7" decimals="-3" id="f-998" unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="-3" id="f-999" unitRef="shares">139039000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-6" decimals="-3" id="f-1000" unitRef="shares">124199000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-1001" unitRef="shares">133352000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-7" decimals="-3" id="f-1002" unitRef="shares">118260000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-5"
      decimals="2"
      id="f-1003"
      unitRef="usdPerShare">-1.26</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-6"
      decimals="2"
      id="f-1004"
      unitRef="usdPerShare">-1.38</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-1005"
      unitRef="usdPerShare">0.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-7"
      decimals="2"
      id="f-1006"
      unitRef="usdPerShare">-3.63</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-5"
      decimals="2"
      id="f-1007"
      unitRef="usdPerShare">-1.26</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-6"
      decimals="2"
      id="f-1008"
      unitRef="usdPerShare">-1.38</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-1009"
      unitRef="usdPerShare">0.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-7"
      decimals="2"
      id="f-1010"
      unitRef="usdPerShare">-3.63</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-1011">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net (loss) income per share because to include them would be anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.545%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Nine Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-312"
      decimals="-3"
      id="f-1012"
      unitRef="shares">768000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-313"
      decimals="-3"
      id="f-1013"
      unitRef="shares">753000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-314"
      decimals="-3"
      id="f-1014"
      unitRef="shares">756000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-315"
      decimals="-3"
      id="f-1015"
      unitRef="shares">711000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-316"
      decimals="-3"
      id="f-1016"
      unitRef="shares">5178000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-317"
      decimals="-3"
      id="f-1017"
      unitRef="shares">3976000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-318"
      decimals="-3"
      id="f-1018"
      unitRef="shares">4770000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-319"
      decimals="-3"
      id="f-1019"
      unitRef="shares">4060000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-5" decimals="-3" id="f-1020" unitRef="shares">5946000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-6" decimals="-3" id="f-1021" unitRef="shares">4729000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="-3" id="f-1022" unitRef="shares">5526000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-7" decimals="-3" id="f-1023" unitRef="shares">4771000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-1024">INCOME TAXES&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's estimated annual effective tax rate significantly fluctuates for fiscal 2025 with small changes to the Company&#x2019;s estimated income. For the three months ended June&#160;30, 2025, the Company has recorded a discrete income tax benefit of $0.4&#160;million. The income tax provision for the three months ended June&#160;30, 2024, resulted in no tax expense. For the nine months ended June&#160;30, 2025, the Company has recorded a discrete income tax expense of $1.4&#160;million, and for the nine months ended June&#160;30, 2024, the Company has recorded a discrete income tax benefit of $3.3&#160;million. Income tax expense for the three and nine months ended June&#160;30, 2025 was based on actual year to date income recorded and statutory tax rates. &lt;/span&gt;&lt;/div&gt;The Company does not anticipate any changes in its unrecognized tax benefits over the next 12 months. Due to the presence of net operating loss carryforwards, all of the income tax years remain open for examination domestically. The Company has not been notified that it is under audit by the Internal Revenue Service or foreign taxing authorities; however, the Company has been notified of an income tax examination by the State of California. There are no other audits in any other jurisdictions.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-5" decimals="-5" id="f-1025" unitRef="usd">-400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-6" decimals="-5" id="f-1026" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-1027" unitRef="usd">1400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-7" decimals="-5" id="f-1028" unitRef="usd">-3300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-1029">SUBSEQUENT EVENTS&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Visirna&lt;/span&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On August 1, 2025, Visirna Therapeutics HK Limited (&#x201c;Visirna HK&#x201d;), a wholly owned subsidiary of Visirna Therapeutics, Inc, a majority owned subsidiary of the Company, entered into an Asset Purchase Agreement (the &#x201c;Asset Purchase Agreement&#x201d;) with Genzyme Corporation (&#x201c;Sanofi&#x201d;), a wholly owned subsidiary of Sanofi S.A., pursuant to which Visirna HK sold all of its assets and rights in investigational plozasiran to Sanofi, which included an assignment of Visirna HK&#x2019;s rights (as successor by assignment from Visirna) to develop and commercialize investigational plozasiran in Greater China pursuant to that certain License Agreement by and between the Company and Visirna dated, April 25, 2022 (the &#x201c;Visirna License Agreement&#x201d;).  The Asset Purchase Agreement is scheduled to close during the second half of the &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;year.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In connection with the Asset Purchase Agreement, the Company consented to the partial assignment of the Visirna License Agreement by Visirna HK to Sanofi (as so assigned, the &#x201c;Sanofi License Agreement&#x201d;), amongst other agreements between the Company and Visirna, effective as of the closing of the Asset Purchase Agreement. After giving effect to the Asset Purchase Agreement, Visirna HK retains rights to develop and commercialize in Greater China three other cardiometabolic drugs licensed to it pursuant to the Visirna License Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Upon closing of the Asset Purchase Agreement, Visirna will receive an upfront payment of $130.0&#160;million from Sanofi and is eligible to receive further milestone payments of up to $265.0&#160;million upon approval of plozasiran across various indications in mainland China. The Company is also eligible to receive royalties from Sanofi on net commercial product sales in Greater China under the Sanofi License Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Sarepta DM1 Milestone&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On July 27, 2025, the Company triggered a $100.0&#160;million milestone payment from Sarepta. The Company reached the first of two prespecified enrollment targets and subsequent authorization to dose escalate in a Phase 1/2 clinical study of ARO-DM1, an investigational RNAi therapeutic for treatment of type 1 myotonic dystrophy (DM1), as outlined in the Sarepta Collaboration Agreement, triggering the milestone. The Company is eligible to receive up to an additional $200.0&#160;million in near-term milestone payments associated with the continued enrollment of certain cohorts of a Phase 1/2 study of ARO-DM1.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <arwr:InitialTransactionPrice contextRef="c-320" decimals="-5" id="f-1030" unitRef="usd">130000000</arwr:InitialTransactionPrice>
    <arwr:FuturePotentialMilestonePayments contextRef="c-320" decimals="-5" id="f-1031" unitRef="usd">265000000</arwr:FuturePotentialMilestonePayments>
    <arwr:DevelopmentMilestonePayments contextRef="c-88" decimals="-5" id="f-1032" unitRef="usd">100000000</arwr:DevelopmentMilestonePayments>
    <arwr:FuturePotentialMilestonePayments contextRef="c-88" decimals="-5" id="f-1033" unitRef="usd">200000000</arwr:FuturePotentialMilestonePayments>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-5" id="f-1034">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-5" id="f-1035">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-5" id="f-1036">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-5" id="f-1037">false</ecd:Rule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
